& quot ; after administration of epoetin alfa , the number of erythrocyte , the Hb value and reticulocyte count increase a well a the 59Fe-incorporation rate .
& quot ;
& quot ; control clinical trial have not show significant benefit attributable to the administration of epoetins when haemoglobin concentration be increase beyond the level necessary to control symptom of anaemia and to avoid blood transfusion .
& quot ;
& quot ; Pharmacokinetics of paclitaxel in patient age over 65 year seem comparable to that in patient le than 65 year .
& quot ;
& quot ; invent name
& quot ;
& quot ; instruction on use
& quot ;
& quot ; these change be interpret a be secondary to decreased maternal body weight gain .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; Hypertensive crisis with encephalopathy-like symptom can occur .
& quot ;
& quot ; stability of the reconstituted suspension in the infusion bag after reconstitution , the reconstituted suspension in the infusion bag should be use immediately .
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; the pre-filled syrinx be ready to use ( see section 4.2 – method of administration ) .
& quot ;
& quot ; 1 .
& quot ;
& quot ; BLISTERS
& quot ;
& quot ; contains aspartame .
& quot ;
& quot ; Lactose monohydrate Maize starch Microcrystalline cellulose Hydroxypropyl cellulose Magnesium stearate
& quot ;
& quot ; although the cause of death be vary , most of the death appear to be either cardiovascular ( e. g. heart failure , sudden death ) or infectious ( e. g. pneumonia ) in nature .
& quot ;
& quot ; general
& quot ;
& quot ; Syringes be emboss with graduation ring and the filling volume be indicate by a stick-on label in order to enable partial use if require .
& quot ;
& quot ; in patient with chronic renal failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommend in section 4.2 .
& quot ;
& quot ; Sverige BRISTOL-MYERS SQUIBB AB Tel : + 46 8 704 71 00
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of at least four week .
& quot ;
& quot ; for atrial fibrillation serious adverse event the pooled incidence be 1.3 % for Aclasta and 0.8 % for placebo .
& quot ;
& quot ; in the long term 26-week maintenance phase of a placebo-controlled trial , the incidence of EPS be 18.2 % for aripiprazole-treated patient and 15.7 % for placebo-treated patient .
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; & quot ; & quot ; Flu-like & quot ; & quot ; symptom such a headache , joint pain , feeling of weakness , dizziness , and tiredness may occur , especially at the start of treatment .
& quot ;
& quot ; what ABILIFY be and what it be use for 2 .
& quot ;
& quot ; Uncommon side effect ( greater than 1 in 1,000 , le than 1 in 100 patient ) some people may feel dizzy , especially when get up from a lying or sit position , or may experience a fast heart rate .
& quot ;
& quot ; this medicinal product do not require any special storage condition .
& quot ;
& quot ; benefit outweighs the potential risk to the foetus .
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; 8 .
& quot ;
& quot ; 2 .
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subject , nor be there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; the daily dose of Abilify should not exceed 30 mg , but this dose should be use with caution in patient who have severe problem with their liver .
& quot ;
& quot ; ABILIFY be use to treat adult who suffer from a condition with symptom such a feeling & quot ; & quot ; high & quot ; & quot ; , have excessive amount of energy , need much le sleep than usual , talk very quickly with race idea and sometimes severe irritability .
& quot ;
& quot ; Breast-feeding mother should not take ABILIFY .
& quot ;
& quot ; patient ) be recommend for chronic renal failure patient whose serum ferritin level be below 100 ng / ml
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; you should check with your doctor or pharmacist if you be not sure .
& quot ;
& quot ; iron status should be evaluate prior to and during treatment and iron supplementation administer if necessary .
& quot ;
& quot ; independent of erythropoietin treatment , thrombotic and vascular event may occur in surgical patient with underlying cardiovascular disease follow repeat phlebotomy .
& quot ;
& quot ; 9 .
& quot ;
& quot ; EXP
& quot ;
& quot ; 0.3 ml ( 10000 IU / ml )
& quot ;
& quot ; the incidence of bone marrow fibrosis be not increase in a study of haemodialysis patient who be treat with epoetin alfa for 3 year compare to a match control group of dialysis patient who have not be treat with epoetin alfa . ) .
& quot ;
& quot ; 178 PARTICULARS to appear on the outer packaging
& quot ;
& quot ; Epoetin alfa obtain by gene technology be glycosylated and be identical in it amino acid and carbohydrate composition to endogenous human erythropoietin that have be isolate from the urine of anaemic patient .
& quot ;
& quot ; • condition or restriction with regard to the safe AND effective use OF the MEDICINAL product
& quot ;
& quot ; syncope , hypertension , thromboembolic event
& quot ;
& quot ; Tel : + 34 91 456 53 00
& quot ;
& quot ; 7 .
& quot ;
& quot ; Cytotoxic action of epoetin alfa on bone marrow cell could not be detect .
& quot ;
& quot ; - treatment of severe anaemia of renal origin accompany by clinical symptom in adult patient
& quot ;
& quot ; during antipsychotic treatment , improvement in the patient & apos ; s clinical condition may take several day to some week .
& quot ;
& quot ; Danmark BRISTOL-MYERS SQUIBB Tlf : + 45 45 93 05 06
& quot ;
& quot ; other
& quot ;
& quot ; Magyarország BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; adult patient with renal insufficiency not yet undergoing dialysis :
& quot ;
& quot ; EPAR summary for the public
& quot ;
& quot ; consequently , haemoglobin and blood pressure should be closely monitor .
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; when the CYP3A4 inducer be withdraw from the combination therapy , the aripiprazole dose should then be reduce to the recommend dose ( see section 4.5 ) .
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; Non-clinical safety data reveal no special hazard for human base on conventional study of safety pharmacology , repeat-dose toxicity , genotoxicity , carcinogenic potential , and toxicity to reproduction .
& quot ;
& quot ; Lietuva BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; 5 .
& quot ;
& quot ; developmental toxicity , include dose-dependent delayed foetal ossification and possible teratogenic effect , be observe in rat at dos result in subtherapeutic exposure ( base on AUC ) and in rabbit at dos result in exposure 3 and 11 time the mean steady-state AUC at the maximum recommend clinical dose .
& quot ;
& quot ; in two large , open-label study , 2697 cancer patient receive non-platinum chemotherapy be include , 1895 with solid tumour ( 683 breast , 260 lung , 174 gynaecological , 300 gastro-intestinal , and 478 other tumour type ) and 802 with haematological malignancy .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; for storage condition of the reconstituted medicinal product , see section 6.3 .
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; 20 The recommend dose be 600 IU / kg epoetin alfa , give weekly for three week ( day 21 , 14 and 7 ) prior to surgery and on the day of surgery ( day 0 ) .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; BRISTOL-MYERS SQUIBB GESMBH Tel : + 43 1 60 14 30
& quot ;
& quot ; this medicinal product must not be administer by intravenous infusion , or mixed with other medicinal product .
& quot ;
& quot ; all patient be treat with epoetin alfa should receive adequate iron supplementation ( e. g. oral iron substitution of 200 mg Fe2 + daily ) throughout the course of epoetin alfa treatment .
& quot ;
& quot ; 14 .
& quot ;
& quot ; Maternal toxicity occur at dos similar to those elicit developmental toxicity .
& quot ;
& quot ; if epoetin alfa be give concomitantly with cyclosporin , blood level of cyclosporin should be monitor and the dose of cyclosporin adjust a the haematocrit rise .
& quot ;
& quot ; there be no progressive reduction of bone turnover marker with repeated annual dosing .
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; Abilify
& quot ;
& quot ; the incidence of bone marrow fibrosis be not increase in a study of haemodialysis patient who be treat with epoetin alfa for 3 year compare to a match control group of dialysis patient who have not be treat with epoetin alfa . ) .
& quot ;
& quot ; Antibody-mediated erythroblastopenia ( PRCA ) have be report after month to year of treatment with epoetin alfa .
& quot ;
& quot ; in most case , the ferritin value in the serum fall simultaneously with the rise in packed cell volume .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; an investigational study ( best study ) in woman with metastatic breast cancer be design to determine whether epoetin alfa treatment that extend beyond the correction of anaemia could improve treatment outcome .
& quot ;
& quot ; this medicinal product contain le than 1 mmol sodium ( 23 mg ) per dose , I. e. essentially “ sodium- free ” .
& quot ;
& quot ; Aripiprazole be widely distribute throughout the body with an apparent volume of distribution of 4.9 l / kg , indicate extensive extravascular distribution .
& quot ;
& quot ; how to store ABILIFY 6 .
& quot ;
& quot ; 100 ml
& quot ;
& quot ; before you take ABILIFY
& quot ;
& quot ; ABILIFY be not approve for the treatment of dementia-related psychosis .
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; Non-specific skin rash have be describe in association with epoetin alfa .
& quot ;
& quot ; 2 year
& quot ;
& quot ; patient should be advise to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole .
& quot ;
& quot ;
& quot ; 10 .
& quot ;
& quot ; Epoetin alfa should be administer by the subcutaneous route to patient with anaemia ( e. g. haemoglobin concentration ≤ 10 g / dl ( 6.2 mmol / l ) .
& quot ;
& quot ; close supervision of high-risk patient should accompany antipsychotic therapy .
& quot ;
& quot ; Intravenous use
& quot ;
& quot ; 6 .
& quot ;
& quot ; Overdose of epoetin alfa may produce effect that be extension of the pharmacological effect of the hormone .
& quot ;
& quot ; animal study could not exclude potential developmental toxicity ( see section 5.3 ) .
& quot ;
& quot ; close supervision of high-risk patient should accompany antipsychotic therapy .
& quot ;
& quot ; if an elevate ( or rise ) serum potassium level be detect then consideration should be give to cease epoetin alfa administration until hyperkalaemia have be correct .
& quot ;
& quot ; in clinical trial with aripiprazole , there be no significant difference in the incidence rate of hyperglycaemia-related adverse event ( include diabetes ) or in abnormal glycaemia laboratory value compare to placebo .
& quot ;
& quot ; child and adolescent ABILIFY be not for use in child and adolescent a it have not be study in patient under 18 year .
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; all other cause of anaemia ( iron deficiency , haemolysis , blood loss , vitamin B12 or folate deficiency ) should be consider and treat prior to initiate therapy with epoetin alfa .
& quot ;
& quot ; * This data be base on Clinical study Report :
& quot ;
& quot ; you should check with your doctor or pharmacist if you be not sure .
& quot ;
& quot ; the therapeutic margin of epoetin alfa be very wide .
& quot ;
& quot ; statement OF active substance ( s )
& quot ;
& quot ; for any information about this medicine , please contact the local representative of the marketing authorisation holder :
& quot ;
& quot ; if anti-erythropoietin , antibody-mediated PRCA be suspect , therapy with Abseamed should be discontinue immediately .
& quot ;
& quot ; in animal study , epoetin alfa have be show to decrease foetal body weight , delay ossification and increase foetal mortality when give in weekly dos of approximately 20 time the recommended human weekly dose .
& quot ;
& quot ; precise risk estimate for hyperglycaemia-related adverse event in patient treat with ABILIFY and with other atypical antipsychotic agent be not available to allow direct comparison .
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; Excipient :
& quot ;
& quot ; in one 3-week , fixed-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole fail to demonstrate superior efficacy to placebo .
& quot ;
& quot ; the frequency of these event be consider not know ( can not be estimate from the available data ) .
& quot ;
& quot ; the extent to which these outcome might apply to the administration of recombinant human erythropoietin to patient with cancer , treat with chemotherapy to achieve haemoglobin concentration le than 13 g / dl , be unclear because few patient with these characteristic be include in the data reviewed .
& quot ;
& quot ; maintenance dose between 17 and 33 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; Abraxane have minor or moderate influence on the ability to drive and use machine .
& quot ;
& quot ; however , little information in patient over 75 year be available a only 3 patient over 75 year of age where include in the pharmacokinetic analysis .
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; Sodium dihydrogen phosphate dihydrate Disodium phosphate dihydrate Sodium chloride Glycine Polysorbate 80 water for injection Hydrochloric acid ( for pH-adjustment ) Sodium hydroxide ( for pH-adjustment )
& quot ;
& quot ; Dialysis prescription may have to be adjust periodically to maintain urea , creatinine and potassium in the desired range .
& quot ;
& quot ; gender :
& quot ;
& quot ; 5 .
& quot ;
& quot ; or Hb increase ≥ 1 g / d
& quot ;
& quot ; 1 pre-filled syringe of 0.4 ml 6 pre-filled syrinx of 0.4 ml
& quot ;
& quot ; 5 mg / ml
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; 8 .
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; read all of this leaflet carefully before you start take this medicine .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; expiry date
& quot ;
& quot ; treatment of anaemia and reduction of transfusion requirement in adult patient receive chemotherapy for solid tumour , malignant lymphoma or multiple myeloma , and at risk of transfusion a assess by the patient & apos ; s general status ( e. g. cardiovascular status , pre-existing anaemia at the start of chemotherapy ) .
& quot ;
& quot ; Abseamed be a sterile but unpreserved product and be for single use only .
& quot ;
& quot ; the rate of increase in haemoglobin should be approximately 1 g / dl
& quot ;
& quot ; 8 It have be propose that aripiprazole ’ s efficacy in schizophrenia and Bipolar I Disorder be mediate through a combination of partial agonism at dopamine D2 and serotonin 5HT1a receptor and antagonism of serotonin 5HT2a receptor .
& quot ;
& quot ; EMEA / H / C / 595
& quot ;
& quot ; the potentially medically serious sign and symptom report included somnolence , transient loss of consciousness and extrapyramidal symptom .
& quot ;
& quot ; immune system disorder :
& quot ;
& quot ; the total body clearance be 5.04 ± 2.5 l / h , independent of dose , and unaffected by gender , age , race or body weight .
& quot ;
& quot ; although there be no information on the effect of haemodialysis in treat an overdose with aripiprazole , haemodialysis be unlikely to be useful in overdose management since aripiprazole be highly bind to plasma protein .
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; generally , child under 30 kg require higher maintenance dos than child over 30 kg and adult .
& quot ;
& quot ; 2 .
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; dose ( IU / kg give 3x / week )
& quot ;
& quot ; Paclitaxel be suspect to cause serious birth defect when administer during pregnancy .
& quot ;
& quot ; le than 1 % of unchanged aripiprazole be excrete in the urine and approximately 18 % be recover unchanged in the faeces .
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6 g / dl or & lt ; 3.75 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 8 g / dl or & gt ; 5 mmol / l ) .
& quot ;
& quot ; justification for not include braille accept .
& quot ;
& quot ; in two 12-week , placebo- and active-controlled monotherapy trial in patient with a manic or mixed episode of Bipolar I Disorder , with or without psychotic feature , aripiprazole demonstrate superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12 .
& quot ;
& quot ; general
& quot ;
& quot ; the maximum daily dose should not exceed 30 mg .
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; ABILIFY dose should be reduce to approximately one-half of it prescribed dose when concomitant administration of ABILIFY with quinidine occurs .
& quot ;
& quot ; the therapeutic margin of epoetin alfa be very wide .
& quot ;
& quot ; Renal disease :
& quot ;
& quot ; a slower injection be preferable in patient who react to the treatment with “ flu-like ” symptom .
& quot ;
& quot ; repeat dose do not lead to further reduction of bone turnover marker .
& quot ;
& quot ; the amount inject in any one place should not normally exceed one mililitre ( 1 ml ) .
& quot ;
& quot ; if you experience headache , particularly sudden , stab migraine-like headache or feel confuse or have fit , tell your doctor immediately .
& quot ;
& quot ; like all medicine , ABILIFY can cause side effect , although not everybody get them .
& quot ;
& quot ; България BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; the injection be give in the thigh or the anterior abdominal wall .
& quot ;
& quot ; you should check with your doctor or pharmacist if you be not sure .
& quot ;
& quot ; method of administration
& quot ;
& quot ; 3 elevate bone turnover be a characteristic of Paget ’ s disease of the bone .
& quot ;
& quot ; expiry date
& quot ;
& quot ; Epoetin alfa should be administer by the subcutaneous route to patient with anaemia ( e. g. haemoglobin concentration ≤ 10 g / dl ( 6.2 mmol / l ) .
& quot ;
& quot ; 14 .
& quot ;
& quot ; in a haloperidol-controlled trial , the proportion of responder patient maintain response to medicinal product at 52-weeks be similar in both group ( aripiprazole 77 % and haloperidol 73 % ) .
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; Abseamed 3000 IU / 0.3 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; there may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with epoetin alfa .
& quot ;
& quot ; Abilify
& quot ;
& quot ; there be not much experience with Abseamed in pregnant woman or woman who be breast-feeding .
& quot ;
& quot ; the target haemoglobin concentration in two study be & gt ; 13 g / dl ; in the remain three study it be 12 - 14 g / dl .
& quot ;
& quot ; however , the maximum daily dose of 30 mg should be use with caution in patient with severe hepatic impairment ( see section 5.2 ) .
& quot ;
& quot ; oral candidiasis , nasopharyngitis , cellulitis , herpes simplex , viral infection , pneumonia , catheter-related infection , fungal infection , herpes zoster , injection site infection Uncommon :
& quot ;
& quot ; jaundice , hepatitis , increase Alanine Aminotransferase ( ALT ) , increased Aspartate Aminotransferase ( AST ) , increase Gamma Glutamyl Transferase ( GGT ) , increase alkaline phosphatase
& quot ;
& quot ; treatment of anaemia and reduction of transfusion requirement in adult patient receive chemotherapy for solid tumour , malignant lymphoma or multiple myeloma , and at risk of transfusion a assess by the patient & apos ; s general status ( e. g. cardiovascular status , pre-existing anaemia at the start of chemotherapy ) .
& quot ;
& quot ; Administer the amount require .
& quot ;
& quot ; Abraxane may have substantially different pharmacological property compare to other paclitaxel formulation .
& quot ;
& quot ; Suomi / Finland OY BRISTOL-MYERS SQUIBB ( Finland ) AB Puh / Tel : + 358 9 251 21 230
& quot ;
& quot ; possible side effect 5 how to store ABILIFY 6 .
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; Hb between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; radiation therapy when administer to target a haemoglobin of greater than 14 g / dl ( 8.7 mmol / l ) ,
& quot ;
& quot ; EXP
& quot ;
& quot ; all special warning and precaution associate with autologous predonation programme , especially routine volume replacement , should be respect .
& quot ;
& quot ; Tel : + 39 06 50 39 61
& quot ;
& quot ; 82.4 year ; range :
& quot ;
& quot ; Erythropoietin be a growth factor that primarily stimulate red cell production .
& quot ;
& quot ; while on treatment , these patient should avoid invasive dental procedure if possible .
& quot ;
& quot ; a half-life of approximately 6 hour have be report in child .
& quot ;
& quot ; Thrombotic / vascular event , such a myocardial ischaemia , myocardial infarction , cerebrovascular accident ( cerebral haemorrhage and cerebral infarction ) , transient ischaemic attack , deep vein thrombosis , arterial thrombosis , pulmonary embolus , aneurysm , retinal thrombosis , and clotting of an artificial kidney have be report in patient receive erythropoietic agent , include patient receive epoetin alfa .
& quot ;
& quot ; 112 PARTICULARS to appear on the outer packaging
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; Dialysis prescription may have to be adjust periodically to maintain urea , creatinine and potassium in the desired range .
& quot ;
& quot ; 3 .
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; patient with active malignant disease receive neither chemotherapy nor radiation therapy .
& quot ;
& quot ; 185 minimum PARTICULARS to appear on small immediate packaging unit
& quot ;
& quot ; bottle ( PET )
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) , the dose should be reduce by approximately 25 to 50 % .
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; 3 Correction phase :
& quot ;
& quot ; България BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; Ísland VISTOR HF Sími : + 354 535 7000
& quot ;
& quot ; an increase relative risk of thromboembolic event ( RR 1.67 , 95 % CI :
& quot ;
& quot ; Orodispersible Tablet
& quot ;
& quot ; oral use
& quot ;
& quot ; potential for ABILIFY to affect other medicinal product :
& quot ;
& quot ; ABILIFY be use to treat adult who suffer from a condition with symptom such a feeling & quot ; & quot ; high & quot ; & quot ; , have excessive amount of energy , need much le sleep than usual , talk very quickly with race idea and sometimes severe irritability .
& quot ;
& quot ; the occurrence of suicidal behaviour be inherent in psychotic illness and mood disorder and in some case have be report early after initiation or switch of antipsychotic therapy , include treatment with aripiprazole ( see section 4.8 ) .
& quot ;
& quot ;
& quot ; the possibility of multiple medicinal product involvement should be consider .
& quot ;
& quot ; iron supplementation should be start a soon a possible , even several week prior to initiate the autologous predeposit , in order to achieve high iron store prior to start Abseamed therapy .
& quot ;
& quot ; 10 .
& quot ;
& quot ; 6 .
& quot ;
& quot ; 5 .
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole , the active metabolite , decrease by 32 % and 47 % .
& quot ;
& quot ; non response to epoetin alfa therapy may have the following cause : iron , folate , or vitamin B12 deficiency ; aluminium intoxication ; intercurrent infection ; inflammatory or traumatic episode ; occult blood loss ; haemolysis , and bone marrow fibrosis of any origin .
& quot ;
& quot ; 57 1 .
& quot ;
& quot ; ABILIFY be indicate for the treatment of schizophrenia .
& quot ;
& quot ; 6 .
& quot ;
& quot ; functional assessment of Cancer Therapy- Anaemia ( FACT-An ) general scale , FACT-An fatigue scale , and Cancer linear Analogue scale ( CLAS ) .
& quot ;
& quot ; in two 3-week , flexible-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole demonstrate superior efficacy to placebo in reduction of manic symptom over 3 week .
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be
& quot ;
& quot ; start dose of 50 IU / kg 3 time per week by the intravenous route , follow if necessary by a dose increase with 25 IU / kg increment ( 3 time per week ) until the desired goal be achieve ( this should be do in step of at least four week ) .
& quot ;
& quot ; during antipsychotic treatment , improvement in the patient & apos ; s clinical condition may take several day to some week .
& quot ;
& quot ; do not shake .
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ;
& quot ; Κύπρος ΑΚΗΣ ΠΑΝΑΓΙΩΤΟΥ & amp ; ΥΙΟΣ Ε .Π .Ε .
& quot ;
& quot ; further information
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; take ABILIFY with some medicine may need to change your dose of ABILIFY .
& quot ;
& quot ; Post-Marketing :
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg , Kuhloweg 37 , D-58638 Iserlohn , Germany
& quot ;
& quot ; general
& quot ;
& quot ; a dental examination with appropriate preventive dentistry should be consider prior to treatment with bisphosphonates in patient with concomitant risk factor ( e. g. cancer , chemotherapy , corticosteroid , poor oral hygiene ) .
& quot ;
& quot ; 121 PARTICULARS to appear on the outer packaging
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; Unopened vial :
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; 1 1 .
& quot ;
& quot ; Tel : + 351 21 440 70 00
& quot ;
& quot ; syncope , hypertension , thromboembolic event
& quot ;
& quot ; Post-Marketing :
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; - if the solution be cloudy or there be particle in it .
& quot ;
& quot ; therefore cardiovascular monitoring should be start immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmia .
& quot ;
& quot ; patient with renal impairment : no dosage adjustment be require in patient with renal impairment .
& quot ;
& quot ; each carton contain one single-use type I glass vial with a rubber butyl stopper and a & quot ; & quot ; flip-off & quot ; & quot ; aluminium seal .
& quot ;
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; 5 .
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; 12 .
& quot ;
& quot ; if blood pressure can not be control , epoetin alfa treatment should be discontinue .
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; how to STOREABILIFY
& quot ;
& quot ; 13 .
& quot ;
& quot ; adult surgery patient in an autologous predonation programme :
& quot ;
& quot ; 2 .
& quot ;
& quot ; ABILIFY may increase the effect of medicine use to lower the blood pressure .
& quot ;
& quot ; the maximum daily dose should not exceed 30 mg .
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; 7000 IU /
& quot ;
& quot ; base on laboratory assessment , transient asymptomatic calcium level below the normal reference range ( le than 2.10 mmol / l ) occur in 2.3 % of Aclasta-treated patient in a large clinical trial compare to 21 % of Aclasta-treated patient in the Paget ’ s disease trial .
& quot ;
& quot ; elderly patient with dementia-related psychosis :
& quot ;
& quot ; 1.35 , 2.06 , 35 trial and 6769 patient ) be observe in patient treat with recombinant human erythropoietin .
& quot ;
& quot ; Hyperkalaemia have be observe in isolated case .
& quot ;
& quot ; 2 .
& quot ;
& quot ; transferrin saturation be below 20 % .
& quot ;
& quot ; 3 .
& quot ;
& quot ; expiry date
& quot ;
& quot ; { MM / YYYY }
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of anaemia and of the symptom of anaemia .
& quot ;
& quot ; in three short-term ( 4 to 6 week ) placebo-controlled trial involve 1,228 schizophrenic patient , present with positive or negative symptom , aripiprazole be associate with statistically significantly greater improvement in psychotic symptom compare to placebo .
& quot ;
& quot ; in order to ensure optimum response to Abseamed adequate iron store should be ensure .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; syncope , hypertension , thromboembolic event
& quot ;
& quot ; in case of larger volume , more than one site should be choose for the injection .
& quot ;
& quot ; Vascular disorder :
& quot ;
& quot ; 1 .
& quot ;
& quot ; Hyperkalaemia have be observe in isolated case .
& quot ;
& quot ; Epoetin alfa IV / SC
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; 2 .
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; in animal study , epoetin alfa have be show to decrease foetal body weight , delay ossification and increase foetal mortality when give in weekly dos of approximately 20 time the recommended human weekly dose .
& quot ;
& quot ; patient must be appropriately hydrate prior to administration of Aclasta .
& quot ;
& quot ; content by weight , by volume or by unit
& quot ;
& quot ; programme , the use of epoetin alfa be not recommend .
& quot ;
& quot ; ask your doctor or pharmacist for advice before take ABILIFY .
& quot ;
& quot ; Schizophrenia - in a long term 52-week controlled trial , aripiprazole-treated patient have an overall-lower incidence ( 25.8 % ) of EPS include parkinsonism , akathisia , dystonia and dyskinesia compare with those treat with haloperidol ( 57.3 % ) .
& quot ;
& quot ; Metabolism :
& quot ;
& quot ; Pharmacovigilance system
& quot ;
& quot ; this mean that Abseamed be similar to a biological medicine that be already authorise in the European Union ( EU ) and contain the same active substance ( also know a the ‘ reference medicine ’ ) .
& quot ;
& quot ; 9 .
& quot ;
& quot ; if the haemoglobin increase be & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , increase the dose to 300 IU / kg 3 time per week .
& quot ;
& quot ; 7 Westferry circus , Canary Wharf , London E14 4HB , UK Tel .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; 51 patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; the therapeutic margin of epoetin alfa be very wide .
& quot ;
& quot ; the highest nontumorigenic exposure in female rat be 7 time the human exposure at the recommend dose .
& quot ;
& quot ; 6 pre-filled syrinx
& quot ;
& quot ; 13 .
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; in addition , case of stroke or & quot ; & quot ; mini & quot ; & quot ; stroke have be report .
& quot ;
& quot ; if you forget to take ABILIFY if you miss a dose , take the missed dose a soon a you remember but do not take two dos in one day .
& quot ;
& quot ; in patient treat with Aclasta , no osteomalacia , marrow fibrosis or weave bone formation be detect .
& quot ;
& quot ; it be hypothesise that this enhance transendothelial transport be mediate by the gp-60 albumin receptor , and that there be accumulation of paclitaxel in the area of tumour due to the albumin-binding protein SPARC ( secrete protein acidic rich in cysteine ) .
& quot ;
& quot ; Hypersensitivity reaction have be rarely report with epoetin alfa include isolated case of angioedema and anaphylactic reaction .
& quot ;
& quot ; these trial include patient with or without psychotic feature and with or without a rapid-cycling course .
& quot ;
& quot ; skin and subcutaneous tissue disorder :
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; outcome
& quot ;
& quot ; solution for infusion
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; data from 106 patient accrue in two single-arm open-label study and from 454 patient treat in a randomised phase III comparative study be available to support the use of Abraxane in metastatic breast cancer .
& quot ;
& quot ; each tablet contain 5 mg of aripiprazole .
& quot ;
& quot ; in controlled clinical study , use of Epoetin alfa and other erythropoiesis-stimulating agent ( ESAs ) have show :
& quot ;
& quot ; 3 year
& quot ;
& quot ; LABELLING AND package LEAFLET
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; the decision to administer recombinant erythropoietin should be base on a benefit-risk assessment with the participation of the individual patient , which should also take into account the specific clinical context .
& quot ;
& quot ; 4 .
& quot ;
& quot ; instruction on use
& quot ;
& quot ; Serum electrolytes should be monitor in chronic renal failure patient .
& quot ;
& quot ; at each step , the increase or reduction in dose should be of 25 IU / kg 3 time per week .
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; a with all growth factor , there be a concern that epoetins could stimulate the growth of tumour .
& quot ;
& quot ; after administration of epoetin alfa , the number of erythrocyte , the Hb value and reticulocyte count increase a well a the 59Fe-incorporation rate .
& quot ;
& quot ; Abseamed 5000 IU / 0.5 ml injection
& quot ;
& quot ; peripheral neuropathy , neuropathy , hypoaesthesia , paraesthesia .
& quot ;
& quot ; pure red Cell Aplasia ( PRCA ) Antibody-mediated PRCA have be very rarely report after month to year of subcutaneous erythropoietin treatment .
& quot ;
& quot ;
& quot ; long-term carcinogenicity study have not be carry out .
& quot ;
& quot ; BRISTOL-MYERS SQUIBB GESMBH Tel : + 43 1 60 14 30
& quot ;
& quot ; 2 .
& quot ;
& quot ; reproduction be authorise provide the source be acknowledge .
& quot ;
& quot ; Abseamed have the highest possible purity accord to the present state of the art .
& quot ;
& quot ; Malta Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; expiry date
& quot ;
& quot ; an increase 3H-thymidine incorporation in the erythroid nucleate spleen cell have be find in vitro ( mouse spleen cell culture ) after incubation with epoetin alfa .
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery
& quot ;
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; if you be an elderly patient suffer from dementia ( loss of memory and other mental ability ) , you or your carer / relative should tell your doctor if you have ever have a stroke or & quot ; & quot ; mini & quot ; & quot ; stroke .
& quot ;
& quot ; Aripiprazole should be use with caution in patient with known cardiovascular disease ( history of myocardial infarction or ischaemic heart disease , heart failure , or conduction abnormality ) , cerebrovascular disease , condition which would predispose patient to hypotension ( dehydration , hypovolemia , and treatment with antihypertensive medication ) or hypertension , include accelerate or malignant .
& quot ;
& quot ; Aripiprazole be the predominant medicinal product moiety in systemic circulation .
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; 15 .
& quot ;
& quot ; general
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; Tablet Round and pink , engrave with & quot ; & quot ; A-011 & quot ; & quot ; and & quot ; & quot ; 30 & quot ; & quot ; on one side .
& quot ;
& quot ; oral use
& quot ;
& quot ; at least one new vertebral fracture ( 0 – 1 year )
& quot ;
& quot ; in two 3-week , flexible-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole demonstrate superior efficacy to placebo in reduction of manic symptom over 3 week .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; market authorisation holder Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; 7.5 mg / ml
& quot ;
& quot ; EU / 1 / 04 / 276 / 004
& quot ;
& quot ; in schizophrenia patient the incidence of akathisia be 6.2 % with aripiprazole and 3.0 % with placebo .
& quot ;
& quot ; treatment of symptomatic anaemia in adult and paediatric chronic renal failure patient :
& quot ;
& quot ; 6 pre-filled syrinx
& quot ;
& quot ; in clinical trial and post-marketing experience , accidental or intentional acute overdosage of aripiprazole alone be identify in adult patient with report estimate dose up to 1,260 mg with no fatality .
& quot ;
& quot ; Abseamed 5000 IU / 0.5 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; Manic episodes in Bipolar I Disorder :
& quot ;
& quot ; 7 .
& quot ;
& quot ; mildly anaemic patient ( haematocrit of 33 - 39 % ) require predeposit of ≥ 4 unit of blood should be treat with Abseamed at a dose of 600 IU / kg body weight 2 time weekly for 3 week prior to surgery .
& quot ;
& quot ; it also prevent this condition from return in patient who have respond to the treatment with ABILIFY .
& quot ;
& quot ; invent name
& quot ;
& quot ; Conduction abnormality :
& quot ;
& quot ; special storage condition
& quot ;
& quot ; Intravenously administer zoledronic acid be eliminate by a triphasic process : rapid biphasic disappearance from the systemic circulation , with half-lives of t ½ α 0.24 and t ½ β 1.87 hour , follow by a long elimination phase with a terminal elimination half-life of t ½ γ 146 hour .
& quot ;
& quot ; the therapeutic margin of epoetin alfa be very wide .
& quot ;
& quot ; these increase in blood pressure can be treat with medicinal product .
& quot ;
& quot ; however , in one of these trial , a fixed-dose trial , there be a significant dose response relationship for cerebrovascular adverse event in patient treat with aripiprazole .
& quot ;
& quot ; Hypersensitivity : a with other medication hypersensitivity reaction , characterise by allergic symptom , may occur with aripiprazole ( see section 4.8 ) .
& quot ;
& quot ; Cardiac disorder :
& quot ;
& quot ; start dose of 50 IU / kg 2 time per week by the intravenous route .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery , with a baseline haemoglobin of 10 to 13 g / dl , the incidence of thrombotic / vascular event ( most of which be DVTs ) , in the overall patient population of the clinical trial , appear to be similar across the different epoetin alfa dose group and placebo group , although the clinical experience be limit .
& quot ;
& quot ; before you take ABILIFY 3 .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; Tel : + 40 ( 0 ) 21 272 16 00
& quot ;
& quot ; Manic episode :
& quot ;
& quot ; it may harm them , even if their symptom be the same a yours .
& quot ;
& quot ; Paclitaxel block the ability of cancer cell to break down their internal ‘ skeleton ’ that allow them to divide and multiply .
& quot ;
& quot ; usual maintenance dose 75 - 150 60 - 150 30 - 100
& quot ;
& quot ; Gloves , goggles and protective clothing should be use .
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; 93 1 .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; after first reconstitution :
& quot ;
& quot ; therefore , the CHMP ’ s view be that , a for Eprex / Erypo , the benefit outweigh the identified risk .
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; the doctor will order regular blood test to see that this be be achieve and to ensure that the haemoglobin value do not exceed a certain level .
& quot ;
& quot ; Antibody-mediated erythroblastopenia ( PRCA ) have be report after month to year of treatment with epoetin alfa .
& quot ;
& quot ; when the CYP3A4 or CYP2D6 inhibitor be withdraw from the combination therapy , aripiprazole dose should then be increase ( see section 4.5 ) .
& quot ;
& quot ; 3 .
& quot ;
& quot ; important information about some of the ingredient of ABILIFY patient who can not take phenylalanine should note that ABILIFY orodispersible tablet contain aspartame , which be a source of phenylalanine .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; the Committee decide that Abraxane ’ s benefit be greater than it risk for the treatment of metastatic breast cancer in patient who have fail first-line treatment for metastatic disease and for whom standard , anthracycline-containing therapy be not indicate .
& quot ;
& quot ; a rise in haemoglobin of greater than 2 g / dl ( 1.25 mmol / l ) over a four week period should be avoid .
& quot ;
& quot ; in addition , other cause of anaemia , such a vitamin B12 or folate deficiency , should be exclude before institute therapy with epoetin alfa .
& quot ;
& quot ; 4 .
& quot ;
& quot ; in a 26-week , placebo-controlled trial in stabilised patient with chronic schizophrenia , aripiprazole have significantly greater reduction in relapse rate , 34 % in aripiprazole group and 57 % in placebo .
& quot ;
& quot ; 158 do not open the blister until ready to administer .
& quot ;
& quot ; Hb between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; do not use ABILIFY after the expiry date which be state on the blister and on the carton .
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6 g / dl or & lt ; 3.75 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 8 g / dl or & gt ; 5 mmol / l ) .
& quot ;
& quot ; Polska BRISTOL-MYERS SQUIBB POLSKA SP .
& quot ;
& quot ; in the open-label study there be no difference in overall survival between patient treat with recombinant human erythropoietin and control .
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ;
& quot ; • condition or restriction regard supply AND use impose on the marketing authorisation holder
& quot ;
& quot ; elderly :
& quot ;
& quot ; 5 The frequency of undesirable effect list in table 1 be define use the following convention :
& quot ;
& quot ; 11 .
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; clear colourless solution
& quot ;
& quot ; 11 .
& quot ;
& quot ; precise risk estimate for hyperglycaemia-related adverse event in patient treat with ABILIFY and with other atypical antipsychotic agent be not available to allow direct comparison .
& quot ;
& quot ; patient treat with any antipsychotic agent , include ABILIFY , should be observe for sign and symptom of hyperglycaemia ( such a polydipsia , polyuria , polyphagia and weakness ) and patient with diabetes mellitus or with risk factor for diabetes mellitus should be monitor regularly for worsen of glucose control .
& quot ;
& quot ; in schizophrenia patient the incidence of akathisia be 6.2 % with aripiprazole and 3.0 % with placebo .
& quot ;
& quot ; Abseamed should be administer intravenously in order to increase haemoglobin to not greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; FOLDING box ( with blue box ) AND BOTTLE label for unit Pack
& quot ;
& quot ; 65 patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; Abilify be a medicine contain the active substance aripiprazole .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; the reconstituted suspension in the intravenous drip may be store for up to 8 hour at a temperature not above 25ºC .
& quot ;
& quot ; Elevations of CPK ( Creatine Phosphokinase ) , generally transient and asymptomatic , be observe in 3.5 % of aripiprazole treated patient a compare to 2.0 % of patient who receive placebo .
& quot ;
& quot ; 126 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; Abseamed can be use to increase the yield of autologous blood from patient in a predonation programme .
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; however , base on the publish literature , paclitaxel be a potentially carcinogenic and genotoxic agent at clinical dos , base upon it pharmacodynamic mechanism of action .
& quot ;
& quot ; 5 .
& quot ;
& quot ; in clinical trial aripiprazole have not be show to induce clinically relevant weight gain ( see section 5.1 ) .
& quot ;
& quot ; general disorder and administration site condition :
& quot ;
& quot ; Albumin be know to mediate endothelial transcytosis of plasma constituent and in vitro study demonstrate that the presence of albumin enhances transport of paclitaxel across endothelial cell .
& quot ;
& quot ; mildly anaemic patient ( haematocrit of 33 - 39 % ) require predeposit of ≥ 4 unit of blood should be treat with Abseamed at a dose of 600 IU / kg body weight 2 time weekly for 3 week prior to surgery .
& quot ;
& quot ; before you take ABILIFY 3 .
& quot ;
& quot ; Τηλ : + 357 22 677038
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; 5 .
& quot ;
& quot ; the occurrence of suicidal behaviour be inherent in psychotic illness and mood disorder and in some case have be report early after initiation or switch of antipsychotic therapy , include treatment with aripiprazole ( see section 4.8 ) .
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole increase by 77 % and 43 % , respectively .
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP3A4 ( ketoconazole ) increase aripiprazole AUC and Cmax by 63 % and 37 % , respectively .
& quot ;
& quot ; the following information be intend for medical or healthcare professional only :
& quot ;
& quot ; Hb between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; EU / 1 / 07 / 412 / 005 EU / 1 / 07 / 412 / 006
& quot ;
& quot ; Italia BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; Chronic renal failure patient
& quot ;
& quot ; information for the user
& quot ;
& quot ; there be no effect of a high fat meal on the pharmacokinetics of aripiprazole .
& quot ;
& quot ; 22 6.4 Special precaution for storage
& quot ;
& quot ; EXP
& quot ;
& quot ; this regress during the course of continued therapy .
& quot ;
& quot ; 11 .
& quot ;
& quot ; ABILIFY dose should be double when concomitant administration of ABILIFY occur with carbamazepine .
& quot ;
& quot ; skin and subcutaneous tissue disorder :
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; Medicines should not be dispose of via wastewater or household waste .
& quot ;
& quot ; the Committee recommend that Abilify be give market authorisation .
& quot ;
& quot ; Erythropoietin be a glycoprotein that stimulate , a a mitosis-stimulating factor and differentiate hormone , the formation of erythrocyte from precursor of the stem cell compartment .
& quot ;
& quot ; however , a with other antipsychotic , patient should be caution about operate hazardous machine , include motor vehicle , until they be reasonably certain that aripiprazole do not affect them adversely .
& quot ;
& quot ; interaction with receptor other than dopamine and serotonin subtypes may explain some of the other clinical effect of aripiprazole .
& quot ;
& quot ; - if the solution have be accidentally frozen .
& quot ;
& quot ; BLISTERS
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; Lactose monohydrate Maize starch Microcrystalline cellulose Hydroxypropyl cellulose Magnesium stearate
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; at steady state , dehydro-aripiprazole , the active metabolite , represent about 40 % of aripiprazole AUC in plasma .
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; ask your pharmacist how to dispose of medicine no longer require .
& quot ;
& quot ; once a syringe have be remove from the refrigerator and have reach room temperature ( up to 25 ° C ) it must either be use within 3 day or dispose of .
& quot ;
& quot ;
& quot ; ABILIFY 30 mg orodispersible tablet aripiprazole
& quot ;
& quot ; name OF the marketing authorisation holder
& quot ;
& quot ; only a few dos of ABILIFY solution for injection may be need .
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; no study on the effect on the ability to drive and use machine have be perform .
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and then reinstitute epoetin alfa therapy at a dose 25 % below the previous level .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; • other condition
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; - if the solution have be accidentally frozen .
& quot ;
& quot ; approximately 42 % of patient have a femoral neck BMD T-score below -2.5 and approximately 45 % of the patient have a femoral neck BMD T-score above -2.5 .
& quot ;
& quot ; Dialysis prescription may have to be adjust periodically to maintain urea , creatinine and potassium in the desired range .
& quot ;
& quot ; • condition or restriction regard supply AND use impose on the marketing authorisation holder
& quot ;
& quot ; Tel : + 370 5 2790 762
& quot ;
& quot ; the biological efficacy of epoetin alfa have be demonstrate in various animal model in vivo ( normal and anaemic rat , polycythaemic mouse ) .
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of anaemia and of the symptom of anaemia .
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6 g / dl or & lt ; 3.75 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 8 g / dl or & gt ; 5 mmol / l ) .
& quot ;
& quot ; 3 mental status and evidence of autonomic instability ( irregular pulse or blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
& quot ;
& quot ; Aripiprazole exhibit antagonist property in animal model of dopaminergic hyperactivity and agonist property in animal model of dopaminergic hypoactivity .
& quot ;
& quot ; Occlusion of the dialysis system be possible if heparinisation be not optimum .
& quot ;
& quot ; adult patient with renal insufficiency not yet undergoing dialysis :
& quot ;
& quot ; 3 .
& quot ;
& quot ; if epoetin alfa be give concomitantly with cyclosporin , blood level of cyclosporin should be monitor and the dose of cyclosporin adjust a the haematocrit rise .
& quot ;
& quot ; no dose adjustment be necessary in patient with creatinine clearance ≥ 35 ml / min .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Immunogenicity data for subcutaneous use of Abseamed in patient at risk for antibody-induced PRCA , I. e. patient with renal anaemia , be not sufficient .
& quot ;
& quot ; the pharmacokinetics of total paclitaxel follow 30- and 180-minute infusion of Abraxane at dose level of 80 to 375 mg / m2 be determine in clinical study .
& quot ;
& quot ; 7 .
& quot ;
& quot ; United Kingdom Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; general disorder and administration site condition :
& quot ;
& quot ; 6 pre-filled syrinx
& quot ;
& quot ; adult surgery patient in an autologous predonation programme :
& quot ;
& quot ; 1 .
& quot ;
& quot ; 147 9 .
& quot ;
& quot ; Medicinal product subject to restrict medical prescription ( see Annex I :
& quot ;
& quot ; no other erythropoietic therapy should be commence because of the risk of cross-reaction .
& quot ;
& quot ; Abseamed have no influence on the ability to drive and use machine .
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; after injection of the necessary amount of the solution from the pre-filled syringe , discard any remain content .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; Uncommon side effect ( greater than 1 in 1,000 , le than 1 in 100 patient ) some people may feel dizzy , especially when get up from a lying or sit position , or may experience a fast heart rate .
& quot ;
& quot ; Immunogenicity data for subcutaneous use of Abseamed in patient at risk for antibody-induced PRCA , I. e. patient with renal anaemia , be not sufficient .
& quot ;
& quot ; Intramuscular use read the package leaflet before use .
& quot ;
& quot ; ABILIFY 15 mg orodispersible tablet aripiprazole
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl or Hb increase ≥ 1 g / dl
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; - In chronic renal failure patient , epoetin alfa should be use in pregnancy only if the potential
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subject , nor be there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ;
& quot ; EPAR summary for the public
& quot ;
& quot ; treatment of patient with chemotherapy induce anaemia :
& quot ;
& quot ; Tel : + 39 06 50 39 61
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; it be recommend that the platelet count be regularly monitor during the first 8 week of therapy .
& quot ;
& quot ; Dysphagia : oesophageal dysmotility and aspiration have be associate with antipsychotic drug use , include ABILIFY .
& quot ;
& quot ; Nederland BRISTOL-MYERS SQUIBB BV Tel : + 31 34 857 42 22
& quot ;
& quot ; maintenance dose between 17 and 33 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; 9 .
& quot ;
& quot ; QT prolongation , ventricular arrhythmia , sudden unexplained death , cardiac arrest , torsades de pointes , bradycardia
& quot ;
& quot ; Abseamed
& quot ;
& quot ; if blood pressure can not be control , epoetin alfa treatment should be discontinue .
& quot ;
& quot ; Haemoglobin level should be measure on a regular basis until a stable level be achieve and periodically thereafter .
& quot ;
& quot ; QT prolongation , ventricular arrhythmia , sudden unexplained death , cardiac arrest , torsades de pointes , bradycardia
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; BATCH number
& quot ;
& quot ; it use in this indication must be balance against the report risk of thromboembolic event .
& quot ;
& quot ; 32 Hepatic disease :
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ; BATCH number
& quot ;
& quot ; - treatment of anaemia associate with chronic renal failure in paediatric and adult patient on
& quot ;
& quot ; read all of this leaflet carefully before you start use this medicine .
& quot ;
& quot ; the bioavailability of subcutaneous injectable epoetin alfa be much lower than that of the intravenous medicinal product : approximately 20 % .
& quot ;
& quot ; 6 .
& quot ;
& quot ; Epoetin alfa do not show any change in bacterial and mammalian cell culture mutagenicity test and an in vivo micronucleus test in mouse .
& quot ;
& quot ; therefore dialysis procedure may have to be adjust to maintain urea , creatinine and potassium in the desired range .
& quot ;
& quot ; Dosage adjustment to maintain haemoglobin concentration between 10 g / dl - 12 g / dl :
& quot ;
& quot ; Aclasta Placebo absolute reduction ( N = 1,065 ) ( N = 1,062 ) in fracture event
& quot ;
& quot ; oropharyngeal spasm , laryngospasm , aspiration pneumonia
& quot ;
& quot ; thus , no dosage adjustment be require for smoker .
& quot ;
& quot ; the four carbohydrate chain be attach via three N-glycosidic bond and one O-glycosidic bond to the protein .
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; 141 package LEAFLET :
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery should receive adequate antithrombotic prophylaxis , a thrombotic and vascular event may occur in surgical patient , especially in those with underlying cardiovascular disease .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; child and adolescent ABILIFY be not for use in child and adolescent a it have not be study in patient under 18 year .
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ;
& quot ; Epoetin alfa obtain by gene technology be glycosylated and be identical in it amino acid and carbohydrate composition to endogenous human erythropoietin that have be isolate from the urine of anaemic patient .
& quot ;
& quot ; any clinical fracture ( 1 ) Clinical vertebral fracture ( 2 ) Non-vertebral fracture ( 1 ) * p-value & lt ; 0.05 , * * p-value & lt ; 0.01
& quot ;
& quot ; name OF the MEDICINAL product AND route ( s ) OF administration
& quot ;
& quot ; base on result of a full range of standard genotoxicity test , aripiprazole be consider non-genotoxic .
& quot ;
& quot ; however , if the haemoglobin have increase & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , response to epoetin alfa therapy be unlikely and treatment should be discontinue .
& quot ;
& quot ; Dosage adjustment to maintain haemoglobin concentration between 10 g / dl - 12 g / dl :
& quot ;
& quot ; Abseamed
& quot ;
& quot ; the therapeutic margin of epoetin alfa be very wide .
& quot ;
& quot ; however , the maximum daily dose of 30 mg should be use with caution in patient with severe hepatic impairment ( see section 5.2 ) .
& quot ;
& quot ;
& quot ; the dose of Abilify should be adjust in patient who be take other medicine that be break down in the same way a Abilify .
& quot ;
& quot ; Luxembourg / Luxemburg BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; Thrombocytosis have be observe but it occurrence be very rare ( see section 4.4 ) .
& quot ;
& quot ; 2 .
& quot ;
& quot ; 2 .
& quot ;
& quot ; expiry date
& quot ;
& quot ; Abraxane be give over a 30 minute period .
& quot ;
& quot ; EU / 1 / 07 / 412 / 007 EU / 1 / 07 / 412 / 008
& quot ;
& quot ;
& quot ; Batch
& quot ;
& quot ; further information
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; follow a single oral dose of & # 91 ; 14C & # 93 ; -labelled aripiprazole , approximately 27 % of the administered radioactivity be recover in the urine and approximately 60 % in the faeces .
& quot ;
& quot ; try to take the ABILIFY tablet at the same time each day .
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subject , nor be there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; 3 year
& quot ;
& quot ; Gastrointestinal disorder :
& quot ;
& quot ; 13 .
& quot ;
& quot ; 10 .
& quot ;
& quot ; solution for injection in a pre-filled syringe ( injection )
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; leukopenia , neutropenia , thrombocytopenia
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; due to it α 1-adrenergic receptor antagonism , aripiprazole have the potential to enhance the effect of certain antihypertensive agent .
& quot ;
& quot ; care should be take to ensure that at the outset of the treatment patient be not iron deficient .
& quot ;
& quot ; some patient may benefit from a higher dose .
& quot ;
& quot ;
& quot ; all special warning and precaution associate with autologous predonation programme , especially routine volume replacement , should be respect .
& quot ;
& quot ; Hypertension may occur in epoetin alfa treat patient .
& quot ;
& quot ; for single use only .
& quot ;
& quot ; 49 of Cmax and AUC after carbamazepine co-administration be 69 % and 71 % lower , respectively , than those following treatment with aripiprazole alone .
& quot ;
& quot ; 26 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; the maximum daily dose should not exceed 30 mg .
& quot ;
& quot ; 4 June 2004
& quot ;
& quot ; 11 .
& quot ;
& quot ; 123 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; 2 .
& quot ;
& quot ; - if the seal be break .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; 109 an increase incidence of thrombotic vascular event ( see section 4.4 and section 4.8 - General ) have be observe in patient receive erythropoietic agent .
& quot ;
& quot ; it have be propose that aripiprazole ’ s efficacy in schizophrenia and Bipolar I Disorder be mediate through a combination of partial agonism at dopamine D2 and serotonin 5HT1a receptor and antagonism of serotonin 5HT2a receptor .
& quot ;
& quot ; seizure : in clinical trial , uncommon case of seizure be report during treatment with aripiprazole .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; Hb between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; 3 .
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; 4 .
& quot ;
& quot ; no evidence exist that indicate that treatment with epoetin alfa alter the metabolism of other medicinal product .
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; discontinue therapy
& quot ;
& quot ; the full EPAR for Abilify can be find here .
& quot ;
& quot ; Epoetin alfa obtain by gene technology be glycosylated and be identical in it amino acid and carbohydrate composition to endogenous human erythropoietin that have be isolate from the urine of anaemic patient .
& quot ;
& quot ; particular attention should be pay to sudden stab migraine- like headache a a possible warning signal .
& quot ;
& quot ; 1 pre-filled syringe
& quot ;
& quot ; table 1 :
& quot ;
& quot ; Aripiprazole orodispersible tablet be bioequivalent to aripiprazole tablet , with a similar rate and extent of absorption .
& quot ;
& quot ; - increase risk of death when administer to target a haemoglobin of 12 g / dl ( 7.5 mmol / l ) in
& quot ;
& quot ; 14 X 1
& quot ;
& quot ; close supervision of high-risk patient should accompany antipsychotic therapy .
& quot ;
& quot ; if haemoglobin have increase by at least 1 g / dl ( 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl above baseline after 4 week of treatment , the dose should remain at 150 IU / kg 3 time a week or 450 IU / kg once weekly .
& quot ;
& quot ; radiation therapy when administer to target a haemoglobin of greater than 14 g / dl ( 8.7 mmol / l ) ,
& quot ;
& quot ; patient treat with any antipsychotic agent , include ABILIFY , should be observe for sign and symptom of hyperglycaemia ( such a polydipsia , polyuria , polyphagia and weakness ) and patient with diabetes mellitus or with risk factor for diabetes mellitus should be monitor regularly for worsen of glucose control .
& quot ;
& quot ; Manic episodes in Bipolar I Disorder - in a 12-week controlled trial , the incidence of EPS be 23.5 % for aripiprazole-treated patient and 53.3 % for haloperidol-treated patient .
& quot ;
& quot ; Alopecia be observe in 90 % of the patient treat with Abraxane .
& quot ;
& quot ; Ελλάδα BRISTOL-MYERS SQUIBB A. e .
& quot ;
& quot ; Blood and the lymphatic system disorder :
& quot ;
& quot ; child and adolescent : there be no experience in child and adolescent under 18 year of age .
& quot ;
& quot ; 184 Deutschland BRISTOL-MYERS SQUIBB GMBH & amp ; CO .
& quot ;
& quot ; in one study , Abraxane be administer a a 30-minute infusion at a dose of 175 mg / m2 to 43 patient with metastatic breast cancer .
& quot ;
& quot ; other
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy male and female subject nor be there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; the follow undesirable effect occur more often ( ≥ 1 / 100 ) than placebo , or be identify a possibly medically relevant adverse reaction ( * ) in clinical trial with aripiprazole solution for injection ( see section 5.1 ) :
& quot ;
& quot ; - increase risk of death when administer to target a haemoglobin of 12 g / dl ( 7.5 mmol / l ) in
& quot ;
& quot ; ABILIFY solution for injection be indicate for the rapid control of agitation and disturbed behaviour in patient with schizophrenia or in patient with manic episode in Bipolar I Disorder , when oral therapy be not appropriate .
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl
& quot ;
& quot ; it stop the action of the osteoclast , the cell in the body that be involve in break down the bone tissue .
& quot ;
& quot ; when either valproate or lithium be administer concomitantly with aripiprazole , there be no clinically significant change in aripiprazole concentration .
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; detail information on this product be available on the website of the European Medicines Agency ( EMEA ) http : / / www . emea . europa . EU /
& quot ;
& quot ; EU / 1 / 04 / 276 / 015
& quot ;
& quot ; Surgery patient in autologous predonation programme
& quot ;
& quot ; Aripiprazole be the predominant medicinal product moiety in systemic circulation .
& quot ;
& quot ; Luxembourg / Luxemburg BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; 36 mental status and evidence of autonomic instability ( irregular pulse or blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
& quot ;
& quot ; at therapeutic concentration , aripiprazole and dehydro-aripiprazole be greater than 99 % bound to serum protein , bind primarily to albumin .
& quot ;
& quot ; take ABILIFY with food and drink ABILIFY can be take regardless of meal .
& quot ;
& quot ; 1 pre-filled syringe
& quot ;
& quot ; 1 .
& quot ;
& quot ; 153 even if you feel better , do not alter or discontinue the daily dose of ABILIFY without first consult your doctor .
& quot ;
& quot ; Blood pressure , pulse , respiratory rate and level of consciousness should be monitor regularly .
& quot ;
& quot ; the subcutaneous route of administration should be use .
& quot ;
& quot ; in clinical trial of aripiprazole , the incidence of QT prolongation be comparable to placebo .
& quot ;
& quot ; like all medicine , ABILIFY can cause side effect , although not everybody get them .
& quot ;
& quot ; in two 3-week , flexible-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole demonstrate superior efficacy to placebo in reduction of manic symptom over 3 week .
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and then reinstitute epoetin alfa therapy at a dose 25 % below the previous level .
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; Hepatobiliary disorder :
& quot ;
& quot ; the maximum daily dose should not exceed 30 mg .
& quot ;
& quot ; Schizophrenia :
& quot ;
& quot ; Medicines to correct heart rhythm Antidepressants or herbal remedy use to treat depression and anxiety Antifungal agent certain medicine to treat HIV infection Anticonvulsants use to treat epilepsy
& quot ;
& quot ; it have be propose that aripiprazole ’ s efficacy in schizophrenia and Bipolar I Disorder be mediate through a combination of partial agonism at dopamine D2 and serotonin 5HT1a receptor and antagonism of serotonin 5HT2a receptor .
& quot ;
& quot ; ask your doctor or pharmacist for advice before take ABILIFY .
& quot ;
& quot ; Lactation .
& quot ;
& quot ; follow subcutaneous injection , serum level of epoetin alfa be much lower than the level achieve follow intravenous injection , the level increase slowly and reach a peak between 12 and
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) , the dose should be reduce by approximately 25 to 50 % .
& quot ;
& quot ; or Hb increase ≥ 1 g / d
& quot ;
& quot ; it can be take with or without liquid .
& quot ;
& quot ; manufacture authorisation holder responsible for BATCH release
& quot ;
& quot ; in Paget ’ s disease the bone break down more quickly , and when it grow back , it be weaker than normal .
& quot ;
& quot ; Toxicologically significant effect be observe only at dos or exposure that be sufficiently in excess of the maximum human dose or exposure , indicate that these effect be limited or of no relevance to clinical use .
& quot ;
& quot ; instruction on use
& quot ;
& quot ; - oral iron substitution of 200 - 300 mg Fe2 + / day be recommend for all cancer patient whose
& quot ;
& quot ; statement OF active substance ( s )
& quot ;
& quot ; long-term carcinogenicity study have not be carry out .
& quot ;
& quot ; Pharmacotherapeutic group : antipsychotic , ATC code :
& quot ;
& quot ; usual maintenance dose 75 - 150 60 - 150 30 - 100
& quot ;
& quot ; the following reaction have also occur in isolated patient with normal or low blood pressure : hypertensive crisis with encephalopathy-like symptom ( e. g. headache and confused state ) and Generalised tonoclonal seizure , require the immediate attention of a physician and intensive medical care .
& quot ;
& quot ; there be no accumulation of the active substance in plasma after multiple dos give every 28 day .
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; 5 .
& quot ;
& quot ; the study either recruited patient who be be treat with chemotherapy ( two study ) or use patient population in which erythropoiesis stimulating agent be not indicate : anaemia in patient with cancer not receive chemotherapy , and head and neck cancer patient receive radiotherapy .
& quot ;
& quot ; the pre-filled syringe should not be shake .
& quot ;
& quot ; EU / 1 / 07 / 412 / 013
& quot ;
& quot ; 2 .
& quot ;
& quot ; Abilify
& quot ;
& quot ; 1 .
& quot ;
& quot ; there be conflict report in the literature regard whether erythropoietin may play a major role a tumour proliferators .
& quot ;
& quot ; Endocrine disorder :
& quot ;
& quot ; Hypersensitivity :
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ; treatment of patient with chemotherapy induce anaemia :
& quot ;
& quot ; 6 .
& quot ;
& quot ; the dose of ABILIFY oral solution must be measure use the calibrated cup or the 2 ml calibrate dropper supply in the carton .
& quot ;
& quot ; if anti-erythropoietin , antibody-mediated PRCA be suspect , therapy with Abseamed should be discontinue immediately .
& quot ;
& quot ; take ABILIFY with some medicine may need to change your dose of ABILIFY .
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; QT prolongation , ventricular arrhythmia , sudden unexplained death , cardiac arrest , torsades de pointes , bradycardia
& quot ;
& quot ; maintenance dose between 17 and 33 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; no other erythropoietic therapy should be commence because of the risk of cross-reaction .
& quot ;
& quot ; 17 10 .
& quot ;
& quot ; the effect of Abraxane ( give on it own ) be compare with those of a conventional paclitaxel- containing medicine ( give together with other medicine to reduce side effect ) .
& quot ;
& quot ; hyperglycaemia , diabetes mellitus , diabetic ketoacidosis , diabetic hyperosmolar coma
& quot ;
& quot ; it do not matter whether you take it with or without food .
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; BLISTERS
& quot ;
& quot ; ABILIFY 30 mg tablet aripiprazole
& quot ;
& quot ; other potent inhibitor of CYP2D6 , such a fluoxetine and paroxetine , may be expect to have similar effect and similar dose reduction should therefore be apply .
& quot ;
& quot ; patient with active malignant disease receive neither chemotherapy nor radiation therapy .
& quot ;
& quot ; the absolute oral bioavailability of the tablet formulation be 87 % .
& quot ;
& quot ; EU / 1 / 07 / 412 / 003
& quot ;
& quot ; EXP
& quot ;
& quot ; Slovenská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; Manic episode :
& quot ;
& quot ; Tel : + 420 221 016 111
& quot ;
& quot ; non response to epoetin alfa therapy may have the following cause : iron , folate , or vitamin B12 deficiency ; aluminium intoxication ; intercurrent infection ; inflammatory or traumatic episode ; occult blood loss ; haemolysis , and bone marrow fibrosis of any origin .
& quot ;
& quot ; treatment of anaemia and reduction of transfusion requirement in adult patient receive chemotherapy for solid tumour , malignant lymphoma or multiple myeloma , and at risk of transfusion a assess by the patient & apos ; s general status ( e. g. cardiovascular status , pre-existing anaemia at the start of chemotherapy ) .
& quot ;
& quot ; Manic episodes in Bipolar I Disorder :
& quot ;
& quot ; 4 .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; other finding :
& quot ;
& quot ; 12 g / dl )
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; LABELLING
& quot ;
& quot ; manufacturer Bristol-Myers Squibb S. r. l .
& quot ;
& quot ; the primary efficacy variable be the incidence of clinical fracture over the duration of the study .
& quot ;
& quot ; 7 .
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; Batch
& quot ;
& quot ; the rate of death in aripiprazole-treated patient be 3.5 % compare to 1.7 % in the placebo group .
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of anaemia and of the symptom of anaemia .
& quot ;
& quot ; 7 .
& quot ;
& quot ; these change be interpret a be secondary to decreased maternal body weight gain .
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of epilepsy and chronic liver failure .
& quot ;
& quot ; for any information about this medicinal product , please contact the local representative of the marketing authorisation holder :
& quot ;
& quot ; alternatively , the injection can be give at the end of the dialysis session via the fistula needle tubing , follow by 10 ml of isotonic saline to rinse the tubing and ensure satisfactory injection of the product into the circulation .
& quot ;
& quot ; Post-Marketing :
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; these trial include patient with or without psychotic feature and with or without a rapid-cycling course .
& quot ;
& quot ; detail information on this product be available on the website of the European Medicines Agency ( EMEA ) http : / / www . emea . europa . EU /
& quot ;
& quot ; - if the seal be break .
& quot ;
& quot ; the target haemoglobin concentration in two study be & gt ; 13 g / dl ; in the remain three study it be 12 - 14 g / dl .
& quot ;
& quot ; - treatment of severe anaemia of renal origin accompany by clinical symptom in adult patient
& quot ;
& quot ;
& quot ; in two 12-week , placebo- and active-controlled monotherapy trial in patient with a manic or mixed episode of Bipolar I Disorder , with or without psychotic feature , aripiprazole demonstrate superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12 .
& quot ;
& quot ; if you have any further question on the use of this product , ask your doctor or pharmacist .
& quot ;
& quot ; * Median time to disease progression & # 91 ; 95 % CI & # 93 ; ( week )
& quot ;
& quot ; kg Tel : + 49- ( 0 ) 2371 937 0
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; 181 minimum PARTICULARS to appear on small immediate packaging unit
& quot ;
& quot ; if you can not reach your doctor , go to the nearest hospital and take the Pack with you .
& quot ;
& quot ; in two large , open-label study , 2697 cancer patient receive non-platinum chemotherapy be include , 1895 with solid tumour ( 683 breast , 260 lung , 174 gynaecological , 300 gastro-intestinal , and 478 other tumour type ) and 802 with haematological malignancy .
& quot ;
& quot ; 1 bottle contain 5 mg zoledronic acid ( anhydrous ) .
& quot ;
& quot ; fracture incidence % ( CI )
& quot ;
& quot ; 8 .
& quot ;
& quot ; s R. O .
& quot ;
& quot ; each vial contain 100 mg of paclitaxel . • after reconstitution , each ml of suspension contains 5 mg of paclitaxel . • The other ingredient be human albumin ( contain sodium , sodium caprylate and N-acetyl DL tryptophanate ) .
& quot ;
& quot ; each ml of solution contain 10 000 IU of epoetin alfa * correspond to 84.0 microgram per ml 1 pre-filled syringe of 0.7 ml contains 7000 international unit ( IU ) correspond to 58.8 microgram epoetin alfa
& quot ;
& quot ; elimination :
& quot ;
& quot ; 6 pre-filled syrinx
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; - if the solution have be accidentally frozen .
& quot ;
& quot ; 14 .
& quot ;
& quot ; attention should be pay to sudden stab migraine-like headache a a possible warning signal .
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; priapism
& quot ;
& quot ; possible side effect 5 how to store ABILIFY 6 .
& quot ;
& quot ; the maximum dose should not exceed 200 IU / kg 3 time per week .
& quot ;
& quot ; iron supplementation should be start a soon a possible , even several week prior to initiate the autologous predeposit , in order to achieve high iron store prior to start Abseamed therapy .
& quot ;
& quot ; 181 tell the doctor or nurse if you feel dizzy or faint after the injection .
& quot ;
& quot ; enhance efficacy at dose higher than a daily dose of 15 mg have not be demonstrate although individual patient may benefit from a higher dose .
& quot ;
& quot ; Shunt thromboses may occur , especially in patient who have a tendency to hypotension or whose arteriovenous fistula exhibit complication ( e. g. stenosis , aneurysm , etc . ) .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; Deutschland BRISTOL-MYERS SQUIBB GMBH & amp ; CO .
& quot ;
& quot ; 117 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; distribution :
& quot ;
& quot ; and Hb increase & lt ; 1 g / dl
& quot ;
& quot ; Cancer patient
& quot ;
& quot ; lot
& quot ;
& quot ; elderly :
& quot ;
& quot ; benefit outweighs the potential risk to the foetus .
& quot ;
& quot ; in patient with chronic renal failure and clinically evident ischaemic heart disease or congestive heart failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration a recommend under section 4.2 .
& quot ;
& quot ; ABILIFY dose should be double when concomitant administration of ABILIFY occur with carbamazepine .
& quot ;
& quot ; Pharmacokinetics in special patient group
& quot ;
& quot ; base on in vitro study , CYP3A4 and CYP2D6 enzyme be responsible for dehydrogenation and hydroxylation of aripiprazole , and N-dealkylation be catalyse by CYP3A4 .
& quot ;
& quot ; this regress during the course of continued therapy .
& quot ;
& quot ; this be give by injection under the skin ( subcutaneously ) .
& quot ;
& quot ; expiry date
& quot ;
& quot ; important information about some of the ingredient of ABILIFY if you have be tell by your doctor that you have an intolerance to some sugar , contact your doctor before take this medicine .
& quot ;
& quot ; follow concomitant administration of carbamazepine , a potent inducer of CYP3A4 , the geometric mean of Cmax and AUC for aripiprazole be 68 % and 73 % lower , respectively , compare to when aripiprazole ( 30 mg ) be administer alone .
& quot ;
& quot ; speech disorder , Neuroleptic Malignant syndrome ( NMS ) , grand mal convulsion
& quot ;
& quot ; Excipients : sodium dihydrogen phosphate dihydrate , disodium phosphate dihydrate , sodium chloride , glycine , polysorbate 80 , hydrochloric acid ( for pH-adjustment ) , sodium hydroxide ( for pH-adjustment ) , and water for injection
& quot ;
& quot ; important information about some of the ingredient of Abseamed
& quot ;
& quot ; Measurement of serum calcium before infusion of Aclasta be recommend for patient with Paget ´ s disease .
& quot ;
& quot ; Thrombotic event can be a risk in this population and this possibility should be carefully weigh against the benefit to be derive from the treatment in this patient group .
& quot ;
& quot ; Tel : + 34 91 456 53 00
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; CNS metastasis be generally not well control by systemic chemotherapy .
& quot ;
& quot ; read all of this leaflet carefully before you start take this medicine .
& quot ;
& quot ; Latvija BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; the active substance in Abilify , aripiprazole , be an antipsychotic medicine .
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; infestation :
& quot ;
& quot ; in clinical trial with aripiprazole , there be no significant difference in the incidence rate of hyperglycaemia-related adverse event ( include diabetes ) or in abnormal glycaemia laboratory value compare to placebo .
& quot ;
& quot ; Zoledronic acid be eliminate by renal excretion .
& quot ;
& quot ; Magyarország BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ;
& quot ; do not shake .
& quot ;
& quot ; Abseamed can also lead to skin rash and flu-like symptom .
& quot ;
& quot ; 9 .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; 165 5 .
& quot ;
& quot ; further information
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ; - to minimise the risk of an increase in blood pressure .
& quot ;
& quot ; at each step , the increase or reduction in dose should be of 25 IU / kg 3 time per week .
& quot ;
& quot ; Blood and the lymphatic system disorder :
& quot ;
& quot ; 1.35 , 2.06 , 35 trial and 6769 patient ) be observe in patient treat with recombinant human erythropoietin .
& quot ;
& quot ; be sure to tell your doctor immediately if you be pregnant , think you may be pregnant , or if you be plan to become pregnant .
& quot ;
& quot ; Abraxane should not be administer until neutrophil count recover to & gt ; 1.5 X 109 / l .
& quot ;
& quot ; if after an additional 4 week of therapy at 300 IU / kg 3 time per week , the haemoglobin have increase ≥ 1 g / dl ( ≥ 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl the dose should remain at 300 IU / kg 3 time per week .
& quot ;
& quot ; 3 .
& quot ;
& quot ; Subcutaneous route
& quot ;
& quot ; care should be take to ensure that at the outset of the treatment patient be not iron deficient .
& quot ;
& quot ; Epoetin alfa obtain by gene technology be glycosylated and be identical in it amino acid and carbohydrate composition to endogenous human erythropoietin that have be isolate from the urine of anaemic patient .
& quot ;
& quot ; Syringes be emboss with graduation ring and the filling volume be indicate by a stick-on label in order to enable partial use if require .
& quot ;
& quot ; 16 .
& quot ;
& quot ; 9 229 patient treat with Abraxane in the randomized , control clinical trial be evaluate for safety .
& quot ;
& quot ; 9 .
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; 14 X 1 tablet 28 X 1 tablet 49 X 1 tablet 56 X 1 tablet 98 X 1 tablet
& quot ;
& quot ; in this leaflet :
& quot ;
& quot ; Tablet
& quot ;
& quot ; NMS be a potentially fatal symptom complex associate with antipsychotic medicinal product .
& quot ;
& quot ; general
& quot ;
& quot ; 6 .
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; further information
& quot ;
& quot ; the hip fracture event rate be 1.44 % for Aclasta-treated patient compare to 2.49 % for placebo-treated patient .
& quot ;
& quot ; Musculoskeletal and connective tissue disorder :
& quot ;
& quot ; store in the original package in order to protect from moisture .
& quot ;
& quot ; 3 .
& quot ;
& quot ; do not shake .
& quot ;
& quot ; when weak inhibitor of CYP3A4 ( e. g . , diltiazem or escitalopram ) or CYP2D6 be use concomitantly with ABILIFY , modest increase in aripiprazole concentration might be expect .
& quot ;
& quot ; EU number
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; solution for injection in a pre-filled syringe .
& quot ;
& quot ; Tardive Dyskinesia : in clinical trial of one year or le duration , there be uncommon report of treatment emergent dyskinesia during treatment with aripiprazole .
& quot ;
& quot ; only use each syringe for one injection .
& quot ;
& quot ; please tell your doctor or pharmacist .
& quot ;
& quot ; name OF the marketing authorisation holder
& quot ;
& quot ; Eesti BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; weight gain : weight gain be commonly see in schizophrenic and bipolar mania patient due to co- morbidity , use of antipsychotic know to cause weight gain , poorly manage life-style , and might lead to severe complication .
& quot ;
& quot ; 16 Posology
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; 1.0 ml ( 2000 IU / ml )
& quot ;
& quot ; manufacturer Bristol-Myers Squibb S. r. l .
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of the symptom of anaemia .
& quot ;
& quot ; in all patient receive epoetin alfa , blood pressure should be closely monitor and control a necessary .
& quot ;
& quot ; Aripiprazole be well absorb , with peak plasma concentration occur within 3-5 hour after dose .
& quot ;
& quot ; the recommended dosing regimen be describe in the following diagram :
& quot ;
& quot ; in several controlled study , epoetins have not be show to improve overall survival or decrease the risk of tumour progression in patient with anaemia associate with cancer .
& quot ;
& quot ; this summary be last updated in 12-2008 .
& quot ;
& quot ; be sure to tell your doctor if you take a medicine to keep your blood pressure under control .
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6 g / dl or & lt ; 3.75 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 8 g / dl or & gt ; 5 mmol / l ) .
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; if epoetin alfa be give concomitantly with cyclosporin , blood level of cyclosporin should be monitor and the dose of cyclosporin adjust a the haematocrit rise .
& quot ;
& quot ; 20 Women of childbearing age should use effective contraception during and up to 1 month after receive treatment with Abraxane .
& quot ;
& quot ; 92 8 .
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ;
& quot ; 91 observe in rat at dos result in subtherapeutic exposure ( base on AUC ) and in rabbit at dos result in exposure 3 and 11 time the mean steady-state AUC at the maximum recommend clinical dose .
& quot ;
& quot ; 4 .
& quot ;
& quot ; Blood and the lymphatic system disorder :
& quot ;
& quot ; patient with hepatic impairment : no dosage adjustment be require for patient with mild to moderate hepatic impairment .
& quot ;
& quot ; to prevent manic episode , the same dose should be continue .
& quot ;
& quot ; take ABILIFY with food and drink ABILIFY can be take regardless of meal .
& quot ;
& quot ; Shunt thromboses may occur , especially in patient who have a tendency to hypotension or whose arteriovenous fistula exhibit complication ( e. g. stenosis , aneurysm , etc . ) .
& quot ;
& quot ; Cerebrovascular adverse event : in the same trial , cerebrovascular adverse event ( e. g. stroke , transient ischaemic attack ) , include fatality , be report in patient ( mean age :
& quot ;
& quot ; adverse reaction report with Abraxane at any dose in clinical trial .
& quot ;
& quot ; Blood and the lymphatic system disorder :
& quot ;
& quot ; Ísland VISTOR HF Sími : + 354 535 7000
& quot ;
& quot ; in most of these patient , antibody to erythropoietin have be observe ( see section 4.3 and 4.4 – pure red Cell Aplasia )
& quot ;
& quot ; name OF the MEDICINAL product AND route ( s ) OF administration
& quot ;
& quot ; in case of larger volume , more than one site should be choose for the injection .
& quot ;
& quot ; 6 .
& quot ;
& quot ; Chronic renal failure patient
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery should receive adequate antithrombotic prophylaxis , a thrombotic and vascular event may occur in surgical patient , especially in those with underlying cardiovascular disease .
& quot ;
& quot ; if you have any further question , ask your doctor or pharmacist .
& quot ;
& quot ; 9 .
& quot ;
& quot ; thus , no dosage adjustment be require for smoker .
& quot ;
& quot ; 100 ml
& quot ;
& quot ; in all patient receive epoetin alfa , blood pressure should be closely monitor and control a necessary .
& quot ;
& quot ; the pre-filled syringe should not be shake .
& quot ;
& quot ; Aripiprazole and other antipsychotic drug should be use cautiously in patient at risk for aspiration pneumonia .
& quot ;
& quot ; this medicinal product contain le than 1 mmol sodium ( 23 mg ) per dose , I. e. essentially “ sodium- free ” .
& quot ;
& quot ; in most case , the ferritin value in the serum fall simultaneously with the rise in packed cell volume .
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; 2 .
& quot ;
& quot ; Abseamed 3000 IU / 0.3 ml solution for injection in a pre-filled syringe The syrinx contain 0.3 ml ( 3000 IU ) of solution .
& quot ;
& quot ; 13 .
& quot ;
& quot ; no other erythropoietic therapy should be commence because of the risk of cross-reaction .
& quot ;
& quot ; Tel : + 370 5 2790 762
& quot ;
& quot ; start dose of 50 IU / kg 3 time per week by the intravenous route , follow if necessary by a dose increase with 25 IU / kg increment ( 3 time per week ) until the desired goal be achieve ( this should be do in step of at least four week ) .
& quot ;
& quot ; Aripiprazole be widely distribute throughout the body with an apparent volume of distribution of 4.9 l / kg , indicate extensive extravascular distribution .
& quot ;
& quot ; - shorten overall survival and increase death attribute to disease progression at 4 month in
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; 9 .
& quot ;
& quot ; what be Abraxane use for ?
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; 6 .
& quot ;
& quot ; lot
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; 84 year ; range :
& quot ;
& quot ; Latvija BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; Abseamed
& quot ;
& quot ; alcohol should be avoid when take ABILIFY .
& quot ;
& quot ;
& quot ; if epoetin alfa be give concomitantly with cyclosporin , blood level of cyclosporin should be monitor and the dose of cyclosporin adjust a the haematocrit rise .
& quot ;
& quot ; Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance , a describe in version 1.0 present in Module 1.8.1. of the marketing authorisation , be in place and functioning before and whilst the product be on the market .
& quot ;
& quot ; further information
& quot ;
& quot ; for 4 week
& quot ;
& quot ; Epoetin alfa do not show any change in bacterial and mammalian cell culture mutagenicity test and an in vivo micronucleus test in mouse .
& quot ;
& quot ; ABILIFY be not approve for the treatment of dementia-related psychosis .
& quot ;
& quot ; the follow undesirable effect occur more often ( ≥ 1 / 100 ) than placebo , or be identify a possibly medically relevant adverse reaction ( * ) :
& quot ;
& quot ; 3 .
& quot ;
& quot ; in schizophrenia patient the incidence of akathisia be 6.2 % with aripiprazole and 3.0 % with placebo .
& quot ;
& quot ; Haematology :
& quot ;
& quot ; control clinical trial have not show significant benefit attributable to the administration of epoetins when haemoglobin concentration be increase beyond the level necessary to control symptom of anaemia and to avoid blood transfusion .
& quot ;
& quot ; ABILIFY dose should be reduce to approximately one-half of it prescribed dose when concomitant administration of ABILIFY with quinidine occurs .
& quot ;
& quot ; Belgique / België / Belgien BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; when consider concomitant administration of ketoconazole or other potent CYP3A4 inhibitor with ABILIFY , potential benefit should outweigh the potential risk to the patient .
& quot ;
& quot ; however , the
& quot ;
& quot ; oral use
& quot ;
& quot ; Teл . : + 359 800 12 400
& quot ;
& quot ; base on in vitro study , CYP3A4 and CYP2D6 enzyme be responsible for dehydrogenation and hydroxylation of aripiprazole , and N-dealkylation be catalyse by CYP3A4 .
& quot ;
& quot ; at steady state , dehydro-aripiprazole , the active metabolite , represent about 40 % of aripiprazole AUC in plasma .
& quot ;
& quot ; Blood and the lymphatic system disorder :
& quot ;
& quot ; take ABILIFY with some medicine may need to change your dose of ABILIFY .
& quot ;
& quot ; instruction on use
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; Abseamed 2000 IU / 1 ml solution for injection in a pre-filled syringe The syrinx contain 1 ml ( 2000 IU ) of solution .
& quot ;
& quot ; EU / 1 / 05 / 308 / 002
& quot ;
& quot ; however , a with other antipsychotic , patient should be caution about operate hazardous machine , include motor vehicle , until they be reasonably certain that aripiprazole do not affect them adversely .
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; the infusion time must not be le than 15 minute .
& quot ;
& quot ; in chronic renal failure patient Abseamed have not to be administer subcutaneously !
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Suicidal thought and behaviour have be report during aripiprazole treatment .
& quot ;
& quot ; Abseamed 3000 IU / 0.3 ml injection
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; BATCH number
& quot ;
& quot ; Luxembourg / Luxemburg BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; it may harm them , even if their symptom be the same a yours .
& quot ;
& quot ; Phlebotomy may be perform if excessively high haemoglobin level occur .
& quot ;
& quot ; in the pooled result , a similar decrease in pain severity and pain interference score relative to baseline be observe over 6 month for Aclasta and risedronate .
& quot ;
& quot ; store in the original package in order to protect from moisture .
& quot ;
& quot ; Dystocia be observe at the lowest dose ( 0.01 mg / kg body weight ) test in rat .
& quot ;
& quot ; in clinical study , 10-30 mg / day dos of aripiprazole have no significant effect on the metabolism of substrate of CYP2D6 ( dextromethorphan / 3-methoxymorphinan ratio ) , 2C9 ( warfarin ) , 2C19 ( omeprazole ) , and 3A4 ( dextromethorphan ) .
& quot ;
& quot ; many have sign of local infection include osteomyelitis .
& quot ;
& quot ; when use to treat schizophrenia , Abilify be more effective than placebo in the short-term study .
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; Elevations of CPK ( Creatine Phosphokinase ) , generally transient and asymptomatic , be observe in 3.5 % of aripiprazole treated patient a compare to 2.0 % of patient who receive placebo .
& quot ;
& quot ; the most frequent adverse reaction during treatment with epoetin alfa be a dose-dependent increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ; 8 ( 0.62 mmol / l ) per month and should not exceed 2 g / dl ( 1.25 mmol / l ) per month to minimise risk of an increase in hypertension .
& quot ;
& quot ; it do not matter whether you take it with or without food .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; package size
& quot ;
& quot ; Abraxane be use for the treatment of breast cancer when other therapy have be try but have not work and if you be unsuitable for anthracycline containing treatment .
& quot ;
& quot ; start dose of 50 IU / kg 3 time per week by the intravenous route , follow if necessary by a dose increase with 25 IU / kg increment ( 3 time per week ) until the desired goal be achieve ( this should be do in step of at least four week ) .
& quot ;
& quot ; the mean total clearance be 15 l / hr / m2 .
& quot ;
& quot ; in clinical study , 10-30 mg / day dos of aripiprazole have no significant effect on the metabolism of substrate of CYP2D6 ( dextromethorphan / 3-methoxymorphinan ratio ) , 2C9 ( warfarin ) , 2C19 ( omeprazole ) , and 3A4 ( dextromethorphan ) .
& quot ;
& quot ; 2 .
& quot ;
& quot ; this correspond to a 96 % reduction of risk of relapse in Aclasta versus risedronate-treated patient .
& quot ;
& quot ; close supervision of high-risk patient should accompany antipsychotic therapy .
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; neither freeze nor refrigeration adversely affect the stability of the product .
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of the symptom of anaemia .
& quot ;
& quot ; Nederland BRISTOL-MYERS SQUIBB BV Tel : + 31 34 857 42 22
& quot ;
& quot ; in three short-term ( 4 to 6 week ) placebo-controlled trial involve 1,228 schizophrenic patient , present with positive or negative symptom , aripiprazole be associate with statistically significantly greater improvement in psychotic symptom compare to placebo .
& quot ;
& quot ; instruction on use
& quot ;
& quot ; Z O. O .
& quot ;
& quot ; if haemoglobin have increase by at least 1 g / dl ( 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl above baseline after 4 week of treatment , the dose should remain at 150 IU / kg 3 time a week or 450 IU / kg once weekly .
& quot ;
& quot ; Erythropoietin be a growth factor that primarily stimulate red cell production .
& quot ;
& quot ; Aripiprazole be well absorb , with peak plasma concentration occur within 3-5 hour after dose .
& quot ;
& quot ; the effect of the infusion last for a year or more .
& quot ;
& quot ; Hypertension may occur in epoetin alfa treat patient .
& quot ;
& quot ; in clinical trial , an increase risk of death and serious cardiovascular event be observe when erythropoiesis stimulate agent ( ESAs ) be administer to target a haemoglobin of greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ;
& quot ; 4 .
& quot ;
& quot ; a with all bisphosphonates , patient take Aclasta may also be at risk of kidney problem , reaction at the site of infusion and osteonecrosis ( death of bone tissue ) in the jaw .
& quot ;
& quot ; Haemoglobin variability should be address through dose management , with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; in the indication “ increase the yield of autologous blood ” : myocardial infarction or stroke in the month precede treatment , unstable angina pectoris , increase risk of deep venous thrombosis such a history of venous thromboembolic disease .
& quot ;
& quot ; & quot ; & quot ; Flu-like & quot ; & quot ; symptom such a headache , joint pain , feeling of weakness , dizziness , and tiredness may occur , especially at the start of treatment .
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; if you forget to take ABILIFY if you miss a dose , take the missed dose a soon a you remember but do not take two dos in one day .
& quot ;
& quot ; EU / 1 / 04 / 276 / 024
& quot ;
& quot ; España BRISTOL-MYERS SQUIBB , S. A .
& quot ;
& quot ; Elevations of CPK ( Creatine Phosphokinase ) , generally transient and asymptomatic , be observe in 3.5 % of aripiprazole treated patient a compare to 2.0 % of patient who receive placebo .
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of epilepsy and chronic liver failure .
& quot ;
& quot ;
& quot ; Antibody-mediated erythroblastopenia ( PRCA ) have be report after month to year of treatment with epoetin alfa .
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; Shunt thromboses may occur , especially in patient who have a tendency to hypotension or whose arteriovenous fistula exhibit complication ( e. g. stenosis , aneurysm , etc . ) .
& quot ;
& quot ; however , your doctor may decide that it be right for you to learn how to inject Abseamed under the skin yourself .
& quot ;
& quot ;
& quot ; rhabdomyolysis , myalgia , stiffness
& quot ;
& quot ; in particular , no residue of the cell line use for the production be detectable at the concentration of the active ingredient that be use in human .
& quot ;
& quot ; Italia BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; for prevent recurrence of manic episode in patient who have be receive aripiprazole , continue therapy at the same dose .
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; priapism
& quot ;
& quot ; after administration of epoetin alfa , the number of erythrocyte , the Hb value and reticulocyte count increase a well a the 59Fe-incorporation rate .
& quot ;
& quot ; alternatively , disperse the tablet in water and drink the resulting suspension .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; particular attention should be pay to sudden stab migraine- like headache a a possible warning signal .
& quot ;
& quot ; in osteoporosis , Aclasta be more effective than placebo at reduce the number of fracture .
& quot ;
& quot ; 12 g / dl )
& quot ;
& quot ; in schizophrenia patient the incidence of akathisia be 6.2 % with aripiprazole and 3.0 % with placebo .
& quot ;
& quot ; it be not know if paclitaxel be excrete in human milk .
& quot ;
& quot ; base on in vitro study , CYP3A4 and CYP2D6 enzyme be responsible for dehydrogenation and hydroxylation of aripiprazole , and N-dealkylation be catalyse by CYP3A4 .
& quot ;
& quot ; it be recommend that the platelet count be regularly monitor during the first 8 week of therapy .
& quot ;
& quot ; Pharmacotherapeutic group : antianaemic , ATC code :
& quot ;
& quot ; the recommended dosing regimen be describe in the following diagram :
& quot ;
& quot ; other
& quot ;
& quot ; the following adverse event have be report during post-marketing surveillance .
& quot ;
& quot ; 7 .
& quot ;
& quot ; BLISTER
& quot ;
& quot ; a gastric acid blocker , the H2 antagonist famotidine , reduces aripiprazole rate of absorption but this effect be deem not clinically relevant .
& quot ;
& quot ; Teл . : + 359 800 12 400
& quot ;
& quot ; Dialysis prescription may have to be adjust periodically to maintain urea , creatinine and potassium in the desired range .
& quot ;
& quot ; 126 for the purpose of ambulatory use , the patient may remove Abseamed from the refrigerator and store it not above 25 ° C for one single period of up to 3 day .
& quot ;
& quot ;
& quot ; general
& quot ;
& quot ; 8 .
& quot ;
& quot ; Κύπρος ΑΚΗΣ ΠΑΝΑΓΙΩΤΟΥ & amp ; ΥΙΟΣ Ε .Π .Ε .
& quot ;
& quot ; follow concomitant administration of carbamazepine , a potent inducer of CYP3A4 , the geometric mean of Cmax and AUC for aripiprazole be 68 % and 73 % lower , respectively , compare to when aripiprazole ( 30 mg ) be administer alone .
& quot ;
& quot ; patient treat with any antipsychotic agent , include ABILIFY , should be observe for sign and symptom of hyperglycaemia ( such a polydipsia , polyuria , polyphagia and weakness ) and patient with diabetes mellitus or with risk factor for diabetes mellitus should be monitor regularly for worsen of glucose control .
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; adult surgery patient in an autologous predonation programme :
& quot ;
& quot ; 9 .
& quot ;
& quot ; in order to ensure optimum response to epoetin alfa , adequate iron store should be assure :
& quot ;
& quot ; 16 .
& quot ;
& quot ; Clinical manifestation of NMS be hyperpyrexia , muscle rigidity , alter mental status and evidence of autonomic instability ( irregular pulse or blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ; in a long term 26-week placebo-controlled trial , the incidence of EPS be 19 % for aripiprazole-treated patient and 13.1 % for placebo-treated patient .
& quot ;
& quot ; Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel : + 353 ( 1 800 ) 749 749
& quot ;
& quot ; similarly , for dehydro-aripiprazole the geometric mean
& quot ;
& quot ; Aripiprazole dose range from 0.5 to 30 mg administer once a day to healthy subject for 2 week produce a dose-dependent reduction in the binding of 11C-raclopride , a D2 / D3 receptor ligand , to the caudate and putamen detect by positron emission tomography .
& quot ;
& quot ; 2 .
& quot ;
& quot ; when see , it be usually in those with significant risk factor such a history of diabetes , thyroid disorder or pituitary adenoma .
& quot ;
& quot ; 78-88 year ) .
& quot ;
& quot ; take other medicine please tell your doctor or pharmacist if you be take or have recently take any other medicine , include medicine obtain without a prescription .
& quot ;
& quot ; oral use .
& quot ;
& quot ; be sure to tell your doctor immediately if you be pregnant , think you may be pregnant , or if you be plan to become pregnant .
& quot ;
& quot ; weight gain : in clinical trial oral aripiprazole have not be show to induce clinically relevant weight gain .
& quot ;
& quot ; driving and use machine do not drive or use any tool or machine , until you know how ABILIFY affect you .
& quot ;
& quot ;
& quot ; give the primary CNS effect of aripiprazole , caution should be use when aripiprazole be take in combination with alcohol or other CNS medicinal product with overlap undesirable effect such a sedation ( see section 4.8 ) .
& quot ;
& quot ; it use in this indication must be balance against the report risk of thromboembolic event .
& quot ;
& quot ; seizure : in clinical trial , uncommon case of seizure be report during treatment with aripiprazole .
& quot ;
& quot ; and Hb increase & lt ; 1 g / dl
& quot ;
& quot ; 4 .
& quot ;
& quot ; 16.1 & # 91 ; 15.0 , 18.3 & # 93 ; ( n = 135 )
& quot ;
& quot ; Hepatobiliary disorder :
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl and Hb increase & lt ; 1 g / dl
& quot ;
& quot ; the inter- and intra-subject variation for plasma clearance of zoledronic acid be show to be 36 % and 34 % , respectively .
& quot ;
& quot ; why have Aclasta be approve ?
& quot ;
& quot ; skin and subcutaneous tissue disorder :
& quot ;
& quot ; Aripiprazole do not impair fertility in reproductive toxicity study .
& quot ;
& quot ; ABILIFY be effective in a dose range of 10 to 30 mg / day .
& quot ;
& quot ; patient ) be recommend for chronic renal failure patient whose serum ferritin level be below 100 ng / ml
& quot ;
& quot ; name OF the marketing authorisation holder
& quot ;
& quot ; severe and occasionally incapacitate bone , joint and / or muscle pain have be infrequently report in patient take bisphosphonates , include Aclasta .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery , with a baseline haemoglobin of 10 to 13 g / dl , the incidence of thrombotic / vascular event ( most of which be DVTs ) , in the overall patient population of the clinical trial , appear to be similar across the different epoetin alfa dose group and placebo group , although the clinical experience be limit .
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ; 2 patient with hepatic impairment :
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; Hyperkalaemia have be observe in isolated case .
& quot ;
& quot ; 1 pre-filled syringe of 0.6 ml 6 pre-filled syrinx of 0.6 ml
& quot ;
& quot ; for the treatment of Paget ’ s disease , Aclasta should be prescribe only by physician with experience in treatment of Paget ’ s disease of the bone .
& quot ;
& quot ; 14 .
& quot ;
& quot ; adult surgery patient in an autologous predonation programme
& quot ;
& quot ; B03XA01
& quot ;
& quot ; Haemoglobin level should be measure on a regular basis until a stable level be achieve and periodically thereafter .
& quot ;
& quot ; discontinue therapy
& quot ;
& quot ; Abseamed 8000 IU / 0.8 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; the use of epoetin alfa in patient schedule for major elective orthopaedic surgery and not participate in an autologous blood predonation programme be contraindicate in patient with severe coronary , peripheral arterial , carotid or cerebral vascular disease , include patient with recent myocardial infarction or cerebral vascular accident .
& quot ;
& quot ; 1 mg / ml
& quot ;
& quot ; Luxembourg / Luxemburg BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; Haemoglobin variability should be address through dose management , with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; the most frequent adverse reaction be an increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ; 2 .
& quot ;
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; in clinical trial with aripiprazole , there be no significant difference in the incidence rate of hyperglycaemia-related adverse event ( include diabetes ) or in abnormal glycaemia laboratory value compare to placebo .
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg Kuhloweg 37 D-58638 Iserlohn
& quot ;
& quot ; use in adult patient in an autologous predonation programme
& quot ;
& quot ; if you take more ABILIFY than you should if you realise you have take more ABILIFY orodispersible tablet than your doctor have recommend ( or if someone else have take some of your ABILIFY orodispersible tablet ) , contact your doctor right away .
& quot ;
& quot ; the incidence of bone marrow fibrosis be not increase in a study of haemodialysis patient who be treat with epoetin alfa for 3 year compare to a match control group of dialysis patient who have not be treat with epoetin alfa . ) .
& quot ;
& quot ; manufacturer Bristol-Myers Squibb S. r. l .
& quot ;
& quot ; 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; keep the vial in the outer carton in order to protect from light .
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; after injection of the necessary amount of the solution from the pre-filled syringe , discard any remain content .
& quot ;
& quot ; * survival & # 91 ; 95 % CI & # 93 ; ( week )
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; 8 .
& quot ;
& quot ; & gt ; 1st-line therapy
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; Medicinal product subject to restrict medical prescription ( see Annex I :
& quot ;
& quot ; 180 package LEAFLET :
& quot ;
& quot ; 2 .
& quot ;
& quot ; 8 .
& quot ;
& quot ; Aripiprazole also demonstrate a comparable proportion of patient in symptomatic remission from mania a lithium or haloperidol at week 12 .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery , with a baseline haemoglobin of 10 to 13 g / dl , the incidence of thrombotic / vascular event ( most of which be DVTs ) , in the overall patient population of the clinical trial , appear to be similar across the different epoetin alfa dose group and placebo group , although the clinical experience be limit .
& quot ;
& quot ; Erythropoietin be a growth factor that primarily stimulate red cell production .
& quot ;
& quot ; Aripiprazole exhibit high binding affinity in vitro for dopamine D2 and D3 , serotonin 5HT1a and 5HT2a receptor and moderate affinity for dopamine D4 , serotonin 5HT2c and 5HT7 , alpha-1 adrenergic and histamine H1 receptor .
& quot ;
& quot ; EU / 1 / 07 / 412 / 015 EU / 1 / 07 / 412 / 016
& quot ;
& quot ; ABILIFY 15 mg orodispersible tablet aripiprazole
& quot ;
& quot ; Elevations of CPK ( Creatine Phosphokinase ) , generally transient and asymptomatic , be observe in 3.5 % of aripiprazole treated patient a compare to 2.0 % of patient who receive placebo .
& quot ;
& quot ; appropriate therapy such a blood transfusion may be give to patient when indicate .
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; Zoledronic acid be not metabolise and be excrete unchanged via the kidney .
& quot ;
& quot ; Blood pressure-lowering medicine :
& quot ;
& quot ; of the 143 Aclasta-treated patient and 107 risedronate-treated patient who enter an extended observation study , after a median duration of follow-up of 18 month from time of dose , 141 Aclasta-treated patient maintain their therapeutic response compare to 71 risedronate-treated patient .
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; in most of these patient , antibody to erythropoietin have be observe ( see section 4.3 and 4.4 – pure red Cell Aplasia )
& quot ;
& quot ; summary of Product characteristic , section 4.2 ) .
& quot ;
& quot ; 7 Westferry circus , Canary Wharf , London E14 4HB , UK Tel .
& quot ;
& quot ; 4 .
& quot ;
& quot ; EU / 1 / 04 / 276 / 011
& quot ;
& quot ; an increase 3H-thymidine incorporation in the erythroid nucleate spleen cell have be find in vitro ( mouse spleen cell culture ) after incubation with epoetin alfa .
& quot ;
& quot ; special storage condition
& quot ;
& quot ; 41 It have be propose that aripiprazole ’ s efficacy in schizophrenia and Bipolar I Disorder be mediate through a combination of partial agonism at dopamine D2 and serotonin 5HT1a receptor and antagonism of serotonin 5HT2a receptor .
& quot ;
& quot ; the haemoglobin concentration aim for be between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) , except in paediatric patient in whom the haemoglobin concentration should be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; weight ( kg ) & lt ; 10 10 - 30 & gt ; 30
& quot ;
& quot ; France BRISTOL-MYERS SQUIBB SARL Tél : + 33 ( 0 ) 810 410 500
& quot ;
& quot ; Shunt thromboses may occur , especially in patient who have a tendency to hypotension or whose arteriovenous fistula exhibit complication ( e. g. stenosis , aneurysm , etc . ) .
& quot ;
& quot ; France Therabel Lucien Pharma Tél : + 33 ( 0 ) 1 47 56 69 00
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Pack of 1 or 6 syrinx .
& quot ;
& quot ; in most of these patient , antibody to erythropoietin have be observe ( see section 4.3 and 4.4 – pure red Cell Aplasia )
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole increase by 77 % and 43 % , respectively .
& quot ;
& quot ; Non-specific skin rash have be describe in association with epoetin alfa .
& quot ;
& quot ; the four carbohydrate chain be attach via three N-glycosidic bond and one O-glycosidic bond to the protein .
& quot ;
& quot ; 14 X 1 orodispersible tablet 28 X 1 orodispersible tablet 49 X 1 orodispersible tablet
& quot ;
& quot ; iron supplementation should be start prior to epoetin alfa therapy , to achieve adequate iron store .
& quot ;
& quot ; in patient with chronic renal failure the medicinal product have to be administer intravenously ( see section 4.4 ) .
& quot ;
& quot ; Sixty-four percent of patient have impair performance status ( ECOG 1 or 2 ) at study entry ; 79 % have visceral metastasis ; and 76 % have & gt ; 3 site of metastasis .
& quot ;
& quot ; moreover , monitoring of the blood pressure be recommend particularly at the start of therapy .
& quot ;
& quot ; 3 .
& quot ;
& quot ; Excipient :
& quot ;
& quot ; contain sodium , see package leaflet for further information .
& quot ;
& quot ; for single use only .
& quot ;
& quot ; thus , no dosage adjustment be require for smoker .
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; Pharmacotherapeutic group : antipsychotic , ATC code :
& quot ;
& quot ; Tel : + 35 ( 0 ) 121 3105610
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; not applicable .
& quot ;
& quot ; Magyarország BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; 12 g / dl )
& quot ;
& quot ; therefore , aripiprazole should be use with caution in patient who have a history of seizure disorder or have condition associate with seizure .
& quot ;
& quot ; Batch
& quot ;
& quot ; Abseamed can be use to reduce exposure to allogeneic blood transfusion in adult non-iron deficient patient prior to major elective orthopaedic surgery , have a high perceive risk for transfusion complication .
& quot ;
& quot ; Tel : + 34 91 456 53 00
& quot ;
& quot ; EMEA / H / C / 727
& quot ;
& quot ; the effectiveness and safety of Abraxane in patient with central nervous system ( CNS ) metastases have not be establish .
& quot ;
& quot ; the subcutaneous route of administration should be use .
& quot ;
& quot ; 84 year ; range :
& quot ;
& quot ; Reproductive system and breast disorder :
& quot ;
& quot ; the protein fraction of the molecule contribute about 58 % and consist of 165 amino acid .
& quot ;
& quot ; Tablet
& quot ;
& quot ; when concomitant administration of ketoconozole with ABILIFY occurs , ABILIFY dose should be reduce to approximately one-half of it prescribed dose .
& quot ;
& quot ; lot
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance , a describe in version 2.0 present in Module 1.8.1. of the marketing authorisation application , be in place and functioning before and whilst the product be on the market .
& quot ;
& quot ; 4 .
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; Non-clinical safety data reveal no special hazard for human base on conventional oral aripiprazole study of safety pharmacology , repeat-dose toxicity , genotoxicity , carcinogenic potential , and toxicity to reproduction .
& quot ;
& quot ; 84 year ; range :
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; weight gain have be report post-marketing among patient prescribe ABILIFY .
& quot ;
& quot ; in addition , special precaution should be take in patient with predisposition for development of deep vein thrombosis ( DVTs ) .
& quot ;
& quot ; 1 .
& quot ;
& quot ; Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel : + 353 ( 1 800 ) 749 749
& quot ;
& quot ; in some preclinical toxicological study in dog and rat , but not in monkey , epoetin alfa therapy be associate with subclinical bone marrow fibrosis ( bone marrow fibrosis be a known complication of chronic renal failure in human and may be relate to secondary hyperparathyroidism or unknown factor .
& quot ;
& quot ; how to use ABILIFY
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; special storage condition
& quot ;
& quot ; attention should be pay to sudden stab migraine-like headache a a possible warning signal .
& quot ;
& quot ; possible side effect
& quot ;
& quot ; - In pregnant or lactating surgical patient participate in an autologous blood predonation
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; in clinical study , 10-30 mg / day dos of aripiprazole have no significant effect on the metabolism of substrate of CYP2D6 ( dextromethorphan / 3-methoxymorphinan ratio ) , 2C9 ( warfarin ) , 2C19 ( omeprazole ) , and 3A4 ( dextromethorphan ) .
& quot ;
& quot ; each vial contain 100 mg paclitaxel .
& quot ;
& quot ; adult and paediatric haemodialysis patient , adult peritoneal dialysis patient and adult patient with renal insufficiency not yet undergoing dialysis
& quot ;
& quot ; early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid , for example , be recommend in these patient .
& quot ;
& quot ; further information on clinical trial :
& quot ;
& quot ; España BRISTOL-MYERS SQUIBB , S. A .
& quot ;
& quot ; manufacturer Bristol-Myers Squibb S. r. l .
& quot ;
& quot ; in clinical trial of aripiprazole , the incidence of QT prolongation be comparable to placebo .
& quot ;
& quot ; Norge BRISTOL-MYERS SQUIBB Norway LTD Tlf : + 47 67 55 53 50
& quot ;
& quot ; Elevations of CPK ( Creatine Phosphokinase ) , generally transient and asymptomatic , be observe in 3.5 % of aripiprazole treated patient a compare to 2.0 % of patient who receive placebo .
& quot ;
& quot ; the most frequent adverse reaction be an increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ; EU / 1 / 07 / 412 / 017 EU / 1 / 07 / 412 / 018
& quot ;
& quot ; skin and subcutaneous tissue disorder :
& quot ;
& quot ; general disorder and administration site condition :
& quot ;
& quot ; overall survival outcome in the trial could not be statisfactorily explain by difference in the incidence of thrombosis and related complication between those give recombinant human erythropoietin and those in the control group .
& quot ;
& quot ; Endocrine disorder :
& quot ;
& quot ; Abseamed 9000 IU / 0.9 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; Musculoskeletal and connective tissue disorder :
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; Paediatric haemodialysis patient :
& quot ;
& quot ; Cardiac disorder :
& quot ;
& quot ; Sverige BRISTOL-MYERS SQUIBB AB Tel : + 46 8 704 71 00
& quot ;
& quot ; lot
& quot ;
& quot ; keep the vial in the outer carton in order to protect from light .
& quot ;
& quot ; 5 .
& quot ;
& quot ; some people may feel depressed .
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; EXP
& quot ;
& quot ; it can be take with or without liquid .
& quot ;
& quot ; market authorisation holder Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; child and adolescent ABILIFY be not for use in child and adolescent a it have not be study in patient under 18 year .
& quot ;
& quot ; Abseamed 4000 IU / 0.4 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; 2 .
& quot ;
& quot ; potential for ABILIFY to affect other medicinal product :
& quot ;
& quot ; an increase 3H-thymidine incorporation in the erythroid nucleate spleen cell have be find in vitro ( mouse spleen cell culture ) after incubation with epoetin alfa .
& quot ;
& quot ; in addition , other cause of anaemia , such a vitamin B12 or folate deficiency , should be exclude before institute therapy with epoetin alfa .
& quot ;
& quot ; the most frequent adverse reaction during treatment with epoetin alfa be a dose-dependent increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ;
& quot ; the initial dose be 150 IU / kg give subcutaneously 3 time per week .
& quot ;
& quot ; patient with hepatic impairment : no dosage adjustment be require for patient with mild to moderate hepatic impairment .
& quot ;
& quot ; be sure to tell your doctor if you take a medicine to keep your blood pressure under control .
& quot ;
& quot ; follow concomitant administration of carbamazepine , a potent inducer of CYP3A4 , the geometric mean of Cmax and AUC for aripiprazole be 68 % and 73 % lower , respectively , compare to when aripiprazole ( 30 mg ) be administer alone .
& quot ;
& quot ; Abseamed should be administer intravenously in order to increase haemoglobin to not greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; in two large , open-label study , 2697 cancer patient receive non-platinum chemotherapy be include , 1895 with solid tumour ( 683 breast , 260 lung , 174 gynaecological , 300 gastro-intestinal , and 478 other tumour type ) and 802 with haematological malignancy .
& quot ;
& quot ; in this leaflet :
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and than reinstitute epoetin alfa therapy at a dose 25 % below the previous dose .
& quot ;
& quot ; the orodispersible tablet should be place in the mouth on the tongue , where it will rapidly disperse in saliva .
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; follow concomitant administration of carbamazepine , a potent inducer of CYP3A4 , the geometric mean of Cmax and AUC for aripiprazole be 68 % and 73 % lower , respectively , compare to when aripiprazole ( 30 mg ) be administer alone .
& quot ;
& quot ; 30 mg
& quot ;
& quot ; at each step , the increase or reduction in dose should be of 25 IU / kg 3 time per week .
& quot ;
& quot ; after first reconstitution , the suspension should be fill into an infusion bag immediately .
& quot ;
& quot ; urinary incontinence , urinary retention
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; Insert the needle into the skin fold with a quick , firm action .
& quot ;
& quot ; for prevent recurrence of manic episode in patient who have be receive aripiprazole , continue therapy at the same dose .
& quot ;
& quot ; oral use .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; overall survival outcome in the trial could not be statisfactorily explain by difference in the incidence of thrombosis and related complication between those give recombinant human erythropoietin and those in the control group .
& quot ;
& quot ; peripheral oedema , mucosal inflammation , pain , rigor , oedema , weakness , decrease performance status , chest pain , influenza-like illness , malaise , lethargy , hyperpyrexia
& quot ;
& quot ; Clinical efficacy in men In the HORIZON-RFT study 508 men be randomise into the study and 185 patient have BMD assess at 24 month .
& quot ;
& quot ; Haemoglobin variability should be address through dose management , with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; how to take ABILIFY 4 .
& quot ;
& quot ; 47 150 IU / kg 3x / week or 450 IU / kg once weekly
& quot ;
& quot ; recurrence prevention of manic episode in Bipolar I Disorder :
& quot ;
& quot ; other infrequently report side effect :
& quot ;
& quot ; Aripiprazole be excrete in the milk of treated rat during lactation .
& quot ;
& quot ; alternatively , epoetin alfa can be administer at an initial dose of 450 IU / kg subcutaneously once weekly .
& quot ;
& quot ; pure red Cell Aplasia ( PRCA ) Antibody-mediated PRCA have be very rarely report after month to year of subcutaneous erythropoietin treatment .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; statement OF active substance ( s )
& quot ;
& quot ; Neurotoxictiy to paclitaxel be evaluate through improvement by one grade for patient experience grade 3 peripheral neuropathy at any time during therapy .
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; bottle ( plastic )
& quot ;
& quot ; Epoetin alfa should be administer by the subcutaneous route to patient with anaemia ( e. g. haemoglobin concentration ≤ 10 g / dl ( 6.2 mmol / l ) .
& quot ;
& quot ; Aclasta be supply in pack contain one bottle a unit Pack or in multi-packs comprise 5 pack , each contain 1 bottle .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; take ABILIFY with food and drink ABILIFY can be take regardless of meal .
& quot ;
& quot ; weight gain : weight gain be commonly see in schizophrenic and bipolar mania patient due to co- morbidity , use of antipsychotic know to cause weight gain , poorly manage life-style , and might lead to severe complication .
& quot ;
& quot ; 5 .
& quot ;
& quot ; a rise in haemoglobin of greater than 2 g / dl ( 1.25 mmol / l ) over a four week period should be avoid .
& quot ;
& quot ; in a haloperidol-controlled trial , the proportion of responder patient maintain response to medicinal product at 52-weeks be similar in both group ( aripiprazole 77 % and haloperidol 73 % ) .
& quot ;
& quot ; 4 .
& quot ;
& quot ; Batch
& quot ;
& quot ; 2 .
& quot ;
& quot ; rash , photosensitivity reaction , alopecia , hyperhidrosis
& quot ;
& quot ; there may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with epoetin alfa .
& quot ;
& quot ; 14 .
& quot ;
& quot ; Correction for anaemia may lead to increase appetite , and potassium and protein intake .
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; - In chronic renal failure patient , epoetin alfa should be use in pregnancy only if the potential
& quot ;
& quot ; EXP
& quot ;
& quot ; take special care with Abseamed if you have epilepsy or chronic liver disease .
& quot ;
& quot ; 165 minimum PARTICULARS to appear on small immediate packaging unit
& quot ;
& quot ; Abseamed 5000 IU / 0.5 ml solution for injection in a pre-filled syringe The syrinx contain 0.5 ml ( 5000 IU ) of solution .
& quot ;
& quot ; functional assessment of Cancer Therapy- Anaemia ( FACT-An ) general scale , FACT-An fatigue scale , and Cancer linear Analogue scale ( CLAS ) .
& quot ;
& quot ; Excipients
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; 143 risk management plan
& quot ;
& quot ; the Committee for Medicinal product for Human use ( CHMP ) note that Abraxane be more effective than conventional paclitaxel-containing medicine in patient whose first treatment have stop work , and that , unlike other paclitaxel-containing medicine , it do not need other medicine to reduce side effect .
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP2D6 ( quinidine ) increase aripiprazole AUC by 107 % , while Cmax be unchanged .
& quot ;
& quot ; if aripiprazole be administer concomitantly with medicine know to cause QT prolongation or electrolyte imbalance , caution should be use .
& quot ;
& quot ; uncontrolled hypertension .
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; if anti-erythropoietin , antibody-mediated PRCA be suspect , therapy with Abseamed should be discontinue immediately .
& quot ;
& quot ; not applicable .
& quot ;
& quot ; additional supportive care should be provide a necessary .
& quot ;
& quot ; 14 .
& quot ;
& quot ; the syrinx contain 0.5 ml ( 5000 IU ) of solution .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; 2 year
& quot ;
& quot ; expiry date
& quot ;
& quot ; when either valproate or lithium be administer concomitantly with aripiprazole , there be no clinically significant change in aripiprazole concentration .
& quot ;
& quot ; market authorisation holder Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; United Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel : + 44 ( 0800 ) 731 1736
& quot ;
& quot ; Aclasta 5 mg solution for infusion Zoledronic acid
& quot ;
& quot ; the target haemoglobin concentration in two study be & gt ; 13 g / dl ; in the remain three study it be 12 - 14 g / dl .
& quot ;
& quot ; there be conflict report in the literature regard whether erythropoietin may play a major role a tumour proliferators .
& quot ;
& quot ; - if the solution have be accidentally frozen .
& quot ;
& quot ; Magyarország BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; if you have any further question on the use of this product , ask your doctor or pharmacist .
& quot ;
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; the follow undesirable effect occur more often ( ≥ 1 / 100 ) than placebo , or be identify a possibly medically relevant adverse reaction ( * ) in clinical trial with oral formulation of aripiprazole ( see section 5.1 ) :
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; there be an increased risk for thromboembolic event in patient with cancer treat with recombinant human erythropoietin and a negative impact on overall survival can not be exclude .
& quot ;
& quot ; Medicines to correct heart rhythm Antidepressants or herbal remedy use to treat depression and anxiety Antifungal agent certain medicine to treat HIV infection Anticonvulsants use to treat epilepsy
& quot ;
& quot ; - if the solution be cloudy or there be particle in it .
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; study in patient with impaired renal function have not be perform and insufficient data be currently available to recommend dose modification in patient with renal impairment ( see section 5.2 ) .
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl and Hb increase & lt ; 1 g / dl
& quot ;
& quot ; read all of this leaflet carefully before you start take this medicine .
& quot ;
& quot ; it can be take with or without liquid .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; enhance efficacy at dose higher than a daily dose of 15 mg have not be demonstrate although individual patient may benefit from a higher dose .
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; 4 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; each ml of solution contain 10 000 IU of epoetin alfa * correspond to 84.0 microgram per ml 1 pre-filled syringe of 0.9 ml contains 9000 international unit ( IU ) correspond to 75.6 microgram epoetin alfa
& quot ;
& quot ; all of these additive factor of anaemia should also be carefully consider when decide to increase the dose of epoetin alfa in cancer patient .
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; a systematic review have also be perform involve more than 9000 cancer patient participate in 57 clinical trial .
& quot ;
& quot ; an increase in heparin dose during haemodialysis be frequently require during the course of therapy with epoetin alfa a a result of the increase packed cell volume .
& quot ;
& quot ; 2 .
& quot ;
& quot ; 1 .
& quot ;
& quot ; 5 .
& quot ;
& quot ; a gastric acid blocker , the H2 antagonist famotidine , reduces aripiprazole rate of absorption but this effect be deem not clinically relevant .
& quot ;
& quot ; 16 .
& quot ;
& quot ; 6 .
& quot ;
& quot ; in addition , other cause of anaemia , such a vitamin B12 or folate deficiency , should be exclude before institute therapy with epoetin alfa .
& quot ;
& quot ; 28 August 2007
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; no study on the effect on the ability to drive and use machine have be perform .
& quot ;
& quot ; 2 .
& quot ;
& quot ; Abraxane should not be use in people who may be hypersensitive ( allergic ) to paclitaxel or any of the other ingredient .
& quot ;
& quot ; Abseamed 6000 IU / 0.6 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; the protein fraction of the molecule contribute about 58 % and consist of 165 amino acid .
& quot ;
& quot ; not applicable .
& quot ;
& quot ; population pharmacokinetic evaluation have reveal no evidence of clinically significant race-related difference or effect from smoke upon the pharmacokinetics of aripiprazole .
& quot ;
& quot ; Abraxane monotherapy be indicate for the treatment of metastatic breast cancer in patient who have fail first-line treatment for metastatic disease and for whom standard , anthracycline contain therapy be not indicate ( see also section 4.4 ) .
& quot ;
& quot ; start dose of 50 IU / kg 2 time per week by the intravenous route .
& quot ;
& quot ; 0.5 ml ( 2000 IU / ml )
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be
& quot ;
& quot ; Abseamed
& quot ;
& quot ; 7 .
& quot ;
& quot ; patient with hepatic impairment : no dosage adjustment be require for patient with mild to moderate hepatic impairment .
& quot ;
& quot ; allergic reaction ( e. g. anaphylactic reaction , angioedema include swollen tongue , tongue oedema , face oedema , pruritus , or urticaria )
& quot ;
& quot ; the recommended total weekly dose be between 75 and 300 IU / kg give by the intravenous route .
& quot ;
& quot ; how be Abseamed use ?
& quot ;
& quot ; Epoetin alfa therapy should continue until one month after the end of chemotherapy .
& quot ;
& quot ; the follow undesirable effect occur more often ( ≥ 1 / 100 ) than placebo , or be identify a possibly medically relevant adverse reaction ( * ) :
& quot ;
& quot ; 148 even if you feel better , do not alter or discontinue the daily dose of ABILIFY without first consult your doctor .
& quot ;
& quot ; what ABILIFY contain The active substance be aripiprazole .
& quot ;
& quot ; caution be indicate when Aclasta be administer in conjunction with medicinal product that can significantly impact renal function ( e. g. aminoglycosides or diuretic that may cause dehydration ) , see section 4.5 .
& quot ;
& quot ; the recommend starting dose for ABILIFY be 15 mg administer on a once-a-day schedule without regard to meal a monotherapy or combination therapy ( see section 5.1 ) .
& quot ;
& quot ; common :
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; study in animal with zoledronic acid have show reproductive toxicological effect include malformation ( see section 5.3 ) .
& quot ;
& quot ; Cardiac disorder :
& quot ;
& quot ; risk factor that may predispose patient to severe complication include obesity and family history of diabetes .
& quot ;
& quot ; patient with active malignant disease receive neither chemotherapy nor radiation therapy .
& quot ;
& quot ; 6 .
& quot ;
& quot ; these trial include patient with or without psychotic feature and with or without a rapid-cycling course .
& quot ;
& quot ; 5 .
& quot ;
& quot ; these increase in blood pressure can be treat with medicinal product .
& quot ;
& quot ; the follow undesirable effect occur more often ( ≥ 1 / 100 ) than placebo , or be identify a possibly medically relevant adverse reaction ( * ) :
& quot ;
& quot ; in clinical trial with aripiprazole , there be no significant difference in the incidence rate of hyperglycaemia-related adverse event ( include diabetes ) or in abnormal glycaemia laboratory value compare to placebo .
& quot ;
& quot ; follow intravenous administration of Abraxane to patient with metastatic breast cancer at the recommended clinical dose of 260 mg / m2 , paclitaxel plasma concentration decline in a multiphasic manner .
& quot ;
& quot ; Tel : + 39 06 50 39 61
& quot ;
& quot ; for any information about this medicine , please contact the local representative of the marketing authorisation holder :
& quot ;
& quot ; EU / 1 / 07 / 412 / 007 EU / 1 / 07 / 412 / 008
& quot ;
& quot ; Tel : + 421 2 59298411
& quot ;
& quot ; patient with hepatic impairment may be at increased risk of toxicity , particularly from myelosuppression , and such patient should be closely monitor for development of profound myelosuppression .
& quot ;
& quot ; Chronic renal failure patient
& quot ;
& quot ; follow a single oral dose of & # 91 ; 14C & # 93 ; -labelled aripiprazole , approximately 27 % of the administered radioactivity be recover in the urine and approximately 60 % in the faeces .
& quot ;
& quot ; Smoking and race :
& quot ;
& quot ; additional supportive care should be provide a necessary .
& quot ;
& quot ; if you notice you be gain weight , experience any difficulty in swallow or allergic symptom , please tell your doctor .
& quot ;
& quot ; le than 1 % of unchanged aripiprazole be excrete in the urine and approximately 18 % be recover unchanged in the faeces .
& quot ;
& quot ; it be give over a period of 30 minute , every three week .
& quot ;
& quot ; red iron oxide ( E172 )
& quot ;
& quot ; Pharmacotherapeutic group : antianaemic , ATC code :
& quot ;
& quot ; expiry date
& quot ;
& quot ; Correction for anaemia may lead to increase appetite , and potassium and protein intake .
& quot ;
& quot ; 5 .
& quot ;
& quot ; therefore cardiovascular monitoring should be start immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmia .
& quot ;
& quot ; when weak inhibitor of CYP3A4 ( e. g . , diltiazem or escitalopram ) or CYP2D6 be use concomitantly with ABILIFY , modest increase in aripiprazole concentration might be expect .
& quot ;
& quot ; 49 X 1
& quot ;
& quot ; BRISTOL-MYERS SQUIBB GESMBH Tel : + 43 1 60 14 30
& quot ;
& quot ; 9 .
& quot ;
& quot ; Annex I
& quot ;
& quot ; Abseamed 8000 IU / 0.8 ml solution for injection in a pre-filled syringe The syrinx contain 0.8 ml ( 8000 IU ) of solution .
& quot ;
& quot ; oropharyngeal spasm , laryngospasm , aspiration pneumonia
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; when aripiprazole be administer concomitantly with either valproate or lithium , there be no clinically important change in valproate or lithium concentration .
& quot ;
& quot ; 3 .
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; increase mortality : in three placebo-controlled trial ( n = 938 ; mean age :
& quot ;
& quot ; Abraxane be more effective than conventional paclitaxel-containing medicine .
& quot ;
& quot ; speech disorder , Neuroleptic Malignant syndrome ( NMS ) , grand mal convulsion
& quot ;
& quot ; 14 X 1
& quot ;
& quot ; patient who have baseline neutrophil count & lt ; 1.5 X 109 / l .
& quot ;
& quot ; Portugal BRISTOL-MYERS SQUIBB FARMACÊUTICA Portuguesa , S. A .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; Tablet
& quot ;
& quot ; Overdose of epoetin alfa may produce effect that be extension of the pharmacological effect of the hormone .
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl and Hb increase & lt ; 1 g / dl
& quot ;
& quot ; iron supplementation should be start a soon a possible , even several week prior to initiate the autologous predeposit , in order to achieve high iron store prior to start Abseamed therapy .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; this be give 3 time a week by injection under the skin ( subcutaneously ) .
& quot ;
& quot ; this medicinal product contain le than 1 mmol sodium ( 23 mg ) per dose , I. e. essentially “ sodium- free ” .
& quot ;
& quot ;
& quot ; the mean elimination half-lives for aripiprazole be approximately 75 hour in extensive metabolisers of CYP2D6 and approximately 146 hour in poor metabolisers of CYP2D6 .
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the sustained haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) reduce the epoetin alfa dose by 25 % .
& quot ;
& quot ; what ABILIFY look like and content of the Pack ABILIFY 15 mg tablet be round and yellow , mark with A-009 and 15 on one side .
& quot ;
& quot ; in several controlled study , epoetins have not be show to improve overall survival or decrease the risk of tumour progression in patient with anaemia associate with cancer .
& quot ;
& quot ; 2 .
& quot ;
& quot ; Aripiprazole also exhibit moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptor .
& quot ;
& quot ; Aripiprazole be the predominant medicinal product moiety in systemic circulation .
& quot ;
& quot ; gender :
& quot ;
& quot ; for prevent recurrence of manic episode in patient who have be receive aripiprazole , continue therapy at the same dose .
& quot ;
& quot ; Cerebrovascular adverse event : in the same trial , cerebrovascular adverse event ( e. g. stroke , transient ischaemic attack ) , include fatality , be report in patient ( mean age :
& quot ;
& quot ; in animal study , epoetin alfa have be show to decrease foetal body weight , delay ossification and increase foetal mortality when give in weekly dos of approximately 20 time the recommended human weekly dose .
& quot ;
& quot ; uncontrolled hypertension .
& quot ;
& quot ; therefore , routine volume replacement should be perform in such patient .
& quot ;
& quot ; however , since cyclosporin be bind by red blood cell there be potential for an interaction .
& quot ;
& quot ; patient with metastatic breast cancer receive chemotherapy when administer to target a haemoglobin of 12 - 14 g / dl ( 7.5 – 8.7 mmol / l ) ,
& quot ;
& quot ; 14 .
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; dose ( IU / kg give 3x / week )
& quot ;
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; Erythropoietins be growth factor that primarily stimulate red blood cell production .
& quot ;
& quot ; 9 .
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; be sure to tell your doctor immediately if you be pregnant , think you may be pregnant , or if you be plan to become pregnant .
& quot ;
& quot ; 6 .
& quot ;
& quot ; in case where there be a medical need to shorten the lead time before surgery to le than three week , 300 IU / kg epoetin alfa should be give daily for 10 consecutive day prior to surgery , on the day of surgery and for four day immediately thereafter .
& quot ;
& quot ; these change be interpret a be secondary to decreased maternal body weight gain .
& quot ;
& quot ; close supervision of high-risk patient should accompany antipsychotic therapy .
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; in a prospective , randomised , double-blind , placebo-controlled trial conduct in 375 anaemic patient with various non-myeloid malignancy receive non-platinum chemotherapy , there be a significant reduction of anaemia-related sequela ( e. g. fatigue , decrease energy , and activity reduction ) , a measure by the following instrument and scale :
& quot ;
& quot ; a half-life of approximately 6 hour have be report in child .
& quot ;
& quot ; the four carbohydrate chain be attach via three N-glycosidic bond and one O-glycosidic bond to the protein .
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; be sure to tell your doctor immediately if you be breast-feeding .
& quot ;
& quot ; in some preclinical toxicological study in dog and rat , but not in monkey , epoetin alfa therapy be associate with subclinical bone marrow fibrosis ( bone marrow fibrosis be a known complication of chronic renal failure in human and may be relate to secondary hyperparathyroidism or unknown factor .
& quot ;
& quot ; expiry date
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy male and female subject nor be there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; Aripiprazole also exhibit moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptor .
& quot ;
& quot ; - In chronic renal failure patient , epoetin alfa should be use in pregnancy only if the potential
& quot ;
& quot ; control clinical trial have not show significant benefit attributable to the administration of epoetins when haemoglobin concentration be increase beyond the level necessary to control symptom of anaemia and to avoid blood transfusion .
& quot ;
& quot ; CA012-0 Addendum date final ( 23 March-2005 ) a Chi-squared test b Log-rank test
& quot ;
& quot ; in a study in patient with advanced solid tumour , the pharmacokinetic characteristic of paclitaxel follow Abraxane administer intravenously at 260 mg / m2 over 30 minute be compare with those follow 175 mg / m2 of the solvent-based paclitaxel injection administer over 3 hour .
& quot ;
& quot ; however chemical and physical in use stability have be demonstrate for 8 hour not above 25 ° C .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; name OF the marketing authorisation holder
& quot ;
& quot ; 5
& quot ;
& quot ; 8 .
& quot ;
& quot ;
& quot ; after administration of epoetin alfa , the number of erythrocyte , the Hb value and reticulocyte count increase a well a the 59Fe-incorporation rate .
& quot ;
& quot ; in all patient receive epoetin alfa , blood pressure should be closely monitor and control a necessary .
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; the recommend dose of 600 International unit ( IU ) per kilogram bodyweight be give weekly for three week before surgery and on the day of surgery .
& quot ;
& quot ; the study in patient receive chemotherapy show that Abseamed be also a effective a Eprex / Erypo when it be inject under the skin .
& quot ;
& quot ; mildly anaemic patient ( haematocrit of 33 - 39 % ) require predeposit of ≥ 4 unit of blood should be treat with Abseamed at a dose of 600 IU / kg body weight 2 time weekly for 3 week prior to surgery .
& quot ;
& quot ; ABILIFY dose should be double when concomitant administration of ABILIFY occur with carbamazepine .
& quot ;
& quot ; always take ABILIFY exactly a your doctor have tell you .
& quot ;
& quot ; the other ingredient be lactose monohydrate , maize starch , microcrystalline cellulose , hydroxypropyl cellulose , magnesium stearate , yellow iron oxide ( E172 ) .
& quot ;
& quot ; in view of the above , in some clinical situation blood transfusion should be the preferred treatment for the management of anaemia in patient with cancer .
& quot ;
& quot ; kg Tel . : + 49- ( 0 ) 2371 937 0
& quot ;
& quot ; Annex
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subject , nor be there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; the expiry date refers to the last day of that month .
& quot ;
& quot ; 169 minimum PARTICULARS to appear on small immediate packaging unit
& quot ;
& quot ; thus , no dosage adjustment be require for smoker .
& quot ;
& quot ; EU / 1 / 07 / 412 / 007
& quot ;
& quot ; the company also present the result of a study compare the effect of Abseamed inject under the skin with those of Eprex / Erypo in 114 cancer patient who be receive chemotherapy .
& quot ;
& quot ; a with all growth factor , there be a concern that epoetins could stimulate the growth of tumour .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Epoetin alfa should be administer by the subcutaneous route to patient with anaemia ( e. g. haemoglobin concentration ≤ 10 g / dl ( 6.2 mmol / l ) .
& quot ;
& quot ; 2 .
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; Excipients : sodium dihydrogen phosphate dihydrate , disodium phosphate dihydrate , sodium chloride , glycine , polysorbate 80 , hydrochloric acid ( for pH-adjustment ) , sodium hydroxide ( for pH-adjustment ) , and water for injection
& quot ;
& quot ; this difference be not statistically significant .
& quot ;
& quot ; România BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; 2.2
& quot ;
& quot ; Abraxane contain human serum albumin-paclitaxel nanoparticles .
& quot ;
& quot ; when weak inhibitor of CYP3A4 ( e. g . , diltiazem or escitalopram ) or CYP2D6 be use concomitantly with ABILIFY , modest increase in aripiprazole concentration might be expect .
& quot ;
& quot ; ask your pharmacist how to dispose of medicine no longer require .
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; 12 .
& quot ;
& quot ; the pharmacokinetic characteristic of aripiprazole and dehydro-aripiprazole be find to be similar in patient with severe renal disease compare to young healthy subject .
& quot ;
& quot ; Abseamed 8000 IU / 0.8 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; Epoetin alfa therapy should continue until one month after the end of chemotherapy .
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; Abraxane should not be use in pregnancy , and in woman of childbearing potential not use effective contraception , unless the clinical condition of the mother require treatment with paclitaxel .
& quot ;
& quot ; the recommend starting dose for ABILIFY be 15 mg administer on a once-a-day schedule without regard to meal a monotherapy or combination therapy ( see section 5.1 ) .
& quot ;
& quot ; the haemoglobin concentration aim for be between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) , except in paediatric patient in whom the haemoglobin concentration should be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP2D6 ( quinidine ) increase aripiprazole AUC by 107 % , while Cmax be unchanged .
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be avoid .
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; Thrombotic event can be a risk in this population and this possibility should be carefully weigh against the benefit to be derive from the treatment in this patient group .
& quot ;
& quot ; Abseamed 5000 IU / 0.5 ml
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; Novartis Europharm limit Wimblehurst Road Horsham West Sussex , RH12 5AB United Kingdom
& quot ;
& quot ; all of these additive factor of anaemia should also be carefully consider when decide to increase the dose of epoetin alfa in cancer patient .
& quot ;
& quot ; study in animal have show reproduction toxicity ( see section 5.3 ) .
& quot ;
& quot ;
& quot ; no evidence exist that indicate an interaction between epoetin alfa and G-CSF or GM-CSF with regard to haematological differentiation or proliferation of tumour biopsy specimen in vitro .
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; Hypersensitivity reaction have be rarely report with epoetin alfa include isolated case of angioedema and anaphylactic reaction .
& quot ;
& quot ; the pharmacokinetic characteristic of aripiprazole and dehydro-aripiprazole be find to be similar in patient with severe renal disease compare to young healthy subject .
& quot ;
& quot ; Measurement of epoetin alfa follow multiple dose intravenous administration reveal a half-life of approximately 4 hour in normal volunteer and a somewhat more prolonged half-life in renal failure patient , approximately 5 hour .
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of the symptom of anaemia .
& quot ;
& quot ; 6 .
& quot ;
& quot ; 9 .
& quot ;
& quot ; when aripiprazole be administer concomitantly with either valproate or lithium , there be no clinically important change in valproate or lithium concentration .
& quot ;
& quot ; additional supportive care should be provide a necessary .
& quot ;
& quot ; jaundice , hepatitis , increase Alanine Aminotransferase ( ALT ) , increased Aspartate Aminotransferase ( AST ) , increase Gamma Glutamyl Transferase ( GGT ) , increase alkaline phosphatase
& quot ;
& quot ; Mannitol , sodium citrate and water for injection .
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; actual score in rating scale use a secondary endpoint , include PANSS and the Montgomery-Asberg Depression rating scale show a significant improvement over haloperidol .
& quot ;
& quot ; only solution which be clear , colourless and free of visible particle may be inject .
& quot ;
& quot ; study in animal have show reproduction toxicity ( see section 5.3 ) .
& quot ;
& quot ; there be an increased risk for thromboembolic event in patient with cancer treat with recombinant human erythropoietin and a negative impact on overall survival can not be exclude .
& quot ;
& quot ; treatment with Abseamed should be continue until one month after the end of chemotherapy .
& quot ;
& quot ; - if the solution have be accidentally frozen .
& quot ;
& quot ; 115 Correction phase :
& quot ;
& quot ; treatment with Abseamed have to be initiate under the supervision of physician experience in the management of patient with the above indication .
& quot ;
& quot ; it be recommend that the platelet count be regularly monitor during the first 8 week of therapy .
& quot ;
& quot ; alternatively , epoetin alfa can be administer at an initial dose of 450 IU / kg subcutaneously once weekly .
& quot ;
& quot ; a with all growth factor , there be a concern that epoetins could stimulate the growth of tumour .
& quot ;
& quot ; this leaflet be last approved in
& quot ;
& quot ; it be especially important to mention the follow to your doctor :
& quot ;
& quot ; Influenza Hypertension , flush Fever Flu-like symptom , chill , fatigue , asthenia , pain , malaise , rigor †
& quot ;
& quot ;
& quot ; 20 PARTICULARS to appear on the intermediate packaging
& quot ;
& quot ; content
& quot ;
& quot ; Tumour growth potential
& quot ;
& quot ; weight gain , weight decrease , anorexia , hyponatremia
& quot ;
& quot ; an investigational study ( best study ) in woman with metastatic breast cancer be design to determine whether epoetin alfa treatment that extend beyond the correction of anaemia could improve treatment outcome .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP3A4 ( ketoconazole ) increase aripiprazole AUC and Cmax by 63 % and 37 % , respectively .
& quot ;
& quot ; the maintenance dose be 15 mg once a day , but higher dos may benefit some patient .
& quot ;
& quot ; the rate of increase in haemoglobin should be approximately 1 g / dl
& quot ;
& quot ; 158 PARTICULARS to appear on the outer packaging
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; 2 .
& quot ;
& quot ; adult peritoneal dialysis patient :
& quot ;
& quot ; 2 .
& quot ;
& quot ; in the four placebo-controlled study the hazard ratio for overall survival range between 1.25 and 2.47 in favour of control .
& quot ;
& quot ; 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; treatment of anaemia and reduction of transfusion requirement in adult patient receive chemotherapy for solid tumour , malignant lymphoma or multiple myeloma , and at risk of transfusion a assess by the patient & apos ; s general status ( e. g. cardiovascular status , pre-existing anaemia at the start of chemotherapy ) .
& quot ;
& quot ; elderly patient with dementia-related psychosis :
& quot ;
& quot ; 9.75 mg ( 1.3ml )
& quot ;
& quot ; in addition , report of accidental overdose with aripiprazole alone ( up to 195 mg ) in child have be receive with no fatality .
& quot ;
& quot ; Excipient :
& quot ;
& quot ; there be no effect of a high fat meal on the pharmacokinetics of aripiprazole .
& quot ;
& quot ; 6 .
& quot ;
& quot ; some people may feel depressed .
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; once the addition be complete , the vial should be allow to stand for a minimum of 5 minute to ensure proper wetting of the solid .
& quot ;
& quot ; the use of epoetin alfa in patient schedule for major elective orthopaedic surgery and not participate in an autologous blood predonation programme be contraindicate in patient with severe coronary , peripheral arterial , carotid or cerebral vascular disease , include patient with recent myocardial infarction or cerebral vascular accident .
& quot ;
& quot ; jaundice , hepatitis , increase Alanine Aminotransferase ( ALT ) , increased Aspartate Aminotransferase ( AST ) , increase Gamma Glutamyl Transferase ( GGT ) , increase alkaline phosphatase
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; 1 .
& quot ;
& quot ; Schizophrenia :
& quot ;
& quot ; the frequency list below be define use the following convention : common ( ≥ 1 / 100 , & lt ; 1 / 10 ) and uncommon ( ≥ 1 / 1,000 , & lt ; 1 / 100 ) .
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; in both study of the solution for injection , patient receive Abilify at dos of 5.25 , 9.75 or 15 mg have a significantly greater reduction in symptom of agitation than those receive placebo .
& quot ;
& quot ; 78-88 year ) .
& quot ;
& quot ; what ABILIFY look like and content of the Pack ABILIFY 5 mg tablet be rectangular and blue , mark with A-007 and 5 on one side .
& quot ;
& quot ; 1 .
& quot ;
& quot ; when aripiprazole be administer concomitantly with either valproate or lithium , there be no clinically important change in valproate or lithium concentration .
& quot ;
& quot ; in patient with chronic renal failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommend in section 4.2 .
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; Syringes be emboss with graduation ring and the filling volume be indicate by a stick-on label in order to enable partial use if require .
& quot ;
& quot ; ABILIFY dose should be reduce to approximately one-half of it prescribed dose when concomitant administration of ABILIFY with quinidine occurs .
& quot ;
& quot ; Haemoglobin variability should be address through dose management with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; expiry date
& quot ;
& quot ; the total body clearance of aripiprazole be 0.7 ml / min / kg , which be primarily hepatic .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; the medicine can only be obtain with a prescription .
& quot ;
& quot ; when see , it be usually in those with significant risk factor such a history of diabetes , thyroid disorder or pituitary adenoma .
& quot ;
& quot ; in the treatment of Paget ’ s disease of the bone , Aclasta must only be use by a doctor who have experience in the treatment of the disease .
& quot ;
& quot ; kg Tel : + 49- ( 0 ) 2371 937 0
& quot ;
& quot ; the following reaction have also occur in isolated patient with normal or low blood pressure : hypertensive crisis with encephalopathy-like symptom ( e. g. headache and confused state ) and Generalised tonoclonal seizure , require the immediate attention of a physician and intensive medical care .
& quot ;
& quot ; no evidence exist that indicate that treatment with epoetin alfa alter the metabolism of other medicinal product .
& quot ;
& quot ; when your condition have be bring under control , you will receive regular dos of Abseamed between 25 and 50 IU / kg twice a week in two equal injection .
& quot ;
& quot ; there be no adequate and well-controlled study in pregnant woman .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; it be especially important to mention the follow to your doctor :
& quot ;
& quot ; statement OF active substance ( s )
& quot ;
& quot ; how have Aclasta be study ?
& quot ;
& quot ; John & apos ; s Wort ) may be expect to have similar effect and similar dose increase should therefore be apply .
& quot ;
& quot ; care should be take to ensure that at the outset of the treatment patient be not iron deficient .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; when concomitant administration of potent CYP3A4 inducer with aripiprazole occurs , the aripiprazole dose should be increase .
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; an increase relative risk of thromboembolic event ( RR 1.67 , 95 % CI :
& quot ;
& quot ; at the time of donate blood , Abseamed should be administer after the completion of the blood donation procedure .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; in clinical trial , an increase risk of death and serious cardiovascular event be observe when erythropoiesis stimulate agent ( ESAs ) be administer to target a haemoglobin of greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; B03XA01
& quot ;
& quot ; 55 6 .
& quot ;
& quot ; all cause mortality be 10 % ( 101 patient ) in the Aclasta-treated group compare to 13 % ( 141 patient ) in the placebo group .
& quot ;
& quot ; risk factor that may predispose patient to severe complication include obesity and family history of diabetes .
& quot ;
& quot ; 4 .
& quot ;
& quot ; urinary incontinence , urinary retention
& quot ;
& quot ; the overall completion rate be significantly higher for patient on aripiprazole ( 43 % ) than for haloperidol ( 30 % ) .
& quot ;
& quot ; discontinue therapy
& quot ;
& quot ; immune system disorder :
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; similarly , for dehydro-aripiprazole the geometric mean of Cmax and AUC after carbamazepine co-administration be 69 % and 71 % lower , respectively , than those following treatment with aripiprazole alone .
& quot ;
& quot ; Pre-filled syrinx ( glass type I ) with plunger ( Teflon-faced rubber ) seal in a blister .
& quot ;
& quot ; child and adolescent : there be no experience in child and adolescent under 18 year of age .
& quot ;
& quot ; Epoetin alfa do not show any change in bacterial and mammalian cell culture mutagenicity test and an in vivo micronucleus test in mouse .
& quot ;
& quot ; Post-Marketing :
& quot ;
& quot ; Ísland VISTOR HF Sími : + 354 535 7000
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; possible side effect 5 how to store ABILIFY 6 .
& quot ;
& quot ; Abraxane should only be give under the supervision of a specialist cancer doctor in ward that be specialise in give ‘ cytotoxic ’ ( cell-killing ) medicine .
& quot ;
& quot ; the follow undesirable effect occur more often ( ≥ 1 / 100 ) than placebo , or be identify a possibly medically relevant adverse reaction ( * ) :
& quot ;
& quot ; the rate of death in aripiprazole-treated patient be 3.5 % compare to 1.7 % in the placebo group .
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; further information on clinical trial :
& quot ;
& quot ; ask your pharmacist how to dispose of medicine no longer require .
& quot ;
& quot ; when perform haematologic assessment during the preoperative period , if the haemoglobin level reach 15 g / dl , or higher , administration of epoetin alfa should be stop and further dos should not be give .
& quot ;
& quot ; owe to the greater sensitivity of this population , a lower start dose should be consider when clinical factor warrant ( see section 4.4 ) .
& quot ;
& quot ; try to take the ABILIFY orodispersible tablet at the same time each day .
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP3A4 ( ketoconazole ) increase aripiprazole AUC and Cmax by 63 % and 37 % , respectively .
& quot ;
& quot ; if it occur , appropriate dose adjustment should be make a provided .
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; after first reconstitution the suspension should be use immediately .
& quot ;
& quot ; 1 .
& quot ;
& quot ; s R. O .
& quot ;
& quot ; Abilify
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; Contrada Fontana del Ceraso I-03012 Anagni-Frosinone - Italy
& quot ;
& quot ; information for the user
& quot ;
& quot ; Haemoglobin variability should be address through dose management , with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; Activated charcoal ( 50 g ) , administer one hour after aripiprazole , decrease aripiprazole Cmax by about 41 % and AUC by about 51 % , suggest that charcoal may be effective in the treatment of overdose .
& quot ;
& quot ; no evidence exist that indicate that treatment with epoetin alfa alter the metabolism of other medicinal product .
& quot ;
& quot ; animal study could not exclude potential developmental toxicity ( see section 5.3 ) .
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; Belgique / België / Belgien BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; - increase risk of death when administer to target a haemoglobin of 12 g / dl ( 7.5 mmol / l ) in
& quot ;
& quot ; the pre-filled syrinx be ready to use ( see section 4.2 – method of administration ) .
& quot ;
& quot ; therefore , aripiprazole should be use with caution in patient who have a history of seizure disorder or have condition associate with seizure .
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; 10 .
& quot ;
& quot ; for any information about this medicine , please contact the local representative of the marketing authorisation holder :
& quot ;
& quot ; in CYP2D6 poor metabolisers , concomitant use of potent inhibitor of CYP3A4 may result in higher plasma concentration of aripiprazole compare to that in CYP2D6 extensive metabolizers .
& quot ;
& quot ; Tel . : + 36 1 301 9700
& quot ;
& quot ; when perform haematologic assessment during the preoperative period , if the haemoglobin level reach 15 g / dl , or higher , administration of epoetin alfa should be stop and further dos should not be give .
& quot ;
& quot ; 2 .
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; in two large , open-label study , 2697 cancer patient receive non-platinum chemotherapy be include , 1895 with solid tumour ( 683 breast , 260 lung , 174 gynaecological , 300 gastro-intestinal , and 478 other tumour type ) and 802 with haematological malignancy .
& quot ;
& quot ; factor that should be consider in this assessment should include the type of tumour and it stage ; the degree of anaemia ; life-expectancy ; the environment in which the patient be be treat ; and patient preference ( see section 5.1 ) .
& quot ;
& quot ; s R. O .
& quot ;
& quot ; NMS be a potentially fatal symptom complex associate with antipsychotic medicinal product .
& quot ;
& quot ; Gastrointestinal disorder :
& quot ;
& quot ;
& quot ; Abilify
& quot ;
& quot ; Abseamed must not be use
& quot ;
& quot ; adult peritoneal dialysis patient :
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ;
& quot ; if you forget to take ABILIFY if you miss a dose , take the missed dose a soon a you remember but do not take two dos in one day .
& quot ;
& quot ; in particular , no residue of the cell line use for the production be detectable at the concentration of the active ingredient that be use in human .
& quot ;
& quot ; after administration of epoetin alfa , the number of erythrocyte , the Hb value and reticulocyte count increase a well a the 59Fe-incorporation rate .
& quot ;
& quot ; further information on clinical trial :
& quot ;
& quot ; EU / 1 / 04 / 276 / 016 14 X 1 tablet EU / 1 / 04 / 276 / 017 28 X 1 tablet EU / 1 / 04 / 276 / 018 49 X 1 tablet EU / 1 / 04 / 276 / 019 56 X 1 tablet EU / 1 / 04 / 276 / 020 98 X 1 tablet
& quot ;
& quot ; 150 Eesti Österreich BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; in view of the above , in some clinical situation blood transfusion should be the preferred treatment for the management of anaemia in patient with cancer .
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; 25 mental status and evidence of autonomic instability ( irregular pulse or blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
& quot ;
& quot ; EU / 1 / 07 / 412 / 011
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; mildly anaemic patient ( haematocrit of 33 - 39 % ) require predeposit of ≥ 4 unit of blood should be treat with Abseamed at a dose of 600 IU / kg body weight 2 time weekly for 3 week prior to surgery .
& quot ;
& quot ; general
& quot ;
& quot ; Administer the amount require .
& quot ;
& quot ; possible side effect
& quot ;
& quot ; manufacturer Bristol-Myers Squibb S. r. l .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery the cause of anaemia should be establish and treat , if possible , before the start of epoetin alfa treatment .
& quot ;
& quot ; these symptom can temporally deteriorate or can even arise after discontinuation of treatment .
& quot ;
& quot ; treatment with Abseamed must be start under the supervision of a doctor who have experience in the management of patient with the condition that the medicine be use for .
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; when concomitant administration of potent CYP3A4 or CYP2D6 inhibitor with aripiprazole occurs , the aripiprazole dose should be reduce .
& quot ;
& quot ; Abseamed must not be use
& quot ;
& quot ;
& quot ; therefore , in patient with renal anaemia the medicinal product have to be administer intravenously .
& quot ;
& quot ; Lietuva BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; patient receive aripiprazole solution for injection should be observe for orthostatic hypotension .
& quot ;
& quot ; if you be an elderly patient suffer from dementia ( loss of memory and other mental ability ) , you or your carer / relative should tell your doctor if you have ever have a stroke or & quot ; & quot ; mini & quot ; & quot ; stroke .
& quot ;
& quot ; justification for not include braille accept .
& quot ;
& quot ; therefore , aripiprazole should be use with caution in patient who have a history of seizure disorder or have condition associate with seizure .
& quot ;
& quot ; Smoking and race :
& quot ;
& quot ; early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid , for example , be recommend in these patient .
& quot ;
& quot ; Cerebrovascular adverse event : in the same trial , cerebrovascular adverse event ( e. g. stroke , transient ischaemic attack ) , include fatality , be report in patient ( mean age :
& quot ;
& quot ; the protein fraction of the molecule contribute about 58 % and consist of 165 amino acid .
& quot ;
& quot ; 2 .
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; a hormone call erythropoietin stimulate the production of red blood cell from the bone marrow .
& quot ;
& quot ; a slower injection be preferable in patient who react to the treatment with “ flu-like ” symptom .
& quot ;
& quot ; further information
& quot ;
& quot ; in addition , case of stroke or & quot ; & quot ; mini & quot ; & quot ; stroke have be report .
& quot ;
& quot ; Aripiprazole and other antipsychotic drug should be use cautiously in patient at risk for aspiration pneumonia .
& quot ;
& quot ; ask your pharmacist how to dispose of medicine no longer require .
& quot ;
& quot ; when use to treat bipolar disorder , Abilify be more effective than placebo at reduce manic symptom in four of the five short-term study .
& quot ;
& quot ; Polska BRISTOL-MYERS SQUIBB POLSKA SP .
& quot ;
& quot ; it do not matter whether you take it with or without food .
& quot ;
& quot ; Arthralgia , myalgia .
& quot ;
& quot ; uncontrolled hypertension .
& quot ;
& quot ; Č eská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; Hypersensitivity : a with other medication hypersensitivity reaction , characterise by allergic symptom , may occur with aripiprazole ( see section 4.8 ) .
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; store in the original package in order to protect from moisture .
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; driving and use machine do not drive or use any tool or machine until you know how ABILIFY affect you .
& quot ;
& quot ; the recommended dosing regimen be describe in the following diagram :
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; overall , 1.3 % of aripiprazole-treated patient report cerebrovascular adverse event compare with 0.6 % of placebo-treated patient in these trial .
& quot ;
& quot ; and Hb increase & lt ; 1 g / dl
& quot ;
& quot ; Hyperglycaemia and diabetes mellitus : hyperglycaemia , in some case extreme and associate with ketoacidosis or hyperosmolar coma or death , have be report in patient treat with atypical antipsychotic agent , include ABILIFY .
& quot ;
& quot ; patient with active malignant disease receive neither chemotherapy nor radiation therapy .
& quot ;
& quot ; elderly patient with dementia-related psychosis :
& quot ;
& quot ; Smoking and race :
& quot ;
& quot ; your doctor will decide when you need another dose of ABILIFY solution for injection .
& quot ;
& quot ; these result be consistent with biochemical marker evidence of normalisation of bone turnover .
& quot ;
& quot ; EU / 1 / 07 / 412 / 009 EU / 1 / 07 / 412 / 010
& quot ;
& quot ; the recommend starting dose for ABILIFY be 10 or 15 mg / day with a maintenance dose of 15 mg / day administer on a once-a-day schedule without regard to meal .
& quot ;
& quot ; this medicinal product must not be administer by intravenous infusion , or mixed with other medicinal product .
& quot ;
& quot ; although the cause of death be vary , most of the death appear to be either cardiovascular ( e. g. heart failure , sudden death ) or infectious ( e. g. pneumonia ) in nature .
& quot ;
& quot ; elderly :
& quot ;
& quot ; 4 .
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) , the dose should be reduce by approximately 25 to 50 % .
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; ABILIFY be not approve for the treatment of dementia-related psychosis .
& quot ;
& quot ; these trial include patient with or without psychotic feature and with or without a rapid-cycling course .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; a rise in haemoglobin of greater than 2 g / dl ( 1.25 mmol / l ) over a four week period should be avoid .
& quot ;
& quot ; Non-specific skin rash have be describe in association with epoetin alfa .
& quot ;
& quot ; Suicidal thought and behaviour have be report during aripiprazole treatment .
& quot ;
& quot ; if you have any further question on the use of this product , ask your doctor or pharmacist .
& quot ;
& quot ; the n , the vial should gently and slowly be swirl and / or invert for at least 2 minute until complete resuspension of any powder occur .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; benefit outweighs the potential risk to the foetus .
& quot ;
& quot ; the bioavailability of subcutaneous injectable epoetin alfa be much lower than that of the intravenous medicinal product : approximately 20 % .
& quot ;
& quot ; Erythropoietin be a growth factor that primarily stimulate red cell production .
& quot ;
& quot ; Shunt thromboses may occur , especially in patient who have a tendency to hypotension or whose arteriovenous fistula exhibit complication ( e. g. stenosis , aneurysm , etc . ) .
& quot ;
& quot ; EU / 1 / 07 / 412 / 016
& quot ;
& quot ; for the full list of all side effect report with Abilify , see the package Leaflet .
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ; when concomitant administration of potent CYP3A4 inducer with aripiprazole occurs , the aripiprazole dose should be increase .
& quot ;
& quot ; however , in one of these trial , a fixed-dose trial , there be a significant dose response relationship for cerebrovascular adverse event in patient treat with aripiprazole .
& quot ;
& quot ; if after an additional 4 week of therapy at 300 IU / kg 3 time per week , the haemoglobin have increase ≥ 1 g / dl ( ≥ 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl the dose should remain at 300 IU / kg 3 time per week .
& quot ;
& quot ; alternatively , the injection can be give at the end of the dialysis session via the fistula needle tubing , follow by 10 ml of isotonic saline to rinse the tubing and ensure satisfactory injection of the product into the circulation .
& quot ;
& quot ; 142 A .
& quot ;
& quot ; therefore , aripiprazole should be use with caution in patient who have a history of seizure disorder or have condition associate with seizure .
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; 56 for the purpose of ambulatory use , the patient may remove Abseamed from the refrigerator and store it not above 25 ° C for one single period of up to 3 day .
& quot ;
& quot ; Tel : + 39 06 50 39 61
& quot ;
& quot ; however , in one of these trial , a fixed-dose trial , there be a significant dose response relationship for cerebrovascular adverse event in patient treat with aripiprazole .
& quot ;
& quot ; the bioavailability of subcutaneous injectable epoetin alfa be much lower than that of the intravenous medicinal product : approximately 20 % .
& quot ;
& quot ; at the time of donate blood , Abseamed should be administer after the completion of the blood donation procedure .
& quot ;
& quot ; the following reaction have also occur in isolated patient with normal or low blood pressure : hypertensive crisis with encephalopathy-like symptom ( e. g. headache and confused state ) and Generalised tonoclonal seizure , require the immediate attention of a physician and intensive medical care .
& quot ;
& quot ; 167 detailed information on this medicine be available on the European Medicines Agency ( EMEA ) web site : http : / / www . emea . europa . EU /
& quot ;
& quot ; what be Abilify use for ?
& quot ;
& quot ; in the absence of compatibility study , this medicinal product must not be mix with other medicinal product .
& quot ;
& quot ; agitation , nervousness ; suicide attempt , suicidal ideation , and complete suicide ( see section 4.4 )
& quot ;
& quot ; method of administration
& quot ;
& quot ; other potent inhibitor of CYP3A4 , such a itraconazole and HIV protease inhibitor , may be expect to have similar effect and similar dose reduction should therefore be apply .
& quot ;
& quot ; 2 .
& quot ;
& quot ; animal study could not exclude potential developmental toxicity ( see section 5.3 ) .
& quot ;
& quot ; 2000 IU / 1.0 ml
& quot ;
& quot ; summary of vertebral fracture efficacy at 12 , 24 and 36 month
& quot ;
& quot ; other potent inhibitor of CYP3A4 , such a itraconazole and HIV protease inhibitor , may be expect to have similar effect and similar dose reduction should therefore be apply .
& quot ;
& quot ; expiry date
& quot ;
& quot ; 4 .
& quot ;
& quot ; the intravenous route have to be use ( please see section 4.4 - chronic renal failure patient ) .
& quot ;
& quot ; it exact mechanism of action be unknown , but it attach to several different receptor on the surface of nerve cell in the brain .
& quot ;
& quot ; Pack of 1 or 6 syrinx .
& quot ;
& quot ; other potent inhibitor of CYP3A4 , such a itraconazole and HIV protease inhibitor , may be expect to have similar effect and similar dose reduction should therefore be apply .
& quot ;
& quot ; upon discontinuation of potent CYP3A4 inducer , the dosage of ABILIFY should be reduce to the recommend dose .
& quot ;
& quot ; in most case , the ferritin value in the serum fall simultaneously with the rise in packed cell volume .
& quot ;
& quot ; 3 .
& quot ;
& quot ; B .
& quot ;
& quot ; EU / 1 / 07 / 428 / 001
& quot ;
& quot ; ask your doctor or pharmacist for advice before take ABILIFY .
& quot ;
& quot ; 61 150 IU / kg 3x / week or 450 IU / kg once weekly
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ; before you take ABILIFY
& quot ;
& quot ; survival and tumour progression have be examine in five large control study involve a total of 2833 patient , of which four be double-blind placebo-controlled study and one be an open- label study .
& quot ;
& quot ; further information on clinical trial :
& quot ;
& quot ; Erythropoietins be growth factor that primarily stimulate red blood cell production .
& quot ;
& quot ; special storage condition
& quot ;
& quot ; oropharyngeal spasm , laryngospasm , aspiration pneumonia
& quot ;
& quot ; B03XA01
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; Aripiprazole be metabolise by multiple pathway involve the CYP2D6 and CYP3A4 enzyme but not CYP1A enzyme .
& quot ;
& quot ; for subcutaneous and intravenous use .
& quot ;
& quot ; 6 .
& quot ;
& quot ; the usual dose be 15 mg once a day .
& quot ;
& quot ; 81 1 .
& quot ;
& quot ; the Member States shall ensure that prior to launch the MAH provide health care professional in dialysis centre and retail pharmacy with :
& quot ;
& quot ; driving and use machine do not drive or use any tool or machine , until you know how ABILIFY affect you .
& quot ;
& quot ; before you take ABILIFY
& quot ;
& quot ; the use of epoetin alfa in patient schedule for major elective orthopaedic surgery and not participate in an autologous blood predonation programme be contraindicate in patient with severe coronary , peripheral arterial , carotid or cerebral vascular disease , include patient with recent myocardial infarction or cerebral vascular accident .
& quot ;
& quot ; & gt ; 1st-line therapy
& quot ;
& quot ; 10 .
& quot ;
& quot ; the first involve almost 8,000 elderly woman with osteoporosis , look at the number of spine and hip fracture over three year .
& quot ;
& quot ; oral use
& quot ;
& quot ; Metabolism and nutrition disorder :
& quot ;
& quot ; 5 .
& quot ;
& quot ; do not shake .
& quot ;
& quot ; instruction on use
& quot ;
& quot ; if foaming or clumping occurs , the suspension should stand for at least 15 minute until foam subsides .
& quot ;
& quot ; Abseamed 6000 IU / 0.6 ml solution for injection in a pre-filled syringe The syrinx contain 0.6 ml ( 6000 IU ) of solution .
& quot ;
& quot ; if anti-erythropoietin , antibody-mediated PRCA be suspect , therapy with Abseamed should be discontinue immediately .
& quot ;
& quot ; 2 .
& quot ;
& quot ; how to use Abseamed 4 .
& quot ;
& quot ; management of overdose should concentrate on supportive therapy , maintain an adequate airway , oxygenation and ventilation , and management of symptom .
& quot ;
& quot ; Orodispersible Tablet
& quot ;
& quot ; Haemoglobin level should be measure on a regular basis until a stable level be achieve and periodically thereafter .
& quot ;
& quot ; developmental toxicity , include dose-dependent delayed foetal ossification and possible teratogenic effect , be observe in rat at dos result in subtherapeutic exposure ( base on AUC ) and in rabbit at dos result in exposure 3 and 11 time the mean steady-state AUC at the maximum recommend clinical dose .
& quot ;
& quot ; Č eská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; Tel . : + 36 1 301 9700
& quot ;
& quot ; generally , child under 30 kg require higher maintenance dos than child over 30 kg and adult .
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; it do not matter whether you take it with or without food .
& quot ;
& quot ; some patient may benefit from a higher dose .
& quot ;
& quot ; a per the CHMP guideline on risk management system for medicinal product for human use , the updated RMP should be submit at the same time a the next Periodic Safety update Report ( PSUR ) .
& quot ;
& quot ; 2 .
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; in the single-dose dog infusion study , 1.0 mg / kg ( 6 fold the recommended human therapeutic exposure base on AUC ) administer over 15 minute be well tolerate with no renal effect .
& quot ;
& quot ; Hypertensive crisis with encephalopathy-like symptom can occur .
& quot ;
& quot ; România BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; method OF administration
& quot ;
& quot ; if you be take cyclosporin ( medicine to suppress your immune system ) during therapy with Abseamed , your doctor may order special blood test to measure cyclosporin level .
& quot ;
& quot ; in controlled clinical study , use of Epoetin alfa and other erythropoiesis-stimulating agent ( ESAs ) have show :
& quot ;
& quot ; Abseamed
& quot ;
& quot ; label / SYRINGE
& quot ;
& quot ; Epoetin alfa IV / SC
& quot ;
& quot ; in elderly patient with dementia , more fatal case have be report while take aripiprazole .
& quot ;
& quot ; - In pregnant or lactating surgical patient participate in an autologous blood predonation
& quot ;
& quot ; 5 .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; the occurrence of suicidal behaviour be inherent in psychotic illness and mood disorder and in some case have be report early after initiation or switch of antipsychotic therapy , include treatment with aripiprazole ( see section 4.8 ) .
& quot ;
& quot ; 5 .
& quot ;
& quot ; how to store ABILIFY
& quot ;
& quot ; BATCH number
& quot ;
& quot ; treatment with a 5 mg annual dose of Aclasta significantly reduce BSAP by 30 % relative to baseline at 12 month which be sustain at 28 % below baseline level at 36 month .
& quot ;
& quot ; the apparent molecular weight of erythropoietin be 32,000 to 40,000 dalton .
& quot ;
& quot ; 188 2 .
& quot ;
& quot ; during antipsychotic treatment , improvement in the patient & apos ; s clinical condition may take several day to some week .
& quot ;
& quot ; Pharmacotherapeutic group : antipsychotic , ATC code :
& quot ;
& quot ; - In pregnant or lactating surgical patient participate in an autologous blood predonation
& quot ;
& quot ; additional supportive care should be provide a necessary .
& quot ;
& quot ; 15 .
& quot ;
& quot ; Smoking and race :
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and then reinstitute epoetin alfa therapy at a dose 25 % below the previous level .
& quot ;
& quot ; 14 .
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg , Kuhloweg 37 , D-58638 Iserlohn , Germany
& quot ;
& quot ; 52 Activated charcoal ( 50 g ) , administer one hour after aripiprazole , decrease aripiprazole Cmax by about 41 % and AUC by about 51 % , suggest that charcoal may be effective in the treatment of overdose .
& quot ;
& quot ; EU / 1 / 07 / 412 / 004
& quot ;
& quot ; do not use ABILIFY after the expiry date which be state on the blister and on the carton .
& quot ;
& quot ; 4 .
& quot ;
& quot ; if the suspension contact the skin , the skin should be wash immediately and thoroughly with soap and water .
& quot ;
& quot ; 1 pre-filled syringe of 0.9 ml contains 9000 international unit ( IU ) correspond to 75.6 microgram epoetin alfa
& quot ;
& quot ; EXP
& quot ;
& quot ; 7 .
& quot ;
& quot ; 82.4 year ; range :
& quot ;
& quot ; detail information on this product be available on the website of the European Medicines Agency ( EMEA ) http : / / www . emea . europa . EU /
& quot ;
& quot ; 13 .
& quot ;
& quot ;
& quot ; Abseamed 5000 IU / 0.5 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; this medicine have be prescribe for you .
& quot ;
& quot ; adjustment of daily dosage , include dose reduction should be consider on the basis of clinical status .
& quot ;
& quot ; the potentially medically serious sign and symptom report included somnolence , transient loss of consciousness and extrapyramidal symptom .
& quot ;
& quot ; no interaction study have be perform .
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; therefore cardiovascular monitoring should be start immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmia .
& quot ;
& quot ; the study either recruited patient who be be treat with chemotherapy ( two study ) or use patient population in which erythropoiesis stimulating agent be not indicate : anaemia in patient with cancer not receive chemotherapy , and head and neck cancer patient receive radiotherapy .
& quot ;
& quot ; 16 .
& quot ;
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; 67 mg lactose per tablet
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; each carton contain 1 bottle and both a calibrate polypropylene measure cup and a calibrated polypropylene low-density polyethylene dropper .
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; Conduction abnormality :
& quot ;
& quot ; independent of erythropoietin treatment , thrombotic and vascular event may occur in surgical patient with underlying cardiovascular disease follow repeat phlebotomy .
& quot ;
& quot ; there be an increased risk for thromboembolic event in patient with cancer treat with recombinant human erythropoietin and a negative impact on overall survival can not be exclude .
& quot ;
& quot ; in patient with severe hepatic impairment , the data available be insufficient to establish recommendation .
& quot ;
& quot ; 5 .
& quot ;
& quot ; EU / 1 / 07 / 412 / 015
& quot ;
& quot ; EU / 1 / 07 / 412 / 005 EU / 1 / 07 / 412 / 006
& quot ;
& quot ; weight gain : in clinical trial aripiprazole have not be show to induce clinically relevant weight gain .
& quot ;
& quot ; start dose of 50 IU / kg 3 time per week by the intravenous route , follow if necessary by a dose increase with 25 IU / kg increment ( 3 time per week ) until the desired goal be achieve ( this should be do in step of at least four week ) .
& quot ;
& quot ; lot
& quot ;
& quot ; le than 1 % of unchanged aripiprazole be excrete in the urine and approximately 18 % be recover unchanged in the faeces .
& quot ;
& quot ; Τηλ : + 357 22 677038
& quot ;
& quot ; 4 .
& quot ;
& quot ; EU / 1 / 07 / 412 / 019 EU / 1 / 07 / 412 / 020
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; what be Aclasta ?
& quot ;
& quot ; in clinical trial and post-marketing experience , accidental or intentional acute overdosage of aripiprazole alone be identify in adult patient with report estimate dose up to 1,260 mg with no fatality .
& quot ;
& quot ; 56-99 year ) of aripiprazole in elderly patient with psychosis associate with Alzheimer & apos ; s disease , patient treat with aripiprazole be at increase risk of death compare to placebo .
& quot ;
& quot ; Erythropoietins be growth factor that primarily stimulate red blood cell production .
& quot ;
& quot ; for subcutaneous and intravenous use .
& quot ;
& quot ; Belgique / België / Belgien BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; patient with metastatic breast cancer receive chemotherapy when administer to target a haemoglobin of 12 - 14 g / dl ( 7.5 – 8.7 mmol / l ) ,
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; Schizophrenia :
& quot ;
& quot ; dose ( IU / kg give 3x / week )
& quot ;
& quot ; - treatment of severe anaemia of renal origin accompany by clinical symptom in adult patient
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ; ask your doctor for advice before take this medicine .
& quot ;
& quot ; BLISTER
& quot ;
& quot ; if you have any further question on the use of this product , ask your doctor or pharmacist .
& quot ;
& quot ; label / SYRINGE
& quot ;
& quot ; Endocrine disorder :
& quot ;
& quot ; Myalgia occur in 24 % of patient on Abraxane and be severe in 7 % of case .
& quot ;
& quot ; ABILIFY 5 mg tablet aripiprazole
& quot ;
& quot ; there be no accumulation : the level remain the same , whether they be determined 24 hour after the first injection or 24 hour after the last injection .
& quot ;
& quot ; 2 mg aspartame ( E951 ) per orodispersible tablet
& quot ;
& quot ; if you be an elderly patient suffer from dementia ( loss of memory and other mental ability ) , you or your carer / relative should tell your doctor if you have ever have a stroke or & quot ; & quot ; mini & quot ; & quot ; stroke .
& quot ;
& quot ; if after an additional 4 week of therapy at 300 IU / kg 3 time per week , the haemoglobin have increase ≥ 1 g / dl ( ≥ 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl the dose should remain at 300 IU / kg 3 time per week .
& quot ;
& quot ; in case where there be a medical need to shorten the lead time before surgery to le than three week , 300 IU / kg epoetin alfa should be give daily for 10 consecutive day prior to surgery , on the day of surgery and for four day immediately thereafter .
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; due to it α 1-adrenergic receptor antagonism , aripiprazole have the potential to enhance the effect of certain antihypertensive agent .
& quot ;
& quot ; in the open-label study there be no difference in overall survival between patient treat with recombinant human erythropoietin and control .
& quot ;
& quot ; Kidney patient
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; management of overdose should concentrate on supportive therapy , maintain an adequate airway , oxygenation and ventilation , and management of symptom .
& quot ;
& quot ; it also prevent this condition from return in patient who have respond to the treatment with ABILIFY .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; care should be take to ensure that at the outset of the treatment patient be not iron deficient .
& quot ;
& quot ; when concomitant administration of potent CYP3A4 inducer with aripiprazole occurs , the aripiprazole dose should be increase .
& quot ;
& quot ; Aclasta be use for the treatment of the following disease : • osteoporosis ( a disease that make bone fragile ) , both in woman who have be through the menopause and in men .
& quot ;
& quot ; other infrequently report side effect :
& quot ;
& quot ; 28 August 2007
& quot ;
& quot ; Manic episode :
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; United Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel : + 44 ( 0800 ) 731 1736
& quot ;
& quot ; Excipients
& quot ;
& quot ; the therapeutic margin of epoetin alfa be very wide .
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; in some preclinical toxicological study in dog and rat , but not in monkey , epoetin alfa therapy be associate with subclinical bone marrow fibrosis ( bone marrow fibrosis be a known complication of chronic renal failure in human and may be relate to secondary hyperparathyroidism or unknown factor .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery , with a baseline haemoglobin of 10 to 13 g / dl , the incidence of thrombotic / vascular event ( most of which be DVTs ) , in the overall patient population of the clinical trial , appear to be similar across the different epoetin alfa dose group and placebo group , although the clinical experience be limit .
& quot ;
& quot ; 1 .
& quot ;
& quot ; Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance , a describe in the version 3.0 date 13 July 2007 present in Module 1.8.1. of the marketing authorisation application , be in place and functioning before and whilst the product be on the market .
& quot ;
& quot ; Toxicologically significant effect be observe only at dos or exposure that be sufficiently in excess of the maximum human dose or exposure , indicate that these effect be limited or of no relevance to clinical use .
& quot ;
& quot ; Ελλάδα BRISTOL-MYERS SQUIBB A. e .
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; what ABILIFY be and what it be use for 2 .
& quot ;
& quot ; 4 .
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; 13 .
& quot ;
& quot ; consequently :
& quot ;
& quot ; Thrombocytosis have be observe but it occurrence be very rare ( see section 4.4 ) .
& quot ;
& quot ; Administer the amount require .
& quot ;
& quot ; animal study could not exclude potential developmental toxicity ( see section 5.3 ) .
& quot ;
& quot ; 26.5 & # 91 ; 18.98 , 34.05 & # 93 ; ( n = 132 )
& quot ;
& quot ; increase Creatine Phosphokinase , blood glucose increase , blood glucose fluctuation , glycosylated haemoglobin increase
& quot ;
& quot ; other
& quot ;
& quot ; thus , aripiprazole be unlikely to cause clinically important medicinal product interaction mediate by these enzyme .
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery should receive adequate antithrombotic prophylaxis , a thrombotic and vascular event may occur in surgical patient , especially in those with underlying cardiovascular disease .
& quot ;
& quot ; single and multiple 5 and 15-minute infusion of 2 , 4 , 8 and 16 mg zoledronic acid in 64 patient yield the following pharmacokinetic data , which be find to be dose independent .
& quot ;
& quot ; Metastatic pain , tumour necrosis Common :
& quot ;
& quot ; 11 .
& quot ;
& quot ; ( 44-20 ) 74 18 84 00 fax ( 44-20 ) 74 18 84 16 e-mail : mail @ emea . europa . EU http : / / www . emea . europa . EU
& quot ;
& quot ; 152 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; Absorption :
& quot ;
& quot ; the medicine can only be obtain with a prescription .
& quot ;
& quot ; in two 12-week , placebo- and active-controlled monotherapy trial in patient with a manic or mixed episode of Bipolar I Disorder , with or without psychotic feature , aripiprazole demonstrate superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12 .
& quot ;
& quot ; in these patient dose should be manage cautiously .
& quot ;
& quot ; 169 tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever , sweat , alter mental status , or very rapid or irregular heart beat .
& quot ;
& quot ; if aripiprazole be administer concomitantly with medicine know to cause QT prolongation or electrolyte imbalance , caution should be use .
& quot ;
& quot ; EXP
& quot ;
& quot ; BRISTOL-MYERS SQUIBB GESMBH Tel : + 43 1 60 14 30
& quot ;
& quot ; Comparisons between aripiprazole and placebo in the proportion of patient experience potentially clinically significant change in routine laboratory parameter reveal no medically important difference .
& quot ;
& quot ; in one 3-week , fixed-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole fail to demonstrate superior efficacy to placebo .
& quot ;
& quot ; Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel : + 353 ( 1 800 ) 749 749
& quot ;
& quot ; Tablet
& quot ;
& quot ; an increase in heparin dose during haemodialysis be frequently require during the course of therapy with epoetin alfa a a result of the increase packed cell volume .
& quot ;
& quot ; ABILIFY be effective in maintain the clinical improvement during continuation therapy in patient who have show an initial treatment response .
& quot ;
& quot ; in addition , special precaution should be take in patient with predisposition for development of deep vein thrombosis ( DVTs ) .
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6.8 g / dl or & lt ; 4.25 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 6.8 g / dl or & gt ; 4.25 mmol / l ) .
& quot ;
& quot ; treatment of patient with chemotherapy induce anaemia :
& quot ;
& quot ; these study have show an consistent unexplained statistically significant excess mortality in patient who have anaemia associate with various common cancer who receive recombinant human erythropoietin compare to control .
& quot ;
& quot ; speech disorder , Neuroleptic Malignant syndrome ( NMS ) , grand mal convulsion
& quot ;
& quot ; EPAR summary for the public
& quot ;
& quot ; Neutropenia be the most notable important haematological toxicity ( report in 79 % of patient ) , and be rapidly reversible and dose dependent ; leukopenia be report in 71 % of patient .
& quot ;
& quot ; 5 .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; in the long term 26-week maintenance phase of a placebo-controlled trial , the incidence of EPS be 18.2 % for aripiprazole-treated patient and 15.7 % for placebo-treated patient .
& quot ;
& quot ; treatment of adult patient schedule for major elective orthopaedic surgery :
& quot ;
& quot ; oral use
& quot ;
& quot ; 73 Correction phase :
& quot ;
& quot ; United Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel : + 44 ( 0800 ) 731 1736
& quot ;
& quot ; in addition , case of stroke or & quot ; & quot ; mini & quot ; & quot ; stroke have be report .
& quot ;
& quot ; however , elevate creatine phosphokinase and rhabdomyolysis , not necessarily in association with NMS , have also be report .
& quot ;
& quot ; 12 .
& quot ;
& quot ; the rate of death in aripiprazole-treated patient be 3.5 % compare to 1.7 % in the placebo group .
& quot ;
& quot ; long-term carcinogenicity study have not be carry out .
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ;
& quot ; Polska BRISTOL-MYERS SQUIBB POLSKA SP .
& quot ;
& quot ; treatment of patient with chemotherapy induce anaemia :
& quot ;
& quot ; take other medicine please tell your doctor or pharmacist if you be take or have recently take any other medicine , include medicine obtain without a prescription .
& quot ;
& quot ; Pre-filled syrinx ( glass type I ) with plunger ( Teflon-faced rubber ) seal in a blister .
& quot ;
& quot ; this medicinal product do not require any special storage condition .
& quot ;
& quot ; - do not use this medicine after the expiry date which be state on the label and carton after
& quot ;
& quot ; in another long-term 26-week control trial , the incidence of EPS be 14.8 % for aripiprazole-treated patient and 15.1 % for olanzapine-treated patient .
& quot ;
& quot ; additional sign may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
& quot ;
& quot ; oral use
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; the pre-filled syrinx be ready to use ( see section 4.2 – method of administration ) .
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; John & apos ; s Wort ) may be expect to have similar effect and similar dose increase should therefore be apply .
& quot ;
& quot ; no study on the effect on the ability to drive and use machine have be perform .
& quot ;
& quot ; in order to ensure optimum response to epoetin alfa , adequate iron store should be assure :
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; cardiovascular disorder :
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; 6 .
& quot ;
& quot ; patient who develop pure red Cell Aplasia ( PRCA ) follow treatment with any erythropoietin should not receive Abseamed or any other erythropoietin ( see section 4.4 - pure red Cell Aplasia ) .
& quot ;
& quot ; this correspond to a 28 % reduction in the risk of all cause mortality ( p = 0.01 ) .
& quot ;
& quot ; the natural course of peripheral neuropathy to resolution to baseline due to cumulative toxicity of Abraxane after & gt ; 6 course of treatment be not evaluate and remain unknown .
& quot ;
& quot ; Cardiac disorder :
& quot ;
& quot ; Ísland VISTOR HF Sími : + 354 535 7000
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; 6 pre-filled syrinx
& quot ;
& quot ; Τηλ : + 30 210 6074300
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; within each frequency grouping , undesirable effect be present in order of decrease seriousness .
& quot ;
& quot ; 0.7 ml ( 10000 IU / ml )
& quot ;
& quot ; Aripiprazole be widely distribute throughout the body with an apparent volume of distribution of 4.9 l / kg , indicate extensive extravascular distribution .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; the procedure for reconstitution be describe in section 6.6 .
& quot ;
& quot ; in the four placebo-controlled study the hazard ratio for overall survival range between 1.25 and 2.47 in favour of control .
& quot ;
& quot ; thus , aripiprazole be unlikely to cause clinically important medicinal product interaction mediate by these enzyme .
& quot ;
& quot ; 4 .
& quot ;
& quot ; 14 .
& quot ;
& quot ; each ml of solution contain 10 000 IU of epoetin alfa * correspond to 84.0 microgram per ml 1 pre-filled syringe of 1 ml contain 10 000 international unit ( IU ) correspond to 84.0 microgram epoetin alfa
& quot ;
& quot ; patient ) be recommend for chronic renal failure patient whose serum ferritin level be below 100 ng / ml
& quot ;
& quot ; the metabolism of paclitaxel be catalyse , in part , by cytochrome P450 isoenzymes CYP2C8 and CYP3A4 ( see section 5.2 ) .
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; temperature regulation disorder ( e. g. hypothermia , pyrexia ) , chest pain , peripheral oedema
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; no evidence exist that indicate an interaction between epoetin alfa and G-CSF or GM-CSF with regard to haematological differentiation or proliferation of tumour biopsy specimen in vitro .
& quot ;
& quot ; human albumin solution ( contain sodium , sodium caprylate and N-acetyl DL tryptophanate )
& quot ;
& quot ;
& quot ; the epoetin alfa in Abseamed be produce by ‘ recombinant DNA technology ’ : it be make by a cell that have receive a gene ( DNA ) , which make it able to produce epoetin alfa .
& quot ;
& quot ; actual score in rating scale use a secondary endpoint , include PANSS and the Montgomery-Asberg Depression rating scale show a significant improvement over haloperidol .
& quot ;
& quot ; iron status should be evaluate prior to and during treatment and iron supplementation administer if necessary .
& quot ;
& quot ; 82.4 year ; range :
& quot ;
& quot ; the extent to which these outcome might apply to the administration of recombinant human erythropoietin to patient with cancer , treat with chemotherapy to achieve haemoglobin concentration le than 13 g / dl , be unclear because few patient with these characteristic be include in the data reviewed .
& quot ;
& quot ; it may be necessary to initiate or increase treatment against high blood pressure .
& quot ;
& quot ; Aripiprazole be the predominant medicinal product moiety in systemic circulation .
& quot ;
& quot ; elimination :
& quot ;
& quot ; tell your doctor immediately if you be have any thought or feeling about hurt yourself .
& quot ;
& quot ; pancreatitis , dysphagia , abdominal discomfort , stomach discomfort , diarrhoea
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; 114 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; undesirable effect know to be associate with antipsychotic therapy and also report during treatment with aripiprazole include neuroleptic malignant syndrome , tardive dyskinesia , seizure , cerebrovascular adverse event and increased mortality in elderly demented patient , hyperglycaemia and diabetes mellitus ( see section 4.4 ) .
& quot ;
& quot ; 7 .
& quot ;
& quot ; Aripiprazole should be use with caution in patient with known cardiovascular disease ( history of myocardial infarction or ischaemic heart disease , heart failure , or conduction abnormality ) , cerebrovascular disease , condition which would predispose patient to hypotension ( dehydration , hypovolemia , and treatment with antihypertensive medication ) or hypertension , include accelerate or malignant .
& quot ;
& quot ; these report be base on in vitro finding from human tumour sample , but be of uncertain significance in the clinical situation .
& quot ;
& quot ; information for the user
& quot ;
& quot ; 82.4 year ; range :
& quot ;
& quot ; 5 .
& quot ;
& quot ; in the long-term study , Abilify be more effective than placebo , and a effective a haloperidol , after up to a year of treatment .
& quot ;
& quot ; what ABILIFY be and what it be use for 2 .
& quot ;
& quot ; in several controlled study , epoetins have not be show to improve overall survival or decrease the risk of tumour progression in patient with anaemia associate with cancer .
& quot ;
& quot ; Pregnancy and breast-feeding you should not take ABILIFY if you be pregnant unless you have discuss this with your doctor .
& quot ;
& quot ; Absorption :
& quot ;
& quot ; Nederland BRISTOL-MYERS SQUIBB BV Tel : + 31 34 857 42 22
& quot ;
& quot ; all of the study measure the change in the patient ’ s symptom use a standard scale for schizophrenia .
& quot ;
& quot ; Abilify can be take with or without food .
& quot ;
& quot ; 6 .
& quot ;
& quot ; the dose you receive be base on your body surface area and blood test result .
& quot ;
& quot ; Phlebotomy may be perform if excessively high haemoglobin level occur .
& quot ;
& quot ; Aripiprazole undergo minimal pre-systemic metabolism .
& quot ;
& quot ; potential for ABILIFY to affect other medicinal product :
& quot ;
& quot ; temperature regulation disorder ( e. g. hypothermia , pyrexia ) , chest pain , peripheral oedema
& quot ;
& quot ; in haemodialysed patient , a bolus injection may be give during the dialysis session through a suitable venous port in the dialysis line .
& quot ;
& quot ; the potentially medically important sign and symptom observe included lethargy , increase blood pressure , somnolence , tachycardia , nausea , vomit and diarrhoea .
& quot ;
& quot ; invent name
& quot ;
& quot ; when see , it be usually in those with significant risk factor such a history of diabetes , thyroid disorder or pituitary adenoma .
& quot ;
& quot ; 160 Danmark BRISTOL-MYERS SQUIBB Tlf : + 45 45 93 05 06
& quot ;
& quot ; these measure will help to protect the environment .
& quot ;
& quot ; Batch
& quot ;
& quot ; Tel : + 421 2 59298411
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole , the active metabolite , decrease by 32 % and 47 % .
& quot ;
& quot ;
& quot ; laboratory test do not show an interaction between epoetin alfa and G-CSF or GM-CSF ( G-CSF and GM-CSF be medicine to stimulate the immune-system e. g. when receive a chemotherapy for cancer or in case of HIV ) .
& quot ;
& quot ; these symptom can temporally deteriorate or can even arise after discontinuation of treatment .
& quot ;
& quot ; 60 Dysphagia : oesophageal dysmotility and aspiration have be associate with antipsychotic drug use , include ABILIFY .
& quot ;
& quot ; the rare side-effects ( report in at least 1 in 10,000 patient ) be : • Lung infection • skin reaction to another agent follow radiation • Blood clot
& quot ;
& quot ; the orodispersible tablet can be take with or without liquid .
& quot ;
& quot ; EXP
& quot ;
& quot ; in placebo-controlled trial , the incidence of akathisia in bipolar patient be 12.1 % with aripiprazole and 3.2 % with placebo .
& quot ;
& quot ; 12.8 2.6 10.7
& quot ;
& quot ; 138 even if you feel better , do not alter or discontinue the daily dose of ABILIFY without first consult your doctor .
& quot ;
& quot ; be sure to tell your doctor immediately if you be pregnant , think you may be pregnant , or if you be plan to become pregnant .
& quot ;
& quot ;
& quot ; this regress during the course of continued therapy .
& quot ;
& quot ; gender :
& quot ;
& quot ; Pharmacotherapeutic group : antianaemic , ATC code :
& quot ;
& quot ; thus , aripiprazole be unlikely to cause clinically important medicinal product interaction mediate by these enzyme .
& quot ;
& quot ; similarly , for dehydro-aripiprazole the geometric mean
& quot ;
& quot ; expiry date
& quot ;
& quot ; Uncommon side effect ( greater than 1 in 1,000 , le than 1 in 100 patient ) some people may feel dizzy , especially when get up from a lying or sit position , or may experience a fast heart rate .
& quot ;
& quot ; before you take ABILIFY 3 .
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; 124 PARTICULARS to appear on the outer packaging
& quot ;
& quot ; in some preclinical toxicological study in dog and rat , but not in monkey , epoetin alfa therapy be associate with subclinical bone marrow fibrosis ( bone marrow fibrosis be a known complication of chronic renal failure in human and may be relate to secondary hyperparathyroidism or unknown factor .
& quot ;
& quot ; Abseamed be a sterile but unpreserved product and be for single use only .
& quot ;
& quot ; BLISTERS
& quot ;
& quot ; immune system disorder :
& quot ;
& quot ;
& quot ; in another long-term 26-week control trial , the incidence of EPS be 14.8 % for aripiprazole-treated patient and 15.1 % for olanzapine-treated patient .
& quot ;
& quot ; allergic reaction ( e. g. anaphylactic reaction , angioedema include swollen tongue , tongue oedema , face oedema , pruritus , or urticaria )
& quot ;
& quot ; contains aspartame .
& quot ;
& quot ; 3 .
& quot ;
& quot ; 6 .
& quot ;
& quot ; no study on the effect on the ability to drive and use machine have be perform .
& quot ;
& quot ; Pharmacokinetics in special patient group
& quot ;
& quot ; follow subcutaneous injection , serum level of epoetin alfa be much lower than the level achieve follow intravenous injection , the level increase slowly and reach a peak between 12 and
& quot ;
& quot ; distribution :
& quot ;
& quot ; Tablet
& quot ;
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; if precipitate or settle be visible , the vial should be gently invert again to ensure complete resuspension prior to use .
& quot ;
& quot ; - treatment of anaemia associate with chronic renal failure in paediatric and adult patient on
& quot ;
& quot ; 5 .
& quot ;
& quot ; - if any of the side effect get serious , or if you notice any side effect not list in this leaflet ,
& quot ;
& quot ; the overall completion rate be significantly higher for patient on aripiprazole ( 43 % ) than for haloperidol ( 30 % ) .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; vial ( glass )
& quot ;
& quot ; Abseamed 1000 IU / 0.5 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; this effect be maintain for up to 12 week .
& quot ;
& quot ; management of overdose should concentrate on supportive therapy , maintain an adequate airway , oxygenation and ventilation , and management of symptom .
& quot ;
& quot ; therefore , aripiprazole should be use with caution in patient who have a history of seizure disorder or have condition associate with seizure .
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; 1 pre-filled syringe of 0.7 ml contains 7000 international unit ( IU ) correspond to 58.8 microgram epoetin alfa
& quot ;
& quot ; Tel . : + 48 22 5796666
& quot ;
& quot ; treatment of symptomatic anaemia associate with chronic renal failure ( CRF ) in adult and paediatric patient :
& quot ;
& quot ; Serum electrolytes should be monitor in chronic renal failure patient .
& quot ;
& quot ; ABSEAMED
& quot ;
& quot ; information for the user
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; therefore , it should not be use in patient with baseline haemoglobin & gt ; 13 g / dl .
& quot ;
& quot ; pure red Cell Aplasia ( PRCA ) Antibody-mediated PRCA have be very rarely report after month to year of subcutaneous erythropoietin treatment .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; the initial dose be 150 IU / kg give subcutaneously 3 time per week .
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; in the indication “ increase the yield of autologous blood ” : myocardial infarction or stroke in the month precede treatment , unstable angina pectoris , increase risk of deep venous thrombosis such a history of venous thromboembolic disease .
& quot ;
& quot ; what benefit have Aclasta show during the study ?
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; Teл . : + 359 800 12 400
& quot ;
& quot ; potential for ABILIFY to affect other medicinal product :
& quot ;
& quot ; after a single treatment with Aclasta in Paget ’ s disease , an extended remission period be observe in respond patient ( see section 5.1 ) .
& quot ;
& quot ; s R. O .
& quot ;
& quot ; the recommended total weekly dose be between 75 and 300 IU / kg give by the intravenous route .
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; Abseamed 4000 IU / 0.4 ml solution for injection in a pre-filled syringe The syrinx contain 0.4 ml ( 4000 IU ) of solution .
& quot ;
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; patient with renal impairment : no dosage adjustment be require in patient with renal impairment .
& quot ;
& quot ; allergic reaction ( e. g. anaphylactic reaction , angioedema include swollen tongue , tongue oedema , face oedema , pruritus , or urticaria )
& quot ;
& quot ; Blood and the lymphatic system disorder :
& quot ;
& quot ; Batch
& quot ;
& quot ; 17 A .
& quot ;
& quot ; 9 .
& quot ;
& quot ; Intravenous route
& quot ;
& quot ; however , since cyclosporin be bind by red blood cell there be potential for an interaction .
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of anaemia and of the symptom of anaemia .
& quot ;
& quot ; Ísland VISTOR HF Sími : + 354 535 7000
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole , the active metabolite , decrease by 32 % and 47 % .
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; syncope , hypertension , thromboembolic event
& quot ;
& quot ; in three short-term ( 4 to 6 week ) placebo-controlled trial involve 1,228 schizophrenic patient , present with positive or negative symptom , aripiprazole be associate with statistically significantly greater improvement in psychotic symptom compare to placebo .
& quot ;
& quot ; the bioavailability of subcutaneous injectable epoetin alfa be much lower than that of the intravenous medicinal product : approximately 20 % .
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; Abseamed have no influence on the ability to drive and use machine .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; ESAs be not indicate for use in this patient population .
& quot ;
& quot ; in three short-term ( 4 to 6 week ) placebo-controlled trial involve 1,228 schizophrenic patient , present with positive or negative symptom , aripiprazole be associate with statistically significantly greater improvement in psychotic symptom compare to placebo .
& quot ;
& quot ; EU / 1 / 07 / 412 / 005
& quot ;
& quot ; lot
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ; base on information available to date , treatment of anaemia with Abseamed in adult patient with chronic kidney failure ( renal insufficiency ) who do not yet require dialysis , do not accelerate the rate of progression of renal insufficiency .
& quot ;
& quot ; ( 1 ) exclude finger , toe and facial fracture ( 2 ) include clinical thoracic and clinical lumbar vertebral fracture
& quot ;
& quot ; additional supportive care should be provide a necessary .
& quot ;
& quot ; these measure will help to protect the environment .
& quot ;
& quot ; 12 g / dl )
& quot ;
& quot ; after reconstitution , each ml of suspension contains 5 mg of paclitaxel .
& quot ;
& quot ; in the study of men and woman who have break their hip , 9 % of the patient receive Aclasta have a fracture ( 92 out of 1,065 ) , compare with 13 % of the patient receive placebo ( 139 out of 1,062 ) .
& quot ;
& quot ; 4 .
& quot ;
& quot ; speech disorder , Neuroleptic Malignant syndrome ( NMS ) , grand mal convulsion
& quot ;
& quot ; Haemoglobin variability should be address through dose management , with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; take special care with ABILIFY before treatment with ABILIFY , tell your doctor if you suffer from High blood sugar or family history of diabetes seizure Involuntary , irregular muscle movement , especially in the face cardiovascular disease , family history of cardiovascular disease , stroke or & quot ; & quot ; mini & quot ; & quot ; stroke , abnormal blood pressure
& quot ;
& quot ; special storage condition
& quot ;
& quot ; follow subcutaneous injection , serum level of epoetin alfa be much lower than the level achieve follow intravenous injection , the level increase slowly and reach a peak between 12 and
& quot ;
& quot ; 28 X 1
& quot ;
& quot ; Aripiprazole be excrete in the milk of treated rat during lactation .
& quot ;
& quot ; 11 .
& quot ;
& quot ; if haemoglobin have increase by at least 1 g / dl ( 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl above baseline after 4 week of treatment , the dose should remain at 150 IU / kg 3 time a week or 450 IU / kg once weekly .
& quot ;
& quot ; this leaflet be last approved in
& quot ;
& quot ; BATCH number
& quot ;
& quot ; Subcutaneous injection : a maximum volume of 1 ml at one injection site should generally not be exceed .
& quot ;
& quot ; Tel . : + 36 1 301 9700
& quot ;
& quot ; patient who for any reason can not receive adequate antithrombotic prophylaxis .
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg Kuhloweg 37 D-58638 Iserlohn
& quot ;
& quot ; Indigo carmine aluminium lake ( E132 )
& quot ;
& quot ; 3 .
& quot ;
& quot ; clear and colourless solution .
& quot ;
& quot ; transferrin saturation be below 20 % .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; the intravenous route have to be use ( please see section 4.4 - chronic renal failure patient ) .
& quot ;
& quot ; in case of larger volume , more than one site should be choose for the injection .
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; upon discontinuation of the CYP2D6 or 3A4 inhibitor , the dosage of ABILIFY should be increase to the level prior to the initiation of the concomitant therapy .
& quot ;
& quot ; with renal insufficiency not yet undergoing dialysis ( see section 4.4 ) .
& quot ;
& quot ; the recommend starting dose for ABILIFY be 10 or 15 mg / day with a maintenance dose of 15 mg / day administer on a once-a-day schedule without regard to meal .
& quot ;
& quot ; Occlusion of the dialysis system be possible if heparinisation be not optimum .
& quot ;
& quot ; haemodialysis and adult patient on peritoneal dialysis ( see section 4.4 ) .
& quot ;
& quot ; gender :
& quot ;
& quot ; Abseamed can be use to increase the yield of autologous blood from patient in a predonation programme .
& quot ;
& quot ; the most frequent adverse reaction be an increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ; 15 mg
& quot ;
& quot ; Abseamed 3000 IU / 0.3 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; if epoetin alfa be give concomitantly with cyclosporin , blood level of cyclosporin should be monitor and the dose of cyclosporin adjust a the haematocrit rise .
& quot ;
& quot ; Hepatic disease :
& quot ;
& quot ; the frequency of these event be consider not know ( can not be estimate from the available data ) .
& quot ;
& quot ; Manic episodes in Bipolar I Disorder - in a 12-week controlled trial , the incidence of EPS be 23.5 % for aripiprazole-treated patient and 53.3 % for haloperidol-treated patient .
& quot ;
& quot ; Clinical manifestation of NMS be hyperpyrexia , muscle rigidity , alter mental status and evidence of autonomic instability ( irregular pulse or blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
& quot ;
& quot ; distribution :
& quot ;
& quot ; Blood and the lymphatic system disorder :
& quot ;
& quot ; no evidence exist that indicate that treatment with epoetin alfa alter the metabolism of other medicinal product .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; it may harm them , even if their symptom be the same a yours .
& quot ;
& quot ; however , if the haemoglobin have increase & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , response to epoetin alfa therapy be unlikely and treatment should be discontinue .
& quot ;
& quot ; Pregnancy and breast-feeding you should not take ABILIFY if you be pregnant unless you have discuss this with your doctor .
& quot ;
& quot ; condition OF the marketing authorisation
& quot ;
& quot ; 6 .
& quot ;
& quot ; a with other antipsychotic , aripiprazole should be use with caution in patient with a family history of QT prolongation .
& quot ;
& quot ; Thrombotic event can be a risk in this population and this possibility should be carefully weigh against the benefit to be derive from the treatment in this patient group .
& quot ;
& quot ; Abseamed be a sterile but unpreserved product and be for single use only .
& quot ;
& quot ; 56-99 year ) of aripiprazole in elderly patient with psychosis associate with Alzheimer & apos ; s disease , patient treat with aripiprazole be at increase risk of death compare to placebo .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; upon discontinuation of the CYP2D6 or 3A4 inhibitor , the dosage of ABILIFY should be increase to the level prior to the initiation of the concomitant therapy .
& quot ;
& quot ; the recommended dosing regimen be describe in the following diagram :
& quot ;
& quot ; in a 6-week , placebo-controlled trial involve patient with a manic or mixed episode of Bipolar I Disorder , with or without psychotic feature , who be partially non-responsive to lithium or valproate monotherapy for 2 week at therapeutic serum level , the addition of aripiprazole a adjunctive therapy result in superior efficacy in reduction of manic symptom than lithium or valproate monotherapy .
& quot ;
& quot ; Lietuva BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; if you take more ABILIFY than you should if you realise you have take more ABILIFY orodispersible tablet than your doctor have recommend ( or if someone else have take some of your ABILIFY orodispersible tablet ) , contact your doctor right away .
& quot ;
& quot ; Magyarország BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; it may be necessary to add or increase antihypertensive treatment .
& quot ;
& quot ; a slower injection be preferable in patient who react to the treatment with “ flu-like ” symptom .
& quot ;
& quot ; the target haemoglobin concentration in two study be & gt ; 13 g / dl ; in the remain three study it be 12 - 14 g / dl .
& quot ;
& quot ; in cancer patient receive chemotherapy , the 2 - 3 week delay between epoetin alfa administration and the appearance of erythropoietin-induced red cell should be take into account when assess if epoetin alfa therapy be appropriate ( patient at risk of be transfuse ) .
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; start dose of 50 IU / kg 2 time per week by the intravenous route .
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; no evidence exist that indicate an interaction between epoetin alfa and G-CSF or GM-CSF with regard to haematological differentiation or proliferation of tumour biopsy specimen in vitro .
& quot ;
& quot ; the rate of death in aripiprazole-treated patient be 3.5 % compare to 1.7 % in the placebo group .
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg Kuhloweg 37 D-58638 Iserlohn
& quot ;
& quot ; a .
& quot ;
& quot ; for Paget ’ s disease , only one infusion of Aclasta be give .
& quot ;
& quot ; additional sign may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg Kuhloweg 37 D-58638 Iserlohn Germany
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; Hypertensive crisis with encephalopathy-like symptom can occur .
& quot ;
& quot ; - keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; the study be not design to measure significant difference in hip fracture , but a trend be see towards reduction in new hip fracture .
& quot ;
& quot ; all special warning and precaution associate with autologous predonation programme , especially routine volume replacement , should be respect .
& quot ;
& quot ; outer carton :
& quot ;
& quot ; at the time of donate blood , Abseamed should be administer after the completion of the blood donation procedure .
& quot ;
& quot ; 64 Activated charcoal ( 50 g ) , administer one hour after aripiprazole , decrease aripiprazole Cmax by about 41 % and AUC by about 51 % , suggest that charcoal may be effective in the treatment of overdose .
& quot ;
& quot ; market authorisation holder Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ;
& quot ; further information
& quot ;
& quot ; the possibility of multiple medicinal product involvement should be consider .
& quot ;
& quot ; the overall completion rate be significantly higher for patient on oral aripiprazole ( 43 % ) than for oral haloperidol ( 30 % ) .
& quot ;
& quot ; EU / 1 / 04 / 276 / 011 14 X 1 tablet EU / 1 / 04 / 276 / 012 28 X 1 tablet EU / 1 / 04 / 276 / 013 49 X 1 tablet EU / 1 / 04 / 276 / 014 56 X 1 tablet EU / 1 / 04 / 276 / 015 98 X 1 tablet
& quot ;
& quot ; these symptom can temporally deteriorate or can even arise after discontinuation of treatment .
& quot ;
& quot ; base on information available to date , correction of anaemia with epoetin alfa in adult patient with renal insufficiency not yet undergoing dialysis do not accelerate the rate of progression of renal insufficiency .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; the potentially medically serious sign and symptom report included somnolence , transient loss of consciousness and extrapyramidal symptom .
& quot ;
& quot ; up to three injection in 24 hour may be give .
& quot ;
& quot ; Tumour growth potential
& quot ;
& quot ; the second trial utilise a dose of 300 mg / m2 a a 30 minute infusion in 63 patient with metastatic breast cancer .
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; if epoetin alfa be give concomitantly with cyclosporin , blood level of cyclosporin should be monitor and the dose of cyclosporin adjust a the haematocrit rise .
& quot ;
& quot ; Medicines to correct heart rhythm Antidepressants or herbal remedy use to treat depression and anxiety Antifungal agent certain medicine to treat HIV infection Anticonvulsants use to treat epilepsy
& quot ;
& quot ; weight gain have be report post-marketing among patient prescribe ABILIFY .
& quot ;
& quot ; these symptom can temporally deteriorate or can even arise after discontinuation of treatment .
& quot ;
& quot ; kg Tel : + 49- ( 0 ) 2371 937 0
& quot ;
& quot ; weight ( kg ) & lt ; 10 10 - 30 & gt ; 30
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; 36 ( 0.62 mmol / l ) per month and should not exceed 2 g / dl ( 1.25 mmol / l ) per month to minimise risk of an increase in hypertension .
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; Epoetin alfa should be administer by the subcutaneous route to patient with anaemia ( e. g. haemoglobin concentration ≤ 10 g / dl ( 6.2 mmol / l ) .
& quot ;
& quot ; study in animal have show reproduction toxicity ( see section 5.3 ) .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; the pre-filled syringe should not be shake .
& quot ;
& quot ; thus , aripiprazole be unlikely to cause clinically important medicinal product interaction mediate by these enzyme .
& quot ;
& quot ; ensure that you only inject the amount a instruct by your doctor or nurse .
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl
& quot ;
& quot ; long-term carcinogenicity study have not be carry out .
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; the study either recruited patient who be be treat with chemotherapy ( two study ) or use patient population in which erythropoiesis stimulating agent be not indicate : anaemia in patient with cancer not receive chemotherapy , and head and neck cancer patient receive radiotherapy .
& quot ;
& quot ; enhance efficacy at dose higher than a daily dose of 15 mg have not be demonstrate although individual patient may benefit from a higher dose .
& quot ;
& quot ; adult surgery patient in an autologous predonation programme
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; may be harmful for people with phenylketonuria .
& quot ;
& quot ; Suicidal thought and behaviour have be report during aripiprazole treatment .
& quot ;
& quot ; for 4 week
& quot ;
& quot ; Tel : + 372 640 1301
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; 153 minimum PARTICULARS to appear on small immediate packaging unit
& quot ;
& quot ; the occurrence of suicidal behaviour be inherent in psychotic illness and mood disorder and in some case have be report early after initiation or switch of antipsychotic therapy , include treatment with aripiprazole ( see section 4.8 ) .
& quot ;
& quot ; Syringes be emboss with graduation ring and the filling volume be indicate by a stick-on label in order to enable partial use if require .
& quot ;
& quot ; 38 when either valproate or lithium be administer concomitantly with aripiprazole , there be no clinically significant change in aripiprazole concentration .
& quot ;
& quot ; Hyperglycaemia and Diabetes Mellitus : hyperglycaemia , in some case extreme and associate with ketoacidosis or hyperosmolar coma or death , have be report in patient treat with atypical antipsychotic agent , include ABILIFY .
& quot ;
& quot ; the effectiveness of the solution for injection be compare with placebo over a period of two hour in two study involve 805 patient with schizophrenia or related condition who be experience symptom of agitation .
& quot ;
& quot ; Lietuva BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; increase mortality : in three placebo-controlled trial ( n = 938 ; mean age :
& quot ;
& quot ; Tablet
& quot ;
& quot ; 7 .
& quot ;
& quot ; 16 when either valproate or lithium be administer concomitantly with aripiprazole , there be no clinically significant change in aripiprazole concentration .
& quot ;
& quot ; if blood pressure can not be control , epoetin alfa treatment should be discontinue .
& quot ;
& quot ; be sure to tell your doctor immediately if you be breast-feeding .
& quot ;
& quot ; consequently , haemoglobin and blood pressure should be closely monitor .
& quot ;
& quot ; always take ABILIFY exactly a your doctor have tell you .
& quot ;
& quot ; Dysphagia , flatulence , glossodynia , dry mouth , gingival pain , loose stool , oesophagitis , lower abdominal pain , mouth ulceration , oral pain , rectal haemorrhage Renal and urinary disorder :
& quot ;
& quot ; Č eská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; therefore , if you be be treat for anaemia associate with kidney disease , Abseamed have to be give by injection into a vein ( intravenously ) .
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; Aripiprazole also exhibit moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptor .
& quot ;
& quot ; s R. O .
& quot ;
& quot ; the protein fraction of the molecule contribute about 58 % and consist of 165 amino acid .
& quot ;
& quot ; there be no adequate and well-controlled study in pregnant woman .
& quot ;
& quot ; special storage condition
& quot ;
& quot ; patient treat with any antipsychotic agent , include ABILIFY , should be observe for sign and symptom of hyperglycaemia ( such a polydipsia , polyuria , polyphagia and weakness ) and patient with diabetes mellitus or with risk factor for diabetes mellitus should be monitor regularly for worsen of glucose control .
& quot ;
& quot ; Hypersensitivity : a with other medication hypersensitivity reaction , characterise by allergic symptom , may occur with aripiprazole ( see section 4.8 ) .
& quot ;
& quot ; 2 year
& quot ;
& quot ; Abseamed must not be use
& quot ;
& quot ; Phlebotomy may be perform if excessively high haemoglobin level occur .
& quot ;
& quot ; Tel : + 39 06 50 39 61
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; in the indication “ increase the yield of autologous blood ” : myocardial infarction or stroke in the month precede treatment , unstable angina pectoris , increase risk of deep venous thrombosis such a history of venous thromboembolic disease .
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; 1 bottle + 1 cup + 1 calibrate dropper
& quot ;
& quot ; the injection be give in the thigh or the anterior abdominal wall .
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; decrease weight , increase alanine aminotransferase , increase aspartate aminotransferase , decrease haematocrit , decrease red blood cell count , increase body temperature , increased investigation : gamma-glutamyltransferase , increase blood alkaline phosphatase
& quot ;
& quot ; the overall percentage of patient who experience post-dose symptom be 44.7 % , 16.7 % and 10.2 % after the first , second and third infusion , respectively .
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; patient with renal impairment : no dosage adjustment be require in patient with renal impairment .
& quot ;
& quot ; Subcutaneous route
& quot ;
& quot ; in addition , case of stroke or & quot ; & quot ; mini & quot ; & quot ; stroke have be report .
& quot ;
& quot ; a gastric acid blocker , the H2 antagonist famotidine , reduces aripiprazole rate of absorption but this effect be deem not clinically relevant .
& quot ;
& quot ; these report be base on in vitro finding from human tumour sample , but be of uncertain significance in the clinical situation .
& quot ;
& quot ; after injection of the necessary amount of the solution from the pre-filled syringe , discard any remain content .
& quot ;
& quot ; Metabolism and nutrition disorder :
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; 12 g / dl )
& quot ;
& quot ; Tel . : + 36 1 301 9700
& quot ;
& quot ; Single-arm open-label study
& quot ;
& quot ; it be especially important to mention the follow to your doctor :
& quot ;
& quot ; the dose of 5 mg zoledronic acid must be administer over at least 15 minute .
& quot ;
& quot ; after injection of the necessary amount of the solution from the pre-filled syringe , discard any remain content .
& quot ;
& quot ; 123 an increase incidence of thrombotic vascular event ( see section 4.4 and section 4.8 - General ) have be observe in patient receive erythropoietic agent .
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; common side effect ( greater than 1 in 100 , le than 1 in 10 patient ) Uncontrollable twitching or jerking movement , headache , tiredness , nausea , vomit , an uncomfortable feeling in the stomach , constipation , increased production of saliva , light-headedness , trouble sleeping , restlessness , feel anxious , sleepiness , shake and blurred vision .
& quot ;
& quot ; treatment of patient with chemotherapy induce anaemia :
& quot ;
& quot ; 16 .
& quot ;
& quot ; Dysuria , pollakiuria , haematuria , nocturia , polyuria , urinary incontinence
& quot ;
& quot ; in haemodialysed patient , a bolus injection may be give during the dialysis session through a suitable venous port in the dialysis line .
& quot ;
& quot ; do not use this medicine
& quot ;
& quot ; the effect of renal or hepatic dysfunction on the disposition of paclitaxel have not be formally investigate .
& quot ;
& quot ; 163 9 .
& quot ;
& quot ; Metabolism :
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP3A4 ( ketoconazole ) increase aripiprazole AUC and Cmax by 63 % and 37 % , respectively .
& quot ;
& quot ; 9 .
& quot ;
& quot ; the efficacy of one infusion of 5 mg zoledronic acid versus daily dos of 30 mg risedronate for 2 month be demonstrate in two 6-month comparative trial .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; treatment with Abseamed have to be initiate under the supervision of physician experience in the management of patient with the above indication .
& quot ;
& quot ; Κύπρος ΑΚΗΣ ΠΑΝΑΓΙΩΤΟΥ & amp ; ΥΙΟΣ Ε .Π .Ε .
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of the symptom of anaemia .
& quot ;
& quot ; 23 10 .
& quot ;
& quot ; statement OF active substance
& quot ;
& quot ; 81 an increase incidence of thrombotic vascular event ( see section 4.4 and section 4.8 - General ) have be observe in patient receive erythropoietic agent .
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be
& quot ;
& quot ; other potent inhibitor of CYP2D6 , such a fluoxetine and paroxetine , may be expect to have similar effect and similar dose reduction should therefore be apply .
& quot ;
& quot ; Sodium dihydrogen phosphate dihydrate Disodium phosphate dihydrate Sodium chloride Glycine Polysorbate 80 water for injection Hydrochloric acid ( for pH-adjustment ) Sodium hydroxide ( for pH-adjustment )
& quot ;
& quot ; Hb between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; 17 Correction phase :
& quot ;
& quot ; - shorten overall survival and increase death attribute to disease progression at 4 month in
& quot ;
& quot ; patient treat with any antipsychotic agent , include ABILIFY , should be observe for sign and symptom of hyperglycaemia ( such a polydipsia , polyuria , polyphagia and weakness ) and patient with diabetes mellitus or with risk factor for diabetes mellitus should be monitor regularly for worsen of glucose control .
& quot ;
& quot ; 7 .
& quot ;
& quot ; actual score in rating scale use a secondary endpoint , include PANSS and the Montgomery-Asberg Depression rating scale show a significant improvement over haloperidol .
& quot ;
& quot ; Malta BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; in addition , patient with Paget ’ s disease should take at least 500 mg calcium twice a day for at least 10 day follow treatment , and patient who have break their hip should receive a large dose of vitamin D ( 50,000 to 125,000 international unit ) by mouth or by injection into a muscle before their first infusion .
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; management of overdose should concentrate on supportive therapy , maintain an adequate airway , oxygenation and ventilation , and management of symptom .
& quot ;
& quot ; Paediatric haemodialysis patient :
& quot ;
& quot ; Tel : + 34 ( 0 ) 91 375 6230
& quot ;
& quot ; the recommended total weekly dose be between 75 and 300 IU / kg give by the intravenous route .
& quot ;
& quot ; to be take into consideration by patient on a controlled sodium diet .
& quot ;
& quot ; any clinical fracture ( 1 ) Clinical vertebral fracture ( 2 ) Non-vertebral fracture ( 1 ) * p-value & lt ; 0.001 , * * p-value & lt ; 0.0001
& quot ;
& quot ; 6 .
& quot ;
& quot ; for any information about this medicine , please contact the local representative of the marketing authorisation holder :
& quot ;
& quot ; the pre-filled syringe should not be shake .
& quot ;
& quot ; България BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; Haemoglobin level should be measure on a regular basis until a stable level be achieve and periodically thereafter .
& quot ;
& quot ; immune system disorder :
& quot ;
& quot ; 2 .
& quot ;
& quot ; 1 .
& quot ;
& quot ; KGAA Tel : + 49 89 121 42-0
& quot ;
& quot ; ABILIFY 10 mg tablet aripiprazole
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; owe to the greater sensitivity of this population , a lower start dose should be consider when clinical factor warrant ( see section 4.4 ) .
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; in two 3-week , flexible-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole demonstrate superior efficacy to placebo in
& quot ;
& quot ; B .
& quot ;
& quot ; general
& quot ;
& quot ; Manic episodes in Bipolar I Disorder - in a 12-week controlled trial , the incidence of EPS be 23.5 % for aripiprazole-treated patient and 53.3 % for haloperidol-treated patient .
& quot ;
& quot ; the bioavailability of subcutaneous injectable epoetin alfa be much lower than that of the intravenous medicinal product : approximately 20 % .
& quot ;
& quot ; 49 X 1
& quot ;
& quot ; 1 .
& quot ;
& quot ; when concomitant administration of ketoconozole with ABILIFY occurs , ABILIFY dose should be reduce to approximately one-half of it prescribed dose .
& quot ;
& quot ; there be no adequate and well-controlled trial of aripiprazole in pregnant woman .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; overall survival outcome in the trial could not be statisfactorily explain by difference in the incidence of thrombosis and related complication between those give recombinant human erythropoietin and those in the control group .
& quot ;
& quot ; 1 / 2 EU / 1 / 04 / 276 / 017
& quot ;
& quot ; Efficacy variable
& quot ;
& quot ; QT prolongation , ventricular arrhythmia , sudden unexplained death , cardiac arrest , torsades de pointes , bradycardia
& quot ;
& quot ; Dysphagia : oesophageal dysmotility and aspiration have be associate with antipsychotic drug use , include ABILIFY .
& quot ;
& quot ; 7 .
& quot ;
& quot ; the apparent molecular weight of erythropoietin be 32,000 to 40,000 dalton .
& quot ;
& quot ;
& quot ; gender : no dosage adjustment be require for female patient a compare to male patient ( see section 5.2 ) .
& quot ;
& quot ; due to insufficient safety information in human and concern raise by animal reproductive study , this medicinal product should not be use in pregnancy unless the expected benefit clearly justify the potential risk to the foetus .
& quot ;
& quot ; 11 5.3 Preclinical safety data
& quot ;
& quot ; 10 .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; patient with hepatic impairment : no dosage adjustment be require for patient with mild to moderate hepatic impairment .
& quot ;
& quot ; at the time of donate blood , Abseamed should be administer after the completion of the blood donation procedure .
& quot ;
& quot ; weight gain , weight decrease , anorexia , hyponatremia
& quot ;
& quot ; Tel : + 351 21 440 70 00
& quot ;
& quot ; the usual dose be 15 mg once a day .
& quot ;
& quot ; 37 patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; the protein fraction of the molecule contribute about 58 % and consist of 165 amino acid .
& quot ;
& quot ; Č eská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; at the time of donate blood , Abseamed should be administer after the completion of the blood donation procedure .
& quot ;
& quot ; a vial contain 9.75 mg aripiprazole .
& quot ;
& quot ; s R. O .
& quot ;
& quot ; Hypersensitivity reaction have be rarely report with epoetin alfa include isolated case of angioedema and anaphylactic reaction .
& quot ;
& quot ; the extent to which these outcome might apply to the administration of recombinant human erythropoietin to patient with cancer , treat with chemotherapy to achieve haemoglobin concentration le than 13 g / dl , be unclear because few patient with these characteristic be include in the data reviewed .
& quot ;
& quot ; follow any confirm or suspect overdose with aripiprazole , close medical supervision and monitoring should continue until the patient recovers .
& quot ;
& quot ; Aripiprazole undergo minimal pre-systemic metabolism .
& quot ;
& quot ; Aripiprazole be widely distribute throughout the body with an apparent volume of distribution of 4.9 l / kg , indicate extensive extravascular distribution .
& quot ;
& quot ; ABILIFY be indicate for the treatment of moderate to severe manic episode in Bipolar I Disorder and for the prevention of a new manic episode in patient who experience predominantly manic episode and whose manic episode respond to aripiprazole treatment ( see section 5.1 ) .
& quot ;
& quot ; the pre-filled syringe should not be shake .
& quot ;
& quot ; Aripiprazole also exhibit moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptor .
& quot ;
& quot ; - shorten overall survival and increase death attribute to disease progression at 4 month in
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; 15 • other condition
& quot ;
& quot ; EU / 1 / 04 / 276 / 006
& quot ;
& quot ; consequently , haemoglobin and blood pressure should be closely monitor .
& quot ;
& quot ; rate % ( CI )
& quot ;
& quot ; Respiratory , thoracic and mediastinal disorder :
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; for single tablet removal , open the package and peel back the foil on the blister to expose the tablet .
& quot ;
& quot ; however , a with other antipsychotic , patient should be caution about operate hazardous machine , include motor vehicle , until they be reasonably certain that aripiprazole do not affect them adversely .
& quot ;
& quot ; 1.35 , 2.06 , 35 trial and 6769 patient ) be observe in patient treat with recombinant human erythropoietin .
& quot ;
& quot ; 3 .
& quot ;
& quot ; Administer the amount require .
& quot ;
& quot ; in schizophrenia patient the incidence of akathisia be 6.2 % with aripiprazole and 3.0 % with placebo .
& quot ;
& quot ; in contrast , in patient who have take other treatment for metastatic breast cancer before , these additional measure show that Abraxane be more effective than conventional paclitaxel-containing medicine .
& quot ;
& quot ; 161 minimum PARTICULARS to appear on small immediate packaging unit
& quot ;
& quot ; although the cause of death be vary , most of the death appear to be either cardiovascular ( e. g. heart failure , sudden death ) or infectious ( e. g. pneumonia ) in nature .
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; special storage condition
& quot ;
& quot ; therefore , in patient with renal anaemia the medicinal product have to be administer intravenously .
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; a single-dose study in subject with vary degree of liver cirrhosis ( Child-Pugh class A , B , and C ) do not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole , but the study include only 3 patient with class C liver cirrhosis , which be insufficient to draw conclusion on their metabolic capacity .
& quot ;
& quot ; if aripiprazole be administer concomitantly with medicine know to cause QT prolongation or electrolyte imbalance , caution should be use .
& quot ;
& quot ; 2 .
& quot ;
& quot ; it be use to treat adult who suffer from a disease characterise by symptom such a hearing , see or sense thing which be not there , suspiciousness , mistaken belief , incoherent speech and behaviour and emotional flatness .
& quot ;
& quot ; yellow iron oxide ( E172 )
& quot ;
& quot ; stability of the reconstituted suspension in the vial after first reconstitution , the suspension should be fill into an infusion bag immediately .
& quot ;
& quot ; the rate of increase in haemoglobin should be approximately 1 g / dl
& quot ;
& quot ; 10 mg
& quot ;
& quot ; condition or restriction with regard to the safe AND effective use OF the MEDICINAL product to be implement by the Member States
& quot ;
& quot ; if you have any further question , ask your doctor or pharmacist .
& quot ;
& quot ; EXP
& quot ;
& quot ; all of these additive factor of anaemia should also be carefully consider when decide to increase the dose of epoetin alfa in cancer patient .
& quot ;
& quot ; it be recommend that the platelet count be regularly monitor during the first 8 week of therapy .
& quot ;
& quot ; in two short- term ( 24-hour ) placebo-controlled trial involve 554 schizophrenic patient present with agitation and disturbed behaviour , aripiprazole solution for injection be associate with statistically significant greater improvement in agitation / behavioural symptom compare to placebo and be similar to haloperidol .
& quot ;
& quot ; - treatment of severe anaemia of renal origin accompany by clinical symptom in adult patient
& quot ;
& quot ; in case of larger volume , more than one site should be choose for the injection .
& quot ;
& quot ; Contrada Fontana del Ceraso I-03012 Anagni-Frosinone - Italy
& quot ;
& quot ; base on result of a full range of standard genotoxicity test , aripiprazole be consider non-genotoxic .
& quot ;
& quot ; 0.4 ml ( 10000 IU / ml )
& quot ;
& quot ; try to take the ABILIFY oral solution at the same time each day .
& quot ;
& quot ; Elevations of CPK ( Creatine Phosphokinase ) , generally transient and asymptomatic , be observe in 3.5 % of aripiprazole treated patient a compare to 2.0 % of patient who receive placebo .
& quot ;
& quot ; Medice
& quot ;
& quot ; Aripiprazole be extensively metabolise by the liver primarily by three biotransformation pathway : dehydrogenation , hydroxylation , and N-dealkylation .
& quot ;
& quot ; reproduction toxicity Teratology study be perform in two specie , both via subcutaneous administration .
& quot ;
& quot ; solution for injection in a pre-filled syringe .
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; 15 .
& quot ;
& quot ; 5000 IU / 0.5 ml
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; these report be base on in vitro finding from human tumour sample , but be of uncertain significance in the clinical situation .
& quot ;
& quot ; fatigue , asthenia , pyrexia .
& quot ;
& quot ; 4 .
& quot ;
& quot ; the company will also provide cool box for patient , which will include illustration show how the medicine should be use .
& quot ;
& quot ; expiry date
& quot ;
& quot ; BATCH number
& quot ;
& quot ; 16 .
& quot ;
& quot ; patient treat with any antipsychotic agent , include ABILIFY , should be observe for sign and symptom of hyperglycaemia ( such a polydipsia , polyuria , polyphagia and weakness ) and patient with diabetes mellitus or with risk factor for diabetes mellitus should be monitor regularly for worsen of glucose control .
& quot ;
& quot ; solution for injection in a pre-filled syringe ( injection )
& quot ;
& quot ; although the cause of death be vary , most of the death appear to be either cardiovascular ( e. g. heart failure , sudden death ) or infectious ( e. g. pneumonia ) in nature .
& quot ;
& quot ; the recommend starting dose for ABILIFY be 15 mg administer on a once-a-day schedule without regard to meal a monotherapy or combination therapy ( see section 5.1 ) .
& quot ;
& quot ; the main measure of effectiveness be the change in the level of haemoglobin between the start of the study and the evaluation period , between week 25 and 29 .
& quot ;
& quot ; clean the skin at the injection site use an alcohol wipe .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; base on information available to date , correction of anaemia with epoetin alfa in adult patient with renal insufficiency not yet undergoing dialysis do not accelerate the rate of progression of renal insufficiency .
& quot ;
& quot ; EXP after opening :
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the sustained haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) reduce the epoetin alfa dose by 25 % .
& quot ;
& quot ; at therapeutic concentration , aripiprazole and dehydro-aripiprazole be greater than 99 % bound to serum protein , bind primarily to albumin .
& quot ;
& quot ; gender : no dosage adjustment be require for female patient a compare to male patient ( see section 5.2 ) .
& quot ;
& quot ; ABILIFY be indicate for the treatment of moderate to severe manic episode in Bipolar I Disorder and for the prevention of a new manic episode in patient who experience predominantly manic episode and whose manic episode respond to aripiprazole treatment ( see section 5.1 ) .
& quot ;
& quot ; adult surgery patient in an autologous predonation programme
& quot ;
& quot ; in case where there be a medical need to shorten the lead time before surgery to le than three week , 300 IU / kg epoetin alfa should be give daily for 10 consecutive day prior to surgery , on the day of surgery and for four day immediately thereafter .
& quot ;
& quot ; the other ingredient be lactose monohydrate , maize starch , microcrystalline cellulose , hydroxypropyl cellulose , magnesium stearate , red iron oxide ( E172 ) .
& quot ;
& quot ;
& quot ; 3 .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; 8 .
& quot ;
& quot ; if blood pressure can not be control , epoetin alfa treatment should be discontinue .
& quot ;
& quot ; expiry date
& quot ;
& quot ; overall survival outcome in the trial could not be statisfactorily explain by difference in the incidence of thrombosis and related complication between those give recombinant human erythropoietin and those in the control group .
& quot ;
& quot ; Pregnancy and breast-feeding you should not take ABILIFY if you be pregnant unless you have discuss this with your doctor .
& quot ;
& quot ; effect on all clinical fracture all clinical fracture be verify base on the radiographic and / or clinical evidence .
& quot ;
& quot ; the potentially medically important sign and symptom observe included lethargy , increase blood pressure , somnolence , tachycardia , nausea , vomit and diarrhoea .
& quot ;
& quot ; Aripiprazole exhibit high binding affinity in vitro for dopamine D2 and D3 , serotonin 5HT1a and 5HT2a receptor and moderate affinity for dopamine D4 , serotonin 5HT2c and 5HT7 , alpha-1 adrenergic and histamine H1 receptor .
& quot ;
& quot ; Mannitol Sodium citrate water for injection
& quot ;
& quot ; strength
& quot ;
& quot ; PRCA mean the inability to produce enough red blood cell in the bone ( see section “ take special care with Abseamed ” ) .
& quot ;
& quot ; in a 26-week , placebo-controlled trial in stabilised patient with chronic schizophrenia , aripiprazole have significantly greater reduction in relapse rate , 34 % in aripiprazole group and 57 % in placebo .
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; Slovenija BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; in patient with chronic renal failure the medicinal product have to be administer intravenously ( see section 4.4 ) .
& quot ;
& quot ; Simultaneous administration of injectable antipsychotic and parenteral benzodiazepine may be associate with excessive sedation and cardiorespiratory depression .
& quot ;
& quot ; content by weight , by volume or by unit
& quot ;
& quot ; Abseamed should not be shake .
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; there be five short-term study that compare the effectiveness of Abilify and placebo over three week in a total of 1,900 patient .
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl or Hb increase ≥ 1 g / dl
& quot ;
& quot ; it may harm them , even if their symptom be the same a yours .
& quot ;
& quot ; and Hb increase & lt ; 1 g / dl
& quot ;
& quot ; additional supportive care should be provide a necessary .
& quot ;
& quot ; in particular , no residue of the cell line use for the production be detectable at the concentration of the active ingredient that be use in human .
& quot ;
& quot ; 5 .
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; Aripiprazole dose range from 0.5 to 30 mg administer once a day to healthy subject for 2 week produce a dose-dependent reduction in the binding of 11C-raclopride , a D2 / D3 receptor ligand , to the caudate and putamen detect by positron emission tomography .
& quot ;
& quot ; follow recurrence of severe neutropenia or severe sensory neuropathy , additional dose reduction should be make to 180 mg / m2 .
& quot ;
& quot ; do not take ABILIFY if you be allergic ( hypersensitive ) to aripiprazole or any of the other ingredient of ABILIFY .
& quot ;
& quot ; Abseamed
& quot ;
& quot ; Aripiprazole exhibit antagonist property in animal model of dopaminergic hyperactivity and agonist property in animal model of dopaminergic hypoactivity .
& quot ;
& quot ; Bone biopsy result show bone of normal quality with no evidence of impaired bone remodelling and no evidence of mineralisation defect .
& quot ;
& quot ; Disodium edetate Fructose Glycerin Lactic acid Methyl parahydroxybenzoate ( E218 ) Propylene glycol Propyl parahydroxybenzoate ( E216 ) Sodium hydroxide Sucrose Purified water
& quot ;
& quot ; treatment of symptomatic anaemia in adult and paediatric chronic renal failure patient :
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be
& quot ;
& quot ; the other ingredient be sulfobutylether β -cyclodextrin ( SBECD ) , tartaric acid , sodium hydroxide , and water for injection .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; take other medicine please tell your doctor or pharmacist if you be take or have recently take any other medicine , include medicine obtain without a prescription .
& quot ;
& quot ; treatment with Abseamed have to be initiate under the supervision of physician experience in the management of patient with the above indication .
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of at least four week .
& quot ;
& quot ; 3 .
& quot ;
& quot ; alcohol should be avoid when take ABILIFY .
& quot ;
& quot ; - treatment of anaemia associate with chronic renal failure in paediatric and adult patient on
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; 13 .
& quot ;
& quot ; each orodispersible tablet contain 30 mg of aripiprazole .
& quot ;
& quot ; potential for other medicinal product to affect ABILIFY :
& quot ;
& quot ; take special care with ABILIFY before treatment with ABILIFY , tell your doctor if you suffer from High blood sugar or family history of diabetes seizure Involuntary , irregular muscle movement , especially in the face cardiovascular disease , family history of cardiovascular disease , stroke or & quot ; & quot ; mini & quot ; & quot ; stroke , abnormal blood pressure
& quot ;
& quot ;
& quot ; EXP
& quot ;
& quot ; start dose of 50 IU / kg 2 time per week by the intravenous route .
& quot ;
& quot ; Abilify
& quot ;
& quot ; Tablet Rectangular and pink , engrave with & quot ; & quot ; A-008 & quot ; & quot ; and & quot ; & quot ; 10 & quot ; & quot ; on one side .
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; strength
& quot ;
& quot ; Aripiprazole dose range from 0.5 to 30 mg administer once a day to healthy subject for 2 week produce a dose-dependent reduction in the binding of 11C-raclopride , a D2 / D3 receptor ligand , to the caudate and putamen detect by positron emission tomography .
& quot ;
& quot ; this medicinal product must not be administer by intravenous infusion , or mixed with other medicinal product .
& quot ;
& quot ; 197 This leaflet be last approved in { MM / YYYY } .
& quot ;
& quot ; between treatment comparison of the incidence of key clinical fracture variable
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; 127 1 .
& quot ;
& quot ; Abraxane should be admin istered under the supervision of a qualified oncologist in unit specialise in the administration of cytotoxic agent .
& quot ;
& quot ; 4 .
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery should receive adequate antithrombotic prophylaxis , a thrombotic and vascular event may occur in surgical patient , especially in those with underlying cardiovascular disease .
& quot ;
& quot ; 10000 IU / 1.0 ml
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; N05AX12
& quot ;
& quot ; ABILIFY be indicate for the treatment of moderate to severe manic episode in Bipolar I Disorder and for the prevention of a new manic episode in patient who experience predominantly manic episode and whose manic episode respond to aripiprazole treatment ( see section 5.1 ) .
& quot ;
& quot ; start dose of 50 IU / kg 3 time per week by the intravenous route , follow if necessary by a dose increase with 25 IU / kg increment ( 3 time per week ) until the desired goal be achieve ( this should be do in step of at least four week ) .
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; care should be take to ensure that at the outset of the treatment patient be not iron deficient .
& quot ;
& quot ; for any information about this medicine , please contact the local representative of the marketing authorisation holder :
& quot ;
& quot ; for subcutaneous and intravenous use .
& quot ;
& quot ;
& quot ; România BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; urinary incontinence , urinary retention
& quot ;
& quot ; Abseamed can be use to reduce exposure to allogeneic blood transfusion in adult non-iron deficient patient prior to major elective orthopaedic surgery , have a high perceive risk for transfusion complication .
& quot ;
& quot ; for prevent recurrence of manic episode in patient who have be receive aripiprazole , continue therapy at the same dose .
& quot ;
& quot ; difference in Cmax and Cmax correct for dose reflect difference in total dose and rate of infusion .
& quot ;
& quot ; condition or restriction regard supply AND use impose on the marketing authorisation holder
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; 12 Annex II
& quot ;
& quot ; Abseamed 7000 IU / 0.7 ml
& quot ;
& quot ; Teл . : + 359 800 12 400
& quot ;
& quot ; 3 .
& quot ;
& quot ; Tel : + 351 21 440 70 00
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl or Hb increase ≥ 1 g / dl
& quot ;
& quot ; 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of at least four week .
& quot ;
& quot ; the use of Abraxane have not be formally study in patient specifically with hepatic impairment .
& quot ;
& quot ; in addition , special precaution should be take in patient with predisposition for development of deep vein thrombosis ( DVTs ) .
& quot ;
& quot ; 177 5 .
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; 0.99 , 1,18 ; 42 trial and 8167 patient ) .
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; in chronic renal failure patient Abseamed have not to be administer subcutaneously !
& quot ;
& quot ; if the haemoglobin increase be & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , increase the dose to 300 IU / kg 3 time per week .
& quot ;
& quot ; please tell your doctor , pharmacist or nurse .
& quot ;
& quot ; EXP
& quot ;
& quot ; all patient be treat with epoetin alfa should receive adequate iron supplementation ( e. g. oral iron substitution of 200 mg Fe2 + daily ) throughout the course of epoetin alfa treatment .
& quot ;
& quot ; 143 even if you feel better , do not alter or discontinue the daily dose of ABILIFY without first consult your doctor .
& quot ;
& quot ; Abseamed should not be use in people who may be hypersensitive ( allergic ) to epoetin alfa or any of the other ingredient .
& quot ;
& quot ; in addition , other cause of anaemia , such a vitamin B12 or folate deficiency , should be exclude before institute therapy with epoetin alfa .
& quot ;
& quot ; the medicine can only be obtain with a prescription .
& quot ;
& quot ; Schizophrenia :
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; an increase relative risk of thromboembolic event ( RR 1.67 , 95 % CI :
& quot ;
& quot ; 2 .
& quot ;
& quot ; name OF the MEDICINAL product AND route ( s ) OF administration
& quot ;
& quot ; ABILIFY 10 mg
& quot ;
& quot ; urinary incontinence , urinary retention
& quot ;
& quot ; driving and use machine Abraxane may cause side effect such a tiredness ( very common ) and dizziness ( common ) that may affect your ability to drive and use machinery .
& quot ;
& quot ; keep the vial in the outer carton in order to protect from light .
& quot ;
& quot ; this summary be last updated in 09-2008 .
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; Tel : + 371 67 50 21 85
& quot ;
& quot ; instruction on use
& quot ;
& quot ; 4 4.8 undesirable effect
& quot ;
& quot ; Tablet
& quot ;
& quot ; pancreatitis , dysphagia , abdominal discomfort , stomach discomfort , diarrhoea
& quot ;
& quot ; EXP after opening :
& quot ;
& quot ; if you have any further question , ask your doctor or pharmacist .
& quot ;
& quot ; do not shake .
& quot ;
& quot ; 4 .
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and than reinstitute epoetin alfa therapy at a dose 25 % below the previous dose .
& quot ;
& quot ; Ελλάδα BRISTOL-MYERS SQUIBB A. e .
& quot ;
& quot ; patient should be inform about symptom of hypocalcaemia and receive adequate clinical monitoring during the period of risk .
& quot ;
& quot ; România BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; a rise in haemoglobin of greater than 2 g / dl ( 1.25 mmol / l ) over a four week period should be avoid .
& quot ;
& quot ; EU / 1 / 04 / 276 / 001
& quot ;
& quot ; Medice
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Meta-analysis of overall survival data produce a hazard ratio point estimate of 1.08 in favour of control ( 95 % CI :
& quot ;
& quot ; overall , 1.3 % of aripiprazole-treated patient report cerebrovascular adverse event compare with 0.6 % of placebo-treated patient in these trial .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; do not take ABILIFY if you be allergic ( hypersensitive ) to aripiprazole or any of the other ingredient of ABILIFY .
& quot ;
& quot ; 1 .
& quot ;
& quot ; 84 year ; range :
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; lot
& quot ;
& quot ; due to it α 1-adrenergic receptor antagonism , aripiprazole have the potential to enhance the effect of certain antihypertensive agent .
& quot ;
& quot ; 10.9
& quot ;
& quot ; however , chemical and physical in use stability have be demonstrate for 8 hour at 2 ° C - 8 ° C in the original carton , and protect from bright light .
& quot ;
& quot ; Aripiprazole do not impair fertility in reproductive toxicity study .
& quot ;
& quot ; 16 .
& quot ;
& quot ; when the CYP3A4 inducer be withdraw from the combination therapy , the aripiprazole dose should then be reduce to the recommend dose ( see section 4.5 ) .
& quot ;
& quot ; the target haemoglobin concentration in two study be & gt ; 13 g / dl ; in the remain three study it be 12 - 14 g / dl .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; 2 .
& quot ;
& quot ; base on result of a full range of standard genotoxicity test , aripiprazole be consider non-genotoxic .
& quot ;
& quot ; day of disability Aclasta significantly reduce the mean day of limited activity and the day of bed rest due to back pain by 17.9 day and 11.3 day respectively compare to placebo and significantly reduce the mean day of limited activity and the day of bed rest due to fracture by 2.9 day and 0.5 day respectively compare to placebo ( all p & lt ; 0.01 ) .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; Excipients : sodium dihydrogen phosphate dihydrate , disodium phosphate dihydrate , sodium chloride , glycine , polysorbate 80 , hydrochloric acid ( for pH-adjustment ) , sodium hydroxide ( for pH-adjustment ) , and water for injection
& quot ;
& quot ; the occurrence of suicidal behaviour be inherent in psychotic illness and mood disorder and in some case have be report early after initiation or switch of antipsychotic therapy , include treatment with aripiprazole ( see section 4.8 ) .
& quot ;
& quot ; in paediatric patient the recommended target haemoglobin range be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; © EMEA 2007
& quot ;
& quot ; the half-life be difficult to evaluate for the subcutaneous route and be estimate about 24 hour .
& quot ;
& quot ; Gastrointestinal symptom :
& quot ;
& quot ; the frequency list below be define use the following convention : common ( & gt ; 1 / 100 , & lt ; 1 / 10 ) and uncommon ( & gt ; 1 / 1 , 000 , & lt ; 1 / 100 ) .
& quot ;
& quot ; what Abraxane contains
& quot ;
& quot ; your doctor will check your level of the red blood pigment ( haemoglobin ) regularly and adjust your dose of Abseamed accordingly to minimise the risk of blood clotting ( thrombotic event ) .
& quot ;
& quot ; Erythropoietin be a glycoprotein that stimulate , a a mitosis-stimulating factor and differentiate hormone , the formation of erythrocyte from precursor of the stem cell compartment .
& quot ;
& quot ; 5 .
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be avoid .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; particular attention should be pay to sudden stab migraine- like headache a a possible warning signal .
& quot ;
& quot ; Lactose : patient with rare hereditary problem of galactose intolerance , the lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product .
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of anaemia and of the symptom of anaemia .
& quot ;
& quot ; be sure to tell your doctor immediately if you be breast-feeding .
& quot ;
& quot ; Phenylketonurics :
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; patient should be advise not to breast feed if they be take aripiprazole .
& quot ;
& quot ; Abseamed should be give by the intravenous route .
& quot ;
& quot ; Thrombotic / vascular event , such a myocardial ischaemia , myocardial infarction , cerebrovascular accident ( cerebral haemorrhage and cerebral infarction ) , transient ischaemic attack , deep vein thrombosis , arterial thrombosis , pulmonary embolus , aneurysm , retinal thrombosis , and clotting of an artificial kidney have be report in patient receive erythropoietic agent , include patient receive epoetin alfa .
& quot ;
& quot ; 30 mg
& quot ;
& quot ; in addition , an updated RMP should be submit • when new information be receive that may impact on the current Safety specification , Pharmacovigilance Plan or risk minimisation activity • within 60 day of an important ( pharmacovigilance or risk minimisation ) milestone be reach • at the request of the EMEA
& quot ;
& quot ; Median 100 75 33
& quot ;
& quot ; for any information about this medicine please contact the local representative of the marketing authorisation holder :
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; Elevations of CPK ( Creatine Phosphokinase ) , generally transient and asymptomatic , be observe in 3.5 % of aripiprazole treated patient a compare to 2.0 % of patient who receive placebo .
& quot ;
& quot ; Hypersensitivity : a with other medication hypersensitivity reaction , characterise by allergic symptom , may occur with aripiprazole ( see section 4.8 ) .
& quot ;
& quot ; Tumour growth potential
& quot ;
& quot ; 4 .
& quot ;
& quot ; other
& quot ;
& quot ; the educational programme contain the following :
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; 13 .
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; Gastrointestinal disorder :
& quot ;
& quot ; transferrin saturation be below 20 % .
& quot ;
& quot ; a rise in haemoglobin of greater than 2 g / dl ( 1.25 mmol / l ) over a four week period should be avoid .
& quot ;
& quot ; iron status should be evaluate prior to and during treatment and iron supplementation administer if necessary .
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; there be no adequate and well-controlled study in pregnant woman .
& quot ;
& quot ; benefit outweighs the potential risk to the foetus .
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; therefore your doctor may prescribe a medicinal product for volume replacement ( infusion ) .
& quot ;
& quot ; these study have show an consistent unexplained statistically significant excess mortality in patient who have anaemia associate with various common cancer who receive recombinant human erythropoietin compare to control .
& quot ;
& quot ; 15 mg
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; a per the CHMP guideline on risk management system for medicinal product for human use , the updated RMP should be submit at the same time a the next Periodic Safety update Report ( PSUR ) .
& quot ;
& quot ; after administration of epoetin alfa , the number of erythrocyte , the Hb value and reticulocyte count increase a well a the 59Fe-incorporation rate .
& quot ;
& quot ; 8 .
& quot ;
& quot ; outer carton :
& quot ;
& quot ; although the cause of death be vary , most of the death appear to be either cardiovascular ( e. g. heart failure , sudden death ) or infectious ( e. g. pneumonia ) in nature .
& quot ;
& quot ; 2 .
& quot ;
& quot ; weight gain , weight decrease , anorexia , hyponatremia
& quot ;
& quot ; do not shake .
& quot ;
& quot ; other
& quot ;
& quot ; iron supplementation should be start prior to epoetin alfa therapy , to achieve adequate iron store .
& quot ;
& quot ; risk factor that may predispose patient to severe complication include obesity and family history of diabetes .
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; try to take the ABILIFY tablet at the same time each day .
& quot ;
& quot ; market authorisation holder Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; Medicines should not be dispose of via wastewater or household waste .
& quot ;
& quot ; if a patient develop sign and symptom indicative of NMS , or present with unexplained high fever without additional clinical manifestation of NMS , all antipsychotic medicinal product , include ABILIFY , must be discontinue .
& quot ;
& quot ; be sure to tell your doctor if you take a medicine to keep your blood pressure under control .
& quot ;
& quot ; elimination :
& quot ;
& quot ; concomitant osteoporosis therapy include : calcitonin , raloxifene , tamoxifen , hormone replacement therapy , tibolone ; but exclude other bisphosphonates .
& quot ;
& quot ; in one 3-week , fixed-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole fail to demonstrate superior efficacy to placebo .
& quot ;
& quot ; other infrequently report side effect :
& quot ;
& quot ; 1 .
& quot ;
& quot ; - oral iron substitution of 200 - 300 mg Fe2 + / day be recommend for all cancer patient whose
& quot ;
& quot ; all other cause of anaemia ( iron deficiency , haemolysis , blood loss , vitamin B12 or folate deficiency ) should be consider and treat prior to initiate therapy with epoetin alfa .
& quot ;
& quot ; these measure will help to protect the environment .
& quot ;
& quot ; * produce in CHO cell line by recombinant DNA technology
& quot ;
& quot ; general
& quot ;
& quot ; Dosage adjustment to maintain haemoglobin concentration between 10 g / dl - 12 g / dl :
& quot ;
& quot ; for the treatment of post-menopausal osteoporosis and osteoporosis in men , the recommend dose be a single intravenous infusion of 5 mg Aclasta administer once a year .
& quot ;
& quot ; in the absence of compatibility study , this medicinal product must not be mix with other medicinal product .
& quot ;
& quot ; however , elevate creatine phosphokinase and rhabdomyolysis , not necessarily in association with NMS , have also be report .
& quot ;
& quot ; NMS be a potentially fatal symptom complex associate with antipsychotic medicinal product .
& quot ;
& quot ; 5 .
& quot ;
& quot ; close supervision of high-risk patient should accompany antipsychotic therapy .
& quot ;
& quot ; Belgique / België / Belgien BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; dihydrate , sodium chloride , glycine , polysorbate 80 , hydrochloric acid ( for pH-adjustment ) , sodium hydroxide ( for pH-adjustment ) , and water for injection .
& quot ;
& quot ; how to store ABILIFY
& quot ;
& quot ; oral use
& quot ;
& quot ; a gastric acid blocker , the H2 antagonist famotidine , reduces aripiprazole rate of absorption but this effect be deem not clinically relevant .
& quot ;
& quot ; alternatively , epoetin alfa can be administer at an initial dose of 450 IU / kg subcutaneously once weekly .
& quot ;
& quot ; any unused solution should be discard .
& quot ;
& quot ; 28 X 1
& quot ;
& quot ; 8 .
& quot ;
& quot ; before you use ABSEAMED
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; in clinical trial , an increase risk of death and serious cardiovascular event be observe when erythropoiesis stimulate agent ( ESAs ) be administer to target a haemoglobin of greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; 5 when either valproate or lithium be administer concomitantly with aripiprazole , there be no clinically significant change in aripiprazole concentration .
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; alternatively , disperse the tablet in water and drink the resulting suspension .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; in paediatric patient the recommended target haemoglobin range be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; this difference be not statistically significant .
& quot ;
& quot ; Aripiprazole should be use with caution in patient with known cardiovascular disease ( history of myocardial infarction or ischaemic heart disease , heart failure , or conduction abnormality ) , cerebrovascular disease , condition which would predispose patient to hypotension ( dehydration , hypovolemia , and treatment with antihypertensive medication ) or hypertension , include accelerate or malignant .
& quot ;
& quot ; method OF administration
& quot ;
& quot ; treatment of adult patient schedule for major elective orthopaedic surgery :
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; distribution :
& quot ;
& quot ; this leaflet be last approved in
& quot ;
& quot ; packaging
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; 3 year
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subject , nor be there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; market authorisation holder Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; Aripiprazole be well absorb , with peak plasma concentration occur within 3-5 hour after dose .
& quot ;
& quot ; Shunt thromboses may occur , especially in patient who have a tendency to hypotension or whose arteriovenous fistula exhibit complication ( e. g. stenosis , aneurysm , etc . ) .
& quot ;
& quot ; 10 .
& quot ;
& quot ; a systematic review have also be perform involve more than 9000 cancer patient participate in 57 clinical trial .
& quot ;
& quot ; 157 tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever , sweat , alter mental status , or very rapid or irregular heart beat .
& quot ;
& quot ; important information about some of the ingredient of ABILIFY if you have be tell by your doctor that you have an intolerance to some sugar , contact your doctor before take this medicine .
& quot ;
& quot ; Τηλ : + 357 22 677038
& quot ;
& quot ; at steady state , dehydro-aripiprazole , the active metabolite , represent about 40 % of aripiprazole AUC in plasma .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Latvija BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy male and female subject nor be there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; all other cause of anaemia ( iron deficiency , haemolysis , blood loss , vitamin B12 or folate deficiency ) should be consider and treat prior to initiate therapy with epoetin alfa .
& quot ;
& quot ; the extent to which these outcome might apply to the administration of recombinant human erythropoietin to patient with cancer , treat with chemotherapy to achieve haemoglobin concentration le than 13 g / dl , be unclear because few patient with these characteristic be include in the data reviewed .
& quot ;
& quot ; store in the original package in order to protect from moisture .
& quot ;
& quot ; if blood pressure can not be control , epoetin alfa treatment should be discontinue .
& quot ;
& quot ; Hb between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; what ABILIFY be and what it be use for 2 .
& quot ;
& quot ; - shorten overall survival and increase death attribute to disease progression at 4 month in
& quot ;
& quot ; weight gain have be report post-marketing among patient prescribe ABILIFY .
& quot ;
& quot ; 78-88 year ) .
& quot ;
& quot ; France BRISTOL-MYERS SQUIBB SARL Tél : + 33 ( 0 ) 810 410 500
& quot ;
& quot ;
& quot ; administration of aripiprazole solution for injection be well tolerate and produce no direct target organ toxicity in rat or monkey after repeat dosing at systemic exposure ( AUC ) that be 15 and 5 time , respectively , human exposure at the maximum recommend human dose of 30 mg intramuscular .
& quot ;
& quot ; in addition , in patient with Paget ’ s disease , it be strongly advise that adequate supplemental calcium correspond to at least 500 mg elemental calcium twice daily be ensure for at least 10 day follow Aclasta administration ( see section 4.4 ) .
& quot ;
& quot ; EU / 1 / 04 / 276 / 012
& quot ;
& quot ; what ABSEAMED be AND what IT be use for
& quot ;
& quot ; this medicine have be prescribe for you .
& quot ;
& quot ; long-term carcinogenicity study have not be carry out .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Subcutaneous route
& quot ;
& quot ; what ABILIFY look like and content of the Pack ABILIFY 10 mg tablet be rectangular and pink , mark with A-008 and 10 on one side .
& quot ;
& quot ; Surgery patient in autologous predonation programme
& quot ;
& quot ; a gastric acid blocker , the H2 antagonist famotidine , reduces aripiprazole rate of absorption but this effect be deem not clinically relevant .
& quot ;
& quot ; Measurement of epoetin alfa follow multiple dose intravenous administration reveal a half-life of approximately 4 hour in normal volunteer and a somewhat more prolonged half-life in renal failure patient , approximately 5 hour .
& quot ;
& quot ; when aripiprazole be administer concomitantly with either valproate or lithium , there be no clinically important change in valproate or lithium concentration .
& quot ;
& quot ; however , the concentration of the sulphate conjugate of hydroxy aripiprazole in human bile at the highest dose propose , 30 mg per day , be no more than 6 % of the bile concentration find in the monkey in the 39-week study and be well below ( 6 % ) their limit of in vitro solubility .
& quot ;
& quot ; overall , 1.3 % of aripiprazole-treated patient report cerebrovascular adverse event compare with 0.6 % of placebo-treated patient in these trial .
& quot ;
& quot ; Immunogenicity data for subcutaneous use of Abseamed in patient at risk for antibody-induced PRCA , I. e. patient with renal anaemia , be not sufficient .
& quot ;
& quot ; what ABILIFY be and what it be use for 2 .
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; Tel . : + 36 1 301 9700
& quot ;
& quot ; take special care with ABILIFY before treatment with ABILIFY , tell your doctor if you suffer from High blood sugar or family history of diabetes seizure Involuntary , irregular muscle movement , especially in the face cardiovascular disease , family history of cardiovascular disease , stroke or & quot ; & quot ; mini & quot ; & quot ; stroke , abnormal blood pressure
& quot ;
& quot ; in a long term 26-week placebo-controlled trial , the incidence of EPS be 19 % for aripiprazole-treated patient and 13.1 % for placebo-treated patient .
& quot ;
& quot ; in patient with chronic renal failure and clinically evident ischaemic heart disease or congestive heart failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration a recommend under section 4.2 .
& quot ;
& quot ; expiry date
& quot ;
& quot ; EU / 1 / 07 / 412 / 013 EU / 1 / 07 / 412 / 014
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl
& quot ;
& quot ; Non-clinical safety data reveal no special hazard for human base on conventional study of safety pharmacology , repeat-dose toxicity , genotoxicity , carcinogenic potential , and toxicity to reproduction .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; Polska BRISTOL-MYERS SQUIBB POLSKA SP .
& quot ;
& quot ; statement OF active substance ( s )
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; due to it α 1-adrenergic receptor antagonism , aripiprazole have the potential to enhance the effect of certain antihypertensive agent .
& quot ;
& quot ; ABILIFY be not approve for the treatment of dementia-related psychosis .
& quot ;
& quot ; 19 It have be propose that aripiprazole ’ s efficacy in schizophrenia and Bipolar I Disorder be mediate through a combination of partial agonism at dopamine D2 and serotonin 5HT1a receptor and antagonism of serotonin 5HT2a receptor .
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP3A4 ( ketoconazole ) increase aripiprazole AUC and Cmax by 63 % and 37 % , respectively .
& quot ;
& quot ; these measure will help to protect the environment .
& quot ;
& quot ; base on in vitro study , CYP3A4 and CYP2D6 enzyme be responsible for dehydrogenation and hydroxylation of aripiprazole , and N-dealkylation be catalyse by CYP3A4 .
& quot ;
& quot ; Pregnant staff should not handle Abraxane .
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg Kuhloweg 37 D-58638 Iserlohn
& quot ;
& quot ; dose ( IU / kg give 3x / week )
& quot ;
& quot ; what Abraxane be and what it be use for 2 .
& quot ;
& quot ; the educational programme contain the following : • Physician educational material • Patient information Pack
& quot ;
& quot ; Non-specific skin rash have be describe in association with epoetin alfa .
& quot ;
& quot ; 4.5 Interactions with other medicinal product and other form of interaction
& quot ;
& quot ; radiation therapy when administer to target a haemoglobin of greater than 14 g / dl ( 8.7 mmol / l ) ,
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; at equivalent dos , the peak plasma concentration of aripiprazole ( Cmax ) from the solution be somewhat higher but the systemic
& quot ;
& quot ; 13 .
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole increase by 77 % and 43 % , respectively .
& quot ;
& quot ; Haemoglobin level should be measure on a regular basis until a stable level be achieve and periodically thereafter .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; Epoetin alfa be produce by a specialised genetic technology and work in exactly the same way a the natural hormone erythropoietin .
& quot ;
& quot ; if after an additional 4 week of therapy at 300 IU / kg 3 time per week , the haemoglobin have increase ≥ 1 g / dl ( ≥ 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl the dose should remain at 300 IU / kg 3 time per week .
& quot ;
& quot ; non response to epoetin alfa therapy may have the following cause : iron , folate , or vitamin B12 deficiency ; aluminium intoxication ; intercurrent infection ; inflammatory or traumatic episode ; occult blood loss ; haemolysis , and bone marrow fibrosis of any origin .
& quot ;
& quot ; independent of erythropoietin treatment , thrombotic and vascular event may occur in surgical patient with underlying cardiovascular disease follow repeat phlebotomy .
& quot ;
& quot ; this medicine have be prescribe for you .
& quot ;
& quot ; if aripiprazole be administer concomitantly with medicine know to cause QT prolongation or electrolyte imbalance , caution should be use .
& quot ;
& quot ; an increase relative risk of thromboembolic event ( RR 1.67 , 95 % CI :
& quot ;
& quot ; ABILIFY be one of a group of medicine call antipsychotic .
& quot ;
& quot ; Magyarország BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; Aripiprazole exhibit high binding affinity in vitro for dopamine D2 and D3 , serotonin 5HT1a and 5HT2a receptor and moderate affinity for dopamine D4 , serotonin 5HT2c and 5HT7 , alpha-1 adrenergic and histamine H1 receptor .
& quot ;
& quot ; Abseamed 6000 IU / 0.6 ml
& quot ;
& quot ; independent of erythropoietin treatment , thrombotic and vascular event may occur in surgical patient with underlying cardiovascular disease follow repeat phlebotomy .
& quot ;
& quot ; in two large , open-label study , 2697 cancer patient receive non-platinum chemotherapy be include , 1895 with solid tumour ( 683 breast , 260 lung , 174 gynaecological , 300 gastro-intestinal , and 478 other tumour type ) and 802 with haematological malignancy .
& quot ;
& quot ; keep the vial in the outer carton in order to protect from light .
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6.8 g / dl or & lt ; 4.25 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 6.8 g / dl or & gt ; 4.25 mmol / l ) .
& quot ;
& quot ; 9 .
& quot ;
& quot ; the oral solution contains sucrose .
& quot ;
& quot ; maintenance dose between 17 and 33 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; s R. O .
& quot ;
& quot ; lot
& quot ;
& quot ; the extent to which these outcome might apply to the administration of recombinant human erythropoietin to patient with cancer , treat with chemotherapy to achieve haemoglobin concentration le than 13 g / dl , be unclear because few patient with these characteristic be include in the data reviewed .
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; 1 .
& quot ;
& quot ; 11 .
& quot ;
& quot ; clear colourless solution
& quot ;
& quot ; ABILIFY 5 mg tablet aripiprazole
& quot ;
& quot ; 8 .
& quot ;
& quot ; the active substance in Abraxane , paclitaxel , belong to the group of anticancer medicine know a the ‘ taxanes ’ .
& quot ;
& quot ; & quot ; & quot ; Flu-like & quot ; & quot ; symptom such a headache , joint pain , feeling of weakness , dizziness , and tiredness may occur , especially at the start of treatment .
& quot ;
& quot ; actual score in rating scale use a secondary endpoint , include PANSS and the Montgomery-Asberg Depression rating scale show a significant improvement over haloperidol .
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; 0.99 , 1,18 ; 42 trial and 8167 patient ) .
& quot ;
& quot ; - increase risk of death when administer to target a haemoglobin of 12 g / dl ( 7.5 mmol / l ) in
& quot ;
& quot ; BATCH number
& quot ;
& quot ; QT prolongation , ventricular arrhythmia , sudden unexplained death , cardiac arrest , torsades de pointes , bradycardia
& quot ;
& quot ; Pharmacodynamic effect Aclasta treatment rapidly reduce the rate of bone turnover from elevate post-menopausal level with the nadir for resorption marker observe at 7 day , and for formation marker at 12 week .
& quot ;
& quot ; the dose may be reduce or treatment interrupt in patient who have certain side effect affect the blood or the nerve .
& quot ;
& quot ; the biological efficacy of epoetin alfa have be demonstrate in various animal model in vivo ( normal and anaemic rat , polycythaemic mouse ) .
& quot ;
& quot ; for more information on biosimilar medicine , see the question-and-answer document here .
& quot ;
& quot ; EXP
& quot ;
& quot ; le than 1 % of unchanged aripiprazole be excrete in the urine and approximately 18 % be recover unchanged in the faeces .
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of 25 IU / kg 3 time per week at interval of at least 4 week until the desired goal be achieve .
& quot ;
& quot ; oral use
& quot ;
& quot ; all participant receive 1,000 to 1,500 mg of elemental calcium plus 800 to 1,200 IU of vitamin D supplementation per day .
& quot ;
& quot ; ABILIFY 10 mg orodispersible tablet aripiprazole
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; functional assessment of Cancer Therapy- Anaemia ( FACT-An ) general scale , FACT-An fatigue scale , and Cancer linear Analogue scale ( CLAS ) .
& quot ;
& quot ; Epoetin alfa therapy should continue until one month after the end of chemotherapy .
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ; 3 .
& quot ;
& quot ; Hypersensitivity : a with other medication hypersensitivity reaction , characterise by allergic symptom , may occur with aripiprazole ( see section 4.8 ) .
& quot ;
& quot ; if hypersensitivity occur , the medicinal product should be discontinue immediately , symptomatic treatment should be initiate , and that patient should not be rechallenged with paclitaxel .
& quot ;
& quot ; EXP
& quot ;
& quot ; subcutaneous ( injection under the skin ) erythropoietin treatment .
& quot ;
& quot ; Aclasta 5 mg solution for infusion Zoledronic acid
& quot ;
& quot ; what ABILIFY be AND what IT be use for
& quot ;
& quot ; 2 .
& quot ;
& quot ; in case where there be a medical need to shorten the lead time before surgery to le than three week , 300 IU / kg epoetin alfa should be give daily for 10 consecutive day prior to surgery , on the day of surgery and for four day immediately thereafter .
& quot ;
& quot ; the subcutaneous route of administration should be use .
& quot ;
& quot ; Pharmacotherapeutic group : antipsychotic , ATC code :
& quot ;
& quot ; patient with renal impairment : no dosage adjustment be require in patient with renal impairment .
& quot ;
& quot ; Thrombotic / vascular event , such a myocardial ischaemia , myocardial infarction , cerebrovascular accident ( cerebral haemorrhage and cerebral infarction ) , transient ischaemic attack , deep vein thrombosis , arterial thrombosis , pulmonary embolus , aneurysm , retinal thrombosis , and clotting of an artificial kidney have be report in patient receive erythropoietic agent , include patient receive epoetin alfa .
& quot ;
& quot ; red iron oxide ( E172 )
& quot ;
& quot ; Abseamed have no influence on the ability to drive and use machine .
& quot ;
& quot ; method of administration
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; P1NP be significantly reduce by 61 % below baseline level at 12 month and be sustain at 52 % below baseline level at 36 month .
& quot ;
& quot ; the decision to administer recombinant erythropoietin should be base on a benefit-risk assessment with the participation of the individual patient , which should also take into account the specific clinical context .
& quot ;
& quot ; 5 .
& quot ;
& quot ; Tel : + 351 21 440 70 00
& quot ;
& quot ; Serum electrolytes should be monitor in chronic renal failure patient .
& quot ;
& quot ; driving and use machine do not drive or use any tool or machine if you feel drowsy after receive ABILIFY solution for injection .
& quot ;
& quot ; the rate of increase in haemoglobin should be approximately 1 g / dl
& quot ;
& quot ; 4 .
& quot ;
& quot ; 14 X 1
& quot ;
& quot ; Pregnancy and breast-feeding you should not take ABILIFY if you be pregnant unless you have discuss this with your doctor .
& quot ;
& quot ; for single tablet removal , open the package and peel back the foil on the blister to expose the tablet .
& quot ;
& quot ; the therapeutic margin of epoetin alfa be very wide .
& quot ;
& quot ; expiry date
& quot ;
& quot ; Aripiprazole be excrete in the milk of treated rat during lactation .
& quot ;
& quot ; some patient may benefit from a higher dose .
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of anaemia and of the symptom of anaemia .
& quot ;
& quot ; contains aspartame .
& quot ;
& quot ; jaundice , hepatitis , increase Alanine Aminotransferase ( ALT ) , increased Aspartate Aminotransferase ( AST ) , increase Gamma Glutamyl Transferase ( GGT ) , increase alkaline phosphatase
& quot ;
& quot ; le than 1 % of unchanged aripiprazole be excrete in the urine and approximately 18 % be recover unchanged in the faeces .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; 5 mg / 100 ml
& quot ;
& quot ; 2 .
& quot ;
& quot ; - oral iron substitution of 200 - 300 mg Fe2 + / day be recommend for all cancer patient whose
& quot ;
& quot ; the syrinx contain 1 ml ( 10 000 IU ) of solution .
& quot ;
& quot ; 159 5 .
& quot ;
& quot ; Manic episodes in Bipolar I Disorder with oral aripiprazole :
& quot ;
& quot ; Aripiprazole solution for injection administer intramuscularly a a single-dose to healthy subject be well absorb and have an absolute bioavailability of 100 % .
& quot ;
& quot ; Cardiac disorder :
& quot ;
& quot ; Epoetin alfa IV / SC
& quot ;
& quot ;
& quot ; other finding :
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; the peak be always well below the peak achieve use the intravenous route ( approximately 1 / 20th of the value ) .
& quot ;
& quot ; these change be interpret a be secondary to decreased maternal body weight gain .
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; jaundice , hepatitis , increase Alanine Aminotransferase ( ALT ) , increased Aspartate Aminotransferase ( AST ) , increase Gamma Glutamyl Transferase ( GGT ) , increase alkaline phosphatase
& quot ;
& quot ; special storage condition
& quot ;
& quot ; animal study could not exclude potential developmental toxicity ( see section 5.3 ) .
& quot ;
& quot ; if anti-erythropoietin , antibody-mediated PRCA be suspect , therapy with Abseamed should be discontinue immediately .
& quot ;
& quot ; 12 .
& quot ;
& quot ; Zoledronic acid be not highly bind to plasma protein ( approximately 43-55 % bound ) and interaction result from displacement of highly protein-bound drug be therefore unlikely .
& quot ;
& quot ; Erythropoietin be a glycoprotein that stimulate , a a mitosis-stimulating factor and differentiate hormone , the formation of erythrocyte from precursor of the stem cell compartment .
& quot ;
& quot ; Medice
& quot ;
& quot ; & quot ; & quot ; Flu-like & quot ; & quot ; symptom such a headache , joint pain , feeling of weakness , dizziness , and tiredness may occur , especially at the start of treatment .
& quot ;
& quot ;
& quot ; Aripiprazole and other antipsychotic drug should be use cautiously in patient at risk for aspiration pneumonia .
& quot ;
& quot ; 1 .
& quot ;
& quot ; therefore , aripiprazole should be use with caution in patient who have a history of seizure disorder or have condition associate with seizure .
& quot ;
& quot ; in this leaflet :
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of epilepsy and chronic liver failure .
& quot ;
& quot ; Meta-analysis of overall survival data produce a hazard ratio point estimate of 1.08 in favour of control ( 95 % CI :
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; Tablet Round and yellow , engrave with & quot ; & quot ; A-009 & quot ; & quot ; and & quot ; & quot ; 15 & quot ; & quot ; on one side .
& quot ;
& quot ; 1 .
& quot ;
& quot ; 3 .
& quot ;
& quot ; Occlusion of the dialysis system be possible if heparinisation be not optimum .
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; when consider concomitant administration of ketoconazole or other potent CYP3A4 inhibitor with ABILIFY , potential benefit should outweigh the potential risk to the patient .
& quot ;
& quot ; it also prevent this condition from return in patient who have respond to the treatment with ABILIFY .
& quot ;
& quot ; 1 mg / ml
& quot ;
& quot ; recurrence prevention of manic episode in Bipolar I Disorder :
& quot ;
& quot ; Τηλ : + 30 210 6074300
& quot ;
& quot ; the maximum dose should not exceed 200 IU / kg 3 time per week .
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; name OF the marketing authorisation holder
& quot ;
& quot ; date OF last revision OF the text
& quot ;
& quot ; in case of larger volume , more than one site should be choose for the injection .
& quot ;
& quot ; developmental toxicity , include dose-dependent delayed foetal ossification and possible teratogenic effect , be observe in rat at dos result in subtherapeutic exposure ( base on AUC ) and in rabbit at dos result in exposure 3 and 11 time the mean steady-state AUC at the maximum recommend clinical dose .
& quot ;
& quot ; market authorisation holder Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; what ABILIFY be AND what IT be use for
& quot ;
& quot ; there be an increased risk for thromboembolic event in patient with cancer treat with recombinant human erythropoietin and a negative impact on overall survival can not be exclude .
& quot ;
& quot ; the apparent molecular weight of erythropoietin be 32,000 to 40,000 dalton .
& quot ;
& quot ; in another 12-week trial , the incidence of EPS be 26.6 % for patient treat with aripiprazole and 17.6 % for those treat with lithium .
& quot ;
& quot ; Eesti Österreich BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery the cause of anaemia should be establish and treat , if possible , before the start of epoetin alfa treatment .
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; oral use
& quot ;
& quot ; Abilify
& quot ;
& quot ; in CYP2D6 poor metabolisers , concomitant use of potent inhibitor of CYP3A4 may result in higher plasma concentration of aripiprazole compare to that in CYP2D6 extensive metabolizers .
& quot ;
& quot ; in several controlled study , epoetins have not be show to improve overall survival or decrease the risk of tumour progression in patient with anaemia associate with cancer .
& quot ;
& quot ; Overdose of epoetin alfa may produce effect that be extension of the pharmacological effect of the hormone .
& quot ;
& quot ; a slower injection be preferable in patient who react to the treatment with “ flu-like ” symptom .
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; usual maintenance dose 75 - 150 60 - 150 30 - 100
& quot ;
& quot ; weight gain : weight gain be commonly see in schizophrenic and bipolar mania patient due to co- morbidity , use of antipsychotic know to cause weight gain , poorly manage life-style , and might lead to severe complication .
& quot ;
& quot ;
& quot ; some settling of the reconstituted suspension may occur .
& quot ;
& quot ; manufacture authorisation holder responsible for BATCH release
& quot ;
& quot ; rash , photosensitivity reaction , alopecia , hyperhidrosis
& quot ;
& quot ; base on information available to date , correction of anaemia with epoetin alfa in adult patient with renal insufficiency not yet undergoing dialysis do not accelerate the rate of progression of renal insufficiency .
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl
& quot ;
& quot ; 150 PARTICULARS to appear on the outer packaging
& quot ;
& quot ; Abilify should not be use in people who may be hypersensitive ( allergic ) to aripiprazole or any of the other ingredient .
& quot ;
& quot ; for the treatment of osteoporosis , the effect of Aclasta give once a year have be compare with those of placebo ( a dummy treatment ) in two main study .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; however , a with other antipsychotic , patient should be caution about operate hazardous machine , include motor vehicle , until they be reasonably certain that aripiprazole do not affect them adversely .
& quot ;
& quot ; result of an epidemiological study find that there be no increase risk of suicidality with aripiprazole compare to other antipsychotic among patient with bipolar disorder .
& quot ;
& quot ; the absolute oral bioavailability of the tablet formulation be 87 % .
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ; Blood pressure-lowering medicine :
& quot ;
& quot ; in the trial for the prevention of clinical fracture follow a recent hip fracture , vitamin D level be not routinely measure but the majority of patient receive a load dose of vitamin D prior to Aclasta administration ( see section 4.2 ) .
& quot ;
& quot ; the usual dose be 15 mg once a day .
& quot ;
& quot ; further information
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; le than 1 % of unchanged aripiprazole be excrete in the urine and approximately 18 % be recover unchanged in the faeces .
& quot ;
& quot ; other finding :
& quot ;
& quot ; 37 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; ABILIFY dose should be double when concomitant administration of ABILIFY occur with carbamazepine .
& quot ;
& quot ; ABILIFY may increase the effect of medicine use to lower the blood pressure .
& quot ;
& quot ; 5 .
& quot ;
& quot ; Additionally , aripiprazole and dehydro-aripiprazole do not show potential for alter CYP1A2-mediated metabolism in vitro .
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; therefore , in patient with renal anaemia the medicinal product have to be administer intravenously .
& quot ;
& quot ; between treatment comparison of the incidence over 3 year
& quot ;
& quot ; Thrombotic / vascular event , such a myocardial ischaemia , myocardial infarction , cerebrovascular accident ( cerebral haemorrhage and cerebral infarction ) , transient ischaemic attack , deep vein thrombosis , arterial thrombosis , pulmonary embolus , aneurysm , retinal thrombosis , and clotting of an artificial kidney have be report in patient receive erythropoietic agent , include patient receive epoetin alfa .
& quot ;
& quot ; an investigational study ( best study ) in woman with metastatic breast cancer be design to determine whether epoetin alfa treatment that extend beyond the correction of anaemia could improve treatment outcome .
& quot ;
& quot ; Tel : + 420 221 016 111
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; when concomitant administration of ketoconozole with ABILIFY occurs , ABILIFY dose should be reduce to approximately one-half of it prescribed dose .
& quot ;
& quot ; 2 .
& quot ;
& quot ; N05AX12
& quot ;
& quot ; the study either recruited patient who be be treat with chemotherapy ( two study ) or use patient population in which erythropoiesis stimulating agent be not indicate : anaemia in patient with cancer not receive chemotherapy , and head and neck cancer patient receive radiotherapy .
& quot ;
& quot ; Abseamed should be administer intravenously in order to increase haemoglobin to not greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; 1 .
& quot ;
& quot ; each tablet contain 30 mg of aripiprazole .
& quot ;
& quot ; Malta BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; Psychiatric disorder :
& quot ;
& quot ; - iron supplementation , e. g .
& quot ;
& quot ; Manic episodes in Bipolar I Disorder - in a 12-week controlled trial , the incidence of EPS be 23.5 % for aripiprazole-treated patient and 53.3 % for haloperidol-treated patient .
& quot ;
& quot ; further information
& quot ;
& quot ; solution for injection in a pre-filled syringe .
& quot ;
& quot ; instruction on use
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; 5 .
& quot ;
& quot ; Hypersensitivity reaction have be rarely report with epoetin alfa include isolated case of angioedema and anaphylactic reaction .
& quot ;
& quot ; your doctor will conduct investigation , for example blood test , to decide if it be necessary for you to have Abseamed .
& quot ;
& quot ; Thrombotic event can be a risk in this population and this possibility should be carefully weigh against the benefit to be derive from the treatment in this patient group .
& quot ;
& quot ; how to take ABILIFY 4 .
& quot ;
& quot ; distribution :
& quot ;
& quot ; the bioavailability of subcutaneous injectable epoetin alfa be much lower than that of the intravenous medicinal product : approximately 20 % .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; in paediatric patient the recommended target haemoglobin range be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; 8 .
& quot ;
& quot ; B03XA01
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ; child and adolescent : there be no experience in child and adolescent under 18 year of age .
& quot ;
& quot ; clear colourless solution
& quot ;
& quot ; Intravenous injection : over at least one to five minute , depend on the total dose .
& quot ;
& quot ; Tel : + 371 67 50 21 85
& quot ;
& quot ; 4 .
& quot ;
& quot ; 6 mg aspartame ( E951 ) per orodispersible tablet
& quot ;
& quot ; owe to the greater sensitivity of this population , a lower start dose should be consider when clinical factor warrant ( see section 4.4 ) .
& quot ;
& quot ; if you notice you be gain weight , experience any difficulty in swallow or allergic symptom , please tell your doctor .
& quot ;
& quot ; when concomitant administration of potent CYP3A4 or CYP2D6 inhibitor with aripiprazole occurs , the aripiprazole dose should be reduce .
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; weight gain : in clinical trial aripiprazole have not be show to induce clinically relevant weight gain .
& quot ;
& quot ; in the long term 26-week maintenance phase of a placebo-controlled trial , the incidence of EPS be 18.2 % for aripiprazole-treated patient and 15.7 % for placebo-treated patient .
& quot ;
& quot ; in another 12-week trial , the incidence of EPS be 26.6 % for patient treat with aripiprazole and 17.6 % for those treat with lithium .
& quot ;
& quot ; give the primary CNS effect of aripiprazole , caution should be use when aripiprazole be take in combination with alcohol or other CNS medicinal product with overlap undesirable effect such a sedation ( see section 4.8 ) .
& quot ;
& quot ; it be available in pre-filled syrinx contain between 1,000 and 10,000 international unit ( IU ) of the active substance , epoetin alfa .
& quot ;
& quot ; expiry date
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; Aripiprazole be extensively metabolise by the liver primarily by three biotransformation pathway : dehydrogenation , hydroxylation , and N-dealkylation .
& quot ;
& quot ; 4 .
& quot ;
& quot ; 8 .
& quot ;
& quot ; EXP
& quot ;
& quot ; at the time of donate blood , Abseamed should be administer after the completion of the blood donation procedure .
& quot ;
& quot ; if blood pressure can not be control , epoetin alfa treatment should be discontinue .
& quot ;
& quot ; you should check with your doctor or pharmacist if you be not sure .
& quot ;
& quot ; transferrin saturation be below 20 % .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; hyperglycaemia , diabetes mellitus , diabetic ketoacidosis , diabetic hyperosmolar coma
& quot ;
& quot ; Abseamed should be give by the intravenous route .
& quot ;
& quot ; Nausea , diarrhoea , vomit , constipation , stomatitis
& quot ;
& quot ; you may need to read it again .
& quot ;
& quot ; in paediatric patient the recommended target haemoglobin range be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; in a haloperidol-controlled trial , the proportion of responder patient maintain response to medicinal product at 52-weeks be similar in both group ( aripiprazole 77 % and haloperidol 73 % ) .
& quot ;
& quot ; Reproductive system and breast disorder :
& quot ;
& quot ; Calcium silicate Croscarmellose sodium Crospovidone Silicon dioxide Xylitol Microcrystalline cellulose Aspartame ( E951 ) Acesulfame potassium Vanilla flavour ( include vanillin and ethyl vanillin ) Tartaric acid Magnesium stearate
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subject , nor be there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; Ελλάδα BRISTOL-MYERS SQUIBB A. e .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel : + 353 ( 1 800 ) 749 749
& quot ;
& quot ; Serum electrolytes should be monitor .
& quot ;
& quot ; Measurement of epoetin alfa follow multiple dose intravenous administration reveal a half-life of approximately 4 hour in normal volunteer and a somewhat more prolonged half-life in renal failure patient , approximately 5 hour .
& quot ;
& quot ; appropriate therapy such a blood transfusion may be give to patient when indicate .
& quot ;
& quot ; expiry date
& quot ;
& quot ; - if the solution be cloudy or there be particle in it .
& quot ;
& quot ; Orodispersible Tablet
& quot ;
& quot ; 4 June 2004
& quot ;
& quot ; Syringes be emboss with graduation ring and the filling volume be indicate by a stick-on label in order to enable partial use if require .
& quot ;
& quot ; if patient experience nausea , vomit and diarrhoea follow the administration of Abraxane , they may be treat with commonly use anti-emetics and constipate agent .
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; if you develop PRCA your Abseamed therapy will be discontinue and your doctor will decide how best to treat your anaemia .
& quot ;
& quot ; { MM / YYYY }
& quot ;
& quot ; ask your doctor or pharmacist for advice before take ABILIFY .
& quot ;
& quot ; however , elevate creatine phosphokinase and rhabdomyolysis , not necessarily in association with NMS , have also be report .
& quot ;
& quot ; if you take more ABILIFY than you should if you realise you have take more ABILIFY oral solution than your doctor have recommend ( or if someone else have take some of your ABILIFY oral solution ) , contact your doctor right away .
& quot ;
& quot ; maintenance dose between 25 and 50 IU / kg 2 time per week into 2 equal injection .
& quot ;
& quot ; the mean elimination half-lives for aripiprazole be approximately 75 hour in extensive metabolisers of CYP2D6 and approximately 146 hour in poor metabolisers of CYP2D6 .
& quot ;
& quot ; each ml contain 7.5 mg of aripiprazole .
& quot ;
& quot ; in order to ensure optimum response to epoetin alfa , adequate iron store should be assure :
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; no evidence exist that indicate an interaction between epoetin alfa and G-CSF or GM-CSF with regard to haematological differentiation or proliferation of tumour biopsy specimen in vitro .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; common side effect ( greater than 1 in 100 , le than 1 in 10 patient ) Uncontrollable twitching or jerking movement , headache , tiredness , nausea , vomit , an uncomfortable feeling in the stomach , constipation , increased production of saliva , light-headedness , trouble sleeping , restlessness , feel anxious , sleepiness , shake and blurred vision .
& quot ;
& quot ; patient with renal impairment ( see section 4.4 ) use of Aclasta in patient with creatinine clearance & lt ; 35 ml / min be not recommend due to limited clinical experience in this population .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; 12 .
& quot ;
& quot ;
& quot ; Absorption :
& quot ;
& quot ; long-term carcinogenicity study have not be carry out .
& quot ;
& quot ; Teл . : + 359 800 12 400
& quot ;
& quot ; 56-99 year ) of aripiprazole in elderly patient with psychosis associate with Alzheimer & apos ; s disease , patient treat with aripiprazole be at increase risk of death compare to placebo .
& quot ;
& quot ; Syringes be emboss with graduation ring and the filling volume be indicate by a stick-on label in order to enable partial use if require .
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; content by weight , by volume or by unit
& quot ;
& quot ; 6 .
& quot ;
& quot ; 7 .
& quot ;
& quot ; Subcutaneous route
& quot ;
& quot ; 15 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; 1 mg / ml
& quot ;
& quot ; Rentschler Biotechnologie GmbH Erwin-Rentschler-Strasse 21 D-88471 Laupheim Germany
& quot ;
& quot ; content
& quot ;
& quot ; this leaflet be last approved in
& quot ;
& quot ; if you notice you be gain weight , experience any difficulty in swallow or allergic symptom , please tell your doctor .
& quot ;
& quot ; it be especially important to mention the follow to your doctor :
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; 179 detailed information on this medicine be available on the European Medicines Agency ( EMEA ) web site : http : / / www . emea . europa . EU /
& quot ;
& quot ; 7 .
& quot ;
& quot ; 8 .
& quot ;
& quot ; Calculate the exact total dosing volume of 5 mg / ml suspension require for the patient and inject the appropriate amount of reconstituted Abraxane into an empty , sterile , PVC or non-PVC type intravenous bag .
& quot ;
& quot ; 7 .
& quot ;
& quot ; Portugal BRISTOL-MYERS SQUIBB FARMACÊUTICA Portuguesa , S. A .
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; each bottle with 100 ml of solution contains 5 mg zoledronic acid anhydrous , correspond to 5.330 mg zoledronic acid monohydrate .
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; control clinical trial have not show significant benefit attributable to the administration of epoetins when haemoglobin concentration be increase beyond the level necessary to control symptom of anaemia and to avoid blood transfusion .
& quot ;
& quot ; weight gain : in clinical trial aripiprazole have not be show to induce clinically relevant weight gain .
& quot ;
& quot ; 33 6.4 Special precaution for storage
& quot ;
& quot ; always take ABILIFY exactly a your doctor have tell you .
& quot ;
& quot ; pure red Cell Aplasia ( PRCA ) Antibody-mediated PRCA have be very rarely report after month to year of subcutaneous erythropoietin treatment .
& quot ;
& quot ; at least one new vertebral fracture ( 0 – 3 year ) * * p & lt ; 0.0001
& quot ;
& quot ; study in animal have show reproduction toxicity ( see section 5.3 ) .
& quot ;
& quot ; - if the solution be cloudy or there be particle in it .
& quot ;
& quot ; 70 ( 62 , 76 ) * *
& quot ;
& quot ; elderly : the effectiveness of ABILIFY in the treatment of schizophrenia and Bipolar I Disorder in patient 65 year of age or older have not be establish .
& quot ;
& quot ; 177 minimum PARTICULARS to appear on small immediate packaging unit
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; PRCA can result in sudden and severe anaemia , the symptom of which be unusual tiredness , feel dizzy or breathlessness .
& quot ;
& quot ;
& quot ; France BRISTOL-MYERS SQUIBB SARL Tél : + 33 ( 0 ) 810 410 500
& quot ;
& quot ; after injection of the necessary amount of the solution from the pre-filled syringe , discard any remain content .
& quot ;
& quot ; increase Creatine Phosphokinase , blood glucose increase , blood glucose fluctuation , glycosylated haemoglobin increase
& quot ;
& quot ; elderly patient with dementia-related psychosis :
& quot ;
& quot ; 6 .
& quot ;
& quot ; Dosage adjustment to maintain haemoglobin concentration between 10 g / dl - 12 g / dl :
& quot ;
& quot ; take ABILIFY with food and drink ABILIFY can be take regardless of meal .
& quot ;
& quot ; a systematic review have also be perform involve more than 9000 cancer patient participate in 57 clinical trial .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; similarly , for dehydro-aripiprazole the geometric mean of Cmax and AUC after carbamazepine co-administration be 69 % and 71 % lower , respectively , than those following treatment with aripiprazole alone .
& quot ;
& quot ; ABILIFY be one of a group of medicine call antipsychotic .
& quot ;
& quot ; increase blood pressure , increase weight , increase blood lactate dehydrogenase , increase blood creatinine , increase blood glucose , increase blood phosphorus , decrease blood potassium Cardiac disorder :
& quot ;
& quot ; however , elevate creatine phosphokinase and rhabdomyolysis , not necessarily in association with NMS , have also be report .
& quot ;
& quot ; in the study of patient with anaemia cause by kidney problem , patient switch to Abseamed maintain haemoglobin level to the same extent a those continue to take Eprex / Erypo .
& quot ;
& quot ; the following reaction have also occur in isolated patient with normal or low blood pressure : hypertensive crisis with encephalopathy-like symptom ( e. g. headache and confused state ) and Generalised tonoclonal seizure , require the immediate attention of a physician and intensive medical care .
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; there be not much experience with subcutaneous use ( injection into the skin ) of Abseamed in kidney patient .
& quot ;
& quot ; 98 X 1
& quot ;
& quot ; EXP
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of at least four week .
& quot ;
& quot ; ABILIFY be indicate for the treatment of schizophrenia .
& quot ;
& quot ; Median 100 75 33
& quot ;
& quot ; 2 .
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; urinary incontinence , urinary retention
& quot ;
& quot ; the frequency of these event be consider not know ( can not be estimate from the available data ) .
& quot ;
& quot ; however chemical and physical in use stability have be demonstrate for 8 hour not above 25 ° C .
& quot ;
& quot ; the four carbohydrate chain be attach via three N-glycosidic bond and one O-glycosidic bond to the protein .
& quot ;
& quot ; Abilify
& quot ;
& quot ; the rate of increase in haemoglobin should be approximately 1 g / dl
& quot ;
& quot ; patient with active malignant disease receive neither chemotherapy nor radiation therapy .
& quot ;
& quot ; Abseamed
& quot ;
& quot ; it be recommend that the platelet count be regularly monitor during the first 8 week of therapy .
& quot ;
& quot ; the potentially medically serious sign and symptom report included somnolence , transient loss of consciousness and extrapyramidal symptom .
& quot ;
& quot ; Aripiprazole exhibit antagonist property in animal model of dopaminergic hyperactivity and agonist property in animal model of dopaminergic hypoactivity .
& quot ;
& quot ; lot
& quot ;
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; Medice
& quot ;
& quot ; due to it α 1-adrenergic receptor antagonism , aripiprazole have the potential to enhance the effect of certain antihypertensive agent .
& quot ;
& quot ; before you take ABILIFY
& quot ;
& quot ; Batch
& quot ;
& quot ; 12 .
& quot ;
& quot ; the effectiveness of Abraxane have be study in one main study involve 460 woman with metastatic breast cancer , around three-quarters of whom have receive an anthracycline in the past .
& quot ;
& quot ; maintenance dose between 17 and 33 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; when consider concomitant administration of ketoconazole or other potent CYP3A4 inhibitor with ABILIFY , potential benefit should outweigh the potential risk to the patient .
& quot ;
& quot ; 176 if you have the impression that the effect of ABILIFY be too strong or too weak , talk to your doctor or pharmacist .
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; in this leaflet :
& quot ;
& quot ; oral use .
& quot ;
& quot ; please tell your doctor .
& quot ;
& quot ; Κύπρος ΑΚΗΣ ΠΑΝΑΓΙΩΤΟΥ & amp ; ΥΙΟΣ Ε .Π .Ε .
& quot ;
& quot ; uncontrolled hypertension .
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of untreated , inadequately treat
& quot ;
& quot ; however , chemical and physical in use stability have be demonstrate for 8 hour at 2 ° C - 8 ° C in the original carton , and protect from bright light .
& quot ;
& quot ; 71 Tardive Dyskinesia : in clinical trial of one year or le duration , there be uncommon report of treatment emergent dyskinesia during treatment with aripiprazole .
& quot ;
& quot ; how to take ABILIFY
& quot ;
& quot ; follow subcutaneous injection , serum level of epoetin alfa be much lower than the level achieve follow intravenous injection , the level increase slowly and reach a peak between 12 and
& quot ;
& quot ; Placebo absolute reduction ( N = 3,861 ) in fracture event
& quot ;
& quot ; Abseamed 6000 IU / 0.6 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery should receive adequate antithrombotic prophylaxis , a thrombotic and vascular event may occur in surgical patient , especially in those with underlying cardiovascular disease .
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; 10 .
& quot ;
& quot ; Z O. O .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; s R. O .
& quot ;
& quot ; elderly patient with dementia-related psychosis :
& quot ;
& quot ; study in animal have show reproduction toxicity ( see section 5.3 ) .
& quot ;
& quot ; it do not matter whether you take it with or without food .
& quot ;
& quot ; if an elevate ( or rise ) serum potassium level be detect then consideration should be give to cease epoetin alfa administration until hyperkalaemia have be correct .
& quot ;
& quot ; in two large , open-label study , 2697 cancer patient receive non-platinum chemotherapy be include , 1895 with solid tumour ( 683 breast , 260 lung , 174 gynaecological , 300 gastro-intestinal , and 478 other tumour type ) and 802 with haematological malignancy .
& quot ;
& quot ; 183 5 .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; before you use Abseamed 3 .
& quot ;
& quot ; 30 Posology
& quot ;
& quot ; if you have any further question , ask your doctor or pharmacist .
& quot ;
& quot ; appropriate therapy such a blood transfusion may be give to patient when indicate .
& quot ;
& quot ; the highest nontumorigenic exposure in female rat be 7 time the human exposure at the recommend dose .
& quot ;
& quot ; the intravenous route have to be use ( please see section 4.4 - chronic renal failure patient ) .
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; powder for suspension for infusion One vial of 100 mg paclitaxel
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; undesirable effect know to be associate with antipsychotic therapy and also report during treatment with aripiprazole include neuroleptic malignant syndrome , tardive dyskinesia , seizure , cerebrovascular adverse event and increased mortality in elderly demented patient , hyperglycaemia and diabetes mellitus ( see section 4.4 ) .
& quot ;
& quot ; Serum electrolytes should be monitor in chronic renal failure patient .
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; Novartis Europharm limit Wimblehurst Road Horsham West Sussex , RH12 5AB United Kingdom
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; 6 .
& quot ;
& quot ; these may be the warning sign of a sudden rise in blood pressure which require urgent treatment .
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; 56-99 year ) of aripiprazole in elderly patient with psychosis associate with Alzheimer & apos ; s disease , patient treat with aripiprazole be at increase risk of death compare to placebo .
& quot ;
& quot ; in addition , an updated RMP should be submit when new information be receive that may impact on the current Safety specification , Pharmacovigilance Plan or risk minimisation activity within 60 day of an important ( pharmacovigilance or risk minimisation ) milestone be reach at the request of the EMEA
& quot ;
& quot ; speech disorder , Neuroleptic Malignant syndrome ( NMS ) , grand mal convulsion
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; in clinical trial aripiprazole have not be show to induce clinically relevant weight gain ( see section 5.1 ) .
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; Aripiprazole be well absorb when administer orally a the solution .
& quot ;
& quot ; the main measure of effectiveness be the number of patient who ‘ respond ’ after at least five week of treatment .
& quot ;
& quot ; no evidence exist that indicate that treatment with epoetin alfa alter the metabolism of other medicinal product .
& quot ;
& quot ; developmental toxicity , include dose-dependent delayed foetal ossification and possible teratogenic effect , be observe in rat at dos result in subtherapeutic exposure ( base on AUC ) and in rabbit at dos result in exposure 3 and 11 time the mean steady-state AUC at the maximum recommend clinical dose .
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl
& quot ;
& quot ; adult surgery patient in an autologous predonation programme
& quot ;
& quot ; 82 721 cancer patient receive non-platinum chemotherapy be include in three placebo-controlled study , 389 patient with haematological malignancy ( 221 multiple myeloma , 144 non-Hodgkin & apos ; s lymphoma , and 24 other haematological malignancy ) and 332 with solid tumour ( 172 breast , 64 gynaecological , 23 lung , 22 prostate , 21 gastro-intestinal , and 30 other tumour type ) .
& quot ;
& quot ; two other smaller , randomise , placebo-controlled trial fail to show a significant improvement in quality of life parameter on the EORTC-QLQ-C30 scale or CLAS , respectively .
& quot ;
& quot ; Metabolism and nutrition disorder :
& quot ;
& quot ; Medicines should not be dispose of via wastewater or household waste .
& quot ;
& quot ; Abraxane be a medicine contain paclitaxel in human albumin ( portion of blood ) .
& quot ;
& quot ; 7 .
& quot ;
& quot ; Slovenská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; all other cause of anaemia ( iron deficiency , haemolysis , blood loss , vitamin B12 or folate deficiency ) should be consider and treat prior to initiate therapy with epoetin alfa .
& quot ;
& quot ; therefore , it should not be use in patient with baseline haemoglobin & gt ; 13 g / dl .
& quot ;
& quot ; adverse reaction report with Abraxane at any dose in clinical trial .
& quot ;
& quot ;
& quot ; 7 Westferry circus , Canary Wharf , London E14 4HB , UK Tel .
& quot ;
& quot ; maintenance dose between 17 and 33 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; in elderly patient with dementia , more fatal case have be report while take aripiprazole .
& quot ;
& quot ; Blood pressure-lowering medicine :
& quot ;
& quot ; the peak be always well below the peak achieve use the intravenous route ( approximately 1 / 20th of the value ) .
& quot ;
& quot ; patient be treat without steroid pre- treatment or plan G-CSF support .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; Abseamed must not be use
& quot ;
& quot ; 84 year ; range :
& quot ;
& quot ; kg Τηλ : + 49- ( 0 ) 2371 937 0
& quot ;
& quot ; other potent inhibitor of CYP3A4 , such a itraconazole and HIV protease inhibitor , may be expect to have similar effect and similar dose reduction should therefore be apply .
& quot ;
& quot ; 4000 IU / 0.4 ml
& quot ;
& quot ; 1 .
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; the recommended total weekly dose be between 75 and 300 IU / kg give by the intravenous route .
& quot ;
& quot ; oral solution clear , colourless to light yellow liquid .
& quot ;
& quot ;
& quot ; 5 .
& quot ;
& quot ;
& quot ; each ml of solution contains 2000 IU of epoetin alfa * correspond to 16.8 microgram per ml 1 pre-filled syringe of 0.5 ml contains 1000 international unit ( IU ) correspond to 8.4 microgram epoetin alfa
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; 30 ml solution / day ) .
& quot ;
& quot ; the rate of death in aripiprazole-treated patient be 3.5 % compare to 1.7 % in the placebo group .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; usual maintenance dose 75 - 150 60 - 150 30 - 100
& quot ;
& quot ; further information
& quot ;
& quot ; 3 .
& quot ;
& quot ; Aripiprazole exhibit high binding affinity in vitro for dopamine D2 and D3 , serotonin 5HT1a and 5HT2a receptor and moderate affinity for dopamine D4 , serotonin 5HT2c and 5HT7 , alpha-1 adrenergic and histamine H1 receptor .
& quot ;
& quot ; the pre-filled syringe should not be shake .
& quot ;
& quot ; 145 Eesti Österreich BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; a single-dose study in subject with vary degree of liver cirrhosis ( Child-Pugh class A , B , and C ) do not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole , but the study include only 3 patient with class C liver cirrhosis , which be insufficient to draw conclusion on their metabolic capacity .
& quot ;
& quot ; an investigational study ( best study ) in woman with metastatic breast cancer be design to determine whether epoetin alfa treatment that extend beyond the correction of anaemia could improve treatment outcome .
& quot ;
& quot ; Abseamed should be administer intravenously in order to increase haemoglobin to not greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; 1 pre-filled syringe
& quot ;
& quot ; Abseamed be a sterile but unpreserved product and be for single use only .
& quot ;
& quot ; 8 .
& quot ;
& quot ; oropharyngeal spasm , laryngospasm , aspiration pneumonia
& quot ;
& quot ; this regress during the course of continued therapy .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; Abseamed must not be use
& quot ;
& quot ; iron supplementation should be start prior to epoetin alfa therapy , to achieve adequate iron store .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; possible side effect
& quot ;
& quot ; in clinical trial , rare case of NMS be report during treatment with aripiprazole .
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; in clinical trial of aripiprazole , the incidence of QT prolongation be comparable to placebo .
& quot ;
& quot ; Intravenous route
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; 5 .
& quot ;
& quot ; in patient with chronic renal failure and clinically evident ischaemic heart disease or congestive heart failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration a recommend under section 4.2 .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; 200 mg oral elemental iron daily ) throughout the course of treatment .
& quot ;
& quot ; risk factor that may predispose patient to severe complication include obesity and family history of diabetes .
& quot ;
& quot ; like all medicine , ABILIFY can cause side effect , although not everybody get them .
& quot ;
& quot ; 98 X 1
& quot ;
& quot ; an increase 3H-thymidine incorporation in the erythroid nucleate spleen cell have be find in vitro ( mouse spleen cell culture ) after incubation with epoetin alfa .
& quot ;
& quot ; store in the original package in order to protect from moisture .
& quot ;
& quot ; in all patient receive epoetin alfa , blood pressure should be closely monitor and control a necessary .
& quot ;
& quot ;
& quot ; thus , aripiprazole be unlikely to cause clinically important medicinal product interaction mediate by these enzyme .
& quot ;
& quot ; 7 .
& quot ;
& quot ; 1 bottle – 100 ml
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; Belgique / België / Belgien BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; 131 10 .
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; Abseamed 9000 IU / 0.9 ml injection
& quot ;
& quot ; 14 .
& quot ;
& quot ; in elderly patient with dementia , more fatal case have be report while take aripiprazole .
& quot ;
& quot ; in patient with chronic renal failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommend in section 4.2 .
& quot ;
& quot ; alcohol should be avoid when take ABILIFY .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; Musculoskeletal and connective tissue disorder :
& quot ;
& quot ; 2 .
& quot ;
& quot ; Abraxane 5 mg / ml powder for suspension for infusion
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery should receive adequate antithrombotic prophylaxis , a thrombotic and vascular event may occur in surgical patient , especially in those with underlying cardiovascular disease .
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; 23 patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; thus , no dosage adjustment be require for smoker .
& quot ;
& quot ; how be Abraxane use ?
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; bottle ( plastic )
& quot ;
& quot ; Schizophrenia :
& quot ;
& quot ; 1 .
& quot ;
& quot ; condition OF the marketing authorisation
& quot ;
& quot ; patient should be closely monitor throughout this period .
& quot ;
& quot ; Abseamed 4000 IU / 0.4 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; Calcium silicate Croscarmellose sodium Crospovidone Silicon dioxide Xylitol Microcrystalline cellulose Aspartame ( E951 ) Acesulfame potassium Vanilla flavour ( include vanillin and ethyl vanillin ) Tartaric acid Magnesium stearate
& quot ;
& quot ; treatment of anaemia and reduction of transfusion requirement in adult patient receive chemotherapy for solid tumour , malignant lymphoma or multiple myeloma , and at risk of transfusion a assess by the patient & apos ; s general status ( e. g. cardiovascular status , pre-existing anaemia at the start of chemotherapy ) .
& quot ;
& quot ; the eighth study look at the effect of add Abilify or placebo to exist treatment with lithium or valproate ( another antipsychotic medicine ) in 384 patient .
& quot ;
& quot ; alcohol should be avoid when take ABILIFY .
& quot ;
& quot ; programme , the use of epoetin alfa be not recommend .
& quot ;
& quot ; 130 PARTICULARS to appear on the outer packaging AND the immediate packaging
& quot ;
& quot ; Malta BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; in cancer patient receive chemotherapy , the 2 - 3 week delay between epoetin alfa administration and the appearance of erythropoietin-induced red cell should be take into account when assess if epoetin alfa therapy be appropriate ( patient at risk of be transfuse ) .
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg Kuhloweg 37 D-58638 Iserlohn
& quot ;
& quot ; strength
& quot ;
& quot ; take ABILIFY with some medicine may need to change your dose of ABILIFY .
& quot ;
& quot ; 29 1 .
& quot ;
& quot ; at each step , the increase or reduction in dose should be of 25 IU / kg 3 time per week .
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) , the dose should be reduce by approximately 25 to 50 % .
& quot ;
& quot ; prophylaxis )
& quot ;
& quot ; a gastric acid blocker , the H2 antagonist famotidine , reduces aripiprazole rate of absorption but this effect be deem not clinically relevant .
& quot ;
& quot ; Tel : + 39 06 50 39 61
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; Abilify
& quot ;
& quot ; consequently :
& quot ;
& quot ; Hepatic disease :
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; a .
& quot ;
& quot ; Excipients
& quot ;
& quot ; due to insufficient safety information in human and concern raise by animal reproductive study , this medicinal product should not be use in pregnancy unless the expected benefit clearly justify the potential risk to the foetus .
& quot ;
& quot ; 62 The recommend dose be 600 IU / kg epoetin alfa , give weekly for three week ( day 21 , 14 and 7 ) prior to surgery and on the day of surgery ( day 0 ) .
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; special storage condition
& quot ;
& quot ; in all patient receive epoetin alfa , blood pressure should be closely monitor and control a necessary .
& quot ;
& quot ; an increase relative risk of thromboembolic event ( RR 1.67 , 95 % CI :
& quot ;
& quot ; the possibility of multiple medicinal product involvement should be consider .
& quot ;
& quot ; in the absence of compatibility study , this medicinal product must not be mix with other medicinal product .
& quot ;
& quot ; oropharyngeal spasm , laryngospasm , aspiration pneumonia
& quot ;
& quot ; when concomitant administration of potent CYP3A4 inducer with aripiprazole occurs , the aripiprazole dose should be increase .
& quot ;
& quot ; with renal insufficiency not yet undergoing dialysis ( see section 4.4 ) .
& quot ;
& quot ; expiry date
& quot ;
& quot ; important information about some of the ingredient of Abraxane This medicinal product contain approximately 425 mg sodium per dose .
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; appropriate therapy such a blood transfusion may be give to patient when indicate .
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and than reinstitute epoetin alfa therapy at a dose 25 % below the previous dose .
& quot ;
& quot ; in most of these patient , antibody to erythropoietin have be observe ( see section 4.3 and 4.4 – pure red Cell Aplasia )
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; adult peritoneal dialysis patient :
& quot ;
& quot ; Aripiprazole exhibit high binding affinity in vitro for dopamine D2 and D3 , serotonin 5HT1a and 5HT2a receptor and moderate affinity for dopamine D4 , serotonin 5HT2c and 5HT7 , alpha-1 adrenergic and histamine H1 receptor .
& quot ;
& quot ; when see , it be usually in those with significant risk factor such a history of diabetes , thyroid disorder or pituitary adenoma .
& quot ;
& quot ; patient who develop pure red Cell Aplasia ( PRCA ) follow treatment with any erythropoietin should not receive Abseamed or any other erythropoietin ( see section 4.4 - pure red Cell Aplasia ) .
& quot ;
& quot ; it be not know whether aripiprazole be excrete in human milk .
& quot ;
& quot ; 2 .
& quot ;
& quot ; Tel : + 420 221 016 111
& quot ;
& quot ; patient with impaired renal function :
& quot ;
& quot ; at steady state , dehydro-aripiprazole , the active metabolite , represent about 40 % of aripiprazole AUC in plasma .
& quot ;
& quot ; consequently , haemoglobin and blood pressure should be closely monitor .
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of epilepsy and chronic liver failure .
& quot ;
& quot ; a half-life of approximately 6 hour have be report in child .
& quot ;
& quot ; 134 ( 0.62 mmol / l ) per month and should not exceed 2 g / dl ( 1.25 mmol / l ) per month to minimise risk of an increase in hypertension .
& quot ;
& quot ; 3 .
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) , the dose should be reduce by approximately 25 to 50 % .
& quot ;
& quot ; 11 .
& quot ;
& quot ; ( see Annex I :
& quot ;
& quot ; of key clinical fracture variable
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; overall , 1.3 % of aripiprazole-treated patient report cerebrovascular adverse event compare with 0.6 % of placebo-treated patient in these trial .
& quot ;
& quot ; market authorisation holder Abraxis BioScience limit West Forest Gate Wellington Road Wokingham Berkshire RG40 2AQ United Kingdom
& quot ;
& quot ; Abseamed should be give by the intravenous route .
& quot ;
& quot ; 57 mg lactose per tablet
& quot ;
& quot ; Abseamed should be give by the intravenous route .
& quot ;
& quot ; Epoetin alfa IV / SC
& quot ;
& quot ; if after an additional 4 week of therapy at 300 IU / kg 3 time per week , the haemoglobin have increase ≥ 1 g / dl ( ≥ 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl the dose should remain at 300 IU / kg 3 time per week .
& quot ;
& quot ; ( 3.0 , 5.8 ) ( 1.5 , 2.7 ) ( 1.4 , 4.0 )
& quot ;
& quot ; 6 .
& quot ;
& quot ; Gastrointestinal disorder :
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; 16 .
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; in paediatric patient the recommended target haemoglobin range be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; it have be propose that aripiprazole ’ s efficacy in schizophrenia and Bipolar I Disorder be mediate through a combination of partial agonism at dopamine D2 and serotonin 5HT1a receptor and antagonism of serotonin 5HT2a receptor .
& quot ;
& quot ; take ABILIFY with some medicine may need to change your dose of ABILIFY .
& quot ;
& quot ; B03XA01
& quot ;
& quot ; a second injection may be administer 2 hour after the first injection , on the basis of individual clinical status and no more than three injection should be give in any 24-hour period .
& quot ;
& quot ; with underlie cardiovascular disease : after donate blood repeatedly vascular and thrombotic event ( blood clot ) can occur independently of treatment with Abseamed .
& quot ;
& quot ; Epoetin alfa IV / SC
& quot ;
& quot ; - if you have any further question , ask your doctor or pharmacist .
& quot ;
& quot ; 78-88 year ) .
& quot ;
& quot ; Surgery patient in autologous predonation programme
& quot ;
& quot ; the injection be give in the thigh or the anterior abdominal wall .
& quot ;
& quot ; caution be indicate when Aclasta be administer in conjunction with medicinal product that can significantly impact renal function ( e. g. aminoglycosides or diuretic that may cause dehydration ) .
& quot ;
& quot ; if you be an elderly patient suffer from dementia ( loss of memory and other mental ability ) , you or your carer / relative should tell your doctor if you have ever have a stroke or & quot ; & quot ; mini & quot ; & quot ; stroke .
& quot ;
& quot ; 10 .
& quot ;
& quot ; Lactose : patient with rare hereditary problem of galactose intolerance , the lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product .
& quot ;
& quot ; use within 6 month after first opening .
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; the intravenous route have to be use ( please see section 4.4 - chronic renal failure patient ) .
& quot ;
& quot ; due to it α 1-adrenergic receptor antagonism , aripiprazole have the potential to enhance the effect of certain antihypertensive agent .
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; some patient may benefit from a higher dose .
& quot ;
& quot ; Dialysis prescription may have to be adjust periodically to maintain urea , creatinine and potassium in the desired range .
& quot ;
& quot ; Abseamed be a sterile but unpreserved product and be for single use only .
& quot ;
& quot ; ask your doctor or pharmacist for advice before take ABILIFY .
& quot ;
& quot ; Excipients The reconstituted medicinal product contain approximately 425 mg sodium per dose .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; 3 .
& quot ;
& quot ; EU / 1 / 07 / 412 / 012
& quot ;
& quot ; 11 .
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; important information about some of the ingredient of ABILIFY each ml of ABILIFY oral solution contain 200 mg of fructose and 400 mg of sucrose .
& quot ;
& quot ; & gt ; 1st-line therapy
& quot ;
& quot ; other
& quot ;
& quot ; in another 12-week trial , the incidence of EPS be 26.6 % for patient treat with aripiprazole and 17.6 % for those treat with lithium .
& quot ;
& quot ; 164 do not open the blister until ready to administer .
& quot ;
& quot ; other potent inhibitor of CYP2D6 , such a fluoxetine and paroxetine , may be expect to have similar effect and similar dose reduction should therefore be apply .
& quot ;
& quot ; - raise blood pressure which may require treatment with medicinal product or adjustment of the
& quot ;
& quot ; the majority of report case have be associate with dental procedure such a tooth extraction .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; this medicinal product contain le than 1 mmol sodium ( 23 mg ) per dose , I. e. essentially “ sodium- free ” .
& quot ;
& quot ; a rise in haemoglobin of greater than 2 g / dl ( 1.25 mmol / l ) over a four week period should be avoid .
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; Smoking status : accord to the metabolic pathway of aripiprazole no dosage adjustment be require for smoker ( see section 4.5 ) .
& quot ;
& quot ; weight gain , weight decrease , anorexia , hyponatremia
& quot ;
& quot ; 1 .
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; 72 Dysphagia : oesophageal dysmotility and aspiration have be associate with antipsychotic drug use , include ABILIFY .
& quot ;
& quot ; 10 .
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; Manic episodes in Bipolar I Disorder - in a 12-week controlled trial , the incidence of EPS be 23.5 % for aripiprazole-treated patient and 53.3 % for haloperidol-treated patient .
& quot ;
& quot ; - treatment of severe anaemia of renal origin accompany by clinical symptom in adult patient
& quot ;
& quot ; ABILIFY be one of a group of medicine call antipsychotic .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; Abseamed be a solution for injection .
& quot ;
& quot ; Tel . : + 48 22 5796666
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; the follow undesirable effect occur more often ( ≥ 1 / 100 ) than placebo , or be identify a possibly medically relevant adverse reaction ( * ) :
& quot ;
& quot ; interaction with receptor other than dopamine and serotonin subtypes may explain some of the other clinical effect of aripiprazole .
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl
& quot ;
& quot ; 8000 IU / 0.8 ml
& quot ;
& quot ; 3 .
& quot ;
& quot ; - treatment of anaemia associate with chronic renal failure in paediatric and adult patient on
& quot ;
& quot ; cardiovascular disorder :
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; it be especially important to mention the follow to your doctor :
& quot ;
& quot ; Aripiprazole be metabolise by multiple pathway involve the CYP2D6 and CYP3A4 enzyme but not CYP1A enzyme .
& quot ;
& quot ; relative fracture
& quot ;
& quot ; at therapeutic concentration , aripiprazole and dehydro-aripiprazole be greater than 99 % bound to serum protein , bind primarily to albumin .
& quot ;
& quot ; - if the solution have be accidentally frozen .
& quot ;
& quot ; formation of a blood clot may occur .
& quot ;
& quot ; the peak be always well below the peak achieve use the intravenous route ( approximately 1 / 20th of the value ) .
& quot ;
& quot ; Dosage adjustment to maintain haemoglobin concentration between 10 g / dl - 12 g / dl :
& quot ;
& quot ;
& quot ; in patient with chronic renal failure and clinically evident ischaemic heart disease or congestive heart failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration a recommend under section 4.2 .
& quot ;
& quot ; Smoking status : accord to the metabolic pathway of aripiprazole no dosage adjustment be require for smoker ( see section 4.5 ) .
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; the initial dose be 150 IU / kg give subcutaneously 3 time per week .
& quot ;
& quot ; the pharmacokinetic characteristic of aripiprazole and dehydro-aripiprazole be find to be similar in patient with severe renal disease compare to young healthy subject .
& quot ;
& quot ; Hypertensive crisis with encephalopathy-like symptom can occur .
& quot ;
& quot ; there be no adequate and well-controlled study in pregnant woman .
& quot ;
& quot ; 166 PARTICULARS to appear on the outer packaging
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; particular attention should be pay to sudden stab migraine- like headache a a possible warning signal .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; treatment should be direct at the major anticipated toxicity , which be bone marrow suppression , mucositis and peripheral neuropathy .
& quot ;
& quot ; 35.3 % - 60.0 % ) , respectively .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; if you have any further question , ask your doctor or pharmacist .
& quot ;
& quot ; Lietuva BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; the correction of your anaemia may lead to increase appetite , and thus increase potassium and protein intake .
& quot ;
& quot ; potential for other medicinal product to affect ABILIFY :
& quot ;
& quot ; usual maintenance dose 75 - 150 60 - 150 30 - 100
& quot ;
& quot ; Conduction abnormality :
& quot ;
& quot ; do not use ABILIFY after the expiry date which be state on the blister and on the carton .
& quot ;
& quot ; the pre-filled syrinx be ready to use ( see section 4.2 – method of administration ) .
& quot ;
& quot ; treatment of symptomatic anaemia associate with chronic renal failure ( CRF ) in adult and paediatric patient :
& quot ;
& quot ; Aripiprazole dose range from 0.5 to 30 mg administer once a day to healthy subject for 2 week produce a dose-dependent reduction in the binding of 11C-raclopride , a D2 / D3 receptor ligand , to the caudate and putamen detect by positron emission tomography .
& quot ;
& quot ; Thrombocytosis have be observe but it occurrence be very rare ( see section 4.4 ) .
& quot ;
& quot ; moreover , monitoring of the blood pressure be recommend particularly at the start of therapy .
& quot ;
& quot ; child and adolescent ABILIFY be not for use in child and adolescent a it have not be study in patient under 18 year .
& quot ;
& quot ; 3 .
& quot ;
& quot ; 5 mg
& quot ;
& quot ; this medicinal product contain le than 1 mmol sodium ( 23 mg ) per dose , I. e. essentially “ sodium- free ” .
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ; 44 6.4 Special precaution for storage
& quot ;
& quot ; Medice Arzneimittel Ges . mbH Tel : + 43- ( 0 ) 800 29 5193
& quot ;
& quot ;
& quot ; special storage condition
& quot ;
& quot ;
& quot ; give the primary CNS effect of aripiprazole , caution should be use when aripiprazole be take in combination with alcohol or other CNS medicinal product with overlap undesirable effect such a sedation ( see section 4.8 ) .
& quot ;
& quot ; Epoetin alfa therapy should continue until one month after the end of chemotherapy .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; lot
& quot ;
& quot ; Occlusion of the dialysis system be possible if heparinisation be not optimum .
& quot ;
& quot ; the highest nontumorigenic exposure in female rat be 7 time the human exposure at the recommend dose .
& quot ;
& quot ; population pharmacokinetic evaluation have reveal no evidence of clinically significant race-related difference or effect from smoke upon the pharmacokinetics of aripiprazole .
& quot ;
& quot ; ABILIFY 15 mg orodispersible tablet
& quot ;
& quot ; in chronic renal failure patient Abseamed have not to be administer subcutaneously !
& quot ;
& quot ; summary OF product characteristic
& quot ;
& quot ; Aluminium perforate unit dose blister in carton of 14 X 1 , 28 X 1 , 49 X 1 , 56 X 1 , 98 X 1 tablet .
& quot ;
& quot ;
& quot ; 171 5 .
& quot ;
& quot ; the pre-filled syringe should not be shake .
& quot ;
& quot ; or Hb increase ≥ 1 g / d
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; follow treatment with any erythropoietin
& quot ;
& quot ; 33 ( 23 , 42 ) * * 77 ( 63 , 86 ) * * 25 ( 13 , 36 ) *
& quot ;
& quot ; therefore cardiovascular monitoring should be start immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmia .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; there be no adequate and well-controlled trial of aripiprazole in pregnant woman .
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; Slovenija BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; Dyspnoea , epistaxis , pharyngolaryngeal pain , cough , rhinitis , rhinorrhoea
& quot ;
& quot ; urinary incontinence , urinary retention
& quot ;
& quot ; other potent inhibitor of CYP2D6 , such a fluoxetine and paroxetine , may be expect to have similar effect and similar dose reduction should therefore be apply .
& quot ;
& quot ; summary OF product characteristic
& quot ;
& quot ; this difference be not statistically significant .
& quot ;
& quot ; EU / 1 / 04 / 276 / 014
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; an investigational study ( best study ) in woman with metastatic breast cancer be design to determine whether epoetin alfa treatment that extend beyond the correction of anaemia could improve treatment outcome .
& quot ;
& quot ; Aripiprazole be the predominant medicinal product moiety in systemic circulation .
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg Kuhloweg 37 D-58638 Iserlohn
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; Hb 10 - 13 g / dl ) who do not have an autologous predonation programme available and with an expected blood loss of 900 to 1800 ml .
& quot ;
& quot ; Abseamed , inject into a vein , be compare with the reference medicine in one main study involve 479 patient with anaemia cause by kidney problem .
& quot ;
& quot ; Sodium dihydrogen phosphate dihydrate Disodium phosphate dihydrate Sodium chloride Glycine Polysorbate 80 water for injection Hydrochloric acid ( for pH-adjustment ) Sodium hydroxide ( for pH-adjustment )
& quot ;
& quot ; there be no effect of a high fat meal on the pharmacokinetics of aripiprazole .
& quot ;
& quot ; oral use .
& quot ;
& quot ; 14 X 1
& quot ;
& quot ; iron status should be evaluate prior to and during treatment and iron supplementation administer if necessary .
& quot ;
& quot ; market authorisation holder Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; Manic episodes in Bipolar I Disorder :
& quot ;
& quot ; EXP
& quot ;
& quot ; 196 България Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; appropriate therapy such a blood transfusion may be give to patient when indicate .
& quot ;
& quot ; patient donate their own blood before surgery
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; these symptom can temporally deteriorate or can even arise after discontinuation of treatment .
& quot ;
& quot ; in placebo-controlled trial , the incidence of akathisia in bipolar patient be 12.1 % with aripiprazole and 3.2 % with placebo .
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; in addition , special precaution should be take in patient with predisposition for development of deep vein thrombosis ( DVTs ) .
& quot ;
& quot ; in chronic renal failure patient Abseamed have not to be administer subcutaneously !
& quot ;
& quot ; Akathisia be more common in patient with bipolar disorder than in those with schizophrenia .
& quot ;
& quot ; why have Abraxane be approve ?
& quot ;
& quot ; Luxembourg / Luxemburg BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; Cardiotoxicity :
& quot ;
& quot ; 4 .
& quot ;
& quot ; Danmark BRISTOL-MYERS SQUIBB Tlf : + 45 45 93 05 06
& quot ;
& quot ; 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of untreated , inadequately treat
& quot ;
& quot ; the subcutaneous route of administration should be use .
& quot ;
& quot ; date of first authorisation :
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; Cardiac disorder :
& quot ;
& quot ; 6 .
& quot ;
& quot ; & quot ; & quot ; Flu-like & quot ; & quot ; symptom such a headache , joint pain , feeling of weakness , dizziness , and tiredness may occur , especially at the start of treatment .
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; or Hb increase ≥ 1 g / d
& quot ;
& quot ; 11 .
& quot ;
& quot ; in this leaflet :
& quot ;
& quot ; 5 .
& quot ;
& quot ; - In pregnant or lactating surgical patient participate in an autologous blood predonation
& quot ;
& quot ; 16 .
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; agitation , nervousness ; suicide attempt , suicidal ideation , and complete suicide ( see section 4.4 )
& quot ;
& quot ; undesirable effect know to be associate with antipsychotic therapy and also report during treatment with aripiprazole include neuroleptic malignant syndrome , tardive dyskinesia , seizure , cerebrovascular adverse event and increased mortality in elderly demented patient , hyperglycaemia and diabetes mellitus ( see section 4.4 ) .
& quot ;
& quot ; European Medicines Agency
& quot ;
& quot ; all other cause of anaemia ( iron deficiency , haemolysis , blood loss , vitamin B12 or folate deficiency ) should be consider and treat prior to initiate therapy with epoetin alfa .
& quot ;
& quot ; urinary incontinence , urinary retention
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; Abraxane will be give to you by a doctor or nurse into a vein from an intravenous drip .
& quot ;
& quot ; Administer the amount require .
& quot ;
& quot ; thus , no dosage adjustment be require for smoker .
& quot ;
& quot ; there be no accumulation : the level remain the same , whether they be determined 24 hour after the first injection or 24 hour after the last injection .
& quot ;
& quot ; potential for ABILIFY to affect other medicinal product :
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; 85 % of patient be bisphosphonate-naïve .
& quot ;
& quot ; Schizophrenia :
& quot ;
& quot ; the formation of these hydroxylated metabolite be catalyse by CYP2C8 , -3A4 , and both -2C8 and -3A4 respectively .
& quot ;
& quot ; the maximum daily dose should not exceed 30 mg .
& quot ;
& quot ; Hypertension may occur in epoetin alfa treat patient .
& quot ;
& quot ; content by weight , by volume or by unit
& quot ;
& quot ; Κύπρος ΑΚΗΣ ΠΑΝΑΓΙΩΤΟΥ & amp ; ΥΙΟΣ Ε .Π .Ε .
& quot ;
& quot ; Aclasta be not recommend in patient with severe renal impairment ( creatinine clearance & lt ; 35 ml / min ) due to limited clinical experience in this population .
& quot ;
& quot ; however , in a single-dose , intramuscular study of aripiprazole ( dose 15 mg ) in healthy subject , administer simultaneously with intramuscular lorazepam ( dose 2 mg ) , the intensity of sedation be greater with the combination a compare to that observe with aripiprazole alone .
& quot ;
& quot ; further information
& quot ;
& quot ; always take ABILIFY exactly a your doctor have tell you .
& quot ;
& quot ; EU / 1 / 04 / 276 / 020
& quot ;
& quot ; Abseamed 1000 IU / 0.5 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; treatment of adult patient schedule for major elective orthopaedic surgery :
& quot ;
& quot ; Cytotoxic action of epoetin alfa on bone marrow cell could not be detect .
& quot ;
& quot ; all other cause of anaemia ( iron deficiency , haemolysis , blood loss , vitamin B12 or folate deficiency ) should be consider and treat prior to initiate therapy with epoetin alfa .
& quot ;
& quot ; human albumin solution ( contain sodium , sodium caprylate and N-acetyl DL tryptophanate ) .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; people with this condition may also feel depressed , guilty , anxious or tense .
& quot ;
& quot ; this medicinal product contain le than 1 mmol sodium ( 23 mg ) per dose , I. e. essentially “ sodium- free ” .
& quot ;
& quot ; Magyarország BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; all patient be treat with epoetin alfa should receive adequate iron supplementation ( e. g. oral iron substitution of 200 mg Fe2 + daily ) throughout the course of epoetin alfa treatment .
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; 1000 IU / 0.5 ml
& quot ;
& quot ; adjustment of daily dosage , include dose reduction should be consider on the basis of clinical status .
& quot ;
& quot ; for any information about this medicine , please contact the local representative of the marketing authorisation holder :
& quot ;
& quot ; 6 .
& quot ;
& quot ; 5 .
& quot ;
& quot ; - decrease locoregional control in patient with advanced head and neck cancer receiving
& quot ;
& quot ; please discuss this with your doctor .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Hypersensitivity : a with other medication hypersensitivity reaction , characterise by allergic symptom , may occur with aripiprazole ( see section 4.8 ) .
& quot ;
& quot ; patient should be advise not to breast feed if they be take aripiprazole .
& quot ;
& quot ; on average , the level of the patient take Abseamed increase by 0.147 g / dl from a start value of 11.7 g / dl .
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; Surgery patient in autologous predonation programme
& quot ;
& quot ; due to insufficient safety information in human and concern raise by animal reproductive study , this medicinal product should not be use in pregnancy unless the expected benefit clearly justify the potential risk to the foetus .
& quot ;
& quot ; see leaflet for further information .
& quot ;
& quot ; do not use Abraxane • if you be allergic ( hypersensitive ) to paclitaxel or any of the other ingredient of Abraxane • if you be breast feeding • if you have a low White blood cell count ( baseline neutrophil count & lt ; 1.5 X 109 / l - your doctor will advise you on this )
& quot ;
& quot ; 50 ml
& quot ;
& quot ; other
& quot ;
& quot ; it may harm them , even if their symptom be the same a yours .
& quot ;
& quot ; it be recommend that the platelet count be regularly monitor during the first 8 week of therapy .
& quot ;
& quot ; ( 44-20 ) 74 18 84 00 fax ( 44-20 ) 74 18 84 16 e-mail : mail @ emea . europa . EU http : / / www . emea . europa . EU
& quot ;
& quot ; 8000 IU / 0.8 ml
& quot ;
& quot ; 8 .
& quot ;
& quot ; Ísland VISTOR HF Sími : + 354 535 7000
& quot ;
& quot ; - if the solution be cloudy or there be particle in it .
& quot ;
& quot ; other
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery the cause of anaemia should be establish and treat , if possible , before the start of epoetin alfa treatment .
& quot ;
& quot ; patient with metastatic breast cancer receive chemotherapy when administer to target a haemoglobin of 12 - 14 g / dl ( 7.5 – 8.7 mmol / l ) ,
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP2D6 ( quinidine ) increase aripiprazole AUC by 107 % , while Cmax be unchanged .
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; name and address of the manufacturer responsible for batch release
& quot ;
& quot ; Administer the amount require .
& quot ;
& quot ; however , a with other antipsychotic , patient should be caution about operate hazardous machine , include motor vehicle , until they be reasonably certain that aripiprazole do not affect them adversely .
& quot ;
& quot ;
& quot ; Occlusion of the dialysis system be possible if heparinisation be not optimum .
& quot ;
& quot ; 3 .
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; Lymphopenia be observe in 45 % of the patient .
& quot ;
& quot ; cardiovascular disorder :
& quot ;
& quot ; your doctor may order regular blood test to see that control be be achieve and to ensure that your haemoglobin do not exceed a certain level .
& quot ;
& quot ; what ABILIFY be and what it be use for 2 .
& quot ;
& quot ; lot
& quot ;
& quot ; in addition , report of accidental overdose with aripiprazole alone ( up to 195 mg ) in child have be receive with no fatality .
& quot ;
& quot ; Suomi / Finland OY BRISTOL-MYERS SQUIBB ( Finland ) AB Puh / Tel : + 358 9 251 21 230
& quot ;
& quot ; since the orodispersible tablet be fragile , it should be take immediately on open the blister .
& quot ;
& quot ; content by weight , by volume or by unit
& quot ;
& quot ; 70 for the purpose of ambulatory use , the patient may remove Abseamed from the refrigerator and store it not above 25 ° C for one single period of up to 3 day .
& quot ;
& quot ; patient treat with any antipsychotic agent , include ABILIFY , should be observe for sign and symptom of hyperglycaemia ( such a polydipsia , polyuria , polyphagia and weakness ) and patient with diabetes mellitus or with risk factor for diabetes mellitus should be monitor regularly for worsen of glucose control .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; see leaflet for further information .
& quot ;
& quot ; ask your doctor or pharmacist for advice before take ABILIFY .
& quot ;
& quot ; Respiratory , thoracic and mediastinal disorder :
& quot ;
& quot ; Pharmacokinetics in special patient group
& quot ;
& quot ; 39 Extrapyramidal symptom ( EPS ) :
& quot ;
& quot ; each carton contain one single-use type I glass vial with a rubber butyl stopper and a & quot ; & quot ; flip-off & quot ; & quot ; aluminium seal .
& quot ;
& quot ; the therapeutic margin of epoetin alfa be very wide .
& quot ;
& quot ; 2 .
& quot ;
& quot ; { MM / YYYY }
& quot ;
& quot ; Tel : + 371 67 50 21 85
& quot ;
& quot ; population pharmacokinetic evaluation have reveal no evidence of clinically significant race-related difference or effect from smoke upon the pharmacokinetics of aripiprazole .
& quot ;
& quot ; a systematic review have also be perform involve more than 9000 cancer patient participate in 57 clinical trial .
& quot ;
& quot ; 4 .
& quot ;
& quot ; in two 3-week , flexible-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole demonstrate superior efficacy to placebo in
& quot ;
& quot ; Haemoglobin variability should be address through dose management with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; take other medicine please tell your doctor or pharmacist if you be take or have recently take any other medicine , include medicine obtain without a prescription .
& quot ;
& quot ; Serum electrolytes should be monitor in chronic renal failure patient .
& quot ;
& quot ; 8 hour in a refrigerator in the vial when kept in the outer carton in order to protect from light .
& quot ;
& quot ; Aripiprazole also demonstrate a comparable proportion of patient in symptomatic remission from mania a lithium or haloperidol at week 12 .
& quot ;
& quot ; the administration of lorazepam solution for injection have no effect on the pharmacokinetics of aripiprazole solution for injection when administer concomitantly .
& quot ;
& quot ; 96 721 cancer patient receive non-platinum chemotherapy be include in three placebo-controlled study , 389 patient with haematological malignancy ( 221 multiple myeloma , 144 non-Hodgkin & apos ; s lymphoma , and 24 other haematological malignancy ) and 332 with solid tumour ( 172 breast , 64 gynaecological , 23 lung , 22 prostate , 21 gastro-intestinal , and 30 other tumour type ) .
& quot ;
& quot ; in clinical trial of aripiprazole , the incidence of QT prolongation be comparable to placebo .
& quot ;
& quot ; ask your pharmacist how to dispose of medicine no longer require .
& quot ;
& quot ; Tablet disintegration occur rapidly in saliva .
& quot ;
& quot ; Intravenous route
& quot ;
& quot ; patient who develop pure red Cell Aplasia ( PRCA ) follow treatment with any erythropoietin should not receive Abseamed or any other erythropoietin ( see section 4.4 - pure red Cell Aplasia ) .
& quot ;
& quot ; it be not know whether aripiprazole be excrete in human milk .
& quot ;
& quot ; other infrequently report side effect :
& quot ;
& quot ; the most frequent finding in the repeat-dose study consist of increased primary spongiosa in the metaphyses of long bone in grow animal at nearly all dos , a finding that reflect the compound ’ s pharmacological antiresorptive activity .
& quot ;
& quot ; leukopenia , neutropenia , thrombocytopenia
& quot ;
& quot ; Ísland Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; 1 .
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; 6 .
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; 2 .
& quot ;
& quot ; Manic episodes in Bipolar I Disorder - in a 12-week controlled trial , the incidence of EPS be 23.5 % for aripiprazole-treated patient and 53.3 % for haloperidol-treated patient .
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; thus , aripiprazole be unlikely to cause clinically important medicinal product interaction mediate by these enzyme .
& quot ;
& quot ; Malta BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; how to store ABILIFY
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) , the dose should be reduce by approximately 25 to 50 % .
& quot ;
& quot ; 0.5 ml ( 2000 IU / ml )
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; there be no accumulation : the level remain the same , whether they be determined 24 hour after the first injection or 24 hour after the last injection .
& quot ;
& quot ; or Hb increase ≥ 1 g / d
& quot ;
& quot ; ABILIFY may increase the effect of medicine use to lower the blood pressure .
& quot ;
& quot ; when weak inhibitor of CYP3A4 ( e. g . , diltiazem or escitalopram ) or CYP2D6 be use concomitantly with ABILIFY , modest increase in aripiprazole concentration might be expect .
& quot ;
& quot ; 28 August 2007
& quot ;
& quot ; it could be show with the aid of cell culture of human bone marrow cell that epoetin alfa stimulates erythropoiesis specifically and do not affect leucopoiesis .
& quot ;
& quot ; what ABILIFY be AND what IT be use for
& quot ;
& quot ; the full EPAR for Abraxane can be find here .
& quot ;
& quot ; Pharmacotherapeutic group : antianaemic , ATC code :
& quot ;
& quot ; seizure : in clinical trial , uncommon case of seizure be report during treatment with aripiprazole .
& quot ;
& quot ; Slovenská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; very common ( ≥ 1 / 10 ) ; common ( ≥ 1 / 100 , & lt ; 1 / 10 ) ; uncommon ( ≥ 1 / 1,000 , & lt ; 1 / 100 ) ; rare ( ≥ 1 / 10,000 , & lt ; 1 / 1,000 ) ; very rare ( & lt ; 1 / 10,000 ) .
& quot ;
& quot ; in most of these patient , antibody to erythropoietin have be observe ( see section 4.3 and 4.4 – pure red Cell Aplasia )
& quot ;
& quot ; no teratological or embryo / foetal effect be observe in rabbit , although maternal toxicity be mark at 0.1 mg / kg due to decreased serum calcium level .
& quot ;
& quot ; at therapeutic concentration , aripiprazole and dehydro-aripiprazole be greater than 99 % bound to serum protein , bind primarily to albumin .
& quot ;
& quot ; 5 .
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; Renal and urinary disorder :
& quot ;
& quot ; 4 .
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; Unopened Vials :
& quot ;
& quot ; 56-99 year ) of aripiprazole in elderly patient with psychosis associate with Alzheimer & apos ; s disease , patient treat with aripiprazole be at increase risk of death compare to placebo .
& quot ;
& quot ; ESAs be not indicate for use in this patient population .
& quot ;
& quot ; Breast-feeding mother should not take ABILIFY .
& quot ;
& quot ; Erythropoietin be a growth factor that primarily stimulate red cell production .
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole increase by 77 % and 43 % , respectively .
& quot ;
& quot ; when concomitant administration of potent CYP3A4 or CYP2D6 inhibitor with aripiprazole occurs , the aripiprazole dose should be reduce .
& quot ;
& quot ; weight gain : in clinical trial aripiprazole have not be show to induce clinically relevant weight gain .
& quot ;
& quot ; and Hb increase & lt ; 1 g / dl
& quot ;
& quot ; EU / 1 / 07 / 412 / 017
& quot ;
& quot ; 1 .
& quot ;
& quot ; all of the patient have be take Eprex / Erypo inject into a vein for at least eight week before they be either switch to Abseamed or remain on Eprex / Erypo .
& quot ;
& quot ; hyperglycaemia , diabetes mellitus , diabetic ketoacidosis , diabetic hyperosmolar coma
& quot ;
& quot ; 3 .
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; the following reaction have also occur in isolated patient with normal or low blood pressure : hypertensive crisis with encephalopathy-like symptom ( e. g. headache and confused state ) and Generalised tonoclonal seizure , require the immediate attention of a physician and intensive medical care .
& quot ;
& quot ; 3 .
& quot ;
& quot ; 2 / 2
& quot ;
& quot ; Metabolism and nutrition disorder :
& quot ;
& quot ; in the open-label study there be no difference in overall survival between patient treat with recombinant human erythropoietin and control .
& quot ;
& quot ; at 24 month a similar significant increase of 3.6 % in total hip BMD be observe for patient treat with Aclasta a compare to the effect observe in post-menopausal woman in the HORIZON-PFT study .
& quot ;
& quot ; Hepatobiliary disorder :
& quot ;
& quot ; in clinical trial of aripiprazole , the incidence of QT prolongation be comparable to placebo .
& quot ;
& quot ; you have low blood pressure or if your arteriovenous fistula have complication .
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl
& quot ;
& quot ; Abseamed 9000 IU / 0.9 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; nervous system disorder :
& quot ;
& quot ; in placebo-controlled trial , the incidence of akathisia in bipolar patient be 12.1 % with aripiprazole and 3.2 % with placebo .
& quot ;
& quot ; NMS be a potentially fatal symptom complex associate with antipsychotic medicinal product .
& quot ;
& quot ; special storage condition
& quot ;
& quot ; 4 .
& quot ;
& quot ; Aripiprazole also demonstrate a comparable proportion of patient in symptomatic remission from mania a lithium or haloperidol at week 12 .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; the reconstituted suspension should be milky and homogenous without visible precipitate .
& quot ;
& quot ; Aripiprazole be well absorb , with peak plasma concentration occur within 3-5 hour after dose .
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; the syrinx contain 0.8 ml ( 8000 IU ) of solution .
& quot ;
& quot ; ABILIFY be effective in maintain the clinical improvement during continuation therapy in patient who have show an initial treatment response .
& quot ;
& quot ; 6 .
& quot ;
& quot ; 1 .
& quot ;
& quot ; at the time of donate blood , Abseamed should be administer after the completion of the blood donation procedure .
& quot ;
& quot ; BATCH number
& quot ;
& quot ;
& quot ; - increase risk of death when administer to target a haemoglobin of 12 g / dl ( 7.5 mmol / l ) in
& quot ;
& quot ; if after an additional 4 week of therapy at 300 IU / kg 3 time per week , the haemoglobin have increase ≥ 1 g / dl ( ≥ 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl the dose should remain at 300 IU / kg 3 time per week .
& quot ;
& quot ; syncope , hypertension , thromboembolic event
& quot ;
& quot ; there be no accumulation : the level remain the same , whether they be determined 24 hour after the first injection or 24 hour after the last injection .
& quot ;
& quot ; dose ( IU / kg give 3x / week )
& quot ;
& quot ; if you take more ABILIFY than you should if you realise you have take more ABILIFY tablet than your doctor have recommend ( or if someone else have take some of your ABILIFY tablet ) , contact your doctor right away .
& quot ;
& quot ; the second involved 2,127 men and woman with osteoporosis who be age over 50 year and have recently break their hip , and look at the number of fracture over up to five year .
& quot ;
& quot ; N05AX12
& quot ;
& quot ; method OF administration
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; 3 year
& quot ;
& quot ; in the long term 26-week maintenance phase of a placebo-controlled trial , the incidence of EPS be 18.2 % for aripiprazole-treated patient and 15.7 % for placebo-treated patient .
& quot ;
& quot ; in a haloperidol-controlled trial , the proportion of responder patient maintain response to medicinal product at 52-weeks be similar in both group ( aripiprazole 77 % and haloperidol 73 % ) .
& quot ;
& quot ; summary OF product characteristic
& quot ;
& quot ; in cancer patient receive chemotherapy , the 2 - 3 week delay between epoetin alfa administration and the appearance of erythropoietin-induced red cell should be take into account when assess if epoetin alfa therapy be appropriate ( patient at risk of be transfuse ) .
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; do not take ABILIFY if you be allergic ( hypersensitive ) to aripiprazole or any of the other ingredient of ABILIFY .
& quot ;
& quot ; a rise in haemoglobin of greater than 2 g / dl ( 1.25 mmol / l ) over a four week period should be avoid .
& quot ;
& quot ; Aripiprazole also exhibit moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptor .
& quot ;
& quot ; 2 .
& quot ;
& quot ; iron supplementation should be start prior to epoetin alfa therapy , to achieve adequate iron store .
& quot ;
& quot ; the usual dose be 15 mg once a day .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; name OF the marketing authorisation holder
& quot ;
& quot ; your doctor will consider warning and precaution associate with autologous blood predonation , especially volume replacement .
& quot ;
& quot ; discard the reconstituted suspension if precipitate be observe .
& quot ;
& quot ; 8 .
& quot ;
& quot ; 2 .
& quot ;
& quot ; 5 .
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; do not use ABILIFY after the expiry date which be state on the blister and on the carton .
& quot ;
& quot ; skin and subcutaneous tissue disorder :
& quot ;
& quot ; Portugal BRISTOL-MYERS SQUIBB FARMACÊUTICA Portuguesa , S. A .
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; 1 pre-filled syringe of 0.9 ml 6 pre-filled syrinx of 0.9 ml
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl
& quot ;
& quot ; patient who for any reason can not receive adequate antithrombotic prophylaxis .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; the most frequent adverse reaction be an increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ; Toxicologically significant effect be observe only at dos or exposure that be sufficiently in excess of the maximum human dose or exposure , indicate that these effect be limited or of no relevance to clinical use .
& quot ;
& quot ; 1 .
& quot ;
& quot ; the potentially medically important sign and symptom observe included lethargy , increase blood pressure , somnolence , tachycardia , nausea , vomit and diarrhoea .
& quot ;
& quot ; 8 .
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; for more information , see the package Leaflet .
& quot ;
& quot ; © European Medicines Agency , 2008 .
& quot ;
& quot ;
& quot ; in paediatric patient the recommended target haemoglobin range be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; what be the risk associate with Aclasta ?
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; the half-life be difficult to evaluate for the subcutaneous route and be estimate about 24 hour .
& quot ;
& quot ; Orodispersible tablet Round and pink , mark with & quot ; & quot ; A & quot ; & quot ; over & quot ; & quot ; 643 & quot ; & quot ; on one side and & quot ; & quot ; 30 & quot ; & quot ; on the other .
& quot ;
& quot ; in patient with chronic renal failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommend in section 4.2 .
& quot ;
& quot ; event rate event rate ( % ) ( % )
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; child and adolescent ABILIFY be not for use in child and adolescent a it have not be study in patient under 18 year .
& quot ;
& quot ; 3 .
& quot ;
& quot ; - you may take Abseamed out of the refrigerator and keep it at room temperature ( up to 25 ° C ) for
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; the extent to which these outcome might apply to the administration of recombinant human erythropoietin to patient with cancer , treat with chemotherapy to achieve haemoglobin concentration le than 13 g / dl , be unclear because few patient with these characteristic be include in the data reviewed .
& quot ;
& quot ; or Hb increase ≥ 1 g / d
& quot ;
& quot ; be sure to tell your doctor if you take a medicine to keep your blood pressure under control .
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; Suomi / Finland Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; consequently :
& quot ;
& quot ; other infrequently report side effect :
& quot ;
& quot ; when consider concomitant administration of ketoconazole or other potent CYP3A4 inhibitor with ABILIFY , potential benefit should outweigh the potential risk to the patient .
& quot ;
& quot ; 1 .
& quot ;
& quot ; if it occur , appropriate dose adjustment should be make a provided .
& quot ;
& quot ; Tablet
& quot ;
& quot ; name OF the marketing authorisation holder
& quot ;
& quot ; Measurement of epoetin alfa follow multiple dose intravenous administration reveal a half-life of approximately 4 hour in normal volunteer and a somewhat more prolonged half-life in renal failure patient , approximately 5 hour .
& quot ;
& quot ; manufacturer Bristol-Myers Squibb S. r. l .
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; the use of epoetin alfa in patient schedule for major elective orthopaedic surgery and not participate in an autologous blood predonation programme be contraindicate in patient with severe coronary , peripheral arterial , carotid or cerebral vascular disease , include patient with recent myocardial infarction or cerebral vascular accident .
& quot ;
& quot ; each tablet contain 15 mg of aripiprazole .
& quot ;
& quot ; 3 .
& quot ;
& quot ; Hb between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; enhance efficacy at dose higher than a daily dose of 15 mg have not be demonstrate although individual patient may benefit from a higher dose .
& quot ;
& quot ; the recommended dosing regimen be describe in the following diagram :
& quot ;
& quot ; adult peritoneal dialysis patient :
& quot ;
& quot ; Antibody-mediated erythroblastopenia ( PRCA ) have be report after month to year of treatment with epoetin alfa .
& quot ;
& quot ; Erythropoietin be a growth factor that primarily stimulate red cell production .
& quot ;
& quot ; if you inject more Abseamed than you should
& quot ;
& quot ; 101 Correction phase :
& quot ;
& quot ; how to take ABILIFY
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; Surgery patient in autologous predonation programme
& quot ;
& quot ; not applicable .
& quot ;
& quot ; Abseamed 7000 IU / 0.7 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; due to it α 1-adrenergic receptor antagonism , aripiprazole have the potential to enhance the effect of certain antihypertensive agent .
& quot ;
& quot ; 7 .
& quot ;
& quot ; 51 nervous system disorder :
& quot ;
& quot ; in two 12-week , placebo- and active-controlled monotherapy trial in patient with a manic or mixed episode of Bipolar I Disorder , with or without psychotic feature , aripiprazole demonstrate superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12 .
& quot ;
& quot ;
& quot ; oral use
& quot ;
& quot ; EU / 1 / 04 / 276 / 013
& quot ;
& quot ; Nederland BRISTOL-MYERS SQUIBB BV Tel : + 31 34 857 42 22
& quot ;
& quot ; Belgique / België / Belgien BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; Hypertensive crisis with encephalopathy-like symptom can occur .
& quot ;
& quot ; ABILIFY 10 mg tablet aripiprazole
& quot ;
& quot ; temperature regulation disorder ( e. g. hypothermia , pyrexia ) , chest pain , peripheral oedema
& quot ;
& quot ; Abseamed be give by injection under the skin ( subcutaneously ) .
& quot ;
& quot ; adult surgery patient in an autologous predonation programme :
& quot ;
& quot ; the maximum daily dose should not exceed 30 mg .
& quot ;
& quot ; distribution :
& quot ;
& quot ; in three short-term ( 4 to 6 week ) placebo-controlled trial involve 1,228 schizophrenic patient , present with positive or negative symptom , aripiprazole be associate with statistically significantly greater improvement in psychotic symptom compare to placebo .
& quot ;
& quot ; discard any remain liquid .
& quot ;
& quot ; Abseamed can be use to reduce exposure to allogeneic blood transfusion in adult non-iron deficient patient prior to major elective orthopaedic surgery , have a high perceive risk for transfusion complication .
& quot ;
& quot ; red iron oxide ( E172 )
& quot ;
& quot ; the following maintenance dos be observe in clinical trial after 6 month of treatment :
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; uncontrolled hypertension .
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; in one 3-week , fixed-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole fail to demonstrate superior efficacy to placebo .
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; generally , child under 30 kg require higher maintenance dos than child over 30 kg and adult .
& quot ;
& quot ; Suomi / Finland OY BRISTOL-MYERS SQUIBB ( Finland ) AB Puh / Tel : + 358 9 251 21 230
& quot ;
& quot ; 2 .
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of anaemia and of the symptom of anaemia .
& quot ;
& quot ; the protein fraction of the molecule contribute about 58 % and consist of 165 amino acid .
& quot ;
& quot ; patient who for any reason can not receive adequate antithrombotic prophylaxis .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; Portugal BRISTOL-MYERS SQUIBB FARMACÊUTICA Portuguesa , S. A .
& quot ;
& quot ; 3 Hepatic Impairment :
& quot ;
& quot ; Renal and urinary disorder :
& quot ;
& quot ; the four carbohydrate chain be attach via three N-glycosidic bond and one O-glycosidic bond to the protein .
& quot ;
& quot ; the biological efficacy of epoetin alfa have be demonstrate in various animal model in vivo ( normal and anaemic rat , polycythaemic mouse ) .
& quot ;
& quot ; if not use immediately , in-use storage time and condition prior to use be the responsibility of the user and would normally not be longer than 24 hour at 2 ° C - 8 ° C .
& quot ;
& quot ; Abilify
& quot ;
& quot ;
& quot ; however your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day .
& quot ;
& quot ; therefore , routine volume replacement should be perform in such patient .
& quot ;
& quot ; 10 .
& quot ;
& quot ; Thrombocytosis have be observe but it occurrence be very rare ( see section 4.4 ) .
& quot ;
& quot ; 8 .
& quot ;
& quot ; it be use to treat adult who suffer from a disease characterise by symptom such a hearing , see or sense thing which be not there , suspiciousness , mistaken belief , incoherent speech and behaviour and emotional flatness .
& quot ;
& quot ; if you can not reach your doctor , go to the nearest hospital and take the Pack with you .
& quot ;
& quot ; Hypertension may occur in epoetin alfa treat patient .
& quot ;
& quot ; particular attention should be pay to sudden stab migraine- like headache a a possible warning signal .
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and than reinstitute epoetin alfa therapy at a dose 25 % below the previous dose .
& quot ;
& quot ; name OF the MEDICINAL product AND route ( s ) OF administration
& quot ;
& quot ; name and address of the manufacturer responsible for batch release
& quot ;
& quot ; Aripiprazole be well absorb , with peak plasma concentration occur within 3-5 hour after dose .
& quot ;
& quot ; 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; Abseamed
& quot ;
& quot ; 5 .
& quot ;
& quot ; temperature regulation disorder ( e. g. hypothermia , pyrexia ) , chest pain , peripheral oedema
& quot ;
& quot ; peripheral sensory neuropathy , headache , dysgeusia , dizziness , peripheral motor neuropathy , ataxia , sensory disturbance , somnolence .
& quot ;
& quot ; people with this condition may also feel depressed , guilty , anxious or tense .
& quot ;
& quot ; ABILIFY be effective in a dose range of 10 to 30 mg / day .
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; there be no adequate and well-controlled trial of aripiprazole in pregnant woman .
& quot ;
& quot ; control clinical trial have not show significant benefit attributable to the administration of epoetins when haemoglobin concentration be increase beyond the level necessary to control symptom of anaemia and to avoid blood transfusion .
& quot ;
& quot ; however your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day .
& quot ;
& quot ; 14 .
& quot ;
& quot ; Κύπρος ΑΚΗΣ ΠΑΝΑΓΙΩΤΟΥ & amp ; ΥΙΟΣ Ε .Π .Ε .
& quot ;
& quot ; further information
& quot ;
& quot ;
& quot ; Non-clinical safety data reveal no special hazard for human base on conventional study of safety pharmacology , repeat-dose toxicity , genotoxicity , carcinogenic potential , and toxicity to reproduction .
& quot ;
& quot ; 8 .
& quot ;
& quot ; Aripiprazole be metabolise by multiple pathway involve the CYP2D6 and CYP3A4 enzyme but not CYP1A enzyme .
& quot ;
& quot ; hyperglycaemia , diabetes mellitus , diabetic ketoacidosis , diabetic hyperosmolar coma
& quot ;
& quot ; iron status should be evaluate prior to and during treatment and iron supplementation administer if necessary .
& quot ;
& quot ; ABILIFY be indicate for the treatment of schizophrenia .
& quot ;
& quot ; other
& quot ;
& quot ; ABILIFY 10 mg orodispersible tablet
& quot ;
& quot ; overall survival outcome in the trial could not be statisfactorily explain by difference in the incidence of thrombosis and related complication between those give recombinant human erythropoietin and those in the control group .
& quot ;
& quot ; 3 year
& quot ;
& quot ; Aclasta Placebo absolute reduction in ( % ) ( % ) fracture incidence % ( CI )
& quot ;
& quot ; when the CYP3A4 inducer be withdraw from the combination therapy , the aripiprazole dose should then be reduce to the recommend dose ( see section 4.5 ) .
& quot ;
& quot ; Lietuva BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of 25 IU / kg 3 time per week at interval of at least 4 week until the desired goal be achieve .
& quot ;
& quot ; 5 .
& quot ;
& quot ; before you take ABILIFY
& quot ;
& quot ; Abraxane be a White to yellow powder for suspension for infusion available in glass vial contain 100 mg paclitaxel .
& quot ;
& quot ; Epoetin alfa IV / SC
& quot ;
& quot ;
& quot ; s R. O .
& quot ;
& quot ; 172 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; Manic episode :
& quot ;
& quot ; 50 ml oral solution 150 ml oral solution 480 ml oral solution
& quot ;
& quot ; BATCH number
& quot ;
& quot ; - treatment of anaemia associate with chronic renal failure in paediatric and adult patient on
& quot ;
& quot ; syncope , hypertension , thromboembolic event
& quot ;
& quot ; 10 mg
& quot ;
& quot ; general disorder and administration site condition :
& quot ;
& quot ; 1 .
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; radiation therapy when administer to target a haemoglobin of greater than 14 g / dl ( 8.7 mmol / l ) ,
& quot ;
& quot ; the study either recruited patient who be be treat with chemotherapy ( two study ) or use patient population in which erythropoiesis stimulating agent be not indicate : anaemia in patient with cancer not receive chemotherapy , and head and neck cancer patient receive radiotherapy .
& quot ;
& quot ; BATCH number
& quot ;
& quot ;
& quot ; Abseamed be not recommend for injection under the skin in the treatment of kidney problem because further study be need to make sure that this do not cause allergic reaction .
& quot ;
& quot ; mildly anaemic patient ( haematocrit of 33 - 39 % ) require predeposit of ≥ 4 unit of blood should be treat with Abseamed at a dose of 600 IU / kg body weight 2 time weekly for 3 week prior to surgery .
& quot ;
& quot ; attention should be pay to sudden stab migraine-like headache a a possible warning signal .
& quot ;
& quot ; 132 The recommend dose be 600 IU / kg epoetin alfa , give weekly for three week ( day 21 , 14 and 7 ) prior to surgery and on the day of surgery ( day 0 ) .
& quot ;
& quot ; Renal and urinary disorder :
& quot ;
& quot ; 14 .
& quot ;
& quot ; ABILIFY be effective in maintain the clinical improvement during continuation therapy in patient who have show an initial treatment response .
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; Measurement of epoetin alfa follow multiple dose intravenous administration reveal a half-life of approximately 4 hour in normal volunteer and a somewhat more prolonged half-life in renal failure patient , approximately 5 hour .
& quot ;
& quot ; this be give 2 time a week by injection into a vein .
& quot ;
& quot ; do not shake .
& quot ;
& quot ; do not take ABILIFY if you be allergic ( hypersensitive ) to aripiprazole or any of the other ingredient of ABILIFY .
& quot ;
& quot ; 480 ml
& quot ;
& quot ; John & apos ; s Wort ) may be expect to have similar effect and similar dose increase should therefore be apply .
& quot ;
& quot ; 3 .
& quot ;
& quot ; leukopenia , neutropenia , thrombocytopenia
& quot ;
& quot ; Excipients :
& quot ;
& quot ; the risk reduction be 51 % in bisphosphonate-naïve patient and 42 % in patient allow to take concomitant osteoporosis therapy .
& quot ;
& quot ; where appropriate you will receive oral dos of iron , ideally start before the Abseamed treatment begin .
& quot ;
& quot ; patient with rare hereditary problem of fructose intolerance , glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take the oral solution .
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; Intravenous injection : over at least one to five minute , depend on the total dose .
& quot ;
& quot ; 5 .
& quot ;
& quot ; for single tablet removal , open the package and peel back the foil on the blister to expose the tablet .
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; an increase 3H-thymidine incorporation in the erythroid nucleate spleen cell have be find in vitro ( mouse spleen cell culture ) after incubation with epoetin alfa .
& quot ;
& quot ; Abseamed be a sterile but unpreserved product and be for single use only .
& quot ;
& quot ; Conduction abnormality :
& quot ;
& quot ; after administration of epoetin alfa , the number of erythrocyte , the Hb value and reticulocyte count increase a well a the 59Fe-incorporation rate .
& quot ;
& quot ; Tardive Dyskinesia : in clinical trial of one year or le duration , there be uncommon report of treatment emergent dyskinesia during treatment with aripiprazole .
& quot ;
& quot ; 59 Tardive Dyskinesia : in clinical trial of one year or le duration , there be uncommon report of treatment emergent dyskinesia during treatment with aripiprazole .
& quot ;
& quot ; good blood management practice should always be use in the perisurgical setting
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; be sure to tell your doctor immediately if you be breast-feeding .
& quot ;
& quot ; United Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel : + 44 ( 0800 ) 731 1736
& quot ;
& quot ; 16 .
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole increase by 77 % and 43 % , respectively .
& quot ;
& quot ; two other smaller , randomise , placebo-controlled trial fail to show a significant improvement in quality of life parameter on the EORTC-QLQ-C30 scale or CLAS , respectively .
& quot ;
& quot ; gender : no dosage adjustment be require for female patient a compare to male patient ( see section 5.2 ) .
& quot ;
& quot ; in clinical trial aripiprazole have not be show to induce clinically relevant weight gain ( see section 5.1 ) .
& quot ;
& quot ; oral use .
& quot ;
& quot ; adult and paediatric haemodialysis patient , adult peritoneal dialysis patient and adult patient with renal insufficiency not yet undergoing dialysis
& quot ;
& quot ; if you take more ABILIFY than you should if you realise you have take more ABILIFY orodispersible tablet than your doctor have recommend ( or if someone else have take some of your ABILIFY orodispersible tablet ) , contact your doctor right away .
& quot ;
& quot ; the study be not power to show a reduction in clinical fracture in men ; the incidence of clinical fracture be 7.5 % in men treat with Aclasta versus 8.7 % for placebo .
& quot ;
& quot ; the occurrence of suicidal behaviour be inherent in psychotic illness and mood disorder and in some case have be report early after initiation or switch of antipsychotic therapy , include treatment with aripiprazole ( see section 4.8 ) .
& quot ;
& quot ; when concomitant administration of ketoconozole with ABILIFY occurs , ABILIFY dose should be reduce to approximately one-half of it prescribed dose .
& quot ;
& quot ; Deutschland BRISTOL-MYERS SQUIBB GMBH & amp ; CO .
& quot ;
& quot ; 2 .
& quot ;
& quot ; Tel . : + 48 22 5796666
& quot ;
& quot ; fourteen percent of the patient have not receive prior chemotherapy ; 27 % have receive chemotherapy in the adjuvant set only , 40 % in the metastatic setting only , and 19 % in both metastatic and adjuvant setting .
& quot ;
& quot ; the active substance in Abseamed , epoetin alfa , be a copy of human erythropoietin and work in exactly the same way a the natural hormone to stimulate red blood cell production .
& quot ;
& quot ; 3 .
& quot ;
& quot ; generally , child under 30 kg require higher maintenance dos than child over 30 kg and adult .
& quot ;
& quot ; Abseamed 10 000 IU / 1 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; - treatment of anaemia associate with chronic renal failure in paediatric and adult patient on
& quot ;
& quot ; distribution :
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; 4 .
& quot ;
& quot ; syncope , hypertension , thromboembolic event
& quot ;
& quot ; however , elevate creatine phosphokinase and rhabdomyolysis , not necessarily in association with NMS , have also be report .
& quot ;
& quot ; however your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day .
& quot ;
& quot ; European Medicines Agency
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; 10 patient who be classify a responder at the end of the 6 month core study be eligible to enter an extended follow-up period .
& quot ;
& quot ; 3 .
& quot ;
& quot ; like all medicine , ABILIFY can cause side effect , although not everybody get them .
& quot ;
& quot ; Taxanes , ATC Code :
& quot ;
& quot ; 7 .
& quot ;
& quot ; the use of epoetin alfa in patient schedule for major elective orthopaedic surgery and not participate in an autologous blood predonation programme be contraindicate in patient with severe coronary , peripheral arterial , carotid or cerebral vascular disease , include patient with recent myocardial infarction or cerebral vascular accident .
& quot ;
& quot ; for 4 week
& quot ;
& quot ; 1 .
& quot ;
& quot ; strength
& quot ;
& quot ; 2 .
& quot ;
& quot ; most side effect with Aclasta tend to occur within the first three day after infusion , become le common with repeated infusion .
& quot ;
& quot ; Aclasta ( N = 3,875 )
& quot ;
& quot ; Tel : + 371 67 50 21 85
& quot ;
& quot ; John & apos ; s Wort ) may be expect to have similar effect and similar dose increase should therefore be apply .
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; Median 100 75 33
& quot ;
& quot ; 1.35 , 2.06 , 35 trial and 6769 patient ) be observe in patient treat with recombinant human erythropoietin .
& quot ;
& quot ; general disorder and administration site condition :
& quot ;
& quot ; Pregnancy and breast-feeding you should not take ABILIFY if you be pregnant unless you have discuss this with your doctor .
& quot ;
& quot ; Meta-analysis of overall survival data produce a hazard ratio point estimate of 1.08 in favour of control ( 95 % CI :
& quot ;
& quot ; 118 The recommend dose be 600 IU / kg epoetin alfa , give weekly for three week ( day 21 , 14 and 7 ) prior to surgery and on the day of surgery ( day 0 ) .
& quot ;
& quot ; like all medicine , Abseamed can cause side effect , although not everybody get them .
& quot ;
& quot ; ABILIFY dose should be double when concomitant administration of ABILIFY occur with carbamazepine .
& quot ;
& quot ; Median 100 75 33
& quot ;
& quot ; Aripiprazole be the predominant medicinal product moiety in systemic circulation .
& quot ;
& quot ; the highest nontumorigenic exposure in female rat be 7 time the human exposure at the recommend dose .
& quot ;
& quot ; Neuropathy :
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; Manic episode :
& quot ;
& quot ; 28 X 1
& quot ;
& quot ; they be supply in perforated unit dose blister pack in carton contain 14 , 28 , 49 , 56 , or 98 tablet .
& quot ;
& quot ; Abilify
& quot ;
& quot ; Chronic renal failure patient
& quot ;
& quot ; some people may feel depressed .
& quot ;
& quot ; a gastric acid blocker , the H2 antagonist famotidine , reduces aripiprazole rate of absorption but this effect be deem not clinically relevant .
& quot ;
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; treatment of adult patient schedule for major elective orthopaedic surgery :
& quot ;
& quot ; radiation therapy when administer to target a haemoglobin of greater than 14 g / dl ( 8.7 mmol / l ) ,
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ;
& quot ; Malta BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; • Physician educational material • Patient information Pack
& quot ;
& quot ; 146 package LEAFLET :
& quot ;
& quot ; be sure to tell your doctor if you take a medicine to keep your blood pressure under control .
& quot ;
& quot ; - oral iron substitution of 200 - 300 mg Fe2 + / day be recommend for all cancer patient whose
& quot ;
& quot ; no evidence exist that indicate an interaction between epoetin alfa and G-CSF or GM-CSF with regard to haematological differentiation or proliferation of tumour biopsy specimen in vitro .
& quot ;
& quot ; iron supplementation should be start prior to epoetin alfa therapy , to achieve adequate iron store .
& quot ;
& quot ;
& quot ; if haemoglobin have increase by at least 1 g / dl ( 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl above baseline after 4 week of treatment , the dose should remain at 150 IU / kg 3 time a week or 450 IU / kg once weekly .
& quot ;
& quot ; your doctor may monitor your blood pressure regularly while you be use Abseamed , particularly at the start of therapy .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery the cause of anaemia should be establish and treat , if possible , before the start of epoetin alfa treatment .
& quot ;
& quot ; Epoetin alfa should be administer by the subcutaneous route to patient with anaemia ( e. g. haemoglobin concentration ≤ 10 g / dl ( 6.2 mmol / l ) .
& quot ;
& quot ; there may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with epoetin alfa .
& quot ;
& quot ; Epoetin alfa obtain by gene technology be glycosylated and be identical in it amino acid and carbohydrate composition to endogenous human erythropoietin that have be isolate from the urine of anaemic patient .
& quot ;
& quot ; the usual dose be 15 mg once a day .
& quot ;
& quot ; these measure will help to protect the environment .
& quot ;
& quot ; B .
& quot ;
& quot ; 4 .
& quot ;
& quot ; patient with renal impairment : no dosage adjustment be require in patient with renal impairment .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; how to use ABILIFY 4 .
& quot ;
& quot ; due to insufficient safety information in human and concern raise by animal reproductive study , this medicinal product should not be use in pregnancy unless the expected benefit clearly justify the potential risk to the foetus .
& quot ;
& quot ; further information
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; 1 1 .
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; Musculoskeletal and connective tissue disorder :
& quot ;
& quot ; Slovenská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; at the time of donate blood , Abseamed should be administer after the completion of the blood donation procedure .
& quot ;
& quot ; after injection of the necessary amount of the solution from the pre-filled syringe , discard any remain content .
& quot ;
& quot ; always take the tablet with water and swallow it whole .
& quot ;
& quot ; 56-99 year ) of aripiprazole in elderly patient with psychosis associate with Alzheimer & apos ; s disease , patient treat with aripiprazole be at increase risk of death compare to placebo .
& quot ;
& quot ; Abraxane be indicate for mono-therapy .
& quot ;
& quot ; 151 9 .
& quot ;
& quot ; Norge BRISTOL-MYERS SQUIBB Norway LTD Tlf : + 47 67 55 53 50
& quot ;
& quot ; although causality have not be determine , it be prudent to avoid dental surgery a recovery may be prolong ( see section 4.4 ) .
& quot ;
& quot ; and address of the manufacturer responsible for batch release
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; there be no effect of a high fat meal on the pharmacokinetics of aripiprazole .
& quot ;
& quot ; uncontrolled hypertension .
& quot ;
& quot ; your doctor will change your treatment to ABILIFY tablet , ABILIFY orodispersible tablet or ABILIFY oral solution a soon a appropriate .
& quot ;
& quot ; the half-life be difficult to evaluate for the subcutaneous route and be estimate about 24 hour .
& quot ;
& quot ; early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid , for example , be recommend in these patient .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of at least four week .
& quot ;
& quot ; Abseamed should be administer intravenously in order to increase haemoglobin to not greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; 3 .
& quot ;
& quot ; 2 .
& quot ;
& quot ; please tell your doctor or pharmacist if you be take or have recently take any other medicine , include medicine obtain without a prescription .
& quot ;
& quot ; he / she will work out the correct dose of Abseamed for you to use and how long the treatment should continue .
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; Epoetin alfa do not show any change in bacterial and mammalian cell culture mutagenicity test and an in vivo micronucleus test in mouse .
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; follow any confirm or suspect overdose with aripiprazole , close medical supervision and monitoring should continue until the patient recovers .
& quot ;
& quot ; 113 10 .
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; kg Tel : + 49- ( 0 ) 2371 937 0
& quot ;
& quot ; content by weight , by volume or by unit
& quot ;
& quot ; manufacturer Bristol-Myers Squibb S. r. l .
& quot ;
& quot ; early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid , for example , be recommend in these patient .
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; 3 .
& quot ;
& quot ; 95 an increase incidence of thrombotic vascular event ( see section 4.4 and section 4.8 - General ) have be observe in patient receive erythropoietic agent .
& quot ;
& quot ; 300 IU / kg 3x / week for 4 week
& quot ;
& quot ; Tel : + 421 2 59298411
& quot ;
& quot ; Psychiatric disorder :
& quot ;
& quot ; teratogenicity be observe in rat at dos ≥ 0.2 mg / kg and be manifest by external , visceral and skeletal malformation .
& quot ;
& quot ; Post-Marketing :
& quot ;
& quot ; however , the
& quot ;
& quot ; 11 .
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; adult peritoneal dialysis patient :
& quot ;
& quot ; the potentially medically serious sign and symptom report included somnolence , transient loss of consciousness and extrapyramidal symptom .
& quot ;
& quot ; priapism
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; 2 .
& quot ;
& quot ; the pre-filled syringe should not be shake .
& quot ;
& quot ; Epoetin alfa IV / SC
& quot ;
& quot ; there be an increased risk for thromboembolic event in patient with cancer treat with recombinant human erythropoietin and a negative impact on overall survival can not be exclude .
& quot ;
& quot ; Abseamed 1000 IU / 0.5 ml
& quot ;
& quot ; Subcutaneous injection : a maximum volume of 1 ml at one injection site should generally not be exceed .
& quot ;
& quot ; male patient be advise to not Father a child during and up to six month after treatment and should seek advice on conservation of sperm prior to treatment because of the possibility of irreversible infertility due to therapy with Abraxane .
& quot ;
& quot ; adverse reaction report with Abraxane at any dose in clinical trial .
& quot ;
& quot ; Tel : + 351 21 440 70 00
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6.8 g / dl or & lt ; 4.25 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 6.8 g / dl or & gt ; 4.25 mmol / l ) .
& quot ;
& quot ; patient should be advise not to drive and use machine if they feel tire or dizzy .
& quot ;
& quot ; the Aclasta group reveal approximately 2.5 mm le height loss compare to placebo ( 95 % CI :
& quot ;
& quot ; s R. O .
& quot ;
& quot ; the injection be give in the thigh or the anterior abdominal wall .
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole , the active metabolite , decrease by 32 % and 47 % .
& quot ;
& quot ; in clinical trial and post-marketing experience , accidental or intentional acute overdosage of aripiprazole alone be identify in adult patient with report estimate dose up to 1,260 mg with no fatality .
& quot ;
& quot ; s R. O .
& quot ;
& quot ; Pre-filled syrinx ( glass type I ) with plunger ( Teflon-faced rubber ) seal in a blister .
& quot ;
& quot ; Orodispersible Tablet
& quot ;
& quot ; Chronic renal failure patient
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; Meta-analysis of overall survival data produce a hazard ratio point estimate of 1.08 in favour of control ( 95 % CI :
& quot ;
& quot ; factor that should be consider in this assessment should include the type of tumour and it stage ; the degree of anaemia ; life-expectancy ; the environment in which the patient be be treat ; and patient preference ( see section 5.1 ) .
& quot ;
& quot ; Abraxane be an albumin-bound nanoparticle formulation of paclitaxel , which may have substantially different pharmacological property compare to other formulation of paclitaxel ( see section 5.1 and 5.2 ) ..
& quot ;
& quot ; Pharmacotherapeutic group : antianaemic , ATC code :
& quot ;
& quot ; Comparisons between aripiprazole and placebo in the proportion of patient experience potentially clinically significant change in routine laboratory parameter reveal no medically important difference .
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg , Kuhloweg 37 , D-58638 Iserlohn , Germany
& quot ;
& quot ; Contrada Fontana del Ceraso I-03012 Anagni-Frosinone - Italy
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; before you use Abraxane 3 .
& quot ;
& quot ; Eesti Österreich BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; the dosage should not normally exceed 200 IU per kilogram , three time a week .
& quot ;
& quot ; in this leaflet :
& quot ;
& quot ; Eesti Österreich BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; 0.5 ml ( 10000 IU / ml )
& quot ;
& quot ; Norge BRISTOL-MYERS SQUIBB Norway LTD Tlf : + 47 67 55 53 50
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of 25 IU / kg 3 time per week at interval of at least 4 week until the desired goal be achieve .
& quot ;
& quot ; 156 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; 156 package LEAFLET :
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; some people may feel depressed .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; - increase risk of death when administer to target a haemoglobin of 12 g / dl ( 7.5 mmol / l ) in
& quot ;
& quot ; like all medicine , Abraxane can cause side-effects , although not everyone get them .
& quot ;
& quot ; when the CYP3A4 inducer be withdraw from the combination therapy , the aripiprazole dose should then be reduce to the recommend dose ( see section 4.5 ) .
& quot ;
& quot ; Excipients : sodium dihydrogen phosphate dihydrate , disodium phosphate dihydrate , sodium chloride , glycine , polysorbate 80 , hydrochloric acid ( for pH-adjustment ) , sodium hydroxide ( for pH-adjustment ) , and water for injection
& quot ;
& quot ; it be recommend that the platelet count be regularly monitor during the first 8 week of therapy .
& quot ;
& quot ; the carcinogenic potential of paclitaxel have not be study .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; s R. O .
& quot ;
& quot ; 56 X 1
& quot ;
& quot ; 300 IU / kg 3x / week for 4 week
& quot ;
& quot ; patient ) be recommend for chronic renal failure patient whose serum ferritin level be below 100 ng / ml
& quot ;
& quot ; alternatively , disperse the tablet in water and drink the resulting suspension .
& quot ;
& quot ; Hepatobiliary disorder :
& quot ;
& quot ; Aripiprazole also demonstrate a comparable proportion of patient in symptomatic remission from mania a lithium or haloperidol at week 12 .
& quot ;
& quot ; nervous system disorder :
& quot ;
& quot ; Comparisons between aripiprazole and placebo in the proportion of patient experience potentially clinically significant change in routine laboratory parameter reveal no medically important difference .
& quot ;
& quot ; overall survival outcome in the trial could not be statisfactorily explain by difference in the incidence of thrombosis and related complication between those give recombinant human erythropoietin and those in the control group .
& quot ;
& quot ; adult patient with renal insufficiency not yet undergoing dialysis :
& quot ;
& quot ; 1 pre-filled syringe
& quot ;
& quot ; Slovenská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; 1 bottle + 1 cup + 1 calibrate dropper
& quot ;
& quot ; John & apos ; s Wort ) may be expect to have similar effect and similar dose increase should therefore be apply .
& quot ;
& quot ; the most frequent adverse reaction during treatment with epoetin alfa be a dose-dependent increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ; while cardiotoxicity unequivocally relate to Abraxane have not be demonstrate , cardiac event be not uncommon in the indicated population , especially in patient who have previously receive anthracyclines or have underlying cardiac or pulmonary disease .
& quot ;
& quot ; it use in this indication must be balance against the report risk of thromboembolic event .
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; Manic episodes in Bipolar I Disorder :
& quot ;
& quot ; Italia BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; the biological efficacy of epoetin alfa have be demonstrate in various animal model in vivo ( normal and anaemic rat , polycythaemic mouse ) .
& quot ;
& quot ; additional sign may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
& quot ;
& quot ; result of an epidemiological study find that there be no increase risk of suicidality with aripiprazole compare to other antipsychotic among patient with bipolar disorder .
& quot ;
& quot ; however , elevate creatine phosphokinase and rhabdomyolysis , not necessarily in association with NMS , have also be report .
& quot ;
& quot ; 30 mg
& quot ;
& quot ; early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid , for example , be recommend in these patient .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Psychiatric disorder :
& quot ;
& quot ; ABILIFY 30 mg tablet aripiprazole
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; Aripiprazole be metabolise by multiple pathway involve the CYP2D6 and CYP3A4 enzyme but not CYP1A enzyme .
& quot ;
& quot ; Activated charcoal ( 50 g ) , administer one hour after aripiprazole , decrease aripiprazole Cmax by about 41 % and AUC by about 51 % , suggest that charcoal may be effective in the treatment of overdose .
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl and Hb increase & lt ; 1 g / dl
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; your doctor may do blood test to decide , if you need iron supplement .
& quot ;
& quot ; Abseamed be a sterile but unpreserved product and be for single use only .
& quot ;
& quot ; 28 August 2007
& quot ;
& quot ; 1.3 ml
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; be sure to tell your doctor immediately if you be breast-feeding .
& quot ;
& quot ; in controlled clinical study , use of Epoetin alfa and other erythropoiesis-stimulating agent ( ESAs ) have show :
& quot ;
& quot ; Occlusion of the dialysis system be possible if heparinisation be not optimum .
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; method of administration
& quot ;
& quot ; Č eská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; Abraxis BioScience limit West Forest Gate Wellington Road Wokingham Berkshire RG40 2AQ United Kingdom
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; 4 .
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; patient who develop pure red Cell Aplasia ( PRCA ) follow treatment with any erythropoietin should not receive Abseamed or any other erythropoietin ( see section 4.4 - pure red Cell Aplasia ) .
& quot ;
& quot ; 15 .
& quot ;
& quot ; name and address of the manufacturer of the biological active substance
& quot ;
& quot ; 4 June 2004
& quot ;
& quot ; - if the solution be cloudy or there be particle in it .
& quot ;
& quot ; Abilify be use to treat moderate to severe manic episode and to prevent manic episode in patient who have respond to the medicine in the past .
& quot ;
& quot ; EU / 1 / 04 / 276 / 009
& quot ;
& quot ; therefore cardiovascular monitoring should be start immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmia .
& quot ;
& quot ; EU / 1 / 04 / 276 / 007
& quot ;
& quot ;
& quot ; with renal insufficiency not yet undergoing dialysis ( see section 4.4 ) .
& quot ;
& quot ; Sodium dihydrogen phosphate dihydrate Disodium phosphate dihydrate Sodium chloride Glycine Polysorbate 80 water for injection Hydrochloric acid ( for pH-adjustment ) Sodium hydroxide ( for pH-adjustment )
& quot ;
& quot ; if epoetin alfa be give concomitantly with cyclosporin , blood level of cyclosporin should be monitor and the dose of cyclosporin adjust a the haematocrit rise .
& quot ;
& quot ; Erythropoietin be a growth factor that primarily stimulate red cell production .
& quot ;
& quot ; all special warning and precaution associate with autologous predonation programme , especially routine volume replacement , should be respect .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; Abseamed should be administer intravenously in order to increase haemoglobin to not greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; Uncommon :
& quot ;
& quot ; recurrence prevention of manic episode in Bipolar I Disorder :
& quot ;
& quot ; oral use .
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and then reinstitute epoetin alfa therapy at a dose 25 % below the previous level .
& quot ;
& quot ; if you notice you be gain weight , experience any difficulty in swallow or allergic symptom , please tell your doctor .
& quot ;
& quot ; elderly :
& quot ;
& quot ; 84 for the purpose of ambulatory use , the patient may remove Abseamed from the refrigerator and store it not above 25 ° C for one single period of up to 3 day .
& quot ;
& quot ; Hypertension may occur in epoetin alfa treat patient .
& quot ;
& quot ; at therapeutic concentration , aripiprazole and dehydro-aripiprazole be greater than 99 % bound to serum protein , bind primarily to albumin .
& quot ;
& quot ; treatment of symptomatic anaemia associate with chronic renal failure ( CRF ) in adult and paediatric patient :
& quot ;
& quot ; the maximum daily dose should not exceed 30 mg .
& quot ;
& quot ; EU / 1 / 05 / 308 / 001
& quot ;
& quot ; patient who for any reason can not receive adequate antithrombotic prophylaxis .
& quot ;
& quot ; the biological efficacy of epoetin alfa have be demonstrate in various animal model in vivo ( normal and anaemic rat , polycythaemic mouse ) .
& quot ;
& quot ;
& quot ; 3 .
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of at least four week .
& quot ;
& quot ; Orodispersible tablet Round and yellow , mark with & quot ; & quot ; A & quot ; & quot ; over & quot ; & quot ; 641 & quot ; & quot ; on one side and & quot ; & quot ; 15 & quot ; & quot ; on the other .
& quot ;
& quot ; these report be base on in vitro finding from human tumour sample , but be of uncertain significance in the clinical situation .
& quot ;
& quot ; adult peritoneal dialysis patient :
& quot ;
& quot ; Italia FIDIA Farmaceutici S. p . a .
& quot ;
& quot ; adjustment of daily dosage , include dose reduction should be consider on the basis of clinical status .
& quot ;
& quot ; the most frequent adverse reaction be an increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ; 4 .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; 1 .
& quot ;
& quot ; Clinical manifestation of NMS be hyperpyrexia , muscle rigidity , alter
& quot ;
& quot ; 78-88 year ) .
& quot ;
& quot ; Aripiprazole be metabolise by multiple pathway involve the CYP2D6 and CYP3A4 enzyme but not CYP1A enzyme .
& quot ;
& quot ; in the four placebo-controlled study the hazard ratio for overall survival range between 1.25 and 2.47 in favour of control .
& quot ;
& quot ; in clinical trial , an increase risk of death and serious cardiovascular event be observe when erythropoiesis stimulate agent ( ESAs ) be administer to target a haemoglobin of greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; other
& quot ;
& quot ; 1 .
& quot ;
& quot ; 23 1 .
& quot ;
& quot ; Pack of 1 or 6 syrinx .
& quot ;
& quot ; 2 .
& quot ;
& quot ; 14 mental status and evidence of autonomic instability ( irregular pulse or blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
& quot ;
& quot ; 44 Posology
& quot ;
& quot ; treatment of patient with chemotherapy induce anaemia :
& quot ;
& quot ; Conduction abnormality :
& quot ;
& quot ; although there be no information on the effect of haemodialysis in treat an overdose with aripiprazole , haemodialysis be unlikely to be useful in overdose management since aripiprazole be highly bind to plasma protein .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; in two 12-week , placebo- and active-controlled monotherapy trial in patient with a manic or mixed episode of Bipolar I Disorder , with or without psychotic feature , aripiprazole demonstrate superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12 .
& quot ;
& quot ; 1 bottle contain 5 mg zoledronic acid ( anhydrous ) .
& quot ;
& quot ; Tel : + 31 ( 0 ) 35 5288377
& quot ;
& quot ; the effectiveness of Abilify in prevent symptom from return be assess in three study last up to a year , two of which use haloperidol ( another antipsychotic medicine ) a a comparator .
& quot ;
& quot ; manufacturer Bristol-Myers Squibb S. r. l .
& quot ;
& quot ; Non-specific skin rash have be describe in association with epoetin alfa .
& quot ;
& quot ; in addition , special precaution should be take in patient with predisposition for development of deep vein thrombosis ( DVTs ) .
& quot ;
& quot ; 2 .
& quot ;
& quot ; rash , photosensitivity reaction , alopecia , hyperhidrosis
& quot ;
& quot ; Tel : + 34 91 456 53 00
& quot ;
& quot ; population pharmacokinetic evaluation have reveal no evidence of clinically significant race-related difference or effect from smoke upon the pharmacokinetics of aripiprazole .
& quot ;
& quot ; 1 .
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be avoid .
& quot ;
& quot ; 110 721 cancer patient receive non-platinum chemotherapy be include in three placebo-controlled study , 389 patient with haematological malignancy ( 221 multiple myeloma , 144 non-Hodgkin & apos ; s lymphoma , and 24 other haematological malignancy ) and 332 with solid tumour ( 172 breast , 64 gynaecological , 23 lung , 22 prostate , 21 gastro-intestinal , and 30 other tumour type ) .
& quot ;
& quot ; Abilify
& quot ;
& quot ; 6 .
& quot ;
& quot ; how to take ABILIFY 4 .
& quot ;
& quot ; date of first authorisation :
& quot ;
& quot ; if anti-erythropoietin , antibody-mediated PRCA be suspect , therapy with Abseamed should be discontinue immediately .
& quot ;
& quot ; Luxembourg / Luxemburg BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; 1 .
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; if you notice you be gain weight , experience any difficulty in swallow or allergic symptom , please tell your doctor .
& quot ;
& quot ; Abseamed have the highest possible purity accord to the present state of the art .
& quot ;
& quot ; 45 Correction phase :
& quot ;
& quot ; BLISTERS
& quot ;
& quot ; urinary incontinence , urinary retention
& quot ;
& quot ; 4 .
& quot ;
& quot ; no other erythropoietic therapy should be commence because of the risk of cross-reaction .
& quot ;
& quot ; owe to the greater sensitivity of this population , a lower start dose should be consider when clinical factor warrant ( see section 4.4 ) .
& quot ;
& quot ; method OF administration
& quot ;
& quot ; take ABILIFY with some medicine may need to change your dose of ABILIFY .
& quot ;
& quot ; date of first authorisation :
& quot ;
& quot ; Bone histology Bone biopsy be obtain from the iliac crest 1 year after the third annual dose in 152 post- menopausal patient with osteoporosis treat with Aclasta ( N = 82 ) or placebo ( N = 70 ) .
& quot ;
& quot ; an investigational study ( best study ) in woman with metastatic breast cancer be design to determine whether epoetin alfa treatment that extend beyond the correction of anaemia could improve treatment outcome .
& quot ;
& quot ; Deutschland BRISTOL-MYERS SQUIBB GMBH & amp ; CO .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; Clinical manifestation of NMS be hyperpyrexia , muscle rigidity , alter mental status and evidence of autonomic instability ( irregular pulse or blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
& quot ;
& quot ; 135 patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; Abseamed 6000 IU / 0.6 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; Syringes be emboss with graduation ring and the filling volume be indicate by a stick-on label in order to enable partial use if require .
& quot ;
& quot ; method OF administration
& quot ;
& quot ; functional assessment of Cancer Therapy- Anaemia ( FACT-An ) general scale , FACT-An fatigue scale , and Cancer linear Analogue scale ( CLAS ) .
& quot ;
& quot ; it be use to treat adult who suffer from a disease characterise by symptom such a hearing , see or sense thing which be not there , suspiciousness , mistaken belief , incoherent speech and behaviour and emotional flatness .
& quot ;
& quot ; Haemoglobin level should be measure on a regular basis until a stable level be achieve and periodically thereafter .
& quot ;
& quot ; you should check with your doctor or pharmacist if you be not sure .
& quot ;
& quot ; EXP
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; ABILIFY 1 mg / ml
& quot ;
& quot ; at steady state , dehydro-aripiprazole , the active metabolite , represent about 40 % of aripiprazole AUC in plasma .
& quot ;
& quot ; Hypertensive crisis with encephalopathy-like symptom can occur .
& quot ;
& quot ; Pharmacotherapeutic group : antipsychotic , ATC code :
& quot ;
& quot ; - oral iron substitution of 200 - 300 mg Fe2 + / day be recommend for all cancer patient whose
& quot ;
& quot ; patient with active malignant disease receive neither chemotherapy nor radiation therapy .
& quot ;
& quot ; what ABILIFY be AND what IT be use for
& quot ;
& quot ; or Hb increase ≥ 1 g / d
& quot ;
& quot ; during antipsychotic treatment , improvement in the patient & apos ; s clinical condition may take several day to some week .
& quot ;
& quot ; in elderly patient with dementia , more fatal case have be report while take aripiprazole .
& quot ;
& quot ; clear colourless solution
& quot ;
& quot ; read all of this leaflet carefully before you start take this medicine .
& quot ;
& quot ; Cytotoxic action of epoetin alfa on bone marrow cell could not be detect .
& quot ;
& quot ; 40 721 cancer patient receive non-platinum chemotherapy be include in three placebo-controlled study , 389 patient with haematological malignancy ( 221 multiple myeloma , 144 non-Hodgkin & apos ; s lymphoma , and 24 other haematological malignancy ) and 332 with solid tumour ( 172 breast , 64 gynaecological , 23 lung , 22 prostate , 21 gastro-intestinal , and 30 other tumour type ) .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; the European Commission grant a marketing authorisation valid throughout the European Union for Abilify to Otsuka pharmaceutical Europe Ltd. on 4 June 2004 .
& quot ;
& quot ; syncope , hypertension , thromboembolic event
& quot ;
& quot ; Shunt thromboses may occur , especially in patient who have a tendency to hypotension or whose arteriovenous fistula exhibit complication ( e. g. stenosis , aneurysm , etc . ) .
& quot ;
& quot ; ABILIFY dose should be reduce to approximately one-half of it prescribed dose when concomitant administration of ABILIFY with quinidine occurs .
& quot ;
& quot ; Tel : + 40 ( 0 ) 21 272 16 00
& quot ;
& quot ; • other condition
& quot ;
& quot ; after administration of epoetin alfa , the number of erythrocyte , the Hb value and reticulocyte count increase a well a the 59Fe-incorporation rate .
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of at least four week .
& quot ;
& quot ; Pre-filled syrinx ( glass type I ) with plunger ( Teflon-faced rubber ) seal in a blister .
& quot ;
& quot ; discontinue therapy
& quot ;
& quot ; two other smaller , randomise , placebo-controlled trial fail to show a significant improvement in quality of life parameter on the EORTC-QLQ-C30 scale or CLAS , respectively .
& quot ;
& quot ; ABILIFY be indicate for the treatment of moderate to severe manic episode in Bipolar I Disorder and for the prevention of a new manic episode in patient who experience predominantly manic episode and whose manic episode respond to aripiprazole treatment ( see section 5.1 ) .
& quot ;
& quot ; Abseamed
& quot ;
& quot ; 28 X 1
& quot ;
& quot ; the following adverse event have be report during post-marketing surveillance .
& quot ;
& quot ; in particular , no residue of the cell line use for the production be detectable at the concentration of the active ingredient that be use in human .
& quot ;
& quot ; Aripiprazole do not impair fertility in reproductive toxicity study .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; Tel : + 421 2 59298411
& quot ;
& quot ; Erythropoietin be also use before surgery to increase the number of red blood cell and help minimise the consequence of blood loss .
& quot ;
& quot ; in placebo-controlled trial , the incidence of akathisia in bipolar patient be 12.1 % with aripiprazole and 3.2 % with placebo .
& quot ;
& quot ; haemodialysis and adult patient on peritoneal dialysis ( see section 4.4 ) .
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; 26 721 cancer patient receive non-platinum chemotherapy be include in three placebo-controlled study , 389 patient with haematological malignancy ( 221 multiple myeloma , 144 non-Hodgkin & apos ; s lymphoma , and 24 other haematological malignancy ) and 332 with solid tumour ( 172 breast , 64 gynaecological , 23 lung , 22 prostate , 21 gastro-intestinal , and 30 other tumour type ) .
& quot ;
& quot ; appropriate therapy such a blood transfusion may be give to patient when indicate .
& quot ;
& quot ; 78-88 year ) .
& quot ;
& quot ; complete resuspension should be ensure by mild agitation of the vial before use .
& quot ;
& quot ; 24 B .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; population pharmacokinetic evaluation have reveal no evidence of clinically significant race-related difference or effect from smoke upon the pharmacokinetics of aripiprazole .
& quot ;
& quot ; at therapeutic concentration , aripiprazole and dehydro-aripiprazole be greater than 99 % bound to serum protein , bind primarily to albumin .
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; the study either recruited patient who be be treat with chemotherapy ( two study ) or use patient population in which erythropoiesis stimulating agent be not indicate : anaemia in patient with cancer not receive chemotherapy , and head and neck cancer patient receive radiotherapy .
& quot ;
& quot ; Additionally , aripiprazole and dehydro-aripiprazole do not show potential for alter CYP1A2-mediated metabolism in vitro .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; these report be base on in vitro finding from human tumour sample , but be of uncertain significance in the clinical situation .
& quot ;
& quot ; Cytotoxic action of epoetin alfa on bone marrow cell could not be detect .
& quot ;
& quot ; the most frequent adverse reaction be an increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ; in view of the above , in some clinical situation blood transfusion should be the preferred treatment for the management of anaemia in patient with cancer .
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery should receive adequate antithrombotic prophylaxis , a thrombotic and vascular event may occur in surgical patient , especially in those with underlying cardiovascular disease .
& quot ;
& quot ; if a patient develop sign and symptom indicative of NMS , or present with unexplained high fever without additional clinical manifestation of NMS , all antipsychotic medicinal product , include ABILIFY , must be discontinue .
& quot ;
& quot ; { MM / YYYY }
& quot ;
& quot ; Epoetin alfa obtain by gene technology be glycosylated and be identical in it amino acid and carbohydrate composition to endogenous human erythropoietin that have be isolate from the urine of anaemic patient .
& quot ;
& quot ; follow a single oral dose of & # 91 ; 14C & # 93 ; -labelled aripiprazole , approximately 27 % of the administered radioactivity be recover in the urine and approximately 60 % in the faeces .
& quot ;
& quot ; 63 nervous system disorder :
& quot ;
& quot ; all patient be treat with epoetin alfa should receive adequate iron supplementation ( e. g. oral iron substitution of 200 mg Fe2 + daily ) throughout the course of epoetin alfa treatment .
& quot ;
& quot ; Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel : + 353 ( 1 800 ) 749 749
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; 46.7 & # 91 ; 39.0 , 55.3 & # 93 ; ( n = 136 )
& quot ;
& quot ;
& quot ; the recommend dose be a single intravenous infusion of 5 mg Aclasta .
& quot ;
& quot ; lot
& quot ;
& quot ; 10 mg
& quot ;
& quot ; Endocrine disorder :
& quot ;
& quot ; 3 .
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and then reinstitute epoetin alfa therapy at a dose 25 % below the previous level .
& quot ;
& quot ; Aripiprazole dose range from 0.5 to 30 mg administer once a day to healthy subject for 2 week produce a dose-dependent reduction in the binding of 11C-raclopride , a D2 / D3 receptor ligand , to the caudate and putamen detect by positron emission tomography .
& quot ;
& quot ; stability Unopened vial of Abraxane be stable until the date indicate on the package when the vial be keep in the outer carton in order to protect from light .
& quot ;
& quot ; BLISTER
& quot ;
& quot ; special storage condition
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; however , the concentration of the sulphate conjugate of hydroxy aripiprazole in human bile at the highest dose propose , 30 mg per day , be no more than 6 % of the bile concentration find in the monkey in the 39-week study and be well below ( 6 % ) their limit of in vitro solubility .
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; uncontrolled hypertension .
& quot ;
& quot ; in the indication “ increase the yield of autologous blood ” : myocardial infarction or stroke in the month precede treatment , unstable angina pectoris , increase risk of deep venous thrombosis such a history of venous thromboembolic disease .
& quot ;
& quot ; Erythropoietins be growth factor that primarily stimulate red blood cell production .
& quot ;
& quot ; - decrease locoregional control in patient with advanced head and neck cancer receiving
& quot ;
& quot ; the frequency of hypocalcaemia be much lower follow subsequent infusion .
& quot ;
& quot ; if after an additional 4 week of therapy at 300 IU / kg 3 time per week , the haemoglobin have increase ≥ 1 g / dl ( ≥ 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl the dose should remain at 300 IU / kg 3 time per week .
& quot ;
& quot ; patient with hepatic impairment : no dosage adjustment be require for patient with mild to moderate hepatic impairment .
& quot ;
& quot ; if you have the impression that the effect of ABILIFY be too strong or too weak , talk to your doctor or pharmacist .
& quot ;
& quot ; & quot ; & quot ; Flu-like & quot ; & quot ; symptom such a headache , joint pain , feeling of weakness , dizziness , and tiredness may occur , especially at the start of treatment .
& quot ;
& quot ; ABILIFY 30 mg
& quot ;
& quot ; 82 for prevent recurrence of manic episode in patient who have be receive aripiprazole , continue therapy at the same dose .
& quot ;
& quot ; give the primary CNS effect of aripiprazole , caution should be use when aripiprazole be take in combination with alcohol or other CNS medicinal product with overlap undesirable effect such a sedation ( see section 4.8 ) .
& quot ;
& quot ; additional supportive care should be provide a necessary .
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; syncope , hypertension , thromboembolic event
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; Aripiprazole be extensively metabolise by the liver primarily by three biotransformation pathway : dehydrogenation , hydroxylation , and N-dealkylation .
& quot ;
& quot ; discontinue therapy
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; Italia BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of the symptom of anaemia .
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; what ABILIFY be and what it be use for 2 .
& quot ;
& quot ; further information
& quot ;
& quot ; BRISTOL-MYERS SQUIBB GESMBH Tel : + 43 1 60 14 30
& quot ;
& quot ; in addition , report of accidental overdose with aripiprazole alone ( up to 195 mg ) in child have be receive with no fatality .
& quot ;
& quot ; Hypertensive crisis with encephalopathy-like symptom can occur .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; EU / 1 / 04 / 276 / 011-015
& quot ;
& quot ; weight gain : in clinical trial aripiprazole have not be show to induce clinically relevant weight gain .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; Abseamed can be use to reduce exposure to allogeneic blood transfusion in adult non-iron deficient patient prior to major elective orthopaedic surgery , have a high perceive risk for transfusion complication .
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and than reinstitute epoetin alfa therapy at a dose 25 % below the previous dose .
& quot ;
& quot ; the subcutaneous route of administration should be use .
& quot ;
& quot ; these report be base on in vitro finding from human tumour sample , but be of uncertain significance in the clinical situation .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; EU / 1 / 07 / 412 / 001
& quot ;
& quot ; oral use
& quot ;
& quot ; Abseamed can be use to increase the yield of autologous blood from patient in a predonation programme .
& quot ;
& quot ; Musculoskeletal and connective tissue disorder :
& quot ;
& quot ; instruction on use
& quot ;
& quot ; therefore , in patient with renal anaemia the medicinal product have to be administer intravenously .
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; upon discontinuation of the CYP2D6 or 3A4 inhibitor , the dosage of ABILIFY should be increase to the level prior to the initiation of the concomitant therapy .
& quot ;
& quot ; when either valproate or lithium be administer concomitantly with aripiprazole , there be no clinically significant change in aripiprazole concentration .
& quot ;
& quot ; Aripiprazole orodispersible tablet be bioequivalent to aripiprazole tablet , with a similar rate and extent of absorption .
& quot ;
& quot ; there be no adequate and well-controlled trial of aripiprazole in pregnant woman .
& quot ;
& quot ; Aripiprazole be well absorb , with peak plasma concentration occur within 3-5 hour after dose .
& quot ;
& quot ; 16 .
& quot ;
& quot ; method OF administration
& quot ;
& quot ; give the primary CNS effect of aripiprazole , caution should be use when aripiprazole be take in combination with alcohol or other CNS medicinal product with overlap undesirable effect such a sedation ( see section 4.8 ) .
& quot ;
& quot ; these increase in blood pressure can be treat with medicinal product .
& quot ;
& quot ; in some patient previously expose to capecitabine , report of palmar-plantar erythrodysaesthesiae have be report a part of the continue surveillance of Abraxane .
& quot ;
& quot ; for prevent recurrence of manic episode in patient who have be receive aripiprazole , continue therapy at the same dose .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; - if the solution have be accidentally frozen .
& quot ;
& quot ; a with other antipsychotic , aripiprazole should be use with caution in patient with a family history of QT prolongation .
& quot ;
& quot ; in cancer patient receive chemotherapy , the 2 - 3 week delay between epoetin alfa administration and the appearance of erythropoietin-induced red cell should be take into account when assess if epoetin alfa therapy be appropriate ( patient at risk of be transfuse ) .
& quot ;
& quot ; 5 .
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; increase mortality : in three placebo-controlled trial ( n = 938 ; mean age :
& quot ;
& quot ; you should check with your doctor or pharmacist if you be not sure .
& quot ;
& quot ; elderly :
& quot ;
& quot ; the total body clearance of aripiprazole be 0.7 ml / min / kg , which be primarily hepatic .
& quot ;
& quot ; clear colourless solution
& quot ;
& quot ; information for the user
& quot ;
& quot ; adjustment of daily dosage , include dose reduction should be consider on the basis of clinical status .
& quot ;
& quot ; elderly : the effectiveness of ABILIFY in the treatment of schizophrenia and Bipolar I Disorder in patient 65 year of age or older have not be establish .
& quot ;
& quot ; 10 .
& quot ;
& quot ; when concomitant administration of potent CYP3A4 or CYP2D6 inhibitor with aripiprazole occurs , the aripiprazole dose should be reduce .
& quot ;
& quot ; Z O. O .
& quot ;
& quot ; treatment of symptomatic anaemia in adult and paediatric chronic renal failure patient :
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; what ABILIFY contain The active substance be aripiprazole .
& quot ;
& quot ; patient should be advise to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole .
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; Paclitaxel at dos below the human therapeutic dose be associate with low fertility and foetal toxicity in rat .
& quot ;
& quot ; Restlessness 1 The frequency of hypersensitivity reaction be calculate base on one definitely related case in a population of 789 patient
& quot ;
& quot ; John & apos ; s Wort ) may be expect to have similar effect and similar dose increase should therefore be apply .
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; adult surgery patient in an autologous predonation programme
& quot ;
& quot ; single use vial Intravenous use
& quot ;
& quot ; chest discomfort , abnormal gait , swell , injection site reaction Uncommon1 :
& quot ;
& quot ; if after an additional 4 week of therapy at 300 IU / kg 3 time per week , the haemoglobin have increase ≥ 1 g / dl ( ≥ 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl the dose should remain at 300 IU / kg 3 time per week .
& quot ;
& quot ; even if you feel better , do not alter or discontinue the daily dose of ABILIFY without first consult your doctor .
& quot ;
& quot ; maintenance dose between 25 and 50 IU / kg 2 time per week into 2 equal injection .
& quot ;
& quot ; generally , child under 30 kg require higher maintenance dos than child over 30 kg and adult .
& quot ;
& quot ; Vascular disorder :
& quot ;
& quot ; 149 minimum PARTICULARS to appear on small immediate packaging unit
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; in cancer patient receive chemotherapy , the 2 - 3 week delay between epoetin alfa administration and the appearance of erythropoietin-induced red cell should be take into account when assess if epoetin alfa therapy be appropriate ( patient at risk of be transfuse ) .
& quot ;
& quot ; outcome
& quot ;
& quot ; Aripiprazole be metabolise by multiple pathway involve the CYP2D6 and CYP3A4 enzyme but not CYP1A enzyme .
& quot ;
& quot ; not applicable .
& quot ;
& quot ; Hb 10 - 13 g / dl ) who do not have an autologous predonation programme available and with an expected blood loss of 900 to 1800 ml .
& quot ;
& quot ; Abseamed should be give by the intravenous route .
& quot ;
& quot ; 2 adequate calcium and vitamin D intake be recommend in association with Aclasta administration .
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) , the dose should be reduce by approximately 25 to 50 % .
& quot ;
& quot ; the absolute oral bioavailability of the tablet formulation be 87 % .
& quot ;
& quot ; Intravenous injection : over at least one to five minute , depend on the total dose .
& quot ;
& quot ; Schizophrenia - in a long term 52-week controlled trial , aripiprazole-treated patient have an overall-lower incidence ( 25.8 % ) of EPS include parkinsonism , akathisia , dystonia and dyskinesia compare with those treat with haloperidol ( 57.3 % ) .
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; Contrada Fontana del Ceraso I-03012 Anagni-Frosinone - Italy
& quot ;
& quot ; Abraxane should only be prepare and administer by personnel appropriately train in the handling of cytotoxic agent .
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; 3 .
& quot ;
& quot ; the absolute oral bioavailability of the tablet formulation be 87 % .
& quot ;
& quot ; some people may feel depressed .
& quot ;
& quot ; information for the user
& quot ;
& quot ; Post-Marketing :
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; 9 .
& quot ;
& quot ; the following maintenance dos be observe in clinical trial after 6 month of treatment :
& quot ;
& quot ; 2 .
& quot ;
& quot ; the initial dose be 150 IU / kg give subcutaneously 3 time per week .
& quot ;
& quot ; 56-99 year ) of aripiprazole in elderly patient with psychosis associate with Alzheimer & apos ; s disease , patient treat with aripiprazole be at increase risk of death compare to placebo .
& quot ;
& quot ; name OF the MEDICINAL product AND route ( s ) OF administration
& quot ;
& quot ; 12 .
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the sustained haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) reduce the epoetin alfa dose by 25 % .
& quot ;
& quot ; be sure to tell your doctor immediately if you be pregnant , think you may be pregnant , or if you be plan to become pregnant .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; the most frequent adverse reaction during treatment with epoetin alfa be a dose-dependent increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ; elderly :
& quot ;
& quot ; take special care with Abseamed :
& quot ;
& quot ; * Median Progression Free survival & # 91 ; 95 % CI & # 93 ; ( week )
& quot ;
& quot ; Metabolism and nutrition disorder :
& quot ;
& quot ; treatment of symptomatic anaemia associate with chronic renal failure ( CRF ) in adult and paediatric patient :
& quot ;
& quot ; kg Tél / Tel : + 49- ( 0 ) 2371 937 0
& quot ;
& quot ; Abseamed 9000 IU / 0.9 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; Abseamed should be give by the intravenous route .
& quot ;
& quot ; ABILIFY be not approve for the treatment of dementia-related psychosis .
& quot ;
& quot ; therefore , routine volume replacement should be perform in such patient .
& quot ;
& quot ; 9 .
& quot ;
& quot ; Aripiprazole should be use with caution in patient with known cardiovascular disease ( history of myocardial infarction or ischaemic heart disease , heart failure , or conduction abnormality ) , cerebrovascular disease , condition which would predispose patient to hypotension ( dehydration , hypovolemia , and treatment with antihypertensive medication ) or hypertension , include accelerate or malignant .
& quot ;
& quot ; 18 month use product immediately after open and discard any unused amount .
& quot ;
& quot ; therefore , routine volume replacement should be perform in such patient .
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of 25 IU / kg 3 time per week at interval of at least 4 week until the desired goal be achieve .
& quot ;
& quot ; European public assessment report ( EPAR )
& quot ;
& quot ; s R. O .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; elimination :
& quot ;
& quot ; - flu-like symptom , such a headache , ache and pain in the joint , feeling of weakness ,
& quot ;
& quot ; however , the
& quot ;
& quot ; 9 .
& quot ;
& quot ; - In pregnant or lactating surgical patient participate in an autologous blood predonation
& quot ;
& quot ; 49 X 1
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Tel : + 421 2 59298411
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery should receive adequate antithrombotic prophylaxis , a thrombotic and vascular event may occur in surgical patient , especially in those with underlying cardiovascular disease .
& quot ;
& quot ; there be an increased risk for thromboembolic event in patient with cancer treat with recombinant human erythropoietin and a negative impact on overall survival can not be exclude .
& quot ;
& quot ; elderly : the effectiveness of ABILIFY solution for injection in patient who be 65 year of age or older have not be establish .
& quot ;
& quot ; factor that should be consider in this assessment should include the type of tumour and it stage ; the degree of anaemia ; life-expectancy ; the environment in which the patient be be treat ; and patient preference ( see section 5.1 ) .
& quot ;
& quot ;
& quot ; 200 mg oral elemental iron daily ) throughout the course of treatment .
& quot ;
& quot ; 10 .
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; recurrence prevention of manic episode in Bipolar I Disorder :
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; 1 .
& quot ;
& quot ; immune system disorder :
& quot ;
& quot ; - In chronic renal failure patient , epoetin alfa should be use in pregnancy only if the potential
& quot ;
& quot ; pure red Cell Aplasia ( PRCA ) Antibody-mediated PRCA have be very rarely report after month to year of subcutaneous erythropoietin treatment .
& quot ;
& quot ; if you forget to take ABILIFY if you miss a dose , take the missed dose a soon a you remember but do not take two dos in one day .
& quot ;
& quot ; Thrombotic / vascular event , such a myocardial ischaemia , myocardial infarction , cerebrovascular accident ( cerebral haemorrhage and cerebral infarction ) , transient ischaemic attack , deep vein thrombosis , arterial thrombosis , pulmonary embolus , aneurysm , retinal thrombosis , and clotting of an artificial kidney have be report in patient receive erythropoietic agent , include patient receive epoetin alfa .
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; rhabdomyolysis , myalgia , stiffness
& quot ;
& quot ; iron supplementation should be start a soon a possible , even several week prior to initiate the autologous predeposit , in order to achieve high iron store prior to start Abseamed therapy .
& quot ;
& quot ; patient should be closely monitor throughout this period .
& quot ;
& quot ; - decrease locoregional control in patient with advanced head and neck cancer receiving
& quot ;
& quot ; { MM / YYYY }
& quot ;
& quot ; the use of specialized DEHP-free solution container or administration set be not necessary to prepare or administer Abraxane infusion .
& quot ;
& quot ; Hb 10 - 13 g / dl ) who do not have an autologous predonation programme available and with an expected blood loss of 900 to 1800 ml .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; in paediatric patient the recommended target haemoglobin range be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; the other ingredient be disodium edetate , fructose , glycerin , lactic acid , methyl parahydroxybenzoate ( E218 ) , propylene glycol , propyl parahydroxybenzoate ( E216 ) , sodium hydroxide , sucrose , purified water , and natural orange cream with other natural flavour .
& quot ;
& quot ; radiation therapy when administer to target a haemoglobin of greater than 14 g / dl ( 8.7 mmol / l ) ,
& quot ;
& quot ; the highest nontumorigenic exposure in female rat be 7 time the human exposure at the recommend dose .
& quot ;
& quot ; Abseamed should be give by the intravenous route .
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; Aclasta
& quot ;
& quot ; - shorten overall survival and increase death attribute to disease progression at 4 month in
& quot ;
& quot ; treatment of symptomatic anaemia in adult and paediatric chronic renal failure patient :
& quot ;
& quot ; base on result of a full range of standard genotoxicity test , aripiprazole be consider non-genotoxic .
& quot ;
& quot ; therefore , aripiprazole should be use with caution in patient who have a history of seizure disorder or have condition associate with seizure .
& quot ;
& quot ; when the CYP3A4 inducer be withdraw from the combination therapy , the aripiprazole dose should then be reduce to the recommend dose ( see section 4.5 ) .
& quot ;
& quot ; ESAs be not indicate for use in this patient population .
& quot ;
& quot ; Erythropoietin be a growth factor that primarily stimulate red cell production .
& quot ;
& quot ; hyperglycaemia , diabetes mellitus , diabetic ketoacidosis , diabetic hyperosmolar coma
& quot ;
& quot ;
& quot ; Nederland BRISTOL-MYERS SQUIBB BV Tel : + 31 34 857 42 22
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; Sodium dihydrogen phosphate dihydrate Disodium phosphate dihydrate Sodium chloride Glycine Polysorbate 80 water for injection Hydrochloric acid ( for pH-adjustment ) Sodium hydroxide ( for pH-adjustment )
& quot ;
& quot ; the other ingredient be calcium silicate , croscarmellose sodium , crospovidone , silicon dioxide , xylitol , microcrystalline cellulose , aspartame , acesulfame potassium , vanilla flavour , tartaric acid , magnesium stearate , red iron oxide ( E172 ) .
& quot ;
& quot ; Tel : + 372 640 1301
& quot ;
& quot ; 1 bottle contain 5 mg zoledronic acid ( anhydrous ) .
& quot ;
& quot ; how to store Abraxane 6 .
& quot ;
& quot ; 2 .
& quot ;
& quot ; the haemoglobin concentration aim for be between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) , except in paediatric patient in whom the haemoglobin concentration should be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; Dialysis prescription may have to be adjust periodically to maintain urea , creatinine and potassium in the desired range .
& quot ;
& quot ; Non-clinical safety data reveal no special hazard for human base on conventional study of safety pharmacology , repeat-dose toxicity , genotoxicity , carcinogenic potential , and toxicity to reproduction .
& quot ;
& quot ; 7 .
& quot ;
& quot ; Abseamed 8000 IU / 0.8 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; 1 .
& quot ;
& quot ; in case of larger volume , more than one site should be choose for the injection .
& quot ;
& quot ; moreover , monitoring of the blood pressure be recommend particularly at the start of therapy .
& quot ;
& quot ; this risk should be carefully weight against the benefit to be derive from treatment with epoetin alfa , particularly if you have an increase risk of thrombotic vascular event , e. g. if you be obese or have a history of thrombotic vascular event ( e. g. deep vein thrombosis or pulmonary embolism ) .
& quot ;
& quot ; Annex I
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; in all patient receive epoetin alfa , blood pressure should be closely monitor and control a necessary .
& quot ;
& quot ; 6000 IU / 0.6 ml
& quot ;
& quot ; Epoetin alfa therapy should continue until one month after the end of chemotherapy .
& quot ;
& quot ; Thrombotic / vascular event , such a myocardial ischaemia , myocardial infarction , cerebrovascular accident ( cerebral haemorrhage and cerebral infarction ) , transient ischaemic attack , deep vein thrombosis , arterial thrombosis , pulmonary embolus , aneurysm , retinal thrombosis , and clotting of an artificial kidney have be report in patient receive erythropoietic agent , include patient receive epoetin alfa .
& quot ;
& quot ; 4 .
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6.8 g / dl or & lt ; 4.25 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 6.8 g / dl or & gt ; 4.25 mmol / l ) .
& quot ;
& quot ; 10 Hepatic disease :
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; each tablet contain 10 mg of aripiprazole .
& quot ;
& quot ; only take other medicine while you be on ABILIFY if your doctor tell you that you can .
& quot ;
& quot ; some patient may benefit from a higher dose .
& quot ;
& quot ; if after an additional 4 week of therapy at 300 IU / kg 3 time per week , the haemoglobin have increase ≥ 1 g / dl ( ≥ 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl the dose should remain at 300 IU / kg 3 time per week .
& quot ;
& quot ; two other smaller , randomise , placebo-controlled trial fail to show a significant improvement in quality of life parameter on the EORTC-QLQ-C30 scale or CLAS , respectively .
& quot ;
& quot ; oral use
& quot ;
& quot ; Musculoskeletal and connective tissue disorder :
& quot ;
& quot ; it could be show with the aid of cell culture of human bone marrow cell that epoetin alfa stimulates erythropoiesis specifically and do not affect leucopoiesis .
& quot ;
& quot ;
& quot ; therefore cardiovascular monitoring should be start immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmia .
& quot ;
& quot ; - shorten overall survival and increase death attribute to disease progression at 4 month in
& quot ;
& quot ; do not push the tablet through the foil because this could damage the tablet .
& quot ;
& quot ; ABILIFY 10 mg orodispersible tablet aripiprazole
& quot ;
& quot ; the other ingredient be lactose monohydrate , maize starch , microcrystalline cellulose , hydroxypropyl cellulose , magnesium stearate , indigo carmine aluminium lake ( E132 ) .
& quot ;
& quot ; 78-88 year ) .
& quot ;
& quot ; Measurement of epoetin alfa follow multiple dose intravenous administration reveal a half-life of approximately 4 hour in normal volunteer and a somewhat more prolonged half-life in renal failure patient , approximately 5 hour .
& quot ;
& quot ; some patient may benefit from a higher dose .
& quot ;
& quot ; 16 .
& quot ;
& quot ; over the first 24 hour , 39 ± 16 % of the administer dose be recover in the urine , while the remainder be principally bind to bone tissue .
& quot ;
& quot ; relative risk reduction in
& quot ;
& quot ; in the event of overdose lead to clinically significant hypocalcaemia , reversal may be achieve with supplemental oral calcium and / or an intravenous infusion of calcium gluconate .
& quot ;
& quot ; Intravenous route
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; like all medicine , ABILIFY can cause side effect , although not everybody get them .
& quot ;
& quot ; Hexal AG Industriestrasse 25 D-83607 Holzkirchen Germany
& quot ;
& quot ; Sverige BRISTOL-MYERS SQUIBB AB Tel : + 46 8 704 71 00
& quot ;
& quot ; Epoetin alfa therapy should continue until one month after the end of chemotherapy .
& quot ;
& quot ; Tablet
& quot ;
& quot ; in chronic renal failure patient Abseamed have not to be administer subcutaneously !
& quot ;
& quot ; Manic episodes in Bipolar I Disorder - in a 12-week controlled trial , the incidence of EPS be 23.5 % for aripiprazole-treated patient and 53.3 % for haloperidol-treated patient .
& quot ;
& quot ; Aripiprazole and other antipsychotic drug should be use cautiously in patient at risk for aspiration pneumonia .
& quot ;
& quot ; adult haemodialysis patient :
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; in another long-term 26-week control trial , the incidence of EPS be 14.8 % for aripiprazole-treated patient and 15.1 % for olanzapine-treated patient .
& quot ;
& quot ; a single-dose study in subject with vary degree of liver cirrhosis ( Child-Pugh class A , B , and C ) do not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole , but the study include only 3 patient with class C liver cirrhosis , which be insufficient to draw conclusion on their metabolic capacity .
& quot ;
& quot ; result of an epidemiological study find that there be no increase risk of suicidality with aripiprazole compare to other antipsychotic among patient with bipolar disorder .
& quot ;
& quot ; pure red Cell Aplasia ( PRCA ) Antibody-mediated PRCA have be very rarely report after month to year of subcutaneous erythropoietin treatment .
& quot ;
& quot ; in addition , other cause of anaemia , such a vitamin B12 or folate deficiency , should be exclude before institute therapy with epoetin alfa .
& quot ;
& quot ; 10 .
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; * produce in CHO cell line by recombinant DNA technology
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; hyperglycaemia , diabetes mellitus , diabetic ketoacidosis , diabetic hyperosmolar coma
& quot ;
& quot ; Dosage adjustment to maintain haemoglobin concentration between 10 g / dl - 12 g / dl :
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; Tumour growth potential
& quot ;
& quot ;
& quot ; consequently :
& quot ;
& quot ; detail information on this product be available on the website of the European Medicines Agency ( EMEA ) http : / / www . emea . europa . EU /
& quot ;
& quot ; moreover , monitoring of the blood pressure be recommend particularly at the start of therapy .
& quot ;
& quot ; if you notice you be gain weight , experience any difficulty in swallow or allergic symptom , please tell your doctor .
& quot ;
& quot ; this document be a summary of the European Public assessment Report ( EPAR ) .
& quot ;
& quot ; Luxembourg / Luxemburg BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; all other cause of anaemia ( iron deficiency , haemolysis , blood loss , vitamin B12 or folate deficiency ) should be consider and treat prior to initiate therapy with epoetin alfa .
& quot ;
& quot ; information for the user
& quot ;
& quot ; 47 Tardive Dyskinesia : in clinical trial of one year or le duration , there be uncommon report of treatment emergent dyskinesia during treatment with aripiprazole .
& quot ;
& quot ; Aclasta be contraindicate during pregnancy and in breast-feeding woman ( see section 4.6 ) .
& quot ;
& quot ; 35 maximum daily dose of 30 mg should be use with caution in patient with severe hepatic impairment ( see section 5.2 ) .
& quot ;
& quot ; 14 X 1
& quot ;
& quot ; 155 9 .
& quot ;
& quot ; pancreatitis , dysphagia , abdominal discomfort , stomach discomfort , diarrhoea
& quot ;
& quot ; ABILIFY may increase the effect of medicine use to lower the blood pressure .
& quot ;
& quot ; Abseamed 8000 IU / 0.8 ml
& quot ;
& quot ; they be supply in perforated unit dose blister pack in carton contain 14 , 28 , 49 , 56 , or 98 tablet .
& quot ;
& quot ; Hypersensitivity reaction have be rarely report with epoetin alfa include isolated case of angioedema and anaphylactic reaction .
& quot ;
& quot ; Aripiprazole orodispersible tablet may be use a an alternative to aripiprazole tablet .
& quot ;
& quot ; expiry date
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; in that study the incidence of fatal thromboembolic event be higher in patient receive epoetin alfa than in those receive placebo ( see section 5.1 ) .
& quot ;
& quot ; 7 .
& quot ;
& quot ; 145 A .
& quot ;
& quot ; Smoking and race :
& quot ;
& quot ; Haemoglobin level should be measure on a regular basis until a stable level be achieve and periodically thereafter .
& quot ;
& quot ; Zoledronic acid be not highly bind to plasma protein ( approximately 43-55 % bound ) and binding be concentration independent .
& quot ;
& quot ; if an elevate ( or rise ) serum potassium level be detect then consideration should be give to cease epoetin alfa administration until hyperkalaemia have be correct .
& quot ;
& quot ; in clinical study , 10-30 mg / day dos of aripiprazole have no significant effect on the metabolism of substrate of CYP2D6 ( dextromethorphan / 3-methoxymorphinan ratio ) , 2C9 ( warfarin ) , 2C19 ( omeprazole ) , and 3A4 ( dextromethorphan ) .
& quot ;
& quot ; Post-marketing experience
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; Teл . : + 359 800 12 400
& quot ;
& quot ; therefore , it should not be use in patient with baseline haemoglobin & gt ; 13 g / dl .
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; 82.4 year ; range :
& quot ;
& quot ; - increase risk of death when administer to target a haemoglobin of 12 g / dl ( 7.5 mmol / l ) in
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy male and female subject nor be there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; in Paget ’ s disease , Aclasta be more effective than risedronate .
& quot ;
& quot ; gender : no dosage adjustment be require for female patient a compare to male patient ( see section 5.2 ) .
& quot ;
& quot ; how have Abseamed be study ?
& quot ;
& quot ; special population ( see section 4.2 ) The renal clearance of zoledronic acid be correlate with creatinine clearance , renal clearance represent 75 ± 33 % of the creatinine clearance , which show a mean of 84 ± 29 ml / min ( range 22 to 143 ml / min ) in the 64 patient study .
& quot ;
& quot ; 3 .
& quot ;
& quot ; speech disorder , Neuroleptic Malignant syndrome ( NMS ) , grand mal convulsion
& quot ;
& quot ; 15 .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; Median 100 75 33
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of epilepsy and chronic liver failure .
& quot ;
& quot ; EXP after opening :
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; an increase in heparin dose during haemodialysis be frequently require during the course of therapy with epoetin alfa a a result of the increase packed cell volume .
& quot ;
& quot ; 166 Danmark BRISTOL-MYERS SQUIBB Tlf : + 45 45 93 05 06
& quot ;
& quot ; it could be show with the aid of cell culture of human bone marrow cell that epoetin alfa stimulates erythropoiesis specifically and do not affect leucopoiesis .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; Vascular disorder :
& quot ;
& quot ; consequently , haemoglobin and blood pressure should be closely monitor .
& quot ;
& quot ; in this leaflet :
& quot ;
& quot ; other potent inhibitor of CYP2D6 , such a fluoxetine and paroxetine , may be expect to have similar effect and similar dose reduction should therefore be apply .
& quot ;
& quot ; Uncommon side effect ( greater than 1 in 1,000 , le than 1 in 100 patient ) some people may feel dizzy , especially when get up from a lying or sit position , or may experience a fast heart rate .
& quot ;
& quot ; España BRISTOL-MYERS SQUIBB , S. A .
& quot ;
& quot ; benefit outweighs the potential risk to the foetus .
& quot ;
& quot ; 0.5 ml ( 10000 IU / ml )
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; this regress during the course of continued therapy .
& quot ;
& quot ; mildly anaemic patient ( haematocrit of 33 - 39 % ) require predeposit of ≥ 4 unit of blood should be treat with Abseamed at a dose of 600 IU / kg body weight 2 time weekly for 3 week prior to surgery .
& quot ;
& quot ; 198
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; 5 .
& quot ;
& quot ; 24 hour at 2 ° C - 8 ° C .
& quot ;
& quot ; Pack of 1 or 6 syrinx .
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; 3 .
& quot ;
& quot ; this leaflet be last approved in
& quot ;
& quot ; instruction on use
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; Non-specific skin rash have be describe in association with epoetin alfa .
& quot ;
& quot ;
& quot ; Surgery patient in autologous predonation programme
& quot ;
& quot ; if you forget to use Abseamed
& quot ;
& quot ; lot
& quot ;
& quot ; BATCH number
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; statement OF active substance
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; in case where there be a medical need to shorten the lead time before surgery to le than three week , 300 IU / kg epoetin alfa should be give daily for 10 consecutive day prior to surgery , on the day of surgery and for four day immediately thereafter .
& quot ;
& quot ; 27 when either valproate or lithium be administer concomitantly with aripiprazole , there be no clinically significant change in aripiprazole concentration .
& quot ;
& quot ; in addition , case of stroke or & quot ; & quot ; mini & quot ; & quot ; stroke have be report .
& quot ;
& quot ; however , if the haemoglobin have increase & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , response to epoetin alfa therapy be unlikely and treatment should be discontinue .
& quot ;
& quot ; in that study the incidence of fatal thromboembolic event be higher in patient receive epoetin alfa than in those receive placebo ( see section 5.1 ) .
& quot ;
& quot ; Abseamed must not be use
& quot ;
& quot ; Orodispersible Tablet
& quot ;
& quot ; priapism
& quot ;
& quot ; 173 detailed information on this medicine be available on the European Medicines Agency ( EMEA ) web site : http : / / www . emea . europa . EU /
& quot ;
& quot ; Epoetin alfa do not show any change in bacterial and mammalian cell culture mutagenicity test and an in vivo micronucleus test in mouse .
& quot ;
& quot ; 39 an increase incidence of thrombotic vascular event ( see section 4.4 and section 4.8 - General ) have be observe in patient receive erythropoietic agent .
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; the following adverse event have be report during post-marketing surveillance .
& quot ;
& quot ; in the open-label study there be no difference in overall survival between patient treat with recombinant human erythropoietin and control .
& quot ;
& quot ; a slower injection be preferable in patient who react to the treatment with “ flu-like ” symptom .
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; the maximum daily dose should not exceed 30 mg .
& quot ;
& quot ; Batch
& quot ;
& quot ; take special care with ABILIFY before treatment with ABILIFY , tell your doctor if you suffer from High blood sugar or family history of diabetes seizure Involuntary , irregular muscle movement , especially in the face cardiovascular disease , family history of cardiovascular disease , stroke or & quot ; & quot ; mini & quot ; & quot ; stroke , abnormal blood pressure
& quot ;
& quot ; in most case , the ferritin value in the serum fall simultaneously with the rise in packed cell volume .
& quot ;
& quot ; the most frequent adverse reaction during treatment with epoetin alfa be a dose-dependent increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ; 0.6 ml ( 10000 IU / ml )
& quot ;
& quot ; 167 9 .
& quot ;
& quot ; overall survival outcome in the trial could not be statisfactorily explain by difference in the incidence of thrombosis and related complication between those give recombinant human erythropoietin and those in the control group .
& quot ;
& quot ; patient with active malignant disease receive neither chemotherapy nor radiation therapy .
& quot ;
& quot ; the haemoglobin concentration aim for be between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) , except in paediatric patient in whom the haemoglobin concentration should be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; for any information about this medicine , please contact the local representative of the marketing authorisation holder :
& quot ;
& quot ; 200 mg oral elemental iron daily ) throughout the course of treatment .
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of the symptom of anaemia .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; 5 .
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; moreover , monitoring of the blood pressure be recommend particularly at the start of therapy .
& quot ;
& quot ; do not use ABILIFY after the expiry date which be state on the blister and on the carton .
& quot ;
& quot ; Pharmacotherapeutic group : antipsychotic , ATC code :
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole , the active metabolite , decrease by 32 % and 47 % .
& quot ;
& quot ; ABILIFY be not approve for the treatment of dementia-related psychosis .
& quot ;
& quot ; however , since cyclosporin be bind by red blood cell there be potential for an interaction .
& quot ;
& quot ; Aclasta 5 mg solution for infusion
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; Hepatobiliary disorder :
& quot ;
& quot ; in view of the above , in some clinical situation blood transfusion should be the preferred treatment for the management of anaemia in patient with cancer .
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; a per the CHMP guideline on risk management system for medicinal product for human use , the updated RMP should be submit at the same time a the next Periodic Safety update Report ( PSUR ) .
& quot ;
& quot ; 2 .
& quot ;
& quot ; the syrinx contain 0.5 ml ( 1000 IU ) of solution .
& quot ;
& quot ; when consider concomitant administration of ketoconazole or other potent CYP3A4 inhibitor with ABILIFY , potential benefit should outweigh the potential risk to the patient .
& quot ;
& quot ; 6 .
& quot ;
& quot ; in another 12-week trial , the incidence of EPS be 26.6 % for patient treat with aripiprazole and 17.6 % for those treat with lithium .
& quot ;
& quot ; in that study the incidence of fatal thromboembolic event be higher in patient receive epoetin alfa than in those receive placebo ( see section 5.1 ) .
& quot ;
& quot ; programme , the use of epoetin alfa be not recommend .
& quot ;
& quot ; Portugal BRISTOL-MYERS SQUIBB FARMACÊUTICA Portuguesa , S. A .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; EXP
& quot ;
& quot ; developmental toxicity , include dose-dependent delayed foetal ossification and possible teratogenic effect , be observe in rat at dos result in subtherapeutic exposure ( base on AUC ) and in rabbit at dos result in exposure 3 and 11 time the mean steady-state AUC at the maximum recommend clinical dose .
& quot ;
& quot ; Abseamed 10 000 IU / 1 ml
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; do not take ABILIFY if you be allergic ( hypersensitive ) to aripiprazole or any of the other ingredient of ABILIFY .
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) , the dose should be reduce by approximately 25 to 50 % .
& quot ;
& quot ; for any information about this medicine , please contact the local representative of the marketing authorisation holder :
& quot ;
& quot ; Sexually active men and woman should use effective method of contraception during treatment and up to six month after treatment for men , and one month after treatment for woman ( see section 4.6 ) .
& quot ;
& quot ; 131 150 IU / kg 3x / week or 450 IU / kg once weekly
& quot ;
& quot ; this represent a 35 % reduction in the risk of fracture in patient receive Aclasta .
& quot ;
& quot ; however , a with other antipsychotic , patient should be caution about operate hazardous machine , include motor vehicle , until they be reasonably certain that aripiprazole do not affect them adversely .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; the medicine can only be obtain with a prescription .
& quot ;
& quot ; Dosage
& quot ;
& quot ; actual score in rating scale use a secondary endpoint , include PANSS and the Montgomery-Asberg Depression rating scale show a significant improvement over haloperidol .
& quot ;
& quot ; no other erythropoietic therapy should be commence because of the risk of cross-reaction .
& quot ;
& quot ; 57 1 .
& quot ;
& quot ; do not push the tablet through the foil because this could damage the tablet .
& quot ;
& quot ; Mannitol , sodium citrate and water for injection .
& quot ;
& quot ;
& quot ; you should check with your doctor or pharmacist if you be not sure .
& quot ;
& quot ; name OF the marketing authorisation holder
& quot ;
& quot ; if an elevate ( or rise ) serum potassium level be detect then consideration should be give to cease epoetin alfa administration until hyperkalaemia have be correct .
& quot ;
& quot ; - increase of blood pressure .
& quot ;
& quot ; 49 X 1
& quot ;
& quot ; how often will you receive Abraxane ?
& quot ;
& quot ; 15 .
& quot ;
& quot ; B03XA01
& quot ;
& quot ; in both study , the patient be allow to take other medicine for osteoporosis , but not other bisphosphonates .
& quot ;
& quot ; in that study the incidence of fatal thromboembolic event be higher in patient receive epoetin alfa than in those receive placebo ( see section 5.1 ) .
& quot ;
& quot ; Alopecia , rash
& quot ;
& quot ; no evidence exist that indicate that treatment with epoetin alfa alter the metabolism of other medicinal product .
& quot ;
& quot ; 10 .
& quot ;
& quot ; jaundice , hepatitis , increase Alanine Aminotransferase ( ALT ) , increased Aspartate Aminotransferase ( AST ) , increase Gamma Glutamyl Transferase ( GGT ) , increase alkaline phosphatase
& quot ;
& quot ; adult surgery patient in an autologous predonation programme :
& quot ;
& quot ; further information on clinical trial :
& quot ;
& quot ; rash , photosensitivity reaction , alopecia , hyperhidrosis
& quot ;
& quot ; - In chronic renal failure patient , epoetin alfa should be use in pregnancy only if the potential
& quot ;
& quot ; base on in vitro study , CYP3A4 and CYP2D6 enzyme be responsible for dehydrogenation and hydroxylation of aripiprazole , and N-dealkylation be catalyse by CYP3A4 .
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; Aluminium perforate unit dose blister in carton of 14 X 1 , 28 X 1 , 49 X 1 , 56 X 1 , 98 X 1 tablet .
& quot ;
& quot ; Lactose : patient with rare hereditary problem of galactose intolerance , the lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product .
& quot ;
& quot ; for intramuscular use .
& quot ;
& quot ; 12 .
& quot ;
& quot ; the pharmacokinetic characteristic of aripiprazole and dehydro-aripiprazole be find to be similar in patient with severe renal disease compare to young healthy subject .
& quot ;
& quot ; patient with hepatic impairment No dose adjustment be require ( see section 5.2 ) .
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; Phlebotomy may be perform if excessively high haemoglobin level occur .
& quot ;
& quot ; functional assessment of Cancer Therapy- Anaemia ( FACT-An ) general scale , FACT-An fatigue scale , and Cancer linear Analogue scale ( CLAS ) .
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; 160 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ;
& quot ; in haemodialysed patient , a bolus injection may be give during the dialysis session through a suitable venous port in the dialysis line .
& quot ;
& quot ; 67 an increase incidence of thrombotic vascular event ( see section 4.4 and section 4.8 - General ) have be observe in patient receive erythropoietic agent .
& quot ;
& quot ; EU / 1 / 04 / 276 / 036
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy male and female subject nor be there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; ABILIFY 5 mg tablet
& quot ;
& quot ; 124 721 cancer patient receive non-platinum chemotherapy be include in three placebo-controlled study , 389 patient with haematological malignancy ( 221 multiple myeloma , 144 non-Hodgkin & apos ; s lymphoma , and 24 other haematological malignancy ) and 332 with solid tumour ( 172 breast , 64 gynaecological , 23 lung , 22 prostate , 21 gastro-intestinal , and 30 other tumour type ) .
& quot ;
& quot ; always take the tablet with water and swallow it whole .
& quot ;
& quot ; Abseamed
& quot ;
& quot ; no evidence exist that indicate that treatment with epoetin alfa alter the metabolism of other medicinal product .
& quot ;
& quot ; if foaming or clumping occurs , the solution must stand for at least 15 minute until foam subsides .
& quot ;
& quot ; also contain : lactose monohydrate .
& quot ;
& quot ; Extrapyramidal symptom ( EPS ) :
& quot ;
& quot ; 100 Posology
& quot ;
& quot ; España BRISTOL-MYERS SQUIBB , S. A .
& quot ;
& quot ; radiation therapy when administer to target a haemoglobin of greater than 14 g / dl ( 8.7 mmol / l ) ,
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; John & apos ; s Wort ) may be expect to have similar effect and similar dose increase should therefore be apply .
& quot ;
& quot ; Tablet Rectangular and blue , engrave with & quot ; & quot ; A-007 & quot ; & quot ; and & quot ; & quot ; 5 & quot ; & quot ; on one side .
& quot ;
& quot ; 6 month .
& quot ;
& quot ; all special warning and precaution associate with autologous predonation programme , especially routine volume replacement , should be respect .
& quot ;
& quot ; 14 X 1
& quot ;
& quot ; in clinical trial and post-marketing experience , accidental or intentional acute overdosage of aripiprazole alone be identify in adult patient with report estimate dose up to 1,260 mg with no fatality .
& quot ;
& quot ; or Hb increase ≥ 1 g / d
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; adult and paediatric haemodialysis patient , adult peritoneal dialysis patient and adult patient with renal insufficiency not yet undergoing dialysis
& quot ;
& quot ; 11 .
& quot ;
& quot ; Intravenous route
& quot ;
& quot ; 16 .
& quot ;
& quot ; Immunogenicity data for subcutaneous use of Abseamed in patient at risk for antibody-induced PRCA , I. e. patient with renal anaemia , be not sufficient .
& quot ;
& quot ; the recommended initial dose for aripiprazole solution for injection be 9.75 mg ( 1.3 ml ) , administer a a single intramuscular injection .
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; Renal and urinary disorder :
& quot ;
& quot ; in cancer patient receive chemotherapy , the 2 - 3 week delay between epoetin alfa administration and the appearance of erythropoietin-induced red cell should be take into account when assess if epoetin alfa therapy be appropriate ( patient at risk of be transfuse ) .
& quot ;
& quot ; Abraxane may cause side effect such a tiredness ( very common ) and dizziness ( common ) that may affect the ability to drive and use machinery .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; Abilify
& quot ;
& quot ; if you forget to take ABILIFY if you miss a dose , take the missed dose a soon a you remember but do not take two dos in one day .
& quot ;
& quot ; ESAs be not indicate for use in this patient population .
& quot ;
& quot ; the maximum daily dose should not exceed 30 mg .
& quot ;
& quot ; - treatment of severe anaemia of renal origin accompany by clinical symptom in adult patient
& quot ;
& quot ; therefore cardiovascular monitoring should be start immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmia .
& quot ;
& quot ;
& quot ; ( 44-20 ) 74 18 84 00 fax ( 44-20 ) 74 18 84 16 e-mail : mail @ emea . europa . EU http : / / www . emea . europa . EU
& quot ;
& quot ; Abseamed must not be use
& quot ;
& quot ; 163 tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever , sweat , alter mental status , or very rapid or irregular heart beat .
& quot ;
& quot ; after administration of epoetin alfa , the number of erythrocyte , the Hb value and reticulocyte count increase a well a the 59Fe-incorporation rate .
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; Aclasta be contraindicate for patient with hypocalcaemia ( see section 4.4 ) .
& quot ;
& quot ; - if the seal be break .
& quot ;
& quot ; follow any confirm or suspect overdose with aripiprazole , close medical supervision and monitoring should continue until the patient recovers .
& quot ;
& quot ; 50 ( 0.62 mmol / l ) per month and should not exceed 2 g / dl ( 1.25 mmol / l ) per month to minimise risk of an increase in hypertension .
& quot ;
& quot ; other disturbance of mineral metabolism must also be effectively treat ( e. g. diminish parathyroid reserve , intestinal calcium malabsorption ) .
& quot ;
& quot ;
& quot ; a systematic review have also be perform involve more than 9000 cancer patient participate in 57 clinical trial .
& quot ;
& quot ; 2 .
& quot ;
& quot ; in view of the above , in some clinical situation blood transfusion should be the preferred treatment for the management of anaemia in patient with cancer .
& quot ;
& quot ; Haemoglobin variability should be address through dose management with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl and Hb increase & lt ; 1 g / dl
& quot ;
& quot ; result for overall response rate , median time to disease progression , and progression-free survival a assess by the investigator
& quot ;
& quot ; in clinical study , 10-30 mg / day dos of aripiprazole have no significant effect on the metabolism of substrate of CYP2D6 ( dextromethorphan / 3-methoxymorphinan ratio ) , 2C9 ( warfarin ) , 2C19 ( omeprazole ) , and 3A4 ( dextromethorphan ) .
& quot ;
& quot ; use Abraxane with food and drink Abraxane be unaffected by food and drink .
& quot ;
& quot ; in paediatric patient the recommended target haemoglobin range be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; the effectiveness of Abilify solution for injection be compare with that of lorazepam ( another antipsychotic medicine ) and of placebo over a period of two hour in one study involve 301 patient with bipolar disorder who be experience symptom of agitation .
& quot ;
& quot ; 4 .
& quot ;
& quot ; 7 .
& quot ;
& quot ; interaction with receptor other than dopamine and serotonin subtypes may explain some of the other clinical effect of aripiprazole .
& quot ;
& quot ; survival and tumour progression have be examine in five large control study involve a total of 2833 patient , of which four be double-blind placebo-controlled study and one be an open- label study .
& quot ;
& quot ; - if the seal be break .
& quot ;
& quot ; start dose of 50 IU / kg 2 time per week by the intravenous route .
& quot ;
& quot ; Elevations of CPK ( Creatine Phosphokinase ) , generally transient and asymptomatic , be observe in 3.5 % of aripiprazole treated patient a compare to 2.0 % of patient who receive placebo .
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP2D6 ( quinidine ) increase aripiprazole AUC by 107 % , while Cmax be unchanged .
& quot ;
& quot ; you may need to read it again .
& quot ;
& quot ; child and adolescent : there be no experience in child and adolescent under 18 year of age .
& quot ;
& quot ; - treatment of anaemia associate with chronic renal failure in paediatric and adult patient on
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; Tel . : + 36 1 301 9700
& quot ;
& quot ; weight gain : weight gain be commonly see in schizophrenic and bipolar mania patient due to co- morbidity , use of antipsychotic know to cause weight gain , poorly manage life-style , and might lead to severe complication .
& quot ;
& quot ; the MAH must ensure that the system of pharmacovigilance , a describe in version 3.0 present in Module 1.8.1. of the marketing authorisation application , be in place and functioning before and whilst the product be on the market .
& quot ;
& quot ; Removal of the intact orodispersible tablet from the mouth be difficult .
& quot ;
& quot ; Mannitol , sodium citrate and water for injection .
& quot ;
& quot ; around half of the patient in the study have already receive treatment for their cancer after it have become metastatic .
& quot ;
& quot ; in comparison , those continue to take Eprex / Erypo have an increase of 0.063 g / dl from a start value of 12.0 g / dl .
& quot ;
& quot ; 185
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; EXP
& quot ;
& quot ; in case of larger volume , more than one site should be choose for the injection .
& quot ;
& quot ; in a 26-week , placebo-controlled trial in stabilised patient with chronic schizophrenia , aripiprazole have significantly greater reduction in relapse rate , 34 % in aripiprazole group and 57 % in placebo .
& quot ;
& quot ; survival and tumour progression have be examine in five large control study involve a total of 2833 patient , of which four be double-blind placebo-controlled study and one be an open- label study .
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be avoid .
& quot ;
& quot ; haemodialysis and adult patient on peritoneal dialysis ( see section 4.4 ) .
& quot ;
& quot ; when see , it be usually in those with significant risk factor such a history of diabetes , thyroid disorder or pituitary adenoma .
& quot ;
& quot ; Haemoglobin variability should be address through dose management with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the sustained haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) reduce the epoetin alfa dose by 25 % .
& quot ;
& quot ; Abilify
& quot ;
& quot ; 6 .
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; for 4 week
& quot ;
& quot ; oropharyngeal spasm , laryngospasm , aspiration pneumonia
& quot ;
& quot ; PRCA mean the inability to produce enough red blood cell in the bone marrow .
& quot ;
& quot ; the bioavailability of subcutaneous injectable epoetin alfa be much lower than that of the intravenous medicinal product : approximately 20 % .
& quot ;
& quot ; the generation of foam must be avoid .
& quot ;
& quot ; 0.99 , 1,18 ; 42 trial and 8167 patient ) .
& quot ;
& quot ; 34 1 .
& quot ;
& quot ; Subcutaneous injection : a maximum volume of 1 ml at one injection site should generally not be exceed .
& quot ;
& quot ; some people may feel depressed .
& quot ;
& quot ; potential for ABILIFY to affect other medicinal product :
& quot ;
& quot ; treatment of symptomatic anaemia associate with chronic renal failure ( CRF ) in adult and paediatric patient :
& quot ;
& quot ; 0.8 ml ( 10000 IU / ml )
& quot ;
& quot ; ABILIFY be effective in maintain the clinical improvement during continuation therapy in patient who have show an initial treatment response .
& quot ;
& quot ; Bone marrow suppression ( primarily neutropenia ) occur frequently with Abraxane .
& quot ;
& quot ; early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid , for example , be recommend in these patient .
& quot ;
& quot ; special storage condition
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; Bristol-Myers Squibb Srl Contrada Fontana Del Ceraso I-03012 Anagni-Frosinone Italy
& quot ;
& quot ; 4 .
& quot ;
& quot ; 1 .
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl or Hb increase ≥ 1 g / dl
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; these symptom can temporally deteriorate or can even arise after discontinuation of treatment .
& quot ;
& quot ; 33 150 IU / kg 3x / week or 450 IU / kg once weekly
& quot ;
& quot ; special storage condition
& quot ;
& quot ; 5 .
& quot ;
& quot ; Latvija BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; lot
& quot ;
& quot ; 7 .
& quot ;
& quot ; 5 .
& quot ;
& quot ; Medicines should not be dispose of via wastewater or household waste .
& quot ;
& quot ; 0.99 , 1,18 ; 42 trial and 8167 patient ) .
& quot ;
& quot ; in placebo-controlled trial , the incidence of akathisia in bipolar patient be 12.1 % with aripiprazole and 3.2 % with placebo .
& quot ;
& quot ; relative risk reduction in
& quot ;
& quot ; the dose you receive be base on your body weight in kilogram .
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of at least four week .
& quot ;
& quot ; 68 date of first authorisation :
& quot ;
& quot ; further information
& quot ;
& quot ; information for the user
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; Aclasta be give a a 100 ml infusion , last at least 15 minute .
& quot ;
& quot ; 6 .
& quot ;
& quot ; oral use .
& quot ;
& quot ; solution for injection in a pre-filled syringe .
& quot ;
& quot ; 9 .
& quot ;
& quot ; - shorten overall survival and increase death attribute to disease progression at 4 month in
& quot ;
& quot ; reduction in incidence % ( CI )
& quot ;
& quot ; other
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; when see , it be usually in those with significant risk factor such a history of diabetes , thyroid disorder or pituitary adenoma .
& quot ;
& quot ; Thrombocytosis have be observe but it occurrence be very rare ( see section 4.4 ) .
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; treatment of adult patient schedule for major elective orthopaedic surgery :
& quot ;
& quot ; Conduction abnormality :
& quot ;
& quot ; Tel : + 34 91 456 53 00
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of 25 IU / kg 3 time per week at interval of at least 4 week until the desired goal be achieve .
& quot ;
& quot ; recurrence prevention of manic episode in Bipolar I Disorder :
& quot ;
& quot ; 4 .
& quot ;
& quot ; package size
& quot ;
& quot ; at each step , the increase or reduction in dose should be of 25 IU / kg 3 time per week .
& quot ;
& quot ; Nederland BRISTOL-MYERS SQUIBB BV Tel : + 31 34 857 42 22
& quot ;
& quot ; Slovenija BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; it may be necessary to add or increase antihypertensive treatment .
& quot ;
& quot ; Z O. O .
& quot ;
& quot ; the orodispersible tablet should be place in the mouth on the tongue , where it will rapidly disperse in saliva .
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; Adults receive haemodialysis
& quot ;
& quot ; all of these additive factor of anaemia should also be carefully consider when decide to increase the dose of epoetin alfa in cancer patient .
& quot ;
& quot ; 7 .
& quot ;
& quot ; Tumour growth potential
& quot ;
& quot ; contains fructose , sucrose , E218 , and E216 .
& quot ;
& quot ; 2 .
& quot ;
& quot ; it be use to treat adult who suffer from a disease characterise by symptom such a hearing , see or sense thing which be not there , suspiciousness , mistaken belief , incoherent speech and behaviour and emotional flatness .
& quot ;
& quot ; 8 .
& quot ;
& quot ; s R. O .
& quot ;
& quot ; ABILIFY dose should be reduce to approximately one-half of it prescribed dose when concomitant administration of ABILIFY with quinidine occurs .
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; in a prospective , randomised , double-blind , placebo-controlled trial conduct in 375 anaemic patient with various non-myeloid malignancy receive non-platinum chemotherapy , there be a significant reduction of anaemia-related sequela ( e. g. fatigue , decrease energy , and activity reduction ) , a measure by the following instrument and scale :
& quot ;
& quot ; Tel : + 39 06 50 39 61
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; other finding :
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of 25 IU / kg 3 time per week at interval of at least 4 week until the desired goal be achieve .
& quot ;
& quot ; Aripiprazole be well absorb , with peak plasma concentration occur within 3-5 hour after dose .
& quot ;
& quot ; patient with severe hepatic impairment ( bilirubin & gt ; 5 X ULN or ASL / ALT & gt ; 10 X ULN ) should not be treat with Abraxane .
& quot ;
& quot ; Lactose monohydrate Maize starch Microcrystalline cellulose Hydroxypropyl cellulose Magnesium stearate
& quot ;
& quot ; 98 X 1
& quot ;
& quot ; Abilify
& quot ;
& quot ; when perform haematologic assessment during the preoperative period , if the haemoglobin level reach 15 g / dl , or higher , administration of epoetin alfa should be stop and further dos should not be give .
& quot ;
& quot ; read all of this leaflet carefully before you start take this medicine .
& quot ;
& quot ; weight gain have be report post-marketing among patient prescribe ABILIFY .
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; ABILIFY may increase the effect of medicine use to lower the blood pressure .
& quot ;
& quot ; expiry date
& quot ;
& quot ; 16 .
& quot ;
& quot ; treatment of symptomatic anaemia in adult and paediatric chronic renal failure patient :
& quot ;
& quot ; jaundice , hepatitis , increase Alanine Aminotransferase ( ALT ) , increased Aspartate Aminotransferase ( AST ) , increase Gamma Glutamyl Transferase ( GGT ) , increase alkaline phosphatase
& quot ;
& quot ; haemodialysis and adult patient on peritoneal dialysis ( see section 4.4 ) .
& quot ;
& quot ; 103 150 IU / kg 3x / week or 450 IU / kg once weekly
& quot ;
& quot ; iron supplementation should be start a soon a possible , even several week prior to initiate the autologous predeposit , in order to achieve high iron store prior to start Abseamed therapy .
& quot ;
& quot ; 178 Danmark BRISTOL-MYERS SQUIBB Tlf : + 45 45 93 05 06
& quot ;
& quot ; always take ABILIFY exactly a your doctor have tell you .
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; detail information on this medicine be available on the European Medicines Agency ( EMEA ) web site : http : / / www . emea . europa . EU /
& quot ;
& quot ; increase Creatine Phosphokinase , blood glucose increase , blood glucose fluctuation , glycosylated haemoglobin increase
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; Abseamed can be use to increase the yield of autologous blood from patient in a predonation programme .
& quot ;
& quot ;
& quot ; at steady state , dehydro-aripiprazole , the active metabolite , represent about 40 % of aripiprazole AUC in plasma .
& quot ;
& quot ; nervous system disorder :
& quot ;
& quot ; - iron supplementation , e. g .
& quot ;
& quot ; it use in this indication must be balance against the report risk of thromboembolic event .
& quot ;
& quot ; s R. O .
& quot ;
& quot ; 1 .
& quot ;
& quot ; the peak be always well below the peak achieve use the intravenous route ( approximately 1 / 20th of the value ) .
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; in the indication “ increase the yield of autologous blood ” : myocardial infarction or stroke in the month precede treatment , unstable angina pectoris , increase risk of deep venous thrombosis such a history of venous thromboembolic disease .
& quot ;
& quot ; Österreich BRISTOL-MYERS SQUIBB GESMBH Tel : + 43 1 60 14 30
& quot ;
& quot ; Abseamed contain a hormone call epoetin alfa , which stimulate the production of red blood cell .
& quot ;
& quot ; Vial 50ml ( type 1 glass ) with a stopper ( butyl rubber ) , with an overseal ( aluminium ) .
& quot ;
& quot ; general
& quot ;
& quot ; in chronic renal failure patient Abseamed have not to be administer subcutaneously !
& quot ;
& quot ; 112 for the purpose of ambulatory use , the patient may remove Abseamed from the refrigerator and store it not above 25 ° C for one single period of up to 3 day .
& quot ;
& quot ; Danmark BRISTOL-MYERS SQUIBB Tlf : + 45 45 93 05 06
& quot ;
& quot ; population pharmacokinetic evaluation have reveal no evidence of clinically significant race-related difference or effect from smoke upon the pharmacokinetics of aripiprazole .
& quot ;
& quot ; Metabolism and nutrition disorder :
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the sustained haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) reduce the epoetin alfa dose by 25 % .
& quot ;
& quot ; treatment of adult patient schedule for major elective orthopaedic surgery :
& quot ;
& quot ; 4 .
& quot ;
& quot ; - if you be donate your own blood before surgery , and :
& quot ;
& quot ; the frequency list below be define use the following convention : common ( & gt ; 1 / 100 , & lt ; 1 / 10 ) and uncommon ( & gt ; 1 / 1 , 000 , & lt ; 1 / 100 ) .
& quot ;
& quot ; the maximum daily dose should not exceed 30 mg .
& quot ;
& quot ; in clinical trial , an increase risk of death and serious cardiovascular event be observe when erythropoiesis stimulate agent ( ESAs ) be administer to target a haemoglobin of greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; general
& quot ;
& quot ; Tel : + 40 ( 0 ) 21 272 16 00
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; a slower injection be preferable in patient who react to the treatment with “ flu-like ” symptom .
& quot ;
& quot ; all woman receive 1,000 to 1,500 mg elemental calcium and 400 to 1,200 IU of vitamin D supplement daily .
& quot ;
& quot ; Epoetin alfa do not show any change in bacterial and mammalian cell culture mutagenicity test and an in vivo micronucleus test in mouse .
& quot ;
& quot ; radiation recall phenomenon
& quot ;
& quot ; elderly : the effectiveness of ABILIFY in the treatment of schizophrenia and Bipolar I Disorder in patient 65 year of age or older have not be establish .
& quot ;
& quot ; 1.35 , 2.06 , 35 trial and 6769 patient ) be observe in patient treat with recombinant human erythropoietin .
& quot ;
& quot ; 1 .
& quot ;
& quot ; recurrence prevention of manic episode in Bipolar I Disorder :
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; when the CYP3A4 inducer be withdraw from the combination therapy , the aripiprazole dose should then be reduce to the recommend dose ( see section 4.5 ) .
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; Abseamed
& quot ;
& quot ; this medicine have be prescribe for you .
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; Asthenia / fatigue be report in 40 % of the patient .
& quot ;
& quot ; in the four placebo-controlled study the hazard ratio for overall survival range between 1.25 and 2.47 in favour of control .
& quot ;
& quot ; 172 Danmark BRISTOL-MYERS SQUIBB Tlf : + 45 45 93 05 06
& quot ;
& quot ;
& quot ; the unopened bottle do not require any special storage condition .
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; they be supply in perforated unit dose blister pack in carton contain 14 , 28 , or 49 orodispersible tablet .
& quot ;
& quot ; powder for suspension for infusion
& quot ;
& quot ; the use of epoetin alfa in patient schedule for major elective orthopaedic surgery and not participate in an autologous blood predonation programme be contraindicate in patient with severe coronary , peripheral arterial , carotid or cerebral vascular disease , include patient with recent myocardial infarction or cerebral vascular accident .
& quot ;
& quot ; EU / 1 / 04 / 276 / 006 14 X 1 tablet EU / 1 / 04 / 276 / 007 28 X 1 tablet EU / 1 / 04 / 276 / 008 49 X 1 tablet EU / 1 / 04 / 276 / 009 56 X 1 tablet EU / 1 / 04 / 276 / 010 98 X 1 tablet
& quot ;
& quot ; ABILIFY may increase the effect of medicine use to lower the blood pressure .
& quot ;
& quot ; Overdose of epoetin alfa may produce effect that be extension of the pharmacological effect of the hormone .
& quot ;
& quot ; kg Tlf : + 49- ( 0 ) 2371 937 0
& quot ;
& quot ; seizure : in clinical trial , uncommon case of seizure be report during treatment with aripiprazole .
& quot ;
& quot ; start dose of 50 IU / kg 2 time per week by the intravenous route .
& quot ;
& quot ; the recommended total weekly dose be between 75 and 300 IU / kg give by the intravenous route .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; 10 .
& quot ;
& quot ; 3 .
& quot ;
& quot ; 8 .
& quot ;
& quot ; KGAA Tel : + 49 89 121 42-0
& quot ;
& quot ; the appropriate dose regimen in patient with le severe hepatic impairment be unknown .
& quot ;
& quot ; 1 pre-filled syringe of 1 ml 6 pre-filled syrinx of 1 ml
& quot ;
& quot ; statement OF active substance
& quot ;
& quot ; further information on clinical trial :
& quot ;
& quot ; Non-specific skin rash have be describe in association with epoetin alfa .
& quot ;
& quot ; it be use to treat adult who suffer from a disease characterise by symptom such a hearing , see or sense thing which be not there , suspiciousness , mistaken belief , incoherent speech and behaviour and emotional flatness .
& quot ;
& quot ; the following maintenance dos be observe in clinical trial after 6 month of treatment :
& quot ;
& quot ; precise risk estimate for hyperglycaemia-related adverse event in patient treat with ABILIFY and with other atypical antipsychotic agent be not available to allow direct comparison .
& quot ;
& quot ; if blood pressure can not be control , Abseamed treatment should be discontinue .
& quot ;
& quot ; Intravenous use .
& quot ;
& quot ; after reconstitution , each ml of suspension contains 5 mg of paclitaxel .
& quot ;
& quot ; 2 year
& quot ;
& quot ; Hb between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; in case where there be a medical need to shorten the lead time before surgery to le than three week , 300 IU / kg epoetin alfa should be give daily for 10 consecutive day prior to surgery , on the day of surgery and for four day immediately thereafter .
& quot ;
& quot ;
& quot ; 10 .
& quot ;
& quot ; EXP
& quot ;
& quot ; s R. O .
& quot ;
& quot ; 200 mg fructose per ml 400 mg sucrose per ml 1.8 mg methyl parahydroxybenzoate ( E218 ) per ml 0.2 mg propyl parahydroxybenzoate ( E216 ) per ml
& quot ;
& quot ; there be conflict report in the literature regard whether erythropoietin may play a major role a tumour proliferators .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; the half-life be difficult to evaluate for the subcutaneous route and be estimate about 24 hour .
& quot ;
& quot ; treatment with Abseamed have to be initiate under the supervision of physician experience in the management of patient with the above indication .
& quot ;
& quot ; 3 .
& quot ;
& quot ; two other smaller , randomise , placebo-controlled trial fail to show a significant improvement in quality of life parameter on the EORTC-QLQ-C30 scale or CLAS , respectively .
& quot ;
& quot ; LABELLING
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; Paediatric haemodialysis patient :
& quot ;
& quot ; some patient may benefit from a higher dose .
& quot ;
& quot ; for subcutaneous and intravenous use .
& quot ;
& quot ; factor that should be consider in this assessment should include the type of tumour and it stage ; the degree of anaemia ; life-expectancy ; the environment in which the patient be be treat ; and patient preference ( see section 5.1 ) .
& quot ;
& quot ; Danmark Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; Abraxane should not be use in patient who have severe problem with their liver .
& quot ;
& quot ; follow concomitant administration of carbamazepine , a potent inducer of CYP3A4 , the geometric mean of Cmax and AUC for aripiprazole be 68 % and 73 % lower , respectively , compare to when aripiprazole ( 30 mg ) be administer alone .
& quot ;
& quot ; elimination :
& quot ;
& quot ; Schizophrenia :
& quot ;
& quot ; Administer the amount require .
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; in patient with chronic renal failure the medicinal product have to be administer intravenously ( see section 4.4 ) .
& quot ;
& quot ; particular attention should be pay to sudden stab migraine- like headache a a possible warning signal .
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; EU / 1 / 07 / 412 / 014
& quot ;
& quot ; Hyperkalaemia have be observe in isolated case .
& quot ;
& quot ; independent of erythropoietin treatment , thrombotic and vascular event may occur in surgical patient with underlying cardiovascular disease follow repeat phlebotomy .
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; Aclasta be administer once a year , until at least 211 patient in the study population have confirm clinical fracture .
& quot ;
& quot ; Correction for anaemia may lead to increase appetite , and potassium and protein intake .
& quot ;
& quot ; Tel : + 386 1 236 47 00
& quot ;
& quot ; ask your pharmacist how to dispose of medicine no longer require .
& quot ;
& quot ; Abseamed
& quot ;
& quot ; 5 .
& quot ;
& quot ; in particular , no residue of the cell line use for the production be detectable at the concentration of the active ingredient that be use in human .
& quot ;
& quot ; special storage condition
& quot ;
& quot ; long-term carcinogenicity study have not be carry out .
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; EU / 1 / 07 / 412 / 015 EU / 1 / 07 / 412 / 016
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; it be use in patient with normal blood iron level who could experience complication if they be to receive a blood transfusion , if they do not have the opportunity to donate their own blood before surgery and be expect to lose 900 to 1,800 ml of blood .
& quot ;
& quot ; when concomitant administration of potent CYP3A4 inducer with aripiprazole occurs , the aripiprazole dose should be increase .
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; a vial provide 9.75 mg in 1.3 ml
& quot ;
& quot ; in elderly patient with dementia , more fatal case have be report while take aripiprazole .
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole , the active metabolite , decrease by 32 % and 47 % .
& quot ;
& quot ; 14 X 1 tablet 28 X 1 tablet 49 X 1 tablet 56 X 1 tablet 98 X 1 tablet
& quot ;
& quot ; all other cause of anaemia ( iron deficiency , haemolysis , blood loss , vitamin B12 or folate deficiency ) should be consider and treat prior to initiate therapy with epoetin alfa .
& quot ;
& quot ; Correction for anaemia may lead to increase appetite , and potassium and protein intake .
& quot ;
& quot ; 78 ( 0.62 mmol / l ) per month and should not exceed 2 g / dl ( 1.25 mmol / l ) per month to minimise risk of an increase in hypertension .
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; enhance efficacy at dose higher than a daily dose of 15 mg have not be demonstrate although individual patient may benefit from a higher dose .
& quot ;
& quot ; 2 .
& quot ;
& quot ; 97 upon discontinuation of the CYP2D6 or 3A4 inhibitor , the dosage of ABILIFY should be increase to the level prior to the initiation of the concomitant therapy .
& quot ;
& quot ; Phenylketonurics :
& quot ;
& quot ; base on the publish literature , in vitro study with human liver microsome and tissue slice show that paclitaxel be metabolise primarily to 6α -hydroxypaclitaxel ; and to two minor metabolite , 3 ’ -p-hydroxypaclitaxel and 6α -3 ’ -p-dihydroxypaclitaxel .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; the incidence of bone marrow fibrosis be not increase in a study of haemodialysis patient who be treat with epoetin alfa for 3 year compare to a match control group of dialysis patient who have not be treat with epoetin alfa . ) .
& quot ;
& quot ; 4 .
& quot ;
& quot ; in a relative bioavailability study compare the pharmacokinetics of 30 mg aripiprazole a the oral solution to 30 mg aripiprazole tablet in healthy subject , the solution to the tablet ratio of geometric mean Cmax value be 122 % ( N = 30 ) .
& quot ;
& quot ; 5 .
& quot ;
& quot ; take special care with ABILIFY before treatment with ABILIFY , tell your doctor if you suffer from High blood sugar or family history of diabetes seizure Involuntary , irregular muscle movement , especially in the face cardiovascular disease , family history of cardiovascular disease , stroke or & quot ; & quot ; mini & quot ; & quot ; stroke , abnormal blood pressure
& quot ;
& quot ; • educational leaflet • summary of product characteristic ( SPC ) and package Leaflet and Labelling • cool box for patient clearly label with a visual aid indicate correct use of product .
& quot ;
& quot ; cardiovascular disorder :
& quot ;
& quot ; between 1 and 10 patient in 100 receive injection of Abilify experience somnolence , dizziness , headache , akathisia , nausea and vomiting .
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP3A4 ( ketoconazole ) increase aripiprazole AUC and Cmax by 63 % and 37 % , respectively .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery the cause of anaemia should be establish and treat , if possible , before the start of epoetin alfa treatment .
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; programme , the use of epoetin alfa be not recommend .
& quot ;
& quot ; L01CD01
& quot ;
& quot ; 3 .
& quot ;
& quot ; treatment of adult patient schedule for major elective orthopaedic surgery :
& quot ;
& quot ; Manic episode :
& quot ;
& quot ; Abseamed 4000 IU / 0.4 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; these symptom can temporally deteriorate or can even arise after discontinuation of treatment .
& quot ;
& quot ; expiry date
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; elderly : the effectiveness of ABILIFY in the treatment of schizophrenia and Bipolar I Disorder in patient 65 year of age or older have not be establish .
& quot ;
& quot ; these measure will help to protect the environment .
& quot ;
& quot ; Abilify
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; Batch
& quot ;
& quot ; BLISTER
& quot ;
& quot ; woman who be evaluate for the incidence of vertebral fracture do not receive concomitant osteoporosis therapy , which be allow for woman contribute to the hip and all clinical fracture evaluation .
& quot ;
& quot ; United Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel : + 44 ( 0800 ) 731 1736
& quot ;
& quot ; Intravenous route
& quot ;
& quot ; 1 pre-filled syringe of 1 ml contains 2000 international unit ( IU ) correspond to 16.8 microgram epoetin alfa
& quot ;
& quot ; oral use .
& quot ;
& quot ; Tel : + 421 2 59298411
& quot ;
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; in these patient dose should be manage cautiously .
& quot ;
& quot ; ( 44-20 ) 74 18 84 00 fax ( 44-20 ) 74 18 84 16 e-mail : mail @ emea . europa . EU http : / / www . emea . europa . EU © EMEA 2007 reproduction and / or distribution of this document be authorise for non commercial purpose only provide the EMEA be acknowledge body , and therefore it benefit and risk , in comparison with conventional medicine contain paclitaxel .
& quot ;
& quot ; in clinical trial , rare case of NMS be report during treatment with aripiprazole .
& quot ;
& quot ; however , if the haemoglobin have increase & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , response to epoetin alfa therapy be unlikely and treatment should be discontinue .
& quot ;
& quot ; 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; Novartis Europharm limit Wimblehurst Road Horsham West Sussex , RH12 5AB United Kingdom
& quot ;
& quot ; and Hb increase & lt ; 1 g / dl
& quot ;
& quot ; B03XA01
& quot ;
& quot ; Tel : + 371 67 50 21 85
& quot ;
& quot ; Abseamed
& quot ;
& quot ; adult patient with renal insufficiency not yet undergoing dialysis :
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; in patient with severe hepatic impairment , the data available be insufficient to establish recommendation .
& quot ;
& quot ; Correction for anaemia may lead to increase appetite , and potassium and protein intake .
& quot ;
& quot ; 28 for the purpose of ambulatory use , the patient may remove Abseamed from the refrigerator and store it not above 25 ° C for one single period of up to 3 day .
& quot ;
& quot ; immune system disorder :
& quot ;
& quot ; the biological efficacy of epoetin alfa have be demonstrate in various animal model in vivo ( normal and anaemic rat , polycythaemic mouse ) .
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; EU / 1 / 04 / 276 / 034
& quot ;
& quot ; Aripiprazole be excrete in the milk of treated rat during lactation .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; gender :
& quot ;
& quot ; it explain how the Committee for Medicinal product for Human use ( CHMP ) assess the study perform , to reach their recommendation on how to use the medicine .
& quot ;
& quot ; it could be show with the aid of cell culture of human bone marrow cell that epoetin alfa stimulates erythropoiesis specifically and do not affect leucopoiesis .
& quot ;
& quot ; common side effect ( greater than 1 in 100 , le than 1 in 10 patient ) of ABILIFY solution for injection include sleepiness , dizziness , headache , restlessness , nausea and vomiting .
& quot ;
& quot ; 14 .
& quot ;
& quot ; in animal study , epoetin alfa have be show to decrease foetal body weight , delay ossification and increase foetal mortality when give in weekly dos of approximately 20 time the recommended human weekly dose .
& quot ;
& quot ;
& quot ; Suicidal thought and behaviour have be report during aripiprazole treatment .
& quot ;
& quot ; take special care with ABILIFY before treatment with ABILIFY , tell your doctor if you suffer from High blood sugar or family history of diabetes seizure Involuntary , irregular muscle movement , especially in the face cardiovascular disease , family history of cardiovascular disease , stroke or & quot ; & quot ; mini & quot ; & quot ; stroke , abnormal blood pressure
& quot ;
& quot ; Median 100 75 33
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; Antibody-mediated erythroblastopenia ( PRCA ) have be report after month to year of treatment with epoetin alfa .
& quot ;
& quot ; if epoetin alfa be give concomitantly with cyclosporin , blood level of cyclosporin should be monitor and the dose of cyclosporin adjust a the haematocrit rise .
& quot ;
& quot ; the target haemoglobin concentration in two study be & gt ; 13 g / dl ; in the remain three study it be 12 - 14 g / dl .
& quot ;
& quot ; the total body clearance of aripiprazole be 0.7 ml / min / kg , which be primarily hepatic .
& quot ;
& quot ; this information be present below .
& quot ;
& quot ; there be no accumulation : the level remain the same , whether they be determined 24 hour after the first injection or 24 hour after the last injection .
& quot ;
& quot ; if you have any further question on the use of this product , ask your doctor or pharmacist .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; 8 .
& quot ;
& quot ; 2 year
& quot ;
& quot ; due to the rapid onset of effect of zoledronic acid on bone turnover , transient hypocalcaemia , sometimes symptomatic , may develop and be usually maximal within the first 10 day after infusion of Aclasta ( see section 4.8 ) .
& quot ;
& quot ; expiry date
& quot ;
& quot ; what be the risk associate with Abseamed ?
& quot ;
& quot ; store in the original package in order to protect from moisture .
& quot ;
& quot ; radiation therapy when administer to target a haemoglobin of greater than 14 g / dl ( 8.7 mmol / l ) ,
& quot ;
& quot ; solution for injection in a pre-filled syringe ( injection )
& quot ;
& quot ; leukopenia , neutropenia , thrombocytopenia
& quot ;
& quot ; Serum electrolytes should be monitor in chronic renal failure patient .
& quot ;
& quot ; weight ( kg ) & lt ; 10 10 - 30 & gt ; 30
& quot ;
& quot ; when perform haematologic assessment during the preoperative period , if the haemoglobin level reach 15 g / dl , or higher , administration of epoetin alfa should be stop and further dos should not be give .
& quot ;
& quot ; 3 .
& quot ;
& quot ; ABILIFY may increase the effect of medicine use to lower the blood pressure .
& quot ;
& quot ; Tablet
& quot ;
& quot ; oral use
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery the cause of anaemia should be establish and treat , if possible , before the start of epoetin alfa treatment .
& quot ;
& quot ; Contrada Fontana del Ceraso I-03012 Anagni-Frosinone - Italy
& quot ;
& quot ; adult haemodialysis patient :
& quot ;
& quot ; factor that should be consider in this assessment should include the type of tumour and it stage ; the degree of anaemia ; life-expectancy ; the environment in which the patient be be treat ; and patient preference ( see section 5.1 ) .
& quot ;
& quot ; possible side effect 5 .
& quot ;
& quot ; Extrapyramidal symptom ( EPS ) :
& quot ;
& quot ; Aripiprazole do not impair fertility in reproductive toxicity study .
& quot ;
& quot ; base on result of a full range of standard genotoxicity test , aripiprazole be consider non-genotoxic .
& quot ;
& quot ; 10 .
& quot ;
& quot ; since zoledronic acid be not metabolise in human and the substance be find to have little or no capacity a a direct- acting and / or irreversible metabolism-dependent inhibitor of P450 enzyme , zoledronic acid be unlikely to reduce the metabolic clearance of substance which be metabolise via the cytochrome P450 enzyme system .
& quot ;
& quot ; elderly :
& quot ;
& quot ; Abseamed be a effective a Eprex / Erypo in increase and maintain red blood cell count .
& quot ;
& quot ; Renal dysfunction Zoledronic acid have be associate with renal dysfunction manifest a deterioration in renal function ( I. e. increase serum creatinine ) and in rare case acute renal failure .
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; instruction on use
& quot ;
& quot ; Sverige BRISTOL-MYERS SQUIBB AB Tel : + 46 8 704 71 00
& quot ;
& quot ; s R. O .
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; appropriate therapy such a blood transfusion may be give to patient when indicate .
& quot ;
& quot ; treatment of symptomatic anaemia associate with chronic renal failure ( CRF ) in adult and paediatric patient :
& quot ;
& quot ; the target haemoglobin concentration in two study be & gt ; 13 g / dl ; in the remain three study it be 12 - 14 g / dl .
& quot ;
& quot ; 15 .
& quot ;
& quot ; take ABILIFY with some medicine may need to change your dose of ABILIFY .
& quot ;
& quot ; follow a single oral dose of & # 91 ; 14C & # 93 ; -labelled aripiprazole , approximately 27 % of the administered radioactivity be recover in the urine and approximately 60 % in the faeces .
& quot ;
& quot ; Tel : + 371 67 50 21 85
& quot ;
& quot ; it be especially important to mention the follow to your doctor :
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; 142 tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever , sweat , alter mental status , or very rapid or irregular heart beat .
& quot ;
& quot ; in the open-label study there be no difference in overall survival between patient treat with recombinant human erythropoietin and control .
& quot ;
& quot ; Abseamed 7000 IU / 0.7 ml injection
& quot ;
& quot ; BATCH number
& quot ;
& quot ; this medicinal product contain le than 1 mmol sodium ( 23 mg ) per dose , I. e. essentially “ sodium- free ” .
& quot ;
& quot ; Suomi / Finland OY BRISTOL-MYERS SQUIBB ( Finland ) AB Puh / Tel : + 358 9 251 21 230
& quot ;
& quot ; Ελλάδα BRISTOL-MYERS SQUIBB A. e .
& quot ;
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; 2 year
& quot ;
& quot ; when see , it be usually in those with significant risk factor such a history of diabetes , thyroid disorder or pituitary adenoma .
& quot ;
& quot ; s R. O .
& quot ;
& quot ; 87 nervous system disorder :
& quot ;
& quot ; In-line filter should not be use .
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of anaemia and of the symptom of anaemia .
& quot ;
& quot ; it be especially important to mention the follow to your doctor :
& quot ;
& quot ; temperature regulation disorder ( e. g. hypothermia , pyrexia ) , chest pain , peripheral oedema
& quot ;
& quot ; ABILIFY be effective in a dose range of 10 to 30 mg / day .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery the cause of anaemia should be establish and treat , if possible , before the start of epoetin alfa treatment .
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; discontinue therapy
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; adult haemodialysis patient :
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; 6 .
& quot ;
& quot ; if aripiprazole be administer concomitantly with medicine know to cause QT prolongation or electrolyte imbalance , caution should be use .
& quot ;
& quot ; all of these study look at the change in symptom use a standard scale for bipolar disorder or at the number of patient who respond to treatment .
& quot ;
& quot ; dose ( IU / kg give 3x / week )
& quot ;
& quot ; 9 .
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; leukopenia , neutropenia , thrombocytopenia
& quot ;
& quot ; 179 9 .
& quot ;
& quot ; a systematic review have also be perform involve more than 9000 cancer patient participate in 57 clinical trial .
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; 43 Hepatic disease :
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; Epoetin alfa should be administer by the subcutaneous route to patient with anaemia ( e. g. haemoglobin concentration ≤ 10 g / dl ( 6.2 mmol / l ) .
& quot ;
& quot ; Endocrine disorder :
& quot ;
& quot ; Suicidal thought and behaviour have be report during aripiprazole treatment .
& quot ;
& quot ; however , the concentration of the sulphate conjugate of hydroxy aripiprazole in human bile at the highest dose propose , 30 mg per day , be no more than 6 % of the bile concentration find in the monkey in the 39-week study and be well below ( 6 % ) their limit of in vitro solubility .
& quot ;
& quot ; & quot ; & quot ; Flu-like & quot ; & quot ; symptom such a headache , joint pain , feeling of weakness , dizziness , and tiredness may occur , especially at the start of treatment .
& quot ;
& quot ; if sign and symptom of tardive dyskinesia appear in a patient on ABILIFY , dose reduction or discontinuation should be consider .
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; alternatively , the injection can be give at the end of the dialysis session via the fistula needle tubing , follow by 10 ml of isotonic saline to rinse the tubing and ensure satisfactory injection of the product into the circulation .
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; 1 .
& quot ;
& quot ; in most of these patient , antibody to erythropoietin have be observe ( see section 4.3 and 4.4 – pure red Cell Aplasia )
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; 56 X 1
& quot ;
& quot ; therefore , it should not be use in patient with baseline haemoglobin & gt ; 13 g / dl .
& quot ;
& quot ; Aripiprazole should be use with caution in patient with known cardiovascular disease ( history of myocardial infarction or ischaemic heart disease , heart failure , or conduction abnormality ) , cerebrovascular disease , condition which would predispose patient to hypotension ( dehydration , hypovolemia , and treatment with antihypertensive medication ) or hypertension , include accelerate or malignant .
& quot ;
& quot ; 15 .
& quot ;
& quot ; 4 .
& quot ;
& quot ; Extrapyramidal symptom ( EPS ) :
& quot ;
& quot ; 12 .
& quot ;
& quot ; for the treatment of schizophrenia , there be three main short-term study of Abilify tablet last four to six week , which involve 1,203 patient and compare Abilify with placebo ( a dummy treatment ) .
& quot ;
& quot ; survival and tumour progression have be examine in five large control study involve a total of 2833 patient , of which four be double-blind placebo-controlled study and one be an open- label study .
& quot ;
& quot ; iron supplementation should be start a soon a possible , even several week prior to initiate the autologous predeposit , in order to achieve high iron store prior to start Abseamed therapy .
& quot ;
& quot ; 193 other side effect :
& quot ;
& quot ; Belgique / België / Belgien BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; EXP
& quot ;
& quot ; 12 .
& quot ;
& quot ; Aripiprazole do not impair fertility in reproductive toxicity study .
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; only clear solution free from particle and discoloration should be use .
& quot ;
& quot ; EXP
& quot ;
& quot ; owe to the greater sensitivity of this population , a lower start dose should be consider when clinical factor warrant ( see section 4.4 ) .
& quot ;
& quot ; no study on the effect on the ability to drive and use machine have be perform .
& quot ;
& quot ; in case where there be a need to shorten the time for treatment before the operation be carry out , a dose of 300 IU / kg be give on each of the next ten day before surgery , on the day of surgery and for four day immediately afterwards .
& quot ;
& quot ; in general , the frequency and severity of neurotoxicity be dose-dependent in patient receive Abraxane .
& quot ;
& quot ; a gastric acid blocker , the H2 antagonist famotidine , reduces aripiprazole rate of absorption but this effect be deem not clinically relevant .
& quot ;
& quot ; powder for suspension for infusion .
& quot ;
& quot ; if you have be tell by your doctor that you have an intolerance to some sugar , contact your doctor before take this medicine .
& quot ;
& quot ; 5 .
& quot ;
& quot ; 22 ( 0.62 mmol / l ) per month and should not exceed 2 g / dl ( 1.25 mmol / l ) per month to minimise risk of an increase in hypertension .
& quot ;
& quot ; Maternal toxicity occur at dos similar to those elicit developmental toxicity .
& quot ;
& quot ; when the CYP3A4 or CYP2D6 inhibitor be withdraw from the combination therapy , aripiprazole dose should then be increase ( see section 4.5 ) .
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; it use in this indication must be balance against the report risk of thromboembolic event .
& quot ;
& quot ; if blood pressure can not be control , epoetin alfa treatment should be discontinue .
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; Post-Marketing :
& quot ;
& quot ; Aripiprazole do not impair fertility in reproductive toxicity study .
& quot ;
& quot ; in patient with chronic renal failure the medicinal product have to be administer intravenously ( see section 4.4 ) .
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; Psychiatric disorder :
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; Aripiprazole be metabolise by multiple pathway involve the CYP2D6 and CYP3A4 enzyme but not CYP1A enzyme .
& quot ;
& quot ; for 4 week
& quot ;
& quot ; Shunt thromboses may occur , especially in patient who have a tendency to hypotension or whose arteriovenous fistula exhibit complication ( e. g. stenosis , aneurysm , etc . ) .
& quot ;
& quot ; this be especially important in the elderly and for patient receive diuretic therapy .
& quot ;
& quot ; in another long-term 26-week control trial , the incidence of EPS be 14.8 % for aripiprazole-treated patient and 15.1 % for olanzapine-treated patient .
& quot ;
& quot ; Immunogenicity data for subcutaneous use of Abseamed in patient at risk for antibody-induced PRCA , I. e. patient with renal anaemia , be not sufficient .
& quot ;
& quot ; survival and tumour progression have be examine in five large control study involve a total of 2833 patient , of which four be double-blind placebo-controlled study and one be an open- label study .
& quot ;
& quot ; Serum electrolytes should be monitor in chronic renal failure patient .
& quot ;
& quot ; after opening :
& quot ;
& quot ; the subcutaneous route of administration should be use .
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; European public assessment report ( EPAR )
& quot ;
& quot ; adult peritoneal dialysis patient :
& quot ;
& quot ; Pharmacotherapeutic group : antipsychotic , ATC code :
& quot ;
& quot ; Tel : + 39 06 50 39 61
& quot ;
& quot ; in one 3-week , fixed-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole fail to demonstrate superior efficacy to placebo .
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; in addition , special precaution should be take in patient with predisposition for development of deep vein thrombosis ( DVTs ) .
& quot ;
& quot ; therefore , in patient with renal anaemia the medicinal product have to be administer intravenously .
& quot ;
& quot ; N05AX12
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; in that study the incidence of fatal thromboembolic event be higher in patient receive epoetin alfa than in those receive placebo ( see section 5.1 ) .
& quot ;
& quot ; the bioavailability of subcutaneous injectable epoetin alfa be much lower than that of the intravenous medicinal product : approximately 20 % .
& quot ;
& quot ; 14 .
& quot ;
& quot ; - if the solution have be accidently frozen .
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; Abseamed 8000 IU / 0.8 ml injection
& quot ;
& quot ; the pre-filled syrinx be ready to use ( see section 4.2 – method of administration ) .
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP2D6 ( quinidine ) increase aripiprazole AUC by 107 % , while Cmax be unchanged .
& quot ;
& quot ; 122 9 .
& quot ;
& quot ; rhabdomyolysis , myalgia , stiffness
& quot ;
& quot ; Haemoglobin variability should be address through dose management with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; Intravenous use .
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; intolerance :
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole , the active metabolite , decrease by 32 % and 47 % .
& quot ;
& quot ; iron supplementation should be start prior to epoetin alfa therapy , to achieve adequate iron store .
& quot ;
& quot ; solution for injection in a pre-filled syringe ( injection )
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; Abseamed 4000 IU / 0.4 ml
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; 6 .
& quot ;
& quot ; Sverige Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; ABILIFY be effective in a dose range of 10 to 30 mg / day .
& quot ;
& quot ; follow a single oral dose of & # 91 ; 14C & # 93 ; -labelled aripiprazole , approximately 27 % of the administered radioactivity be recover in the urine and approximately 60 % in the faeces .
& quot ;
& quot ; do not give by injection under the skin ( subcutaneously ) .
& quot ;
& quot ; therefore , routine volume replacement should be perform in such patient .
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; other infrequently report side effect :
& quot ;
& quot ; 1 pre-filled syringe of 0.8 ml 6 pre-filled syrinx of 0.8 ml
& quot ;
& quot ; alternatively , epoetin alfa can be administer at an initial dose of 450 IU / kg subcutaneously once weekly .
& quot ;
& quot ; Ísland VISTOR HF Sími : + 354 535 7000
& quot ;
& quot ; 7 .
& quot ;
& quot ; Tel : + 386 1 236 47 00
& quot ;
& quot ; 13 .
& quot ;
& quot ; this can be repeat once a year in patient be treat for osteoporosis .
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; Z O. O .
& quot ;
& quot ; iron supplementation should be start a soon a possible , even several week prior to initiate the autologous predeposit , in order to achieve high iron store prior to start Abseamed therapy .
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; 171 9 .
& quot ;
& quot ; although the cause of death be vary , most of the death appear to be either cardiovascular ( e. g. heart failure , sudden death ) or infectious ( e. g. pneumonia ) in nature .
& quot ;
& quot ; Pre-filled syrinx ( glass type I ) with plunger ( Teflon-faced rubber ) seal in a blister .
& quot ;
& quot ; factor that should be consider in this assessment should include the type of tumour and it stage ; the degree of anaemia ; life-expectancy ; the environment in which the patient be be treat ; and patient preference ( see section 5.1 ) .
& quot ;
& quot ; overall , 1.3 % of aripiprazole-treated patient report cerebrovascular adverse event compare with 0.6 % of placebo-treated patient in these trial .
& quot ;
& quot ; Abseamed 9000 IU / 0.9 ml solution for injection in a pre-filled syringe The syrinx contain 0.9 ml ( 9000 IU ) of solution .
& quot ;
& quot ; always take the tablet with water and swallow it whole .
& quot ;
& quot ; detail information on this product be available on the website of the European Medicines Agency ( EMEA ) http : / / www . emea . europa . EU /
& quot ;
& quot ; EXP
& quot ;
& quot ; Respiratory , thoracic and mediastinal disorder :
& quot ;
& quot ; there may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with epoetin alfa .
& quot ;
& quot ; patient who develop pure red Cell Aplasia ( PRCA ) follow treatment with any erythropoietin should not receive Abseamed or any other erythropoietin ( see section 4.4 - pure red Cell Aplasia ) .
& quot ;
& quot ; - if any of the side effect get serious , or if you notice any side effect not list in this leaflet ,
& quot ;
& quot ; this document be a summary of the European Public assessment Report ( EPAR ) .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; - to ensure that your haemoglobin do not exceed a certain level a high haemoglobin could put
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; BATCH number
& quot ;
& quot ; you may need to read it again .
& quot ;
& quot ; a rise in haemoglobin of greater than 2 g / dl ( 1.25 mmol / l ) over a four week period should be avoid .
& quot ;
& quot ; Aripiprazole be the predominant medicinal product moiety in systemic circulation .
& quot ;
& quot ; 15 mg
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the sustained haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) reduce the epoetin alfa dose by 25 % .
& quot ;
& quot ; expiry date
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; Aripiprazole orodispersible tablet may be use a an alternative to aripiprazole tablet .
& quot ;
& quot ; EU / 1 / 04 / 276 / 016
& quot ;
& quot ; in clinical trial and post-marketing experience , accidental or intentional acute overdosage of aripiprazole alone be identify in adult patient with report estimate dose up to 1,260 mg with no fatality .
& quot ;
& quot ; Zoledronic acid be not systemically metabolise and do not affect human cytochrome P450 enzymes in vitro ( see section 5.2 ) .
& quot ;
& quot ; Aclasta should not be use in people who may be hypersensitive ( allergic ) to zoledronic acid , to other bisphosphonates or to any of the other ingredient .
& quot ;
& quot ; Meta-analysis of overall survival data produce a hazard ratio point estimate of 1.08 in favour of control ( 95 % CI :
& quot ;
& quot ; 64 ( 0.62 mmol / l ) per month and should not exceed 2 g / dl ( 1.25 mmol / l ) per month to minimise risk of an increase in hypertension .
& quot ;
& quot ; Luxembourg / Luxemburg BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; a with all growth factor , there be a concern that epoetins could stimulate the growth of tumour .
& quot ;
& quot ; the mean volume of distribution be 632 l / m2 ; the large volume of distribution indicates extensive extravascular distribution and / or tissue binding of paclitaxel .
& quot ;
& quot ; people with this condition may also feel depressed , guilty , anxious or tense .
& quot ;
& quot ; 3 .
& quot ;
& quot ; the doctor may also want to measure your blood pressure and pulse .
& quot ;
& quot ; Aripiprazole also exhibit moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptor .
& quot ;
& quot ; what ABILIFY look like and content of the Pack ABILIFY 10 mg orodispersible tablet be round and pink , mark with & quot ; & quot ; A & quot ; & quot ; over & quot ; & quot ; 640 & quot ; & quot ; on one side and 10 on the other .
& quot ;
& quot ; * produce in CHO cell line by recombinant DNA technology
& quot ;
& quot ; patient who for any reason can not receive adequate antithrombotic prophylaxis .
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; treatment with Abseamed have to be initiate under the supervision of physician experience in the management of patient with the above indication .
& quot ;
& quot ; 1 .
& quot ;
& quot ; due to insufficient safety information in human and concern raise by animal reproductive study , this medicinal product should not be use in pregnancy unless the expected benefit clearly justify the potential risk to the foetus .
& quot ;
& quot ; Haemoglobin variability should be address through dose management with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; oral use
& quot ;
& quot ; it be use to treat adult who suffer from a disease characterise by symptom such a hearing , see or sense thing which be not there , suspiciousness , mistaken belief , incoherent speech and behaviour and emotional flatness .
& quot ;
& quot ; please discuss this with your doctor .
& quot ;
& quot ; allergic reaction ( e. g. anaphylactic reaction , angioedema include swollen tongue , tongue oedema , face oedema , pruritus , or urticaria )
& quot ;
& quot ; therefore , in patient with renal anaemia the medicinal product have to be administer intravenously .
& quot ;
& quot ; an increase 3H-thymidine incorporation in the erythroid nucleate spleen cell have be find in vitro ( mouse spleen cell culture ) after incubation with epoetin alfa .
& quot ;
& quot ; for subcutaneous and intravenous use .
& quot ;
& quot ; Cytotoxic action of epoetin alfa on bone marrow cell could not be detect .
& quot ;
& quot ; name
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; it be use in patient who be at risk of fracture ( bone break ) , include patient who have recently break their hip in a minor trauma , such a a fall ; • Paget ’ s disease of the bone , a disease where the normal process of bone growth be change .
& quot ;
& quot ; in several controlled study , epoetins have not be show to improve overall survival or decrease the risk of tumour progression in patient with anaemia associate with cancer .
& quot ;
& quot ; the appropriate dos for patient with mild or moderate liver problem or with kidney problem be not know .
& quot ;
& quot ; Epoetin alfa IV / SC
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of untreated , inadequately treat
& quot ;
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; overall survival outcome in the trial could not be statisfactorily explain by difference in the incidence of thrombosis and related complication between those give recombinant human erythropoietin and those in the control group .
& quot ;
& quot ; lot
& quot ;
& quot ; 7 .
& quot ;
& quot ; 16 .
& quot ;
& quot ; - if the solution be cloudy or there be particle in it .
& quot ;
& quot ; Reconstitution of the product and administration
& quot ;
& quot ; Aripiprazole be the predominant medicinal product moiety in systemic circulation .
& quot ;
& quot ; 0.3 ml ( 10000 IU / ml )
& quot ;
& quot ; if you have the impression that the effect of ABILIFY be too strong or too weak , talk to your doctor or pharmacist .
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg , Kuhloweg 37 , D-58638 Iserlohn , Germany
& quot ;
& quot ; Tel : + 421 2 59298411
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; Tablet
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; & quot ; & quot ; Flu-like & quot ; & quot ; symptom such a headache , joint pain , feeling of weakness , dizziness , and tiredness may occur , especially at the start of treatment .
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; animal study could not exclude potential developmental toxicity ( see section 5.3 ) .
& quot ;
& quot ; weight gain have be report post-marketing among patient prescribe ABILIFY .
& quot ;
& quot ; patient who for any reason can not receive adequate antithrombotic prophylaxis .
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; Seventy-seven percent of the patient have be previously expose to anthracyclines .
& quot ;
& quot ; the potentially medically important sign and symptom observe included lethargy , increase blood pressure , somnolence , tachycardia , nausea , vomit and diarrhoea .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; adult surgery patient in an autologous predonation programme
& quot ;
& quot ; 56 X 1
& quot ;
& quot ; 1 .
& quot ;
& quot ; Excipients
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; kg Tel : + 49- ( 0 ) 2371 937 0
& quot ;
& quot ; summary of Product characteristic , section 4.2 )
& quot ;
& quot ; Musculoskeletal and connective tissue disorder :
& quot ;
& quot ; 75 150 IU / kg 3x / week or 450 IU / kg once weekly
& quot ;
& quot ; Erythropoietin be a glycoprotein that stimulate , a a mitosis-stimulating factor and differentiate hormone , the formation of erythrocyte from precursor of the stem cell compartment .
& quot ;
& quot ; 19 150 IU / kg 3x / week or 450 IU / kg once weekly
& quot ;
& quot ; Polska BRISTOL-MYERS SQUIBB POLSKA SP .
& quot ;
& quot ; Aripiprazole and other antipsychotic drug should be use cautiously in patient at risk for aspiration pneumonia .
& quot ;
& quot ; these measure will help to protect the environment .
& quot ;
& quot ; 168 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; Paediatric haemodialysis patient :
& quot ;
& quot ; long-term carcinogenicity study have not be carry out .
& quot ;
& quot ; EU / 1 / 04 / 276 / 036
& quot ;
& quot ; the target haemoglobin concentration in two study be & gt ; 13 g / dl ; in the remain three study it be 12 - 14 g / dl .
& quot ;
& quot ; there be no accumulation : the level remain the same , whether they be determined 24 hour after the first injection or 24 hour after the last injection .
& quot ;
& quot ; Cardiac disorder :
& quot ;
& quot ; the other ingredient be calcium silicate , croscarmellose sodium , crospovidone , silicon dioxide , xylitol , microcrystalline cellulose , aspartame , acesulfame potassium , vanilla flavour , tartaric acid , magnesium stearate , yellow iron oxide ( E172 ) .
& quot ;
& quot ; Maternal toxicity occur at dos similar to those elicit developmental toxicity .
& quot ;
& quot ; in patient with a recent low-trauma hip fracture , it be recommend to give the Aclasta infusion two or more week after hip fracture repair ( see section 5.1 ) .
& quot ;
& quot ; in a prospective , randomised , double-blind , placebo-controlled trial conduct in 375 anaemic patient with various non-myeloid malignancy receive non-platinum chemotherapy , there be a significant reduction of anaemia-related sequela ( e. g. fatigue , decrease energy , and activity reduction ) , a measure by the following instrument and scale :
& quot ;
& quot ; Non-specific skin rash have be describe in association with epoetin alfa .
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; because the active substance in Aclasta be the same a the active substance in Zometa , some of the data present for Zometa be take into account when assess Aclasta .
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP2D6 ( quinidine ) increase aripiprazole AUC by 107 % , while Cmax be unchanged .
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; in most case , the ferritin value in the serum fall simultaneously with the rise in packed cell volume .
& quot ;
& quot ; Manic episodes in Bipolar I Disorder :
& quot ;
& quot ; Median 100 75 33
& quot ;
& quot ; investigation :
& quot ;
& quot ; name OF the MEDICINAL product AND route ( s ) OF administration
& quot ;
& quot ; Paclitaxel have be show to be clastogenic in vitro ( chromosome aberration in human lymphocyte ) and in vivo ( micronucleus test in mouse ) .
& quot ;
& quot ; a half-life of approximately 6 hour have be report in child .
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; in schizophrenia patient the incidence of akathisia be 6.2 % with aripiprazole and 3.0 % with placebo .
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; Pharmacotherapeutic group : antianaemic , ATC code :
& quot ;
& quot ; no other erythropoietic therapy should be commence because of the risk of cross-reaction .
& quot ;
& quot ; a half-life of approximately 6 hour have be report in child .
& quot ;
& quot ; Smoking status : accord to the metabolic pathway of ABILIFY no dosage adjustment be require for smoker ( see section 4.5 ) .
& quot ;
& quot ; package size
& quot ;
& quot ; Schizophrenia - in a long term 52-week controlled trial , aripiprazole-treated patient have an overall-lower incidence ( 25.8 % ) of EPS include parkinsonism , akathisia , dystonia and dyskinesia compare with those treat with haloperidol ( 57.3 % ) .
& quot ;
& quot ; 88 Activated charcoal ( 50 g ) , administer one hour after aripiprazole , decrease aripiprazole Cmax by about 41 % and AUC by about 51 % , suggest that charcoal may be effective in the treatment of overdose .
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; a slower injection be preferable in patient who react to the treatment with “ flu-like ” symptom .
& quot ;
& quot ; special storage condition
& quot ;
& quot ; ABILIFY dose should be double when concomitant administration of ABILIFY occur with carbamazepine .
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg , Kuhloweg 37 , D-58638 Iserlohn , Germany
& quot ;
& quot ; if aripiprazole be administer concomitantly with medicine know to cause QT prolongation or electrolyte imbalance , caution should be use .
& quot ;
& quot ; EU / 1 / 04 / 276 / 008
& quot ;
& quot ; Subcutaneous route
& quot ;
& quot ; ABILIFY 30 mg tablet
& quot ;
& quot ; 10 .
& quot ;
& quot ; in the absence of compatibility study , this medicinal product must not be mix with other medicinal product .
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; if a patient develop sign and symptom indicative of NMS , or present with unexplained high fever without additional clinical manifestation of NMS , all antipsychotic medicinal product , include ABILIFY , must be discontinue .
& quot ;
& quot ; Malta BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; Aripiprazole do not impair fertility in reproductive toxicity study .
& quot ;
& quot ; - shorten overall survival and increase death attribute to disease progression at 4 month in
& quot ;
& quot ; Tel . : + 36 1 301 9700
& quot ;
& quot ; in the study of elderly woman , the risk of spine fracture be reduce by 70 % in patient take Aclasta ( without any other medicine for osteoporosis ) over three year , compare with those take placebo .
& quot ;
& quot ; these study have show an consistent unexplained statistically significant excess mortality in patient who have anaemia associate with various common cancer who receive recombinant human erythropoietin compare to control .
& quot ;
& quot ; Aripiprazole be extensively metabolise by the liver primarily by three biotransformation pathway : dehydrogenation , hydroxylation , and N-dealkylation .
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; if it occur , appropriate dose adjustment should be make a provided .
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; it use in this indication must be balance against the report risk of thromboembolic event .
& quot ;
& quot ; ask your pharmacist how to dispose of medicine no longer require .
& quot ;
& quot ; 12 721 cancer patient receive non-platinum chemotherapy be include in three placebo-controlled study , 389 patient with haematological malignancy ( 221 multiple myeloma , 144 non-Hodgkin & apos ; s lymphoma , and 24 other haematological malignancy ) and 332 with solid tumour ( 172 breast , 64 gynaecological , 23 lung , 22 prostate , 21 gastro-intestinal , and 30 other tumour type ) .
& quot ;
& quot ; Thrombocytosis have be observe but it occurrence be very rare ( see section 4.4 ) .
& quot ;
& quot ; in order to ensure optimum response to epoetin alfa , adequate iron store should be assure :
& quot ;
& quot ; iron supplementation should be start a soon a possible , even several week prior to initiate the autologous predeposit , in order to achieve high iron store prior to start Abseamed therapy .
& quot ;
& quot ; effect on all clinical fracture The incidence rate of key clinical fracture variable be present in table 4 .
& quot ;
& quot ; therefore , routine volume replacement should be perform in such patient .
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; 12 .
& quot ;
& quot ; expiry date
& quot ;
& quot ; Respiratory , thoracic and mediastinal disorder :
& quot ;
& quot ; ABILIFY 30 mg orodispersible tablet aripiprazole
& quot ;
& quot ; recurrence prevention of manic episode in Bipolar I Disorder :
& quot ;
& quot ; Tablet
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; 12 g / dl )
& quot ;
& quot ; s R. O .
& quot ;
& quot ; rhabdomyolysis , myalgia , stiffness
& quot ;
& quot ;
& quot ; 3 .
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; the haemoglobin concentration aim for be between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) , except in paediatric patient in whom the haemoglobin concentration should be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; the peak be always well below the peak achieve use the intravenous route ( approximately 1 / 20th of the value ) .
& quot ;
& quot ; EU / 1 / 04 / 276 / 026
& quot ;
& quot ; Schizophrenia :
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; if your level of the red blood pigment ( haemoglobin ) be too high you should not receive Abseamed , since you have an increase risk of blood clotting after the surgery .
& quot ;
& quot ; EXP
& quot ;
& quot ; ABILIFY be indicate for the treatment of moderate to severe manic episode in Bipolar I Disorder and for the prevention of a new manic episode in patient who experience predominantly manic episode and whose manic episode respond to aripiprazole treatment ( see section 5.1 ) .
& quot ;
& quot ; - Occlusion in the connection between artery and vein ( shunt thrombosis ) may occur especially if
& quot ;
& quot ; Paclitaxel have be available a an anticancer medicine since 1993 .
& quot ;
& quot ; 8 .
& quot ;
& quot ; Chronic renal failure patient
& quot ;
& quot ; ABILIFY orodispersible tablet contain aspartame , a source of phenylalanine which may be harmful for people with phenylketonuria .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; 1 / 2 EU / 1 / 07 / 412 / 018
& quot ;
& quot ; priapism
& quot ;
& quot ; United Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel : + 44 ( 0800 ) 731 1736
& quot ;
& quot ; not applicable
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; independent of erythropoietin treatment , thrombotic and vascular event may occur in surgical patient with underlying cardiovascular disease follow repeat phlebotomy .
& quot ;
& quot ; 116 10 .
& quot ;
& quot ; for 4 week
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; weight ( kg ) & lt ; 10 10 - 30 & gt ; 30
& quot ;
& quot ; Breast-feeding mother should not take ABILIFY .
& quot ;
& quot ; adult haemodialysis patient :
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; if you have the impression that the effect of ABILIFY be too strong or too weak , talk to your doctor or pharmacist .
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ; base on information available to date , correction of anaemia with epoetin alfa in adult patient with renal insufficiency not yet undergoing dialysis do not accelerate the rate of progression of renal insufficiency .
& quot ;
& quot ; the incidence of these symptom decrease markedly with subsequent dos of Aclasta .
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; weight gain : weight gain be commonly see in schizophrenic and bipolar mania patient due to co- morbidity , use of antipsychotic know to cause weight gain , poorly manage life-style , and might lead to severe complication .
& quot ;
& quot ; Abilify be also more effective than placebo at prevent manic episode return in previously treat patient for up to 74 week , and when it be use a an add-on to exist treatment .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; thus , aripiprazole be unlikely to cause clinically important medicinal product interaction mediate by these enzyme .
& quot ;
& quot ; dose ( IU / kg give 3x / week )
& quot ;
& quot ; Dialysis prescription may have to be adjust periodically to maintain urea , creatinine and potassium in the desired range .
& quot ;
& quot ; kg Tel : + 49- ( 0 ) 2371 937 0
& quot ;
& quot ; in the absence of compatibility study , this medicinal product must not be mix with other medicinal product .
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; close supervision of high-risk patient should accompany antipsychotic therapy .
& quot ;
& quot ; Reproductive system and breast disorder :
& quot ;
& quot ; upon discontinuation of the CYP2D6 or 3A4 inhibitor , the dosage of ABILIFY should be increase to the level prior to the initiation of the concomitant therapy .
& quot ;
& quot ; immune system disorder :
& quot ;
& quot ; 8 .
& quot ;
& quot ; generally , child under 30 kg require higher maintenance dos than child over 30 kg and adult .
& quot ;
& quot ; 5 .
& quot ;
& quot ; upon discontinuation of potent CYP3A4 inducer , the dosage of ABILIFY should be reduce to the recommend dose .
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl
& quot ;
& quot ; your doctor will order regular blood test to ensure that your medicine be continue to work properly .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; if you have the impression that the effect of ABILIFY be too strong or too weak , talk to your doctor or pharmacist .
& quot ;
& quot ; the recommend starting dose for ABILIFY be 15 mg administer on a once-a-day schedule without regard to meal a monotherapy or combination therapy ( see section 5.1 ) .
& quot ;
& quot ; Slovenija BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; upon discontinuation of potent CYP3A4 inducer , the dosage of ABILIFY should be reduce to the recommend dose .
& quot ;
& quot ; rhabdomyolysis , myalgia , stiffness
& quot ;
& quot ; however , in a single-dose , intramuscular study of aripiprazole ( dose 15 mg ) in healthy subject , administer simultaneously with intramuscular lorazepam ( dose 2 mg ) , the orthostatic hypotension observe be greater with the combination a compare to that observe with lorazepam alone .
& quot ;
& quot ; Aripiprazole should be use with caution in patient with known cardiovascular disease ( history of myocardial infarction or ischaemic heart disease , heart failure , or
& quot ;
& quot ; 147 tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever , sweat , alter mental status , or very rapid or irregular heart beat .
& quot ;
& quot ; 15 A .
& quot ;
& quot ; label / SYRINGE
& quot ;
& quot ; take other medicine please tell your doctor or pharmacist if you be take or have recently take any other medicine , include medicine obtain without a prescription .
& quot ;
& quot ; in clinical trial with aripiprazole , there be no significant difference in the incidence rate of hyperglycaemia-related adverse event ( include diabetes ) or in abnormal glycaemia laboratory value compare to placebo .
& quot ;
& quot ; you at risk of have a problem of the heart or the blood vessel and could increase risk of death
& quot ;
& quot ; therefore , it should not be use in patient with baseline haemoglobin & gt ; 13 g / dl .
& quot ;
& quot ; speech disorder , Neuroleptic Malignant syndrome ( NMS ) , grand mal convulsion
& quot ;
& quot ; pancreatitis , dysphagia , abdominal discomfort , stomach discomfort , diarrhoea
& quot ;
& quot ; Clinical manifestation of NMS be hyperpyrexia , muscle rigidity , alter
& quot ;
& quot ; summary of Product Characterisitics , Section 4.2 ) .
& quot ;
& quot ; Tel : + 351 21 440 70 00
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; a with other antipsychotic , aripiprazole should be use with caution in patient with a family history of QT prolongation .
& quot ;
& quot ; risk factor that may predispose patient to severe complication include obesity and family history of diabetes .
& quot ;
& quot ; 2 year
& quot ;
& quot ; 28 August 2007
& quot ;
& quot ; the follow undesirable effect occur more often ( ≥ 1 / 100 ) than placebo , or be identify a possibly medically relevant adverse reaction ( * ) :
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; if you can not reach your doctor , go to the nearest hospital and take the Pack with you .
& quot ;
& quot ; 28 August 2007
& quot ;
& quot ; do not shake .
& quot ;
& quot ; although there be no information on the effect of haemodialysis in treat an overdose with aripiprazole , haemodialysis be unlikely to be useful in overdose management since aripiprazole be highly bind to plasma protein .
& quot ;
& quot ; productive cough , exertional dyspnoea , sinus congestion , decrease breath sound , pleural effusion , allergic rhinitis , hoarseness , nasal congestion , nasal dryness , wheeze
& quot ;
& quot ; Uncommon side effect ( greater than 1 in 1,000 , le than 1 in 100 patient ) some people may feel dizzy , especially when get up from a lying or sit position , or may experience a fast heart rate .
& quot ;
& quot ; Aripiprazole exhibit high binding affinity in vitro for dopamine D2 and D3 , serotonin 5HT1a and 5HT2a receptor and moderate affinity for dopamine D4 , serotonin 5HT2c and 5HT7 , alpha-1 adrenergic and histamine H1 receptor .
& quot ;
& quot ; 46 The orodispersible tablet may be use a an alternative to ABILIFY tablet for patient who have difficulty to swallow ABILIFY tablet ( see also section 5.2 ) .
& quot ;
& quot ; there be no adequate and well-controlled trial of aripiprazole in pregnant woman .
& quot ;
& quot ; it may be necessary to add or increase antihypertensive treatment .
& quot ;
& quot ; 8 .
& quot ;
& quot ; Lactose : patient with rare hereditary problem of galactose intolerance , the lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product .
& quot ;
& quot ; Erythropoietin be a glycoprotein that stimulate , a a mitosis-stimulating factor and differentiate hormone , the formation of erythrocyte from precursor of the stem cell compartment .
& quot ;
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; BATCH number
& quot ;
& quot ; effect on morphometric vertebral fracture Aclasta significantly decrease the incidence of one or more new vertebral fracture over three year and a early a the one year timepoint ( see table 2 ) .
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP2D6 ( quinidine ) increase aripiprazole AUC by 107 % , while Cmax be unchanged .
& quot ;
& quot ; if you have the impression that the effect of ABILIFY be too strong or too weak , talk to your doctor or pharmacist .
& quot ;
& quot ; in subpopulation analysis on patient with mixed episode or on patient with severe agitation , a similar pattern of efficacy to the overall population be observe but statistical significance could not be establish due to a reduced sample size .
& quot ;
& quot ; Ελλάδα BRISTOL-MYERS SQUIBB A. e .
& quot ;
& quot ; do not shake .
& quot ;
& quot ; precise risk estimate for hyperglycaemia-related adverse event in patient treat with ABILIFY and with other atypical antipsychotic agent be not available to allow direct comparison .
& quot ;
& quot ; if the haemoglobin increase be & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , increase the dose to 300 IU / kg 3 time per week .
& quot ;
& quot ; consequently , haemoglobin and blood pressure should be closely monitor .
& quot ;
& quot ; Tel : + 372 640 1301
& quot ;
& quot ; general disorder and administration site condition :
& quot ;
& quot ; this medicinal product contain le than 1 mmol sodium ( 23 mg ) per dose , I. e. essentially “ sodium- free ”
& quot ;
& quot ; risk management Plan The MAH commits to perform the study and additional pharmacovigilance activity detail in the Pharmacovigilance Plan , a agree in version 4 of the risk management Plan ( RMP ) and present in Module 1.8.2. of the marketing authorisation application and any subsequent update of the RMP agree by the CHMP .
& quot ;
& quot ; depend on how your anaemia respond to treatment , the dose may be adjust approximately every four week until your condition be control .
& quot ;
& quot ; 10 .
& quot ;
& quot ; in these case , erythropoietin be use to replace the miss hormone or to increase red blood cell count .
& quot ;
& quot ; when look only at the patient who be receive their first treatment for metastatic breast cancer , there be no difference between the medicine in term of measure of effectiveness such a the time until the disease get worse and survival .
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; how to use Abraxane 4 .
& quot ;
& quot ; 22 5 .
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; EU / 1 / 04 / 276 / 010
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; it use in this indication must be balance against the report risk of thromboembolic event .
& quot ;
& quot ; Aripiprazole orodispersible tablet be bioequivalent to aripiprazole tablet , with a similar rate and extent of absorption .
& quot ;
& quot ; if you have the impression that the effect of ABILIFY be too strong or too weak , talk to your doctor or pharmacist .
& quot ;
& quot ; • The active substance be paclitaxel .
& quot ;
& quot ; ABILIFY orodispersible tablet contain aspartame , a source of phenylalanine which may be harmful for people with phenylketonuria .
& quot ;
& quot ; ABILIFY be use to treat adult who suffer from a condition with symptom such a feeling & quot ; & quot ; high & quot ; & quot ; , have excessive amount of energy , need much le sleep than usual , talk very quickly with race idea and sometimes severe irritability .
& quot ;
& quot ; a half-life of approximately 6 hour have be report in child .
& quot ;
& quot ; Erythropoietins be growth factor that primarily stimulate red blood cell production .
& quot ;
& quot ; Renal disease :
& quot ;
& quot ; Sverige BRISTOL-MYERS SQUIBB AB Tel : + 46 8 704 71 00
& quot ;
& quot ; 1 .
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; 16.1 & # 91 ; 15.0 , 19.3 & # 93 ; ( n = 135 )
& quot ;
& quot ; Renal and urinary disorder :
& quot ;
& quot ; in most case , the ferritin value in the serum fall simultaneously with the rise in packed cell volume .
& quot ;
& quot ; clear colourless solution
& quot ;
& quot ; method OF administration
& quot ;
& quot ; Tel : + 351 21 440 70 00
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; 1 .
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; 1 / 1
& quot ;
& quot ; due to insufficient safety information in human and concern raise by animal reproductive study , this medicinal product should not be use in pregnancy unless the expected benefit clearly justify the potential risk to the foetus .
& quot ;
& quot ; Aripiprazole undergo minimal pre-systemic metabolism .
& quot ;
& quot ; - treatment of severe anaemia of renal origin accompany by clinical symptom in adult patient
& quot ;
& quot ; ABILIFY be use to treat adult who suffer from a condition with symptom such a feeling & quot ; & quot ; high & quot ; & quot ; , have excessive amount of energy , need much le sleep than usual , talk very quickly with race idea and sometimes severe irritability .
& quot ;
& quot ; elimination :
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; when the CYP3A4 inducer be withdraw from the combination therapy , the aripiprazole dose should then be reduce to the recommend dose ( see section 4.5 ) .
& quot ;
& quot ; what ABILIFY be AND what IT be use for
& quot ;
& quot ; in two 12-week , placebo- and active-controlled monotherapy trial in patient with a manic or mixed episode of Bipolar I Disorder , with or without psychotic feature , aripiprazole demonstrate superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12 .
& quot ;
& quot ; Abdominal pain , abdominal distension , upper abdominal pain , Gastrointestinal dyspepsia , gastrooesophageal reflux disease , oral hypoaesthesia disorder :
& quot ;
& quot ; oral use
& quot ;
& quot ; iron supplementation should be start prior to epoetin alfa therapy , to achieve adequate iron store .
& quot ;
& quot ; non response to epoetin alfa therapy may have the following cause : iron , folate , or vitamin B12 deficiency ; aluminium intoxication ; intercurrent infection ; inflammatory or traumatic episode ; occult blood loss ; haemolysis , and bone marrow fibrosis of any origin .
& quot ;
& quot ; the recommended dosing regimen be describe in the following diagram :
& quot ;
& quot ; distribution :
& quot ;
& quot ; elderly patient ( ≥ 65 year ) No dose adjustment be necessary since bioavailability , distribution and elimination be similar in elderly patient and younger subject .
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; instruction on use
& quot ;
& quot ; if a patient develop sign and symptom indicative of NMS , or present with unexplained high fever without additional clinical manifestation of NMS , all antipsychotic medicinal product , include ABILIFY , must be discontinue .
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; Hyperkalaemia have be observe in isolated case .
& quot ;
& quot ; Phlebotomy may be perform if excessively high haemoglobin level occur .
& quot ;
& quot ; priapism
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; QT prolongation , ventricular arrhythmia , sudden unexplained death , cardiac arrest , torsades de pointes , bradycardia
& quot ;
& quot ; Contrada Fontana del Ceraso I-03012 Anagni-Frosinone - Italy
& quot ;
& quot ; 98 4.8 undesirable effect
& quot ;
& quot ; if you experience any of these condition your doctor may wish to stop treatment or reduce the dose .
& quot ;
& quot ; EU / 1 / 04 / 276 / 032
& quot ;
& quot ; patient with active malignant disease receive neither chemotherapy nor radiation therapy .
& quot ;
& quot ; Portugal BRISTOL-MYERS SQUIBB FARMACÊUTICA Portuguesa , S. A .
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; Aluminium perforate unit dose blister in carton of 14 X 1 , 28 X 1 , 49 X 1 , 56 X 1 , 98 X 1 tablet .
& quot ;
& quot ; thus , aripiprazole be unlikely to cause clinically important medicinal product interaction mediate by these enzyme .
& quot ;
& quot ; base on result of a full range of standard genotoxicity test , aripiprazole be consider non-genotoxic .
& quot ;
& quot ; elderly : the effectiveness of ABILIFY in the treatment of schizophrenia and Bipolar I Disorder in patient 65 year of age or older have not be establish .
& quot ;
& quot ; 3 .
& quot ;
& quot ; start dose of 50 IU / kg 3 time per week by the intravenous route , follow if necessary by a dose increase with 25 IU / kg increment ( 3 time per week ) until the desired goal be achieve ( this should be do in step of at least four week ) .
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; although there be no information on the effect of haemodialysis in treat an overdose with aripiprazole , haemodialysis be unlikely to be useful in overdose management since aripiprazole be highly bind to plasma protein .
& quot ;
& quot ; in most of these patient , antibody to erythropoietin have be observe ( see section 4.3 and 4.4 – pure red Cell Aplasia )
& quot ;
& quot ; adult patient with renal insufficiency not yet undergoing dialysis :
& quot ;
& quot ; in controlled clinical study , use of Epoetin alfa and other erythropoiesis-stimulating agent ( ESAs ) have show :
& quot ;
& quot ; route of Administration
& quot ;
& quot ; this medicinal product must not be administer by intravenous infusion , or mixed with other medicinal product .
& quot ;
& quot ; adult surgery patient in an autologous predonation programme
& quot ;
& quot ; Hypertension may occur in epoetin alfa treat patient .
& quot ;
& quot ; Respiratory , thoracic and mediastinal disorder :
& quot ;
& quot ; these report be base on in vitro finding from human tumour sample , but be of uncertain significance in the clinical situation .
& quot ;
& quot ; try to take the ABILIFY orodispersible tablet at the same time each day .
& quot ;
& quot ; the frequency list below be define use the following convention : common ( & gt ; 1 / 100 , & lt ; 1 / 10 ) and uncommon ( & gt ; 1 / 1 , 000 , & lt ; 1 / 100 ) .
& quot ;
& quot ; Abseamed have no influence on the ability to drive and use machine .
& quot ;
& quot ; after injection of the necessary amount of the solution from the pre-filled syringe , discard any remain content .
& quot ;
& quot ; 3 .
& quot ;
& quot ; Paclitaxel belong to a group of medicine call taxanes use to treat cancer .
& quot ;
& quot ; in elderly patient with dementia , more fatal case have be report while take aripiprazole .
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; important information about some of the ingredient of ABILIFY patient who can not take phenylalanine should note that ABILIFY orodispersible tablet contain aspartame , which be a source of phenylalanine .
& quot ;
& quot ; the incidence of bone marrow fibrosis be not increase in a study of haemodialysis patient who be treat with epoetin alfa for 3 year compare to a match control group of dialysis patient who have not be treat with epoetin alfa . ) .
& quot ;
& quot ; 300 IU / kg 3x / week for 4 week
& quot ;
& quot ; it also prevent this condition from return in patient who have respond to the treatment with ABILIFY .
& quot ;
& quot ; read all of this leaflet carefully before you start take this medicine .
& quot ;
& quot ; condition OF the marketing authorisation
& quot ;
& quot ; 141 Annex II
& quot ;
& quot ; Anaemia ( Hb & lt ; 10 g / dl ) be observe in 46 % of patient on Abraxane , and be severe ( Hb & lt ; 8 g / dl ) in three case .
& quot ;
& quot ; if it occur , appropriate dose adjustment should be make a provided .
& quot ;
& quot ; 3 .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; BATCH number
& quot ;
& quot ; the total body clearance of aripiprazole be 0.7 ml / min / kg , which be primarily hepatic .
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; driving and use machine do not drive or use any tool or machine , until you know how ABILIFY affect you .
& quot ;
& quot ; general
& quot ;
& quot ; 70 The orodispersible tablet may be use a an alternative to ABILIFY tablet for patient who have difficulty to swallow ABILIFY tablet ( see also section 5.2 ) .
& quot ;
& quot ; Tel . : + 48 22 5796666
& quot ;
& quot ; Additionally , aripiprazole and dehydro-aripiprazole do not show potential for alter CYP1A2-mediated metabolism in vitro .
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; if haemoglobin have increase by at least 1 g / dl ( 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl above baseline after 4 week of treatment , the dose should remain at 150 IU / kg 3 time a week or 450 IU / kg once weekly .
& quot ;
& quot ; Aluminium perforate unit dose blister in carton of 14 X 1 , 28 X 1 , 49 X 1 , 56 X 1 , 98 X 1 tablet .
& quot ;
& quot ; 174 package LEAFLET :
& quot ;
& quot ; ABILIFY be one of a group of medicine call antipsychotic .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; the decision to administer recombinant erythropoietin should be base on a benefit-risk assessment with the participation of the individual patient , which should also take into account the specific clinical context .
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of epilepsy and chronic liver failure .
& quot ;
& quot ; 170 PARTICULARS to appear on the outer packaging
& quot ;
& quot ; alternatively , epoetin alfa can be administer at an initial dose of 450 IU / kg subcutaneously once weekly .
& quot ;
& quot ; if it occur , appropriate dose adjustment should be make a provided .
& quot ;
& quot ; the frequency of these event be consider not know ( can not be estimate from the available data ) .
& quot ;
& quot ; 2000 IU / 1.0 ml
& quot ;
& quot ; the solution should be direct onto the inside wall of the vial .
& quot ;
& quot ; Intravenous injection : over at least one to five minute , depend on the total dose .
& quot ;
& quot ; it use in this indication must be balance against the report risk of thromboembolic event .
& quot ;
& quot ; 12 g / dl )
& quot ;
& quot ; your doctor may order regular blood test to see that this be be achieve and to ensure that your medicine be continue to work properly and your haemoglobin do not exceed a certain level .
& quot ;
& quot ; 4 .
& quot ;
& quot ; however , the concentration of the sulphate conjugate of hydroxy aripiprazole in human bile at the highest dose propose , 30 mg per day , be no more than 6 % of the bile concentration find in the monkey in the 39-week study and be well below ( 6 % ) their limit of in vitro solubility .
& quot ;
& quot ; 1 .
& quot ;
& quot ; 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; 9 .
& quot ;
& quot ; 8 .
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; in order to ensure optimum response to epoetin alfa , adequate iron store should be assure :
& quot ;
& quot ; if you forget to take ABILIFY if you miss a dose , take the missed dose a soon a you remember but do not take two dos in one day .
& quot ;
& quot ; Abraxane be usually give every three week .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; - shorten overall survival and increase death attribute to disease progression at 4 month in
& quot ;
& quot ; 1 .
& quot ;
& quot ; - iron supplementation , e. g .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; once the addition be complete , the vial should be allow to stand for a minimum of 5 minute to ensure proper wetting of the solid .
& quot ;
& quot ; in clinical trial and post-marketing experience , accidental or intentional acute overdosage of aripiprazole alone be identify in adult patient with report estimate dose up to 1,260 mg with no fatality .
& quot ;
& quot ; Osteonecrosis of the jaw have multiple well document risk factor include a diagnosis of cancer , concomitant therapy ( e. g. chemotherapy , radiotherapy , corticosteroid ) and co-morbid condition ( e. g. anaemia , coagulopathies , infection , pre- exist dental disease ) .
& quot ;
& quot ; particular attention should be pay to sudden stab migraine- like headache a a possible warning signal .
& quot ;
& quot ; 300 IU / kg 3x / week for 4 week
& quot ;
& quot ; BLISTER
& quot ;
& quot ; 4 .
& quot ;
& quot ; in patient with chronic renal failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommend in section 4.2 .
& quot ;
& quot ; general disorder and administration site condition :
& quot ;
& quot ; try to take the ABILIFY orodispersible tablet at the same time each day .
& quot ;
& quot ; you may need to read it again .
& quot ;
& quot ; the oral solution should not be dilute with other liquid or mixed with any food prior to administration .
& quot ;
& quot ; the peak be always well below the peak achieve use the intravenous route ( approximately 1 / 20th of the value ) .
& quot ;
& quot ; all special warning and precaution associate with autologous predonation programme , especially routine volume replacement , should be respect .
& quot ;
& quot ; clear colourless solution
& quot ;
& quot ; 5 .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery , with a baseline haemoglobin of 10 to 13 g / dl , the incidence of thrombotic / vascular event ( most of which be DVTs ) , in the overall patient population of the clinical trial , appear to be similar across the different epoetin alfa dose group and placebo group , although the clinical experience be limit .
& quot ;
& quot ; each ml contain 1 mg of aripiprazole .
& quot ;
& quot ; programme , the use of epoetin alfa be not recommend .
& quot ;
& quot ; label / SYRINGE
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; store in the original package in order to protect from moisture .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; possible side effect 5 how to store ABILIFY 6 .
& quot ;
& quot ; Maternal toxicity occur at dos similar to those elicit developmental toxicity .
& quot ;
& quot ; some people may feel depressed .
& quot ;
& quot ; other
& quot ;
& quot ; method OF administration
& quot ;
& quot ; it may be necessary to add or increase antihypertensive treatment .
& quot ;
& quot ; the decision to administer recombinant erythropoietin should be base on a benefit-risk assessment with the participation of the individual patient , which should also take into account the specific clinical context .
& quot ;
& quot ; in chronic renal failure patient Abseamed have not to be administer subcutaneously !
& quot ;
& quot ; in another study in men ( study CZOL446M2308 ) an annual infusion of Aclasta be non-inferior to weekly alendronate for the percentage change in lumbar spine BMD at month 24 relative to baseline .
& quot ;
& quot ; at therapeutic concentration , aripiprazole and dehydro-aripiprazole be greater than 99 % bound to serum protein , bind primarily to albumin .
& quot ;
& quot ; the following maintenance dos be observe in clinical trial after 6 month of treatment :
& quot ;
& quot ; 30 ml ) once a day .
& quot ;
& quot ; how be Abilify use ?
& quot ;
& quot ; ABILIFY 30 mg
& quot ;
& quot ; s R. O .
& quot ;
& quot ; two of these study use haloperidol and lithium ( another antipsychotic medicine ) a comparators and continue for a further nine week to look at the maintenance of the effect of the medicine .
& quot ;
& quot ; Pregnant staff should not handle Abraxane .
& quot ;
& quot ; 12 .
& quot ;
& quot ; in addition , special precaution should be take in patient with predisposition for development of deep vein thrombosis ( DVTs ) .
& quot ;
& quot ; 21 Hepatic disease :
& quot ;
& quot ; the pre-filled syringe should not be shake .
& quot ;
& quot ; Thrombotic event can be a risk in this population and this possibility should be carefully weigh against the benefit to be derive from the treatment in this patient group .
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; in chronic renal failure patient Abseamed have not to be administer subcutaneously !
& quot ;
& quot ; the frequency list below be define use the following convention : common ( & gt ; 1 / 100 , & lt ; 1 / 10 ) and uncommon ( & gt ; 1 / 1 , 000 , & lt ; 1 / 100 ) .
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; 111 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; the frequency of these event be consider not know ( can not be estimate from the available data ) .
& quot ;
& quot ; agitation , nervousness ; suicide attempt , suicidal ideation , and complete suicide ( see section 4.4 )
& quot ;
& quot ; Tablet
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; increase mortality : in three placebo-controlled trial ( n = 938 ; mean age :
& quot ;
& quot ; further information on clinical trial :
& quot ;
& quot ; the incidence of bone marrow fibrosis be not increase in a study of haemodialysis patient who be treat with epoetin alfa for 3 year compare to a match control group of dialysis patient who have not be treat with epoetin alfa . ) .
& quot ;
& quot ; 14 X 1 tablet 28 X 1 tablet 49 X 1 tablet 56 X 1 tablet 98 X 1 tablet
& quot ;
& quot ; other information about Abraxane :
& quot ;
& quot ; oral use
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; Teл . : + 359 800 12 400
& quot ;
& quot ; Italia BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; this stability result in the inhibition of the normal dynamic reorganisation of the microtubule network that be essential for vital interphase and mitotic cellular function .
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; how to store ABILIFY
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6 g / dl or & lt ; 3.75 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 8 g / dl or & gt ; 5 mmol / l ) .
& quot ;
& quot ; information for the user
& quot ;
& quot ; what ABILIFY look like and content of the Pack ABILIFY 15 mg orodispersible tablet be round and yellow , mark with & quot ; & quot ; A & quot ; & quot ; over & quot ; & quot ; 641 & quot ; & quot ; on one side and 15 on the other .
& quot ;
& quot ; 1 pre-filled syringe of 0.5 ml 6 pre-filled syrinx of 0.5 ml
& quot ;
& quot ; store in the original package in order to protect from moisture .
& quot ;
& quot ; the initial dose be 150 IU / kg give subcutaneously 3 time per week .
& quot ;
& quot ; further information
& quot ;
& quot ; in elderly patient with dementia , more fatal case have be report while take aripiprazole .
& quot ;
& quot ; Tel : + 420 221 016 111
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; the patient receive one infusion of Aclasta or they receive risedronate once a day for two month .
& quot ;
& quot ; Aclasta should not be use in patient with hypocalcaemia ( low blood calcium level ) or in pregnant or breast-feeding woman .
& quot ;
& quot ; in addition , other cause of anaemia , such a vitamin B12 or folate deficiency , should be exclude before institute therapy with epoetin alfa .
& quot ;
& quot ; 13 .
& quot ;
& quot ; in all patient receive epoetin alfa , blood pressure should be closely monitor and control a necessary .
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ; there be no adequate and well-controlled study in pregnant woman .
& quot ;
& quot ; Blood pressure-lowering medicine :
& quot ;
& quot ; 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; content by weight , by volume or by unit
& quot ;
& quot ; Measurement of epoetin alfa follow multiple dose intravenous administration reveal a half-life of approximately 4 hour in normal volunteer and a somewhat more prolonged half-life in renal failure patient , approximately 5 hour .
& quot ;
& quot ; possible side effect
& quot ;
& quot ; EU / 1 / 04 / 276 / 036
& quot ;
& quot ; 3 year after first opening :
& quot ;
& quot ; adjustment of daily dosage , include dose reduction should be consider on the basis of clinical status .
& quot ;
& quot ; do not use Abraxane after the expiry date which be state on the carton and the vial after EXP .
& quot ;
& quot ; 3 mg aspartame ( E951 ) per orodispersible tablet
& quot ;
& quot ; each ml of solution contain 10 000 IU of epoetin alfa * correspond to 84.0 microgram per ml 1 pre-filled syringe of 0.5 ml contains 5000 international unit ( IU ) correspond to 42.0 microgram epoetin alfa
& quot ;
& quot ; before you take ABILIFY 3 .
& quot ;
& quot ; therefore , aripiprazole should be use with caution in patient who have a history of seizure disorder or have condition associate with seizure .
& quot ;
& quot ; additional sign may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
& quot ;
& quot ; special storage condition
& quot ;
& quot ; patient who for any reason can not receive adequate antithrombotic prophylaxis .
& quot ;
& quot ; base on in vitro study , CYP3A4 and CYP2D6 enzyme be responsible for dehydrogenation and hydroxylation of aripiprazole , and N-dealkylation be catalyse by CYP3A4 .
& quot ;
& quot ; Cerebrovascular adverse event : in the same trial , cerebrovascular adverse event ( e. g. stroke , transient ischaemic attack ) , include fatality , be report in patient ( mean age :
& quot ;
& quot ; weight gain : in clinical trial aripiprazole have not be show to induce clinically relevant weight gain .
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; NMS be a potentially fatal symptom complex associate with antipsychotic medicinal product .
& quot ;
& quot ; * produce in CHO cell line by recombinant DNA technology
& quot ;
& quot ; in addition , case of stroke or & quot ; & quot ; mini & quot ; & quot ; stroke have be report .
& quot ;
& quot ; how to store ABILIFY
& quot ;
& quot ; Vascular disorder :
& quot ;
& quot ; each tablet contain 10 mg of aripiprazole .
& quot ;
& quot ; - decrease locoregional control in patient with advanced head and neck cancer receiving
& quot ;
& quot ; a with all growth factor , there be a concern that epoetins could stimulate the growth of tumour .
& quot ;
& quot ; Abseamed be give by injection into a vein ( intravenously ) .
& quot ;
& quot ; Batch
& quot ;
& quot ; if you have any further question , ask your doctor or pharmacist .
& quot ;
& quot ; if sign and symptom of tardive dyskinesia appear in a patient on ABILIFY , dose reduction or discontinuation should be consider .
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; precise risk estimate for hyperglycaemia-related adverse event in patient treat with ABILIFY and with other atypical antipsychotic agent be not available to allow direct comparison .
& quot ;
& quot ; if you notice you be gain weight , experience any difficulty in swallow or allergic symptom , please tell your doctor .
& quot ;
& quot ; Clinical manifestation of NMS be hyperpyrexia , muscle rigidity , alter mental status and evidence of autonomic instability ( irregular pulse or blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; cardiovascular disorder :
& quot ;
& quot ; how have Abilify be study ?
& quot ;
& quot ;
& quot ; when concomitant administration of potent CYP3A4 inducer with aripiprazole occurs , the aripiprazole dose should be increase .
& quot ;
& quot ; this medicinal product must not be administer by intravenous infusion , or mixed with other medicinal product .
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; in a 26-week , placebo-controlled trial in stabilised patient with chronic schizophrenia , aripiprazole have significantly greater reduction in relapse rate , 34 % in aripiprazole group and 57 % in placebo .
& quot ;
& quot ; Abseamed must not be use
& quot ;
& quot ; adjustment of daily dosage , include dose reduction should be consider on the basis of clinical status .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; weight ( kg ) & lt ; 10 10 - 30 & gt ; 30
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; adult patient with renal insufficiency not yet undergoing dialysis :
& quot ;
& quot ; all patient be treat with epoetin alfa should receive adequate iron supplementation ( e. g. oral iron substitution of 200 mg Fe2 + daily ) throughout the course of epoetin alfa treatment .
& quot ;
& quot ; possible side effect 5 how to store ABILIFY 6 .
& quot ;
& quot ; Τηλ : + 357 22 677038
& quot ;
& quot ; however , elevate creatine phosphokinase and rhabdomyolysis , not necessarily in association with NMS , have also be report .
& quot ;
& quot ; European public assessment report ( EPAR )
& quot ;
& quot ; Tablet
& quot ;
& quot ; patient should be closely monitor throughout this period .
& quot ;
& quot ; pancreatitis , dysphagia , abdominal discomfort , stomach discomfort , diarrhoea
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; in the four placebo-controlled study the hazard ratio for overall survival range between 1.25 and 2.47 in favour of control .
& quot ;
& quot ; store in the original package in order to protect from moisture .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ; your doctor may check your shunt and prescribe a medicinal product to prevent thrombosis .
& quot ;
& quot ; patient should be advise to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole .
& quot ;
& quot ; immediately upon open the blister , use dry hand , remove the tablet and place the entire orodispersible tablet on the tongue .
& quot ;
& quot ; if you have any further question on the use of this product , ask your doctor or pharmacist .
& quot ;
& quot ; Arthralgia occur in 32 % of patient on Abraxane and be severe in 6 % of case .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; in haemodialysed patient , a bolus injection may be give during the dialysis session through a suitable venous port in the dialysis line .
& quot ;
& quot ; result of an epidemiological study find that there be no increase risk of suicidality with aripiprazole compare to other antipsychotic among patient with bipolar disorder .
& quot ;
& quot ; the dose may be adjust by your doctor depend on how your anaemia respond to treatment .
& quot ;
& quot ; an investigational study ( best study ) in woman with metastatic breast cancer be design to determine whether epoetin alfa treatment that extend beyond the correction of anaemia could improve treatment outcome .
& quot ;
& quot ; 13 .
& quot ;
& quot ; 3 .
& quot ;
& quot ; ABILIFY dose should be double when concomitant administration of ABILIFY occur with carbamazepine .
& quot ;
& quot ; immune system disorder :
& quot ;
& quot ; 15 mg
& quot ;
& quot ; after reconstitution , each ml of suspension contains 5 mg of paclitaxel .
& quot ;
& quot ; Antibody-mediated erythroblastopenia ( PRCA ) have be report after month to year of treatment with epoetin alfa .
& quot ;
& quot ; Cerebrovascular adverse event : in the same trial , cerebrovascular adverse event ( e. g. stroke , transient ischaemic attack ) , include fatality , be report in patient ( mean age :
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; these symptom can temporally deteriorate or can even arise after discontinuation of treatment .
& quot ;
& quot ; ABILIFY 15 mg
& quot ;
& quot ; study in animal have show reproduction toxicity ( see section 5.3 ) .
& quot ;
& quot ; the potential risk for human be unknown .
& quot ;
& quot ; 9 table 4
& quot ;
& quot ; there be conflict report in the literature regard whether erythropoietin may play a major role a tumour proliferators .
& quot ;
& quot ; EXP
& quot ;
& quot ; in addition , the following side effect have be see in patient treat with oral formulation of ABILIFY :
& quot ;
& quot ; additional sign may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
& quot ;
& quot ; Musculoskeletal and connective tissue disorder :
& quot ;
& quot ; tell your doctor immediately if you be have any thought or feeling about hurt yourself .
& quot ;
& quot ; in case where there be a medical need to shorten the lead time before surgery to le than three week , 300 IU / kg epoetin alfa should be give daily for 10 consecutive day prior to surgery , on the day of surgery and for four day immediately thereafter .
& quot ;
& quot ; Aripiprazole exhibit high binding affinity in vitro for dopamine D2 and D3 , serotonin 5HT1a and 5HT2a receptor and moderate affinity for dopamine D4 , serotonin 5HT2c and 5HT7 , alpha-1 adrenergic and histamine H1 receptor .
& quot ;
& quot ; Hepatobiliary disorder Reproductive system and breast disorder :
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; 2 .
& quot ;
& quot ; Epoetin alfa do not show any change in bacterial and mammalian cell culture mutagenicity test and an in vivo micronucleus test in mouse .
& quot ;
& quot ; when aripiprazole be administer concomitantly with either valproate or lithium , there be no clinically important change in valproate or lithium concentration .
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; Abseamed
& quot ;
& quot ; 10 mg
& quot ;
& quot ; Abraxane should not be use in combination with other anticancer agent .
& quot ;
& quot ; Abseamed have no influence on the ability to drive and use machine .
& quot ;
& quot ; what be Abseamed use for ?
& quot ;
& quot ; if you can not reach your doctor , go to the nearest hospital and take the Pack with you .
& quot ;
& quot ; 183 9 .
& quot ;
& quot ; however , in one of these trial , a fixed-dose trial , there be a significant dose response relationship for cerebrovascular adverse event in patient treat with aripiprazole .
& quot ;
& quot ; 7 .
& quot ;
& quot ; adequate supplement of vitamin D and calcium be also recommend for all patient receive Aclasta .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; take special care with ABILIFY before treatment with ABILIFY , tell your doctor if you suffer from High blood sugar or family history of diabetes seizure Involuntary , irregular muscle movement , especially in the face cardiovascular disease , family history of cardiovascular disease , stroke or & quot ; & quot ; mini & quot ; & quot ; stroke , abnormal blood pressure
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; the potentially medically serious sign and symptom report included somnolence , transient loss of consciousness and extrapyramidal symptom .
& quot ;
& quot ; non response to epoetin alfa therapy may have the following cause : iron , folate , or vitamin B12 deficiency ; aluminium intoxication ; intercurrent infection ; inflammatory or traumatic episode ; occult blood loss ; haemolysis , and bone marrow fibrosis of any origin .
& quot ;
& quot ; the apparent molecular weight of erythropoietin be 32,000 to 40,000 dalton .
& quot ;
& quot ; lot
& quot ;
& quot ; Medicines should not be dispose of via wastewater or household waste .
& quot ;
& quot ; Overdose of epoetin alfa may produce effect that be extension of the pharmacological effect of the hormone .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; the recommended total weekly dose be between 75 and 300 IU / kg give by the intravenous route .
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; 8 .
& quot ;
& quot ; the most frequent adverse reaction be an increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ; however , a with other antipsychotic , patient should be caution about operate hazardous machine , include motor vehicle , until they be reasonably certain that aripiprazole do not affect them adversely .
& quot ;
& quot ; 2 .
& quot ;
& quot ; oral solution
& quot ;
& quot ; before you take ABILIFY 3 .
& quot ;
& quot ; route of Administration
& quot ;
& quot ; for subcutaneous and intravenous use .
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; instruction on use
& quot ;
& quot ; Tel : + 372 640 1301
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl
& quot ;
& quot ; - skin rash
& quot ;
& quot ; 2 .
& quot ;
& quot ; Ísland VISTOR HF Sími : + 354 535 7000
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; the half-life be difficult to evaluate for the subcutaneous route and be estimate about 24 hour .
& quot ;
& quot ; 28 X 1
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ; in patient with chronic renal failure the medicinal product have to be administer intravenously ( see section 4.4 ) .
& quot ;
& quot ; patient schedule for orthopaedic surgery
& quot ;
& quot ; however , the concentration of the sulphate conjugate of hydroxy aripiprazole in human bile at the highest dose propose , 30 mg per day , be no more than 6 % of the bile concentration find in the monkey in the 39-week study and be well below ( 6 % ) their limit of in vitro solubility .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; 1 bottle + 1 cup + 1 calibrate dropper
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; manufacture authorisation holder responsible for BATCH release
& quot ;
& quot ; patient should be advise not to breast feed if they be take aripiprazole .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; solution for injection clear , colourless , aqueous solution .
& quot ;
& quot ; the orodispersible tablet can be take with or without liquid .
& quot ;
& quot ; Abraxane be supply a a sterile lyophilise powder for reconstitution before use .
& quot ;
& quot ; programme , the use of epoetin alfa be not recommend .
& quot ;
& quot ; • other condition
& quot ;
& quot ; ABILIFY solution for injection be use to treat quickly symptom of agitation and distress behaviour that may occur in a disease characterise by symptom such a : hearing , see or sense thing which be not there , suspiciousness , mistaken belief , incoherent speech and behaviour and emotional flatness .
& quot ;
& quot ; if you have any further question on the use of this product , ask your doctor or pharmacist .
& quot ;
& quot ; it be not know whether aripiprazole be excrete in human milk .
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; other
& quot ;
& quot ; Abseamed
& quot ;
& quot ; Tardive Dyskinesia : in clinical trial of one year or le duration , there be uncommon report of treatment emergent dyskinesia during treatment with aripiprazole .
& quot ;
& quot ; the solution should not be inject directly onto the powder a this will result in foaming .
& quot ;
& quot ; what ABILIFY be and what it be use for 2 .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; EU / 1 / 04 / 276 / 001 14 X 1 tablet EU / 1 / 04 / 276 / 002 28 X 1 tablet EU / 1 / 04 / 276 / 003 49 X 1 tablet EU / 1 / 04 / 276 / 004 56 X 1 tablet EU / 1 / 04 / 276 / 005 98 X 1 tablet
& quot ;
& quot ; general
& quot ;
& quot ; Aclasta 5 mg solution for infusion Zoledronic acid
& quot ;
& quot ; moreover , monitoring of the blood pressure be recommend particularly at the start of therapy .
& quot ;
& quot ; oral solution :
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6.8 g / dl or & lt ; 4.25 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 6.8 g / dl or & gt ; 4.25 mmol / l ) .
& quot ;
& quot ; how to take ABILIFY
& quot ;
& quot ; 15 .
& quot ;
& quot ; these increase in blood pressure can be treat with medicinal product .
& quot ;
& quot ; thereafter bone marker stabilise within the pre-menopausal range .
& quot ;
& quot ; 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; Tel : + 421 2 59298411
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; label / SYRINGE
& quot ;
& quot ; before you take ABILIFY 3 .
& quot ;
& quot ; Slovenija BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; 5.5 ( 4.4 , 6.6 )
& quot ;
& quot ; the incidence of post-dose symptom occur within the first three day after administration of Aclasta can be reduce with the administration of paracetamol or ibuprofen shortly follow Aclasta administration .
& quot ;
& quot ; patient should be advise not to breast feed if they be take aripiprazole .
& quot ;
& quot ; 30 mg
& quot ;
& quot ; mildly anaemic patient ( haematocrit of 33 - 39 % ) require predeposit of ≥ 4 unit of blood should be treat with Abseamed at a dose of 600 IU / kg body weight 2 time weekly for 3 week prior to surgery .
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; 49 X 1
& quot ;
& quot ; Epoetin alfa obtain by gene technology be glycosylated and be identical in it amino acid and carbohydrate composition to endogenous human erythropoietin that have be isolate from the urine of anaemic patient .
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; other potent inhibitor of CYP2D6 , such a fluoxetine and paroxetine , may be expect to have similar effect and similar dose reduction should therefore be apply .
& quot ;
& quot ; if anti-erythropoietin , antibody-mediated PRCA be suspect , therapy with Abseamed should be discontinue immediately .
& quot ;
& quot ; Thrombotic event can be a risk in this population and this possibility should be carefully weigh against the benefit to be derive from the treatment in this patient group .
& quot ;
& quot ; Abraxane be use on it own .
& quot ;
& quot ; the study either recruited patient who be be treat with chemotherapy ( two study ) or use patient population in which erythropoiesis stimulating agent be not indicate : anaemia in patient with cancer not receive chemotherapy , and head and neck cancer patient receive radiotherapy .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; - if the solution have be accidentally frozen .
& quot ;
& quot ; event rate ( % )
& quot ;
& quot ; non response to epoetin alfa therapy may have the following cause : iron , folate , or vitamin B12 deficiency ; aluminium intoxication ; intercurrent infection ; inflammatory or traumatic episode ; occult blood loss ; haemolysis , and bone marrow fibrosis of any origin .
& quot ;
& quot ; a .
& quot ;
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; in animal study , epoetin alfa have be show to decrease foetal body weight , delay ossification and increase foetal mortality when give in weekly dos of approximately 20 time the recommended human weekly dose .
& quot ;
& quot ; other infrequently report side effect :
& quot ;
& quot ; Abilify
& quot ;
& quot ; 300 IU / kg 3x / week for 4 week
& quot ;
& quot ; Epoetin alfa obtain by gene technology be glycosylated and be identical in it amino acid and carbohydrate composition to endogenous human erythropoietin that have be isolate from the urine of anaemic patient .
& quot ;
& quot ; KGAA Tel : + 49 89 121 42-0
& quot ;
& quot ; other
& quot ;
& quot ; ABILIFY 30 mg orodispersible tablet aripiprazole
& quot ;
& quot ; weight gain , weight decrease , anorexia , hyponatremia
& quot ;
& quot ; the reference medicine for Abseamed be Eprex / Erypo .
& quot ;
& quot ; Abseamed 5000 IU / 0.5 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; if you can not reach your doctor , go to the nearest hospital and take the Pack with you .
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; investigation :
& quot ;
& quot ; adult haemodialysis patient :
& quot ;
& quot ; Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel : + 353 ( 1 800 ) 749 749
& quot ;
& quot ; people with this condition may also feel depressed , guilty , anxious or tense .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; therefore cardiovascular monitoring should be start immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmia .
& quot ;
& quot ; Hypertensive crisis with encephalopathy-like symptom can occur .
& quot ;
& quot ; priapism
& quot ;
& quot ; route of Administration
& quot ;
& quot ; elimination :
& quot ;
& quot ; pre-existing hypocalcaemia must be treat by adequate intake of calcium and vitamin D before initiate therapy with Aclasta ( see section 4.3 ) .
& quot ;
& quot ; Dialysis prescription may have to be adjust periodically to maintain urea , creatinine and potassium in the desired range .
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; may be harmful for people with phenylketonuria .
& quot ;
& quot ; a rise in haemoglobin of greater than 2 g / dl ( 1.25 mmol / l ) over a four week period should be avoid .
& quot ;
& quot ; Medicines to correct heart rhythm Antidepressants or herbal remedy use to treat depression and anxiety Antifungal agent certain medicine to treat HIV infection Anticonvulsants use to treat epilepsy
& quot ;
& quot ; EU / 1 / 07 / 412 / 011 EU / 1 / 07 / 412 / 012
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; allergic reaction ( e. g. anaphylactic reaction , angioedema include swollen tongue , tongue oedema , face oedema , pruritus , or urticaria )
& quot ;
& quot ; Pharmacotherapeutic group : antianaemic , ATC code :
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; 1.5
& quot ;
& quot ; although there be no information on the effect of haemodialysis in treat an overdose with aripiprazole , haemodialysis be unlikely to be useful in overdose management since aripiprazole be highly bind to plasma protein .
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; Tel : + 39 06 50 39 61
& quot ;
& quot ; speech disorder , Neuroleptic Malignant syndrome ( NMS ) , grand mal convulsion
& quot ;
& quot ; 1 pre-filled syringe of 1 ml 6 pre-filled syrinx of 1 ml
& quot ;
& quot ; 2 year
& quot ;
& quot ; in several controlled study , epoetins have not be show to improve overall survival or decrease the risk of tumour progression in patient with anaemia associate with cancer .
& quot ;
& quot ; Τηλ : + 30 210 6074300
& quot ;
& quot ; - Thrombotic event ( blood clot ) in blood vessel , such a disturbed blood perfusion of the
& quot ;
& quot ; Tel : + 386 1 236 47 00
& quot ;
& quot ; Abseamed can be use to increase the yield of autologous blood from patient in a predonation programme .
& quot ;
& quot ; - pure red cell aplasia ( PRCA ) have be very rarely report in patient after month to year of
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; there be no adequate and well-controlled study in pregnant woman .
& quot ;
& quot ; in the absence of compatibility study , this medicinal product must not be mix with other medicinal product .
& quot ;
& quot ; the intravenous route have to be use ( please see section 4.4 - chronic renal failure patient ) .
& quot ;
& quot ; Abseamed be a sterile but unpreserved product and be for single use only .
& quot ;
& quot ; Aripiprazole undergo minimal pre-systemic metabolism .
& quot ;
& quot ; iron status should be evaluate prior to and during treatment and iron supplementation administer if necessary .
& quot ;
& quot ; keep the vial in the outer carton in order to protect from light .
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; Medice
& quot ;
& quot ; 200 mg oral elemental iron daily ) throughout the course of treatment .
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl or Hb increase ≥ 1 g / dl
& quot ;
& quot ; patient should be advise not to breast feed if they be take aripiprazole .
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; Tel : + 39 06 50 39 61
& quot ;
& quot ; the mean Cmax of paclitaxel , which occur at the end of the infusion , be 18.7 µg / ml .
& quot ;
& quot ; Abseamed have no influence on the ability to drive and use machine .
& quot ;
& quot ; non response to epoetin alfa therapy may have the following cause : iron , folate , or vitamin B12 deficiency ; aluminium intoxication ; intercurrent infection ; inflammatory or traumatic episode ; occult blood loss ; haemolysis , and bone marrow fibrosis of any origin .
& quot ;
& quot ; in an infusion bag : up to 8 hour not above 25oC
& quot ;
& quot ; alternatively , epoetin alfa can be administer at an initial dose of 450 IU / kg subcutaneously once weekly .
& quot ;
& quot ; EU / 1 / 07 / 412 / 011 EU / 1 / 07 / 412 / 012
& quot ;
& quot ;
& quot ; 1 pre-filled syringe
& quot ;
& quot ; ABILIFY 30 mg orodispersible tablet
& quot ;
& quot ; in one short-term ( 24-hour ) placebo-controlled trial involve 291 patient with bipolar disorder present with agitation and disturbed behaviour , aripiprazole solution for injection be associate with statistically significant greater improvement in agitation / behavioural symptom compare to placebo and be similar to the reference arm lorazepam .
& quot ;
& quot ; Excipients : sodium dihydrogen phosphate dihydrate , disodium phosphate dihydrate , sodium chloride , glycine , polysorbate 80 , hydrochloric acid ( for pH-adjustment ) , sodium hydroxide ( for pH-adjustment ) , and water for injection
& quot ;
& quot ; rhabdomyolysis , myalgia , stiffness
& quot ;
& quot ; the syrinx contain 0.7 ml ( 7000 IU ) of solution .
& quot ;
& quot ; additional sign may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
& quot ;
& quot ; in placebo-controlled trial , the incidence of akathisia in bipolar patient be 12.1 % with aripiprazole and 3.2 % with placebo .
& quot ;
& quot ; ask your doctor or pharmacist for advice before take ABILIFY .
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; 3 .
& quot ;
& quot ; common side effect ( greater than 1 in 100 , le than 1 in 10 patient ) Uncontrollable twitching or jerking movement , headache , tiredness , nausea , vomit , an uncomfortable feeling in the stomach , constipation , increased production of saliva , light-headedness , trouble sleeping , restlessness , feel anxious , sleepiness , shake and blurred vision .
& quot ;
& quot ; Abseamed 7000 IU / 0.7 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; 6 .
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; for subcutaneous and intravenous use .
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; 71 1 .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; patient treat with any antipsychotic agent , include ABILIFY , should be observe for sign and symptom of hyperglycaemia ( such a polydipsia , polyuria , polyphagia and weakness ) and patient with diabetes mellitus or with risk factor for diabetes mellitus should be monitor regularly for worsen of glucose control .
& quot ;
& quot ; 12 1 .
& quot ;
& quot ; Carton of 49 X 1 tablet in cold-formed aluminium perforate unit dose blister .
& quot ;
& quot ; during antipsychotic treatment , improvement in the patient & apos ; s clinical condition may take several day to some week .
& quot ;
& quot ; it could be show with the aid of cell culture of human bone marrow cell that epoetin alfa stimulates erythropoiesis specifically and do not affect leucopoiesis .
& quot ;
& quot ; Tel : + 40 ( 0 ) 21 272 16 00
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; Endocrine disorder :
& quot ;
& quot ; lot
& quot ;
& quot ; driving and use machine do not drive or use any tool or machine , until you know how ABILIFY affect you .
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; instruction on use
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be avoid .
& quot ;
& quot ; patient donate their own blood before surgery
& quot ;
& quot ; ABILIFY 30 mg tablet aripiprazole
& quot ;
& quot ; adult surgery patient in an autologous predonation programme
& quot ;
& quot ; in haemodialysed patient , a bolus injection may be give during the dialysis session through a suitable venous port in the dialysis line .
& quot ;
& quot ; in patient with chronic renal failure the medicinal product have to be administer intravenously ( see section 4.4 ) .
& quot ;
& quot ; detail information on this product be available on the website of the European Medicines Agency ( EMEA ) http : / / www . emea . europa . EU /
& quot ;
& quot ; Danmark BRISTOL-MYERS SQUIBB Tlf : + 45 45 93 05 06
& quot ;
& quot ; the highest nontumorigenic exposure in female rat be 7 time the human exposure at the recommend dose .
& quot ;
& quot ; it be not know whether aripiprazole be excrete in human milk .
& quot ;
& quot ; Teл . : + 359 800 12 400
& quot ;
& quot ; Erythropoietins be growth factor that primarily stimulate red blood cell production .
& quot ;
& quot ; Sverige BRISTOL-MYERS SQUIBB AB Tel : + 46 8 704 71 00
& quot ;
& quot ; in a long term 26-week placebo-controlled trial , the incidence of EPS be 19 % for aripiprazole-treated patient and 13.1 % for placebo-treated patient .
& quot ;
& quot ; Cytotoxic action of epoetin alfa on bone marrow cell could not be detect .
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; the safety and efficacy of aripiprazole solution for injection have not be evaluate in patient with alcohol or medicinal product intoxication ( either with prescribed or illicit medicinal product ) .
& quot ;
& quot ; the company that make Abseamed will provide information pack for healthcare worker in all Member States , include information on the safety of the medicine .
& quot ;
& quot ; 1 .
& quot ;
& quot ; child and adolescent : there be no experience in child and adolescent under 18 year of age .
& quot ;
& quot ; 4 .
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ; alcohol should be avoid when take ABILIFY .
& quot ;
& quot ; 9000 IU /
& quot ;
& quot ; result of an epidemiological study find that there be no increase risk of suicidality with aripiprazole compare to other antipsychotic among patient with bipolar disorder .
& quot ;
& quot ; 0.8 ml ( 10000 IU / ml )
& quot ;
& quot ; cardiovascular disorder :
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; 54 721 cancer patient receive non-platinum chemotherapy be include in three placebo-controlled study , 389 patient with haematological malignancy ( 221 multiple myeloma , 144 non-Hodgkin & apos ; s lymphoma , and 24 other haematological malignancy ) and 332 with solid tumour ( 172 breast , 64 gynaecological , 23 lung , 22 prostate , 21 gastro-intestinal , and 30 other tumour type ) .
& quot ;
& quot ; statement OF active substance
& quot ;
& quot ; 100 ml transparent plastic ( cycloolefinic polymer ) bottle close with a fluoro-polymer coated bromobutyl rubber stopper and an aluminium / polypropylene CAP with a flip component .
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; Intravenous route
& quot ;
& quot ; { MM / YYYY }
& quot ;
& quot ; Correction for anaemia may lead to increase appetite , and potassium and protein intake .
& quot ;
& quot ; 107 Annex III
& quot ;
& quot ; content
& quot ;
& quot ; 15 .
& quot ;
& quot ; start dose of 50 IU / kg 2 time per week by the intravenous route .
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; instruction on use
& quot ;
& quot ; 14 .
& quot ;
& quot ; therefore , interaction result from displacement of highly protein-bound drug be unlikely .
& quot ;
& quot ; 15 .
& quot ;
& quot ; Abraxane 5 mg / ml powder for suspension for infusion .
& quot ;
& quot ; an increase in heparin dose during haemodialysis be frequently require during the course of therapy with epoetin alfa a a result of the increase packed cell volume .
& quot ;
& quot ; the half-life be difficult to evaluate for the subcutaneous route and be estimate about 24 hour .
& quot ;
& quot ; the European Commission grant a marketing authorisation valid throughout the EU for Abseamed to Medice Arzneimittel Pütter GmbH & amp ; Co kg on 28 August 2007 .
& quot ;
& quot ; Tel : + 386 1 236 47 00
& quot ;
& quot ; Respiratory , thoracic and mediastinal disorder :
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; cardiovascular disorder :
& quot ;
& quot ; * produce in CHO cell line by recombinant DNA technology
& quot ;
& quot ; base on in vitro study , CYP3A4 and CYP2D6 enzyme be responsible for dehydrogenation and hydroxylation of aripiprazole , and N-dealkylation be catalyse by CYP3A4 .
& quot ;
& quot ; store in the original package in order to protect from moisture .
& quot ;
& quot ; in addition , report of accidental overdose with aripiprazole alone ( up to 195 mg ) in child have be receive with no fatality .
& quot ;
& quot ; 20.9 & # 91 ; 15.7 , 25.9 & # 93 ; ( n = 131 )
& quot ;
& quot ; adult haemodialysis patient :
& quot ;
& quot ; Intravenous route
& quot ;
& quot ; other potent inhibitor of CYP2D6 , such a fluoxetine and paroxetine , may be expect to have similar effect and similar dose reduction should therefore be apply .
& quot ;
& quot ; Orodispersible Tablet
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; България BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; possible side effect 5 .
& quot ;
& quot ; instruction on use
& quot ;
& quot ; treatment of symptomatic anaemia in adult and paediatric chronic renal failure patient :
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; pancreatitis , dysphagia , abdominal discomfort , stomach discomfort , diarrhoea
& quot ;
& quot ; Sodium dihydrogen phosphate dihydrate Disodium phosphate dihydrate Sodium chloride Glycine Polysorbate 80 water for injection Hydrochloric acid ( for pH-adjustment ) Sodium hydroxide ( for pH-adjustment )
& quot ;
& quot ; treatment of symptomatic anaemia in adult and paediatric chronic renal failure patient :
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ;
& quot ; in another 12-week trial , the incidence of EPS be 26.6 % for patient treat with aripiprazole and 17.6 % for those treat with lithium .
& quot ;
& quot ; Renal disease :
& quot ;
& quot ; Aripiprazole be extensively metabolise by the liver primarily by three biotransformation pathway : dehydrogenation , hydroxylation , and N-dealkylation .
& quot ;
& quot ; Immunogenicity data for subcutaneous use of Abseamed in patient at risk for antibody-induced PRCA , I. e. patient with renal anaemia , be not sufficient .
& quot ;
& quot ; 7 table 2
& quot ;
& quot ; Excipients : sodium dihydrogen phosphate dihydrate , disodium phosphate dihydrate , sodium chloride , glycine , polysorbate 80 , hydrochloric acid ( for pH-adjustment ) , sodium hydroxide ( for pH-adjustment ) , and water for injection
& quot ;
& quot ; in case of larger volume , more than one site should be choose for the injection .
& quot ;
& quot ; the Committee recommend that Abseamed be give market authorisation .
& quot ;
& quot ; child and adolescent : there be no experience in child and adolescent under 18 year of age .
& quot ;
& quot ; 16 .
& quot ;
& quot ; complete resuspension should be ensure by mild agitation before use .
& quot ;
& quot ; Administer the amount require .
& quot ;
& quot ; this medicinal product must not be administer by intravenous infusion , or mixed with other medicinal product .
& quot ;
& quot ; no evidence exist that indicate that treatment with epoetin alfa alter the metabolism of other medicinal product .
& quot ;
& quot ; the maximum dose should not exceed 200 IU / kg 3 time per week .
& quot ;
& quot ; in patient with chronic renal failure and clinically evident ischaemic heart disease or congestive heart failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration a recommend under section 4.2 .
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; when concomitant administration of potent CYP3A4 or CYP2D6 inhibitor with aripiprazole occurs , the aripiprazole dose should be reduce .
& quot ;
& quot ; patient with renal impairment : no dosage adjustment be require in patient with renal impairment .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; 2 .
& quot ;
& quot ; try to take the ABILIFY tablet at the same time each day .
& quot ;
& quot ; lot
& quot ;
& quot ; 1 .
& quot ;
& quot ; 4000 IU / 0.4 ml
& quot ;
& quot ; Blood pressure-lowering medicine :
& quot ;
& quot ; 3 .
& quot ;
& quot ; it could be show with the aid of cell culture of human bone marrow cell that epoetin alfa stimulates erythropoiesis specifically and do not affect leucopoiesis .
& quot ;
& quot ; in three short-term ( 4 to 6 week ) placebo-controlled trial involve 1,228 schizophrenic patient , present with positive or negative symptom , aripiprazole be associate with statistically significantly greater improvement in psychotic symptom compare to placebo .
& quot ;
& quot ;
& quot ; România BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; 12 g / dl )
& quot ;
& quot ; ABILIFY 10 mg
& quot ;
& quot ; 10 .
& quot ;
& quot ; 3 .
& quot ;
& quot ; Gastrointestinal disorder :
& quot ;
& quot ; ABILIFY 15 mg orodispersible tablet aripiprazole
& quot ;
& quot ; Abseamed must not be use
& quot ;
& quot ; Hepatobiliary disorder :
& quot ;
& quot ; the generation of foam should be avoid .
& quot ;
& quot ; EXP
& quot ;
& quot ; attention should be pay to sudden stab migraine-like headache a a possible warning signal .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; * produce in CHO cell line by recombinant DNA technology
& quot ;
& quot ; Aclasta be contraindicate during pregnancy and in breast-feeding woman ( see section 4.3 ) .
& quot ;
& quot ; 1.35 , 2.06 , 35 trial and 6769 patient ) be observe in patient treat with recombinant human erythropoietin .
& quot ;
& quot ; EU / 1 / 07 / 412 / 019 EU / 1 / 07 / 412 / 020
& quot ;
& quot ; general
& quot ;
& quot ; in the open-label study there be no difference in overall survival between patient treat with recombinant human erythropoietin and control .
& quot ;
& quot ; Breastfeeding must be discontinue for the duration of therapy .
& quot ;
& quot ; Antibody-mediated PRCA have be very rarely report in patient after month to year of subcutaneous ( injection under the skin ) erythropoietin treatment .
& quot ;
& quot ; 4 June 2004
& quot ;
& quot ; in some preclinical toxicological study in dog and rat , but not in monkey , epoetin alfa therapy be associate with subclinical bone marrow fibrosis ( bone marrow fibrosis be a known complication of chronic renal failure in human and may be relate to secondary hyperparathyroidism or unknown factor .
& quot ;
& quot ; other finding :
& quot ;
& quot ; for patient with kidney problem and patient who be go to donate their own blood , Abseamed must be inject into a vein .
& quot ;
& quot ; patient should be advise to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole .
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and then reinstitute epoetin alfa therapy at a dose 25 % below the previous level .
& quot ;
& quot ; the pre-filled syrinx be ready to use ( see section 4.2 – method of administration ) .
& quot ;
& quot ; other
& quot ;
& quot ; what ABILIFY be AND what IT be use for
& quot ;
& quot ; instruction on use
& quot ;
& quot ; in view of the above , in some clinical situation blood transfusion should be the preferred treatment for the management of anaemia in patient with cancer .
& quot ;
& quot ; 30 mg
& quot ;
& quot ; Paediatric haemodialysis patient :
& quot ;
& quot ; all special warning and precaution associate with autologous predonation programme , especially routine volume replacement , should be respect .
& quot ;
& quot ; expiry date
& quot ;
& quot ; EU / 1 / 04 / 276 / 027 14 X 1 orodispersible tablet EU / 1 / 04 / 276 / 028 28 X 1 orodispersible tablet EU / 1 / 04 / 276 / 029 49 X 1 orodispersible tablet
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; Abraxane also affect non-cancer cell such a blood and nerve cell , which can cause side effect .
& quot ;
& quot ; there be no accumulation : the level remain the same , whether they be determined 24 hour after the first injection or 24 hour after the last injection .
& quot ;
& quot ; Uncommon side effect ( greater than 1 in 1,000 , le than 1 in 100 patient ) some people may feel dizzy , especially when get up from a lying or sit position , or may experience a fast heart rate .
& quot ;
& quot ; 1 .
& quot ;
& quot ; Thrombotic event can be a risk in this population and this possibility should be carefully weigh against the benefit to be derive from the treatment in this patient group .
& quot ;
& quot ; the orodispersible tablet be take by be place on the tongue , where they disintegrate quickly in the saliva , or by mix them in water before swallowing .
& quot ;
& quot ; adult and paediatric haemodialysis patient , adult peritoneal dialysis patient and adult patient with renal insufficiency not yet undergoing dialysis
& quot ;
& quot ; 3 .
& quot ;
& quot ; - This medicine have be prescribe for you .
& quot ;
& quot ; 1 .
& quot ;
& quot ; Abseamed should be administer intravenously in order to increase haemoglobin to not greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; if an elevate ( or rise ) serum potassium level be detect then consideration should be give to cease epoetin alfa administration until hyperkalaemia have be correct .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; in the osteoporosis trial ( PFT , horizon - Recurrent fracture trial & # 91 ; RFT & # 93 ; ) the pooled atrial fibrillation incidence be comparable between Aclasta ( 2.6 % ) and placebo ( 2.1 % ) .
& quot ;
& quot ; Thrombocytosis have be observe but it occurrence be very rare ( see section 4.4 ) .
& quot ;
& quot ; skin and subcutaneous tissue disorder :
& quot ;
& quot ; special storage condition
& quot ;
& quot ; the median time to disease progression be 5.3 month ( 175 mg / m2 ; 95 % CI :
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; Thrombotic event can be a risk in this population and this possibility should be carefully weigh against the benefit to be derive from the treatment in this patient group .
& quot ;
& quot ; package LEAFLET
& quot ;
& quot ; when the CYP3A4 or CYP2D6 inhibitor be withdraw from the combination therapy , aripiprazole dose should then be increase ( see section 4.5 ) .
& quot ;
& quot ; Contrada Fontana del Ceraso I-03012 Anagni-Frosinone - Italy
& quot ;
& quot ; България BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; it also prevent this condition from return in patient who have respond to the treatment with ABILIFY .
& quot ;
& quot ; when concomitant administration of potent CYP3A4 or CYP2D6 inhibitor with aripiprazole occurs , the aripiprazole dose should be reduce .
& quot ;
& quot ; Tel . : + 48 22 5796666
& quot ;
& quot ; programme , the use of epoetin alfa be not recommend .
& quot ;
& quot ; Dysphagia : oesophageal dysmotility and aspiration have be associate with antipsychotic drug use , include ABILIFY .
& quot ;
& quot ; adult and paediatric haemodialysis patient , adult peritoneal dialysis patient and adult patient with renal insufficiency not yet undergoing dialysis
& quot ;
& quot ; there be no adequate data on the use of zoledronic acid in pregnant woman .
& quot ;
& quot ; treatment with aripiprazole solution for injection should be discontinue a soon a clinically appropriate and the use of oral aripiprazole should be initiate .
& quot ;
& quot ; the oral solution contains fructose .
& quot ;
& quot ; tell your doctor immediately if you be have any thought or feeling about hurt yourself .
& quot ;
& quot ; functional assessment of Cancer Therapy- Anaemia ( FACT-An ) general scale , FACT-An fatigue scale , and Cancer linear Analogue scale ( CLAS ) .
& quot ;
& quot ; usual maintenance dose 75 - 150 60 - 150 30 - 100
& quot ;
& quot ; information for the user
& quot ;
& quot ; common side effect ( greater than 1 in 100 , le than 1 in 10 patient ) Uncontrollable twitching or jerking movement , headache , tiredness , nausea , vomit , an uncomfortable feeling in the stomach , constipation , increased production of saliva , light-headedness , trouble sleeping , restlessness , feel anxious , sleepiness , shake and blurred vision .
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; a with other antipsychotic , aripiprazole should be use with caution in patient with a family history of QT prolongation .
& quot ;
& quot ; Abseamed
& quot ;
& quot ; people with this condition may also feel depressed , guilty , anxious or tense .
& quot ;
& quot ; in clinical trial , an increase risk of death and serious cardiovascular event be observe when erythropoiesis stimulate agent ( ESAs ) be administer to target a haemoglobin of greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; Uncommon side effect ( greater than 1 in 1,000 , le than 1 in 100 patient ) some people may feel dizzy , especially when get up from a lying or sit position , or may experience a fast heart rate .
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; Gastrointestinal disorder :
& quot ;
& quot ; two other smaller , randomise , placebo-controlled trial fail to show a significant improvement in quality of life parameter on the EORTC-QLQ-C30 scale or CLAS , respectively .
& quot ;
& quot ; 182 ABILIFY solution for injection be ready to use .
& quot ;
& quot ; ABILIFY 15 mg tablet aripiprazole
& quot ;
& quot ; Batch
& quot ;
& quot ; allergic reaction ( e. g. anaphylactic reaction , angioedema include swollen tongue , tongue oedema , face oedema , pruritus , or urticaria )
& quot ;
& quot ; detail information on this product be available on the website of the European Medicines Agency ( EMEA ) http : / / www . emea . europa . EU /
& quot ;
& quot ; overall survival outcome in the trial could not be statisfactorily explain by difference in the incidence of thrombosis and related complication between those give recombinant human erythropoietin and those in the control group .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; the pre-filled syrinx be ready to use ( see section 4.2 – method of administration ) .
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; United Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel : + 44 ( 0800 ) 731 1736
& quot ;
& quot ; developmental toxicity , include dose-dependent delayed foetal ossification and possible teratogenic effect , be observe in rat at dos result in subtherapeutic exposure ( base on AUC ) and in rabbit at dos result in exposure 3 and 11 time the mean steady-state AUC at the maximum recommend clinical dose .
& quot ;
& quot ; in a prospective , randomised , double-blind , placebo-controlled trial conduct in 375 anaemic patient with various non-myeloid malignancy receive non-platinum chemotherapy , there be a significant reduction of anaemia-related sequela ( e. g. fatigue , decrease energy , and activity reduction ) , a measure by the following instrument and scale :
& quot ;
& quot ; EU / 1 / 05 / 308 / 001 EU / 1 / 05 / 308 / 002
& quot ;
& quot ; at steady state , dehydro-aripiprazole , the active metabolite , represent about 40 % of aripiprazole AUC in plasma .
& quot ;
& quot ; 4 .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; patient should be advise to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole .
& quot ;
& quot ; common side effect ( greater than 1 in 100 , le than 1 in 10 patient ) Uncontrollable twitching or jerking movement , headache , tiredness , nausea , vomit , an uncomfortable feeling in the stomach , constipation , increased production of saliva , light-headedness , trouble sleeping , restlessness , feel anxious , sleepiness , shake and blurred vision .
& quot ;
& quot ; 1.35 , 2.06 , 35 trial and 6769 patient ) be observe in patient treat with recombinant human erythropoietin .
& quot ;
& quot ; Orodispersible tablet Round and pink , mark with & quot ; & quot ; A & quot ; & quot ; over & quot ; & quot ; 640 & quot ; & quot ; on one side and & quot ; & quot ; 10 & quot ; & quot ; on the other .
& quot ;
& quot ; no other erythropoietic therapy should be commence because of the risk of cross-reaction .
& quot ;
& quot ; insufficient data be currently available to recommend dose modification in patient with mild to moderate hepatic impairment ( see section 4.4. and 5.2 ) .
& quot ;
& quot ; in two 12-week , placebo- and active-controlled monotherapy trial in patient with a manic or mixed episode of Bipolar I Disorder , with or without psychotic feature , aripiprazole demonstrate superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12 .
& quot ;
& quot ; treatment with Abseamed may be associate with an increase risk of blood clotting after the surgery ( postoperative thrombotic / vascular disorder ) if your level of the red blood pigment be too high .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; the injection be give in the thigh or the anterior abdominal wall .
& quot ;
& quot ; 58 Posology
& quot ;
& quot ; Aripiprazole exhibit antagonist property in animal model of dopaminergic hyperactivity and agonist property in animal model of dopaminergic hypoactivity .
& quot ;
& quot ; Slovenija BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; in a 6-week , placebo-controlled trial involve patient with a manic or mixed episode of Bipolar I Disorder , with or without psychotic feature , who be partially non-responsive to lithium or valproate monotherapy for 2 week at therapeutic serum level , the addition of aripiprazole a adjunctive therapy result in superior efficacy in reduction of manic symptom than lithium or valproate monotherapy .
& quot ;
& quot ; leukopenia , neutropenia , thrombocytopenia
& quot ;
& quot ; Comparisons between aripiprazole and placebo in the proportion of patient experience potentially clinically significant change in routine laboratory parameter reveal no medically important difference .
& quot ;
& quot ; driving and use machine do not drive or use any tool or machine , until you know how ABILIFY affect you .
& quot ;
& quot ; ABILIFY 10 mg tablet aripiprazole
& quot ;
& quot ; España BRISTOL-MYERS SQUIBB , S. A .
& quot ;
& quot ; Aripiprazole and other antipsychotic drug should be use cautiously in patient at risk for aspiration pneumonia .
& quot ;
& quot ; how to store ABILIFY
& quot ;
& quot ; it be not know if paclitaxel pass into breast milk .
& quot ;
& quot ; this lead to less bone loss in osteoporosis and le disease activity in Paget ’ s disease .
& quot ;
& quot ; table 2 :
& quot ;
& quot ; base on information available to date , correction of anaemia with epoetin alfa in adult patient with renal insufficiency not yet undergoing dialysis do not accelerate the rate of progression of renal insufficiency .
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of untreated , inadequately treat
& quot ;
& quot ; Abseamed 10 000 IU / 1 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; alternatively , the injection can be give at the end of the dialysis session via the fistula needle tubing , follow by 10 ml of isotonic saline to rinse the tubing and ensure satisfactory injection of the product into the circulation .
& quot ;
& quot ; in another long-term 26-week control trial , the incidence of EPS be 14.8 % for aripiprazole-treated patient and 15.1 % for olanzapine-treated patient .
& quot ;
& quot ; what be Abseamed ?
& quot ;
& quot ; when consider concomitant administration of ketoconazole or other potent CYP3A4 inhibitor with ABILIFY , potential benefit should outweigh the potential risk to the patient .
& quot ;
& quot ; the incidence of delayed hip fracture healing be comparable between Aclasta ( 34 & # 91 ; 3.2 % & # 93 ; ) and placebo ( 29 & # 91 ; 2.7 % & # 93 ; ) .
& quot ;
& quot ; instruction for use , handle and disposal
& quot ;
& quot ; if an elevate ( or rise ) serum potassium level be detect then consideration should be give to cease epoetin alfa administration until hyperkalaemia have be correct .
& quot ;
& quot ; factor that should be consider in this assessment should include the type of tumour and it stage ; the degree of anaemia ; life-expectancy ; the environment in which the patient be be treat ; and patient preference ( see section 5.1 ) .
& quot ;
& quot ; Abseamed
& quot ;
& quot ; Epoetin alfa therapy should continue until one month after the end of chemotherapy .
& quot ;
& quot ; 6 pre-filled syrinx
& quot ;
& quot ; Polska BRISTOL-MYERS SQUIBB POLSKA SP .
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; the possibility of multiple medicinal product involvement should be consider .
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; 11 .
& quot ;
& quot ; EU / 1 / 04 / 276 / 025
& quot ;
& quot ; България BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; in addition , other cause of anaemia , such a vitamin B12 or folate deficiency , should be exclude before institute therapy with epoetin alfa .
& quot ;
& quot ; weight ( kg ) & lt ; 10 10 - 30 & gt ; 30
& quot ;
& quot ; ABILIFY orodispersible tablet contain aspartame , a source of phenylalanine which may be harmful for people with phenylketonuria .
& quot ;
& quot ; maintenance dose between 17 and 33 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; Occlusion of the dialysis system be possible if heparinisation be not optimum .
& quot ;
& quot ; if sign and symptom of tardive dyskinesia appear in a patient on ABILIFY , dose reduction or discontinuation should be consider .
& quot ;
& quot ; Pregnancy and breast-feeding Paclitaxel may cause serious birth defect and should therefore not be use if you be pregnant .
& quot ;
& quot ; possible side effect
& quot ;
& quot ; EU / 1 / 07 / 412 / 008
& quot ;
& quot ; label / SYRINGE
& quot ;
& quot ; Abseamed
& quot ;
& quot ; in the long term 26-week maintenance phase of a placebo-controlled trial , the incidence of EPS be 18.2 % for aripiprazole-treated patient and 15.7 % for placebo-treated patient .
& quot ;
& quot ; Eesti Österreich BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the sustained haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) reduce the epoetin alfa dose by 25 % .
& quot ;
& quot ; statement OF active substance ( s )
& quot ;
& quot ; 3 .
& quot ;
& quot ; BLISTER
& quot ;
& quot ; developmental toxicity , include dose-dependent delayed foetal ossification and possible teratogenic effect , be observe in rat at dos result in subtherapeutic exposure ( base on AUC ) and in rabbit at dos result in exposure 3 and 11 time the mean steady-state AUC at the maximum recommend clinical dose .
& quot ;
& quot ; it may be necessary to add or increase antihypertensive treatment .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; ABILIFY 5 mg
& quot ;
& quot ;
& quot ; Abseamed 10 000 IU / 1 ml solution for injection in a pre-filled syringe The syrinx contain 1 ml ( 10 000 IU ) of solution .
& quot ;
& quot ; this medicinal product must not be administer by intravenous infusion , or mixed with other medicinal product .
& quot ;
& quot ; it contain the active substance paclitaxel ( 5 mg / ml ) .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; instruction on use
& quot ;
& quot ; do not use ABILIFY if you be allergic ( hypersensitive ) to aripiprazole or any of the other ingredient of ABILIFY .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; Cancer patient
& quot ;
& quot ; Surgery patient in autologous predonation programme
& quot ;
& quot ; if you have any further question on the use of this product ask your doctor .
& quot ;
& quot ;
& quot ; date of first authorisation :
& quot ;
& quot ; Pre-filled syrinx ( glass type I ) with plunger ( Teflon-faced rubber ) seal in a blister .
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; Epoetin alfa should be administer by the subcutaneous route to patient with anaemia ( e. g. haemoglobin concentration ≤ 10 g / dl ( 6.2 mmol / l ) .
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; 15 mg
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; 15.04.2005
& quot ;
& quot ; if you need more information about your medical condition or your treatment , read the package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
& quot ;
& quot ; within each frequency grouping , undesirable effect be present in order of decrease seriousness .
& quot ;
& quot ; the injection be give preferably in the thigh or the front part of the abdominal wall .
& quot ;
& quot ; Haemoglobin variability should be address through dose management , with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; form a skin fold by pinch the skin between thumb and forefinger .
& quot ;
& quot ; general
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; Cancer patient receive treatment with erythropoietin have an increase risk of blood clot / blood clotting disorder ( thrombotic vascular event ) .
& quot ;
& quot ; Schizophrenia :
& quot ;
& quot ; when the CYP3A4 inducer be withdraw from the combination therapy , the aripiprazole dose should then be reduce to the recommend dose ( see section 4.5 ) .
& quot ;
& quot ; when concomitant administration of ketoconozole with ABILIFY occurs , ABILIFY dose should be reduce to approximately one-half of it prescribed dose .
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; 200 mg oral elemental iron daily ) throughout the course of treatment .
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; 9 .
& quot ;
& quot ; special storage condition
& quot ;
& quot ; patient receive chemotherapy or about to undergo orthopaedic surgery receive it under the skin .
& quot ;
& quot ; Polska BRISTOL-MYERS SQUIBB POLSKA SP .
& quot ;
& quot ; Norge BRISTOL-MYERS SQUIBB Norway LTD Tlf : + 47 67 55 53 50
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; increase Creatine Phosphokinase , blood glucose increase , blood glucose fluctuation , glycosylated haemoglobin increase
& quot ;
& quot ; adult and paediatric haemodialysis patient , adult peritoneal dialysis patient and adult patient with renal insufficiency not yet undergoing dialysis
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; Toxicologically significant effect be observe only at dos or exposure that be sufficiently in excess of the maximum human dose or exposure , indicate that these effect be limited or of no relevance to clinical use .
& quot ;
& quot ; if an elevate ( or rise ) serum potassium level be detect then consideration should be give to cease epoetin alfa administration until hyperkalaemia have be correct .
& quot ;
& quot ; in some preclinical toxicological study in dog and rat , but not in monkey , epoetin alfa therapy be associate with subclinical bone marrow fibrosis ( bone marrow fibrosis be a known complication of chronic renal failure in human and may be relate to secondary hyperparathyroidism or unknown factor .
& quot ;
& quot ; non response to epoetin alfa therapy may have the following cause : iron , folate , or vitamin B12 deficiency ; aluminium intoxication ; intercurrent infection ; inflammatory or traumatic episode ; occult blood loss ; haemolysis , and bone marrow fibrosis of any origin .
& quot ;
& quot ; in chronic renal failure patient Abseamed have not to be administer subcutaneously !
& quot ;
& quot ; this medicinal product must not be administer by intravenous infusion , or mixed with other medicinal product .
& quot ;
& quot ; 3 .
& quot ;
& quot ; patient with severe hepatic impairment should not be treat with paclitaxel .
& quot ;
& quot ; Parenteral medicinal product should be inspect visually for particulate matter and discoloration prior to administration whenever solution and container permit .
& quot ;
& quot ; Abraxane induce infertility in male rat ( see section 5.3 ) .
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; there be no effect of a high fat meal on the pharmacokinetics of aripiprazole .
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; 15 mg
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of epilepsy and chronic liver failure .
& quot ;
& quot ; 133 10 .
& quot ;
& quot ; 16 .
& quot ;
& quot ; 7 .
& quot ;
& quot ; in the long term 26-week maintenance phase of a placebo-controlled trial , the incidence of EPS be 18.2 % for aripiprazole-treated patient and 15.7 % for placebo-treated patient .
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of the symptom of anaemia .
& quot ;
& quot ; Hb 10 - 13 g / dl ) who do not have an autologous predonation programme available and with an expected blood loss of 900 to 1800 ml .
& quot ;
& quot ; Norge BRISTOL-MYERS SQUIBB Norway LTD Tlf : + 47 67 55 53 50
& quot ;
& quot ; Tel : + 40 ( 0 ) 21 272 16 00
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; Pharmacotherapeutic group : antianaemic , ATC code :
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; Excipients
& quot ;
& quot ; increase mortality : in three placebo-controlled trial ( n = 938 ; mean age :
& quot ;
& quot ; Abseamed have the highest possible purity accord to the present state of the art .
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; it use in this indication must be balance against the report risk of thromboembolic event .
& quot ;
& quot ; Cytotoxic action of epoetin alfa on bone marrow cell could not be detect .
& quot ;
& quot ; for both illness , the oral solution or orodispersible tablet can be use in patient who have difficulty swallow tablet .
& quot ;
& quot ; 120 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; investigation :
& quot ;
& quot ; 184 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; close supervision of high-risk patient should accompany antipsychotic therapy .
& quot ;
& quot ; this medicinal product must not be administer by intravenous infusion , or mixed with other medicinal product .
& quot ;
& quot ; weight ( kg ) & lt ; 10 10 - 30 & gt ; 30
& quot ;
& quot ; your doctor will check that your haemoglobin do not exceed a certain level .
& quot ;
& quot ; this medicine have be prescribe for you .
& quot ;
& quot ; seizure : in clinical trial , uncommon case of seizure be report during treatment with aripiprazole .
& quot ;
& quot ; 3 .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; in another long-term 26-week control trial , the incidence of EPS be 14.8 % for aripiprazole-treated patient and 15.1 % for olanzapine-treated patient .
& quot ;
& quot ; EU / 1 / 04 / 276 / 031
& quot ;
& quot ; the haemoglobin concentration aim for be between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) , except in paediatric patient in whom the haemoglobin concentration should be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; QT prolongation , ventricular arrhythmia , sudden unexplained death , cardiac arrest , torsades de pointes , bradycardia
& quot ;
& quot ; also contain sulfobutylether b-cyclodextrin , tartaric acid , sodium hydroxide , and water for injection .
& quot ;
& quot ; if you take more ABILIFY than you should if you realise you have take more ABILIFY tablet than your doctor have recommend ( or if someone else have take some of your ABILIFY tablet ) , contact your doctor right away .
& quot ;
& quot ; possible side effect 5 how to store ABILIFY 6 .
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; at least one new vertebral fracture ( 0 – 2 year )
& quot ;
& quot ; Tel . : + 48 22 5796666
& quot ;
& quot ; N05AX12
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; 86 Posology
& quot ;
& quot ; consequently :
& quot ;
& quot ; these increase in blood pressure can be treat with medicinal product .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; Schizophrenia :
& quot ;
& quot ; it be an inhibitor of osteoclast-mediated bone resorption .
& quot ;
& quot ; Sodium dihydrogen phosphate dihydrate Disodium phosphate dihydrate Sodium chloride Glycine Polysorbate 80 water for injection Hydrochloric acid ( for pH-adjustment ) Sodium hydroxide ( for pH-adjustment )
& quot ;
& quot ; they be supply in perforated unit dose blister pack in carton contain 14 , 28 , 49 , 56 , or 98 tablet .
& quot ;
& quot ; actual score in rating scale use a secondary endpoint , include PANSS and the Montgomery-Asberg Depression rating scale show a significant improvement over haloperidol .
& quot ;
& quot ; consequently :
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; EU / 1 / 04 / 276 / 005
& quot ;
& quot ; ABILIFY be indicate for the treatment of schizophrenia .
& quot ;
& quot ; 109 PARTICULARS to appear on the outer packaging
& quot ;
& quot ; KGAA Tel : + 49 89 121 42-0
& quot ;
& quot ; in all patient treat with Abseamed blood pressure should be closely monitored and treat , if necessary .
& quot ;
& quot ; however , the maximum daily dose of 30 mg should be use with caution in patient with severe hepatic impairment ( see section 5.2 ) .
& quot ;
& quot ; early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid , for example , be recommend in these patient .
& quot ;
& quot ; all patient be treat with epoetin alfa should receive adequate iron supplementation ( e. g. oral iron substitution of 200 mg Fe2 + daily ) throughout the course of epoetin alfa treatment .
& quot ;
& quot ; 3 .
& quot ;
& quot ; what ABILIFY contain The active substance be aripiprazole .
& quot ;
& quot ; Tel : + 420 221 016 111
& quot ;
& quot ; transferrin saturation be below 20 % .
& quot ;
& quot ; expiry date
& quot ;
& quot ; Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel : + 353 ( 1 800 ) 749 749
& quot ;
& quot ; 8 .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; Aripiprazole and other antipsychotic drug should be use cautiously in patient at risk for aspiration pneumonia .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery , with a baseline haemoglobin of 10 to 13 g / dl , the incidence of thrombotic / vascular event ( most of which be DVTs ) , in the overall patient population of the clinical trial , appear to be similar across the different epoetin alfa dose group and placebo group , although the clinical experience be limit .
& quot ;
& quot ; 1.35 , 2.06 , 35 trial and 6769 patient ) be observe in patient treat with recombinant human erythropoietin .
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; 3 .
& quot ;
& quot ; in the indication “ increase the yield of autologous blood ” : myocardial infarction or stroke in the month precede treatment , unstable angina pectoris , increase risk of deep venous thrombosis such a history of venous thromboembolic disease .
& quot ;
& quot ; a slower injection be preferable in patient who react to the treatment with “ flu-like ” symptom .
& quot ;
& quot ; 0.99 , 1,18 ; 42 trial and 8167 patient ) .
& quot ;
& quot ; 7000 IU / 0.7 ml
& quot ;
& quot ; Tel : + 370 5 2790 762
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy male and female subject nor be there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; Absorption :
& quot ;
& quot ; Eesti Österreich Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; yellow iron oxide ( E172 )
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ; 2 .
& quot ;
& quot ; early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid , for example , be recommend in these patient .
& quot ;
& quot ; special storage condition
& quot ;
& quot ; ABILIFY 7.5 mg / ml solution for injection aripiprazole
& quot ;
& quot ; Respiratory , thoracic and mediastinal disorder :
& quot ;
& quot ; survival and tumour progression have be examine in five large control study involve a total of 2833 patient , of which four be double-blind placebo-controlled study and one be an open- label study .
& quot ;
& quot ; Aripiprazole exhibit high binding affinity in vitro for dopamine D2 and D3 , serotonin 5HT1a and 5HT2a receptor and moderate affinity for dopamine D4 , serotonin 5HT2c and 5HT7 , alpha-1 adrenergic and histamine H1 receptor .
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; these study have show an consistent unexplained statistically significant excess mortality in patient who have anaemia associate with various common cancer who receive recombinant human erythropoietin compare to control .
& quot ;
& quot ; take other medicine please tell your doctor or pharmacist if you be take or have recently take any other medicine , include medicine obtain without a prescription .
& quot ;
& quot ; immune system disorder :
& quot ;
& quot ; the rate of death in aripiprazole-treated patient be 3.5 % compare to 1.7 % in the placebo group .
& quot ;
& quot ; patient with rare hereditary problem of fructose intolerance should not take this medicinal product .
& quot ;
& quot ; if parenteral benzodiazepine therapy be deem necessary in addition to aripiprazole solution for injection , patient should be monitor for excessive sedation and for orthostatic hypotension ( see section 4.5 ) .
& quot ;
& quot ; one ml solution contain 0.05 mg zoledronic acid anhydrous , correspond to 0.0533 mg zoledronic acid monohydrate .
& quot ;
& quot ; 9 .
& quot ;
& quot ; the maximum dose should not exceed 200 IU / kg 3 time per week .
& quot ;
& quot ; Suomi / Finland OY BRISTOL-MYERS SQUIBB ( Finland ) AB Puh / Tel : + 358 9 251 21 230
& quot ;
& quot ; 3.7
& quot ;
& quot ; Multi-pack comprise 5 bottle , each bottle of 100 ml .
& quot ;
& quot ; in patient with chronic renal failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommend in section 4.2 .
& quot ;
& quot ; Medicines should not be dispose of via wastewater or household waste .
& quot ;
& quot ; the syrinx contain 1 ml ( 2000 IU ) of solution .
& quot ;
& quot ; in clinical trial with aripiprazole , there be no significant difference in the incidence rate of hyperglycaemia-related adverse event ( include diabetes ) or in abnormal glycaemia laboratory value compare to placebo .
& quot ;
& quot ; an increase relative risk of thromboembolic event ( RR 1.67 , 95 % CI :
& quot ;
& quot ; Mutagenicity and carcinogenic potential Zoledronic acid be not mutagenic in the mutagenicity test perform and carcinogenicity test do not provide any evidence of carcinogenic potential .
& quot ;
& quot ; in patient with severe hepatic impairment , the data available be insufficient to establish recommendation .
& quot ;
& quot ; 10 mg
& quot ;
& quot ; 6 .
& quot ;
& quot ; a with other antipsychotic , aripiprazole should be use with caution in patient with a family history of QT prolongation .
& quot ;
& quot ; - iron supplementation , e. g .
& quot ;
& quot ; what ABILIFY look like and content of the Pack ABILIFY 1 mg / ml oral solution be a clear , colourless to light yellow liquid supply in bottle with polypropylene child-resistant closure contain 50 ml , 150 ml or 480 ml per bottle .
& quot ;
& quot ; at the start of your therapy , Abseamed may be inject under the supervision of experienced medical staff .
& quot ;
& quot ; Pharmacotherapeutic group : antipsychotic , ATC code :
& quot ;
& quot ; ABILIFY be indicate for the treatment of schizophrenia .
& quot ;
& quot ; 3 .
& quot ;
& quot ; Tel : + 370 5 2790 762
& quot ;
& quot ; overall , 1.3 % of aripiprazole-treated patient report cerebrovascular adverse event compare with 0.6 % of placebo-treated patient in these trial .
& quot ;
& quot ; Reproductive system and breast disorder :
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; Deutschland BRISTOL-MYERS SQUIBB GMBH & amp ; CO .
& quot ;
& quot ; Hyperglycaemia and Diabetes Mellitus : hyperglycaemia , in some case extreme and associate with ketoacidosis or hyperosmolar coma or death , have be report in patient treat with atypical antipsychotic agent , include ABILIFY .
& quot ;
& quot ; special storage condition
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; le than 1 % of unchanged aripiprazole be excrete in the urine and approximately 18 % be recover unchanged in the faeces .
& quot ;
& quot ; in two large , open-label study , 2697 cancer patient receive non-platinum chemotherapy be include , 1895 with solid tumour ( 683 breast , 260 lung , 174 gynaecological , 300 gastro-intestinal , and 478 other tumour type ) and 802 with haematological malignancy .
& quot ;
& quot ; - In pregnant or lactating surgical patient participate in an autologous blood predonation
& quot ;
& quot ; investigation :
& quot ;
& quot ; alternatively , the injection can be give at the end of the dialysis session via the fistula needle tubing , follow by 10 ml of isotonic saline to rinse the tubing and ensure satisfactory injection of the product into the circulation .
& quot ;
& quot ; the most frequent adverse reaction during treatment with epoetin alfa be a dose-dependent increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ; there may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with epoetin alfa .
& quot ;
& quot ; kg Tel : + 49- ( 0 ) 2371 937 0
& quot ;
& quot ; this document be a summary of the European Public assessment Report ( EPAR ) .
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; Pack of 1 or 6 syrinx .
& quot ;
& quot ; how to take ABILIFY 4 .
& quot ;
& quot ; Breast-feeding mother should not take ABILIFY .
& quot ;
& quot ; store in the original package in order to protect from moisture .
& quot ;
& quot ; EU / 1 / 07 / 412 / 001 EU / 1 / 07 / 412 / 002
& quot ;
& quot ; in a long term 26-week placebo-controlled trial , the incidence of EPS be 19 % for aripiprazole-treated patient and 13.1 % for placebo-treated patient .
& quot ;
& quot ; the extent to which these outcome might apply to the administration of recombinant human erythropoietin to patient with cancer , treat with chemotherapy to achieve haemoglobin concentration le than 13 g / dl , be unclear because few patient with these characteristic be include in the data reviewed .
& quot ;
& quot ; this medicine have be prescribe for you .
& quot ;
& quot ; base on information available to date , correction of anaemia with epoetin alfa in adult patient with renal insufficiency not yet undergoing dialysis do not accelerate the rate of progression of renal insufficiency .
& quot ;
& quot ; in some preclinical toxicological study in dog and rat , but not in monkey , epoetin alfa therapy be associate with subclinical bone marrow fibrosis ( bone marrow fibrosis be a known complication of chronic renal failure in human and may be relate to secondary hyperparathyroidism or unknown factor .
& quot ;
& quot ; at the start of your therapy , Abseamed may be inject by medical staff .
& quot ;
& quot ; Breast-feeding mother should not take ABILIFY .
& quot ;
& quot ; Measurement of epoetin alfa follow multiple dose intravenous administration reveal a half-life of approximately 4 hour in normal volunteer and a somewhat more prolonged half-life in renal failure patient , approximately 5 hour .
& quot ;
& quot ; ABILIFY dose should be double when concomitant administration of ABILIFY occur with carbamazepine .
& quot ;
& quot ; 12 .
& quot ;
& quot ; 6 .
& quot ;
& quot ; 4 .
& quot ;
& quot ; when perform haematologic assessment during the preoperative period , if the haemoglobin level reach 15 g / dl , or higher , administration of epoetin alfa should be stop and further dos should not be give .
& quot ;
& quot ; 1 pre-filled syringe
& quot ;
& quot ; Additionally , aripiprazole and dehydro-aripiprazole do not show potential for alter CYP1A2-mediated metabolism in vitro .
& quot ;
& quot ; read all of this leaflet carefully before you start take this medicine .
& quot ;
& quot ; { MM / YYYY }
& quot ;
& quot ; in patient with chronic renal failure and clinically evident ischaemic heart disease or congestive heart failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration a recommend under section 4.2 .
& quot ;
& quot ; Carton of 49 X 1 tablet in cold-formed aluminium perforate unit dose blister .
& quot ;
& quot ; solution for injection in a pre-filled syringe ( injection )
& quot ;
& quot ; the initial dose be 150 IU / kg give subcutaneously 3 time per week .
& quot ;
& quot ; investigation :
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery the cause of anaemia should be establish and treat , if possible , before the start of epoetin alfa treatment .
& quot ;
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; patient should be advise to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole .
& quot ;
& quot ; in this leaflet :
& quot ;
& quot ; Abseamed have the highest possible purity accord to the present state of the art .
& quot ;
& quot ; - oral iron substitution of 200 - 300 mg Fe2 + / day be recommend for all cancer patient whose
& quot ;
& quot ; it explain how the Committee for Medicinal product for Human use ( CHMP ) assess the study perform , to reach their recommendation on how to use the medicine .
& quot ;
& quot ; Paediatric haemodialysis patient :
& quot ;
& quot ; these study have show an consistent unexplained statistically significant excess mortality in patient who have anaemia associate with various common cancer who receive recombinant human erythropoietin compare to control .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; your doctor will check on this .
& quot ;
& quot ; Aripiprazole and other antipsychotic drug should be use cautiously in patient at risk for aspiration pneumonia .
& quot ;
& quot ; Aripiprazole also exhibit moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptor .
& quot ;
& quot ; however , the
& quot ;
& quot ; ABILIFY be effective in maintain the clinical improvement during continuation therapy in patient who have show an initial treatment response .
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; Sodium dihydrogen phosphate dihydrate Disodium phosphate dihydrate Sodium chloride Glycine Polysorbate 80 water for injection Hydrochloric acid ( for pH-adjustment ) Sodium hydroxide ( for pH-adjustment )
& quot ;
& quot ; EXP
& quot ;
& quot ; 78-88 year ) .
& quot ;
& quot ; Metabolism :
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; also contain : lactose monohydrate .
& quot ;
& quot ; before you take ABILIFY
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg , Kuhloweg 37 , D-58638 Iserlohn , Germany
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; 2 .
& quot ;
& quot ; general disorder and administration site condition :
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; follow any confirm or suspect overdose with aripiprazole , close medical supervision and monitoring should continue until the patient recovers .
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; 59 Correction phase :
& quot ;
& quot ; Intravenous injection : over at least one to five minute , depend on the total dose .
& quot ;
& quot ; 117 150 IU / kg 3x / week or 450 IU / kg once weekly
& quot ;
& quot ; Ireland Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; in paediatric patient the recommended target haemoglobin range be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; it also prevent this condition from return in patient who have respond to the treatment with ABILIFY .
& quot ;
& quot ; immediately upon open the blister , use dry hand , remove the tablet and place the entire orodispersible tablet on the tongue .
& quot ;
& quot ; B .
& quot ;
& quot ; 8 .
& quot ;
& quot ; 16 .
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; 73 of Cmax and AUC after carbamazepine co-administration be 69 % and 71 % lower , respectively , than those following treatment with aripiprazole alone .
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; before you take ABILIFY 3 .
& quot ;
& quot ; in case where there be a medical need to shorten the lead time before surgery to le than three week , 300 IU / kg epoetin alfa should be give daily for 10 consecutive day prior to surgery , on the day of surgery and for four day immediately thereafter .
& quot ;
& quot ; 6 .
& quot ;
& quot ; Tumour growth potential
& quot ;
& quot ; NMS be a potentially fatal symptom complex associate with antipsychotic medicinal product .
& quot ;
& quot ; precise risk estimate for hyperglycaemia-related adverse event in patient treat with ABILIFY and with other atypical antipsychotic agent be not available to allow direct comparison .
& quot ;
& quot ; statement OF active substance ( s )
& quot ;
& quot ; both case resolve .
& quot ;
& quot ; there be an increased risk for thromboembolic event in patient with cancer treat with recombinant human erythropoietin and a negative impact on overall survival can not be exclude .
& quot ;
& quot ; the peak be always well below the peak achieve use the intravenous route ( approximately 1 / 20th of the value ) .
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; 56 date of first authorisation :
& quot ;
& quot ; 15 ml solution / day ) administer on a once-a-day schedule without regard to meal a monotherapy or combination therapy ( see section 5.1 ) .
& quot ;
& quot ; 30 mg
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; it also prevent this condition from return in patient who have respond to the treatment with ABILIFY .
& quot ;
& quot ; Slovenija BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; EU / 1 / 07 / 412 / 020
& quot ;
& quot ; these trial include patient with or without psychotic feature and with or without a rapid-cycling course .
& quot ;
& quot ; the injection be give in the thigh or the anterior abdominal wall .
& quot ;
& quot ; Excipient :
& quot ;
& quot ; KGAA Tel : + 49 89 121 42-0
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; - iron supplementation , e. g .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; BATCH number
& quot ;
& quot ; Tardive Dyskinesia : in clinical trial of one year or le duration , there be uncommon report of treatment emergent dyskinesia during treatment with aripiprazole .
& quot ;
& quot ; the solution should not be inject directly onto the powder a this will result in foaming .
& quot ;
& quot ; 0.99 , 1,18 ; 42 trial and 8167 patient ) .
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; Medice
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; 5 .
& quot ;
& quot ; expiry date
& quot ;
& quot ; functional assessment of Cancer Therapy- Anaemia ( FACT-An ) general scale , FACT-An fatigue scale , and Cancer linear Analogue scale ( CLAS ) .
& quot ;
& quot ; 103 Renal disease :
& quot ;
& quot ; method OF administration
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery should receive adequate antithrombotic prophylaxis , a thrombotic and vascular event may occur in surgical patient , especially in those with underlying cardiovascular disease .
& quot ;
& quot ; it may harm them , even if their symptom be the same a yours .
& quot ;
& quot ; each tablet contain 30 mg of aripiprazole .
& quot ;
& quot ; however , since cyclosporin be bind by red blood cell there be potential for an interaction .
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; uncontrolled hypertension .
& quot ;
& quot ; lot
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; - blood clotting ( thrombotic vascular event ) ( see section “ take special care with Abseamed ” ) .
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6 g / dl or & lt ; 3.75 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 8 g / dl or & gt ; 5 mmol / l ) .
& quot ;
& quot ; 1 .
& quot ;
& quot ; Abseamed 6000 IU / 0.6 ml injection
& quot ;
& quot ; in clinical study , 10-30 mg / day dos of aripiprazole have no significant effect on the metabolism of substrate of CYP2D6 ( dextromethorphan / 3-methoxymorphinan ratio ) , 2C9 ( warfarin ) , 2C19 ( omeprazole ) , and 3A4 ( dextromethorphan ) .
& quot ;
& quot ; do not use ABILIFY after the expiry date which be state on the carton and on the vial .
& quot ;
& quot ; adult haemodialysis patient :
& quot ;
& quot ; 0.6 ml ( 10000 IU / ml )
& quot ;
& quot ; © European Medicines Agency , 2008 .
& quot ;
& quot ; if you need more information about your medical condition or your treatment , read the package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
& quot ;
& quot ; risk management Plan The MAH commits to perform the study and additional pharmacovigilance activity detail in the Pharmacovigilance Plan , a agree in version 3.0 of the risk management Plan ( RMP ) present in Module 1.8.2. of the marketing authorisation and any subsequent update of the RMP agree by the CHMP .
& quot ;
& quot ; oral use
& quot ;
& quot ; other
& quot ;
& quot ; in two 12-week , placebo- and active-controlled monotherapy trial in patient with a manic or mixed episode of Bipolar I Disorder , with or without psychotic feature , aripiprazole demonstrate superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12 .
& quot ;
& quot ; solution for injection in a pre-filled syringe .
& quot ;
& quot ; Latvija BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; treatment of osteoporosis • in post-menopausal woman • in men at increase risk of fracture , include those with a recent low-trauma hip fracture .
& quot ;
& quot ; Smoking and race :
& quot ;
& quot ; Hypocalcaemia In clinical trial in osteoporosis , approximately 0.2 % of patient have notable decline of serum calcium level ( le than 1.87 mmol / l ) follow Aclasta administration .
& quot ;
& quot ; not applicable
& quot ;
& quot ; a systematic review have also be perform involve more than 9000 cancer patient participate in 57 clinical trial .
& quot ;
& quot ; upon discontinuation of the CYP2D6 or 3A4 inhibitor , the dosage of ABILIFY should be increase to the level prior to the initiation of the concomitant therapy .
& quot ;
& quot ; survival and tumour progression have be examine in five large control study involve a total of 2833 patient , of which four be double-blind placebo-controlled study and one be an open- label study .
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl
& quot ;
& quot ; 6 .
& quot ;
& quot ; like all medicine , ABILIFY can cause side effect , although not everybody get them .
& quot ;
& quot ; Pregnancy and breast-feeding you should not take ABILIFY if you be pregnant unless you have discuss this with your doctor .
& quot ;
& quot ; Aripiprazole also demonstrate a comparable proportion of patient in symptomatic remission from mania a lithium or haloperidol at week 12 .
& quot ;
& quot ; treatment of anaemia and reduction of transfusion requirement in adult patient receive chemotherapy for solid tumour , malignant lymphoma or multiple myeloma , and at risk of transfusion a assess by the patient & apos ; s general status ( e. g. cardiovascular status , pre-existing anaemia at the start of chemotherapy ) .
& quot ;
& quot ; Dysphagia : oesophageal dysmotility and aspiration have be associate with antipsychotic drug use , include ABILIFY .
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of epilepsy and chronic liver failure .
& quot ;
& quot ; child and adolescent ABILIFY be not for use in child and adolescent a it have not be study in patient under 18 year .
& quot ;
& quot ; the intravenous route have to be use ( please see section 4.4 - chronic renal failure patient ) .
& quot ;
& quot ; 1 pre-filled syringe
& quot ;
& quot ; 18 PARTICULARS to appear on the outer packaging AND on the immediate packaging
& quot ;
& quot ; weight gain : in clinical trial aripiprazole have not be show to induce clinically relevant weight gain .
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; Chronic renal failure patient
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; therefore , it should not be use in patient with baseline haemoglobin & gt ; 13 g / dl .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; Haemoglobin variability should be address through dose management , with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; how to store ABILIFY
& quot ;
& quot ; these increase in blood pressure can be treat with medicinal product .
& quot ;
& quot ; the following maintenance dos be observe in clinical trial after 6 month of treatment :
& quot ;
& quot ; Medicines to correct heart rhythm Antidepressants or herbal remedy use to treat depression and anxiety Antifungal agent certain medicine to treat HIV infection Anticonvulsants use to treat epilepsy
& quot ;
& quot ; 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; treatment with Abseamed have to be initiate under the supervision of physician experience in the management of patient with the above indication .
& quot ;
& quot ; in this leaflet :
& quot ;
& quot ; in a 6-week , placebo-controlled trial involve patient with a manic or mixed episode of Bipolar I Disorder , with or without psychotic feature , who be partially non-responsive to lithium or valproate monotherapy for 2 week at therapeutic serum level , the addition of aripiprazole a adjunctive therapy result in superior efficacy in reduction of manic symptom than lithium or valproate monotherapy .
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy male and female subject nor be there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; other finding :
& quot ;
& quot ; Abilify
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; in a long term 26-week placebo-controlled trial , the incidence of EPS be 19 % for aripiprazole-treated patient and 13.1 % for placebo-treated patient .
& quot ;
& quot ; at steady state , dehydro-aripiprazole , the active metabolite , represent about 40 % of aripiprazole AUC in plasma .
& quot ;
& quot ; { MM / YYYY }
& quot ;
& quot ; be sure to tell your doctor immediately if you be pregnant , think you may be pregnant , or if you be plan to become pregnant .
& quot ;
& quot ; 79 patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; however , in one of these trial , a fixed-dose trial , there be a significant dose response relationship for cerebrovascular adverse event in patient treat with aripiprazole .
& quot ;
& quot ; EU number
& quot ;
& quot ; expiry date
& quot ;
& quot ; iron status should be evaluate prior to and during treatment and iron supplementation administer if necessary .
& quot ;
& quot ; in the open-label study there be no difference in overall survival between patient treat with recombinant human erythropoietin and control .
& quot ;
& quot ; further information on clinical trial :
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; the following maintenance dos be observe in clinical trial after 6 month of treatment :
& quot ;
& quot ; potential for other medicinal product to affect ABILIFY :
& quot ;
& quot ; Polska BRISTOL-MYERS SQUIBB POLSKA SP .
& quot ;
& quot ; 2 .
& quot ;
& quot ; 5 .
& quot ;
& quot ; solution for injection in a pre-filled syringe ( injection )
& quot ;
& quot ; all patient be treat with epoetin alfa should receive adequate iron supplementation ( e. g. oral iron substitution of 200 mg Fe2 + daily ) throughout the course of epoetin alfa treatment .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; when weak inhibitor of CYP3A4 ( e. g . , diltiazem or escitalopram ) or CYP2D6 be use concomitantly with ABILIFY , modest increase in aripiprazole concentration might be expect .
& quot ;
& quot ; patient with hepatic impairment : no dosage adjustment be require for patient with mild to moderate hepatic impairment .
& quot ;
& quot ; the pharmacokinetic characteristic of aripiprazole and dehydro-aripiprazole be find to be similar in patient with severe renal disease compare to young healthy subject .
& quot ;
& quot ; 11 .
& quot ;
& quot ; Annex 1
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; result of an epidemiological study find that there be no increase risk of suicidality with aripiprazole compare to other antipsychotic among patient with bipolar disorder .
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; 2 .
& quot ;
& quot ; 56.4 & # 91 ; 45.1 , 76.9 & # 93 ; ( n = 131 )
& quot ;
& quot ; 5 .
& quot ;
& quot ; why have Abseamed be approve ?
& quot ;
& quot ; Abseamed 2000 IU / 1 ml injection
& quot ;
& quot ; method OF administration
& quot ;
& quot ; Correction for anaemia may lead to increase appetite , and potassium and protein intake .
& quot ;
& quot ; for 4 week
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; this mean that aripiprazole act like 5-hydroxytryptamine and dopamine to activate the receptor , but to a lesser extent than the neurotransmitter .
& quot ;
& quot ; the incidence of post-dose symptom occur within the first three day after administration of Aclasta can be reduce with the administration of paracetamol or ibuprofen shortly follow Aclasta administration ( see section 4.2 ) .
& quot ;
& quot ; in order to ensure optimum response to epoetin alfa , adequate iron store should be assure :
& quot ;
& quot ; the half-life be difficult to evaluate for the subcutaneous route and be estimate about 24 hour .
& quot ;
& quot ; mildly anaemic patient ( haematocrit of 33 - 39 % ) require predeposit of ≥ 4 unit of blood should be treat with Abseamed at a dose of 600 IU / kg body weight 2 time weekly for 3 week prior to surgery .
& quot ;
& quot ; the mean elimination half-lives for aripiprazole be approximately 75 hour in extensive metabolisers of CYP2D6 and approximately 146 hour in poor metabolisers of CYP2D6 .
& quot ;
& quot ; 6 .
& quot ;
& quot ; Abseamed 3000 IU / 0.3 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; during this entire time period bone turnover marker be within the pre-menopausal range at the end of each year .
& quot ;
& quot ; care should be take to ensure that at the outset of the treatment patient be not iron deficient .
& quot ;
& quot ; Subcutaneous route
& quot ;
& quot ; - if you have high blood pressure which be not properly control
& quot ;
& quot ; the decision to administer recombinant erythropoietin should be base on a benefit-risk assessment with the participation of the individual patient , which should also take into account the specific clinical context .
& quot ;
& quot ; European Medicines Agency
& quot ;
& quot ; however , if the haemoglobin have increase & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , response to epoetin alfa therapy be unlikely and treatment should be discontinue .
& quot ;
& quot ; base on the publish literature , in vitro study of bind to human serum protein , use paclitaxel at concentration range from 0.03 to 1.2 µM , indicate that about 87 % of paclitaxel be bind ; the presence of ranitidine , dexamethasone , or diphenhydramine do not affect protein binding of paclitaxel .
& quot ;
& quot ; 4 .
& quot ;
& quot ; clear colourless solution
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; other potent inhibitor of CYP3A4 , such a itraconazole and HIV protease inhibitor , may be expect to have similar effect and similar dose reduction should therefore be apply .
& quot ;
& quot ; the start dose may be adjust by your doctor approximately every 4 week until your condition be control .
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; patient must be appropriately hydrate prior to administration of Aclasta .
& quot ;
& quot ; 42 for the purpose of ambulatory use , the patient may remove Abseamed from the refrigerator and store it not above 25 ° C for one single period of up to 3 day .
& quot ;
& quot ; if aripiprazole be administer concomitantly with medicine know to cause QT prolongation or electrolyte imbalance , caution should be use .
& quot ;
& quot ; Blood clot ( thrombotic event ) can be a
& quot ;
& quot ; the active substance in Aclasta , zoledronic acid , be a bisphosphonate .
& quot ;
& quot ; 2 .
& quot ;
& quot ; Abseamed have no influence on the ability to drive and use machine .
& quot ;
& quot ;
& quot ; Tel : + 39 06 50 39 61
& quot ;
& quot ; temperature regulation disorder ( e. g. hypothermia , pyrexia ) , chest pain , peripheral oedema
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; when either valproate or lithium be administer concomitantly with aripiprazole , there be no clinically significant change in aripiprazole concentration .
& quot ;
& quot ; at each step , the increase or reduction in dose should be of 25 IU / kg 3 time per week .
& quot ;
& quot ; in a long term 26-week placebo-controlled trial , the incidence of EPS be 19 % for aripiprazole-treated patient and 13.1 % for placebo-treated patient .
& quot ;
& quot ; a ABILIFY 7.5 mg / ml solution for injection be only intend for administration by health care professional , no information will be include in Braille .
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; the maximum dose should not exceed 200 IU / kg 3 time per week .
& quot ;
& quot ; - an increase in level of blood platelet ( thrombocyte ) which be normally involve in the
& quot ;
& quot ; România BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; 30 It have be propose that aripiprazole ’ s efficacy in schizophrenia and Bipolar I Disorder be mediate through a combination of partial agonism at dopamine D2 and serotonin 5HT1a receptor and antagonism of serotonin 5HT2a receptor .
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; base on in vitro study , CYP3A4 and CYP2D6 enzyme be responsible for dehydrogenation and hydroxylation of aripiprazole , and N-dealkylation be catalyse by CYP3A4 .
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; it be especially important to mention the follow to your doctor :
& quot ;
& quot ; in order to ensure optimum response to epoetin alfa , adequate iron store should be assure :
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; Hb 10 - 13 g / dl ) who do not have an autologous predonation programme available and with an expected blood loss of 900 to 1800 ml .
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; Epoetin alfa therapy should continue until one month after the end of chemotherapy .
& quot ;
& quot ; people with this condition may also feel depressed , guilty , anxious or tense .
& quot ;
& quot ; these change be interpret a be secondary to decreased maternal body weight gain .
& quot ;
& quot ; Hb 10 - 13 g / dl ) who do not have an autologous predonation programme available and with an expected blood loss of 900 to 1800 ml .
& quot ;
& quot ; Subcutaneous injection : a maximum volume of 1 ml at one injection site should generally not be exceed .
& quot ;
& quot ; similarly , for dehydro-aripiprazole the geometric mean of Cmax and AUC after carbamazepine co-administration be 69 % and 71 % lower , respectively , than those following treatment with aripiprazole alone .
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; Slovenská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; - store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; the most frequent adverse reaction be an increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; usual maintenance dose 75 - 150 60 - 150 30 - 100
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP2D6 ( quinidine ) increase aripiprazole AUC by 107 % , while Cmax be unchanged .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; Z O. O .
& quot ;
& quot ; increase Creatine Phosphokinase , blood glucose increase , blood glucose fluctuation , glycosylated haemoglobin increase
& quot ;
& quot ; in the indication “ increase the yield of autologous blood ” : myocardial infarction or stroke in the month precede treatment , unstable angina pectoris , increase risk of deep venous thrombosis such a history of venous thromboembolic disease .
& quot ;
& quot ; good blood management practice should always be use in the perisurgical setting
& quot ;
& quot ; due to insufficient safety information in human and concern raise by animal reproductive study , this medicinal product should not be use in pregnancy unless the expected benefit clearly justify the potential risk to the foetus .
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl and Hb increase & lt ; 1 g / dl
& quot ;
& quot ; the pre-filled syrinx be ready to use ( see section 4.2 – method of administration ) .
& quot ;
& quot ; Subcutaneous injection : a maximum volume of 1 ml at one injection site should generally not be exceed .
& quot ;
& quot ; Blood and the lymphatic system disorder :
& quot ;
& quot ; usual maintenance dose 75 - 150 60 - 150 30 - 100
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; there may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with epoetin alfa .
& quot ;
& quot ; if anti-erythropoietin , antibody-mediated PRCA be suspect , therapy with Abseamed should be discontinue immediately .
& quot ;
& quot ; rash , photosensitivity reaction , alopecia , hyperhidrosis
& quot ;
& quot ; ESAs be not indicate for use in this patient population .
& quot ;
& quot ; s R. O .
& quot ;
& quot ; Hb 10 - 13 g / dl ) who do not have an autologous predonation programme available and with an expected blood loss of 900 to 1800 ml .
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; there be a 41 % risk reduction in hip fracture , when compare all woman take Aclasta ( with or without other osteoporosis medicine ) with those take placebo .
& quot ;
& quot ; Non-clinical safety data reveal no special hazard for human base on conventional study of safety pharmacology , repeat-dose toxicity , genotoxicity , carcinogenic potential , and toxicity to reproduction .
& quot ;
& quot ; after six month , the proportion of patient who have respond to treatment be 95 % in one study and 97 % in the other , compare with 75 % and 73 % of the patient who receive risedronate .
& quot ;
& quot ; the possibility of multiple medicinal product involvement should be consider .
& quot ;
& quot ; no effect on ability to drive or use machine have be observe .
& quot ;
& quot ; 159 9 .
& quot ;
& quot ; 5 .
& quot ;
& quot ; 15 mg
& quot ;
& quot ; you should receive adequate measure in order to prevent blood clot ( thrombotic prophylaxis ) , particularly if you have cardiovascular disorder .
& quot ;
& quot ; in haemodialysed patient , a bolus injection may be give during the dialysis session through a suitable venous port in the dialysis line .
& quot ;
& quot ; if their symptom be the same a yours .
& quot ;
& quot ; ABILIFY be one of a group of medicine call antipsychotic .
& quot ;
& quot ; 15 1 .
& quot ;
& quot ; Longer-term repeat administration at cumulative exposure sufficiently exceed the maximum intend human exposure produce toxicological effect in other organ , include the gastrointestinal tract and liver , and at the site of intravenous administration .
& quot ;
& quot ; further information
& quot ;
& quot ; B03XA01
& quot ;
& quot ; 9 .
& quot ;
& quot ; transferrin saturation be below 20 % .
& quot ;
& quot ; 9 .
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; if you forget to take ABILIFY if you miss a dose , take the missed dose a soon a you remember but do not take two dos in one day .
& quot ;
& quot ; when concomitant administration of potent CYP3A4 or CYP2D6 inhibitor with aripiprazole occurs , the aripiprazole dose should be reduce .
& quot ;
& quot ; special storage condition
& quot ;
& quot ; how have Abraxane be study ?
& quot ;
& quot ; 2 .
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of untreated , inadequately treat
& quot ;
& quot ; 85 when weak inhibitor of CYP3A4 ( e. g . , diltiazem or escitalopram ) or CYP2D6 be use concomitantly with ABILIFY , modest increase in aripiprazole concentration might be expect .
& quot ;
& quot ; * produce in CHO cell line by recombinant DNA technology
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl
& quot ;
& quot ; Extrapyramidal symptom ( EPS ) :
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; content by weight , by volume or by unit
& quot ;
& quot ; if sign and symptom of tardive dyskinesia appear in a patient on ABILIFY , dose reduction or discontinuation should be consider .
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; 2 .
& quot ;
& quot ; in patient with chronic renal failure and clinically evident ischaemic heart disease or congestive heart failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration a recommend under section 4.2 .
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; Suomi / Finland OY BRISTOL-MYERS SQUIBB ( Finland ) AB Puh / Tel : + 358 9 251 21 230
& quot ;
& quot ; when the CYP3A4 inducer be withdraw from the combination therapy , the aripiprazole dose should then be reduce to the recommend dose ( see section 4.5 ) .
& quot ;
& quot ; 28 X 1
& quot ;
& quot ; Orodispersible Tablet
& quot ;
& quot ; Pack size of 1 or 6 pre-filled syringe ( s ) .
& quot ;
& quot ; 2 .
& quot ;
& quot ; owe to the greater sensitivity of this population , a lower start dose should be consider when clinical factor warrant ( see section 4.4 ) .
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; in clinical trial in osteoporosis , the change in creatinine clearance ( measure annually prior to dose ) and the incidence of renal failure and impairment be comparable for both the Aclasta and placebo treatment group over three year .
& quot ;
& quot ; when reconstitute , Abraxane contain approximately 425 mg sodium per dose .
& quot ;
& quot ; upon discontinuation of potent CYP3A4 inducer , the dosage of ABILIFY should be reduce to the recommend dose .
& quot ;
& quot ; in most case , the ferritin value in the serum fall simultaneously with the rise in packed cell volume .
& quot ;
& quot ; functional assessment of Cancer Therapy- Anaemia ( FACT-An ) general scale , FACT-An fatigue scale , and Cancer linear Analogue scale ( CLAS ) .
& quot ;
& quot ; driving and use machine do not drive or use any tool or machine , until you know how ABILIFY affect you .
& quot ;
& quot ; how to store ABILIFY
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; it be important that level of iron in your blood be normal throughout Abseamed treatment .
& quot ;
& quot ; the intravenous route have to be use ( please see section 4.4 - chronic renal failure patient ) .
& quot ;
& quot ; 24 month
& quot ;
& quot ; Comparisons between aripiprazole and placebo in the proportion of patient experience potentially clinically significant change in routine laboratory parameter reveal no medically important difference .
& quot ;
& quot ; risk factor that may predispose patient to severe complication include obesity and family history of diabetes .
& quot ;
& quot ; these study have show an consistent unexplained statistically significant excess mortality in patient who have anaemia associate with various common cancer who receive recombinant human erythropoietin compare to control .
& quot ;
& quot ; if you need more information about your medical condition or your treatment , read the package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
& quot ;
& quot ; Intravenous injection : over at least one to five minute , depend on the total dose .
& quot ;
& quot ; expiry date
& quot ;
& quot ; 13 .
& quot ;
& quot ; read all of this leaflet carefully before you start use this medicine .
& quot ;
& quot ; Hepatic disease :
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be
& quot ;
& quot ; 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole increase by 77 % and 43 % , respectively .
& quot ;
& quot ; in these patient dose should be manage cautiously .
& quot ;
& quot ; consequently :
& quot ;
& quot ; Portugal BRISTOL-MYERS SQUIBB FARMACÊUTICA Portuguesa , S. A .
& quot ;
& quot ; 0.7 ml ( 10000 IU / ml )
& quot ;
& quot ; 1 .
& quot ;
& quot ; packaging
& quot ;
& quot ; - iron supplementation , e. g .
& quot ;
& quot ; ABILIFY be use to treat adult who suffer from a condition with symptom such a feeling & quot ; & quot ; high & quot ; & quot ; , have excessive amount of energy , need much le sleep than usual , talk very quickly with race idea and sometimes severe irritability .
& quot ;
& quot ; Abseamed 1000 IU / 0.5 ml solution for injection in a pre-filled syringe The syrinx contain 0.5 ml ( 1000 IU ) of solution .
& quot ;
& quot ; pure red Cell Aplasia ( PRCA ) Antibody-mediated PRCA have be very rarely report after month to year of subcutaneous erythropoietin treatment .
& quot ;
& quot ; the intravenous route have to be use ( please see section 4.4 - chronic renal failure patient ) .
& quot ;
& quot ; undesirable effect know to be associate with antipsychotic therapy and also report during treatment with aripiprazole include neuroleptic malignant syndrome , tardive dyskinesia , seizure , cerebrovascular adverse event and increased mortality in elderly demented patient , hyperglycaemia and diabetes mellitus ( see section 4.4 ) .
& quot ;
& quot ; N05AX12
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; Cardiac disorder :
& quot ;
& quot ; s R. O .
& quot ;
& quot ; 1 .
& quot ;
& quot ; allergic reaction ( e. g. anaphylactic reaction , angioedema include swollen tongue , tongue oedema , face oedema , pruritus , or urticaria )
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; 170 do not open the blister until ready to administer .
& quot ;
& quot ; this medicinal product must not be mix with other medicinal product except those mention in section 6.6 .
& quot ;
& quot ; there be no accumulation : the level remain the same , whether they be determined 24 hour after the first injection or 24 hour after the last injection .
& quot ;
& quot ; treatment of anaemia and reduction of transfusion requirement in adult patient receive chemotherapy for solid tumour , malignant lymphoma or multiple myeloma , and at risk of transfusion a assess by the patient & apos ; s general status ( e. g. cardiovascular status , pre-existing anaemia at the start of chemotherapy ) .
& quot ;
& quot ; each ml of solution contain 10 000 IU of epoetin alfa * correspond to 84.0 microgram per ml 1 pre-filled syringe of 0.8 ml contains 8000 international unit ( IU ) correspond to 67.2 microgram epoetin alfa
& quot ;
& quot ; however your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day .
& quot ;
& quot ; Tablet
& quot ;
& quot ; there be conflict report in the literature regard whether erythropoietin may play a major role a tumour proliferators .
& quot ;
& quot ; 6 .
& quot ;
& quot ; 45 1 .
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; if you have miss an injection , or inject too little , talk to your doctor .
& quot ;
& quot ; 1 .
& quot ;
& quot ; the biological efficacy of epoetin alfa have be demonstrate in various animal model in vivo ( normal and anaemic rat , polycythaemic mouse ) .
& quot ;
& quot ; Aripiprazole undergo minimal pre-systemic metabolism .
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6.8 g / dl or & lt ; 4.25 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 6.8 g / dl or & gt ; 4.25 mmol / l ) .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery , with a baseline haemoglobin of 10 to 13 g / dl , the incidence of thrombotic / vascular event ( most of which be DVTs ) , in the overall patient population of the clinical trial , appear to be similar across the different epoetin alfa dose group and placebo group , although the clinical experience be limit .
& quot ;
& quot ; Abseamed should be give by the intravenous route .
& quot ;
& quot ; the total body clearance of aripiprazole be 0.7 ml / min / kg , which be primarily hepatic .
& quot ;
& quot ; Batch
& quot ;
& quot ; the highest nontumorigenic exposure in female rat be 7 time the human exposure at the recommend dose .
& quot ;
& quot ; 6 .
& quot ;
& quot ; - if the seal be break .
& quot ;
& quot ; the initial dose be 150 IU / kg give subcutaneously 3 time per week .
& quot ;
& quot ; Intravenous route
& quot ;
& quot ; in patient with chronic renal failure the medicinal product have to be administer intravenously ( see section 4.4 ) .
& quot ;
& quot ; in the absence of compatibility study , this medicinal product must not be mix with other medicinal product .
& quot ;
& quot ; Nederland Eurocept B. V .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; in clinical trial with aripiprazole , there be no significant difference in the incidence rate of hyperglycaemia-related adverse event ( include diabetes ) or in abnormal glycaemia laboratory value compare to placebo .
& quot ;
& quot ; Subcutaneous route
& quot ;
& quot ; Aripiprazole also exhibit moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptor .
& quot ;
& quot ; 15 .
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; management of overdose should concentrate on supportive therapy , maintain an adequate airway , oxygenation and ventilation , and management of symptom .
& quot ;
& quot ; 155 Eesti Österreich BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; Paclitaxel be a cytotoxic anticancer medicinal product and , a with other potentially toxic compound , caution should be exercise in handle Abraxane .
& quot ;
& quot ; clear colourless solution
& quot ;
& quot ; - oral iron substitution of 200 - 300 mg Fe2 + / day be recommend for all cancer patient whose
& quot ;
& quot ; Tel : + + 39 ( 0 ) 49 823 2111
& quot ;
& quot ; the subcutaneous route of administration should be use .
& quot ;
& quot ; label / SYRINGE
& quot ;
& quot ; 4 .
& quot ;
& quot ; Metabolism :
& quot ;
& quot ; patient who develop pure red Cell Aplasia ( PRCA ) follow treatment with any erythropoietin should not receive Abseamed or any other erythropoietin ( see section 4.4 - pure red Cell Aplasia ) .
& quot ;
& quot ; 7 .
& quot ;
& quot ; do not take a double dose to make up for a forgotten dose .
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; 3 .
& quot ;
& quot ; the mean elimination half-lives for aripiprazole be approximately 75 hour in extensive metabolisers of CYP2D6 and approximately 146 hour in poor metabolisers of CYP2D6 .
& quot ;
& quot ; Aripiprazole be excrete in the milk of treated rat during lactation .
& quot ;
& quot ; depend on how your anaemia responds , the dose may be adjust until your condition be control .
& quot ;
& quot ; oropharyngeal spasm , laryngospasm , aspiration pneumonia
& quot ;
& quot ; 4.2 – 9.8 month ) .
& quot ;
& quot ; 9 .
& quot ;
& quot ; population pharmacokinetic evaluation have reveal no evidence of clinically significant race-related difference or effect from smoke upon the pharmacokinetics of aripiprazole .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; adult surgery patient in an autologous predonation programme :
& quot ;
& quot ; QT prolongation , ventricular arrhythmia , sudden unexplained death , cardiac arrest , torsades de pointes , bradycardia
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; 2 .
& quot ;
& quot ; in the open-label study there be no difference in overall survival between patient treat with recombinant human erythropoietin and control .
& quot ;
& quot ; an increase relative risk of thromboembolic event ( RR 1.67 , 95 % CI :
& quot ;
& quot ; upon discontinuation of potent CYP3A4 inducer , the dosage of ABILIFY should be reduce to the recommend dose .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; the possibility of multiple medicinal product involvement should be consider .
& quot ;
& quot ; a with all growth factor , there be a concern that epoetins could stimulate the growth of tumour .
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; in the four placebo-controlled study the hazard ratio for overall survival range between 1.25 and 2.47 in favour of control .
& quot ;
& quot ; long-term carcinogenicity study have not be carry out .
& quot ;
& quot ; Italia BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; care should be take to ensure that at the outset of the treatment patient be not iron deficient .
& quot ;
& quot ; early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid , for example , be recommend in these patient .
& quot ;
& quot ; 2 .
& quot ;
& quot ; 1 1 .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; Meta-analysis of overall survival data produce a hazard ratio point estimate of 1.08 in favour of control ( 95 % CI :
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; oral use .
& quot ;
& quot ; all patient be treat with epoetin alfa should receive adequate iron supplementation ( e. g. oral iron substitution of 200 mg Fe2 + daily ) throughout the course of epoetin alfa treatment .
& quot ;
& quot ; 7 .
& quot ;
& quot ; Metabolism :
& quot ;
& quot ; manufacturer OF the biological active substance AND manufacturing authorisation holder responsible for BATCH release
& quot ;
& quot ; - decrease locoregional control in patient with advanced head and neck cancer receiving
& quot ;
& quot ; manufacturer Bristol-Myers Squibb S. r. l .
& quot ;
& quot ; 107 patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; in three short-term ( 4 to 6 week ) placebo-controlled trial involve 1,228 schizophrenic patient , present with positive or negative symptom , aripiprazole be associate with statistically significantly greater improvement in psychotic symptom compare to placebo .
& quot ;
& quot ; Non-specific skin rash have be describe in association with epoetin alfa .
& quot ;
& quot ; patient should be advise not to breast feed if they be take aripiprazole .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; iron supplementation should be start a soon a possible , even several week prior to initiate the autologous predeposit , in order to achieve high iron store prior to start Abseamed therapy .
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; Aripiprazole be extensively metabolise by the liver primarily by three biotransformation pathway : dehydrogenation , hydroxylation , and N-dealkylation .
& quot ;
& quot ;
& quot ; España Laboratorios Farmacéuticos ROVI S. A .
& quot ;
& quot ; if Abraxane suspension contact the skin , the skin should be wash immediately and thoroughly with soap and water .
& quot ;
& quot ; 200 mg oral elemental iron daily ) throughout the course of treatment .
& quot ;
& quot ; EXP
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl or Hb increase ≥ 1 g / dl
& quot ;
& quot ; 4 .
& quot ;
& quot ; Abseamed should be use with caution in the presence of untreated , inadequately treat or poorly controllable hypertension .
& quot ;
& quot ; 5 .
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; the frequency of these event be consider not know ( can not be estimate from the available data ) .
& quot ;
& quot ; no specific drug-drug interaction study have be conduct with zoledronic acid .
& quot ;
& quot ; patient should be closely monitor throughout this period .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients or to any bisphosphonates .
& quot ;
& quot ; weight gain have be report post-marketing among patient prescribe ABILIFY .
& quot ;
& quot ; Intravenous injection : over at least one to five minute , depend on the total dose .
& quot ;
& quot ; the effective dose range of aripiprazole solution for injection be 5.25-15 mg a a single injection .
& quot ;
& quot ; 5 .
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP3A4 ( ketoconazole ) increase aripiprazole AUC and Cmax by 63 % and 37 % , respectively .
& quot ;
& quot ; in addition , in patient with Paget & apos ; s disease , it be strongly advise that adequate supplemental calcium correspond to at least 500 mg elemental calcium twice daily be ensure for at least 10 day follow Aclasta administration ( see section 4.2 ) .
& quot ;
& quot ; Aripiprazole be widely distribute throughout the body with an apparent volume of distribution of 4.9 l / kg , indicate extensive extravascular distribution .
& quot ;
& quot ; - if the solution be cloudy or there be particle in it .
& quot ;
& quot ; condition OF the marketing authorisation
& quot ;
& quot ; statement OF active substance ( s )
& quot ;
& quot ; at therapeutic concentration , aripiprazole and dehydro-aripiprazole be greater than 99 % bound to serum protein , bind primarily to albumin .
& quot ;
& quot ; the recommend dose be 260 mg per square metre of body surface area ( calculate use the patient ’ s height and weight ) .
& quot ;
& quot ; the use of glove , goggles and protective clothing be recommend .
& quot ;
& quot ; ABILIFY be effective in maintain the clinical improvement during continuation therapy in patient who have show an initial treatment response .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; adult patient with renal insufficiency not yet undergoing dialysis :
& quot ;
& quot ; 1 .
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; the syrinx contain 0.9 ml ( 9000 IU ) of solution .
& quot ;
& quot ; 24 hour at 2 ° C - 8 ° C .
& quot ;
& quot ; Norge BRISTOL-MYERS SQUIBB Norway LTD Tlf : + 47 67 55 53 50
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; if an elevate ( or rise ) serum potassium level be detect then consideration should be give to cease epoetin alfa administration until hyperkalaemia have be correct .
& quot ;
& quot ; Thrombotic / vascular event , such a myocardial ischaemia , myocardial infarction , cerebrovascular accident ( cerebral haemorrhage and cerebral infarction ) , transient ischaemic attack , deep vein thrombosis , arterial thrombosis , pulmonary embolus , aneurysm , retinal thrombosis , and clotting of an artificial kidney have be report in patient receive erythropoietic agent , include patient receive epoetin alfa .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; with renal insufficiency not yet undergoing dialysis ( see section 4.4 ) .
& quot ;
& quot ; 84 Dysphagia : oesophageal dysmotility and aspiration have be associate with antipsychotic drug use , include ABILIFY .
& quot ;
& quot ; KGAA Tel : + 49 89 121 42-0
& quot ;
& quot ; in schizophrenia patient the incidence of akathisia be 6.2 % with aripiprazole and 3.0 % with placebo .
& quot ;
& quot ; 9000 IU /
& quot ;
& quot ; use ABILIFY with food and drink ABILIFY can be administer regardless of meal .
& quot ;
& quot ; Renal and urinary disorder :
& quot ;
& quot ; 11 .
& quot ;
& quot ; iron supplementation should be start prior to epoetin alfa therapy , to achieve adequate iron store .
& quot ;
& quot ; other
& quot ;
& quot ; it could be show with the aid of cell culture of human bone marrow cell that epoetin alfa stimulates erythropoiesis specifically and do not affect leucopoiesis .
& quot ;
& quot ; 98 X 1
& quot ;
& quot ; Hyperglycaemia and Diabetes Mellitus : hyperglycaemia , in some case extreme and associate with ketoacidosis or hyperosmolar coma or death , have be report in patient treat with atypical antipsychotic agent , include ABILIFY .
& quot ;
& quot ; Cerebrovascular adverse event : in the same trial , cerebrovascular adverse event ( e. g. stroke , transient ischaemic attack ) , include fatality , be report in patient ( mean age :
& quot ;
& quot ; grade 4 neutropenia ( & lt ; 0.5 X 109 / l ) occur in 9 % of patient treat with Abraxane .
& quot ;
& quot ; the recommend starting dose for ABILIFY be 10 or 15 mg / day with a maintenance dose of 15 mg / day administer on a once-a-day schedule without regard to meal .
& quot ;
& quot ; elderly patient with dementia-related psychosis :
& quot ;
& quot ; the potentially medically important sign and symptom observe included lethargy , increase blood pressure , somnolence , tachycardia , nausea , vomit and diarrhoea .
& quot ;
& quot ; the syrinx contain 0.4 ml ( 4000 IU ) of solution .
& quot ;
& quot ; it be recommend that the platelet count be regularly monitor during the first 8 week of therapy .
& quot ;
& quot ; the company also present data from the publish literature .
& quot ;
& quot ; treatment of adult patient schedule for major elective orthopaedic surgery :
& quot ;
& quot ; Aripiprazole be well absorb , with peak plasma concentration occur within 3-5 hour after dose .
& quot ;
& quot ; the therapeutic margin of epoetin alfa be very wide .
& quot ;
& quot ; investigation :
& quot ;
& quot ; Subcutaneous injection : a maximum volume of 1 ml at one injection site should generally not be exceed .
& quot ;
& quot ; in that study the incidence of fatal thromboembolic event be higher in patient receive epoetin alfa than in those receive placebo ( see section 5.1 ) .
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; other potent inhibitor of CYP2D6 , such a fluoxetine and paroxetine , may be expect to have similar effect and similar dose reduction should therefore be apply .
& quot ;
& quot ; method of administration
& quot ;
& quot ; Pre-filled syrinx ( glass type I ) with plunger ( Teflon-faced rubber ) seal in a blister .
& quot ;
& quot ; rash , photosensitivity reaction , alopecia , hyperhidrosis
& quot ;
& quot ; jaundice , hepatitis , increase Alanine Aminotransferase ( ALT ) , increased Aspartate Aminotransferase ( AST ) , increase Gamma Glutamyl Transferase ( GGT ) , increase alkaline phosphatase
& quot ;
& quot ; Cerebrovascular adverse event : in the same trial , cerebrovascular adverse event ( e. g. stroke , transient ischaemic attack ) , include fatality , be report in patient ( mean age :
& quot ;
& quot ; the European Commission grant a marketing authorisation valid throughout the European Union for Abraxane to Abraxis BioScience limit on 11 January 2008 .
& quot ;
& quot ; 69 1 .
& quot ;
& quot ; 121 patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; all of these additive factor of anaemia should also be carefully consider when decide to increase the dose of epoetin alfa in cancer patient .
& quot ;
& quot ; Tel . : + 48 22 5796666
& quot ;
& quot ; in addition , report of accidental overdose with aripiprazole alone ( up to 195 mg ) in child have be receive with no fatality .
& quot ;
& quot ; the MAH commits to perform the study and additional pharmacovigilance activity detail in the Pharmacovigilance Plan , a agree in version 5 of the risk management Plan ( RMP ) present in Module 1.8.2. of the marketing authorisation application and any subsequent update of the RMP agree by the CHMP .
& quot ;
& quot ; during antipsychotic treatment , improvement in the patient & apos ; s clinical condition may take several day to some week .
& quot ;
& quot ; Antibody-mediated erythroblastopenia ( PRCA ) have be report after month to year of treatment with epoetin alfa .
& quot ;
& quot ; 157 minimum PARTICULARS to appear on small immediate packaging unit
& quot ;
& quot ; Aclasta 5 mg solution for infusion Zoledronic acid
& quot ;
& quot ; Additionally , aripiprazole and dehydro-aripiprazole do not show potential for alter CYP1A2-mediated metabolism in vitro .
& quot ;
& quot ; name OF the MEDICINAL product AND route ( s ) OF administration
& quot ;
& quot ; the initial dose be 150 IU / kg give subcutaneously 3 time per week .
& quot ;
& quot ; 6.2 Incompatibilities
& quot ;
& quot ; 137 tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever , sweat , alter mental status , or very rapid or irregular heart beat .
& quot ;
& quot ; the bioavailability of subcutaneous injectable epoetin alfa be much lower than that of the intravenous medicinal product : approximately 20 % .
& quot ;
& quot ;
& quot ; each ml of solution contains 2000 IU of epoetin alfa * correspond to 16.8 microgram per ml 1 pre-filled syringe of 1 ml contains 2000 international unit ( IU ) correspond to 16.8 microgram epoetin alfa
& quot ;
& quot ; 1 .
& quot ;
& quot ; Surgery patient in autologous predonation programme
& quot ;
& quot ; Syringes be emboss with graduation ring and the filling volume be indicate by a stick-on label in order to enable partial use if require .
& quot ;
& quot ; 2 Posology
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; some patient may benefit from a higher dose .
& quot ;
& quot ; Aripiprazole dose range from 0.5 to 30 mg administer once a day to healthy subject for 2 week produce a dose-dependent reduction in the binding of 11C-raclopride , a D2 / D3 receptor ligand , to the caudate and putamen detect by positron emission tomography .
& quot ;
& quot ; in CYP2D6 poor metabolisers , concomitant use of potent inhibitor of CYP3A4 may result in higher plasma concentration of aripiprazole compare to that in CYP2D6 extensive metabolizers .
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; if anti-erythropoietin , antibody-mediated PRCA be suspect , therapy with Abseamed should be discontinue immediately .
& quot ;
& quot ; Schizophrenia - in a long term 52-week controlled trial , aripiprazole-treated patient have an overall-lower incidence ( 25.8 % ) of EPS include parkinsonism , akathisia , dystonia and dyskinesia compare with those treat with haloperidol ( 57.3 % ) .
& quot ;
& quot ; general disorder and administration site condition :
& quot ;
& quot ; always take the tablet with water and swallow it whole .
& quot ;
& quot ; 200 mg oral elemental iron daily ) throughout the course of treatment .
& quot ;
& quot ; be sure to tell your doctor if you take a medicine to keep your blood pressure under control .
& quot ;
& quot ; each tablet contain 15 mg of aripiprazole .
& quot ;
& quot ; Measurement of epoetin alfa follow multiple dose intravenous administration reveal a half-life of approximately 4 hour in normal volunteer and a somewhat more prolonged half-life in renal failure patient , approximately 5 hour .
& quot ;
& quot ; the study either recruited patient who be be treat with chemotherapy ( two study ) or use patient population in which erythropoiesis stimulating agent be not indicate : anaemia in patient with cancer not receive chemotherapy , and head and neck cancer patient receive radiotherapy .
& quot ;
& quot ; България BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; EXP
& quot ;
& quot ; Syringes be emboss with graduation ring and the filling volume be indicate by a stick-on label in order to enable partial use if require .
& quot ;
& quot ; Latvija Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ;
& quot ; these increase in blood pressure can be treat with medicinal product .
& quot ;
& quot ; oral use .
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl
& quot ;
& quot ; the subcutaneous route of administration should be use .
& quot ;
& quot ; 60 ( 43 , 72 ) * *
& quot ;
& quot ; alternatively , the injection can be give at the end of the dialysis session via the fistula needle tubing , follow by 10 ml of isotonic saline to rinse the tubing and ensure satisfactory injection of the product into the circulation .
& quot ;
& quot ; B03XA01
& quot ;
& quot ; it could be show with the aid of cell culture of human bone marrow cell that epoetin alfa stimulates erythropoiesis specifically and do not affect leucopoiesis .
& quot ;
& quot ; what Abseamed contains
& quot ;
& quot ; Tel : + 420 221 016 111
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; cycle be administer at 3 week interval .
& quot ;
& quot ; each ml of solution contain 10 000 IU of epoetin alfa * correspond to 84.0 microgram per ml 1 pre-filled syringe of 0.4 ml contains 4000 international unit ( IU ) correspond to 33.6 microgram epoetin alfa
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; a with other antipsychotic , aripiprazole should be use with caution in patient with a family history of QT prolongation .
& quot ;
& quot ; EU / 1 / 04 / 276 / 030-032
& quot ;
& quot ; however , if the haemoglobin have increase & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , response to epoetin alfa therapy be unlikely and treatment should be discontinue .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; ABILIFY solution for injection be give when treatment with oral formulation of ABILIFY be not appropriate .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; Tel : + 351 21 440 70 00
& quot ;
& quot ; 6 pre-filled syrinx
& quot ;
& quot ; - iron supplementation , e. g .
& quot ;
& quot ; 8 .
& quot ;
& quot ; management of overdose should concentrate on supportive therapy , maintain an adequate airway , oxygenation and ventilation , and management of symptom .
& quot ;
& quot ; control clinical trial have not show significant benefit attributable to the administration of epoetins when haemoglobin concentration be increase beyond the level necessary to control symptom of anaemia and to avoid blood transfusion .
& quot ;
& quot ; Italia BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ;
& quot ; other finding :
& quot ;
& quot ; appropriate therapy such a blood transfusion may be give to patient when indicate .
& quot ;
& quot ; if not use immediately , the suspension may be store in a refrigerator ( 2 ° C – 8 ° C ) for up to 8 hour in the vial when kept in the outer carton in order to protect it from light .
& quot ;
& quot ; adult patient with renal insufficiency not yet undergoing dialysis :
& quot ;
& quot ; 0.99 , 1,18 ; 42 trial and 8167 patient ) .
& quot ;
& quot ; always take ABILIFY exactly a your doctor have tell you .
& quot ;
& quot ; child and adolescent : there be no experience in child and adolescent under 18 year of age .
& quot ;
& quot ; the haemoglobin concentration aim for be between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) , except in paediatric patient in whom the haemoglobin concentration should be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; Suomi / Finland OY BRISTOL-MYERS SQUIBB ( Finland ) AB Puh / Tel : + 358 9 251 21 230
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be avoid .
& quot ;
& quot ; in some preclinical toxicological study in dog and rat , but not in monkey , epoetin alfa therapy be associate with subclinical bone marrow fibrosis ( bone marrow fibrosis be a known complication of chronic renal failure in human and may be relate to secondary hyperparathyroidism or unknown factor .
& quot ;
& quot ; store in the original package in order to protect from moisture .
& quot ;
& quot ; attention should be pay to sudden stab migraine-like headache a a possible warning signal .
& quot ;
& quot ; patient who have receive dos higher than those recommend should be carefully monitor .
& quot ;
& quot ; interaction with receptor other than dopamine and serotonin subtypes may explain some of the other clinical effect of aripiprazole .
& quot ;
& quot ; Abseamed can be use to increase the yield of autologous blood from patient in a predonation programme .
& quot ;
& quot ; Latvija BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; 4 .
& quot ;
& quot ; however , if the haemoglobin have increase & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , response to epoetin alfa therapy be unlikely and treatment should be discontinue .
& quot ;
& quot ; study in animal have show reproduction toxicity ( see section 5.3 ) .
& quot ;
& quot ; Abraxane be supply a a sterile lyophilise powder for reconstitution before use .
& quot ;
& quot ; your doctor can decide whether Abseamed be not work properly for you .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; fracture incidence % ( CI )
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; in addition , paclitaxel induces abnormal array or “ bundle ” of microtubule throughout the cell cycle and multiple aster of microtubule during mitosis .
& quot ;
& quot ; in addition , case of stroke or & quot ; & quot ; mini & quot ; & quot ; stroke have be report .
& quot ;
& quot ; Smoking status : accord to the metabolic pathway of ABILIFY no dosage adjustment be require for smoker ( see section 4.5 ) .
& quot ;
& quot ; 13 .
& quot ;
& quot ; oral use
& quot ;
& quot ; thus , aripiprazole be unlikely to cause clinically important medicinal product interaction mediate by these enzyme .
& quot ;
& quot ; BLISTER
& quot ;
& quot ; attention should be pay to sudden stab migraine-like headache a a possible warning signal .
& quot ;
& quot ; Median 100 75 33
& quot ;
& quot ; solution for injection in a pre-filled syringe ( injection )
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; people with this condition may also feel depressed , guilty , anxious or tense . feeling & quot ; & quot ; high & quot ; & quot ; , have excessive amount of energy , need much le sleep than usual , talk very quickly with race idea and sometimes severe irritability .
& quot ;
& quot ; the extent to which these outcome might apply to the administration of recombinant human erythropoietin to patient with cancer , treat with chemotherapy to achieve haemoglobin concentration le than 13 g / dl , be unclear because few patient with these characteristic be include in the data reviewed .
& quot ;
& quot ; these change be interpret a be secondary to decreased maternal body weight gain .
& quot ;
& quot ; ( 1 ) exclude finger , toe and facial fracture ( 2 ) include clinical thoracic and clinical lumbar vertebral fracture
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6 g / dl or & lt ; 3.75 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 8 g / dl or & gt ; 5 mmol / l ) .
& quot ;
& quot ; 2 .
& quot ;
& quot ; Medicines should not be dispose of via wastewater or household waste .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Erythropoietin be a growth factor that primarily stimulate red cell production .
& quot ;
& quot ; 3 / 3
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; Hyperglycaemia and Diabetes Mellitus : hyperglycaemia , in some case extreme and associate with ketoacidosis or hyperosmolar coma or death , have be report in patient treat with atypical antipsychotic agent , include ABILIFY .
& quot ;
& quot ; Tumour growth potential
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; general
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; upon discontinuation of the CYP2D6 or 3A4 inhibitor , the dosage of ABILIFY should be increase to the level prior to the initiation of the concomitant therapy .
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; always take ABILIFY exactly a your doctor have tell you .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; in the indication “ increase the yield of autologous blood ” : myocardial infarction or stroke in the month precede treatment , unstable angina pectoris , increase risk of deep venous thrombosis such a history of venous thromboembolic disease .
& quot ;
& quot ; România Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; 2 .
& quot ;
& quot ; 2 .
& quot ;
& quot ; 10 .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; seizure : in clinical trial , uncommon case of seizure be report during treatment with aripiprazole .
& quot ;
& quot ; each tablet contain 10 mg of aripiprazole .
& quot ;
& quot ; the solution for injection be use for the rapid control of agitation or disturb behaviour when take the medicine by mouth be not appropriate .
& quot ;
& quot ; however your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day .
& quot ;
& quot ; the potentially medically serious sign and symptom report included somnolence , transient loss of consciousness and extrapyramidal symptom .
& quot ;
& quot ; Hypertension may occur in epoetin alfa treat patient .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; 8 .
& quot ;
& quot ;
& quot ; base on result of a full range of standard genotoxicity test , aripiprazole be consider non-genotoxic .
& quot ;
& quot ; Cancer patient
& quot ;
& quot ; all special warning and precaution associate with autologous predonation programme , especially routine volume replacement , should be respect .
& quot ;
& quot ; 6000 IU / 0.6 ml
& quot ;
& quot ; in clinical trial , an increase risk of death and serious cardiovascular event be observe when erythropoiesis stimulate agent ( ESAs ) be administer to target a haemoglobin of greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; 0.9 ml ( 10000 IU / ml )
& quot ;
& quot ; agitation , nervousness ; suicide attempt , suicidal ideation , and complete suicide ( see section 4.4 )
& quot ;
& quot ; in haemodialysed patient , a bolus injection may be give during the dialysis session through a suitable venous port in the dialysis line .
& quot ;
& quot ; take other medicine please tell your doctor or pharmacist if you be take or have recently take any other medicine , include medicine obtain without a prescription .
& quot ;
& quot ; 6 .
& quot ;
& quot ; Slovenská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; 104 The recommend dose be 600 IU / kg epoetin alfa , give weekly for three week ( day 21 , 14 and 7 ) prior to surgery and on the day of surgery ( day 0 ) .
& quot ;
& quot ; 14 X 1
& quot ;
& quot ; depend on your individual situation a blood transfusion may be preferable .
& quot ;
& quot ; kg Teл . : + 49- ( 0 ) 2371 937 0
& quot ;
& quot ; Bone histology be evaluate in 7 patient with Paget ’ s disease 6 month after treatment with 5 mg zoledronic acid .
& quot ;
& quot ; Pack of 1 or 6 syrinx .
& quot ;
& quot ; statement OF active substance ( s )
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; 120 ( 0.62 mmol / l ) per month and should not exceed 2 g / dl ( 1.25 mmol / l ) per month to minimise risk of an increase in hypertension .
& quot ;
& quot ; justification for not include Braille accept .
& quot ;
& quot ; and Hb increase & lt ; 1 g / dl
& quot ;
& quot ; Tumour growth potential
& quot ;
& quot ; there be no adequate and well-controlled study in pregnant woman .
& quot ;
& quot ; in case of larger volume , more than one site should be choose for the injection .
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; some people may feel depressed .
& quot ;
& quot ; there be no adequate and well-controlled trial of aripiprazole in pregnant woman .
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; at the time of donate blood , Abseamed should be administer after the completion of the blood donation procedure .
& quot ;
& quot ; Suicidal thought and behaviour have be report during aripiprazole treatment .
& quot ;
& quot ; people with this condition may also feel depressed , guilty , anxious or tense .
& quot ;
& quot ; programme , the use of epoetin alfa be not recommend .
& quot ;
& quot ; 4 .
& quot ;
& quot ; agitation , nervousness ; suicide attempt , suicidal ideation , and complete suicide ( see section 4.4 )
& quot ;
& quot ; the frequency list below be define use the following convention : common ( & gt ; 1 / 100 , & lt ; 1 / 10 ) and uncommon ( & gt ; 1 / 1 , 000 , & lt ; 1 / 100 ) .
& quot ;
& quot ; in patient receive chemotherapy or with kidney problem , anaemia can be cause by a lack of erythropoietin , or by the body not respond enough to the erythropoietin it have naturally .
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; maintenance dose between 25 and 50 IU / kg 2 time per week into 2 equal injection .
& quot ;
& quot ; ABILIFY 15 mg tablet aripiprazole
& quot ;
& quot ; even if you feel better , do not alter or discontinue the daily dose of ABILIFY without first consult your doctor .
& quot ;
& quot ; 15 .
& quot ;
& quot ; treatment of anaemia and reduction of transfusion requirement in adult patient receive chemotherapy for solid tumour , malignant lymphoma or multiple myeloma , and at risk of transfusion a assess by the patient & apos ; s general status ( e. g. cardiovascular status , pre-existing anaemia at the start of chemotherapy ) .
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; for 4 week
& quot ;
& quot ; Renal and urinary disorder :
& quot ;
& quot ; in placebo-controlled trial , the incidence of akathisia in bipolar patient be 12.1 % with aripiprazole and 3.2 % with placebo .
& quot ;
& quot ; Phlebotomy may be perform if excessively high haemoglobin level occur .
& quot ;
& quot ; if you want more information on the basis of the CHMP recommendation , read the Scientific discussion ( also part of the EPAR ) .
& quot ;
& quot ; Hypersensitivity : a with other medication hypersensitivity reaction , characterise by allergic symptom , may occur with aripiprazole ( see section 4.8 ) .
& quot ;
& quot ;
& quot ; adult and paediatric haemodialysis patient , adult peritoneal dialysis patient and adult patient with renal insufficiency not yet undergoing dialysis
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of 25 IU / kg 3 time per week at interval of at least 4 week until the desired goal be achieve .
& quot ;
& quot ; method of administration
& quot ;
& quot ; patient ) be recommend for chronic renal failure patient whose serum ferritin level be below 100 ng / ml
& quot ;
& quot ; follow a single oral dose of & # 91 ; 14C & # 93 ; -labelled aripiprazole , approximately 27 % of the administered radioactivity be recover in the urine and approximately 60 % in the faeces .
& quot ;
& quot ; the reconstituted suspension should be milky and homogenous without visible precipitate .
& quot ;
& quot ; ABRAXANE
& quot ;
& quot ; adult surgery patient in an autologous predonation programme :
& quot ;
& quot ; Abraxane should only be administer under the supervision of a qualified oncologist in unit specialise in the administration of cytotoxic agent .
& quot ;
& quot ; NMS be a potentially fatal symptom complex associate with antipsychotic medicinal product .
& quot ;
& quot ; EXP
& quot ;
& quot ; & quot ; & quot ; Flu-like & quot ; & quot ; symptom such a headache , joint pain , feeling of weakness , dizziness , and tiredness may occur , especially at the start of treatment .
& quot ;
& quot ; 12 from a microbiological point of view , the product should be use immediately .
& quot ;
& quot ; therefore , it should not be use in patient with baseline haemoglobin & gt ; 13 g / dl .
& quot ;
& quot ; when perform haematologic assessment during the preoperative period , if the haemoglobin level reach 15 g / dl , or higher , administration of epoetin alfa should be stop and further dos should not be give .
& quot ;
& quot ; in addition , an updated RMP should be submit • when new information be receive that may impact on the current Safety specification , Pharmacovigilance Plan or risk minimisation activity • within 60 day of an important ( pharmacovigilance or risk minimisation ) milestone be reach • at the request of the EMEA
& quot ;
& quot ; these report be base on in vitro finding from human tumour sample , but be of uncertain significance in the clinical situation .
& quot ;
& quot ; 4 .
& quot ;
& quot ; the usual dose be 15 mg once a day .
& quot ;
& quot ; 58 The orodispersible tablet may be use a an alternative to ABILIFY tablet for patient who have difficulty to swallow ABILIFY tablet ( see also section 5.2 ) .
& quot ;
& quot ; expiry date
& quot ;
& quot ; enhance efficacy at dose higher than a daily dose of 15 mg have not be demonstrate although individual patient may benefit from a higher dose .
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; Aripiprazole be extensively metabolise by the liver primarily by three biotransformation pathway : dehydrogenation , hydroxylation , and N-dealkylation .
& quot ;
& quot ; EU / 1 / 07 / 412 / 006
& quot ;
& quot ; in a haloperidol-controlled trial , the proportion of responder patient maintain response to medicinal product at 52-weeks be similar in both group ( aripiprazole 77 % and haloperidol 73 % ) .
& quot ;
& quot ; the decision to administer recombinant erythropoietin should be base on a benefit-risk assessment with the participation of the individual patient , which should also take into account the specific clinical context .
& quot ;
& quot ; Dialysis prescription may have to be adjust periodically to maintain urea , creatinine and potassium in the desired range .
& quot ;
& quot ; 5 .
& quot ;
& quot ; an increase relative risk of thromboembolic event ( RR 1.67 , 95 % CI :
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; Abseamed have no influence on the ability to drive and use machine .
& quot ;
& quot ; 300 IU / kg 3x / week for 4 week
& quot ;
& quot ; skin and subcutaneous tissue disorder :
& quot ;
& quot ; a with other antipsychotic , aripiprazole should be use with caution in patient with a family history of QT prolongation .
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; ABILIFY dose should be double when concomitant administration of ABILIFY occur with carbamazepine .
& quot ;
& quot ; with renal insufficiency not yet undergoing dialysis ( see section 4.4 ) .
& quot ;
& quot ; ABILIFY dose should be reduce to approximately one-half of it prescribed dose when concomitant administration of ABILIFY with quinidine occurs .
& quot ;
& quot ; 83 Tardive dyskinesia : in clinical trial of one year or le duration , there be uncommon report of treatment emergent dyskinesia during treatment with aripiprazole .
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; this leaflet be last approved in
& quot ;
& quot ; iron status should be evaluate prior to and during treatment and iron supplementation administer if necessary .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; method of administration
& quot ;
& quot ; Norge BRISTOL-MYERS SQUIBB Norway LTD Tlf : + 47 67 55 53 50
& quot ;
& quot ; 154 PARTICULARS to appear on the outer packaging
& quot ;
& quot ; Annex
& quot ;
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; Hepatobiliary disorder :
& quot ;
& quot ; name OF the MEDICINAL product AND route ( s ) OF administration
& quot ;
& quot ; the recommended weekly dose be between 75 and 300 IU per kilogram .
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6.8 g / dl or & lt ; 4.25 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 6.8 g / dl or & gt ; 4.25 mmol / l ) .
& quot ;
& quot ; Hb between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; 12 g / dl )
& quot ;
& quot ; 1 .
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; all of these additive factor of anaemia should also be carefully consider when decide to increase the dose of epoetin alfa in cancer patient .
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; - if you have any further question , ask your doctor .
& quot ;
& quot ; Antibody-mediated erythroblastopenia ( PRCA ) have be report after month to year of treatment with epoetin alfa .
& quot ;
& quot ; the absolute oral bioavailability of the tablet formulation be 87 % .
& quot ;
& quot ; Excipients : sodium dihydrogen phosphate dihydrate , disodium phosphate dihydrate , sodium chloride , glycine , polysorbate 80 , hydrochloric acid ( for pH-adjustment ) , sodium hydroxide ( for pH-adjustment ) , and water for injection
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; if it contact mucous membrane , the membrane should be flush thoroughly with water .
& quot ;
& quot ; s R. O .
& quot ;
& quot ; dose ( IU / kg give 3x / week )
& quot ;
& quot ; Aripiprazole exhibit antagonist property in animal model of dopaminergic hyperactivity and agonist property in animal model of dopaminergic hypoactivity .
& quot ;
& quot ; in a prospective , randomised , double-blind , placebo-controlled trial conduct in 375 anaemic patient with various non-myeloid malignancy receive non-platinum chemotherapy , there be a significant reduction of anaemia-related sequela ( e. g. fatigue , decrease energy , and activity reduction ) , a measure by the following instrument and scale :
& quot ;
& quot ; Č eská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; the company that make Aclasta will provide educational pack for doctor who prescribe Aclasta for osteoporosis , remind them how the medicine should be use , and similar pack for patient , which explain the medicine ’ s side effect and when they should contact their doctor .
& quot ;
& quot ; Manic episodes in Bipolar I Disorder - in a 12-week controlled trial , the incidence of EPS be 23.5 % for aripiprazole-treated patient and 53.3 % for haloperidol-treated patient .
& quot ;
& quot ; 1 .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; Hb between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; Manic episode :
& quot ;
& quot ; the injection be give in the thigh or the anterior abdominal wall .
& quot ;
& quot ; ABILIFY be indicate for the treatment of schizophrenia .
& quot ;
& quot ; Aripiprazole be extensively metabolise by the liver primarily by three biotransformation pathway : dehydrogenation , hydroxylation , and N-dealkylation .
& quot ;
& quot ; there be no accumulation : the level remain the same , whether they be determined 24 hour after the first injection or 24 hour after the last injection .
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; Τηλ : + 30 210 6074300
& quot ;
& quot ; tell your doctor immediately if you be have any thought or feeling about hurt yourself .
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; ABILIFY be not approve for the treatment of dementia-related psychosis .
& quot ;
& quot ; ear pain , tinnitus Common :
& quot ;
& quot ; France BRISTOL-MYERS SQUIBB SARL Tél : + 33 ( 0 ) 810 410 500
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of the symptom of anaemia .
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; take ABILIFY with food and drink ABILIFY can be take regardless of meal .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; 30 mg
& quot ;
& quot ; * additional adverse event which be report in the individual study but be not include due to the pool presentation be :
& quot ;
& quot ; Hb 10 - 13 g / dl ) who do not have an autologous predonation programme available and with an expected blood loss of 900 to 1800 ml .
& quot ;
& quot ; Hexal AG Industriestrasse 25 D-83607 Holzkirchen Germany
& quot ;
& quot ; at the time of donate blood , Abseamed should be administer after the completion of the blood donation procedure .
& quot ;
& quot ; Τηλ : + 357 22 677038
& quot ;
& quot ; in addition , other cause of anaemia , such a vitamin B12 or folate deficiency , should be exclude before institute therapy with epoetin alfa .
& quot ;
& quot ; 10 mg
& quot ;
& quot ; for information on the infusion of Aclasta , see section 6.6 .
& quot ;
& quot ; the initial dose be 150 IU / kg give subcutaneously 3 time per week .
& quot ;
& quot ; follow subcutaneous injection , serum level of epoetin alfa be much lower than the level achieve follow intravenous injection , the level increase slowly and reach a peak between 12 and
& quot ;
& quot ; 7 .
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; it be recommend that the platelet count be regularly monitor during the first 8 week of therapy .
& quot ;
& quot ; 10 to 30 ml solution / day ) .
& quot ;
& quot ; priapism
& quot ;
& quot ; 2 .
& quot ;
& quot ; Abseamed 2000 IU / 1 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; 144 Annex III
& quot ;
& quot ; BLISTER
& quot ;
& quot ; possible side effect
& quot ;
& quot ; if you be an elderly patient suffer from dementia ( loss of memory and other mental ability ) , you or your carer / relative should tell your doctor if you have ever have a stroke or & quot ; & quot ; mini & quot ; & quot ; stroke .
& quot ;
& quot ; Subcutaneous injection : a maximum volume of 1 ml at one injection site should generally not be exceed .
& quot ;
& quot ; in patient with severe hepatic impairment , the data available be insufficient to
& quot ;
& quot ; in controlled clinical study , use of Epoetin alfa and other erythropoiesis-stimulating agent ( ESAs ) have show :
& quot ;
& quot ; Aclasta must not be mixed or give intravenously with any other medicinal product .
& quot ;
& quot ; 175 9 .
& quot ;
& quot ; Abseamed can be use to reduce exposure to allogeneic blood transfusion in adult non-iron deficient patient prior to major elective orthopaedic surgery , have a high perceive risk for transfusion complication .
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; Abseamed 1000 IU / 0.5 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; do not pass it on to others .
& quot ;
& quot ; in clinical trial and post-marketing experience , accidental or intentional acute overdosage of aripiprazole alone be identify in adult patient with report estimate dose up to 1,260 mg with no fatality .
& quot ;
& quot ; 9 .
& quot ;
& quot ; Danmark BRISTOL-MYERS SQUIBB Tlf : + 45 45 93 05 06
& quot ;
& quot ; - In pregnant or lactating surgical patient participate in an autologous blood predonation
& quot ;
& quot ; each ml contain 1 mg of aripiprazole .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; what ABILIFY be AND what IT be use for
& quot ;
& quot ; 8 .
& quot ;
& quot ; Hepatic disease :
& quot ;
& quot ; this difference be not statistically significant .
& quot ;
& quot ; Abseamed 4000 IU / 0.4 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; Abraxane be not recommend for use in child below age 18 year due to insufficient data on safety and efficacy .
& quot ;
& quot ; manufacture authorisation holder responsible for BATCH release
& quot ;
& quot ; it also decide that the benefit of the solution for injection outweigh it risk for the rapid control of agitation and disturbed behaviour in patient with schizophrenia or in patient with manic episode in bipolar I disorder , when oral therapy be not appropriate .
& quot ;
& quot ; generally , child under 30 kg require higher maintenance dos than child over 30 kg and adult .
& quot ;
& quot ; with their skeleton still in place , the cell can not divide and they eventually die .
& quot ;
& quot ; discontinue therapy
& quot ;
& quot ; if the haemoglobin increase be & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , increase the dose to 300 IU / kg 3 time per week .
& quot ;
& quot ; in addition , report of accidental overdose with aripiprazole alone ( up to 195 mg ) in child have be receive with no fatality .
& quot ;
& quot ; 186.54 mg lactose per tablet
& quot ;
& quot ; the decision to administer recombinant erythropoietin should be base on a benefit-risk assessment with the participation of the individual patient , which should also take into account the specific clinical context .
& quot ;
& quot ; allergic reaction ( e. g. anaphylactic reaction , angioedema include swollen tongue , tongue oedema , face oedema , pruritus , or urticaria )
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; all patient be treat with epoetin alfa should receive adequate iron supplementation ( e. g. oral iron substitution of 200 mg Fe2 + daily ) throughout the course of epoetin alfa treatment .
& quot ;
& quot ; Tablet disintegration occur rapidly in saliva .
& quot ;
& quot ; in CYP2D6 poor metabolisers , concomitant use of potent inhibitor of CYP3A4 may result in higher plasma concentration of aripiprazole compare to that in CYP2D6 extensive metabolizers .
& quot ;
& quot ; 15 .
& quot ;
& quot ; 13 .
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; however , if the haemoglobin have increase & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , response to epoetin alfa therapy be unlikely and treatment should be discontinue .
& quot ;
& quot ; Abseamed 3000 IU / 0.3 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; Renal and urinary disorder :
& quot ;
& quot ; Hypersensitivity reaction have be rarely report with epoetin alfa include isolated case of angioedema and anaphylactic reaction .
& quot ;
& quot ; a systematic review have also be perform involve more than 9000 cancer patient participate in 57 clinical trial .
& quot ;
& quot ; two other smaller , randomise , placebo-controlled trial fail to show a significant improvement in quality of life parameter on the EORTC-QLQ-C30 scale or CLAS , respectively .
& quot ;
& quot ; in controlled clinical study , use of Epoetin alfa and other erythropoiesis-stimulating agent ( ESAs ) have show :
& quot ;
& quot ; in clinical trial of aripiprazole , the incidence of QT prolongation be comparable to placebo .
& quot ;
& quot ; additional sign may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
& quot ;
& quot ; follow subcutaneous injection , serum level of epoetin alfa be much lower than the level achieve follow intravenous injection , the level increase slowly and reach a peak between 12 and
& quot ;
& quot ; ABILIFY 10 mg tablet
& quot ;
& quot ; ABILIFY be indicate for the treatment of schizophrenia .
& quot ;
& quot ; 4 .
& quot ;
& quot ; investigation :
& quot ;
& quot ; elimination :
& quot ;
& quot ; each ml contain 7.5 mg aripiprazole .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; expiry date
& quot ;
& quot ; an investigational study ( best study ) in woman with metastatic breast cancer be design to determine whether epoetin alfa treatment that extend beyond the correction of anaemia could improve treatment outcome .
& quot ;
& quot ; 3 .
& quot ;
& quot ; Abseamed can be use to reduce exposure to allogeneic blood transfusion in adult non-iron deficient patient prior to major elective orthopaedic surgery , have a high perceive risk for transfusion complication .
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of untreated , inadequately treat
& quot ;
& quot ; effect on height In the three-year osteoporosis study stand height be measure annually use a stadiometer .
& quot ;
& quot ; Hyperglycaemia and Diabetes Mellitus : hyperglycaemia , in some case extreme and associate with ketoacidosis or hyperosmolar coma or death , have be report in patient treat with atypical antipsychotic agent , include ABILIFY .
& quot ;
& quot ; 14 .
& quot ;
& quot ; 28 Extrapyramidal symptom ( EPS ) :
& quot ;
& quot ; Parahydroxybenzoates may cause allergic reaction ( possibly delay ) .
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; 6 pre-filled syrinx
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; detail information on this product be available on the website of the European Medicines Agency ( EMEA ) http : / / www . emea . europa . EU /
& quot ;
& quot ; Luxembourg / Luxemburg Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; in several controlled study , epoetins have not be show to improve overall survival or decrease the risk of tumour progression in patient with anaemia associate with cancer .
& quot ;
& quot ; if a patient develop sign and symptom indicative of NMS , or present with unexplained high fever without additional clinical manifestation of NMS , all antipsychotic medicinal product , include ABILIFY , must be discontinue .
& quot ;
& quot ; these increase in blood pressure can be treat with medicinal product .
& quot ;
& quot ; solution for injection in a pre-filled syringe ( injection )
& quot ;
& quot ; statement OF active substance ( s )
& quot ;
& quot ;
& quot ; gender :
& quot ;
& quot ; frequent monitoring of blood cell count should be perform during Abraxane therapy .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; Tel : + 34 91 456 53 00
& quot ;
& quot ; - iron supplementation , e. g .
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl
& quot ;
& quot ; the bioavailability of subcutaneous injectable epoetin alfa be much lower than that of the intravenous medicinal product : approximately 20 % .
& quot ;
& quot ; in addition , report of accidental overdose with aripiprazole alone ( up to 195 mg ) in child have be receive with no fatality .
& quot ;
& quot ; be control .
& quot ;
& quot ; keep the vial in the outer carton in order to protect from light .
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; result of an epidemiological study find that there be no increase risk of suicidality with aripiprazole compare to other antipsychotic among patient with bipolar disorder .
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; Latvija BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; Intravenous injection : over at least one to five minute , depend on the total dose .
& quot ;
& quot ; outcome
& quot ;
& quot ; name OF the marketing authorisation holder
& quot ;
& quot ; 4 .
& quot ;
& quot ; Abseamed have no influence on the ability to drive and use machine .
& quot ;
& quot ; lot
& quot ;
& quot ; a rise in haemoglobin of greater than 2 g / dl ( 1.25 mmol / l ) over a four week period should be avoid .
& quot ;
& quot ; the subcutaneous route of administration should be use .
& quot ;
& quot ; patient with hepatic impairment : no dosage adjustment be require for patient with mild to moderate hepatic impairment .
& quot ;
& quot ; discontinue therapy
& quot ;
& quot ; Norge BRISTOL-MYERS SQUIBB Norway LTD Tlf : + 47 67 55 53 50
& quot ;
& quot ; oral use
& quot ;
& quot ; content by weight , by volume or by unit
& quot ;
& quot ; 113 1 .
& quot ;
& quot ; the apparent molecular weight of erythropoietin be 32,000 to 40,000 dalton .
& quot ;
& quot ; 25 an increase incidence of thrombotic vascular event ( see section 4.4 and section 4.8 - General ) have be observe in patient receive erythropoietic agent .
& quot ;
& quot ; male patient should seek advice on conservation of sperm prior to treatment because of the possibility of irreversible infertility due to therapy with Abraxane .
& quot ;
& quot ; Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel : + 353 ( 1 800 ) 749 749
& quot ;
& quot ; these change be interpret a be secondary to decreased maternal body weight gain .
& quot ;
& quot ; ABILIFY be not approve for the treatment of dementia-related psychosis .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; Abseamed have the highest possible purity accord to the present state of the art .
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; expiry date
& quot ;
& quot ; this medicinal product contain le than 1 mmol sodium ( 23 mg ) per dose , I. e. essentially “ sodium- free ” .
& quot ;
& quot ; adult patient with renal insufficiency not yet undergoing dialysis :
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; Febrile neutropenia occur in four patient on Abraxane .
& quot ;
& quot ; it be available a 5 mg , 10 mg , 15 mg and 30 mg tablet , a 10 mg , 15 mg and 30 mg orodispersible tablet ( tablet that dissolve in the mouth ) , a an oral solution ( 1 mg / ml ) and a a solution for injection ( 7.5 mg / ml ) .
& quot ;
& quot ; Lietuva BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; the mean elimination half-lives for aripiprazole be approximately 75 hour in extensive metabolisers of CYP2D6 and approximately 146 hour in poor metabolisers of CYP2D6 .
& quot ;
& quot ; Cerebrovascular adverse event : in the same trial , cerebrovascular adverse event ( e. g. stroke , transient ischaemic attack ) , include fatality , be report in patient ( mean age :
& quot ;
& quot ; in cancer patient receive chemotherapy , the 2 - 3 week delay between epoetin alfa administration and the appearance of erythropoietin-induced red cell should be take into account when assess if epoetin alfa therapy be appropriate ( patient at risk of be transfuse ) .
& quot ;
& quot ; the incidence of bone marrow fibrosis be not increase in a study of haemodialysis patient who be treat with epoetin alfa for 3 year compare to a match control group of dialysis patient who have not be treat with epoetin alfa . ) .
& quot ;
& quot ; Meta-analysis of overall survival data produce a hazard ratio point estimate of 1.08 in favour of control ( 95 % CI :
& quot ;
& quot ; management of overdose should concentrate on supportive therapy , maintain an adequate airway , oxygenation and ventilation , and management of symptom .
& quot ;
& quot ; Hypertensive crisis with encephalopathy-like symptom can occur .
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; - if the solution have be accidentally frozen .
& quot ;
& quot ; other
& quot ;
& quot ; Abseamed can be use to increase the yield of autologous blood from patient in a predonation programme .
& quot ;
& quot ; N05AX12
& quot ;
& quot ; Ninety-five percent of the patient receive their infusion two or more week after the hip fracture repair and the median timing of infusion be approximately six week after the hip fracture repair .
& quot ;
& quot ; 96 weight gain : weight gain be commonly see in schizophrenic and bipolar mania patient due to co- morbidity , use of antipsychotic know to cause weight gain , poorly manage life-style , and might lead to severe complication .
& quot ;
& quot ; in that study the incidence of fatal thromboembolic event be higher in patient receive epoetin alfa than in those receive placebo ( see section 5.1 ) .
& quot ;
& quot ; 1 .
& quot ;
& quot ; EXP
& quot ;
& quot ; adult surgery patient in an autologous predonation programme
& quot ;
& quot ; Suicidal thought and behaviour have be report during aripiprazole treatment .
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; patient should be advise to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole .
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl
& quot ;
& quot ; if it occur , appropriate dose adjustment should be make a provided .
& quot ;
& quot ; patient should be advise not to breast feed if they be take aripiprazole .
& quot ;
& quot ; 1 .
& quot ;
& quot ; • condition or restriction regard supply AND use impose on the marketing authorisation holder
& quot ;
& quot ; Post-Marketing :
& quot ;
& quot ; 1 .
& quot ;
& quot ; elderly patient with dementia-related psychosis :
& quot ;
& quot ; - if the seal be break .
& quot ;
& quot ; 14 .
& quot ;
& quot ; Τηλ : + 30 210 6074300
& quot ;
& quot ; Additionally , aripiprazole and dehydro-aripiprazole do not show potential for alter CYP1A2-mediated metabolism in vitro .
& quot ;
& quot ; 2 .
& quot ;
& quot ; adult and paediatric haemodialysis patient , adult peritoneal dialysis patient and adult patient with renal insufficiency not yet undergoing dialysis
& quot ;
& quot ; no longer than 3 day .
& quot ;
& quot ; nervous system disorder :
& quot ;
& quot ; 16 .
& quot ;
& quot ; Tel : + 386 1 236 47 00
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; if grade 3 sensory neuropathy develops , treatment should be withhold until resolution to grade 1 or 2 follow by a dose reduction for all subsequent course of Abraxane be recommend ( see section 4.2 ) .
& quot ;
& quot ; usual maintenance dose 75 - 150 60 - 150 30 - 100
& quot ;
& quot ; what benefit have Abseamed show during the study ?
& quot ;
& quot ; Incidence of individual symptom follow the first infusion be : fever ( 17.1 % ) , myalgia ( 7.8 % ) , flu-like symptom ( 6.7 % ) , arthralgia ( 4.8 % ) and headache ( 5.1 % ) .
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; Cerebrovascular adverse event : in the same trial , cerebrovascular adverse event ( e. g. stroke , transient ischaemic attack ) , include fatality , be report in patient ( mean age :
& quot ;
& quot ; Abraxane do not contain these solvent .
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; study in animal have show reproduction toxicity ( see section 5.3 ) .
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; name OF the MEDICINAL product AND route ( s ) OF administration
& quot ;
& quot ; Κύπρος ΑΚΗΣ ΠΑΝΑΓΙΩΤΟΥ & amp ; ΥΙΟΣ Ε .Π .Ε .
& quot ;
& quot ; Tel : + 39 06 50 39 61
& quot ;
& quot ; Conduction abnormality :
& quot ;
& quot ; your doctor may do regular blood test to check your blood platelet count during the first 8 week of therapy .
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; - if the seal be break .
& quot ;
& quot ; if an elevate ( or rise ) serum potassium level be detect then consideration should be give to cease epoetin alfa administration until hyperkalaemia have be correct .
& quot ;
& quot ; male patient treat with Abraxane be advise not to Father a child during and up to six month after treatment .
& quot ;
& quot ; however , the concentration of the sulphate conjugate of hydroxy aripiprazole in human bile at the highest dose propose , 30 mg per day , be no more than 6 % of the bile concentration find in the monkey in the 39-week study and be well below ( 6 % ) their limit of in vitro solubility .
& quot ;
& quot ; 12 .
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and than reinstitute epoetin alfa therapy at a dose 25 % below the previous dose .
& quot ;
& quot ; this regress during the course of continued therapy .
& quot ;
& quot ; functional assessment of Cancer Therapy- Anaemia ( FACT-An ) general scale , FACT-An fatigue scale , and Cancer linear Analogue scale ( CLAS ) .
& quot ;
& quot ; in order to ensure optimum response to epoetin alfa , adequate iron store should be assure :
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; patient who develop pure red Cell Aplasia ( PRCA ) follow treatment with any erythropoietin should not receive Abseamed or any other erythropoietin ( see section 4.4 - pure red Cell Aplasia ) .
& quot ;
& quot ; ABILIFY be one of a group of medicine call antipsychotic .
& quot ;
& quot ; Toxicologically significant effect be observe only at dos or exposure that be sufficiently in excess of the maximum human dose or exposure , indicate that these effect be limited or of no relevance to clinical use .
& quot ;
& quot ; when weak inhibitor of CYP3A4 ( e. g . , diltiazem or escitalopram ) or CYP2D6 be use concomitantly with ABILIFY , modest increase in aripiprazole concentration might be expect .
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; Thrombotic / vascular event , such a myocardial ischaemia , myocardial infarction , cerebrovascular accident ( cerebral haemorrhage and cerebral infarction ) , transient ischaemic attack , deep vein thrombosis , arterial thrombosis , pulmonary embolus , aneurysm , retinal thrombosis , and clotting of an artificial kidney have be report in patient receive erythropoietic agent , include patient receive epoetin alfa .
& quot ;
& quot ; treatment of anaemia and reduction of transfusion requirement in adult patient receive chemotherapy for solid tumour , malignant lymphoma or multiple myeloma , and at risk of transfusion a assess by the patient & apos ; s general status ( e. g. cardiovascular status , pre-existing anaemia at the start of chemotherapy ) .
& quot ;
& quot ; Occlusion of the dialysis system be possible if heparinisation be not optimum .
& quot ;
& quot ; the decision to administer recombinant erythropoietin should be base on a benefit-risk assessment with the participation of the individual patient , which should also take into account the specific clinical context .
& quot ;
& quot ; 115 PARTICULARS to appear on the outer packaging
& quot ;
& quot ; Cytotoxic action of epoetin alfa on bone marrow cell could not be detect .
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; there be no accumulation : the level remain the same , whether they be determined 24 hour after the first injection or 24 hour after the last injection .
& quot ;
& quot ; label / SYRINGE
& quot ;
& quot ; adult surgery patient in an autologous predonation programme :
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6.8 g / dl or & lt ; 4.25 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 6.8 g / dl or & gt ; 4.25 mmol / l ) .
& quot ;
& quot ; what Abseamed be and what it be use for 2 .
& quot ;
& quot ; 7 .
& quot ;
& quot ; each tablet contain 30 mg of aripiprazole .
& quot ;
& quot ; Additionally , aripiprazole and dehydro-aripiprazole do not show potential for alter CYP1A2-mediated metabolism in vitro .
& quot ;
& quot ; the pharmacokinetic characteristic of aripiprazole and dehydro-aripiprazole be find to be similar in patient with severe renal disease compare to young healthy subject .
& quot ;
& quot ; 0.99 , 1,18 ; 42 trial and 8167 patient ) .
& quot ;
& quot ; România BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; a half-life of approximately 6 hour have be report in child .
& quot ;
& quot ; 4 June 2004
& quot ;
& quot ; an increase 3H-thymidine incorporation in the erythroid nucleate spleen cell have be find in vitro ( mouse spleen cell culture ) after incubation with epoetin alfa .
& quot ;
& quot ; the incidence of bone marrow fibrosis be not increase in a study of haemodialysis patient who be treat with epoetin alfa for 3 year compare to a match control group of dialysis patient who have not be treat with epoetin alfa . ) .
& quot ;
& quot ; dose adjustment during treatment :
& quot ;
& quot ; Tel : + 370 5 2790 762
& quot ;
& quot ; there be no adequate and well-controlled trial of aripiprazole in pregnant woman .
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; in some preclinical toxicological study in dog and rat , but not in monkey , epoetin alfa therapy be associate with subclinical bone marrow fibrosis ( bone marrow fibrosis be a known complication of chronic renal failure in human and may be relate to secondary hyperparathyroidism or unknown factor .
& quot ;
& quot ; patient with active malignant disease receive neither chemotherapy nor radiation therapy .
& quot ;
& quot ; elderly : the effectiveness of ABILIFY in the treatment of schizophrenia and Bipolar I Disorder in patient 65 year of age or older have not be establish .
& quot ;
& quot ; Malta BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; precise risk estimate for hyperglycaemia-related adverse event in patient treat with ABILIFY and with other atypical antipsychotic agent be not available to allow direct comparison .
& quot ;
& quot ; 13 .
& quot ;
& quot ; Smoking status : accord to the metabolic pathway of ABILIFY no dosage adjustment be require for smoker ( see section 4.5 ) .
& quot ;
& quot ; EU / 1 / 04 / 276 / 001-005
& quot ;
& quot ; Abseamed 2000 IU / 1 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; follow any confirm or suspect overdose with aripiprazole , close medical supervision and monitoring should continue until the patient recovers .
& quot ;
& quot ; the frequency of these event be consider not know ( can not be estimate from the available data ) .
& quot ;
& quot ; owe to the greater sensitivity of this population , a lower start dose should be consider when clinical factor warrant ( see section 4.4 ) .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; a with all growth factor , there be a concern that epoetins could stimulate the growth of tumour .
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; EXP
& quot ;
& quot ; 3 .
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; an investigational study ( best study ) in woman with metastatic breast cancer be design to determine whether epoetin alfa treatment that extend beyond the correction of anaemia could improve treatment outcome .
& quot ;
& quot ; 2 .
& quot ;
& quot ; Pharmacokinetics in special patient group
& quot ;
& quot ; * produce in CHO cell line by recombinant DNA technology
& quot ;
& quot ; treatment of patient with chemotherapy induce anaemia :
& quot ;
& quot ; statement OF active substance ( s )
& quot ;
& quot ; Abseamed 2000 IU / 1 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; Serum electrolytes should be monitor in chronic renal failure patient .
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; 2 / 2
& quot ;
& quot ; other information about Abseamed :
& quot ;
& quot ; EU / 1 / 04 / 276 / 030
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; in all patient receive epoetin alfa , blood pressure should be closely monitor and control a necessary .
& quot ;
& quot ; this be give three time a week , inject into a vein .
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; treatment with Aclasta result in a 6.7 % increase in BMD at the lumbar spine , 6.0 % at the total hip , 5.1 % at the femoral neck , and 3.2 % at the distal radius over 3 year a compare to placebo .
& quot ;
& quot ; 19 package LEAFLET :
& quot ;
& quot ; do not push the tablet through the foil because this could damage the tablet .
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; Renal disease :
& quot ;
& quot ; generally , child under 30 kg require higher maintenance dos than child over 30 kg and adult .
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; Τηλ : + 30 210 6074300
& quot ;
& quot ; - iron supplementation , e. g .
& quot ;
& quot ; 5 .
& quot ;
& quot ; other potent inhibitor of CYP3A4 , such a itraconazole and HIV protease inhibitor , may be expect to have similar effect and similar dose reduction should therefore be apply .
& quot ;
& quot ; Τηλ : + 357 22 677038
& quot ;
& quot ;
& quot ; - if you be due to have major orthopaedic surgery and :
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; 76 Activated charcoal ( 50 g ) , administer one hour after aripiprazole , decrease aripiprazole Cmax by about 41 % and AUC by about 51 % , suggest that charcoal may be effective in the treatment of overdose .
& quot ;
& quot ; take ABILIFY with food and drink ABILIFY can be take regardless of meal .
& quot ;
& quot ; patient should be closely monitor throughout this period .
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; in view of the above , in some clinical situation blood transfusion should be the preferred treatment for the management of anaemia in patient with cancer .
& quot ;
& quot ; Activated charcoal ( 50 g ) , administer one hour after aripiprazole , decrease aripiprazole Cmax by about 41 % and AUC by about 51 % , suggest that charcoal may be effective in the treatment of overdose .
& quot ;
& quot ; - increase risk of death when administer to target a haemoglobin of 12 g / dl ( 7.5 mmol / l ) in
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; 5 .
& quot ;
& quot ; 76 The recommend dose be 600 IU / kg epoetin alfa , give weekly for three week ( day 21 , 14 and 7 ) prior to surgery and on the day of surgery ( day 0 ) .
& quot ;
& quot ; Respiratory , thoracic and mediastinal disorder :
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ; ABILIFY be one of a group of medicine call antipsychotic .
& quot ;
& quot ; Τηλ : + 30 210 6074300
& quot ;
& quot ; Chronic renal failure patient
& quot ;
& quot ; QT prolongation , ventricular arrhythmia , sudden unexplained death , cardiac arrest , torsades de pointes , bradycardia
& quot ;
& quot ; Pre-filled syrinx ( glass type I ) with plunger ( Teflon-faced rubber ) seal in a blister .
& quot ;
& quot ; after reconstitution , each ml of suspension contains 5 mg of paclitaxel .
& quot ;
& quot ; in clinical trial , an increase risk of death and serious cardiovascular event be observe when erythropoiesis stimulate agent ( ESAs ) be administer to target a haemoglobin of greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; Epoetin alfa obtain by gene technology be glycosylated and be identical in it amino acid and carbohydrate composition to endogenous human erythropoietin that have be isolate from the urine of anaemic patient .
& quot ;
& quot ; they be supply in perforated unit dose blister pack in carton contain 14 , 28 , or 49 orodispersible tablet .
& quot ;
& quot ; Renal and urinary disorder :
& quot ;
& quot ; rate % ( CI )
& quot ;
& quot ; Manic episode :
& quot ;
& quot ; Hb 10 - 13 g / dl ) who do not have an autologous predonation programme available and with an expected blood loss of 900 to 1800 ml .
& quot ;
& quot ; 3 .
& quot ;
& quot ; 138 721 cancer patient receive non-platinum chemotherapy be include in three placebo-controlled study , 389 patient with haematological malignancy ( 221 multiple myeloma , 144 non-Hodgkin & apos ; s lymphoma , and 24 other haematological malignancy ) and 332 with solid tumour ( 172 breast , 64 gynaecological , 23 lung , 22 prostate , 21 gastro-intestinal , and 30 other tumour type ) .
& quot ;
& quot ; generally , child under 30 kg require higher maintenance dos than child over 30 kg and adult .
& quot ;
& quot ; in a haloperidol-controlled trial , the proportion of responder patient maintain response to medicinal product at 52-weeks be similar in both group ( aripiprazole 77 % and haloperidol 73 % ) .
& quot ;
& quot ; 1.6 mm , 3.5 mm ) & # 91 ; p & lt ; 0.0001 & # 93 ; .
& quot ;
& quot ; Abilify
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; Correction for anaemia may lead to increase appetite , and potassium and protein intake .
& quot ;
& quot ; the maximum daily dose should not exceed 30 mg .
& quot ;
& quot ; Immunogenicity data for subcutaneous use of Abseamed in patient at risk for antibody-induced PRCA , I. e. patient with renal anaemia , be not sufficient .
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the sustained haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) reduce the epoetin alfa dose by 25 % .
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; patient should be advise to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole .
& quot ;
& quot ; 98 for the purpose of ambulatory use , the patient may remove Abseamed from the refrigerator and store it not above 25 ° C for one single period of up to 3 day .
& quot ;
& quot ; be sure to tell your doctor if you take a medicine to keep your blood pressure under control .
& quot ;
& quot ; in patient with severe hepatic impairment , the data available be insufficient to establish recommendation .
& quot ;
& quot ; the haemoglobin concentration aim for be between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) , except in paediatric patient in whom the haemoglobin concentration should be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; manufacturer ’ s BATCH number
& quot ;
& quot ; an investigational study ( best study ) in woman with metastatic breast cancer be design to determine whether epoetin alfa treatment that extend beyond the correction of anaemia could improve treatment outcome .
& quot ;
& quot ; EU / 1 / 04 / 276 / 035
& quot ;
& quot ; take special care with ABILIFY before treatment with ABILIFY , tell your doctor if you suffer from High blood sugar or family history of diabetes seizure Involuntary , irregular muscle movement , especially in the face cardiovascular disease , family history of cardiovascular disease , stroke or & quot ; & quot ; mini & quot ; & quot ; stroke , abnormal blood pressure
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; the rate of death in aripiprazole-treated patient be 3.5 % compare to 1.7 % in the placebo group .
& quot ;
& quot ; you will receive appropriate training for you to do this .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; if it occur , appropriate dose adjustment should be make a provided .
& quot ;
& quot ; 4 .
& quot ;
& quot ; patient with hepatic impairment : no dosage adjustment be require for patient with mild to moderate hepatic impairment .
& quot ;
& quot ; the maximum daily dose should not exceed 30 mg .
& quot ;
& quot ; the use of epoetin alfa in patient schedule for major elective orthopaedic surgery and not participate in an autologous blood predonation programme be contraindicate in patient with severe coronary , peripheral arterial , carotid or cerebral vascular disease , include patient with recent myocardial infarction or cerebral vascular accident .
& quot ;
& quot ; Norge BRISTOL-MYERS SQUIBB Norway LTD Tlf : + 47 67 55 53 50
& quot ;
& quot ; treatment of patient with chemotherapy induce anaemia :
& quot ;
& quot ; s R. O .
& quot ;
& quot ; 53 an increase incidence of thrombotic vascular event ( see section 4.4 and section 4.8 - General ) have be observe in patient receive erythropoietic agent .
& quot ;
& quot ; Psychiatric disorder :
& quot ;
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6.8 g / dl or & lt ; 4.25 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 6.8 g / dl or & gt ; 4.25 mmol / l ) .
& quot ;
& quot ; for bipolar disorder , the recommend starting dose be 15 mg by mouth once a day , either on it own or in combination with other medicine .
& quot ;
& quot ; Maternal toxicity occur at dos similar to those elicit developmental toxicity .
& quot ;
& quot ; Abilify
& quot ;
& quot ; patient should be advise not to breast feed if they be take aripiprazole .
& quot ;
& quot ; Toxicologically significant effect be observe only at dos or exposure that be sufficiently in excess of the maximum human dose or exposure , indicate that these effect be limited or of no relevance to clinical use .
& quot ;
& quot ; the four carbohydrate chain be attach via three N-glycosidic bond and one O-glycosidic bond to the protein .
& quot ;
& quot ; haemodialysis and adult patient on peritoneal dialysis ( see section 4.4 ) .
& quot ;
& quot ; 4 .
& quot ;
& quot ; possible side effect
& quot ;
& quot ; the drug exposure ( AUC ) increase linearly from 2653 to 16736 ng . hr / ml follow dose from 80 to 300 mg / m2 .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; in two 12-week , placebo- and active-controlled monotherapy trial in patient with a manic or mixed episode of Bipolar I Disorder , with or without psychotic feature , aripiprazole demonstrate superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12 .
& quot ;
& quot ; 140 for the purpose of ambulatory use , the patient may remove Abseamed from the refrigerator and store it not above 25 ° C for one single period of up to 3 day .
& quot ;
& quot ; EXP
& quot ;
& quot ; consequently , haemoglobin and blood pressure should be closely monitor .
& quot ;
& quot ; 5 .
& quot ;
& quot ; 82.4 year ; range :
& quot ;
& quot ; Excipient :
& quot ;
& quot ; control clinical trial have not show significant benefit attributable to the administration of epoetins when haemoglobin concentration be increase beyond the level necessary to control symptom of anaemia and to avoid blood transfusion .
& quot ;
& quot ; Pack of 1 or 6 syrinx .
& quot ;
& quot ; if you be a cancer patient be aware that erythropoietins may act a growth factor .
& quot ;
& quot ; mechanism of action Zoledronic acid belongs to the class of nitrogen-containing bisphosphonates and act primarily on bone .
& quot ;
& quot ; treatment of patient with chemotherapy induce anaemia :
& quot ;
& quot ; 6 .
& quot ;
& quot ; oral use
& quot ;
& quot ; the mean elimination half-lives for aripiprazole be approximately 75 hour in extensive metabolisers of CYP2D6 and approximately 146 hour in poor metabolisers of CYP2D6 .
& quot ;
& quot ; oropharyngeal spasm , laryngospasm , aspiration pneumonia
& quot ;
& quot ; 5 mg
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; name OF the marketing authorisation holder
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; the recommended total weekly dose be between 75 and 300 IU / kg give by the intravenous route .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; Hypersensitivity : a with other medication hypersensitivity reaction , characterise by allergic symptom , may occur with aripiprazole ( see section 4.8 ) .
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be
& quot ;
& quot ; EMEA / H / C / 471
& quot ;
& quot ; Hypersensitivity reaction have be rarely report with epoetin alfa include isolated case of angioedema and anaphylactic reaction .
& quot ;
& quot ; patient who develop pure red Cell Aplasia ( PRCA ) follow treatment with any erythropoietin should not receive Abseamed or any other erythropoietin ( see section 4.4 - pure red Cell Aplasia ) .
& quot ;
& quot ; - decrease locoregional control in patient with advanced head and neck cancer receiving
& quot ;
& quot ; 1 .
& quot ;
& quot ; Aripiprazole be the predominant medicinal product moiety in systemic circulation .
& quot ;
& quot ; Thrombotic / vascular event , such a myocardial ischaemia , myocardial infarction , cerebrovascular accident ( cerebral haemorrhage and cerebral infarction ) , transient ischaemic attack , deep vein thrombosis , arterial thrombosis , pulmonary embolus , aneurysm , retinal thrombosis , and clotting of an artificial kidney have be report in patient receive erythropoietic agent , include patient receive epoetin alfa .
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; 108 A .
& quot ;
& quot ; Κύπρος Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; EXP
& quot ;
& quot ; like all medicine , ABILIFY can cause side effect , although not everybody get them .
& quot ;
& quot ; EU / 1 / 04 / 276 / 019
& quot ;
& quot ; Comparisons between aripiprazole and placebo in the proportion of patient experience potentially clinically significant change in routine laboratory parameter reveal no medically important difference .
& quot ;
& quot ; BLISTERS
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; Psychiatric disorder :
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; stability of the reconstituted suspension in the infusion bag :
& quot ;
& quot ; in most of these patient , antibody to erythropoietin have be observe ( see section 4.3 and 4.4 – pure red Cell Aplasia )
& quot ;
& quot ; label / SYRINGE
& quot ;
& quot ; in view of the above , in some clinical situation blood transfusion should be the preferred treatment for the management of anaemia in patient with cancer .
& quot ;
& quot ; name OF the MEDICINAL product AND route ( s ) OF administration
& quot ;
& quot ; a systematic review have also be perform involve more than 9000 cancer patient participate in 57 clinical trial .
& quot ;
& quot ; ABILIFY be use to treat adult who suffer from a condition with symptom such a feeling & quot ; & quot ; high & quot ; & quot ; , have excessive amount of energy , need much le sleep than usual , talk very quickly with race idea and sometimes severe irritability .
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6 g / dl or & lt ; 3.75 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 8 g / dl or & gt ; 5 mmol / l ) .
& quot ;
& quot ; the pharmacokinetic characteristic of aripiprazole and dehydro-aripiprazole be find to be similar in patient with severe renal disease compare to young healthy subject .
& quot ;
& quot ; Intravenous use .
& quot ;
& quot ; 14 .
& quot ;
& quot ; Abilify
& quot ;
& quot ; EU / 1 / 07 / 412 / 003 EU / 1 / 07 / 412 / 004
& quot ;
& quot ; 6 .
& quot ;
& quot ; instruction on use
& quot ;
& quot ; treatment with Aclasta result in an increase in BMD of 5.4 % at the total hip and 4.3 % at the femoral neck over 24 month a compare to placebo .
& quot ;
& quot ; Abseamed 8000 IU / 0.8 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; in patient with chronic renal failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommend in section 4.2 .
& quot ;
& quot ; in a 26-week , placebo-controlled trial in stabilised patient with chronic schizophrenia , aripiprazole have significantly greater reduction in relapse rate , 34 % in aripiprazole group and 57 % in placebo .
& quot ;
& quot ; the maximum daily dose should not exceed 30 mg .
& quot ;
& quot ; lot
& quot ;
& quot ; although there be no information on the effect of haemodialysis in treat an overdose with aripiprazole , haemodialysis be unlikely to be useful in overdose management since aripiprazole be highly bind to plasma protein .
& quot ;
& quot ; follow subcutaneous injection , serum level of epoetin alfa be much lower than the level achieve follow intravenous injection , the level increase slowly and reach a peak between 12 and
& quot ;
& quot ; undesirable effect know to be associate with antipsychotic therapy and also report during treatment with aripiprazole include neuroleptic malignant syndrome , tardive dyskinesia , seizure , cerebrovascular adverse event and increased mortality in elderly demented patient , hyperglycaemia and diabetes mellitus ( see section 4.4 ) .
& quot ;
& quot ; ABILIFY be use to treat adult who suffer from a condition with symptom such a feeling & quot ; & quot ; high & quot ; & quot ; , have excessive amount of energy , need much le sleep than usual , talk very quickly with race idea and sometimes severe irritability .
& quot ;
& quot ; 24
& quot ;
& quot ; Pack of 1 or 6 syrinx .
& quot ;
& quot ; there may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with epoetin alfa .
& quot ;
& quot ; recurrence prevention of manic episode in Bipolar I Disorder :
& quot ;
& quot ; weight ( kg ) & lt ; 10 10 - 30 & gt ; 30
& quot ;
& quot ; each ml contain 7.5 mg of aripiprazole .
& quot ;
& quot ; upon discontinuation of potent CYP3A4 inducer , the dosage of ABILIFY should be reduce to the recommend dose .
& quot ;
& quot ; Thrombocytosis have be observe but it occurrence be very rare ( see section 4.4 ) .
& quot ;
& quot ; therefore , in patient with renal anaemia the medicinal product have to be administer intravenously .
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; VIAL label
& quot ;
& quot ; 1 pre-filled syringe
& quot ;
& quot ; Excipients : sodium dihydrogen phosphate dihydrate , disodium phosphate dihydrate , sodium chloride , glycine , polysorbate 80 , hydrochloric acid ( for pH-adjustment ) , sodium hydroxide ( for pH-adjustment ) , and water for injection
& quot ;
& quot ; in a prospective , randomised , double-blind , placebo-controlled trial conduct in 375 anaemic patient with various non-myeloid malignancy receive non-platinum chemotherapy , there be a significant reduction of anaemia-related sequela ( e. g. fatigue , decrease energy , and activity reduction ) , a measure by the following instrument and scale :
& quot ;
& quot ; patient who experience severe neutropenia ( neutrophil count & lt ; 0.50 X 109 / l for a week or longer ) or severe sensory neuropathy during Abraxane therapy should have the dose reduce to 220 mg / m2 for subsequent course .
& quot ;
& quot ; additional sign may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; 8.6 13.9 1.7 3.8 7.6 10.7
& quot ;
& quot ; the pre-filled syrinx be ready to use ( see section 4.2 – method of administration ) .
& quot ;
& quot ; - if you have any further question , ask your doctor , pharmacist or nurse .
& quot ;
& quot ; nervous system disorder :
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; when aripiprazole be administer concomitantly with either valproate or lithium , there be no clinically important change in valproate or lithium concentration .
& quot ;
& quot ; 7 .
& quot ;
& quot ; ABILIFY 15 mg tablet
& quot ;
& quot ; it use in this indication must be balance against the report risk of thromboembolic event .
& quot ;
& quot ; Abraxane should only be prepare and administer by personnel appropriately train in the handling of cytotoxic agent .
& quot ;
& quot ; the follow undesirable effect occur more often ( ≥ 1 / 100 ) than placebo , or be identify a possibly medically relevant adverse reaction ( * ) :
& quot ;
& quot ; ask your doctor or pharmacist for advice before take ABILIFY .
& quot ;
& quot ; good blood management practice should always be use in the perisurgical setting
& quot ;
& quot ; Z O. O .
& quot ;
& quot ; a with other antipsychotic , aripiprazole should be use with caution in patient with a family history of QT prolongation .
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP3A4 ( ketoconazole ) increase aripiprazole AUC and Cmax by 63 % and 37 % , respectively .
& quot ;
& quot ; these measure will help to protect the environment .
& quot ;
& quot ; 1 condition or restriction with regard to the safe AND effective use OF MEDICINAL product to be implement by the Member States
& quot ;
& quot ; 4 June 2004
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; not applicable .
& quot ;
& quot ; for patient who develop osteonecrosis of the jaw while on bisphosphonate therapy , dental surgery may exacerbate the condition .
& quot ;
& quot ; Gastrointestinal disorder :
& quot ;
& quot ; in clinical trial of aripiprazole , the incidence of QT prolongation be comparable to placebo .
& quot ;
& quot ; good blood management practice should always be use in the perisurgical setting
& quot ;
& quot ; store in the original package in order to protect from moisture .
& quot ;
& quot ; this disrupt signal transmit between brain cell by ‘ neurotransmitter ’ , chemical that allow nerve cell to communicate with each other .
& quot ;
& quot ; Hypertension may occur in epoetin alfa treat patient .
& quot ;
& quot ; you should inform the doctor immediately if you think too much Abseamed have be inject .
& quot ;
& quot ; no other erythropoietic therapy should be commence because of the risk of cross-reaction .
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; the pre-filled syringe should not be shake .
& quot ;
& quot ; if it occur , appropriate dose adjustment should be make a provided .
& quot ;
& quot ; an increase in heparin dose during haemodialysis be frequently require during the course of therapy with epoetin alfa a a result of the increase packed cell volume .
& quot ;
& quot ; the following maintenance dos be observe in clinical trial after 6 month of treatment :
& quot ;
& quot ; if any of these applies to you , or might apply , tell your doctor at once .
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; Polska BRISTOL-MYERS SQUIBB POLSKA SP .
& quot ;
& quot ; 4.6 – 6.2 month ) and 6.1 month ( 300 mg / m2 ; 95 % CI :
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; be sure to tell your doctor immediately if you be breast-feeding .
& quot ;
& quot ; Subcutaneous route
& quot ;
& quot ; Tardive Dyskinesia : in clinical trial of one year or le duration , there be uncommon report of treatment emergent dyskinesia during treatment with aripiprazole .
& quot ;
& quot ; Blood pressure-lowering medicine :
& quot ;
& quot ; if it occur , appropriate dose adjustment should be make a provided .
& quot ;
& quot ; priapism
& quot ;
& quot ; maintenance dose between 25 and 50 IU / kg 2 time per week into 2 equal injection .
& quot ;
& quot ; Deutschland BRISTOL-MYERS SQUIBB GMBH & amp ; CO .
& quot ;
& quot ; 87 Correction phase :
& quot ;
& quot ; developmental toxicity , include dose-dependent delayed foetal ossification and possible teratogenic effect , be
& quot ;
& quot ; all of these additive factor of anaemia should also be carefully consider when decide to increase the dose of epoetin alfa in cancer patient .
& quot ;
& quot ; it could be show with the aid of cell culture of human bone marrow cell that epoetin alfa stimulates erythropoiesis specifically and do not affect leucopoiesis .
& quot ;
& quot ; in view of the above , in some clinical situation blood transfusion should be the preferred treatment for the management of anaemia in patient with cancer .
& quot ;
& quot ; in CYP2D6 poor metabolisers , concomitant use of potent inhibitor of CYP3A4 may result in higher plasma concentration of aripiprazole compare to that in CYP2D6 extensive metabolizers .
& quot ;
& quot ; treatment of patient with chemotherapy induce anaemia :
& quot ;
& quot ; child and adolescent : there be no experience in child and adolescent under 18 year of age .
& quot ;
& quot ; patient schedule for orthopaedic surgery
& quot ;
& quot ; Abseamed should be administer intravenously in order to increase haemoglobin to not greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; Abilify
& quot ;
& quot ; what be Abraxane ?
& quot ;
& quot ; general
& quot ;
& quot ; in a haloperidol-controlled trial , the proportion of responder patient maintain response to medicinal product at 52-weeks be similar in both group ( aripiprazole 77 % and haloperidol 73 % ) .
& quot ;
& quot ; the mean elimination half-lives for aripiprazole be approximately 75 hour in extensive metabolisers of CYP2D6 and approximately 146 hour in poor metabolisers of CYP2D6 .
& quot ;
& quot ; although there be no information on the effect of haemodialysis in treat an overdose with aripiprazole , haemodialysis be unlikely to be useful in overdose management since aripiprazole be highly bind to plasma protein .
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of untreated , inadequately treat
& quot ;
& quot ; Fifty-nine percent receive study medicinal product a second or greater than second-line therapy .
& quot ;
& quot ; then , the vial should gently and slowly be swirl and / or invert for at least 2 minute until complete resuspension of any powder occur .
& quot ;
& quot ; 84 year ; range :
& quot ;
& quot ; what ABILIFY contain The active substance be aripiprazole .
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; Aripiprazole also exhibit moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptor .
& quot ;
& quot ; Pharmacotherapeutic group : antipsychotic , ATC code :
& quot ;
& quot ; for subcutaneous and intravenous use .
& quot ;
& quot ; 24.9 % - 54.2 % ) and 47.6 %
& quot ;
& quot ; oral use
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; Non-specific skin rash have be describe in association with epoetin alfa .
& quot ;
& quot ; there be no effect of a high fat meal on the pharmacokinetics of aripiprazole .
& quot ;
& quot ; ABILIFY 15 mg tablet aripiprazole
& quot ;
& quot ; if blood test in the period before the operation show your haemoglobin level to be too high , the treatment will be stop .
& quot ;
& quot ; Breast-feeding mother should not take ABILIFY .
& quot ;
& quot ;
& quot ; base on in vitro study , CYP3A4 and CYP2D6 enzyme be responsible for dehydrogenation and hydroxylation of aripiprazole , and N-dealkylation be catalyse by CYP3A4 .
& quot ;
& quot ; it may harm them , even
& quot ;
& quot ; vial ( glass )
& quot ;
& quot ; ABILIFY solution for injection be ready to use and intend for short-term use only ( see section 5.1 ) .
& quot ;
& quot ; 300 IU / kg 3x / week for 4 week
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; BLISTER
& quot ;
& quot ; 175 tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever , sweat , alter mental status , or very rapid or irregular heart beat .
& quot ;
& quot ; detail information on this product be available on the website of the European Medicines Agency ( EMEA ) http : / / www . emea . europa . EU /
& quot ;
& quot ; alcohol should be avoid when take ABILIFY .
& quot ;
& quot ; Κύπρος ΑΚΗΣ ΠΑΝΑΓΙΩΤΟΥ & amp ; ΥΙΟΣ Ε .Π .Ε .
& quot ;
& quot ; Batch
& quot ;
& quot ; there be no adequate and well-controlled trial of aripiprazole in pregnant woman .
& quot ;
& quot ; elderly : the effectiveness of ABILIFY in the treatment of schizophrenia and Bipolar I Disorder in patient 65 year of age or older have not be establish .
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; Blood and the lymphatic system disorder :
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; name OF the marketing authorisation holder
& quot ;
& quot ; the overall completion rate be significantly higher for patient on aripiprazole ( 43 % ) than for haloperidol ( 30 % ) .
& quot ;
& quot ; the four carbohydrate chain be attach via three N-glycosidic bond and one O-glycosidic bond to the protein .
& quot ;
& quot ; further information
& quot ;
& quot ; base on information available to date , correction of anaemia with epoetin alfa in adult patient with renal insufficiency not yet undergoing dialysis do not accelerate the rate of progression of renal insufficiency .
& quot ;
& quot ; overall , 1.3 % of aripiprazole-treated patient report cerebrovascular adverse event compare with 0.6 % of placebo-treated patient in these trial .
& quot ;
& quot ; further information
& quot ;
& quot ; Erythropoietin be a glycoprotein that stimulate , a a mitosis-stimulating factor and differentiate hormone , the formation of erythrocyte from precursor of the stem cell compartment .
& quot ;
& quot ; during antipsychotic treatment , improvement in the patient & apos ; s clinical condition may take several day to some week .
& quot ;
& quot ; 5 .
& quot ;
& quot ; 2 .
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; solution for injection
& quot ;
& quot ; no evidence exist that indicate an interaction between epoetin alfa and G-CSF or GM-CSF with regard to haematological differentiation or proliferation of tumour biopsy specimen in vitro .
& quot ;
& quot ; there be very limited data on the use of paclitaxel in human pregnancy .
& quot ;
& quot ; Tel : + 371 67 50 21 85
& quot ;
& quot ; Medicines to correct heart rhythm Antidepressants or herbal remedy use to treat depression and anxiety Antifungal agent certain medicine to treat HIV infection Anticonvulsants use to treat epilepsy
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; in two 3-week , flexible-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole demonstrate superior efficacy to placebo in reduction of manic symptom over 3 week .
& quot ;
& quot ; 12 .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ;
& quot ; Infections and
& quot ;
& quot ; France BRISTOL-MYERS SQUIBB SARL Tél : + 33 ( 0 ) 810 410 500
& quot ;
& quot ; 20.6 & # 91 ; 15.6 , 25.9 & # 93 ; ( n = 131 )
& quot ;
& quot ; Italia BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; when concomitant administration of potent CYP3A4 inducer with aripiprazole occurs , the aripiprazole dose should be increase .
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; Surgery patient in autologous predonation programme
& quot ;
& quot ; the maximum daily dose should not exceed 30 mg .
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; EXP
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; this be give three time a week by injection into a vein .
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; Microcomputed
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery , with a baseline haemoglobin of 10 to 13 g / dl , the incidence of thrombotic / vascular event ( most of which be DVTs ) , in the overall patient population of the clinical trial , appear to be similar across the different epoetin alfa dose group and placebo group , although the clinical experience be limit .
& quot ;
& quot ; the maximum dose should not exceed 200 IU / kg 3 time per week .
& quot ;
& quot ; due to it α 1-adrenergic receptor antagonism , aripiprazole have the potential to enhance the effect of certain antihypertensive agent .
& quot ;
& quot ; in clinical trial of aripiprazole , the incidence of QT prolongation be comparable to placebo .
& quot ;
& quot ; in another 12-week trial , the incidence of EPS be 26.6 % for patient treat with aripiprazole and 17.6 % for those treat with lithium .
& quot ;
& quot ; this difference be not statistically significant .
& quot ;
& quot ; if you can not reach your doctor , go to the nearest hospital and take the Pack with you .
& quot ;
& quot ;
& quot ; the following reaction have also occur in isolated patient with normal or low blood pressure : hypertensive crisis with encephalopathy-like symptom ( e. g. headache and confused state ) and Generalised tonoclonal seizure , require the immediate attention of a physician and intensive medical care .
& quot ;
& quot ; Malta BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; when perform haematologic assessment during the preoperative period , if the haemoglobin level reach 15 g / dl , or higher , administration of epoetin alfa should be stop and further dos should not be give .
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the sustained haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) reduce the epoetin alfa dose by 25 % .
& quot ;
& quot ; therefore your haemoglobin-levels and your blood pressure should
& quot ;
& quot ; this medicinal product must not be administer by intravenous infusion , or mixed with other medicinal product .
& quot ;
& quot ; 10 .
& quot ;
& quot ; Antibody-mediated erythroblastopenia ( PRCA ) have be report after month to year of treatment with epoetin alfa .
& quot ;
& quot ; 4 .
& quot ;
& quot ; if sign and symptom of tardive dyskinesia appear in a patient on ABILIFY , dose reduction or discontinuation should be consider .
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy male and female subject nor be there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; if aripiprazole be administer concomitantly with medicine know to cause QT prolongation or electrolyte imbalance , caution should be use .
& quot ;
& quot ; Correction for anaemia may lead to increase appetite , and potassium and protein intake .
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; elderly :
& quot ;
& quot ; detail information on this medicine be available on the European Medicines Agency ( EMEA ) web site : http : / / www . emea . europa . EU /
& quot ;
& quot ; when perform haematologic assessment during the preoperative period , if the haemoglobin level reach 15 g / dl , or higher , administration of epoetin alfa should be stop and further dos should not be give .
& quot ;
& quot ; each tablet contain 15 mg of aripiprazole .
& quot ;
& quot ; potential for other medicinal product to affect ABILIFY :
& quot ;
& quot ; management of overdose should concentrate on supportive therapy , maintain an adequate airway , oxygenation and ventilation , and management of symptom .
& quot ;
& quot ; attention should be pay to sudden stab migraine-like headache a a possible warning signal .
& quot ;
& quot ; the following adverse event have be report during post-marketing surveillance .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; transferrin saturation be below 20 % .
& quot ;
& quot ; Pack size one vial of 100 mg paclitaxel .
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; for full detail , see the package Leaflet .
& quot ;
& quot ; if the haemoglobin increase be & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , increase the dose to 300 IU / kg 3 time per week .
& quot ;
& quot ; the recommend starting dose for ABILIFY be 10 or 15 mg / day with a maintenance dose of 15 mg / day administer on a once-a-day schedule without regard to meal .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; 28 August 2007
& quot ;
& quot ; weight gain , weight decrease , anorexia , hyponatremia
& quot ;
& quot ; take ABILIFY with food and drink ABILIFY can be take regardless of meal .
& quot ;
& quot ; increase level of potassium ( hyperkalaemia ) have be observe in isolated case .
& quot ;
& quot ; 15 .
& quot ;
& quot ; general
& quot ;
& quot ; and Hb increase & lt ; 1 g / dl
& quot ;
& quot ; Phlebotomy may be perform if excessively high haemoglobin level occur .
& quot ;
& quot ; Pregnancy and breast-feeding you should not take ABILIFY if you be pregnant unless you have discuss this with your doctor .
& quot ;
& quot ; the following adverse event have be report during post-marketing surveillance .
& quot ;
& quot ; 8 .
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; Haemoglobin variability should be address through dose management with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; each orodispersible tablet contain 10 mg of aripiprazole .
& quot ;
& quot ; 10 mg
& quot ;
& quot ; Occlusion of the dialysis system be possible if heparinisation be not optimum .
& quot ;
& quot ; Vascular disorder :
& quot ;
& quot ; for subcutaneous and intravenous use .
& quot ;
& quot ; Aripiprazole undergo minimal pre-systemic metabolism .
& quot ;
& quot ; management of overdose should concentrate on supportive therapy , maintain an adequate airway , oxygenation and ventilation , and management of symptom .
& quot ;
& quot ; 4 .
& quot ;
& quot ; Ísland VISTOR HF Sími : + 354 535 7000
& quot ;
& quot ; BLISTERS
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; EU / 1 / 07 / 412 / 009 EU / 1 / 07 / 412 / 010
& quot ;
& quot ; iron status should be evaluate prior to and during treatment and iron supplementation administer if necessary .
& quot ;
& quot ; even if you feel better , do not alter or discontinue the daily dose of ABILIFY without first consult your doctor .
& quot ;
& quot ; good blood management practice should always be use in the perisurgical setting
& quot ;
& quot ; Aripiprazole also demonstrate a comparable proportion of patient in symptomatic remission from mania a lithium or haloperidol at week 12 .
& quot ;
& quot ; 127 PARTICULARS to appear on the outer packaging
& quot ;
& quot ; 30 mg
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ; weight gain , weight decrease , anorexia , hyponatremia
& quot ;
& quot ; if haemoglobin have increase by at least 1 g / dl ( 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl above baseline after 4 week of treatment , the dose should remain at 150 IU / kg 3 time a week or 450 IU / kg once weekly .
& quot ;
& quot ; local reaction In a large clinical trial , local reaction at the infusion site , such a redness , swell and / or pain , be report ( 0.7 % ) follow the administration of zoledronic acid .
& quot ;
& quot ; 140 Eesti Österreich BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; Batch
& quot ;
& quot ; how to take ABILIFY
& quot ;
& quot ; in a 26-week , placebo-controlled trial in stabilised patient with chronic schizophrenia , aripiprazole have significantly greater reduction in relapse rate , 34 % in aripiprazole group and 57 % in placebo .
& quot ;
& quot ; 3 .
& quot ;
& quot ; Abseamed can be use to reduce exposure to allogeneic blood transfusion in adult non-iron deficient patient prior to major elective orthopaedic surgery , have a high perceive risk for transfusion complication .
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and then reinstitute epoetin alfa therapy at a dose 25 % below the previous level .
& quot ;
& quot ; 3 .
& quot ;
& quot ; this regress during the course of continued therapy .
& quot ;
& quot ; 8 .
& quot ;
& quot ; your doctor will check your level of the red blood pigment ( haemoglobin ) regularly
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; the biological efficacy of epoetin alfa have be demonstrate in various animal model in vivo ( normal and anaemic rat , polycythaemic mouse ) .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; if the haemoglobin increase be & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , increase the dose to 300 IU / kg 3 time per week .
& quot ;
& quot ; Tel : + 386 1 236 47 00
& quot ;
& quot ; agitation , nervousness ; suicide attempt , suicidal ideation , and complete suicide ( see section 4.4 )
& quot ;
& quot ; Abilify
& quot ;
& quot ; in that study the incidence of fatal thromboembolic event be higher in patient receive epoetin alfa than in those receive placebo ( see section 5.1 ) .
& quot ;
& quot ; agitation , nervousness ; suicide attempt , suicidal ideation , and complete suicide ( see section 4.4 )
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl or Hb increase ≥ 1 g / dl
& quot ;
& quot ; BATCH number
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; in particular , no residue of the cell line use for the production be detectable at the concentration of the active ingredient that be use in human .
& quot ;
& quot ; there be no difference in terminal half-lives .
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; 14 .
& quot ;
& quot ; Absorption :
& quot ;
& quot ; be sure to tell your doctor immediately if you be breast-feeding .
& quot ;
& quot ; the total body clearance of aripiprazole be 0.7 ml / min / kg , which be primarily hepatic .
& quot ;
& quot ; in controlled clinical study , use of Epoetin alfa and other erythropoiesis-stimulating agent ( ESAs ) have show :
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subject , nor be there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; Abraxane be a powder that be make up into a suspension for infusion ( drip into a vein ) .
& quot ;
& quot ; instruction on use
& quot ;
& quot ; maintenance dose between 17 and 33 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl or Hb increase ≥ 1 g / dl
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; statement OF active substance ( s )
& quot ;
& quot ; each tablet contain 30 mg of aripiprazole .
& quot ;
& quot ; B03XA01
& quot ;
& quot ; Abseamed have the highest possible purity accord to the present state of the art .
& quot ;
& quot ; Tel : + 40 ( 0 ) 21 272 16 00
& quot ;
& quot ; however , elevate creatine phosphokinase and rhabdomyolysis , not necessarily in association with NMS , have also be report .
& quot ;
& quot ; risk management Plan The MAH commits to perform the study and additional pharmacovigilance activity detail in the Pharmacovigilance Plan , a agree in version 004 of the risk management Plan ( RMP ) present in Module 1.8.2. of the marketing authorisation application and any subsequent update of the RMP agree by the CHMP .
& quot ;
& quot ; alternatively , epoetin alfa can be administer at an initial dose of 450 IU / kg subcutaneously once weekly .
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; however , the oral solution should not be dilute with other liquid or mixed with any food prior to administration .
& quot ;
& quot ; 6 .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; Hypertension may occur in epoetin alfa treat patient .
& quot ;
& quot ; after initiation of the zoledronic acid infusion , plasma concentration of the active substance increase rapidly , achieve their peak at the end of the infusion period , follow by a rapid decline to & lt ; 10 % of peak after 4 hour and & lt ; 1 % of peak after 24 hour , with a subsequent prolonged period of very low concentration not exceed 0.1 % of peak level .
& quot ;
& quot ; Tel : + 370 5 2790 762
& quot ;
& quot ; 5 mg / 100 ml
& quot ;
& quot ; there be conflict report in the literature regard whether erythropoietin may play a major role a tumour proliferators .
& quot ;
& quot ; there be no known antidote for paclitaxel overdose .
& quot ;
& quot ; 10 .
& quot ;
& quot ; Haemoglobin variability should be address through dose management with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy male and female subject nor be there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; Unopened vial :
& quot ;
& quot ; it have be propose that aripiprazole ’ s efficacy in schizophrenia and Bipolar I Disorder be mediate through a combination of partial agonism at dopamine D2 and serotonin 5HT1a receptor and antagonism of serotonin 5HT2a receptor .
& quot ;
& quot ; Batch
& quot ;
& quot ; event rate ( % )
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; Thrombotic / vascular event , such a myocardial ischaemia , myocardial infarction , cerebrovascular accident ( cerebral haemorrhage and cerebral infarction ) , transient ischaemic attack , deep vein thrombosis , arterial thrombosis , pulmonary embolus , aneurysm , retinal thrombosis , and clotting of an artificial kidney have be report in patient receive erythropoietic agent , include patient receive epoetin alfa .
& quot ;
& quot ; in a clinical trial in healthy subject , a potent inhibitor of CYP3A4 ( ketoconazole ) increase aripiprazole AUC and Cmax by 63 % and 37 % , respectively .
& quot ;
& quot ; Aclasta
& quot ;
& quot ; the decision to administer recombinant erythropoietin should be base on a benefit-risk assessment with the participation of the individual patient , which should also take into account the specific clinical context .
& quot ;
& quot ; solution for injection 1 vial
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; 11 .
& quot ;
& quot ; interaction with receptor other than dopamine and serotonin subtypes may explain some of the other clinical effect of aripiprazole .
& quot ;
& quot ; overall survival outcome in the trial could not be statisfactorily explain by difference in the incidence of thrombosis and related complication between those give recombinant human erythropoietin and those in the control group .
& quot ;
& quot ; Contrada Fontana del Ceraso I-03012 Anagni-Frosinone - Italy
& quot ;
& quot ; Abseamed 2000 IU / 1 ml
& quot ;
& quot ; investigation :
& quot ;
& quot ; haemodialysis and adult patient on peritoneal dialysis ( see section 4.4 ) .
& quot ;
& quot ; - if the seal be break .
& quot ;
& quot ; always take ABILIFY exactly a your doctor have tell you .
& quot ;
& quot ; EU / 1 / 04 / 276 / 030 14 X 1 orodispersible tablet EU / 1 / 04 / 276 / 031 28 X 1 orodispersible tablet EU / 1 / 04 / 276 / 032 49 X 1 orodispersible tablet
& quot ;
& quot ; 8 .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery the cause of anaemia should be establish and treat , if possible , before the start of epoetin alfa treatment .
& quot ;
& quot ; it do not matter whether you take it with or without food .
& quot ;
& quot ; 3.3
& quot ;
& quot ; BATCH number
& quot ;
& quot ; the protein fraction of the molecule contribute about 58 % and consist of 165 amino acid .
& quot ;
& quot ; 4.5 interaction with other medicinal product and other form of interaction
& quot ;
& quot ; patient with metastatic breast cancer receive chemotherapy when administer to target a haemoglobin of 12 - 14 g / dl ( 7.5 – 8.7 mmol / l ) ,
& quot ;
& quot ; Abilify also have a similar effect to haloperidol and to lithium over three week .
& quot ;
& quot ; Excipient :
& quot ;
& quot ; 1 pre-filled syringe
& quot ;
& quot ; 2 / 2
& quot ;
& quot ; weight gain , weight decrease , anorexia , hyponatremia
& quot ;
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; Tumour growth potential
& quot ;
& quot ; Tablet
& quot ;
& quot ; the frequency of these event be consider not know ( can not be estimate from the available data ) .
& quot ;
& quot ; patient with metastatic breast cancer receive chemotherapy when administer to target a haemoglobin of 12 - 14 g / dl ( 7.5 – 8.7 mmol / l ) ,
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; start dose of 50 IU / kg 2 time per week by the intravenous route .
& quot ;
& quot ; actual score in rating scale use a secondary endpoint , include PANSS and the Montgomery-Asberg Depression rating scale show a significant improvement over haloperidol .
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; 0.99 , 1,18 ; 42 trial and 8167 patient ) .
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; 180 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; an increase relative risk of thromboembolic event ( RR 1.67 , 95 % CI :
& quot ;
& quot ; further information
& quot ;
& quot ; Aripiprazole undergo minimal pre-systemic metabolism .
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) , the dose should be reduce by approximately 25 to 50 % .
& quot ;
& quot ; you may need to read it again .
& quot ;
& quot ; potential for other medicinal product to affect ABILIFY :
& quot ;
& quot ;
& quot ; patient with metastatic breast cancer receive chemotherapy when administer to target a haemoglobin of 12 - 14 g / dl ( 7.5 – 8.7 mmol / l ) ,
& quot ;
& quot ; adult haemodialysis patient :
& quot ;
& quot ; - keep out of the reach and sight of child .
& quot ;
& quot ; effect on hip fracture Aclasta demonstrate a consistent effect over 3 year , result in a 41 % reduction in the risk of hip fracture ( 95 % CI , 17 % to 58 % ) .
& quot ;
& quot ; Excipients : sodium dihydrogen phosphate dihydrate , disodium phosphate dihydrate , sodium chloride , glycine , polysorbate 80 , hydrochloric acid ( for pH-adjustment ) , sodium hydroxide ( for pH-adjustment ) , and water for injection
& quot ;
& quot ; you may need to read it again .
& quot ;
& quot ; 92 ( 0.62 mmol / l ) per month and should not exceed 2 g / dl ( 1.25 mmol / l ) per month to minimise risk of an increase in hypertension .
& quot ;
& quot ; Tel : + 40 ( 0 ) 21 272 16 00
& quot ;
& quot ; 1 pre-filled syringe of 0.8 ml contains 8000 international unit ( IU ) correspond to 67.2 microgram epoetin alfa
& quot ;
& quot ; before you take ABILIFY
& quot ;
& quot ; overall , 1.3 % of aripiprazole-treated patient report cerebrovascular adverse event compare with 0.6 % of placebo-treated patient in these trial .
& quot ;
& quot ; other finding :
& quot ;
& quot ; iron status should be evaluate prior to and during treatment and iron supplementation administer if necessary .
& quot ;
& quot ; developmental toxicity , include dose-dependent delayed foetal ossification and possible teratogenic effect , be observe in rat at dos result in subtherapeutic exposure ( base on AUC ) and in rabbit at dos result in exposure 3 and 11 time the mean steady-state AUC at the maximum recommend clinical dose .
& quot ;
& quot ; expiry date
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; kg Tel : + 49- ( 0 ) 2371 937 0
& quot ;
& quot ; EXP
& quot ;
& quot ; Absorption :
& quot ;
& quot ; hyperglycaemia , diabetes mellitus , diabetic ketoacidosis , diabetic hyperosmolar coma
& quot ;
& quot ; 11 .
& quot ;
& quot ; if the haemoglobin be rise by more than 2 g / dl ( 1.25 mmol / l ) per month , or if the haemoglobin exceed 12 g / dl ( 7.5 mmol / l ) , the dose should be reduce by approximately 25 to 50 % .
& quot ;
& quot ; consequently :
& quot ;
& quot ; therefore , routine volume replacement should be perform in such patient .
& quot ;
& quot ; Ελλάδα BRISTOL-MYERS SQUIBB A. e .
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; class effect :
& quot ;
& quot ; in a 26-week , placebo-controlled trial in stabilised patient with chronic schizophrenia , aripiprazole have significantly greater reduction in relapse rate , 34 % in aripiprazole group and 57 % in placebo .
& quot ;
& quot ; ABILIFY be indicate for the treatment of moderate to severe manic episode in Bipolar I Disorder and for the prevention of a new manic episode in patient who experience predominantly manic episode and whose manic episode respond to aripiprazole treatment ( see section 5.1 ) .
& quot ;
& quot ; Shunt thromboses may occur , especially in patient who have a tendency to hypotension or whose arteriovenous fistula exhibit complication ( e. g. stenosis , aneurysm , etc . ) .
& quot ;
& quot ; this difference be not statistically significant .
& quot ;
& quot ; Dosage adjustment to maintain haemoglobin concentration between 10 g / dl - 12 g / dl :
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; it may be necessary to add or increase antihypertensive treatment .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; Lancaster way Wingates industrial Park Westhoughton BL5 3XX United Kingdom
& quot ;
& quot ; an increase in dose of a particular blood-thinning medicine ( heparin ) during haemodialysis be frequently require during the course of therapy with Abseamed .
& quot ;
& quot ; other information about Abilify :
& quot ;
& quot ; 11 .
& quot ;
& quot ; the recommended dosing regimen be describe in the following diagram :
& quot ;
& quot ; general
& quot ;
& quot ; the possibility of multiple medicinal product involvement should be consider .
& quot ;
& quot ; elderly patient with dementia-related psychosis :
& quot ;
& quot ; seizure : in clinical trial , uncommon case of seizure be report during treatment with aripiprazole .
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; in the absence of compatibility study , this medicinal product must not be mix with other medicinal product .
& quot ;
& quot ; increase mortality : in three placebo-controlled trial ( n = 938 ; mean age :
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; Batch
& quot ;
& quot ; in clinical study , 10-30 mg / day dos of aripiprazole have no significant effect on the metabolism of substrate of CYP2D6 ( dextromethorphan / 3-methoxymorphinan ratio ) , 2C9 ( warfarin ) , 2C19 ( omeprazole ) , and 3A4 ( dextromethorphan ) .
& quot ;
& quot ; due to it α 1-adrenergic receptor antagonism , aripiprazole have the potential to enhance the effect of certain antihypertensive agent .
& quot ;
& quot ; 1 .
& quot ;
& quot ; PET-bottles with polypropylene child-resistant closure contain 50 , 150 or 480 ml per bottle .
& quot ;
& quot ; if you have any further question on the use of this product , ask your doctor or pharmacist .
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; Infections and infestation Vascular disorder General disorder and administration site condition
& quot ;
& quot ; 66 Pharmacokinetics in special patient group
& quot ;
& quot ; 5 .
& quot ;
& quot ; undesirable effect know to be associate with antipsychotic therapy and also report during treatment with aripiprazole include neuroleptic malignant syndrome , tardive dyskinesia , seizure , cerebrovascular adverse event and increased mortality in elderly demented patient , hyperglycaemia and diabetes mellitus ( see section 4.4 ) .
& quot ;
& quot ; name OF the marketing authorisation holder
& quot ;
& quot ; in the Paget ’ s disease trial , symptomatic hypocalcaemia be observe in approximately 1 % of patient , in all of whom it resolve .
& quot ;
& quot ; Paediatric haemodialysis patient :
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; hyperglycaemia , diabetes mellitus , diabetic ketoacidosis , diabetic hyperosmolar coma
& quot ;
& quot ; oral use .
& quot ;
& quot ; Aclasta be a solution for infusion ( drip into a vein ) contain the active substance zoledronic acid ( 5 mg / 100 ml ) .
& quot ;
& quot ; Tel : + 39 06 50 39 61
& quot ;
& quot ; in a large clinical trial in 7,736 patient , osteonecrosis of the jaw have be report in one patient treat with Aclasta and one patient treat with placebo .
& quot ;
& quot ; in addition , case of stroke or & quot ; & quot ; mini & quot ; & quot ; stroke have be report .
& quot ;
& quot ; oral use .
& quot ;
& quot ; Intravenous injection : over at least one to five minute , depend on the total dose .
& quot ;
& quot ; in that study the incidence of fatal thromboembolic event be higher in patient receive epoetin alfa than in those receive placebo ( see section 5.1 ) .
& quot ;
& quot ; 1 .
& quot ;
& quot ;
& quot ; 152 tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever , sweat , alter mental status , or very rapid or irregular heart beat .
& quot ;
& quot ; although the cause of death be vary , most of the death appear to be either cardiovascular ( e. g. heart failure , sudden death ) or infectious ( e. g. pneumonia ) in nature .
& quot ;
& quot ;
& quot ; each tablet contain 15 mg of aripiprazole .
& quot ;
& quot ; package LEAFLET
& quot ;
& quot ; Belgique / België / Belgien BRISTOL-MYERS SQUIBB Belgium S. A . / N. V .
& quot ;
& quot ; in patient with severe hepatic impairment , the data available be insufficient to establish recommendation .
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; Tel : + 34 91 456 53 00
& quot ;
& quot ; Thrombocytosis have be observe but it occurrence be very rare ( see section 4.4 ) .
& quot ;
& quot ; 4 .
& quot ;
& quot ; in addition , report of accidental overdose with aripiprazole alone ( up to 195 mg ) in child have be receive with no fatality .
& quot ;
& quot ; ask your pharmacist how to dispose of medicine no longer require .
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; in that study the incidence of fatal thromboembolic event be higher in patient receive epoetin alfa than in those receive placebo ( see section 5.1 ) .
& quot ;
& quot ; -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -
& quot ;
& quot ; they be supply in perforated unit dose blister pack in carton contain 14 , 28 , or 49 orodispersible tablet .
& quot ;
& quot ; if a patient develop sign and symptom indicative of NMS , or present with unexplained high fever without additional clinical manifestation of NMS , all antipsychotic medicinal product , include ABILIFY , must be discontinue .
& quot ;
& quot ; - decrease locoregional control in patient with advanced head and neck cancer receiving
& quot ;
& quot ; the occurrence of grade 1 or 2 sensory neuropathy do not generally require dose reduction .
& quot ;
& quot ; the main measure of effectiveness be whether blood level of serum alkaline phosphatase ( an enzyme involve in the breakdown of bone ) return to normal or fell by at least 75 % of the way back to normal level .
& quot ;
& quot ; name OF the marketing authorisation holder
& quot ;
& quot ; Hepatic disease :
& quot ;
& quot ; 134 minimum PARTICULARS to appear on small immediate packaging unit
& quot ;
& quot ; 10 .
& quot ;
& quot ; an increase in heparin dose during haemodialysis be frequently require during the course of therapy with epoetin alfa a a result of the increase packed cell volume .
& quot ;
& quot ; adult peritoneal dialysis patient :
& quot ;
& quot ; 1 .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; base on information available to date , correction of anaemia with epoetin alfa in adult patient with renal insufficiency not yet undergoing dialysis do not accelerate the rate of progression of renal insufficiency .
& quot ;
& quot ; 7 .
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6 g / dl or & lt ; 3.75 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 8 g / dl or & gt ; 5 mmol / l ) .
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ; 6 .
& quot ;
& quot ; if you be a kidney patient Abseamed have to be give by injection into a vein .
& quot ;
& quot ; - In pregnant or lactating surgical patient participate in an autologous blood predonation
& quot ;
& quot ; the company also carry out study look at the absorption of the orodispersible tablet and oral solution by the body .
& quot ;
& quot ; statement OF active substance
& quot ;
& quot ; the haemoglobin concentration aim for be between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) , except in paediatric patient in whom the haemoglobin concentration should be between 9.5 and 11 g / dl ( 5.9 - 6.8 mmol / l ) .
& quot ;
& quot ; 164 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; the total body clearance of aripiprazole be 0.7 ml / min / kg , which be primarily hepatic .
& quot ;
& quot ; Č eská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; moreover , monitoring of the blood pressure be recommend particularly at the start of therapy .
& quot ;
& quot ; 7 .
& quot ;
& quot ; adult surgery patient in an autologous predonation programme :
& quot ;
& quot ; it may harm them , even if their symptom be the same a yours .
& quot ;
& quot ; however , since cyclosporin be bind by red blood cell there be potential for an interaction .
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; if refrigerate , allow the refrigerated solution to reach room temperature before administration .
& quot ;
& quot ; if you want more information on the basis of the CHMP recommendation , read the Scientific discussion ( also part of the EPAR ) .
& quot ;
& quot ; 9 .
& quot ;
& quot ; 16 PARTICULARS to appear on the outer packaging AND the immediate packaging Carton and Vial
& quot ;
& quot ;
& quot ; interaction with receptor other than dopamine and serotonin subtypes may explain some of the other clinical effect of aripiprazole .
& quot ;
& quot ; in woman , osteoporosis be more common after the menopause , when the level of the female hormone oestrogen 7 Westferry circus , Canary Wharf , London E14 4HB , UK Tel .
& quot ;
& quot ; Erythropoietin be a glycoprotein that stimulate , a a mitosis-stimulating factor and differentiate hormone , the formation of erythrocyte from precursor of the stem cell compartment .
& quot ;
& quot ; follow subcutaneous injection , serum level of epoetin alfa be much lower than the level achieve follow intravenous injection , the level increase slowly and reach a peak between 12 and
& quot ;
& quot ; 21 10 .
& quot ;
& quot ; like all medicine , ABILIFY can cause side effect , although not everybody get them .
& quot ;
& quot ; Metabolism :
& quot ;
& quot ; these trial include patient with or without psychotic feature and with or without a rapid-cycling course .
& quot ;
& quot ; 3 .
& quot ;
& quot ; the recommend starting dose for ABILIFY be 10 or 15 mg / day with a maintenance dose of 15 mg / day administer on a once-a-day schedule without regard to meal .
& quot ;
& quot ; 5 .
& quot ;
& quot ; 4 .
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; ABILIFY be effective in maintain the clinical improvement during continuation therapy in patient who have show an initial treatment response .
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; Z O. O .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; Abseamed 3000 IU / 0.3 ml
& quot ;
& quot ; for grade 3 sensory neuropathy withhold treatment until resolution to grade 1 or 2 , follow by a dose reduction for all subsequent course .
& quot ;
& quot ; 2 .
& quot ;
& quot ; if you have any further question , ask your doctor or pharmacist .
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; these symptom can temporally deteriorate or can even arise after discontinuation of treatment .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; before you use ABILIFY
& quot ;
& quot ; 24 maximum daily dose of 30 mg should be use with caution in patient with severe hepatic impairment ( see section 5.2 ) .
& quot ;
& quot ; if you want more information on the basis of the CHMP recommendation , read the Scientific discussion ( also part of the EPAR ) .
& quot ;
& quot ; there be no effect of a high fat meal on the pharmacokinetics of aripiprazole .
& quot ;
& quot ; Latvija BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; solution for infusion
& quot ;
& quot ; adult haemodialysis patient :
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; 4 .
& quot ;
& quot ; Contusion rare :
& quot ;
& quot ; no study on the effect on the ability to drive and use machine have be perform .
& quot ;
& quot ; 6.1 list of excipients
& quot ;
& quot ; be sure to tell your doctor immediately if you be breast-feeding .
& quot ;
& quot ; effect on bone mineral density ( BMD ) Aclasta significantly increase BMD at the lumbar spine , hip , and distal radius relative to treatment with placebo at all timepoints ( 6 , 12 , 24 and 36 month ) .
& quot ;
& quot ; Abseamed be a sterile but unpreserved product and be for single use only .
& quot ;
& quot ; 8 .
& quot ;
& quot ; Erythropoietins be growth factor that primarily stimulate red blood cell production .
& quot ;
& quot ; maintenance dose between 25 and 50 IU / kg 2 time per week into 2 equal injection .
& quot ;
& quot ; 11 .
& quot ;
& quot ; the biological efficacy of epoetin alfa have be demonstrate in various animal model in vivo ( normal and anaemic rat , polycythaemic mouse ) .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; base on information available to date , correction of anaemia with epoetin alfa in adult patient with renal insufficiency not yet undergoing dialysis do not accelerate the rate of progression of renal insufficiency .
& quot ;
& quot ; after your condition have be bring under control , you will receive regular dos of Abseamed between 17 and 33 IU / kg , three time a week .
& quot ;
& quot ; Hyperglycaemia and Diabetes Mellitus : hyperglycaemia , in some case extreme and associate with ketoacidosis or hyperosmolar coma or death , have be report in patient treat with atypical antipsychotic agent , include ABILIFY .
& quot ;
& quot ; interaction with receptor other than dopamine and serotonin subtypes may explain some of the other clinical effect of aripiprazole .
& quot ;
& quot ; there be no adequate and well-controlled study in pregnant woman .
& quot ;
& quot ; an increase in heparin dose during haemodialysis be frequently require during the course of therapy with epoetin alfa a a result of the increase packed cell volume .
& quot ;
& quot ; like all medicine , ABILIFY can cause side effect , although not everybody get them .
& quot ;
& quot ; in patient with chronic renal failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommend in section 4.2 .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; - In chronic renal failure patient , epoetin alfa should be use in pregnancy only if the potential
& quot ;
& quot ; programme , the use of epoetin alfa be not recommend .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; Malta BRISTOL-MYERS SQUIBB S. R. l .
& quot ;
& quot ; benefit outweighs the potential risk to the foetus .
& quot ;
& quot ; however your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day .
& quot ;
& quot ; do not take ABILIFY if you be allergic ( hypersensitive ) to aripiprazole or any of the other ingredient of ABILIFY .
& quot ;
& quot ; Excipient :
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; in clinical trial with aripiprazole , there be no significant difference in the incidence rate of hyperglycaemia-related adverse event ( include diabetes ) or in abnormal glycaemia laboratory value compare to placebo .
& quot ;
& quot ; the aripiprazole AUC in the first 2 hour after an intramuscular injection be 90 % greater than the AUC after the same dose a a tablet ; systemic exposure be generally similar between the 2 formulation .
& quot ;
& quot ; Dosage adjustment to maintain haemoglobin concentration between 10 g / dl - 12 g / dl :
& quot ;
& quot ; Aripiprazole be metabolise by multiple pathway involve the CYP2D6 and CYP3A4 enzyme but not CYP1A enzyme .
& quot ;
& quot ; EU / 1 / 04 / 276 / 024 14 X 1 orodispersible tablet EU / 1 / 04 / 276 / 025 28 X 1 orodispersible tablet EU / 1 / 04 / 276 / 026 49 X 1 orodispersible tablet
& quot ;
& quot ; special PRECAUTIONS for disposal OF unused MEDICINAL product or waste material DERIVED from such MEDICINAL product , if appropriate
& quot ;
& quot ; solution for infusion
& quot ;
& quot ; the total body clearance of aripiprazole be 0.7 ml / min / kg , which be primarily hepatic .
& quot ;
& quot ; Teл . : + 359 800 12 400
& quot ;
& quot ; 2 .
& quot ;
& quot ; transferrin saturation be below 20 % .
& quot ;
& quot ; the majority of these symptom be mild to moderate and resolve within three day of the event onset .
& quot ;
& quot ; the effect of Abraxane be first test in experimental model before be study in human .
& quot ;
& quot ; 6 The recommend dose be 600 IU / kg epoetin alfa , give weekly for three week ( day 21 , 14 and 7 ) prior to surgery and on the day of surgery ( day 0 ) .
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; Kidney patient
& quot ;
& quot ; oral use
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of 25 IU / kg 3 time per week at interval of at least 4 week until the desired goal be achieve .
& quot ;
& quot ; Suicidal thought and behaviour have be report during aripiprazole treatment .
& quot ;
& quot ; 161 detailed information on this medicine be available on the European Medicines Agency ( EMEA ) web site : http : / / www . emea . europa . EU /
& quot ;
& quot ; mildly anaemic patient ( haematocrit of 33 - 39 % ) require predeposit of ≥ 4 unit of blood should be treat with Abseamed at a dose of 600 IU / kg body weight 2 time weekly for 3 week prior to surgery .
& quot ;
& quot ; 7 .
& quot ;
& quot ; follow any confirm or suspect overdose with aripiprazole , close medical supervision and monitoring should continue until the patient recovers .
& quot ;
& quot ; 1 .
& quot ;
& quot ; 4 .
& quot ;
& quot ; cardiovascular disorder :
& quot ;
& quot ; each ml of solution contain 10 000 IU of epoetin alfa * correspond to 84.0 microgram per ml 1 pre-filled syringe of 0.6 ml contains 6000 international unit ( IU ) correspond to 50.4 microgram epoetin alfa
& quot ;
& quot ; 2 .
& quot ;
& quot ; red iron oxide ( E172 )
& quot ;
& quot ; Abseamed can be use to reduce exposure to allogeneic blood transfusion in adult non-iron deficient patient prior to major elective orthopaedic surgery , have a high perceive risk for transfusion complication .
& quot ;
& quot ; the recommend starting dose for ABILIFY be 10 or 15 mg / day with a maintenance dose of 15 mg / day administer on a once-a-day schedule without regard to meal .
& quot ;
& quot ; jaundice , hepatitis , increase Alanine Aminotransferase ( ALT ) , increased Aspartate Aminotransferase ( AST ) , increase Gamma Glutamyl Transferase ( GGT ) , increase alkaline phosphatase
& quot ;
& quot ; 11 an increase incidence of thrombotic vascular event ( see section 4.4 and section 4.8 - General ) have be observe in patient receive erythropoietic agent .
& quot ;
& quot ; 3000 IU / 0.3 ml
& quot ;
& quot ; a single-dose study in subject with vary degree of liver cirrhosis ( Child-Pugh class A , B , and C ) do not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole , but the study include only 3 patient with class C liver cirrhosis , which be insufficient to draw conclusion on their metabolic capacity .
& quot ;
& quot ; Abseamed 4000 IU / 0.4 ml injection
& quot ;
& quot ; Respiratory , thoracic and mediastinal disorder :
& quot ;
& quot ; BATCH number
& quot ;
& quot ; attention should be pay to sudden stab migraine-like headache a a possible warning signal .
& quot ;
& quot ; the possibility of multiple medicinal product involvement should be consider .
& quot ;
& quot ; EU / 1 / 04 / 276 / 002
& quot ;
& quot ; 154 store in the original package in order to protect from moisture .
& quot ;
& quot ; if you take more ABILIFY than you should if you realise you have take more ABILIFY tablet than your doctor have recommend ( or if someone else have take some of your ABILIFY tablet ) , contact your doctor right away .
& quot ;
& quot ; thus , no dosage adjustment be require for smoker .
& quot ;
& quot ; N05AX12
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; 15 .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; Abseamed 10 000 IU / 1 ml solution for injection in a pre-filled syringe Epoetin alfa
& quot ;
& quot ; functional assessment of Cancer Therapy- Anaemia ( FACT-An ) general scale , FACT-An fatigue scale , and Cancer linear Analogue scale ( CLAS ) .
& quot ;
& quot ; all patient be treat with epoetin alfa should receive adequate iron supplementation ( e. g. oral iron substitution of 200 mg Fe2 + daily ) throughout the course of epoetin alfa treatment .
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; you may need to read it again .
& quot ;
& quot ; 3 .
& quot ;
& quot ; pancreatitis , dysphagia , abdominal discomfort , stomach discomfort , diarrhoea
& quot ;
& quot ; overall , 1.3 % of aripiprazole-treated patient report cerebrovascular adverse event compare with 0.6 % of placebo-treated patient in these trial .
& quot ;
& quot ; & gt ; 1st-line therapy
& quot ;
& quot ; skin and subcutaneous tissue disorder :
& quot ;
& quot ; Schizophrenia :
& quot ;
& quot ; Psychiatric disorder :
& quot ;
& quot ; gender : no dosage adjustment be require for female patient a compare to male patient ( see section 5.2 ) .
& quot ;
& quot ; Hypersensitivity : a with other medication hypersensitivity reaction , characterise by allergic symptom , may occur with aripiprazole ( see section 4.8 ) .
& quot ;
& quot ; EU / 1 / 04 / 276 / 006-010
& quot ;
& quot ; all other cause of anaemia ( iron deficiency , haemolysis , blood loss , vitamin B12 or folate deficiency ) should be consider and treat prior to initiate therapy with epoetin alfa .
& quot ;
& quot ; alternatively , the injection can be give at the end of the dialysis session via the fistula needle tubing , follow by 10 ml of isotonic saline to rinse the tubing and ensure satisfactory injection of the product into the circulation .
& quot ;
& quot ; Excipients : sodium dihydrogen phosphate dihydrate , disodium phosphate dihydrate , sodium chloride , glycine , polysorbate 80 , hydrochloric acid ( for pH-adjustment ) , sodium hydroxide ( for pH-adjustment ) , and water for injection
& quot ;
& quot ; 6 .
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; adult cancer patient with symptomatic anaemia receive chemotherapy
& quot ;
& quot ; take special care with Abraxane • if you have poor kidney function • if you experience numbness , tingle , prick sensation , sensitivity to touch , or muscle weakness • if you have severe liver problem • if you have heart problem
& quot ;
& quot ; Abseamed must not be use
& quot ;
& quot ; Maternal toxicity occur at dos similar to those elicit developmental toxicity .
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ; similarly , for dehydro-aripiprazole the geometric mean
& quot ;
& quot ; it also prevent this condition from return in patient who have respond to the treatment with ABILIFY .
& quot ;
& quot ; 12 .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; Schizophrenia - in a long term 52-week controlled trial , aripiprazole-treated patient have an overall-lower incidence ( 25.8 % ) of EPS include parkinsonism , akathisia , dystonia and dyskinesia compare with those treat with haloperidol ( 57.3 % ) .
& quot ;
& quot ; be sure to tell your doctor if you take a medicine to keep your blood pressure under control .
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; Removal of the intact orodispersible tablet from the mouth be difficult .
& quot ;
& quot ; the absolute oral bioavailability of the tablet formulation be 87 % .
& quot ;
& quot ; Phlebotomy may be perform if excessively high haemoglobin level occur .
& quot ;
& quot ; the orodispersible tablet should be place in the mouth on the tongue , where it will rapidly disperse in saliva .
& quot ;
& quot ; Tablet disintegration occur rapidly in saliva .
& quot ;
& quot ; packaging
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; in particular , no residue of the cell line use for the production be detectable at the concentration of the active ingredient that be use in human .
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; after administration of epoetin alfa , the number of erythrocyte , the Hb value and reticulocyte count increase a well a the 59Fe-incorporation rate .
& quot ;
& quot ; Excipients
& quot ;
& quot ; 1 pre-filled syringe of 0.5 ml 6 pre-filled syrinx of 0.5 ml
& quot ;
& quot ; 3 year
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; Lactose monohydrate Maize starch Microcrystalline cellulose Hydroxypropyl cellulose Magnesium stearate
& quot ;
& quot ; ask your pharmacist how to dispose of medicine no longer require .
& quot ;
& quot ;
& quot ; this summary be last updated in 07-2008 .
& quot ;
& quot ; the injection be give in the thigh or the anterior abdominal wall .
& quot ;
& quot ; in CYP2D6 poor metabolisers , concomitant use of potent inhibitor of CYP3A4 may result in higher plasma concentration of aripiprazole compare to that in CYP2D6 extensive metabolizers .
& quot ;
& quot ; the usual dose be 15 ml solution ( correspond to 15 mg aripiprazole ) once a day .
& quot ;
& quot ; patient with metastatic breast cancer receive chemotherapy when administer to target a haemoglobin of 12 - 14 g / dl ( 7.5 – 8.7 mmol / l ) ,
& quot ;
& quot ; this be give twice a week by injection into a vein .
& quot ;
& quot ; alternatively , the injection can be give at the end of the dialysis session via the fistula needle tubing , follow by 10 ml of isotonic saline to rinse the tubing and ensure satisfactory injection of the product into the circulation .
& quot ;
& quot ; this regress during the course of continued therapy .
& quot ;
& quot ; it may be necessary to add or increase antihypertensive treatment .
& quot ;
& quot ; this medicinal product contain le than 1 mmol sodium ( 23 mg ) per dose , I. e. essentially “ sodium- free ” .
& quot ;
& quot ; B .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; 14 X 1 orodispersible tablet 28 X 1 orodispersible tablet 49 X 1 orodispersible tablet
& quot ;
& quot ; Unopened vial :
& quot ;
& quot ; weight gain have be report post-marketing among patient prescribe ABILIFY .
& quot ;
& quot ; 9 .
& quot ;
& quot ; 3 .
& quot ;
& quot ; increase Creatine Phosphokinase , blood glucose increase , blood glucose fluctuation , glycosylated haemoglobin increase
& quot ;
& quot ; peripheral neuropathy ( mostly grade 1 or 2 sensory neuropathy ) be observe in 68 % of patient on Abraxane with 10 % be grade 3 , and no case of grade 4 .
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; Haemoglobin variability should be address through dose management , with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; Aripiprazole should be use with caution in patient with known cardiovascular disease ( history of myocardial infarction or ischaemic heart disease , heart failure , or conduction abnormality ) , cerebrovascular disease , condition which would predispose patient to hypotension ( dehydration , hypovolemia , and treatment with antihypertensive medication ) or hypertension , include accelerate or malignant .
& quot ;
& quot ; if you be a cancer patient you should be aware that Abseamed may act a a blood cell growth factor and in some circumstance may have a negative impact on your cancer .
& quot ;
& quot ; Abilify
& quot ;
& quot ; NMS be a potentially fatal symptom complex associate with antipsychotic medicinal product .
& quot ;
& quot ; adult surgery patient in an autologous predonation programme
& quot ;
& quot ; 128 Posology
& quot ;
& quot ; 15 .
& quot ;
& quot ; Novartis Pharma GmbH Roonstraße 25 D-90429 Nuremberg Germany
& quot ;
& quot ; the frequency list below be define use the following convention : common ( & gt ; 1 / 100 , & lt ; 1 / 10 ) and uncommon ( & gt ; 1 / 1 , 000 , & lt ; 1 / 100 ) .
& quot ;
& quot ; Smoking status : accord to the metabolic pathway of ABILIFY no dosage adjustment be require for smoker ( see section 4.5 ) .
& quot ;
& quot ; general
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole increase by 77 % and 43 % , respectively .
& quot ;
& quot ; - if the solution be cloudy or there be particle in it .
& quot ;
& quot ; 84 year ; range :
& quot ;
& quot ; Uncommon :
& quot ;
& quot ; N05AX12
& quot ;
& quot ; 22 PARTICULARS to appear on the outer CARTON OF MULTI-PACK ( include blue box )
& quot ;
& quot ; Aripiprazole should be use with caution in patient with known cardiovascular disease ( history of myocardial infarction or ischaemic heart disease , heart failure , or conduction abnormality ) , cerebrovascular disease , condition which would predispose patient to hypotension ( dehydration , hypovolemia , and treatment with antihypertensive medication ) or hypertension , include accelerate or malignant .
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; a slower injection be preferable in patient who react to the treatment with “ flu-like ” symptom .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ;
& quot ; 1 pre-filled syringe of 0.7 ml 6 pre-filled syrinx of 0.7 ml
& quot ;
& quot ; Hyperkalaemia have be observe in isolated case .
& quot ;
& quot ; important information about some of the ingredient of ABILIFY if you have be tell by your doctor that you have an intolerance to some sugar , contact your doctor before take this medicine .
& quot ;
& quot ; rash , photosensitivity reaction , alopecia , hyperhidrosis
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; what ABILIFY look like and content of the Pack ABILIFY 30 mg tablet be round and pink , mark with A-011 and 30 on one side .
& quot ;
& quot ; Clinical manifestation of NMS be hyperpyrexia , muscle rigidity , alter mental status and evidence of autonomic instability ( irregular pulse or blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; method OF administration
& quot ;
& quot ; there be conflict report in the literature regard whether erythropoietin may play a major role a tumour proliferators .
& quot ;
& quot ; under no circumstance should you attempt to inject yourself unless you have be train to do so .
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; if you forget to take ABILIFY if you miss a dose , take the missed dose a soon a you remember but do not take two dos in one day .
& quot ;
& quot ; oral use
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; 16 .
& quot ;
& quot ; at each step , the increase or reduction in dose should be of 25 IU / kg 3 time per week .
& quot ;
& quot ; base on information available to date , correction of anaemia with epoetin alfa in adult patient with renal insufficiency not yet undergoing dialysis do not accelerate the rate of progression of renal insufficiency .
& quot ;
& quot ; the syrinx be seal in a blister .
& quot ;
& quot ; the overall completion rate be significantly higher for patient on aripiprazole ( 43 % ) than for haloperidol ( 30 % ) .
& quot ;
& quot ; Latvija BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; what ABRAXANE be AND what IT be use for
& quot ;
& quot ; this difference be not statistically significant .
& quot ;
& quot ; 5 mg
& quot ;
& quot ; in the open-label study there be no difference in overall survival between patient treat with recombinant human erythropoietin and control .
& quot ;
& quot ; weight ( kg ) & lt ; 10 10 - 30 & gt ; 30
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and then reinstitute epoetin alfa therapy at a dose 25 % below the previous level .
& quot ;
& quot ; care should be take to ensure that at the outset of the treatment patient be not iron deficient .
& quot ;
& quot ; maintenance dose between 17 and 33 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; this document be a summary of the European Public assessment Report ( EPAR ) .
& quot ;
& quot ; the response rate in all patient be 39.5 % ( 95 % CI :
& quot ;
& quot ; factor that should be consider in this assessment should include the type of tumour and it stage ; the degree of anaemia ; life-expectancy ; the environment in which the patient be be treat ; and patient preference ( see section 5.1 ) .
& quot ;
& quot ; if you be an elderly patient suffer from dementia ( loss of memory and other mental ability ) , you or your carer / relative should tell your doctor if you have ever have a stroke or & quot ; & quot ; mini & quot ; & quot ; stroke .
& quot ;
& quot ; it be not know whether aripiprazole be excrete in human milk .
& quot ;
& quot ; upon discontinuation of the CYP2D6 or 3A4 inhibitor , the dosage of ABILIFY should be increase to the level prior to the initiation of the concomitant therapy .
& quot ;
& quot ; 5 .
& quot ;
& quot ; usual maintenance dose 75 - 150 60 - 150 30 - 100
& quot ;
& quot ; it be especially important to mention the follow to your doctor :
& quot ;
& quot ; statement OF active substance
& quot ;
& quot ; these report be base on in vitro finding from human tumour sample , but be of uncertain significance in the clinical situation .
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and than reinstitute epoetin alfa therapy at a dose 25 % below the previous dose .
& quot ;
& quot ; 23 Paclitaxel be a cytotoxic anticancer medicinal product and , a with other potentially toxic compound , caution should be exercise in handle Abraxane .
& quot ;
& quot ; in clinical trial , rare case of NMS be report during treatment with aripiprazole .
& quot ;
& quot ; agitation , nervousness ; suicide attempt , suicidal ideation , and complete suicide ( see section 4.4 )
& quot ;
& quot ; 11 .
& quot ;
& quot ; 5 .
& quot ;
& quot ; radiation therapy when administer to target a haemoglobin of greater than 14 g / dl ( 8.7 mmol / l ) ,
& quot ;
& quot ; BRISTOL-MYERS SQUIBB GESMBH Tel : + 43 1 60 14 30
& quot ;
& quot ; the clinical judgement of the treat physician should guide the management plan of each patient base on individual benefit / risk assessment .
& quot ;
& quot ; Abseamed 10 000 IU / 1 ml injection
& quot ;
& quot ; 12 .
& quot ;
& quot ; the overall completion rate be significantly higher for patient on aripiprazole ( 43 % ) than for haloperidol ( 30 % ) .
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; Renal disease :
& quot ;
& quot ; ABILIFY 1 mg / ml oral solution
& quot ;
& quot ; the maximum dose should not exceed 200 IU / kg 3 time per week .
& quot ;
& quot ; - In pregnant or lactating surgical patient participate in an autologous blood predonation
& quot ;
& quot ; in most case , the ferritin value in the serum fall simultaneously with the rise in packed cell volume .
& quot ;
& quot ; LABELLING AND package LEAFLET
& quot ;
& quot ; if you take more ABILIFY than you should if you realise you have take more ABILIFY tablet than your doctor have recommend ( or if someone else have take some of your ABILIFY tablet ) , contact your doctor right away .
& quot ;
& quot ; the initial dose be 150 IU / kg give subcutaneously 3 time per week .
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; maintenance dose between 25 and 50 IU / kg 2 time per week into 2 equal injection .
& quot ;
& quot ; Batch
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; 89 150 IU / kg 3x / week or 450 IU / kg once weekly
& quot ;
& quot ; if blood pressure can not be control , epoetin alfa treatment should be discontinue .
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; independent of erythropoietin treatment , thrombotic and vascular event may occur in surgical patient with underlying cardiovascular disease follow repeat phlebotomy .
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; before you take ABILIFY
& quot ;
& quot ; Tablet
& quot ;
& quot ; - In chronic renal failure patient , epoetin alfa should be use in pregnancy only if the potential
& quot ;
& quot ; in animal study , epoetin alfa have be show to decrease foetal body weight , delay ossification and increase foetal mortality when give in weekly dos of approximately 20 time the recommended human weekly dose .
& quot ;
& quot ; Clinical manifestation of NMS be hyperpyrexia , muscle rigidity , alter
& quot ;
& quot ; potential for ABILIFY to affect other medicinal product :
& quot ;
& quot ; ACLASTA
& quot ;
& quot ; Č eská republika OncoEurope Tel : + 36 ( 0 ) 20 501 76 03
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; 10 .
& quot ;
& quot ; Hunton House Highbridge business Park , Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
& quot ;
& quot ; your doctor may order regular blood test to see that this be be achieve and to ensure that your medicine be continue to work properly and your haemoglobin do not exceed a certain level .
& quot ;
& quot ; however , since cyclosporin be bind by red blood cell there be potential for an interaction .
& quot ;
& quot ; Adults with kidney disease not yet receive dialysis
& quot ;
& quot ; therefore , routine volume replacement should be perform in such patient .
& quot ;
& quot ; 11 .
& quot ;
& quot ; - treatment of severe anaemia of renal origin accompany by clinical symptom in adult patient
& quot ;
& quot ; Abseamed 7000 IU / 0.7 ml solution for injection in a pre-filled syringe The syrinx contain 0.7 ml ( 7000 IU ) of solution .
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; however , since cyclosporin be bind by red blood cell there be potential for an interaction .
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; thus , no dosage adjustment be require for smoker .
& quot ;
& quot ; what be the risk associate with Abraxane ?
& quot ;
& quot ; it should also not be use in patient who be breast feeding or who have low level of neutrophil in the blood before start treatment .
& quot ;
& quot ; how to take ABILIFY 4 .
& quot ;
& quot ; if blood pressure can not be control , epoetin alfa treatment should be discontinue .
& quot ;
& quot ; gender : no dosage adjustment be require for female patient a compare to male patient ( see section 5.2 ) .
& quot ;
& quot ; Aripiprazole do not impair fertility in reproductive toxicity study .
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; Hyperkalaemia have be observe in isolated case .
& quot ;
& quot ; what benefit have Abilify show during the study ?
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; oral use
& quot ;
& quot ; 5000 IU / 0.5 ml
& quot ;
& quot ; when the CYP3A4 or CYP2D6 inhibitor be withdraw from the combination therapy , aripiprazole dose should then be increase ( see section 4.5 ) .
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; Slovenija BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; 6 .
& quot ;
& quot ; Tel : + 370 5 2790 762
& quot ;
& quot ; in clinical trial aripiprazole have not be show to induce clinically relevant weight gain ( see section 5.1 ) .
& quot ;
& quot ; in several controlled study , epoetins have not be show to improve overall survival or decrease the risk of tumour progression in patient with anaemia associate with cancer .
& quot ;
& quot ; 6 .
& quot ;
& quot ; Medice
& quot ;
& quot ; because of potential serious adverse reaction in breast-feeding infant , Abraxane be contraindicate during lactation .
& quot ;
& quot ; - The active substance be epoetin alfa .
& quot ;
& quot ; 1 pre-filled syringe of 1 ml contain 10 000 international unit ( IU ) correspond to 84.0 microgram epoetin alfa
& quot ;
& quot ; the protein fraction of the molecule contribute about 58 % and consist of 165 amino acid .
& quot ;
& quot ; therefore , it should not be use in patient with baseline haemoglobin & gt ; 13 g / dl .
& quot ;
& quot ; 4 .
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; similarly , for dehydro-aripiprazole the geometric mean of Cmax and AUC after carbamazepine co-administration be 69 % and 71 % lower , respectively , than those following treatment with aripiprazole alone .
& quot ;
& quot ; Aripiprazole also demonstrate a comparable proportion of patient in symptomatic remission from mania a lithium or haloperidol at week 12 .
& quot ;
& quot ; therefore cardiovascular monitoring should be start immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmia .
& quot ;
& quot ; however , if the haemoglobin have increase & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , response to epoetin alfa therapy be unlikely and treatment should be discontinue .
& quot ;
& quot ; in animal study , epoetin alfa have be show to decrease foetal body weight , delay ossification and increase foetal mortality when give in weekly dos of approximately 20 time the recommended human weekly dose .
& quot ;
& quot ; treatment with Abseamed have to be initiate under the supervision of physician experience in the management of patient with the above indication .
& quot ;
& quot ; however your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day .
& quot ;
& quot ; it be not know whether zoledronic acid be excrete into human breast milk .
& quot ;
& quot ; the usual dose be 260 mg / m2 of body surface area .
& quot ;
& quot ; these may be more common at the start of treatment .
& quot ;
& quot ; appropriate therapy such a blood transfusion may be give to patient when indicate .
& quot ;
& quot ; patient ) be recommend for chronic renal failure patient whose serum ferritin level be below 100 ng / ml
& quot ;
& quot ; in case where there be a medical need to shorten the lead time before surgery to le than three week , 300 IU / kg epoetin alfa should be give daily for 10 consecutive day prior to surgery , on the day of surgery and for four day immediately thereafter .
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; when concomitant administration of potent CYP3A4 inducer with aripiprazole occurs , the aripiprazole dose should be increase .
& quot ;
& quot ; alcohol should be avoid when take ABILIFY .
& quot ;
& quot ; owe to the greater sensitivity of this population , a lower start dose should be consider when clinical factor warrant ( see section 4.4 ) .
& quot ;
& quot ; oral use .
& quot ;
& quot ; in patient with severe hepatic impairment , the data available be insufficient to establish recommendation .
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; the rate of increase in haemoglobin should be approximately 1 g / dl
& quot ;
& quot ; Erythropoietin be a glycoprotein that stimulate , a a mitosis-stimulating factor and differentiate hormone , the formation of erythrocyte from precursor of the stem cell compartment .
& quot ;
& quot ; Abseamed be a sterile but unpreserved product and be for single use only .
& quot ;
& quot ; an increase in heparin dose during haemodialysis be frequently require during the course of therapy with epoetin alfa a a result of the increase packed cell volume .
& quot ;
& quot ; Sodium dihydrogen phosphate dihydrate Disodium phosphate dihydrate Sodium chloride Glycine Polysorbate 80 water for injection Hydrochloric acid ( for pH-adjustment ) Sodium hydroxide ( for pH-adjustment )
& quot ;
& quot ; the peak be always well below the peak achieve use the intravenous route ( approximately 1 / 20th of the value ) .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; it be not know whether aripiprazole be excrete in human milk .
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; result of an epidemiological study find that there be no increase risk of suicidality with aripiprazole compare to other antipsychotic among patient with bipolar disorder .
& quot ;
& quot ; España BRISTOL-MYERS SQUIBB , S. A .
& quot ;
& quot ; 9 .
& quot ;
& quot ; you may need to read it again .
& quot ;
& quot ; take other medicine please tell your doctor if you be take or have recently take any other medicine , include medicine obtain without a prescription , because they could interact with Abraxane .
& quot ;
& quot ; it be recommend that the platelet count be regularly monitor during the first 8 week of therapy .
& quot ;
& quot ; ABILIFY be one of a group of medicine call antipsychotic .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; 1 .
& quot ;
& quot ; the efficacy of aripiprazole solution for injection in patient with agitation and disturbed behaviour have not be establish relate to condition other than schizophrenia and manic episode in Bipolar I Disorder .
& quot ;
& quot ; if precipitate or settle be visible , the vial should be gently invert again to ensure complete resuspension prior to use .
& quot ;
& quot ; 125 9 .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; Abilify
& quot ;
& quot ; haemodialysis and adult patient on peritoneal dialysis ( see section 4.4 ) .
& quot ;
& quot ; Tel : + 34 91 456 53 00
& quot ;
& quot ; ABILIFY be effective in a dose range of 10 to 30 mg / day .
& quot ;
& quot ; 5 .
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; expiry date
& quot ;
& quot ; what ABILIFY contain The active substance be aripiprazole .
& quot ;
& quot ; Suicidal thought and behaviour have be report during aripiprazole treatment .
& quot ;
& quot ; this be define a the patient ’ s main tumour have disappear or have shrink in size by at least 30 % .
& quot ;
& quot ; Adults receive peritoneal dialysis
& quot ;
& quot ; the most frequent adverse reaction be an increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ; Tel : + 372 640 1301
& quot ;
& quot ; give the primary CNS effect of aripiprazole , caution should be use when aripiprazole be take in combination with alcohol or other CNS medicinal product with overlap undesirable effect such a sedation ( see section 4.8 ) .
& quot ;
& quot ; 4 .
& quot ;
& quot ; Pregnancy and breast-feeding
& quot ;
& quot ; the syrinx contain 0.3 ml ( 3000 IU ) of solution .
& quot ;
& quot ; 137 an increase incidence of thrombotic vascular event ( see section 4.4 and section 4.8 - General ) have be observe in patient receive erythropoietic agent .
& quot ;
& quot ; in particular , no residue of the cell line use for the production be detectable at the concentration of the active ingredient that be use in human .
& quot ;
& quot ; - In chronic renal failure patient , epoetin alfa should be use in pregnancy only if the potential
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; - In chronic renal failure patient , epoetin alfa should be use in pregnancy only if the potential
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; no evidence exist that indicate that treatment with epoetin alfa alter the metabolism of other medicinal product .
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg , Kuhloweg 37 , D-58638 Iserlohn , Germany
& quot ;
& quot ; in elderly patient with dementia , more fatal case have be report while take aripiprazole .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; even if you feel better , do not alter or discontinue the daily dose of ABILIFY without first consult your doctor .
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; oral use .
& quot ;
& quot ; 4 .
& quot ;
& quot ; if continue treatment be indicate with oral aripiprazole , see the summary of Product characteristic for ABILIFY tablet , ABILIFY orodispersible tablet , or ABILIFY oral solution .
& quot ;
& quot ; s R. O .
& quot ;
& quot ; independent of erythropoietin treatment , thrombotic and vascular event may occur in surgical patient with underlying cardiovascular disease follow repeat phlebotomy .
& quot ;
& quot ; 162 PARTICULARS to appear on the outer packaging
& quot ;
& quot ; each carton contain one bottle and both a calibrate polypropylene measure cup and a calibrated polypropylene low-density polyethylene dropper .
& quot ;
& quot ; iron supplementation should be start a soon a possible , even several week prior to initiate the autologous predeposit , in order to achieve high iron store prior to start Abseamed therapy .
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of at least four week .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery , with a baseline haemoglobin of 10 to 13 g / dl , the incidence of thrombotic / vascular event ( most of which be DVTs ) , in the overall patient population of the clinical trial , appear to be similar across the different epoetin alfa dose group and placebo group , although the clinical experience be limit .
& quot ;
& quot ; in another 12-week trial , the incidence of EPS be 26.6 % for patient treat with aripiprazole and 17.6 % for those treat with lithium .
& quot ;
& quot ; 15 .
& quot ;
& quot ; if you can not reach your doctor , go to the nearest hospital and take the Pack with you .
& quot ;
& quot ; Schizophrenia - in a long term 52-week controlled trial , aripiprazole-treated patient have an overall-lower incidence ( 25.8 % ) of EPS include parkinsonism , akathisia , dystonia and dyskinesia compare with those treat with haloperidol ( 57.3 % ) .
& quot ;
& quot ; 176 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; there be conflict report in the literature regard whether erythropoietin may play a major role a tumour proliferators .
& quot ;
& quot ; Abilify
& quot ;
& quot ; 3 .
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; Abseamed 7000 IU / 0.7 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; expiry date
& quot ;
& quot ; the usual dose be 9.75 mg ( 1.3 ml ) for the first injection .
& quot ;
& quot ; each orodispersible tablet contain 15 mg of aripiprazole .
& quot ;
& quot ; before you use ABRAXANE
& quot ;
& quot ; there may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with epoetin alfa .
& quot ;
& quot ; weight gain have be report post-marketing among patient prescribe ABILIFY .
& quot ;
& quot ; since these report be from a population of uncertain size and be subject to confound factor , it be not possible to reliably estimate their frequency or establish a causal relationship to exposure to the medicinal product .
& quot ;
& quot ; in addition , report of accidental overdose with aripiprazole alone ( up to 195 mg ) in child have be receive with no fatality .
& quot ;
& quot ; if haemoglobin have increase by at least 1 g / dl ( 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl above baseline after 4 week of treatment , the dose should remain at 150 IU / kg 3 time a week or 450 IU / kg once weekly .
& quot ;
& quot ; the half-life be difficult to evaluate for the subcutaneous route and be estimate about 24 hour .
& quot ;
& quot ; in several controlled study , epoetins have not be show to improve overall survival or decrease the risk of tumour progression in patient with anaemia associate with cancer .
& quot ;
& quot ; child and adolescent ABILIFY be not for use in child and adolescent a it have not be study in patient under 18 year .
& quot ;
& quot ; be sure to tell your doctor immediately if you be pregnant , think you may be pregnant , or if you be plan to become pregnant .
& quot ;
& quot ; it explain how the Committee for Medicinal product for Human use ( CHMP ) assess the study perform , to reach their recommendation on how to use the medicine .
& quot ;
& quot ; discontinue therapy
& quot ;
& quot ; all other cause of anaemia ( iron deficiency , haemolysis , blood loss , vitamin B12 or folate deficiency ) should be consider and treat prior to initiate therapy with epoetin alfa .
& quot ;
& quot ; in one 3-week , fixed-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole fail to demonstrate superior efficacy to placebo .
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; 5 .
& quot ;
& quot ; Manic episodes in Bipolar I Disorder - in a 12-week controlled trial , the incidence of EPS be 23.5 % for aripiprazole-treated patient and 53.3 % for haloperidol-treated patient .
& quot ;
& quot ; Abseamed can be use to increase the yield of autologous blood from patient in a predonation programme .
& quot ;
& quot ; this difference be not statistically significant .
& quot ;
& quot ; if sign and symptom of tardive dyskinesia appear in a patient on ABILIFY , dose reduction or discontinuation should be consider .
& quot ;
& quot ; Polska Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; what be Aclasta use for ?
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; in clinical trial aripiprazole have not be show to induce clinically relevant weight gain ( see section 5.1 ) .
& quot ;
& quot ; 5 X 1 bottle ( unit Pack )
& quot ;
& quot ; people with this condition may also feel depressed , guilty , anxious or tense .
& quot ;
& quot ; Slovenija Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; Measurement of epoetin alfa follow multiple dose intravenous administration reveal a half-life of approximately 4 hour in normal volunteer and a somewhat more prolonged half-life in renal failure patient , approximately 5 hour .
& quot ;
& quot ; 144 store in the original package in order to protect from moisture .
& quot ;
& quot ; before you take ABILIFY 3 .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; the following reaction have also occur in isolated patient with normal or low blood pressure : hypertensive crisis with encephalopathy-like symptom ( e. g. headache and confused state ) and Generalised tonoclonal seizure , require the immediate attention of a physician and intensive medical care .
& quot ;
& quot ; since the orodispersible tablet be fragile , it should be take immediately on open the blister .
& quot ;
& quot ; EXP
& quot ;
& quot ; in clinical trial with aripiprazole , there be no significant difference in the incidence rate of hyperglycaemia-related adverse event ( include diabetes ) or in abnormal glycaemia laboratory value compare to placebo .
& quot ;
& quot ; for the full list of all side effect report with Abraxane , see the package Leaflet .
& quot ;
& quot ; - treatment of anaemia associate with chronic renal failure in paediatric and adult patient on
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; start dose of 50 IU / kg 3 time per week by the intravenous route , follow if necessary by a dose increase with 25 IU / kg increment ( 3 time per week ) until the desired goal be achieve ( this should be do in step of at least four week ) .
& quot ;
& quot ; risk factor that may predispose patient to severe complication include obesity and family history of diabetes .
& quot ;
& quot ; what be Abilify ?
& quot ;
& quot ; 1 pre-filled syringe of 0.6 ml contains 6000 international unit ( IU ) correspond to 50.4 microgram epoetin alfa
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; Medicines to correct heart rhythm Antidepressants or herbal remedy use to treat depression and anxiety Antifungal agent certain medicine to treat HIV infection Anticonvulsants use to treat epilepsy
& quot ;
& quot ; EU / 1 / 04 / 276 / 028
& quot ;
& quot ; 43 1 .
& quot ;
& quot ; for the full list of all side effect report with Abseamed , see the package Leaflet .
& quot ;
& quot ; also contain : lactose monohydrate .
& quot ;
& quot ; Meta-analysis of overall survival data produce a hazard ratio point estimate of 1.08 in favour of control ( 95 % CI :
& quot ;
& quot ; owe to the greater sensitivity of this population , a lower start dose should be consider when clinical factor warrant ( see section 4.4 ) .
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; EU / 1 / 04 / 276 / 033-035
& quot ;
& quot ; this be give three time a week by injection into a vein .
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl and Hb increase & lt ; 1 g / dl
& quot ;
& quot ; no evidence exist that indicate an interaction between epoetin alfa and G-CSF or GM-CSF with regard to haematological differentiation or proliferation of tumour biopsy specimen in vitro .
& quot ;
& quot ; in the event of an overdose , the patient should be closely monitor .
& quot ;
& quot ; the apparent molecular weight of erythropoietin be 32,000 to 40,000 dalton .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; the injection be give in the thigh or the anterior abdominal wall .
& quot ;
& quot ; 139 store in the original package in order to protect from moisture .
& quot ;
& quot ; common side effect ( greater than 1 in 100 , le than 1 in 10 patient ) Uncontrollable twitching or jerking movement , headache , tiredness , nausea , vomit , an uncomfortable feeling in the stomach , constipation , increased production of saliva , light-headedness , trouble sleeping , restlessness , feel anxious , sleepiness , shake and blurred vision .
& quot ;
& quot ; a combination of ABILIFY solution for injection with medicine take for anxiety might make you feel drowsy or dizzy .
& quot ;
& quot ; Schizophrenia :
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; Toxicologically significant effect be observe only at dos or exposure that be sufficiently in excess of the maximum human dose or exposure , indicate that these effect be limited or of no relevance to clinical use .
& quot ;
& quot ; 2 .
& quot ;
& quot ; - oral iron substitution of 200 - 300 mg Fe2 + / day be recommend for all cancer patient whose
& quot ;
& quot ; the recommended total weekly dose be between 75 and 300 IU / kg give by the intravenous route .
& quot ;
& quot ; 1 .
& quot ;
& quot ; gender : no dosage adjustment be require for female patient a compare to male patient ( see section 5.2 ) .
& quot ;
& quot ; pure red Cell Aplasia ( PRCA ) Antibody-mediated PRCA have be very rarely report after month to year of subcutaneous erythropoietin treatment .
& quot ;
& quot ; with renal insufficiency not yet undergoing dialysis ( see section 4.4 ) .
& quot ;
& quot ; Suomi / Finland OY BRISTOL-MYERS SQUIBB ( Finland ) AB Puh / Tel : + 358 9 251 21 230
& quot ;
& quot ; upon discontinuation of potent CYP3A4 inducer , the dosage of ABILIFY should be reduce to the recommend dose .
& quot ;
& quot ; the maximum dose should not exceed 200 IU / kg 3 time per week .
& quot ;
& quot ; after 6 month , Aclasta show 96 % ( 169 / 176 ) and 89 % ( 156 / 176 ) response and serum alkaline phosphatase ( SAP ) normalisation rate compare to 74 % ( 127 / 171 ) and 58 % ( 99 / 171 ) for risedronate ( all p & lt ; 0.001 ) .
& quot ;
& quot ; method of administration
& quot ;
& quot ; in one 3-week , fixed-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole fail to demonstrate superior efficacy to placebo .
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; the target haemoglobin concentration in two study be & gt ; 13 g / dl ; in the remain three study it be 12 - 14 g / dl .
& quot ;
& quot ; each ml contain 1 mg of aripiprazole .
& quot ;
& quot ; Deutschland Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; the use of specialized DEHP-free solution container or administration set be not necessary to prepare or administer Abraxane infusion .
& quot ;
& quot ; lot
& quot ;
& quot ; enhance efficacy at dose higher than a daily dose of 15 mg have not be demonstrate although individual patient may benefit from a higher dose .
& quot ;
& quot ; the biological efficacy of epoetin alfa have be demonstrate in various animal model in vivo ( normal and anaemic rat , polycythaemic mouse ) .
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of epilepsy and chronic liver failure .
& quot ;
& quot ; Randomised comparative study :
& quot ;
& quot ; tell your doctor immediately if you be have any thought or feeling about hurt yourself .
& quot ;
& quot ; Τηλ : + 357 22 677038
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of anaemia and of the symptom of anaemia .
& quot ;
& quot ; • condition or restriction with regard to the safe AND effective use OF the MEDICINAL product
& quot ;
& quot ; le than 1 % of unchanged aripiprazole be excrete in the urine and approximately 18 % be recover unchanged in the faeces .
& quot ;
& quot ; oral use
& quot ;
& quot ; s R. O .
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; the potentially medically serious sign and symptom report included somnolence , transient loss of consciousness and extrapyramidal symptom .
& quot ;
& quot ;
& quot ; date of first authorisation :
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; Vascular disorder :
& quot ;
& quot ; name OF the marketing authorisation holder
& quot ;
& quot ; in most of these patient , antibody to erythropoietin have be observe ( see section 4.3 and 4.4 – pure red Cell Aplasia )
& quot ;
& quot ; Sulfobutylether β -cyclodextrin ( SBECD ) Tartaric acid Sodium hydroxide water for injection
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; an increase 3H-thymidine incorporation in the erythroid nucleate spleen cell have be find in vitro ( mouse spleen cell culture ) after incubation with epoetin alfa .
& quot ;
& quot ; Immunogenicity data for subcutaneous use of Abseamed in patient at risk for antibody-induced PRCA , I. e. patient with renal anaemia , be not sufficient .
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and than reinstitute epoetin alfa therapy at a dose 25 % below the previous dose .
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg Kuhloweg 37 D-58638 Iserlohn
& quot ;
& quot ; how to take ABILIFY 4 .
& quot ;
& quot ; Retreatment of Paget ’ s disease : specific retreatment data be not available .
& quot ;
& quot ; Medicines should not be dispose of via wastewater or household waste .
& quot ;
& quot ; Slovenská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; España BRISTOL-MYERS SQUIBB , S. A .
& quot ;
& quot ; 5 .
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; Medicines to correct heart rhythm Antidepressants or herbal remedy use to treat depression and anxiety Antifungal agent certain medicine to treat HIV infection Anticonvulsants use to treat epilepsy
& quot ;
& quot ; solution for injection in a pre-filled syringe .
& quot ;
& quot ; Vascular disorder :
& quot ;
& quot ; it be not know whether aripiprazole be excrete in human milk .
& quot ;
& quot ; an increase relative risk of thromboembolic event ( RR 1.67 , 95 % CI :
& quot ;
& quot ; the highest nontumorigenic exposure in female rat be 7 time the human exposure at the recommend dose .
& quot ;
& quot ; lot
& quot ;
& quot ; haemodialysis and adult patient on peritoneal dialysis ( see section 4.4 ) .
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; Batch
& quot ;
& quot ; generally , child under 30 kg require higher maintenance dos than child over 30 kg and adult .
& quot ;
& quot ; in clinical trial aripiprazole have not be show to induce clinically relevant weight gain ( see section 5.1 ) .
& quot ;
& quot ; 1 .
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; good blood management practice should always be use in the perisurgical setting
& quot ;
& quot ; 1 pre-filled syringe of 0.3 ml contains 3000 international unit ( IU ) correspond to 25.2 microgram epoetin alfa
& quot ;
& quot ; there may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with epoetin alfa .
& quot ;
& quot ; reproduction be authorise provide the source be acknowledge . fall .
& quot ;
& quot ; 1 pre-filled syringe of 0.5 ml contains 5000 international unit ( IU ) correspond to 42.0 microgram epoetin alfa
& quot ;
& quot ; in two large , open-label study , 2697 cancer patient receive non-platinum chemotherapy be include , 1895 with solid tumour ( 683 breast , 260 lung , 174 gynaecological , 300 gastro-intestinal , and 478 other tumour type ) and 802 with haematological malignancy .
& quot ;
& quot ; Abseamed 7000 IU / 0.7 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; 2 .
& quot ;
& quot ; in case where there be a medical need to shorten the lead time before surgery to le than three week , 300 IU / kg epoetin alfa should be give daily for 10 consecutive day prior to surgery , on the day of surgery and for four day immediately thereafter .
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be avoid .
& quot ;
& quot ; a single-dose study in subject with vary degree of liver cirrhosis ( Child-Pugh class A , B , and C ) do not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole , but the study include only 3 patient with class C liver cirrhosis , which be insufficient to draw conclusion on their metabolic capacity .
& quot ;
& quot ; Musculoskeletal and connective tissue disorder :
& quot ;
& quot ; each orodispersible tablet contain 10 mg of aripiprazole .
& quot ;
& quot ; in patient with chronic renal failure the medicinal product have to be administer intravenously ( see section 4.4 ) .
& quot ;
& quot ; seizure : in clinical trial , uncommon case of seizure be report during treatment with aripiprazole .
& quot ;
& quot ; enhance efficacy at dose higher than a daily dose of 15 mg have not be demonstrate although individual patient may benefit from a higher dose .
& quot ;
& quot ; Tumour growth potential
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; do not use ABILIFY after the expiry date which be state on the bottle and on the carton .
& quot ;
& quot ; in the indication “ increase the yield of autologous blood ” : myocardial infarction or stroke in the month precede treatment , unstable angina pectoris , increase risk of deep venous thrombosis such a history of venous thromboembolic disease .
& quot ;
& quot ; however , since cyclosporin be bind by red blood cell there be potential for an interaction .
& quot ;
& quot ; Blood pressure-lowering medicine :
& quot ;
& quot ; - treatment of severe anaemia of renal origin accompany by clinical symptom in adult patient
& quot ;
& quot ; Breast carcinoma :
& quot ;
& quot ; survival and tumour progression have be examine in five large control study involve a total of 2833 patient , of which four be double-blind placebo-controlled study and one be an open- label study .
& quot ;
& quot ; the following maintenance dos be observe in clinical trial after 6 month of treatment :
& quot ;
& quot ; Tel : + 372 640 1301
& quot ;
& quot ; consequently , haemoglobin and blood pressure should be closely monitor .
& quot ;
& quot ; general disorder and administration site condition :
& quot ;
& quot ; each vial contain 100 mg of paclitaxel .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; Aripiprazole be excrete in the milk of treated rat during lactation .
& quot ;
& quot ; “ EXP ” .
& quot ;
& quot ; there be no effect of a high fat meal on the pharmacokinetics of aripiprazole .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; general
& quot ;
& quot ; how long will it take to give you your intravenous drip ?
& quot ;
& quot ; in order to ensure optimum response to epoetin alfa , adequate iron store should be assure :
& quot ;
& quot ; Medicines to correct heart rhythm Antidepressants or herbal remedy use to treat depression and anxiety Antifungal agent certain medicine to treat HIV infection Anticonvulsants use to treat epilepsy
& quot ;
& quot ; benefit outweighs the potential risk to the foetus .
& quot ;
& quot ; the correct amount of solution will be inject into your muscle by your doctor or nurse .
& quot ;
& quot ; therefore , in patient with renal anaemia the medicinal product have to be administer intravenously .
& quot ;
& quot ; 16 .
& quot ;
& quot ; take special care with ABILIFY before treatment with ABILIFY , tell your doctor if you suffer from High blood sugar or family history of diabetes seizure Involuntary , irregular muscle movement , especially in the face cardiovascular disease , family history of cardiovascular disease , stroke or & quot ; & quot ; mini & quot ; & quot ; stroke , abnormal blood pressure
& quot ;
& quot ; date of first authorisation :
& quot ;
& quot ; when see , it be usually in those with significant risk factor such a history of diabetes , thyroid disorder or pituitary adenoma .
& quot ;
& quot ; 2 .
& quot ;
& quot ; adjustment of daily dosage , include dose reduction should be consider on the basis of clinical status .
& quot ;
& quot ; alternatively , disperse the tablet in water and drink the resulting suspension .
& quot ;
& quot ; do not take ABILIFY if you be allergic ( hypersensitive ) to aripiprazole or any of the other ingredient of ABILIFY .
& quot ;
& quot ; survival and tumour progression have be examine in five large control study involve a total of 2833 patient , of which four be double-blind placebo-controlled study and one be an open- label study .
& quot ;
& quot ; 35 ( 16 , 50 ) * * 46 ( 8 , 68 ) * 27 ( 2 , 45 ) *
& quot ;
& quot ; increase mortality : in three placebo-controlled trial ( n = 938 ; mean age :
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of epilepsy and chronic liver failure .
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; take ABILIFY with food and drink ABILIFY can be take regardless of meal .
& quot ;
& quot ; Aripiprazole be excrete in the milk of treated rat during lactation .
& quot ;
& quot ; for the full list of all side effect report with Aclasta , see the package Leaflet .
& quot ;
& quot ; adult and paediatric haemodialysis patient , adult peritoneal dialysis patient and adult patient with renal insufficiency not yet undergoing dialysis
& quot ;
& quot ; haemodialysis and adult patient on peritoneal dialysis ( see section 4.4 ) .
& quot ;
& quot ; Pregnancy and breast-feeding you should not use ABILIFY if you be pregnant unless you have discuss this with your doctor .
& quot ;
& quot ; Additionally , aripiprazole and dehydro-aripiprazole do not show potential for alter CYP1A2-mediated metabolism in vitro .
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg , Kuhloweg 37 , D-58638 Iserlohn , Germany
& quot ;
& quot ; the exact total dosing volume of 5 mg / ml suspension require for the patient should be calculate and the appropriate amount of reconstituted Abraxane should be inject into an empty , sterile , polyvinyl chloride ( PVC ) type IV bag .
& quot ;
& quot ; other infrequently report side effect :
& quot ;
& quot ; 4 .
& quot ;
& quot ; in animal study , epoetin alfa have be show to decrease foetal body weight , delay ossification and increase foetal mortality when give in weekly dos of approximately 20 time the recommended human weekly dose .
& quot ;
& quot ; in all patient receive epoetin alfa , blood pressure should be closely monitor and control a necessary .
& quot ;
& quot ; 1 pre-filled syringe of 0.3 ml 6 pre-filled syrinx of 0.3 ml
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; Conventional type of paclitaxel contain substance ( solvent ) that dissolve the paclitaxel , but can cause side effect .
& quot ;
& quot ; detail information on this medicine be available on the European Medicines Agency ( EMEA ) web site : http : / / www . emea . europa . EU /
& quot ;
& quot ; since the orodispersible tablet be fragile , it should be take immediately on open the blister .
& quot ;
& quot ; 6 .
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; { MM / YYYY }
& quot ;
& quot ; rhabdomyolysis , myalgia , stiffness
& quot ;
& quot ; patient with hepatic impairment : no dosage adjustment be require for patient with mild to moderate hepatic impairment .
& quot ;
& quot ; Epoetin alfa should be administer by the subcutaneous route to patient with anaemia ( e. g. haemoglobin concentration ≤ 10 g / dl ( 6.2 mmol / l ) .
& quot ;
& quot ; 6 .
& quot ;
& quot ; in haemodialysed patient , a bolus injection may be give during the dialysis session through a suitable venous port in the dialysis line .
& quot ;
& quot ; a gastric acid blocker , the H2 antagonist famotidine , reduces aripiprazole rate of absorption but this effect be deem not clinically relevant .
& quot ;
& quot ; the rate of increase in haemoglobin should be approximately 1 g / dl
& quot ;
& quot ; 2 .
& quot ;
& quot ; weight gain : weight gain be commonly see in schizophrenic and bipolar mania patient due to co- morbidity , use of antipsychotic know to cause weight gain , poorly manage life-style , and might lead to severe complication .
& quot ;
& quot ; do not shake .
& quot ;
& quot ; EU / 1 / 07 / 412 / 002
& quot ;
& quot ; Hypertension may occur in epoetin alfa treat patient .
& quot ;
& quot ; the possibility of multiple medicinal product involvement should be consider .
& quot ;
& quot ; 6 .
& quot ;
& quot ; Tel : + 40 ( 0 ) 21 272 16 00
& quot ;
& quot ; Phlebotomy may be perform if excessively high haemoglobin level occur .
& quot ;
& quot ; patient who for any reason can not receive adequate antithrombotic prophylaxis .
& quot ;
& quot ; Aripiprazole and other antipsychotic drug should be use cautiously in patient at risk for aspiration pneumonia .
& quot ;
& quot ; EU / 1 / 07 / 412 / 003 EU / 1 / 07 / 412 / 004
& quot ;
& quot ; alternatively , epoetin alfa can be administer at an initial dose of 450 IU / kg subcutaneously once weekly .
& quot ;
& quot ; when a dose adjustment be necessary , this should be do in step of 25 IU / kg 3 time per week at interval of at least 4 week until the desired goal be achieve .
& quot ;
& quot ; in the horizon – pivotal fracture trial & # 91 ; PFT & # 93 ; ( see section 5.1 ) , the overall incidence of atrial fibrillation be 2.5 % ( 96 out of 3,862 ) and 1.9 % ( 75 out of 3,852 ) in patient receive Aclasta and placebo , respectively .
& quot ;
& quot ; Aripiprazole also demonstrate a comparable proportion of patient in symptomatic remission from mania a lithium or haloperidol at week 12 .
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be avoid .
& quot ;
& quot ; do not give by injection under the skin ( subcutaneously ) .
& quot ;
& quot ; EXP
& quot ;
& quot ; the full EPAR for Abseamed can be find here .
& quot ;
& quot ; Deutschland BRISTOL-MYERS SQUIBB GMBH & amp ; CO .
& quot ;
& quot ; 189 Kidney patient
& quot ;
& quot ; do not use ABILIFY after the expiry date which be state on the blister and on the carton .
& quot ;
& quot ; a half-life of approximately 6 hour have be report in child .
& quot ;
& quot ; no study on the effect on the ability to drive and use machine have be perform .
& quot ;
& quot ; common side effect ( greater than 1 in 100 , le than 1 in 10 patient ) Uncontrollable twitching or jerking movement , headache , tiredness , nausea , vomit , an uncomfortable feeling in the stomach , constipation , increased production of saliva , light-headedness , trouble sleeping , restlessness , feel anxious , sleepiness , shake and blurred vision .
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; patient with metastatic breast cancer receive chemotherapy when administer to target a haemoglobin of 12 - 14 g / dl ( 7.5 – 8.7 mmol / l ) ,
& quot ;
& quot ; the terminal half-life be about 27 hour .
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; population pharmacokinetic evaluation have reveal no evidence of clinically significant race-related difference or effect from smoke upon the pharmacokinetics of aripiprazole .
& quot ;
& quot ; Tel : + 40 ( 0 ) 21 272 16 00
& quot ;
& quot ; you may need to read it again .
& quot ;
& quot ; 1 .
& quot ;
& quot ; a single-dose study in subject with vary degree of liver cirrhosis ( Child-Pugh class A , B , and C ) do not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole , but the study include only 3 patient with class C liver cirrhosis , which be insufficient to draw conclusion on their metabolic capacity .
& quot ;
& quot ; in clinical trial , an increase risk of death and serious cardiovascular event be observe when erythropoiesis stimulate agent ( ESAs ) be administer to target a haemoglobin of greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; lot
& quot ;
& quot ; in a long term 26-week placebo-controlled trial , the incidence of EPS be 19 % for aripiprazole-treated patient and 13.1 % for placebo-treated patient .
& quot ;
& quot ; Manic episodes in Bipolar I Disorder :
& quot ;
& quot ; treatment of symptomatic anaemia in adult and paediatric chronic renal failure patient :
& quot ;
& quot ; therefore , in patient with renal anaemia the medicinal product have to be administer intravenously .
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; 28 August 2007
& quot ;
& quot ; patient should be closely monitor throughout this period .
& quot ;
& quot ; read all of this leaflet carefully before you start take this medicine .
& quot ;
& quot ; the most frequent adverse reaction during treatment with epoetin alfa be a dose-dependent increase in blood pressure or aggravation of exist hypertension .
& quot ;
& quot ; two other smaller , randomise , placebo-controlled trial fail to show a significant improvement in quality of life parameter on the EORTC-QLQ-C30 scale or CLAS , respectively .
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; ABILIFY oral solution may be use a an alternative to ABILIFY tablet for patient who have difficulty swallow ABILIFY tablet ( see section 5.2 ) .
& quot ;
& quot ; Antibody-mediated erythroblastopenia ( PRCA ) have be report after month to year of treatment with epoetin alfa .
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; NMS be a potentially fatal symptom complex associate with antipsychotic medicinal product .
& quot ;
& quot ; treatment of symptomatic anaemia associate with chronic renal failure ( CRF ) in adult and paediatric patient :
& quot ;
& quot ; EU / 1 / 07 / 412 / 019
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; 162 package LEAFLET :
& quot ;
& quot ; content by weight , by volume or by unit
& quot ;
& quot ; with renal insufficiency not yet undergoing dialysis ( see section 4.4 ) .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; Thrombotic event can be a risk in this population and this possibility should be carefully weigh against the benefit to be derive from the treatment in this patient group .
& quot ;
& quot ; 3 .
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; 4 .
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; Paediatric patient :
& quot ;
& quot ; 7.6 ( 6.3 , 9.0 )
& quot ;
& quot ; Non-clinical safety data reveal no special hazard for human base on conventional study of safety pharmacology , repeat-dose toxicity , genotoxicity , carcinogenic potential , and toxicity to reproduction .
& quot ;
& quot ; ESAs be not indicate for use in this patient population .
& quot ;
& quot ; 4 .
& quot ;
& quot ; no study on the effect on the ability to drive and use machine have be perform .
& quot ;
& quot ; Tel . : + 36 1 301 9700
& quot ;
& quot ; store in the original package in order to protect from moisture .
& quot ;
& quot ; the syrinx contain 0.6 ml ( 6000 IU ) of solution .
& quot ;
& quot ; 2 .
& quot ;
& quot ; Pack of 1 or 6 syrinx .
& quot ;
& quot ; Smoking and race :
& quot ;
& quot ; condition OF the marketing authorisation
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; 119 10 .
& quot ;
& quot ; Abseamed 5000 IU / 0.5 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; 16 .
& quot ;
& quot ; Aripiprazole undergo minimal pre-systemic metabolism .
& quot ;
& quot ; 4 Women of childbearing potential should use effective contraception during and up to 1 month after receive treatment with Abraxane .
& quot ;
& quot ; treatment with Abseamed have to be initiate under the supervision of physician experience in the management of patient with the above indication .
& quot ;
& quot ; child and adolescent Aclasta be not recommend for use in child and adolescent below 18 year of age due to lack of data on safety and efficacy .
& quot ;
& quot ; Reproductive system and breast disorder :
& quot ;
& quot ; Comparisons between aripiprazole and placebo in the proportion of patient experience potentially clinically significant change in routine laboratory parameter reveal no medically important difference .
& quot ;
& quot ; when either valproate or lithium be administer concomitantly with aripiprazole , there be no clinically significant change in aripiprazole concentration .
& quot ;
& quot ; in two large , open-label study , 2697 cancer patient receive non-platinum chemotherapy be include , 1895 with solid tumour ( 683 breast , 260 lung , 174 gynaecological , 300 gastro-intestinal , and 478 other tumour type ) and 802 with haematological malignancy .
& quot ;
& quot ; 78-88 year ) .
& quot ;
& quot ; many of these patient have sign of local infection include osteomyelitis , and the majority of the report refer to cancer patient follow tooth extraction or other dental surgery .
& quot ;
& quot ; actual score in rating scale use a secondary endpoint , include PANSS and the Montgomery-Asberg Depression rating scale show a significant improvement over haloperidol .
& quot ;
& quot ; during antipsychotic treatment , improvement in the patient & apos ; s clinical condition may take several day to some week .
& quot ;
& quot ; at each step , the increase or reduction in dose should be of 25 IU / kg 3 time per week .
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; from the bone tissue it be release very slowly back into the systemic circulation and eliminate via the kidney .
& quot ;
& quot ; the recommend dose of Abraxane be 260 mg / m2 administer intravenously over 30 minute every 3 week .
& quot ;
& quot ; 5 .
& quot ;
& quot ; Epoetin alfa should be use with caution in the presence of untreated , inadequately treat
& quot ;
& quot ; Tel : + 39 06 50 39 61
& quot ;
& quot ; 5.3 2.1 3.1
& quot ;
& quot ; 8.4 0.5 8.0
& quot ;
& quot ; 62.18 mg lactose per tablet
& quot ;
& quot ; how to take ABILIFY 4 .
& quot ;
& quot ; patient who develop pure red Cell Aplasia ( PRCA ) follow treatment with any erythropoietin should not receive Abseamed or any other erythropoietin ( see section 4.4 - pure red Cell Aplasia ) .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery the cause of anaemia should be establish and treat , if possible , before the start of epoetin alfa treatment .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; there be an increased risk for thromboembolic event in patient with cancer treat with recombinant human erythropoietin and a negative impact on overall survival can not be exclude .
& quot ;
& quot ; Lietuva BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Overdose of epoetin alfa may produce effect that be extension of the pharmacological effect of the hormone .
& quot ;
& quot ; follow a single oral dose of & # 91 ; 14C & # 93 ; -labelled aripiprazole , approximately 27 % of the administered radioactivity be recover in the urine and approximately 60 % in the faeces .
& quot ;
& quot ; България BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; Cranial nerve palsy , vocal cord paresis , and rare report of severe hypersensitivity reaction have be report during post-marketing surveillance of Abraxane .
& quot ;
& quot ; Excipients :
& quot ;
& quot ; EPAR summary for the public
& quot ;
& quot ; population pharmacokinetic evaluation have reveal no evidence of clinically significant race-related difference or effect from smoke upon the pharmacokinetics of aripiprazole .
& quot ;
& quot ; how do Abseamed work ?
& quot ;
& quot ; 2 .
& quot ;
& quot ; Tél / Tel : + 31 ( 0 ) 35 5288377
& quot ;
& quot ; 10 or 15 ml solution / day ) with a maintenance dose of 15 mg / day administer on a once-a-day schedule without regard to meal .
& quot ;
& quot ; if any of the side effect get serious , or if you notice any side effect not list in this leaflet , please tell your doctor or pharmacist .
& quot ;
& quot ; how to take ABILIFY 4 .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; Reticulocyte count increase & lt ; 40,000 / µl
& quot ;
& quot ; in clinical trial , an increase risk of death and serious cardiovascular event be observe when erythropoiesis stimulate agent ( ESAs ) be administer to target a haemoglobin of greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; with renal insufficiency not yet undergoing dialysis ( see section 4.4 ) .
& quot ;
& quot ; in a haloperidol-controlled trial , the proportion of responder patient maintain response to medicinal product at 52-weeks be similar in both group ( aripiprazole 77 % and haloperidol 73 % ) .
& quot ;
& quot ; le than 1 % of unchanged aripiprazole be excrete in the urine and approximately 18 % be recover unchanged in the faeces .
& quot ;
& quot ; in addition , case of stroke or & quot ; & quot ; mini & quot ; & quot ; stroke have be report .
& quot ;
& quot ; 151 package LEAFLET :
& quot ;
& quot ; these trial include patient with or without psychotic feature and with or without a rapid-cycling course .
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; which measure be be take to ensure the safe use of Aclasta ?
& quot ;
& quot ; with renal insufficiency not yet undergoing dialysis ( see section 4.4 ) .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; Sodium dihydrogen phosphate dihydrate Disodium phosphate dihydrate Sodium chloride Glycine Polysorbate 80 water for injection Hydrochloric acid ( for pH-adjustment ) Sodium hydroxide ( for pH-adjustment )
& quot ;
& quot ; 5 150 IU / kg 3x / week or 450 IU / kg once weekly
& quot ;
& quot ; adult and paediatric haemodialysis patient , adult peritoneal dialysis patient and adult patient with renal insufficiency not yet undergoing dialysis
& quot ;
& quot ; kg Puh / Tel : + 49- ( 0 ) 2371 937 0
& quot ;
& quot ; be sure to tell your doctor immediately if you be pregnant , think you may be pregnant , or if you be plan to become pregnant .
& quot ;
& quot ; with renal insufficiency not yet undergoing dialysis ( see section 4.4 ) .
& quot ;
& quot ; each ml of solution contain 10 000 IU of epoetin alfa * correspond to 84.0 microgram per ml 1 pre-filled syringe of 0.3 ml contains 3000 international unit ( IU ) correspond to 25.2 microgram epoetin alfa
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; 1 .
& quot ;
& quot ; therefore , it should not be use in patient with baseline haemoglobin & gt ; 13 g / dl .
& quot ;
& quot ; investigation :
& quot ;
& quot ; if Abraxane contact mucous membrane , the membrane should be flush thoroughly with water .
& quot ;
& quot ; a half-life of approximately 6 hour have be report in child .
& quot ;
& quot ; 106 ( 0.62 mmol / l ) per month and should not exceed 2 g / dl ( 1.25 mmol / l ) per month to minimise risk of an increase in hypertension .
& quot ;
& quot ; if an elevated or increase serum potassium level be detect , your doctor may consider to discontinue the treatment with Abseamed until the potassium level have return to the normal range .
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; the maximum dose should not exceed 200 IU / kg 3 time per week .
& quot ;
& quot ; Aripiprazole dose range from 0.5 to 30 mg administer once a day to healthy subject for 2 week produce a dose-dependent reduction in the binding of 11C-raclopride , a D2 / D3 receptor ligand , to the caudate and putamen detect by positron emission tomography .
& quot ;
& quot ; to enhance absorption and minimise variability , injection into the deltoid or deep within the gluteus maximus muscle , avoid adipose region , be recommend .
& quot ;
& quot ; EU / 1 / 07 / 412 / 009
& quot ;
& quot ;
& quot ; Immunogenicity data for subcutaneous use of Abseamed in patient at risk for antibody-induced PRCA , I. e. patient with renal anaemia , be not sufficient .
& quot ;
& quot ; the extent to which these outcome might apply to the administration of recombinant human erythropoietin to patient with cancer , treat with chemotherapy to achieve haemoglobin concentration le than 13 g / dl , be unclear because few patient with these characteristic be include in the data reviewed .
& quot ;
& quot ; it may be necessary to add or increase antihypertensive treatment .
& quot ;
& quot ; 5.2 Pharmacokinetic property
& quot ;
& quot ; the frequency of these event be consider not know ( can not be estimate from the available data ) .
& quot ;
& quot ; Endocrine disorder :
& quot ;
& quot ; 192 adult patient schedule for orthopaedic surgery
& quot ;
& quot ; oral use
& quot ;
& quot ; 72 Posology
& quot ;
& quot ; the observed mean improvement from baseline on the PANSS Excitement component score at the primary 2-hour endpoint be 5.8 for placebo , 9.6 for lorazepam , and 8.7 for aripiprazole .
& quot ;
& quot ; Schizophrenia - in a long term 52-week controlled trial , aripiprazole-treated patient have an overall-lower incidence ( 25.8 % ) of EPS include parkinsonism , akathisia , dystonia and dyskinesia compare with those treat with haloperidol ( 57.3 % ) .
& quot ;
& quot ; the percentage of patient who experience post-dose symptom be lower in a smaller study ( 19.5 % , 10.4 % , 10.7 % after the first , second and third infusion , respectively ) , where prophylaxis against post-dose symptom be use a described below .
& quot ;
& quot ; ABILIFY be one of a group of medicine call antipsychotic .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; what ABILIFY be AND what IT be use for
& quot ;
& quot ; elderly :
& quot ;
& quot ; when concomitant administration of potent CYP3A4 or CYP2D6 inhibitor with aripiprazole occurs , the aripiprazole dose should be reduce .
& quot ;
& quot ; the solution should be direct onto the inside wall of the vial .
& quot ;
& quot ; at steady state , dehydro-aripiprazole , the active metabolite , represent about 40 % of aripiprazole AUC in plasma .
& quot ;
& quot ; 31 Correction phase :
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; Maternal toxicity occur at dos similar to those elicit developmental toxicity .
& quot ;
& quot ; EU / 1 / 07 / 412 / 017 EU / 1 / 07 / 412 / 018
& quot ;
& quot ; in most case , the ferritin value in the serum fall simultaneously with the rise in packed cell volume .
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; 14 X 1 tablet 28 X 1 tablet 49 X 1 tablet 56 X 1 tablet 98 X 1 tablet
& quot ;
& quot ; EU / 1 / 05 / 308 / 002
& quot ;
& quot ; the decision to administer recombinant erythropoietin should be base on a benefit-risk assessment with the participation of the individual patient , which should also take into account the specific clinical context .
& quot ;
& quot ; temperature regulation disorder ( e. g. hypothermia , pyrexia ) , chest pain , peripheral oedema
& quot ;
& quot ; patient should be closely monitor throughout this period .
& quot ;
& quot ; 4 .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; Abraxane be use to treat metastatic breast cancer in patient whose first treatment for their metastatic disease have stop work and for whom standard treatment include an ‘ anthracycline ’ ( a type of anticancer medicine ) be not suitable . ‘ Metastatic ’ mean that the cancer have spread to other part of the body .
& quot ;
& quot ; 82.4 year ; range :
& quot ;
& quot ; ( 2.3 , 8.3 ) ( 0.5 , 3.7 ) ( 0.3 , 5.9 )
& quot ;
& quot ; 11 6.4 Special precaution for storage
& quot ;
& quot ; oral solution
& quot ;
& quot ; lot
& quot ;
& quot ; the clinical relevance of these finding be unknown .
& quot ;
& quot ; patient should be advise to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole .
& quot ;
& quot ; withdraw the needle quickly and apply pressure over the injection site with a dry , sterile pad .
& quot ;
& quot ; other
& quot ;
& quot ; the follow undesirable effect occur more often ( ≥ 1 / 100 ) than placebo , or be identify a possibly medically relevant adverse reaction ( * ) :
& quot ;
& quot ; child receive haemodialysis
& quot ;
& quot ; Smoking status : accord to the metabolic pathway of aripiprazole no dosage adjustment be require for smoker ( see section 4.5 ) .
& quot ;
& quot ; the use of epoetin alfa in patient schedule for major elective orthopaedic surgery and not participate in an autologous blood predonation programme be contraindicate in patient with severe coronary , peripheral arterial , carotid or cerebral vascular disease , include patient with recent myocardial infarction or cerebral vascular accident .
& quot ;
& quot ; 0.99 , 1,18 ; 42 trial and 8167 patient ) .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; Overdose of epoetin alfa may produce effect that be extension of the pharmacological effect of the hormone .
& quot ;
& quot ; Blood pressure-lowering medicine :
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; if after an additional 4 week of therapy at 300 IU / kg 3 time per week , the haemoglobin have increase ≥ 1 g / dl ( ≥ 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl the dose should remain at 300 IU / kg 3 time per week .
& quot ;
& quot ; a with all growth factor , there be a concern that epoetins could stimulate the growth of tumour .
& quot ;
& quot ; how to store ABRAXANE
& quot ;
& quot ; 4.8 undesirable effect
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; Portugal BRISTOL-MYERS SQUIBB FARMACÊUTICA Portuguesa , S. A .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; lot
& quot ;
& quot ; 0.9 ml ( 10000 IU / ml )
& quot ;
& quot ; driving and use machine
& quot ;
& quot ; patient with metastatic breast cancer receive chemotherapy when administer to target a haemoglobin of 12 - 14 g / dl ( 7.5 – 8.7 mmol / l ) ,
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; in schizophrenia patient the incidence of akathisia be 6.2 % with aripiprazole and 3.0 % with placebo .
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; when weak inhibitor of CYP3A4 ( e. g . , diltiazem or escitalopram ) or CYP2D6 be use concomitantly with ABILIFY , modest increase in aripiprazole concentration might be expect .
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; benefit outweighs the potential risk to the foetus .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; patient must have adequate fluid before and after treatment .
& quot ;
& quot ; Tel . : + 48 22 5796666
& quot ;
& quot ; Breast-feeding mother should not take ABILIFY .
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and than reinstitute epoetin alfa therapy at a dose 25 % below the previous dose .
& quot ;
& quot ; store and transport refrigerate ( 2 ° C - 8 ° C ) .
& quot ;
& quot ; Τηλ : + 357 22 677038
& quot ;
& quot ; Sverige BRISTOL-MYERS SQUIBB AB Tel : + 46 8 704 71 00
& quot ;
& quot ; Thrombotic event can be a risk in this population and this possibility should be carefully weigh against the benefit to be derive from the treatment in this patient group .
& quot ;
& quot ; alcohol should be avoid when take ABILIFY .
& quot ;
& quot ; an increase 3H-thymidine incorporation in the erythroid nucleate spleen cell have be find in vitro ( mouse spleen cell culture ) after incubation with epoetin alfa .
& quot ;
& quot ; Abseamed be study to show that it be comparable with the reference medicine , Eprex / Erypo , in experimental model and in human .
& quot ;
& quot ; Haemoglobin level should be measure on a regular basis until a stable level be achieve and periodically thereafter .
& quot ;
& quot ; the recommend starting dose for ABILIFY be 15 mg administer on a once-a-day schedule without regard to meal a monotherapy or combination therapy ( see section 5.1 ) .
& quot ;
& quot ; ABILIFY be not approve for the treatment of dementia-related psychosis .
& quot ;
& quot ; s R. O .
& quot ;
& quot ; 3 .
& quot ;
& quot ; pancreatitis , dysphagia , abdominal discomfort , stomach discomfort , diarrhoea
& quot ;
& quot ; however , the maximum daily dose of 30 mg should be use with caution in patient with severe hepatic impairment ( see section 5.2 ) .
& quot ;
& quot ; oral use
& quot ;
& quot ; name and address of the manufacturer responsible for batch release :
& quot ;
& quot ; precise risk estimate for hyperglycaemia-related adverse event in patient treat with ABILIFY and with other atypical antipsychotic agent be not available to allow direct comparison .
& quot ;
& quot ; in particular , no residue of the cell line use for the production be detectable at the concentration of the active ingredient that be use in human .
& quot ;
& quot ; the usual dose be 15 mg once a day .
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; instruction on use
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole , the active metabolite , decrease by 32 % and 47 % .
& quot ;
& quot ; 7 .
& quot ;
& quot ; in a prospective , randomised , double-blind , placebo-controlled trial conduct in 375 anaemic patient with various non-myeloid malignancy receive non-platinum chemotherapy , there be a significant reduction of anaemia-related sequela ( e. g. fatigue , decrease energy , and activity reduction ) , a measure by the following instrument and scale :
& quot ;
& quot ; Abseamed can be use to increase the yield of autologous blood from patient in a predonation programme .
& quot ;
& quot ; important information about some of the ingredient of ABILIFY patient who can not take phenylalanine should note that ABILIFY orodispersible tablet contain aspartame , which be a source of phenylalanine .
& quot ;
& quot ; Manic episodes in Bipolar I Disorder :
& quot ;
& quot ; in clinical trial aripiprazole have not be show to induce clinically relevant weight gain ( see section 5.1 ) .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; 1 .
& quot ;
& quot ; 10 .
& quot ;
& quot ; keep the pre-filled syringe in the outer carton in order to protect from light .
& quot ;
& quot ; method of administration
& quot ;
& quot ; not applicable .
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; the potentially medically serious sign and symptom report included somnolence , transient loss of consciousness and extrapyramidal symptom .
& quot ;
& quot ; Erythropoietin be a growth factor that primarily stimulate red cell production .
& quot ;
& quot ; Erythropoietin be a glycoprotein that stimulate , a a mitosis-stimulating factor and differentiate hormone , the formation of erythrocyte from precursor of the stem cell compartment .
& quot ;
& quot ; a only limited data be available in severe renal impairment ( creatinine clearance & lt ; 30 ml / min ) , no dosing recommendation be possible for this population .
& quot ;
& quot ; EU / 1 / 04 / 276 / 029
& quot ;
& quot ; possible side effect
& quot ;
& quot ; Batch :
& quot ;
& quot ; in the absence of compatibility study , this medicinal product must not be mix with other medicinal product .
& quot ;
& quot ; in the absence of compatibility study , this medicinal product must not be mix with other medicinal product .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Renal disease :
& quot ;
& quot ; España BRISTOL-MYERS SQUIBB , S. A .
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; in a 26-week , placebo-controlled trial in stabilised patient with chronic schizophrenia , aripiprazole have significantly greater reduction in relapse rate , 34 % in aripiprazole group and 57 % in placebo .
& quot ;
& quot ; in addition , other cause of anaemia , such a vitamin B12 or folate deficiency , should be exclude before institute therapy with epoetin alfa .
& quot ;
& quot ; 1.0 ml ( 2000 IU / ml )
& quot ;
& quot ; the AUC and Cmax of dehydro-aripiprazole , the active metabolite , decrease by 32 % and 47 % .
& quot ;
& quot ; immune system disorder :
& quot ;
& quot ; uncontrolled hypertension .
& quot ;
& quot ; 4 June 2004
& quot ;
& quot ; 4.9 Overdose
& quot ;
& quot ; the administration of aripiprazole solution for injection have no effect on the pharmacokinetics of lorazepam solution for injection when administer concomitantly .
& quot ;
& quot ; control clinical trial have not show significant benefit attributable to the administration of epoetins when haemoglobin concentration be increase beyond the level necessary to control symptom of anaemia and to avoid blood transfusion .
& quot ;
& quot ; Aripiprazole be excrete in the milk of treated rat during lactation .
& quot ;
& quot ; additional supportive care should be provide a necessary .
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery
& quot ;
& quot ; adult peritoneal dialysis patient :
& quot ;
& quot ; a lower dose of 5.25 mg ( 0.7 ml ) may be give , on the basis of individual clinical status , which should also include consideration of medicinal product already administer either for maintenance or acute treatment ( see section 4.5 ) .
& quot ;
& quot ; child and adolescent : there be no experience in child and adolescent under 18 year of age .
& quot ;
& quot ; 10 .
& quot ;
& quot ; gender : no dosage adjustment be require for female patient a compare to male patient ( see section 4.4 and 5.2 ) .
& quot ;
& quot ; Tel : + 421 2 59298411
& quot ;
& quot ; Paediatric haemodialysis patient :
& quot ;
& quot ; independent of erythropoietin treatment , thrombotic and vascular event may occur in surgical patient with underlying cardiovascular disease follow repeat phlebotomy .
& quot ;
& quot ; CLINICAL PARTICULARS
& quot ;
& quot ; 84 year ; range :
& quot ;
& quot ; if haemoglobin have increase by at least 1 g / dl ( 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl above baseline after 4 week of treatment , the dose should remain at 150 IU / kg 3 time a week or 450 IU / kg once weekly .
& quot ;
& quot ; unit dose perforate blister ( alu / alu )
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; Cardiac disorder Uncommon : tachycardia * nervous system disorder Common : somnolence , dizziness , headache , akathisia Gastrointestinal disorder Common : nausea , vomit Uncommon : dry mouth * Vascular disorder Uncommon : orthostatic hypotension * , increase diastolic blood pressure * General disorder and administration site condition Uncommon : fatigue *
& quot ;
& quot ; patient with active malignant disease receive neither chemotherapy nor radiation therapy .
& quot ;
& quot ; leukopenia , neutropenia , thrombocytopenia
& quot ;
& quot ; the other ingredient be calcium silicate , croscarmellose sodium , crospovidone , silicon dioxide , xylitol , microcrystalline cellulose , aspartame , acesulfame potassium , vanilla flavour , tartaric acid , magnesium stearate , red iron oxide ( E172 ) .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; in elderly patient with dementia , more fatal case have be report while take aripiprazole .
& quot ;
& quot ; Tablet
& quot ;
& quot ; other
& quot ;
& quot ; before you use ABILIFY 3 .
& quot ;
& quot ; 14 .
& quot ;
& quot ; Medice
& quot ;
& quot ; 0.4 ml ( 10000 IU / ml )
& quot ;
& quot ; the European Commission grant a marketing authorisation valid throughout the European Union for Aclasta to Novartis Europharm limit on 15 April 2005 .
& quot ;
& quot ; speech disorder , Neuroleptic Malignant syndrome ( NMS ) , grand mal convulsion
& quot ;
& quot ; 4.1 Therapeutic indication
& quot ;
& quot ; the following be the most common and important incidence of adverse reaction relate to 229 patient with metastatic breast cancer who be treat with 260 mg / m2 Abraxane once every three week in the pivotal phase III clinical study .
& quot ;
& quot ; Hypersensitivity reaction have be rarely report with epoetin alfa include isolated case of angioedema and anaphylactic reaction .
& quot ;
& quot ; 14 A .
& quot ;
& quot ; 1.0 ml ( 10000 IU / ml )
& quot ;
& quot ; solution for injection in a pre-filled syringe ( injection )
& quot ;
& quot ; in one 3-week , fixed-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole fail to demonstrate superior efficacy to placebo .
& quot ;
& quot ; Tel : + 34 91 456 53 00
& quot ;
& quot ; 15 .
& quot ;
& quot ; increase mortality : in three placebo-controlled trial ( n = 938 ; mean age :
& quot ;
& quot ; Histomorphometric analysis show a 63 % reduction in bone turnover .
& quot ;
& quot ; 136 package LEAFLET :
& quot ;
& quot ; Phenylketonurics :
& quot ;
& quot ; Hypersensitivity reaction have be rarely report with epoetin alfa include isolated case of angioedema and anaphylactic reaction .
& quot ;
& quot ; patient who for any reason can not receive adequate antithrombotic prophylaxis .
& quot ;
& quot ; ABILIFY 1 mg / ml oral solution aripiprazole
& quot ;
& quot ; a with other antipsychotic , aripiprazole should be use with caution in patient with a family history of QT prolongation .
& quot ;
& quot ; a systematic review have also be perform involve more than 9000 cancer patient participate in 57 clinical trial .
& quot ;
& quot ; each orodispersible tablet contain 15 mg of aripiprazole .
& quot ;
& quot ; Pregnancy :
& quot ;
& quot ; common side effect ( greater than 1 in 100 , le than 1 in 10 patient ) Uncontrollable twitching or jerking movement , headache , tiredness , nausea , vomit , an uncomfortable feeling in the stomach , constipation , increased production of saliva , light-headedness , trouble sleeping , restlessness , feel anxious , sleepiness , shake and blurred vision .
& quot ;
& quot ; name OF the marketing authorisation holder
& quot ;
& quot ; 5.3 Preclinical safety data
& quot ;
& quot ; Erythropoietins be growth factor that primarily stimulate red blood cell production .
& quot ;
& quot ; in a long term 26-week placebo-controlled trial , the incidence of EPS be 19 % for aripiprazole-treated patient and 13.1 % for placebo-treated patient .
& quot ;
& quot ; 13 maximum daily dose of 30 mg should be use with caution in patient with severe hepatic impairment ( see section 5.2 ) .
& quot ;
& quot ; you should check with your doctor or pharmacist if you be not sure .
& quot ;
& quot ; Deutschland BRISTOL-MYERS SQUIBB GMBH & amp ; CO .
& quot ;
& quot ; 12 .
& quot ;
& quot ; because of the possibility of harm to the infant , breast-feeding must be discontinue for the duration of treatment .
& quot ;
& quot ; 9 .
& quot ;
& quot ; treatment of adult patient schedule for major elective orthopaedic surgery :
& quot ;
& quot ; an increase in heparin dose during haemodialysis be frequently require during the course of therapy with epoetin alfa a a result of the increase packed cell volume .
& quot ;
& quot ; 6 pre-filled syrinx
& quot ;
& quot ; Norge Medice Arzneimittel GmbH & amp ; Co .
& quot ;
& quot ; 34 The recommend dose be 600 IU / kg epoetin alfa , give weekly for three week ( day 21 , 14 and 7 ) prior to surgery and on the day of surgery ( day 0 ) .
& quot ;
& quot ; 56-99 year ) of aripiprazole in elderly patient with psychosis associate with Alzheimer & apos ; s disease , patient treat with aripiprazole be at increase risk of death compare to placebo .
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; possible side effect
& quot ;
& quot ; solution for injection in a pre-filled syringe .
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; upon discontinuation of potent CYP3A4 inducer , the dosage of ABILIFY should be reduce to the recommend dose .
& quot ;
& quot ; some settling of the reconstituted suspension may occur .
& quot ;
& quot ; expiry date
& quot ;
& quot ; justification for not include braille accept .
& quot ;
& quot ; outer CARTON
& quot ;
& quot ; ABILIFY be effective in maintain the clinical improvement during continuation therapy in patient who have show an initial treatment response .
& quot ;
& quot ; the early disposition phase ( α and β , with t ½ value above ) presumably represent rapid uptake into bone and excretion via the kidney .
& quot ;
& quot ; pharmaceutical form AND content
& quot ;
& quot ; how be Aclasta use ?
& quot ;
& quot ; - if the solution be cloudy or there be particle in it .
& quot ;
& quot ; treatment of symptomatic anaemia associate with chronic renal failure ( CRF ) in adult and paediatric patient :
& quot ;
& quot ; 13 .
& quot ;
& quot ; 16 .
& quot ;
& quot ; - treatment of severe anaemia of renal origin accompany by clinical symptom in adult patient
& quot ;
& quot ; animal study could not exclude potential developmental toxicity ( see section 5.3 ) .
& quot ;
& quot ; if you be an elderly patient suffer from dementia ( loss of memory and other mental ability ) , you or your carer / relative should tell your doctor if you have ever have a stroke or & quot ; & quot ; mini & quot ; & quot ; stroke .
& quot ;
& quot ; expiry date
& quot ;
& quot ; 4.7 effect on ability to drive and use machine
& quot ;
& quot ; programme , the use of epoetin alfa be not recommend .
& quot ;
& quot ; if the haemoglobin increase be & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , increase the dose to 300 IU / kg 3 time per week .
& quot ;
& quot ; good blood management practice should always be use in the perisurgical setting
& quot ;
& quot ; Schizophrenia :
& quot ;
& quot ; mildly anaemic patient ( haematocrit of 33 - 39 % ) require predeposit of ≥ 4 unit of blood should be treat with Abseamed at a dose of 600 IU / kg body weight 2 time weekly for 3 week prior to surgery .
& quot ;
& quot ; what benefit have Abraxane show during the study ?
& quot ;
& quot ; - increase risk of death when administer to target a haemoglobin of 12 g / dl ( 7.5 mmol / l ) in
& quot ;
& quot ; * produce in CHO cell line by recombinant DNA technology
& quot ;
& quot ; ABILIFY 7.5 mg / ml solution for injection
& quot ;
& quot ; the absolute oral bioavailability of the tablet formulation be 87 % .
& quot ;
& quot ; adult patient with renal insufficiency not yet undergoing dialysis :
& quot ;
& quot ; Pharmacokinetics in special patient group
& quot ;
& quot ; pharmaceutical form
& quot ;
& quot ; Intravenous route
& quot ;
& quot ; maintenance dose between 25 and 50 IU / kg 2 time per week into 2 equal injection .
& quot ;
& quot ; this summary be last updated in 11-2007 .
& quot ;
& quot ; EU / 1 / 04 / 276 / 018
& quot ;
& quot ; be sure to tell your doctor if you take a medicine to keep your blood pressure under control .
& quot ;
& quot ; the four carbohydrate chain be attach via three N-glycosidic bond and one O-glycosidic bond to the protein .
& quot ;
& quot ; in all patient receive epoetin alfa , blood pressure should be closely monitor and control a necessary .
& quot ;
& quot ; moreover , monitoring of the blood pressure be recommend particularly at the start of therapy .
& quot ;
& quot ; Metabolism and nutrition disorder :
& quot ;
& quot ; - if the seal be break .
& quot ;
& quot ; give the primary CNS effect of aripiprazole , caution should be use when aripiprazole be take in combination with alcohol or other CNS medicinal product with overlap undesirable effect such a sedation ( see section 4.8 ) .
& quot ;
& quot ; Tel : + 371 67 50 21 85
& quot ;
& quot ; kg Tel : + 49- ( 0 ) 2371 937 0
& quot ;
& quot ; these change be interpret a be secondary to decreased maternal body weight gain .
& quot ;
& quot ; Tel : + 386 1 236 47 00
& quot ;
& quot ; Abseamed 1000 IU / 0.5 ml injection
& quot ;
& quot ; 85 1 .
& quot ;
& quot ; the Committee recommend that Aclasta be give market authorisation .
& quot ;
& quot ; the single- dose pharmacokinetics of aripiprazole be linear and dose-proportional .
& quot ;
& quot ; Epoetin alfa should be administer by the subcutaneous route to patient with anaemia ( e. g. haemoglobin concentration ≤ 10 g / dl ( 6.2 mmol / l ) .
& quot ;
& quot ; any unused product or waste material should be dispose of in accordance with local requirement .
& quot ;
& quot ; Dialysis prescription may have to be adjust periodically to maintain urea , creatinine and potassium in the desired range .
& quot ;
& quot ; B condition OF the marketing authorisation
& quot ;
& quot ; consequently :
& quot ;
& quot ; qualitative AND quantitative composition
& quot ;
& quot ; a manufacturing authorisation holder responsible for BATCH release
& quot ;
& quot ; the apparent molecular weight of erythropoietin be 32,000 to 40,000 dalton .
& quot ;
& quot ; 3 .
& quot ;
& quot ; 129 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; if a patient develop sign and symptom indicative of NMS , or present with unexplained high fever without additional clinical manifestation of NMS , all antipsychotic medicinal product , include ABILIFY , must be discontinue .
& quot ;
& quot ; Hb between 10 and 12 g / dl ( 6.2 - 7.5 mmol / l ) .
& quot ;
& quot ; this leaflet be last approved in { MM / YYYY }
& quot ;
& quot ; Nausea occur in 29 % of the patient and diarrhoea in 25 % of the patient .
& quot ;
& quot ; LABELLING
& quot ;
& quot ; the overall completion rate be significantly higher for patient on aripiprazole ( 43 % ) than for haloperidol ( 30 % ) .
& quot ;
& quot ; Musculoskeletal and connective tissue disorder :
& quot ;
& quot ; 10 .
& quot ;
& quot ; the oral solution contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reaction ( possibly delay ) .
& quot ;
& quot ; Excipients
& quot ;
& quot ; 2 / 3 What be the risk associate with Abilify ?
& quot ;
& quot ; Aripiprazole exhibit antagonist property in animal model of dopaminergic hyperactivity and agonist property in animal model of dopaminergic hypoactivity .
& quot ;
& quot ; Polyneuropathy , areflexia , dyskinesia , hyporeflexia , neuralgia , sensory loss , syncope , postural dizziness , neuropathic pain , tremor Common :
& quot ;
& quot ; in patient with chronic renal failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommend in section 4.2 .
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; if the haemoglobin exceed 13 g / dl ( 8.1 mmol / l ) , discontinue therapy until it fall below 12 g / dl ( 7.5 mmol / l ) and then reinstitute epoetin alfa therapy at a dose 25 % below the previous level .
& quot ;
& quot ; Paediatric haemodialysis patient :
& quot ;
& quot ; not all Pack size may be market .
& quot ;
& quot ; Τηλ : + 30 210 6074300
& quot ;
& quot ; after injection of the necessary amount of the solution from the pre-filled syringe , discard any remain content .
& quot ;
& quot ; Pharmacokinetics in special patient group
& quot ;
& quot ; date OF revision OF the text
& quot ;
& quot ; in haemodialysed patient , a bolus injection may be give during the dialysis session through a suitable venous port in the dialysis line .
& quot ;
& quot ; moreover , in patient with a baseline haemoglobin of & gt ; 13 g / dl , the possibility that epoetin alfa treatment may be associate with an increase risk of postoperative thrombotic / vascular event can not be exclude .
& quot ;
& quot ; discontinue therapy
& quot ;
& quot ; in most case , the ferritin value in the serum fall simultaneously with the rise in packed cell volume .
& quot ;
& quot ; Anaemia symptom and sequela may vary with age , gender , and overall burden of disease ; a physician ´ s evaluation of the individual patient ´ s clinical course and condition be necessary .
& quot ;
& quot ; precise risk estimate for hyperglycaemia-related adverse event in patient treat with ABILIFY and with other atypical antipsychotic agent be not available to allow direct comparison .
& quot ;
& quot ; the rate of increase in haemoglobin should be approximately 1 g / dl
& quot ;
& quot ; ESAs be not indicate for use in this patient population .
& quot ;
& quot ; additional sign may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
& quot ;
& quot ; 14 .
& quot ;
& quot ; information for the user
& quot ;
& quot ; oral use
& quot ;
& quot ; Abseamed be a ‘ biosimilar ’ medicine .
& quot ;
& quot ; - shorten overall survival and increase death attribute to disease progression at 4 month in
& quot ;
& quot ; Abseamed 1000 IU / 0.5 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; patient schedule for major elective orthopaedic surgery should receive adequate antithrombotic prophylaxis , a thrombotic and vascular event may occur in surgical patient , especially in those with underlying cardiovascular disease .
& quot ;
& quot ; Tel : + 370 5 2790 762
& quot ;
& quot ; how to store ABSEAMED
& quot ;
& quot ; in clinical trial aripiprazole have not be show to induce clinically relevant weight gain ( see section 5.1 ) .
& quot ;
& quot ; 104 6.2 Incompatibilities
& quot ;
& quot ; the use of epoetin alfa in patient schedule for major elective orthopaedic surgery and not participate in an autologous blood predonation programme be contraindicate in patient with severe coronary , peripheral arterial , carotid or cerebral vascular disease , include patient with recent myocardial infarction or cerebral vascular accident .
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; when the CYP3A4 or CYP2D6 inhibitor be withdraw from the combination therapy , aripiprazole dose should then be increase ( see section 4.5 ) .
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; adult peritoneal dialysis patient :
& quot ;
& quot ; in the long term 26-week maintenance phase of a placebo-controlled trial , the incidence of EPS be 18.2 % for aripiprazole-treated patient and 15.7 % for placebo-treated patient .
& quot ;
& quot ; remove one syringe from the Pack and remove the protective CAP from the injection needle .
& quot ;
& quot ; condition OF the marketing authorisation
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; a per the CHMP guideline on risk management system for medicinal product for human use , the updated RMP should be submit at the same time a the next Periodic Safety update Report ( PSUR ) .
& quot ;
& quot ; 6 .
& quot ;
& quot ; in patient schedule for major elective orthopaedic surgery , with a baseline haemoglobin of 10 to 13 g / dl , the incidence of thrombotic / vascular event ( most of which be DVTs ) , in the overall patient population of the clinical trial , appear to be similar across the different epoetin alfa dose group and placebo group , although the clinical experience be limit .
& quot ;
& quot ; treatment of symptomatic anaemia associate with chronic renal failure ( CRF ) in adult and paediatric patient :
& quot ;
& quot ; no study on the effect on the ability to drive and use machine have be perform .
& quot ;
& quot ; 300 IU / kg 3x / week for 4 week
& quot ;
& quot ; 4 .
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; additional supportive care should be provide a necessary .
& quot ;
& quot ; name AND address OF the marketing authorisation holder
& quot ;
& quot ; Epoetin alfa IV / SC
& quot ;
& quot ; particular attention should be pay to sudden stab migraine- like headache a a possible warning signal .
& quot ;
& quot ; all other cause of anaemia , e. g. iron deficiency , damage of red blood cell ( haemolysis ) , blood loss , vitamin B12 or folate deficiency , should be take into account and treat prior to initiate therapy with Abseamed .
& quot ;
& quot ; the protein binding of paclitaxel follow Abraxane administration be estimate at about 90 % .
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ; in the four placebo-controlled study the hazard ratio for overall survival range between 1.25 and 2.47 in favour of control .
& quot ;
& quot ; be sure to tell your doctor immediately if you be pregnant , think you may be pregnant , or if you be plan to become pregnant .
& quot ;
& quot ; 15 .
& quot ;
& quot ; FOLDING box ( with blue box ) AND BOTTLE label for intermediate Pack
& quot ;
& quot ; EU / 1 / 04 / 276 / 016-020
& quot ;
& quot ; in patient with severe hepatic impairment , the data available be insufficient to establish recommendation .
& quot ;
& quot ; these change be interpret a be secondary to decreased maternal body weight gain .
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; how to take ABILIFY
& quot ;
& quot ; Aripiprazole dose range from 0.5 to 30 mg administer once a day to healthy subject for 2 week produce a dose-dependent reduction in the binding of 11C-raclopride , a D2 / D3 receptor ligand , to the caudate and putamen detect by positron emission tomography .
& quot ;
& quot ; there be no difference in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subject , nor be there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patient .
& quot ;
& quot ; oral use
& quot ;
& quot ; general classification for supply
& quot ;
& quot ; the following reaction have also occur in isolated patient with normal or low blood pressure : hypertensive crisis with encephalopathy-like symptom ( e. g. headache and confused state ) and Generalised tonoclonal seizure , require the immediate attention of a physician and intensive medical care .
& quot ;
& quot ; the highest nontumorigenic exposure in female rat be 7 time the human exposure at the recommend dose .
& quot ;
& quot ; the potentially medically important sign and symptom observe included lethargy , increase blood pressure , somnolence , tachycardia , nausea , vomit and diarrhoea .
& quot ;
& quot ; the clinical data available suggest that those patient whose initial haemoglobin be very low ( & lt ; 6.8 g / dl or & lt ; 4.25 mmol / l ) may require higher maintenance dos than those whose initial anaemia be le severe ( Hb & gt ; 6.8 g / dl or & gt ; 4.25 mmol / l ) .
& quot ;
& quot ; patient treat with any antipsychotic agent , include ABILIFY , should be observe for sign and symptom of hyperglycaemia ( such a polydipsia , polyuria , polyphagia and weakness ) and patient with diabetes mellitus or with risk factor for diabetes mellitus should be monitor regularly for worsen of glucose control .
& quot ;
& quot ; 8 .
& quot ;
& quot ; 1 .
& quot ;
& quot ; the rate of atrial fibrillation serious adverse event be increase in patient receive Aclasta ( 1.3 % ) ( 51 out of 3,862 ) compare with patient receive placebo ( 0.6 % ) ( 22 out of 3,852 ) .
& quot ;
& quot ; 200 mg oral elemental iron daily ) throughout the course of treatment .
& quot ;
& quot ; statement OF active substance
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; gender :
& quot ;
& quot ; the intravenous route have to be use ( please see section 4.4 - chronic renal failure patient ) .
& quot ;
& quot ; România BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; Hyperbilirubinaemia , hepatomegaly Uncommon :
& quot ;
& quot ;
& quot ; in a prospective , randomised , double-blind , placebo-controlled trial conduct in 375 anaemic patient with various non-myeloid malignancy receive non-platinum chemotherapy , there be a significant reduction of anaemia-related sequela ( e. g. fatigue , decrease energy , and activity reduction ) , a measure by the following instrument and scale :
& quot ;
& quot ; - keep this leaflet .
& quot ;
& quot ; 17 Extrapyramidal symptom ( EPS ) :
& quot ;
& quot ; Extrapyramidal symptom ( EPS ) :
& quot ;
& quot ; patient ) be recommend for chronic renal failure patient whose serum ferritin level be below 100 ng / ml
& quot ;
& quot ; there be a transient increase in serum creatinine observe within 10 day in 1.8 % of Aclasta-treated patient versus 0.8 % of placebo-treated patient .
& quot ;
& quot ; 6 .
& quot ;
& quot ; if you experience these symptom , do not drive or operate machinery until they have fully resolve .
& quot ;
& quot ; Portugal BRISTOL-MYERS SQUIBB FARMACÊUTICA Portuguesa , S. A .
& quot ;
& quot ; 6 Extrapyramidal symptom ( EPS ) :
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg Kuhloweg 37 D-58638 Iserlohn
& quot ;
& quot ; packaging
& quot ;
& quot ; Aclasta must not be allow to come into contact with any calcium-containing solution .
& quot ;
& quot ; in the clinical study , no toxicity occur notably more frequently among elderly patient who receive Abraxane .
& quot ;
& quot ; the clearance of paclitaxel with Abraxane be larger ( 43 % ) than that follow a solvent-based paclitaxel injection and it volume of distribution be also higher ( 53 % ) .
& quot ;
& quot ; Absorption :
& quot ;
& quot ; Abseamed have no influence on the ability to drive and use machine .
& quot ;
